{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/andresmmujica/products-with-openai/blob/main/Summarize_Clinical_Trials_for_Heart_Disease_and_Nutrition.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "kOsnXzIrYlXv"
      },
      "source": [
        "# Summarize Clinical Trials for Heart Disease and Nutrition\n",
        "\n",
        "This project is an LLM app that summarizes important studies and clinical trials that have happened for any given disease!\n",
        "\n",
        "# The Problem\n",
        "\n",
        "There are so many clinical trials for each disease, but it's very hard to decipher and understand them."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "XPYb-1-wp8nb"
      },
      "source": [
        "# Solution\n",
        "\n",
        "Show the clinical trials in summarized way so that it's easy to understand for general population.\n",
        "\n",
        "**Flow**\n",
        "\n",
        "1.   Get the list of first 50 clinical trials for user-selcted diseases using API from https://clinicaltrials.gov.\n",
        "2.   Only look at the diseases with results to narrow down the list.\n",
        "3.  To further narrow down the list to stay within gpt-3.5-turbo-16k limits, just get first 5 studies from the narrowed down list.\n",
        "4. In the streamlit app, initially show the clinical trials related to \"heart disease\" and \"nutrition\".\n",
        "5. The streamlit app also has option to select another disease and term if the user wants to view any other disease results.\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "vENdlMWhd4Cn"
      },
      "outputs": [],
      "source": [
        "!pip install openai\n",
        "!pip install tiktoken\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import openai\n",
        "from getpass import getpass\n",
        "\n",
        "openai.api_key = getpass('Enter the OpenAI API Key in the cell  ')"
      ],
      "metadata": {
        "id": "zUKM9J6OM1lJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "WMtzXFrJfNRs",
        "outputId": "4311abdf-5186-4e60-8ac4-97b9981b5274"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'FullStudiesResponse': {'APIVrs': '1.01.05', 'DataVrs': '2023:08:16 23:57:56.293', 'Expression': 'stroke nutrition', 'NStudiesAvail': 462815, 'NStudiesFound': 319, 'MinRank': 1, 'MaxRank': 100, 'NStudiesReturned': 100, 'FullStudies': [{'Rank': 1, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03825419', 'OrgStudyIdInfo': {'OrgStudyId': 'MASS'}, 'Organization': {'OrgFullName': 'Turkish Stroke Research and Clinical Trials Network', 'OrgClass': 'NETWORK'}, 'BriefTitle': 'Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition (MASS)', 'OfficialTitle': 'Muscle Assessment in Stroke Study (MASS): Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition', 'Acronym': 'MASS'}, 'StatusModule': {'StatusVerifiedDate': 'April 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 23, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 30, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 30, 2019', 'StudyFirstSubmitQCDate': 'January 30, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 31, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 27, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ethem Murat Arsava', 'ResponsiblePartyInvestigatorTitle': 'Prof.Dr.', 'ResponsiblePartyInvestigatorAffiliation': 'Turkish Stroke Research and Clinical Trials Network'}, 'LeadSponsor': {'LeadSponsorName': 'Turkish Stroke Research and Clinical Trials Network', 'LeadSponsorClass': 'NETWORK'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Abbott Nutrition', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'Klinar CRO', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Turkish Neurological Society', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The degree of muscle loss over the course of inpatient stay will be evaluated in patients with a diagnosis of acute ischemic stroke admitted to Neurocritical Care Units and necessitating enteral nutrition.', 'DetailedDescription': 'This study is a multicenter, prospective observational study. The study period is 12 months. There are no investigational products to be followed or used in the study.\\n\\nDemographic data, stroke subtype, lesion localization, anthropometric measures will be recorded. Muscle in three different anatomical sites will be measured by CT following admission in patients included in the study.\\n\\nFor anthropometric measurements, height, body weight, body mass index, waist circumference, triceps skin thickness and calf circumference values will be used.\\n\\nThe muscle mass will be measured from the paraspinal muscles at the L3 vertebra level and from the muscles around the humerus and femur on the non-paralytic side of the extremities by CT.\\n\\nAll patients will receive standard enteral nutritional support with a standardized calorie and protein-based protocol recommended by international guidelines. The choice of the commercial enteral product will be left to the investigator, without any encouragement or restriction for use of any commercial product.\\n\\nThe enteral nutrition protocol will be implemented as follows;\\n\\nNasogastric or nasojejunal access\\nContinuous infusion\\nTargeted daily calories - 25-30 kcal / kg\\nTargeted daily protein - 1.2-1.5 gr / kg\\n20 ml / h initial infusion rate\\nIncrease infusion rate by 10-20 ml / h in 8-12 hours\\nTargeted calorie-protein requirement will be reached at the end of 72 hours.\\n\\nPatients will continue their routine follow-up in the neurology intensive care unit / stroke unit / neurology department. Daily enteral nutrition dose, complications attributed to enteral nutrition and systemic comorbidities will be recorded. Anthropometric measurements and muscle mass measurements with CT at three different locations will be repeated at the end of the second week (14 days ± 3 days) .\\n\\nThe study will evaluate whether or not muscle mass develops 14 days after acute ischemic stroke. The end points of the study is deterioration of anthropometric measurements and loss of muscle mass demonstrated by CT at follow up. The differences between patients with and without muscle loss will be assessed from the the aspects of demographic characteristics, ischemic stroke subtype, comorbidities and the success attained in reaching enteral nutritional goals.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Ischemic Stroke']}, 'KeywordList': {'Keyword': ['Stroke, Acute, Neurocritical Care, Nutrition, Sarcopenia']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '125', 'EnrollmentType': 'Actual'}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in muscle mass', 'PrimaryOutcomeDescription': 'Comparison of anthropometric measurements and CT based muscle mass measurements obtained at admission and at day 14 (± 3 days)', 'PrimaryOutcomeTimeFrame': '14 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients to be included in this study are required to meet all of the following inclusion criteria:\\n\\nAcute ischemic stroke\\nAdmission within first 24 hours after symptom onset\\nAdmission NIHSS score > 8\\nBeing unable to walk\\nNeed for enteral tube feeding due to problems with consciousness or dysphagia\\n\\nExclusion Criteria:\\n\\nPatients with any of the following exclusion criteria can not be included in the study:\\n\\nRetained ability for oral feeding\\nKnown muscle disease, neuropathy, neuromuscular junction disease', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with a diagnosis of acute ischemic stroke admitted to Neurocritical Care Units for whom enteral nutrition is indicated', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Ankara University Faculty of Medicine', 'LocationCity': 'Ankara', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Gazi University Faculty Of Medicine', 'LocationCity': 'Ankara', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Hacettepe University Faculty of Medicine', 'LocationCity': 'Ankara', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Eskişehir Osmangazi Faculty of Medicine', 'LocationCity': 'Eskişehir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Gaziantep University Faculty of Medicine', 'LocationCity': 'Gaziantep', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'İstanbul Şişli Hamidiye Etfal Training and Research Hospital', 'LocationCity': 'Istanbul', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Dokuz Eylül University Faculty of Medicine', 'LocationCity': 'İzmir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Ege University Faculty of Medicine', 'LocationCity': 'İzmir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'İzmir Katip Çelebi University Atatürk Training and Research Hospital', 'LocationCity': 'İzmir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Ondokuz Mayıs University Faculty of Medicine', 'LocationCity': 'Samsun', 'LocationCountry': 'Turkey'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28017450', 'ReferenceType': 'background', 'ReferenceCitation': 'Shiraishi A, Yoshimura Y, Wakabayashi H, Tsuji Y. Prevalence of stroke-related sarcopenia and its association with poor oral status in post-acute stroke patients: Implications for oral sarcopenia. Clin Nutr. 2018 Feb;37(1):204-207. doi: 10.1016/j.clnu.2016.12.002. Epub 2016 Dec 10.'}, {'ReferencePMID': '25676847', 'ReferenceType': 'background', 'ReferenceCitation': 'Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10.'}, {'ReferencePMID': '24108501', 'ReferenceType': 'background', 'ReferenceCitation': 'Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. doi: 10.1001/jama.2013.278481. Erratum In: JAMA. 2014 Feb 12;311(6):625. Padhke, Rahul [corrected to Phadke, Rahul].'}, {'ReferencePMID': '25726722', 'ReferenceType': 'background', 'ReferenceCitation': 'Coelen RJ, Wiggers JK, Nio CY, Besselink MG, Busch OR, Gouma DJ, van Gulik TM. Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford). 2015 Jun;17(6):520-8. doi: 10.1111/hpb.12394. Epub 2015 Feb 28.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Acute Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 2, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03422900', 'OrgStudyIdInfo': {'OrgStudyId': 'CASVE-NM-17-315'}, 'Organization': {'OrgFullName': 'Endocrinology and Clinical Nutrition Research Center, Spain', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Hyperglycemia in Patients With Stroke and Indication of Enteral Nutrition', 'OfficialTitle': 'Influence of Two Enteral Nutrition Formulas on Hyperglycemia and Morbidity in Patients With Stroke', 'Acronym': 'GlyENStroke'}, 'StatusModule': {'StatusVerifiedDate': 'January 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 12, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 15, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 15, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 10, 2017', 'StudyFirstSubmitQCDate': 'January 30, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 30, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Daniel de Luis Roman', 'ResponsiblePartyInvestigatorTitle': 'Profesor Doctor', 'ResponsiblePartyInvestigatorAffiliation': 'Endocrinology and Clinical Nutrition Research Center, Spain'}, 'LeadSponsor': {'LeadSponsorName': 'Endocrinology and Clinical Nutrition Research Center, Spain', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to evaluate the effect of a specific nutritional formula for diabetics on the development of hyperglycemia in patients with recent non-diabetic stroke who require admission and enteral nutritional support by nasogastric tube. As well as the effect on metabolic control, development of comorbidities, hospital stay, readmissions, mortality and tolerance of the formula under study.', 'DetailedDescription': 'MAIN GOAL:\\n\\nTo evaluate the effect on the development of hyperglycemia diagnosed as glycemia> 126 mg / dl on an empty stomach or> 150 mg / dl during the infusion of enteral nutrition determined by capillary glycemia during the admission of a specific formula in patients with a first episode of ischemic stroke or hemorrhagic entry into the non-diabetic HCUV stroke unit requiring enteral nutrition by nasogastric tube.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Hyperglycaemia (Non Diabetic)', 'Enteral Feeding Intolerance', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Comparison of two formulas of enteral nutrition (diabetes-specific enteral formula (lower glycemic index and presence of soluble and insoluble fiber) compared to an standard formula (isocaloric and isonitrogenated formula without fiber)) in patients without diabetes mellitus admitted due to stroke and with indication of nutritional support by nasogastric tube', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignMaskingDescription': 'cover label', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider']}}}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Specific Diabetes Formula', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Diabetes-Specific Enteral Formula:\\n\\nCaloric density: 1,0 kcal/ml\\nEnergy: 100 kcal\\nCarbohydrates: 10,1 g/100 ml;\\nFat: 4,5 g/100 ml\\nProt: 3,8 g/100 ml\\nOsmolarity: 345 mOsm/l\\nFiber: 1,78 g/100 ml (80% soluble; 20% insoluble).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Diabetes-Specific enteral formula']}}, {'ArmGroupLabel': 'Standard Formula', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Standard Enteral Formula:\\n\\nCaloric density: 1,0 kcal/ml\\nEnergy: 100 kcal\\nCarbohydrates: 13,8 g/100 ml;\\nFat: 3,4 g/100 ml\\nProt: 3,8 g/100 ml\\nOsmolarity: 220 mOsm/l\\nFiber: 0 g/100 ml', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Standard formula']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Diabetes-Specific enteral formula', 'InterventionDescription': 'Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Specific Diabetes Formula']}, 'InterventionOtherNameList': {'InterventionOtherName': ['DIABA']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Standard formula', 'InterventionDescription': 'Complete enteral formula normocaloric hormoproteic without fiber', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard Formula']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Fresubin Original']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'HYPERGLUCEMIA POST-ENTERAL NUTRITION', 'PrimaryOutcomeDescription': 'Glycemia over 150 mg / dl after the beginning of infusion of complete enteral. nutrition determined by capillary glycemia during admission. Dicotomic variable (Yes/No)', 'PrimaryOutcomeTimeFrame': '2 WEEKS'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'MORTALITY', 'SecondaryOutcomeDescription': 'Mortality during study period. Dicotomic variable (Yes/No)', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'ORAL FEEDING RECOVERY', 'SecondaryOutcomeDescription': 'Recovery of oral feeding (More than 75% of energy needs) and withdrawal of nasogastric tube during admission. Dicotomic variable (Yes/No)', 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdmitted for a first episode of ischemic or hemorrhagic stroke.\\nRequiring total enteral nutrition by tube for at least 7 days\\n\\nExclusion Criteria:\\n\\nContraindication to enteral nutrition\\nDiabetes Mellitus\\nGastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting, abdominal pain\\nNeed for admission to the ICU\\nPrevious neurodegenerative disease\\nAntibiotherapy for 7 days prior to the inclusion visit\\nAllergies or intolerances to any of the components of the formula under study\\nPregnant patients', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Juan J López-Gómez, Prof. Dr.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '983420000', 'CentralContactPhoneExt': '86158', 'CentralContactEMail': 'jjlopez161282@hotmail.com'}, {'CentralContactName': 'Daniel A De Luis-Román, Prof. Dr.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '983420000', 'CentralContactPhoneExt': '86660', 'CentralContactEMail': 'dadluis@yahoo.es'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Daniel A De Luis Román, Prof. Dr.', 'OverallOfficialAffiliation': 'Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Juan J López-Gómez, Prof. Dr.', 'OverallOfficialAffiliation': 'Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Javier F Arenillas-Lara, Prof. Dr.', 'OverallOfficialAffiliation': 'Service of Neurology. Clinic Hospital University of Valladolid', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Clinic Universitary Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Valladolid', 'LocationZip': '47003', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan J López-Gómez, Prof. Dr.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '983420000', 'LocationContactPhoneExt': '86158', 'LocationContactEMail': 'jjlopez161282@hotmail.com'}, {'LocationContactName': 'Daniel A De Luis-Román, Prof. Dr.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '983420000', 'LocationContactPhoneExt': '86660', 'LocationContactEMail': 'dadluis@yahoo.es'}, {'LocationContactName': 'Daniel A De Luis-Román, Prof. Dr.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Juan J López-Gómez, Prof. Dr.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Javier F Arenillas-Lara, Prof. Dr.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Esther Delgado-García, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Emilia Gómez-Hoyos, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ana Ortolá-Buigues, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Beatriz Torres-Torres, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ana Calleja-Sanz, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Elisa Cortijo-García, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Mercedes De Lera, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ángeles Castro-Lozano, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Silvia Rodríguez-Gómez, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Lourdes De Marcos-White, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Beatriz Gómez-Vicente, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Pedro L Muñoz-Rubio, Dipl', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Javier Reyes-Muñoz, Dipl', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Rosa Alcaide-Flores, Dipl', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ana Martín, Dipl', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000006943', 'ConditionMeshTerm': 'Hyperglycemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9684', 'ConditionBrowseLeafName': 'Hyperglycemia', 'ConditionBrowseLeafAsFound': 'Hyperglycemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}}, {'Rank': 3, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05454397', 'OrgStudyIdInfo': {'OrgStudyId': 'NFEC-2020-234'}, 'Organization': {'OrgFullName': 'Nanfang Hospital, Southern Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients', 'OfficialTitle': 'A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'October 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 15, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'October 15, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 1, 2022', 'StudyFirstSubmitQCDate': 'July 7, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 12, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 7, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 12, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Nanfang Hospital, Southern Medical University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'First Affiliated Hospital of Fujian Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Yantai Yuhuangding Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The First Hospital of Jilin University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Qilu Hospital of Shandong University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'ZHEJIANG PROVINCE XIAOSHAN HOSPITAL', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"The First People's Hospital of Wenling\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Ganzhou People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Affiliated Hospital of Jining Medical hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Henan Provincial People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Zhongda Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Second Affiliated Hospital of Harbin Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"The First People's Hospital of Kunshan\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The 2nd Affiliated Hospital of Wenzhou Medical University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"THE FIRST PEOPLE'S HOSPITAL OF JIASHAN\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"The First Affiliated Hospital of Xi'an Jiaotong University Medical College\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Fujian Province Zhangzhou Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"People's Hospital of Chongqing\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Nanjing Zijin Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Red Cross Hospital, Hangzhou, China', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Wenzhou Hospital of Chinese Medicine', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Kaifeng Central Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'First Affiliated Hospital of Guangxi Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Zhongshan Hospital of Xiamen University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Xi'an Encephalopathy of Traditional Chinese Medicine Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Xiangya Hospital of Central South University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Second Affiliated Hospital of Suzhou University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Tongji Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Affiliated Hospital o fQingdao University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The First Affiliated Hospital of Anhui Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Yancheng Third People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Linyi People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Dongfang Hospital of Beijing University of Chinese Medicine', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The Affiliated Hospital of Qingdao University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is the leading cause of premature death and disability, and early recognition and treatment of dysphagia is fundamental to stroke management. Early and full tube feeding in the acute phase of stroke helps to address nutritional problems resulting from dysphagia and impaired consciousness and helps to reduce morbidity and mortality and poor outcomes. Current guidelines for acute stroke management do not address the goal of tube feeding of enteral nutrition for energy and protein. In the treatment of acute stroke, there is a strong global focus on pharmacological thrombolysis or mechanical thrombolysis, with nutritional interventions being a less explored topic. Real-world evidence on large samples, feeding attainment and outcomes, and nutrition in the acute phase of stroke is lacking in China . The aim of this study was to understand the current status of nutritional therapy in stroke hospitalization in neurology and its impact on prognosis nationwide, and to improve the standardized management process of enteral nutrition therapy in the acute phase of stroke.', 'DetailedDescription': \"Malnutrition is a common geriatric syndrome with a disproportionate incidence in geriatric and neurology inpatients. In recent years, national nutritional surveys of geriatric inpatients have shown that about 2/3 of geriatric inpatients have nutritional problems; only half of neurology inpatients at high risk receive nutritional support, and inadequate nutrition exacerbates primary disease, increases complications, makes hospital stays longer, and ultimately affects patient survival outcomes.\\n\\nTo increase comprehensive and up-to-date research on the current status of nutritional therapy in geriatric and neurology inpatients, and to lay the foundation for future standardized treatment and standardized management, we conducted a nationwide survey on the current status of nutritional risk screening and treatment in geriatric and neurology inpatients. The aim is to raise the level of clinicians' awareness of malnutrition and nutritional risk in hospitalized patients, standardize clinical practice, and properly implement nutritional support to improve patients' clinical outcomes.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Stroke']}, 'KeywordList': {'Keyword': ['Stroke; Dysphagia;Nutrition management；']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '2000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'case group', 'ArmGroupDescription': 'Patients with acute stroke with nutritional risk', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Observational study, no intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Observational study, no intervention', 'InterventionDescription': 'Observational study, no intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['case group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Nutrition implementation rate', 'PrimaryOutcomeDescription': 'Proportion of patients hospitalized for stroke who were given nutritional support', 'PrimaryOutcomeTimeFrame': 'The first day of admission； the seventh day of admission； the day before discharge.'}, {'PrimaryOutcomeMeasure': 'Nutrition compliance rate of stroke inpatients', 'PrimaryOutcomeDescription': 'Percentage of patients hospitalized for stroke whose nutritional indicators and nutritional status met the guidelines after being given nutritional support', 'PrimaryOutcomeTimeFrame': 'The first day of admission； the seventh day of admission； the day before discharge.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': '30-day post-discharge mortality', 'SecondaryOutcomeDescription': 'Proportion of enrolled patients who died 30 days after discharge from the hospital', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}, {'SecondaryOutcomeMeasure': 'Infection rate', 'SecondaryOutcomeDescription': 'Proportion of enrolled patients with pulmonary infection 30 days after discharge from hospital.', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}, {'SecondaryOutcomeMeasure': 'Readmission rate', 'SecondaryOutcomeDescription': 'Proportion of patients enrolled who were readmitted for various reasons 30 days after discharge.', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}, {'SecondaryOutcomeMeasure': 'Functional prognosis', 'SecondaryOutcomeDescription': 'Functional prognosis of the enrolled patients, such as life skills, motor and sensory functions, cognitive functions and swallowing functions.', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nNewly admitted stroke patients admitted to neurology, age ≥18 years, within 7 days of onset, expected survival >3 months (i.e., not end-stage), expected neurology stay 7-10 days；\\nAt risk of malnutrition (MUST ≥ 2 points) or at nutritional risk (NRS2002 ≥ 3 points), sign an informed notice.\\n\\nExclusion Criteria:\\n\\nTransferred during treatment, contraindications to nutritional therapy (e.g., hemodynamic instability, gastrointestinal bleeding (bleeding >100 ml), other nutritional studies, pregnancy.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': \"Newly admitted stroke patients admitted to the neurology unit, ≥18 years of age, within 7 days of onset, expected survival >3 months, expected neurology stay 7-10 days, and at risk of malnutrition (MUST ≥2 points) or at nutritional risk (NRS2002 ≥3 points). Patients' age, sex, hospital, hospitalization number, height, primary diagnosis on admission, and previous underlying disease were collected.\", 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'JinYu Chen, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+8615876578154', 'CentralContactEMail': '568344684@qq.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Suyue Pan, M.D., Ph.D.', 'OverallOfficialAffiliation': 'Department of Neurology, Nanfang Hospital, Southern Medical University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'The First Affiliated Hospital of Anhui Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hefei', 'LocationState': 'Anhui', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yajuan Hu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13956912105'}]}}, {'LocationFacility': 'Dongfang Hospital of Beijing University of Chinese Medicine', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Baoxin Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13581546499'}]}}, {'LocationFacility': 'The First Afilliated Hospital of Fujian Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fuzhou', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhiqiang Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13805059300'}]}}, {'LocationFacility': 'Zhongshan Hospital Xiamen University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Xiamen', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lihong Su, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18060486879'}]}}, {'LocationFacility': 'Fujian Province Zhangzhou Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Zhengzhou', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bailing Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15892014859'}]}}, {'LocationFacility': 'Nanfang Hospital of Southern Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'JinYu Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactEMail': '568344684@qq.com'}, {'LocationContactName': 'Suyue Pan, M.D., Ph.D.', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'The First Affiliated Hospital of Guangxi Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanning', 'LocationState': 'Guangxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhijian Liang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13737944579'}]}}, {'LocationFacility': 'The second Affiliated Hospital of Harbin Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': \"Ha'erbin\", 'LocationState': 'Heilongjiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lihua Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13100881600'}]}}, {'LocationFacility': 'Kaifeng Central Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Kai Feng', 'LocationState': 'Henan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yan Zhao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15137884148'}]}}, {'LocationFacility': \"Henan Provincial People'S Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Zhengzhou', 'LocationState': 'Henan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yong Yao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13837136563'}]}}, {'LocationFacility': 'Tongji Hospital of Tongji Medical College of HUST', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wuhan', 'LocationState': 'Hubei', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Furong Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18627126298'}]}}, {'LocationFacility': 'Xiangya Hospital Central South University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Changsha', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Fangfang Bi, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13739064027'}]}}, {'LocationFacility': \"The First People'S Hospital of Kunshan\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Kunshan', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yan Zhang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13962638897'}]}}, {'LocationFacility': 'Nanjing Zijin Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanjing', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Changbao Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13770722709'}]}}, {'LocationFacility': 'Zhongda Hospital Southeast Universtiy', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanjing', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hui Jiao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '1581881150'}]}}, {'LocationFacility': 'The second Affiliated Hospital of Suzhou University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Suzhou', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Weidong Hu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '1351003701'}]}}, {'LocationFacility': \"Yancheng Third People's Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Yancheng', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lijuan Wu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13912569779'}]}}, {'LocationFacility': \"Ganzhou People'S Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Ganzhou', 'LocationState': 'Jiangxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chaohui Lai, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13879729792'}]}}, {'LocationFacility': 'The First Hospital of Jilin University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Changchun', 'LocationState': 'Jilin', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xin Sun, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13596116866'}]}}, {'LocationFacility': 'Qilu Hospital of Shandong University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Jinan', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Qinzhou Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18560085523'}]}}, {'LocationFacility': 'Affiliated Hospital of Jining Medical Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Jining', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shaoying Wu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18678766806'}]}}, {'LocationFacility': \"Linyi People'S Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Linyi', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Guangying Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13695395899'}]}}, {'LocationFacility': 'Qilu Hospital of Shandong University(Qingdao)', 'LocationStatus': 'Recruiting', 'LocationCity': 'Qingdao', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jijun Teng, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18661806108'}]}}, {'LocationFacility': 'The Affiliated Hospital of Qingdao University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Qingdao', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Cuiping Zhao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18561810336'}]}}, {'LocationFacility': 'Yantai Yuhuangding Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Yantai', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hong Liu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13964528128'}]}}, {'LocationFacility': \"The First Affiliated Hospital of Xi'an Jiaotong University\", 'LocationStatus': 'Recruiting', 'LocationCity': \"Xi'an\", 'LocationState': 'Shanxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chen Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13363954570'}]}}, {'LocationFacility': \"Xi'an Encephalopathy of Traditional Chinese Medicine Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': \"Xi'an\", 'LocationState': 'Shanxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bingcan Yan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13379236669'}]}}, {'LocationFacility': \"Chongqing People's Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Chongqing', 'LocationState': 'Sichuang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chengqun Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15998950878'}]}}, {'LocationFacility': 'Red Cross Hospital of Hangzhou', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hangzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mingming Ma, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13738132607\\u202c'}]}}, {'LocationFacility': 'Zhejiang Province Xiaoshan Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hanzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kai Fang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18967168308'}]}}, {'LocationFacility': \"The First People'S Hospital of Jiashan\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Jiaxing', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yingshuai Shi, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18358364799'}]}}, {'LocationFacility': \"The First People'S Hospital of Wenling\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Wenling', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Haibo Cai, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13905565806'}]}}, {'LocationFacility': \"The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Wenzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Beilei Hu', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15858515599'}]}}, {'LocationFacility': 'Wenzhou Hospital of Chinese Medicine', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wenzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ling Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13868403777'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 4, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01578629', 'OrgStudyIdInfo': {'OrgStudyId': '2011H0242'}, 'Organization': {'OrgFullName': 'Ohio State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event', 'OfficialTitle': 'Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA', 'Acronym': 'NUTRITION'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 5, 2012', 'StudyFirstSubmitQCDate': 'April 13, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 17, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 13, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 20, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Andrew Slivka', 'ResponsiblePartyInvestigatorTitle': 'MD, Professor of Neurology', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'}, 'LeadSponsor': {'LeadSponsorName': 'Andrew Slivka', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Government of Malaysia', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I & IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol.', 'DetailedDescription': 'A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I & IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol. Phase I subjects will be healthy volunteers, recruited by an advertisement. Phase IIA subjects will be hyperlipidemic (having high cholesterol), and will be referred to us by their Wound Care Center Physicians. Patients will be randomized to receive placebo pills, (400 or 800 mg) TCT pills, low-dose 81 mg aspirin (commonly used for secondary prevention of stroke), or TCT and aspirin together. Potential subjects for Phase-I who meet study criteria and agree to participate will be in the study for 6 months and have the following study related procedures, blood draw total 4 times, tape stripping (non-invasive procedure), BMI, and blood pressure measurement at each visit (every month). Participants in Phase-IIA will have blood drawn a total of 6 times, tape stripping, BMI and blood pressure measurement and participants will be in the study for 13 months.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke', 'Transient Ischemic Attack (TIA)']}, 'KeywordList': {'Keyword': ['stroke', 'ischemia', 'TIA']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1', 'Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '210', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Healthy Volunteers', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin', 'Other: Placebo vehicle control']}}, {'ArmGroupLabel': 'Hyperlipidemic', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin', 'Other: Placebo vehicle control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin', 'InterventionDescription': 'Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Volunteers', 'Hyperlipidemic']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo vehicle control', 'InterventionDescription': 'vehicle control compared to Vitamin E TCT pills', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Volunteers', 'Hyperlipidemic']}, 'InterventionOtherNameList': {'InterventionOtherName': ['placebo capsule']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Platelet function panel', 'PrimaryOutcomeDescription': 'Blood draw followed by platelet aggregometry', 'PrimaryOutcomeTimeFrame': 'up to one year'}, {'PrimaryOutcomeMeasure': 'Lipid profile', 'PrimaryOutcomeDescription': 'blood lipid panel including HDL, LDL, total cholesterol', 'PrimaryOutcomeTimeFrame': 'up to one year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Tape Stripping Test', 'SecondaryOutcomeDescription': 'HPLC vitamin E analysis of tape strips for compliance', 'SecondaryOutcomeTimeFrame': 'up to one year'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Phase IA\\n\\nInclusion Criteria:\\n\\nHealthy subjects between 40 and 70 years of age\\nNo history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation greater than or equal to 6mos; within the past 5 years)\\nNo current vitamin E supplementation in multivitamin\\n\\nExclusion Criteria - (as self reported by potential participants during review of eligibility criteria with Research Nurse,)\\n\\nEvidence of heart disease as diagnosed by a physician by one or more of the following tests; EKG, chest x-ray, stress test, tilt table test, echocardiogram, coronary angiogram, electrophysiology test, CT heart scan, coronary MRI, pericardiocentesis\\nHigh cholesterol (total cholesterol >240mg/dL, LDL>160mg/dL)\\nPrior cancer diagnosis\\nPregnancy - To exclude the possibility of pregnant women entering the study or becoming pregnant during the study only post-menopausal women or women who have had hysterectomies or bilateral oophorectomies will be included.\\nBreast feeding\\nSmoker (Must have quit 5 or more years ago)\\nAlcohol dependence (>4 drinks per day for more than 1yr anytime in the last 3 years)\\nMedication exclusion criteria - current use or recent discontinuation (within last 28 days) of any medication including the following: anti-coagulants and blood-thinners (e.g., Warfarin), psychotropic medications including antipsychotics, mood-stabilizers (e.g., lithium, valproic acid, carbamazepine/tegretol); anti-depressants (tricyclics, SSRI's, MAOI's, nonselective MAOIs, Wellbutrin, St. John's Wort); anti-anxiety/anti-panic agents; anti-obsessive agents; prescription stimulants (e.g., Provigil, Ritalin); diet pills/anorectics; daily medication for chronic pain (e.g., opiates) or muscle spasms; daily use of over the counter stimulants in pill form (e.g., ephedrine); daily medication for asthma, Parkinson's disease medications (e.g., levodopa, methyldopa, apomorphine), smoking cessation medications (Wellbutrin/Zyban, Chantix/varenicline); statin use is not grounds for exclusion.\\n\\nPhase IIA\\n\\nInclusion Criteria:\\n\\nHyperlipidemic patients between 40 and 70 years of age currently taking statins\\nLDL>130mg/dL\\nTG>150mg/dL\\nHDL<40mg/dL\\nNo history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation greater than or equal to 6mos; within the past 5 years)\\nNo current vitamin E supplementation in multivitamin\\n\\nExclusion Criteria:\\n\\nEvidence of heart disease as diagnosed by a physician by one or more of the following tests; EKG, chest x-ray, stress test, tilt table test, echocardiogram, coronary angiogram, electrophysiology test, CT heart scan, coronary MRI, pericardiocentesis\\nPrior cancer diagnosis\\nCurrently taking blood thinners\\nPregnancy - To exclude the possibility of pregnant women entering the study or becoming pregnant during the study only post-menopausal women or women who have had hysterectomies or bilateral oophorectomy will be included.\\nBreast feeding\\nSmoking (Must have quit within the past 6 months)\\nAlcohol dependence - (>4 drinks per day for more than 1yr anytime in the last 3 years)\\nMedication exclusion criteria - current use or recent discontinuation (within last 28 days) of any medication including the following: anti-coagulants and blood-thinners (e.g., Warfarin), psychotropic medications including antipsychotics, mood-stabilizers (e.g., lithium, valproic acid, carbamazepine/tegretol); anti-depressants (tricyclics, SSRI's, MAOI's, nonselective MAOIs, Wellbutrin, St. John's Wort); anti-anxiety/anti-panic agents; anti-obsessive agents; prescription stimulants (e.g., Provigil, Ritalin); diet pills/anorectics; daily medication for chronic pain (e.g., opiates) or muscle spasms; daily use of over the counter stimulants in pill form (e.g., ephedrine); daily medication for asthma, Parkinson's disease medications (e.g., levodopa, methyldopa, apomorphine), smoking cessation medications (Wellbutrin/Zyban, Chantix/varenicline)\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'The Ohio state University Medical Center', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000002546', 'ConditionMeshTerm': 'Ischemic Attack, Transient'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000002545', 'ConditionAncestorTerm': 'Brain Ischemia'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5485', 'ConditionBrowseLeafName': 'Ischemic Attack, Transient', 'ConditionBrowseLeafAsFound': 'Transient Ischemic Attack (TIA)', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5484', 'ConditionBrowseLeafName': 'Brain Ischemia', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000001241', 'InterventionMeshTerm': 'Aspirin'}, {'InterventionMeshId': 'D000014810', 'InterventionMeshTerm': 'Vitamin E'}, {'InterventionMeshId': 'D000024505', 'InterventionMeshTerm': 'Tocopherols'}, {'InterventionMeshId': 'D000024508', 'InterventionMeshTerm': 'Tocotrienols'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000014815', 'InterventionAncestorTerm': 'Vitamins'}, {'InterventionAncestorId': 'D000018977', 'InterventionAncestorTerm': 'Micronutrients'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000000894', 'InterventionAncestorTerm': 'Anti-Inflammatory Agents, Non-Steroidal'}, {'InterventionAncestorId': 'D000018712', 'InterventionAncestorTerm': 'Analgesics, Non-Narcotic'}, {'InterventionAncestorId': 'D000000700', 'InterventionAncestorTerm': 'Analgesics'}, {'InterventionAncestorId': 'D000018689', 'InterventionAncestorTerm': 'Sensory System Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000000893', 'InterventionAncestorTerm': 'Anti-Inflammatory Agents'}, {'InterventionAncestorId': 'D000018501', 'InterventionAncestorTerm': 'Antirheumatic Agents'}, {'InterventionAncestorId': 'D000005343', 'InterventionAncestorTerm': 'Fibrinolytic Agents'}, {'InterventionAncestorId': 'D000050299', 'InterventionAncestorTerm': 'Fibrin Modulating Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000010975', 'InterventionAncestorTerm': 'Platelet Aggregation Inhibitors'}, {'InterventionAncestorId': 'D000016861', 'InterventionAncestorTerm': 'Cyclooxygenase Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000058633', 'InterventionAncestorTerm': 'Antipyretics'}, {'InterventionAncestorId': 'D000000975', 'InterventionAncestorTerm': 'Antioxidants'}, {'InterventionAncestorId': 'D000020011', 'InterventionAncestorTerm': 'Protective Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M4238', 'InterventionBrowseLeafName': 'Aspirin', 'InterventionBrowseLeafAsFound': 'Complete', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17243', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Untreated', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22662', 'InterventionBrowseLeafName': 'Tocopherols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M22665', 'InterventionBrowseLeafName': 'Tocotrienols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22659', 'InterventionBrowseLeafName': 'alpha-Tocopherol', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16575', 'InterventionBrowseLeafName': 'Trace Elements', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20699', 'InterventionBrowseLeafName': 'Micronutrients', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3907', 'InterventionBrowseLeafName': 'Anti-Inflammatory Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3908', 'InterventionBrowseLeafName': 'Anti-Inflammatory Agents, Non-Steroidal', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3722', 'InterventionBrowseLeafName': 'Analgesics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20476', 'InterventionBrowseLeafName': 'Analgesics, Non-Narcotic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20294', 'InterventionBrowseLeafName': 'Antirheumatic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8163', 'InterventionBrowseLeafName': 'Fibrinolytic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13555', 'InterventionBrowseLeafName': 'Platelet Aggregation Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18899', 'InterventionBrowseLeafName': 'Cyclooxygenase Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7641', 'InterventionBrowseLeafName': 'Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M28866', 'InterventionBrowseLeafName': 'Antipyretics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21559', 'InterventionBrowseLeafName': 'Protective Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T480', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Untreated', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T466', 'InterventionBrowseLeafName': 'Tocopherol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T467', 'InterventionBrowseLeafName': 'Tocotrienol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Antipy', 'InterventionBrowseBranchName': 'Antipyretics'}, {'InterventionBrowseBranchAbbrev': 'Infl', 'InterventionBrowseBranchName': 'Anti-Inflammatory Agents'}, {'InterventionBrowseBranchAbbrev': 'ARhu', 'InterventionBrowseBranchName': 'Antirheumatic Agents'}, {'InterventionBrowseBranchAbbrev': 'FiAg', 'InterventionBrowseBranchName': 'Fibrinolytic Agents'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'PlAggInh', 'InterventionBrowseBranchName': 'Platelet Aggregation Inhibitors'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}]}}}}}, {'Rank': 5, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01497886', 'OrgStudyIdInfo': {'OrgStudyId': 'AAAF3455'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01NS067443-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01NS067443-01A1'}]}, 'Organization': {'OrgFullName': 'Columbia University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Intervention to Improve Stroke Recognition', 'OfficialTitle': 'Randomized Controlled Trial Effect of Novel Intervention to Improve Stroke Symptom Recognition'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2011', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 23, 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 16, 2011', 'StudyFirstSubmitQCDate': 'December 22, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 23, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 13, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 15, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Olajide Williams', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Neurology', 'ResponsiblePartyInvestigatorAffiliation': 'Columbia University'}, 'LeadSponsor': {'LeadSponsorName': 'Columbia University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Despite the abundance of stroke education materials available, studies continue to reveal severe deficiencies in stroke literacy (knowledge of symptoms, urgent action, and prevention measures). Expensive mass media stroke education campaigns are not sustainable for this purpose, particularly in economically disadvantaged populations. Instead, the investigators propose to intervene in school classrooms with children aged 9 to 11 years, to teach the five cardinal stroke symptoms, the correct course of action when they occur, and to highlight the potential therapeutic benefit of early hospital arrival, with the intent that the children will then educate their parents. To help accomplish this, the investigators have developed a program called Hip Hop Stroke (HHS), which is comprised of rap songs and two animated musical cartoons that incorporate stroke knowledge.', 'DetailedDescription': 'Stroke is the leading cause of serious long-term adult disability in the U.S. and third leading cause of death, and has a 2-fold greater incidence in Blacks compared to the majority Americans. Thrombolytic revascularization treatment administered within a maximum of 3 hours from symptom onset reduces morbidity, mortality and cost; however, only 3% of patients arrive at the hospital within 3 hours,4 mostly due to the public\\'s lack of knowledge concerning stroke symptoms, and the appropriate response when they are recognized, which is to call 911. The investigators propose to reduce these delays using a novel behavioral intervention to improve symptom recognition and response in a high-risk, minority, economically disadvantaged population. Despite the abundance of stroke education materials available, studies continue to reveal severe deficiencies in stroke literacy (knowledge of symptoms, urgent action, and prevention measures). Expensive mass media stroke education campaigns are not sustainable for this purpose, particularly in economically disadvantaged populations. Instead, the investigators propose to intervene in school classrooms with children aged 9 to 11 years, to teach the five cardinal stroke symptoms, the correct course of action when they occur, and to highlight the potential therapeutic benefit of early hospital arrival, with the intent that the children will then educate their parents. To help accomplish this, the investigators have developed a program called Hip Hop Stroke (HHS), which is comprised of rap songs and two animated musical cartoons that incorporate stroke knowledge.\\n\\nTargeting children to intervene with their parents has been rarely and sporadically attempted in various content areas, but the interventions have used traditional teaching methods that do not engage the children, and little success has been reported. In contrast, the HHS intervention was designed in collaboration with school-aged children, children\\'s education television/media experts, as well as public health experts, school principals, and neurologists. As a result, not only is the targeting of children for this purpose an important innovation, but so is the careful development of materials designed to appeal to them. Moreover, the investigators note that utilizing children as a \"transmission vector\" for carrying out interventions aimed at their parents has the potential to serve as the basis for intervention in any number of other areas, for example, medication adherence, healthy eating and weight loss, treatment of diabetes, and so on.Thus, the significance of the proposed trial addresses the public health problem under study stroke symptom identification and response as well as development and refinement of a more general model of intervention.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Stroke', 'Children', 'Hip Hop Stroke', 'New York City']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '4614', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Hip Hop Stroke educational program', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Hip Hop Stroke educational program']}}, {'ArmGroupLabel': 'Nutrition Education program', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'The investigators will use what they will refer to as a \"usual care\" control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for \"attention\", i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Nutrition Education program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Hip Hop Stroke educational program', 'InterventionDescription': 'Three one-hour sessions, conducted over three consecutive days', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Hip Hop Stroke educational program']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Nutrition Education program', 'InterventionDescription': 'The investigators will use what they will refer to as a \"usual care\" control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for \"attention\", i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nutrition Education program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Stroke Symptom and Response Knowledge Assessment (student)', 'PrimaryOutcomeDescription': 'Knowledge of stroke prevention measures will be assessed by 8 YES/NO questions: 5 real and 3 distracters: eating lots of fruits and vegetables, exercising everyday, always taking medications given by doctor for high blood pressure/diabetes/high cholesterol, smoking avoidance or cessation, avoiding drug abuse, exercising once-a-week, eating lots of red meat, adding salt to meals.', 'PrimaryOutcomeTimeFrame': 'Up to 3 days from baseline'}, {'PrimaryOutcomeMeasure': \"Assessment of child's communication to parent regarding stroke symptoms.\", 'PrimaryOutcomeDescription': 'This measure assesses whether the child has talked with one of the adults in the household about what the child learned in school in both the HHS and control arms concerning symptoms of stroke and correct response.', 'PrimaryOutcomeTimeFrame': 'Up to 7 days from baseline'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Assessment of events, latency to arrival at the emergency room.', 'SecondaryOutcomeDescription': 'The investigators will ask the participating parents to report any diagnosis of stroke received, at 12 months, continuing through the duration of the funding period. If the parent reports a stroke,the investigators will ask for permission to conduct a chart review to confirm the stroke diagnosis, and the treatment given (especially regarding thrombolytic therapy. The investigators will also ask the patient (or family member if the patient is non verbal), who recognized the symptoms (self or other or child) and who called 911.', 'SecondaryOutcomeTimeFrame': '12 months from completion, and every 12 months afterwards'}, {'SecondaryOutcomeMeasure': 'Longitudinal Stroke Symptom and Response Knowledge Assessment (student)', 'SecondaryOutcomeDescription': 'Knowledge of stroke prevention measures will be assessed by 8 YES/NO questions: 5 real and 3 distracters: eating lots of fruits and vegetables, exercising everyday, always taking medications given by doctor for high blood pressure/diabetes/high cholesterol, smoking avoidance or cessation, avoiding drug abuse, exercising once-a-week, eating lots of red meat, adding salt to meals.', 'SecondaryOutcomeTimeFrame': '3 months after participation'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n4th-6th grade children and their parents in selected elementary public schools in the same geographical region/community with similar socioeconomic status (SES) and Ethnic composition.\\n\\nExclusion Criteria:\\n\\nSchool located in Harlem, New York.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '7 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Olajide A. Williams, MD MS', 'OverallOfficialAffiliation': 'Columbia University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Columbia University Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22875089', 'ReferenceType': 'background', 'ReferenceCitation': 'Williams O, DeSorbo A, Noble J, Shaffer M, Gerin W. Long-term learning of stroke knowledge among children in a high-risk community. Neurology. 2012 Aug 21;79(8):802-6. doi: 10.1212/WNL.0b013e3182661f08. Epub 2012 Aug 8.'}, {'ReferencePMID': '22033995', 'ReferenceType': 'background', 'ReferenceCitation': 'Williams O, DeSorbo A, Noble J, Gerin W. Child-Mediated Stroke Communication: findings from Hip Hop Stroke. Stroke. 2012 Jan;43(1):163-9. doi: 10.1161/STROKEAHA.111.621029. Epub 2011 Oct 27.'}, {'ReferencePMID': '29567762', 'ReferenceType': 'derived', 'ReferenceCitation': 'Williams O, Leighton-Herrmann Quinn E, Teresi J, Eimicke JP, Kong J, Ogedegbe G, Noble J. Improving Community Stroke Preparedness in the HHS (Hip-Hop Stroke) Randomized Clinical Trial. Stroke. 2018 Apr;49(4):972-979. doi: 10.1161/STROKEAHA.117.019861.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T187', 'InterventionBrowseLeafName': 'Hops', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 6, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03635476', 'OrgStudyIdInfo': {'OrgStudyId': 'LIFOCUS'}, 'Organization': {'OrgFullName': 'Cereneo AG', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Survey of Lifelong Food and Nutrition Assistance (LIFANA) in Stroke Patients and Caregivers', 'OfficialTitle': 'Survey of Lifelong Food and Nutrition Assistance (LIFANA) in Stroke Patients and Caregivers - Cereneo Schweiz AG (Center for Neurology and Rehabilitation)'}, 'StatusModule': {'StatusVerifiedDate': 'January 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 20, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 1, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 14, 2018', 'StudyFirstSubmitQCDate': 'August 14, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 17, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 26, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 27, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Krizia Ferrini', 'ResponsiblePartyInvestigatorTitle': 'Nutritional Specialist', 'ResponsiblePartyInvestigatorAffiliation': 'Cereneo AG'}, 'LeadSponsor': {'LeadSponsorName': 'Cereneo AG', 'LeadSponsorClass': 'INDUSTRY'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'cereneo Institute for Interdsciplinary Research (cefir)', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Many elderly suffer from nutritional problems that can cause (or can be caused by) a number of complications such as weakened immune systems and chronic health conditions (diabetes type 2, high blood pressure, cardiovascular diseases or even osteoporosis).\\n\\nThrough appropriate adjustments in the diets, on the basis of nutritional advice, the burden of established diseases as well as the risks of developing further conditions can be diminished. The goal of our proposed project LIFANA is to develop and evaluate the LIFANA Nutrition Solution to support healthy nutrition.. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists. This is a national project co-funded by the European Union.\\n\\nOne of the activities of the project is to collect information through a survey with patients. These questions will contribute to creating solutions that can explore the perspectives of patients.', 'DetailedDescription': 'Patients will be approached in the clinic by a neurologist and health care professionals. The questionnaire will take place at cereneo. The group will consist of 25 participants and last between 1h. The Survey will be conducted by a clinician who will take notes. Semi-structured discussion guide will be used. With regard to the communication, the moderator will identify factors that will influence communication in a positive or negative way.\\n\\nThe health professionals will perform content analyses on the transcripts; the schema of categories will be oriented towards the research questions, using open questions, directly addressing quiet participants, and handling the discussion guide in a flexible way.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Relatives', 'Diet Modification']}, 'KeywordList': {'Keyword': ['Stroke Rehabilitation', 'Personalized Nutrition', 'Mobile-Health', 'Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Other']}}, 'EnrollmentInfo': {'EnrollmentCount': '5', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Qualitative interview study', 'InterventionDescription': \"The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.\", 'InterventionOtherNameList': {'InterventionOtherName': ['Survey']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'User Needs', 'PrimaryOutcomeDescription': 'The primary endpoint of this study is to explore the perspectives of patients through appropriate adjustments of focus group questions on user needs for managing nutritional status', 'PrimaryOutcomeTimeFrame': '1 day/session'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nstroke patients undergoing rehabilitation\\ncaregivers of stroke patients\\n\\nExclusion Criteria:\\n\\nSevere aphasia\\nSevere cognitive deficits', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'stroke patients undergoing rehabilitation', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Krizia Ferrini, PhD', 'OverallOfficialAffiliation': 'cereneo Schweiz AG | center for neurology & rehabilitation', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Doris Mösinger, MSc', 'OverallOfficialAffiliation': 'cereneo Schweiz AG | center for neurology & rehabilitation', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Leopold Zizlsperger, MD', 'OverallOfficialAffiliation': 'cereneo Schweiz AG | center for neurology & rehabilitation', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'cereneo Schweiz AG', 'LocationCity': 'Vitznau', 'LocationState': 'LU', 'LocationZip': '6354', 'LocationCountry': 'Switzerland'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21550', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 7, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04923165', 'OrgStudyIdInfo': {'OrgStudyId': 'FDG_Nutristroke_2021'}, 'Organization': {'OrgFullName': 'Fondazione Don Carlo Gnocchi Onlus', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutritional Status in Subacute Stroke Patients Under Rehabilitation', 'OfficialTitle': 'Influence of Nutritional Status on Rehabilitation Outcome in Subacute Stroke Patients', 'Acronym': 'Nutristroke'}, 'StatusModule': {'StatusVerifiedDate': 'July 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 4, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 10, 2023', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 10, 2023', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 22, 2021', 'StudyFirstSubmitQCDate': 'June 7, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 11, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 18, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Irene Giovanna Aprile', 'ResponsiblePartyInvestigatorTitle': 'Md, PhD, Principal Investigator, Head of Rehabilitation Unit', 'ResponsiblePartyInvestigatorAffiliation': 'Fondazione Don Carlo Gnocchi Onlus'}, 'LeadSponsor': {'LeadSponsorName': 'Fondazione Don Carlo Gnocchi Onlus', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Recently, is becoming more evident a relationship between malnutrition, stroke-related sarcopenia and/or altered systemic oxidative status in patients with subacute stroke .\\n\\nThe aim of this study is the evaluation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status in patients with subacute stroke outcomes; another aim is to investigate the correlation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status on admission with the rehabilitative outcomes.', 'DetailedDescription': 'Stroke is the third leading cause of mortality and the second leading cause of permanent disability in adults, and is therefore very expensive. Some patients with stroke outcomes, regardless of baseline motor and cognitive function, for unknown reasons show an unexpectedly worse outcome than others and this suggests other factors, in addition to the degree of initial disability, that influence the response to rehabilitative treatment.\\n\\nNutrition is an essential aspect in the overall picture of the stroke patient. Malnutrition in the hospital setting is an important issue that can negatively influence the rehabilitation outcome (Cederholm et al. 2017; 2019).\\n\\nMalnutrition is also responsible for the increase in complications, negatively affects the results of treatment, reduces the immune response and predisposes to infections, delays healing, compromises the function of organs and systems, reduces muscle mass and strength, induces psychic effects with depression and low interest in food.\\n\\nAll this leads to a demand for greater and more prolonged care, with a delay in the recovery of the performance (National Guidelines for hospital and care catering. Min. of Health, 2015).\\n\\nA picture of malnutrition also leads to an alteration of biochemical and haematochemical indexes. Our retrospective pilot study on 30 patients with subacute stroke, showed a positive correlation between the reduction of disability following rehabilitation treatment and the calcium at admission (Siotto et al, 2020). In addition, a recent study with 100 patients admitted to a rehabilitation unit showed that the functional status at the time of admission and the improvement following the rehabilitation program were positively influenced by high blood levels of vitamin D (Lelli et al. 2019).\\n\\nMalnourished patients experience \"sarcopenia\", which is characterized by the reduction of muscle mass and strength, and is a phenomenon strongly related to age: after the age of 70 years, in fact, there is a loss of 15% of muscle mass. It is a risk factor for falls, fractures, physical disability and mortality and it is a phenomenon dependent on various factors such as metabolic imbalance, inactivity, malnutrition and inflammatory states. Sarcopenia is accompanied by body weight loss, neuro-hormonal activation and a systemic shift towards catabolic over-activation (Knops et al. 2013).\\n\\nSarcopenia is frequently found in patients with stroke outcomes and can contribute negatively to the rehabilitation process. A recent study of 267 stroke patients admitted to a rehabilitation unit showed that those with sarcopenia (n=129 48%) had severe lower limb paralysis, lower Body Mass Index (BMI) values and a lower Functional Independence Measure (FIM) score, compared to patients without sarcopenia. In addition, patients with sarcopenia had a longer average stay with less chance of returning home and were less autonomous in walking. Finally, patients with sarcopenia showed a lower recovery of functional autonomy compared to non sarcopenic patients (Matsushita et al. 2019).\\n\\nIn stroke patients there is also \"stroke-related sarcopenia\" (Scherbakov, Sandek, and Doehner 2015) with distinctive features. The reasons are to be attributed to a complex of pathophysiological reactions including: altered neurovegetative control, alterations in the local and systemic metabolic system, difficulty in nutrition and inflammation (Scherbakov, Sandek, and Doehner 2015).\\n\\nSome studies have led to hypothesize a correlation between sarcopenia and systemic oxidative stress. The general oxidative state is the result between levels of circulating oxidants (e.g. peroxides) and levels of endogenous or dietary acquired antioxidants (glutathione or vitamins, such as tocopherols, vitamin E, K). Our research team has recently demonstrated that circulating peroxides increase in stroke and are related to clinical severity (Squitti et al., 2018). The measurement of circulating peroxides evaluates the prooxidant state of a subject because it depends on circulating free radicals (Reactive Oxygen Species, ROS); these molecules have a great chemical reactivity, which, in extreme cases, compromises the function of all cellular macromolecules causing cell death; for this reason it is thought that sarcopenia may be at least partly due to an over-regulation of oxidative metabolism that produces high levels of circulating free radicals (Fulle et al. 2004).\\n\\nThe hypothesis of the study is that there is a negative relationship between malnutrition, stroke-related sarcopenia and/or altered systemic oxidative status in patients on admission and recovery following rehabilitative treatment.\\n\\ntherefore the aims of this study are:\\n\\nEvaluation of nutritional status, presence of stroke-related sarcopenia and systemic oxidative status in patients with subacute stroke outcomes;\\nthe correlation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status on admission with the rehabilitative outcome.\\n\\nImproving the nutritional picture of stroke patients from acute or post-acute wards will lead to a faster and more effective motor recovery and improve their autonomies and quality of life. This may lead to a lower impact of disability on families and caregivers and, more generally, a reduction in health care costs.\\n\\nLongitudinal prospective multicentric, non-profit, longitudinal observational study conducted in patients with first stroke (ischemic or hemorrhagic) in subacute phase (within six months after the acute event). The study involves the collection of clinical, instrumental and biochemical data that do not deviate from routine clinical practice. Since it is not an experimental study, no specific intervention is planned; patients will be observed before and after the usual rehabilitative intervention.\\n\\nThe study will have a total duration of 18 months starting in January 2021 and a patient enrolment time of 1 year.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Stroke', 'Nutrition', 'Rehabilitation', 'Oxidative stress', 'Sarcopenia']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '119', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with stroke', 'ArmGroupDescription': \"Inpatients and outpatients admitted to the investigators' rehabilitation facility .\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: robotic assisted intervention', 'Diagnostic Test: biochemical analyses', 'Device: BIA, hand grip', 'Diagnostic Test: nutritional assessment, MNA']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'robotic assisted intervention', 'InterventionDescription': 'Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'biochemical analyses', 'InterventionDescription': 'ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}, {'InterventionType': 'Device', 'InterventionName': 'BIA, hand grip', 'InterventionDescription': 'bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'nutritional assessment, MNA', 'InterventionDescription': 'nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'change in Mini nutritional Assessment (MNA) scores', 'PrimaryOutcomeDescription': 'it is a questionnaire that evaluates the nutritional status', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Body Mass Index', 'PrimaryOutcomeDescription': 'it is a measure of body fat based on height and weight that applies to adult men and women expressed in kg/m²', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'weight change', 'PrimaryOutcomeDescription': 'detection of the weight drop or weight increase', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in food income detection', 'PrimaryOutcomeDescription': 'detection of food intake by measurement of portion of dish assumed from the patients', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Bioimpedance analysis (BIA) measurements', 'PrimaryOutcomeDescription': 'it is a non-invasive measurement of body fat, lean muscle mass and hydration', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in hand grip strenght test score', 'PrimaryOutcomeDescription': 'it is a test to measure the maximum isometric strenght of the hand and forearm muscles', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Time Up & Go test (TUG) scores', 'PrimaryOutcomeDescription': 'The Time Up And Go is a test used to assess mobility, balance, and walking in people with balance impairments. The subject must stand up from a chair (which should not be leant against a wall), walk a distance of 3 meters, turn around, walk back to the chair and sit down - all performed as quickly and as safely as possible. Time will be measured using a chronometer.', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Barthel index (BI) scores', 'PrimaryOutcomeDescription': 'The BI is designed to assess the ability of an individual with a neuromuscular or musculoskeletal disorder to care for him/herself. It ranges from 0 to 100, with a higher number meaning better performance in activities of daily living.', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Fugl-Meyer Assessment of Motor Recovery after Stroke for Upper Extremity portion (FMA-UL) scores', 'PrimaryOutcomeDescription': 'The FMA-UL is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. The upper limb portion of the FMA-UL ranges from 0 (hemiplegia) to 66 points (normal upper limb motor performance)', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Motricity Index (MI) scores', 'PrimaryOutcomeDescription': 'The MI aims to evaluate lower limb motor impairment after stroke, administrated on both sides.\\n\\nItems to assess the lower limbs are 3, scoring from 0 to 33 each: (1) ankle dorsiflexion with foot in a plantar flexed position (2) knee extension with the foot unsupported and the knee at 90° (3) hip flexion with the hip at 90° moving the knee as close as possible to the chin. (no movement: 0, palpable flicker but no movement: 9, movement but not against gravity :14, movement against gravity movement against gravity: 19, movement against resistance: 25, normal:33).', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Numerical Rating Scale (NRS) scores', 'PrimaryOutcomeDescription': 'The Numeric Rating Scale (NRS) is the simplest and most commonly used numeric scale to rate the pain from 0 (no pain) to 10 (worst pain).', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Neuropathic Pain Four Questions (DN4) scores', 'PrimaryOutcomeDescription': \"The DN4 used to evaluate presence of neuropathic pain, and consist of a brief interview of four questions answered yes/no: two on what the patient has conceived and two during the exam for the evaluation of hypoesthesia to the touch or sting and the evaluation of allodynia with the skimming of the skin. For each 'yes' a point is assigned. The total score is given by the sum of the individuals. The cut off for the presence of neuropathic pain is '4'.\", 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Modified Ashworth Scale (MAS) scores', 'PrimaryOutcomeDescription': \"The MAS is a 6 point ordinal scale used for grading hypertonia in individuals with neurological diagnoses. A score of 0 on the scale indicates no increase in tone while a score of 4 indicates rigidity. Tone is scored by passively moving the individual's limb and assessing the amount of resistance to movement felt by the examiner.\", 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in 10 Meter Walk Test scores', 'PrimaryOutcomeDescription': \"This test will assess the patient's speed during gait. Patients will be asked to walk at their preferred maximum and safe speed. Patients will be positioned 1 meter before the start line and instructed to walk 10 meters, and pass the end line approximately 1 meter after. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be measured using a stopwatch and recorded to the one hundred of a second (ex: 2.15 s). The test will be recorded 3 times, with adequate rests between them. The average of the 3 times should be recorded.\", 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Six-Minute Walking Test (6MWT) scores', 'PrimaryOutcomeDescription': 'The 6MWT measures the distance a subject covers during an indoor gait on a flat, hard surface in 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The minimal detectable change in distance for people with sub-acute stroke is 60.98 meters. The 6MWT is a patient self-paced walk test and assesses the level of functional capacity. Patients are allowed to stop and rest during the test. However, the timer does not stop. If the patient is unable to complete the test, the time is stopped at that moment. The missing time and the reason of the stop are recorded. This test will be administered while wearing a pulse oximeter to monitor heart rate and oxygen saturation, also integrated with Borg scale to assess dyspnea.', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in blood levels of systemic oxidative stress (dROMs)', 'PrimaryOutcomeDescription': 'dROMs test measures circulating hydroperoxides (UCarr)', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in antioxydant capacity of serum (BAP)', 'PrimaryOutcomeDescription': 'BAP test measures total antioxidant status in serum in micromol/L', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in thiol serum levels (SHp)', 'PrimaryOutcomeDescription': 'SHp test measures the circulating thiolic antioxidants in serum in micromol/L', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change haemoglobin serum levels', 'PrimaryOutcomeDescription': 'serum measurements of haemoglobin g/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in glucose serum levels', 'PrimaryOutcomeDescription': 'serum measurements of glucose in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in albumine serum levels', 'PrimaryOutcomeDescription': 'serum measurements of glucose in g/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in triglycerides serum levels', 'PrimaryOutcomeDescription': 'serum measurements of triglycerides in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in total cholesterol serum levels', 'PrimaryOutcomeDescription': 'serum measurements of total cholesterol in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in HDL cholesterol serum levels', 'PrimaryOutcomeDescription': 'serum measurements of HDL cholesterol in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in calcium serum levels', 'PrimaryOutcomeDescription': 'serum measurements of calcium in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in magnesium serum levels', 'PrimaryOutcomeDescription': 'serum measurements of magnesium in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in creatinin serum levels', 'PrimaryOutcomeDescription': 'serum measurements of creatinin in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in iron serum levels', 'PrimaryOutcomeDescription': 'serum measurements of iron in microg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in latent iron binding capacity serum levels', 'PrimaryOutcomeDescription': 'serum measurements of latent iron binding capacity in microg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in hepatic status serum levels (ALT-GPT)', 'PrimaryOutcomeDescription': 'serum measurements o ALT-GPT in U/L', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nstroke patients (hemorrhagic or ischemic) documented through Magnetic Resonance Imaging (MRI) or Computed Tomography (CT);\\nage between 18 and 85 years;\\nlatency time within 6 months after the stroke event\\nsufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent\\n\\nExclusion Criteria:\\n\\npresence of a previous stroke based on the medical history;\\nbehavioral and cognitive disorders that may interfere with the therapeutic activity;\\nother orthopedic or neurological complications that may interfere with the rehabilitation protocol;\\ninability to understand and sign informed consent;\\npresence of pacemakers (for interference with bioimpedance measures).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with first ischemic stroke (of ischemic or hemorrhagic aetiology) in subacute phase (within six months after the acute event), hospitalized at the participating intensive-extensive rehabilitation centers will be included.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Irene APRILE, MD,PHD', 'OverallOfficialAffiliation': 'IRCCS Fondazione Don Carlo Gnocchi', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Don Gnocchi Foundation', 'LocationCity': 'Rome', 'LocationZip': '00168', 'LocationCountry': 'Italy'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27642056', 'ReferenceType': 'background', 'ReferenceCitation': 'Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, Jensen GL, Malone A, Muscaritoli M, Nyulasi I, Pirlich M, Rothenberg E, Schindler K, Schneider SM, de van der Schueren MA, Sieber C, Valentini L, Yu JC, Van Gossum A, Singer P. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017 Feb;36(1):49-64. doi: 10.1016/j.clnu.2016.09.004. Epub 2016 Sep 14.'}, {'ReferencePMID': '30181091', 'ReferenceType': 'background', 'ReferenceCitation': 'Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002. Epub 2018 Sep 3.'}, {'ReferencePMID': '20392703', 'ReferenceType': 'background', 'ReferenceCitation': 'Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.'}, {'ReferencePMID': '14724060', 'ReferenceType': 'background', 'ReferenceCitation': 'Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, Vecchiet L, Fano G. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol. 2004 Jan;39(1):17-24. doi: 10.1016/j.exger.2003.09.012.'}, {'ReferencePMID': '23483531', 'ReferenceType': 'background', 'ReferenceCitation': 'Knops M, Werner CG, Scherbakov N, Fiebach J, Dreier JP, Meisel A, Heuschmann PU, Jungehulsing GJ, von Haehling S, Dirnagl U, Anker SD, Doehner W. Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS). J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):199-207. doi: 10.1007/s13539-013-0103-0. Epub 2013 Mar 13.'}, {'ReferencePMID': '30652217', 'ReferenceType': 'background', 'ReferenceCitation': 'Lelli D, Perez Bazan LM, Calle Egusquiza A, Onder G, Morandi A, Ortolani E, Mesas Cervilla M, Pedone C, Inzitari M. 25(OH) vitamin D and functional outcomes in older adults admitted to rehabilitation units: the safari study. Osteoporos Int. 2019 Apr;30(4):887-895. doi: 10.1007/s00198-019-04845-7. Epub 2019 Jan 16.'}, {'ReferencePMID': '25676847', 'ReferenceType': 'background', 'ReferenceCitation': 'Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10.'}, {'ReferencePMID': '29899723', 'ReferenceType': 'background', 'ReferenceCitation': 'Squitti R, Siotto M, Assenza G, Giannantoni NM, Rongioletti M, Zappasodi F, Tecchio F. Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study. Front Neurol. 2018 May 30;9:333. doi: 10.3389/fneur.2018.00333. eCollection 2018.'}, {'ReferencePMID': '31591820', 'ReferenceType': 'background', 'ReferenceCitation': 'Matsushita T, Nishioka S, Taguchi S, Yamanouchi A. Sarcopenia as a predictor of activities of daily living capability in stroke patients undergoing rehabilitation. Geriatr Gerontol Int. 2019 Nov;19(11):1124-1128. doi: 10.1111/ggi.13780. Epub 2019 Oct 7.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Siotto, M., Germanotta, M., Santoro, M., Di Blasi, C., Loreti, C., Mastropaolo, S. & Aprile, I.,Total serum calcium and recovery after rehabilitation in patients with stroke Nov 1 2020, In : Applied Sciences (Switzerland). 10, 21, p. 1-8 8 p., 7893.'}, {'ReferencePMID': '33182716', 'ReferenceType': 'background', 'ReferenceCitation': 'Santoro M, Siotto M, Germanotta M, Bray E, Mastrorosa A, Galli C, Papadopoulou D, Aprile I. BDNF rs6265 Polymorphism and Its Methylation in Patients with Stroke Undergoing Rehabilitation. Int J Mol Sci. 2020 Nov 10;21(22):8438. doi: 10.3390/ijms21228438.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 8, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05477732', 'OrgStudyIdInfo': {'OrgStudyId': 'N202011038'}, 'Organization': {'OrgFullName': 'Taipei Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Bifidobacterium Longum OLP-01 Supplement on Cognitive Function, Exercise Performance, Nutritional Status and Gut Microbiota in Stroke Patients', 'OfficialTitle': 'Effects of Bifidobacterium Longum OLP-01 Supplement on Cognitive Function, Exercise Performance, Nutritional Status and Gut Microbiota in Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 12, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 11, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 11, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 18, 2022', 'StudyFirstSubmitQCDate': 'July 25, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 28, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 25, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 28, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Taipei Medical University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a syndrome of acute, focal neurological deficit attributed to vascular injury of the central nervous system. It was the 2nd leading cause of death worldwide and accompanied by high disability rate also increases the social burden.Our research is to investigate the effects of intervention with Bifidobacterium longum OLP-01 on cognitive function, exercise performance, nutritional status and gut microbiota in stroke patients.\\n\\nStudy population:\\n\\nWe will recruit 120 stroke patients and the inclusion criteria are: (1) Aged 20-75 years old, (2) Diagnosed with stroke more than 3 months, (3) Undergoing outpatient rehabilitation and the condition is stable. The exclusion criteria are: (1) Aphasia, dementia or depression, (2) BMI ≥ 35 kg/m2, (3) Cancer treatment in 3 months, (4) Some severe disease may interfere patients to join the study, (5) Failed to cooperate the examination and treatment because of emotion or mental condition.\\n\\nStudy design:\\n\\nA two-arm single-blind randomized controlled clinical trial will be performed for 12 weeks and the subjects will be divided in to 2 groups: (1) placebo group, (2) supplement group. Subjects were asked to supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day or placebo for 12 weeks. Medical history, drug use and life style questionnaires were giving before intervention. Outcomes will be assess in week 0 and week 12 during intervention.\\n\\n3. Outcome assessment:\\n\\nAnthropometry data: height, weight, body mass index, waist circumference, mid-upper arm circumference, hip circumference, calf circumference, waist to hip ratio.\\nBody composition: muscle mass, body fat, basal metabolic rate.\\nClinical data: blood pressure, stroke related characteristics.\\n\\nBlood biochemistry:\\n\\nA. Nutritional status: albumin, prealbumin, transferrin.\\n\\nB. Glycemic profiles: fasting blood glucose, glycated hemoglobin A1c (HbA1c).\\n\\nC. Lipid profiles: total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG).\\n\\nD. Complete blood counts: white blood cells (WBC), red blood cells (RBC), hemoglobin (HB), platelet count (PLT), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC).\\n\\nE. WBC differential counts: neutrophils (NEUT), lymphocytes (LYM), monocytes (MONO), eosinophils (EOS), basophils (BASO).\\n\\nF. C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor alpha (TNF-α).\\n\\nGut microbiota: relative abundance, α-diversity, β-diversity.\\nNutritional status: 3-day dietary record, mini-nutritional assessment (MNA).\\nCognitive function: Montreal cognitive assessment (MoCA), trail-making test A and B (TMT A and B), Stroop color naming test.\\nExercise performance: timed up and go test (TUGT), 6-min walking test.\\n\\nThe purpose of the study is to investigate the intervention of Bifidobacterium longum OLP-01 supplement on cognitive function, physiological performance, nutritional status, and gut microbiota in stroke patients.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Bifidobacterium longum OLP-01', 'Stroke', 'Cognitive function', 'Exercise performance', 'Nutritional status', 'Gut microbiota']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo group', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Subjects in placebo group will treat with placebo.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}}, {'ArmGroupLabel': 'Supplement group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects in supplement group will treat with Bifidobacterium longum OLP-01.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Bifidobacterium longum OLP-01']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Bifidobacterium longum OLP-01', 'InterventionDescription': 'Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Supplement group']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo', 'InterventionDescription': 'Subjects in placebo group will supplement with placebo powder per day for 12 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montreal cognitive assessment (MoCA)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Montreal cognitive assessment (MoCA)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Montreal cognitive assessment (MoCA) (change)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Trail-making test A and B (TMT A and B)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Trail-making test A and B (TMT A and B)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Trail-making test A and B (TMT A and B) (change)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Stroop color naming test', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Stroop color naming test', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Stroop color naming test (change)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Timed up and go test (TUGT)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Timed up and go test (TUGT)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Timed up and go test (TUGT) (change)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': '6-min walking test', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': '6-min walking test', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': '6-min walking test (change)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Albumin (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Pre-albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Pre-albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Pre-albumin (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Transferrin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Transferrin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Transferrin (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': '3-day dietary record', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': '3-day dietary record', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': '3-day dietary record (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Mini-nutritional assessment (MNA)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Mini-nutritional assessment (MNA)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Mini-nutritional assessment (MNA) (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Relative abundance', 'PrimaryOutcomeDescription': 'Gut microbiota Use the 16s RNA sequencing to conduct the next generation sequencing (NGS) measure the relative abundance, including the phylum, class, family, genus.', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Relative abundance', 'PrimaryOutcomeDescription': 'Gut microbiota Use the 16s RNA sequencing to conduct the next generation sequencing (NGS) measure the relative abundance, including the phylum, class, family, genus.', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'α-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'α-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'β-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'β-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Height', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Height', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Height (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Weight', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Weight', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Weight (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Body mass index (BMI)', 'SecondaryOutcomeDescription': 'Anthropometry data Weight and height will be combined to report BMI in kg/m^2', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Body mass index (BMI)', 'SecondaryOutcomeDescription': 'Anthropometry data Weight and height will be combined to report BMI in kg/m^2', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Body mass index (BMI) (change)', 'SecondaryOutcomeDescription': 'Anthropometry data Weight and height will be combined to report BMI in kg/m^2', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Waist circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Waist circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Waist circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mid-upper arm circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mid-upper arm circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mid-upper arm circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Hip circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Hip circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Hip circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Calf circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Calf circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Calf circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Waist to hip ratio', 'SecondaryOutcomeDescription': 'Anthropometry data Waist circumference and hip circumference will be combined to report waist to hip ratio', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Waist to hip ratio', 'SecondaryOutcomeDescription': 'Anthropometry data Waist circumference and hip circumference will be combined to report waist to hip ratio', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Waist to hip ratio (change)', 'SecondaryOutcomeDescription': 'Anthropometry data Waist circumference and hip circumference will be combined to report waist to hip ratio', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Muscle mass', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Muscle mass', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Muscle mass (change)', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Body fat', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Body fat', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Body fat (change)', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Basal metabolic rate', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Basal metabolic rate', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Basal metabolic rate (change)', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Blood pressure', 'SecondaryOutcomeDescription': 'Clinical data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Blood pressure', 'SecondaryOutcomeDescription': 'Clinical data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Blood pressure (change)', 'SecondaryOutcomeDescription': 'Clinical data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Stroke related characteristics (including the time since stroke diagnosed, side of lesion, stroke type, use of aid)', 'SecondaryOutcomeDescription': 'Stroke related characteristics would collect form clinical data or ask form subjects directly', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Stroke related characteristics (including the time since stroke diagnosed, side of lesion, stroke type, use of aid)', 'SecondaryOutcomeDescription': 'Stroke related characteristics would collect form clinical data or ask form subjects directly', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Medical history, drug use and life style questionnaires', 'SecondaryOutcomeDescription': 'Clinical data This questionnaires including 3 parts (medical history, drug use and life style). Medical history and drug use will write by subjects. Life style (e.g. smocking habit, exercise frequency) will ask the subjects.', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Medical history, drug use and life style questionnaires', 'SecondaryOutcomeDescription': 'Clinical data This questionnaires including 3 parts (medical history, drug use and life style). Medical history and drug use will write by subjects. Life style (e.g. smocking habit, exercise frequency) will ask the subjects.', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Fasting blood glucose', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Fasting blood glucose', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Fasting blood glucose (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Glycated hemoglobin A1c (HbA1c)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Glycated hemoglobin A1c (HbA1c)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Glycated hemoglobin A1c (HbA1c) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Total cholesterol (TC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Total cholesterol (TC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Total cholesterol (TC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'High density lipoprotein cholesterol (HDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'High density lipoprotein cholesterol (HDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'High density lipoprotein cholesterol (HDL-C) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Low density lipoprotein cholesterol (LDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Low density lipoprotein cholesterol (LDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Low density lipoprotein cholesterol (LDL-C) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Triglycerides (TG)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Triglycerides (TG)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Triglycerides (TG) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'White blood cells (WBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'White blood cells (WBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'White blood cells (WBC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Red blood cells (RBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Red blood cells (RBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Red blood cells (RBC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Hemoglobin (HB)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Hemoglobin (HB)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Hemoglobin (HB) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Platelet count (PLT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Platelet count (PLT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Platelet count (PLT) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Hematocrit (HCT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Hematocrit (HCT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Hematocrit (HCT) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular volume (MCV)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular volume (MCV)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular volume (MCV) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin (MCH)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin (MCH)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin (MCH) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin concentration (MCHC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin concentration (MCHC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin concentration (MCHC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Neutrophils (NEUT)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Neutrophils (NEUT)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Neutrophils (NEUT)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Lymphocytes (LYM)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Lymphocytes (LYM)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Lymphocytes (LYM)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Monocytes (MONO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Monocytes (MONO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Monocytes (MONO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Eosinophils (EOS)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Eosinophils (EOS)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Eosinophils (EOS)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Basophils (BASO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Basophils (BASO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Basophils (BASO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α)', 'SecondaryOutcomeDescription': 'Blood biochemistry (cytokines)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α)', 'SecondaryOutcomeDescription': 'Blood biochemistry (cytokines)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry (cytokines)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'C-reactive protein (CRP)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'C-reactive protein (CRP)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'C-reactive protein (CRP) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\\n\\nAged 20-75 years old\\nDiagnosed with stroke more than 3 months\\nUndergoing outpatient rehabilitation and the condition is stable\\n\\nExclusion criteria\\n\\nAphasia, dementia or depression\\nBMI ≥ 35 kg/m2\\nCancer treatment in 3 months\\nSome severe disease may interfere patients to join the study\\nFailed to cooperate the examination and treatment because of emotion or mental condition.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '25 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Chao Jane C-J, PhD', 'OverallOfficialAffiliation': 'Taipei Medical University, Taiwan, R.O.C.', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of rehabilitation, ShuangHo Hospital', 'LocationCity': 'New Taipei City', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Department of rehabilitation, Taipei Medical University Hospital', 'LocationCity': 'Taipei city', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Department of rehabilitation, WanFang Hospital', 'LocationCity': 'Taipei city', 'LocationCountry': 'Taiwan'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M15891', 'InterventionBrowseLeafName': 'Sulfalene', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T367', 'InterventionBrowseLeafName': 'Bifidobacterium', 'InterventionBrowseLeafAsFound': 'Cap', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}]}}}}}, {'Rank': 9, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02856009', 'OrgStudyIdInfo': {'OrgStudyId': 'Béjot 2015'}, 'Organization': {'OrgFullName': 'Centre Hospitalier Universitaire Dijon', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Role of Nutrition in Patients Over 75 Years of Age With Stroke', 'OfficialTitle': 'Impact of Nutritional Status and Frailty on the Prognosis of Patients Over 75 Years Old Who Suffered a Stroke', 'Acronym': 'INFRA'}, 'StatusModule': {'StatusVerifiedDate': 'July 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 2, 2016', 'StudyFirstSubmitQCDate': 'August 3, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 4, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 9, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 10, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Centre Hospitalier Universitaire Dijon', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Stroke in elderly subjects has a more severe clinical presentation (in terms of frequency of aphasia, hemiplegia or consciousness disorders), and a worse functional and vital prognosis. Patients older than 75 years also show excess mortality. One of the hypotheses to explain this situation is the high level of frailty in this population. Many tools to measure the concept of frailty have been developed. One important dimension of these tools is the nutritional status. Indeed, protein-energy malnutrition in the elderly, though a frequent situation, is also a complex phenomenon.\\n\\nThe aim of this study is therefore to analyse the impact of protein-energy malnutrition, as a marker of frailty, on the early prognosis (at 28 days) in the aftermath of stroke in subjects older than 75 years hospitalized in Dijon CHU.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '177', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patient', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: completion of a quality of life questionnaire']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'completion of a quality of life questionnaire', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patient']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Mortality rate', 'PrimaryOutcomeTimeFrame': 'Day 28'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with symptomatic stroke defined according to WHO criteria (including cerebral infarction and intracerebral haemorrhage) managed at the stroke ICU, Neurology 1, Neurology 2, Internal Medicine 2 or Geriatrics at Dijon CHU during the period from 1st November 2015 to 30th September 2016.\\nPatients aged 75 years and older.\\nPatients who have provided informed consent to take part in the study.\\n\\nExclusion Criteria:\\n\\nPatients with meningeal haemorrhage or TIA.\\nPatients who refuse to take part in the study.\\nPatients with hypo-albuminemia not related to malnutrition: chronic infectious or inflammatory syndrome, nephrotic syndrome, exudative enteropathy, hydration disorders.\\nSubjects in custody.\\nPatients (or person of trust) who cannot be contacted by telephone during the follow-up.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '75 Years', 'StdAgeList': {'StdAge': ['Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Centre Hospitalier Universitaire', 'LocationCity': 'Dijon', 'LocationZip': '21079', 'LocationCountry': 'France'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M1175', 'ConditionBrowseLeafName': 'Frailty', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 10, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01721538', 'OrgStudyIdInfo': {'OrgStudyId': 'SCENARIO OP1'}, 'Organization': {'OrgFullName': 'Philipps University Marburg Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction', 'OfficialTitle': 'Secondary Prevention of Stroke Through Participation in the Non-drug Therapeutic Weight Reduction Program: A Single-blinded Randomized Controlled Multicenter Trial', 'Acronym': 'SCENARIO'}, 'StatusModule': {'StatusVerifiedDate': 'November 2012', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2015', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 2015', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 1, 2012', 'StudyFirstSubmitQCDate': 'November 2, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 4, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 2, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 4, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Yaroslav Winter', 'ResponsiblePartyInvestigatorTitle': 'Neurologist and Research Fellow', 'ResponsiblePartyInvestigatorAffiliation': 'Philipps University Marburg Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Philipps University Marburg Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Von Behring-Röntgen Foundation', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms. The therapy arm is participating in a comprehensive weight reducing program, whereas the control group takes part in a lecture on healthy nutrition. The primary study objective is to assess the efficacy of non-drug therapeutic weight reduction in the secondary prevention of stroke. Secondary objectives are functional outcome, cognitive status, post stroke depression, and health-related quality of life.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Obesity']}, 'KeywordList': {'Keyword': ['stroke', 'prevention', 'obesity', 'weight reduction']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Therapy arm', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Non-drug therapeutic weight reduction program (15 weeks)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Weight reduction program']}}, {'ArmGroupLabel': 'Control arm', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Lecture on healthy nutrition (1 hour)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Lecture on healthy nutrition']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Weight reduction program', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Therapy arm']}}, {'InterventionType': 'Other', 'InterventionName': 'Lecture on healthy nutrition', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The primary endpoint is the number of deaths or major vascular events defined as stroke, TIA, myocardial infarction or hospitalization due to angina pectoris, which occur between the randomization and last follow-up.', 'PrimaryOutcomeTimeFrame': '18 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Functional outcome', 'SecondaryOutcomeDescription': 'Functional outcome as measured by the modified Rankin Scale (mRS), NIH Stroke Scale (NIHSS) and Barthel Index (BI)', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': 'Cognitive deficits', 'SecondaryOutcomeDescription': 'Cognitive deficits in terms of vascular dementia as measured by the Structural Interview for diagnosis of Alzheimer dementia and multi-infarct dementia (SIDAM), the Vascular Dementia Assessment Scale cognitive subscale (VADAS-Cog), Stroop test and the Trail Makin Test', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': 'Post stroke depression', 'SecondaryOutcomeDescription': 'Post stroke depression as measured by Beck Depression Inventar (BDI II) and health-related quality of life (HrQoL) as measured by the EuroQol (EQ5D, visual analogue scale), Stroke Specific Quality of Life Scale, Stroke Impact Scale.', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': 'Severity of arterial hypertension, diabetes mellitus and hyperlipidemia', 'SecondaryOutcomeTimeFrame': '18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDiagnosis of ischemic stroke\\nAge: 20 - 85 years\\nBMI ≥ 25.0 kg/m² or waist circumference in men ≥ 94cm and in women ≥ 80cm\\nFunctional impairment, which would allow to participate in weight reduction program (mRS 0-4, NIHSS 0-12)\\nPatient must be capable of understanding informed consent\\nWritten informed consent for participation in the study\\n\\nExclusion Criteria:\\n\\nIntracerebral hemorrhage as primary cause of stroke (secondary hemorrhage is not an exclusion criterion)\\nSpeech disturbance (aphasia or sever dysarthria)\\nDimming of consciousness\\nStroke due to arterial dissection or coagulation disorder\\nDrug-related weight changes during previous 3 months\\nChanges in appetite influencing medication listed in appendix during previous 3 months\\nBariatric surgery in the past\\nDiabetes mellitus with a history of severe ketoacidosis\\nPregnancy or nursing\\n\\nSevere co-morbid disorders, e.g.:\\n\\nAV-Block ≥ 2nd degree\\nHeart insufficiency (NYHA > 2)\\nPericarditis, pericardial effusion\\nSevere kidney insufficiency (Creatinine > 3 mg/dl; Urea > 150 mg/dl)\\nHepatic insufficiency (GOT > 3 x ULN; GPT > 3 x ULN)\\nSevere psychiatric disease within the last six months (psychosis, suicide attempts)\\nChronic alcohol addiction or drug addiction\\nHIV- or hepatitis infection\\nBleeding peptic ulcer (unless there is radiological evidence of healing 6 months prior to start of obesity program)\\nCognitive impairment with MMSE < 20\\nDepression with BDI > 20\\nPatients who are unable to give consent to study participation (MMSE < 20, aphasia)\\nRecurrent stroke or myocardial infarction in the period between screening for study participation and start of weight reduction program\\nSimultaneous participation in another clinical trial', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Yaroslav Winter, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '00496421-5865200', 'CentralContactEMail': 'wintery@med.uni-marburg.de'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Neurology, Philipps-University Marburg', 'LocationStatus': 'Recruiting', 'LocationCity': 'Marburg', 'LocationCountry': 'Germany', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Winter Yaroslav, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '004964215865200', 'LocationContactEMail': 'wintery@med.uni-marburg.de'}, {'LocationContactName': 'Yaroslav Winter, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18703800', 'ReferenceType': 'background', 'ReferenceCitation': 'Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J, Back T. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke. 2008 Dec;39(12):3145-51. doi: 10.1161/STROKEAHA.108.523001. Epub 2008 Aug 14.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000015431', 'ConditionMeshTerm': 'Weight Loss'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}, {'ConditionAncestorId': 'D000001836', 'ConditionAncestorTerm': 'Body Weight Changes'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17792', 'ConditionBrowseLeafName': 'Weight Loss', 'ConditionBrowseLeafAsFound': 'Weight Reduction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11997', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4805', 'ConditionBrowseLeafName': 'Body Weight Changes', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}]}}}}}, {'Rank': 11, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04259307', 'OrgStudyIdInfo': {'OrgStudyId': '2019-06-109'}, 'Organization': {'OrgFullName': 'Samsung Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Intensive Nutritional Support in Subacute Stroke Patient', 'OfficialTitle': 'Effect of Intensive Nutritional Support on Functional Recovery in Subacute Stroke Patient'}, 'StatusModule': {'StatusVerifiedDate': 'May 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 29, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 31, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 4, 2020', 'StudyFirstSubmitQCDate': 'February 4, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 5, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Won Hyuk Chang', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Samsung Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Samsung Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Korean Center for Disease Control and Prevention', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Proper nutritional support during early rehabilitation may be beneficial for functional improvements in gaining functional independence and preventing complications in stroke patients. However, there was no consensus of proper amount of nutritional support in stroke patients. In this study, the investigators aimed to clarigy the effects of the intensive nutritional support during comprehensive rehabilitation during subacute phase to improve function in patients with first-ever strokes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Rehabilitation', 'Nutrition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intensive nutrition group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omapone Peri 724mL or Winuf Peri 654mL']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Standard nutritional support only per day for 3 weeks'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Omapone Peri 724mL or Winuf Peri 654mL', 'InterventionDescription': 'Additional intravenous nutrition of 500 kcal per day for 3 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intensive nutrition group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Comprehensive rehabilitation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Korean modified Barthel Index (K-MBI) at 6 months after onset', 'PrimaryOutcomeDescription': 'Korean modified Barthel Index (0~100)', 'PrimaryOutcomeTimeFrame': '6 months after onset'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAcute first-ever stroke patients less than 7 days after onset\\n\\nmore than 19 years old at stroke onset ③ stroke confirmed by brain CT or MRI\\n\\nbody mass index (BMI) <25 before the comprehensive rehabilitation ⑤ Mini Nutritional Assessment < 12 before the comprehensive rehabilitation ⑥ Fugl-Meyer assessment < 85 at 7 days after stroke onset\\n\\nExclusion Criteria:\\n\\nTransient ischemic stroke\\n\\nProgressive or unstable stroke\\n\\nPre-existing and active major neurological disease, e.g., spinal cord injury, Parkinson's disease, et al.\\n\\nPre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease or dementia ⑤ Advanced liver, kidney, cardiac, or pulmonary disease, e.g., advanced hepatocellular carcinoma, end-stage renal failure, et al.)\\n\\nA terminal medical diagnosis consistent with survival < 1 year\\n\\nDiabetes mellitus, Hyperlipidemia, Metabolic syndrome, Heart failure) ⑧ Pregnant or lactating women ⑨ Prohibited from taking medication (Omapone Peri 724mL or Winuf Peri 654mL)\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '19 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Won Hyuk Chang, MD.,PhD.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '82-2-3410-6068', 'CentralContactEMail': 'wh.chang@samsung.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Samsung Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Seoul', 'LocationZip': '135-710', 'LocationCountry': 'Korea, Republic of', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Won Hyuk Chang, Prof', 'LocationContactRole': 'Contact', 'LocationContactPhone': '82-2-3410-6068', 'LocationContactEMail': 'wh.chang@samsung.com'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 12, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01858311', 'OrgStudyIdInfo': {'OrgStudyId': '2012H0113'}, 'Organization': {'OrgFullName': 'Ohio State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutrition Blood Outcomes Following Tocotrienol N2B', 'OfficialTitle': 'Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB', 'Acronym': 'NIIB'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 9, 2013', 'StudyFirstSubmitQCDate': 'May 20, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 21, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 13, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 20, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Andrew Slivka', 'ResponsiblePartyInvestigatorTitle': 'MD, Professor of Neurology', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'}, 'LeadSponsor': {'LeadSponsorName': 'Ohio State University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Malaysia Palm Oil Board', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol lowering properties, both of which may benefit stroke survivors. This study is being conducted to determine the blood thinning and cholesterol lowering properties of TCT in stroke or TIA (transient ischemic attack, which is also referred to as a \"mini-stroke\") survivors that are receiving the standard treatment for prevention of recurrent stroke.\\n\\nStudy Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders, increases the extent of inhibition of platelet aggregation, and decreases LDL without significant side effects in stroke patients.', 'DetailedDescription': 'In this Phase IIB trial the goal is to determine the effects of orally supplemented TCT on platelet function and cholesterol as well as the safety in patients with TIA (transient ischemic attack) or stroke in addition to the standard treatment for stroke prevention. Recurrent cardiovascular events including stroke, TIA, heart attack, venous thrombosis, pulmonary embolism, systemic embolism will also be recorded. In patients with recurrent stroke, severity of the stroke and stroke size measured from MR (magnetic resonance) or CT (computed tomography) imaging will also be collected. We expect that TCT will inhibit blood clotting and lower cholesterol more than current standard treatment without significantly increasing bleeding risks or other side effects. Future work is planned in a larger TIA/stroke population to examine whether TCT adds to standard medical care in terms of decreasing incidence of stroke and improving outcomes following stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Stroke survivors', 'TIA survivors', 'Vitamin E', 'Carotech', 'Tocotrienol']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Blood Draw'}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo vehicle', 'ArmGroupDescription': '(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo Vehicle']}}, {'ArmGroupLabel': 'Tocotrienol capsules (400 mg)', 'ArmGroupDescription': '(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Tocotrienol Capsules']}}, {'ArmGroupLabel': 'Tocotrienol Capsules (800 mg)', 'ArmGroupDescription': '(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Tocotrienol Capsules']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Tocotrienol Capsules', 'InterventionDescription': 'Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Tocotrienol Capsules (800 mg)', 'Tocotrienol capsules (400 mg)']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo Vehicle', 'InterventionDescription': 'Placebo capsules per day (2 in the morning and 2 in the evening)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo vehicle']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'platelet aggregation activity', 'PrimaryOutcomeDescription': 'Platelet aggregation activity will be measured using standard clinical laboratory procedures', 'PrimaryOutcomeTimeFrame': 'up to 1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Incidence of recurrent stroke', 'SecondaryOutcomeDescription': 'Incidence of recurrent stroke after previous diagnosed stroke or TIA.', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA (transient ischemic attack) for whom anticoagulation is not indicated\\nEnrollment in trial must occur within 6 months of clinical presentation for first stroke or TIA event\\nNo history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation at least 6mos; within the past 5 years)\\nNo current vitamin E supplementation in multi-vitamin\\n\\nExclusion Criteria:\\n\\nDisabling stroke ( Modified Rankin Scale > 3)\\nPrior intracranial hemorrhage (excluding traumatic)\\nHigh risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active peptic ulcer disease)\\nAnticipated requirement for long term use of anticoagulation\\nContraindications to antiplatelet agents (bleeding disorder, thrombocytopenia, prolonged INR)\\nIrreversible medical condition likely to affect short-term survival or ability to participate in study such as cancer or other chronic disease with predicted survival of less than a year or severe psychiatric or neurologic disease that might complicate evaluation of study outcomes like dementia or schizophrenia\\nPregnancy or women of child bearing age who are not following an effective method of contraception\\nBreast feeding\\nUnable or unwilling to provide informed\\nUnlikely to be compliant with therapy or unwilling to return for follow up frequent clinic visits\\nConcurrent participation in another study with an investigational drug or devise\\nOther likely specific cause of stroke such as dissection, infectious or noninfectious vasculitis, prothrombotic state', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Stroke survivors within 6 months of clinical presentation for ischemic stroke or TIA event', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'The Ohio State University', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mount Carmel Health System', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43213', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000024508', 'InterventionMeshTerm': 'Tocotrienols'}, {'InterventionMeshId': 'D000014810', 'InterventionMeshTerm': 'Vitamin E'}, {'InterventionMeshId': 'D000024505', 'InterventionMeshTerm': 'Tocopherols'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000975', 'InterventionAncestorTerm': 'Antioxidants'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000020011', 'InterventionAncestorTerm': 'Protective Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000014815', 'InterventionAncestorTerm': 'Vitamins'}, {'InterventionAncestorId': 'D000018977', 'InterventionAncestorTerm': 'Micronutrients'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M17243', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22662', 'InterventionBrowseLeafName': 'Tocopherols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M22665', 'InterventionBrowseLeafName': 'Tocotrienols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22659', 'InterventionBrowseLeafName': 'alpha-Tocopherol', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21559', 'InterventionBrowseLeafName': 'Protective Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16575', 'InterventionBrowseLeafName': 'Trace Elements', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20699', 'InterventionBrowseLeafName': 'Micronutrients', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T480', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T466', 'InterventionBrowseLeafName': 'Tocopherol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T467', 'InterventionBrowseLeafName': 'Tocotrienol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}]}}}}}, {'Rank': 13, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03844139', 'OrgStudyIdInfo': {'OrgStudyId': 'zhang yuejiao'}, 'Organization': {'OrgFullName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect and Complication of Two Types of Nasogastric Tube Feeding for Elderly Dysphagia Patient After Stroke', 'OfficialTitle': 'Observation of Effect and Complication of Two Types of Nasogastric Tube Feeding Enteral Nutrition for Elderly Dysphagia Patients After Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 13, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 1, 2019', 'StudyFirstSubmitQCDate': 'February 13, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 18, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 11, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 13, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Dysphagia is a common problem after stroke.Patients after stroke with swallow problem will have a nasogastric tube to be feeded. In this study , investigators have including and excluding criteria. Continous feeding group and intermittent feeding group had been widely used in enteral nutrition feeding in investigators' institution. Investigators will observe participants' nutrition condition and tube-feeding related complications. In continous group patients, participants usually are given prescribed enteral nutrient solution using nutrition pump in 24 hours; while in intermittent feeding group, participants will be given prescribed enteral nutrient solution in 4-5 times by special syringe. During the whole process, investigators will observe all participants' nutrition condition (body mass index, plasma albumin and calf girth) and tube-feeding related complications( regurgitation, aspiration,gastric retention, diarrhea,constipation). With all those data, the investigators will assess which feeding type is better.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Deglutition Disorders']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '100', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Feeding pump group(continous)', 'ArmGroupDescription': 'Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Feeding pump and glycerin syringe']}}, {'ArmGroupLabel': 'Glycerin syringe group(intermittent)', 'ArmGroupDescription': 'Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Feeding pump and glycerin syringe']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Feeding pump and glycerin syringe', 'InterventionDescription': 'The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Feeding pump group(continous)', 'Glycerin syringe group(intermittent)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'weight', 'PrimaryOutcomeDescription': 'weight in kilogram every week', 'PrimaryOutcomeTimeFrame': '4-6 weeks'}, {'PrimaryOutcomeMeasure': 'plasma albumin', 'PrimaryOutcomeDescription': 'plasma albumin every week', 'PrimaryOutcomeTimeFrame': '4-6 weeks'}, {'PrimaryOutcomeMeasure': 'tube-feeding related complications( regurgitation, aspiration,gastric retention, diarrhea,constipation)', 'PrimaryOutcomeDescription': 'incidence of each complication', 'PrimaryOutcomeTimeFrame': '4-6 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'calf girth', 'SecondaryOutcomeDescription': 'length of calf girth', 'SecondaryOutcomeTimeFrame': '4-6 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nOlder than 65 years old\\nClinical diagnosis of stroke( ischemic and hemorrhage)\\nWith moderate and/or sever swallow problem(water swallow test IV-V degree)\\nWith nasogastric feeding tube more than 4 weeks\\nDo rehabilitation in our hospital or designated hospitals\\n\\nExclusion Criteria:\\n\\nWithout nasogastric feeding tube\\nPatients with fever and other infection\\nChronic or acute anoxia\\nPoor obedience\\nQuit treatment or go back home to take rehabilitation\\nCritically ill or died', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '65 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'Every 50 patients in each group', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Zhang Yuejiao, Bachelor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+8613606525359', 'CentralContactEMail': '2507088@zju.edu.cn'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Zhangy Yuejiao', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hangzhou', 'LocationState': 'Zhejiang', 'LocationZip': '310009', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhangy Yuejiao', 'LocationContactRole': 'Contact'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000005990', 'InterventionMeshTerm': 'Glycerol'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000003451', 'InterventionAncestorTerm': 'Cryoprotective Agents'}, {'InterventionAncestorId': 'D000020011', 'InterventionAncestorTerm': 'Protective Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21550', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8786', 'InterventionBrowseLeafName': 'Glycerol', 'InterventionBrowseLeafAsFound': 'Generate', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M21559', 'InterventionBrowseLeafName': 'Protective Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 14, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05728229', 'OrgStudyIdInfo': {'OrgStudyId': '0033318/22'}, 'Organization': {'OrgFullName': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Nutrition on Post Stroke Fatigue', 'OfficialTitle': 'Effetti Della Nutrizione Sulla Fatica Post Stroke', 'Acronym': 'NUTRE-S'}, 'StatusModule': {'StatusVerifiedDate': 'August 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 7, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 4, 2023', 'StudyFirstSubmitQCDate': 'February 4, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 15, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 1, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 2, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'GIOVANNINI SILVIA', 'ResponsiblePartyInvestigatorTitle': 'Principal investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS'}, 'LeadSponsor': {'LeadSponsorName': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Fatigue, which is commonly defined as a feeling of tiredness during or after usual activities, or a feeling of insufficient energy to initiate these activities, is one of the most common secondary conditions among patients presenting with stroke.\\n\\nPost Stroke Fatigue (PSF) is a multidimensional motor-perceptual, emotional, and cognitive experience characterized by a feeling of early exhaustion with tiredness, lack of energy, and difficulty making efforts, which develops during physical or mental activities, and usually does not improve with rest.\\n\\nTo try to counteract fatigue and its effects on daily life activities, in addition to the known pharmacological approach (Modafinil), the use of vitamins and minerals is known to mitigate, among others, the effects of fatigue. Nutrients provide the energy needed to maintain the body\\'s structural and biochemical integrity. Energy is associated with a feeling of well-being, increased stamina and vitality which often translates into the ability to undertake daily physical or cognitive activities and social relationships, as opposed to fatigue.\\n\\nA common feature of fatigue is a \"sense of energy exhaustion\" which can objectively be related to not enough energy. Physical and cognitive tiredness occurs when the continuous demand for energy from the brain and muscles is not met. In humans, dietary macronutrients provide the fuel needed, among other things, to perform physical activity. In fact, mineral salts and vitamins are essential for the production of cellular energy, for the maintenance of brain structures and for allowing the formation of intercellular connections.\\n\\nWhen the intake of vitamins and mineral salts is adequate, their biochemical properties translate into normal physiological functions; a lower intake of mineral salts and vitamins is associated with lethargy and physical and cognitive fatigue. However, few studies have evaluated the effect of vitamin and mineral supplementation for the management of physical and cognitive fatigue.\\n\\nSiderAL® Med is a food for Special Medical Purposes (AFMS), with a complete formulation that contains vitamins, sucrosomial minerals (Iron, Iodine, Magnesium, Zinc and Selenium), copper and algal calcium, with enhanced dosages to meet particular needs nutritional. AFMS are products formulated for the dietary management of patients with proven nutritional needs, for whom modifications to the normal diet are not sufficient.\\n\\nIn some cases, these are subjects with limited, disturbed or altered ability to take, digest, absorb, metabolize or eliminate certain nutrients, in other cases, however, nutritional needs can be determined by specific clinical conditions.\\n\\nOn the basis of scientific evidences, therefore, the aim of the study is to evaluate whether the nutritional supplement with SiderAL® Med improves the symptom of fatigue, motor and cognitive function in patients with stroke outcomes.', 'DetailedDescription': 'Twenty-four patients of both sexes will be recruiteed, evaluated and treated at the Post-Acute Rehabilitation Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome.\\n\\nPatients will be divided into two groups by randomization, as specified later. One group (experimental group, GS), in association with the drug therapy already underway, will take the nutritional supplement with SiderAL® Med 1 sachet per day for 28 consecutive days, while another group will continue its clinical and rehabilitation treatment as per the daily routine (control group, GC).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Fatigue', 'Stroke']}, 'KeywordList': {'Keyword': ['Stroke', 'Fatigue', 'Older Adults', 'Nutrition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Interventional randomized controlled pilot study', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Experimental Group (GS)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'GS patients, in addition to the pharmacological therapy foreseen by the clinical conditions, will take 1 sachet a day of SiderAl® Med, a food for special purposes, for 28 days. GS patients will take the food for special purposes during hospitalization (between T0 and T1) and during the 1 month of returning home (between T1 and T2). During the second month of returning home (between T2 and T3), GS patients will no longer take the food for special purposes.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Supplement with SiderAl® Med']}}, {'ArmGroupLabel': 'Control Group (GC)', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'The patients of the GC, on the other hand, will continue to take the drug as required by their clinical conditions and will not take the SiderAL® Med food for special purposes, but will only be observed and evaluated at the various time-points foreseen by the study.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Supplement with SiderAl® Med', 'InterventionDescription': 'Nutritional supplementation with special purpose food', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Experimental Group (GS)']}, 'InterventionOtherNameList': {'InterventionOtherName': ['SiderAl® Med']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Modified Fatigue Impact Scale (MFIS)', 'PrimaryOutcomeDescription': 'The MFIS is an instrument that provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning. The full-length MFIS consists of 21 items while the abbreviated version has 5 items.\\n\\nThe MFIS is a structured, self-report questionnaire that the patient can generally complete with little or no intervention from an interviewer. However, patients with visual or upper extremity impairments may need to have the MFIS administered as an interview. Interviewers should be trained in basic interviewing skills and in the use of this instrument.\\n\\nThe total score for the MFIS is the sum of the scores for the 21 items. Individual subscale scores for physical, cognitive, and psychosocial functioning can also be generated by calculating the sum of specific sets of items.', 'PrimaryOutcomeTimeFrame': 'Change from Baseline MFIS at 4, 8 and 16 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Fatigue Scale for Motor and Cognitive Function (FSMC)', 'SecondaryOutcomeDescription': \"The FSMC is an assessment of MS-related cognitive and motor fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue). Two subscales (mental and physical fatigue) can be made. Items included in the subscale mental are 1-4-7-8-11-13-15-17-18-20 and items included in the subscale physical are 2-3-5-6-9-10-12-14-16-19.\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline FSMC at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Berg Balance Scale (BBS)', 'SecondaryOutcomeDescription': \"BBS is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete. It does not include the assessment of gait.\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline BBS at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Short Physical Performance Battery (SPPB)', 'SecondaryOutcomeDescription': 'SPPB is an objective measurement instrument of balance, lower extremity strength, and functional capacity in older adults (>65 years of age). Three domains, which include balance, usual or self-selected gait speed, and lower limb strength, are assessed by a three-stage balance test (feet side-by-side, semitandem, and tandem positions), a 3-m or 4-m gait speed test (time spent to walk the course), and a repetitive chair stand test (five times chair sit-to-stand test), respectively. A 0- to 12-point scale is used to score the sum of the three assessments with higher point values corresponding with greater levels of physical function and lower disability, whereas lower point values correspond with lower levels of physical function and higher disability, respectively.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline SPPB at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Motricity Index (MI)', 'SecondaryOutcomeDescription': 'MI can be used to assess the motor impairment in a patient who has had a stroke.\\n\\nTest for each upper limb:\\n\\npincer grip\\nelbow flexion\\nshoulder abduction\\n\\nTest for each lower limb:\\n\\nankle dorsiflexion\\nknee extension\\nhip flexion\\n\\nFor the pincer grip:\\n\\n0 points, no movement 19 points, grip possible but not against gravity 33 points, normal grip\\n\\nFor all other items:\\n\\n0 points, no movement 14 points, Visible movement but not for the entire joint range or against gravity 19 points, movement possible for the entire joint range against gravity but not against resistance 33 points movement performed with normal force\\n\\nEach segment has a total score obtained by adding the value \"1\" to the score of each individual item. The total score then ranges from 1 (no movement) to 100 (normal movement).', 'SecondaryOutcomeTimeFrame': 'Change from Baseline MI at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Timed Up and Go Test (TUG)', 'SecondaryOutcomeDescription': \"TUG measures in seconds the time it takes a subject to rise from a chair, walk a distance of 3 meters, turn, walk back to the chair and sit down.\\n\\nThe performance is rated on a scale of 1 to 5 (where 1 is normal and 5 is severely abnormal) according to the observer's perception of the patient's risk of falling.\\n\\nThe timed part of the test records the mean time (in seconds) from initial getting up to re-seating. Patients are compared with the mean time of adults in their age group, 60 to 69, 70 to 79, and 80 to 99 years of age.\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline TUG at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'HandGrip Test (HGT)', 'SecondaryOutcomeDescription': 'HGT is a test performed with a dynamometer, which goes to assess muscle strength (in kilograms). Starting with the elbow flexed to 90°, the patient must squeeze the dynamometer as hard as they can at one time. Three repeated measurements are taken on each side 20 seconds apart.\\n\\nThe average of the three assessments is used as the final value.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline HGT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Ambulation Index (AI)', 'SecondaryOutcomeDescription': \"AI is a rating scale to assess mobility by evaluating the time and degree of assistance required to walk 8 meters. Scores range from 0 (asymptomatic and fully active) to 10 (bedridden). The patient is asked to walk a marked 8 meters course as quickly and safely as possible. The examiner records the time and type of assistance (e.g., cane, walker, crutches) needed. Although the patient's walking is timed, the time is not used directly but is utilized in conjunction with other factors to rate the patient on an ordinal scale with 11 gradations.\\n\\n0 = Asymptomatic; fully active. 10 = Bedridden\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline AI at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Walking handicap scale (WHS)', 'SecondaryOutcomeDescription': 'WHS is an assessment tool that allows us to evaluate the quality of walking in the home and social environment through a a scale comprising six categories.\\n\\n1 = Physiological walking: walking only as exercise 6 = Unrestricted walking in social settings: independent in all activities, on uneven ground, in crowded places, shows complete independence in public places.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline WHS at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Functional Ambulation Classification (FAC)', 'SecondaryOutcomeDescription': 'FAC is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device.\\n\\nTo use the FAC, an assessor asks the subject various questions and briefly observes their walking ability to provide a rating from 0 to 5.\\n\\nA score of 0 indicates that the patient is a non-functional ambulator (cannot walk); A score of 1, 2 or 3 denotes a dependent ambulator who requires assistance from another person in the form of continuous manual contact (1), continuous or intermittent manual contact (2), or verbal supervision/guarding (3).\\n\\nA score of 4 or 5 describes an independent ambulator who can walk freely on: level surfaces only (4) or any surface (5=maximum score).', 'SecondaryOutcomeTimeFrame': 'Change from Baseline FAC at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': '10 Meter Walk Test (10mWT)', 'SecondaryOutcomeDescription': 'The 10mWT is used to assess walking speed in meters/second (m/s) over a short distance. The total time taken to ambulate 6 meters (m) is recorded to the nearest hundredth of a second. 6 m is then divided by the total time (in seconds) taken to ambulate and recorded in m/s.\\n\\nThe time is measured for the middle 6 m to allow for patient acceleration and deceleration.\\n\\nThe time is started when any part of the leading foot crosses the plane of the 2-m mark.\\n\\nThe time is stopped when any part of the leading foot crosses the plane of the 8-m mark.1 The time to walk the middle 6m, the level of assistance, and type of assistive device and/or bracing used will be documented.\\n\\nIf a patient requires total assistance or is unable to ambulate at all, a score of 0 m/s will be documented.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline 10MWT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Six-minute walk test (6MWT)', 'SecondaryOutcomeDescription': 'The 6MWT is a sub-maximal exercise test used to assess walking endurance and aerobic capacity. Participants will walk around the perimeter of a set circuit for a total of six minutes. The score of the test is the distance a patient walks in 6 minutes (measured in meters and can round to the nearest decimal point).\\n\\nDistance (in meters) covered in six minutes is calculated by multiplying the number of total laps by 12 meters and adding the distance of the partial lap completed at the time the test ended.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline 6MWT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'modified Barthel Index (mBI)', 'SecondaryOutcomeDescription': 'mBI for activities of daily living is meant to be used in the assessment of patient performance (or degree of assistance required) with respect to self-care, sphincter management, transfers and locomotion. The index consist of 10 items (each scored with a number of points) that relate to activities of daily living (ADLs) where the final score is calculated by summing the points awarded to each item. A five-point rating scales for each item to improve sensitivity to detecting change.\\n\\nThe 10 items assessed relate to:\\n\\nHelp needed with feeding;\\nHelp needed with bathing;\\nHelp needed with grooming;\\nHelp needed with dressing;\\nPresence or absence of fecal incontinence;\\nPresence or absence of urinary incontinence;\\nHelp needed with transfers;\\nHelp needed with walking;\\nHelp needed with climbing stairs.\\n\\nInterpretation:\\n\\n91-100 Slight dependency\\n61-90 Moderate dependency\\n21-60 Severe dependency\\n0-20 Total dependency', 'SecondaryOutcomeTimeFrame': 'Change from Baseline mBI at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'EuroQol- 5 Dimension (EQ-5D)', 'SecondaryOutcomeDescription': 'EQ-5D is an instrument which evaluates the generic quality of life. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers given to ED-5D permit to find 243 unique health states or can be converted into EQ- 5D index an utility scores anchored at 0 for death and 1 for perfect health.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline EQ-5D at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Frontal Assessment Battery (FAB)', 'SecondaryOutcomeDescription': 'The FAB is a brief tool that can be used at the bedside or in a clinic setting to assist in discriminating between dementias with a frontal dysexecutive phenotype and Dementia of Alzheimer\"s Type (DAT).\\n\\nThe FAB has validity in distinguishing Fronto-temporal type dementia from DAT in mildly demented patients (MMSE > 24). Total score is from a maximum of 18, higher scores indicating better performance.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline FAB at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Stroop Colour Word Test (SCWT)', 'SecondaryOutcomeDescription': 'The SCWT is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. The subject is asked to read the words in the first task, to name colors in the second and third tasks. It is necessary to mark both any mistakes made but also the time spent on each task. The cut-off for the error interference effect is 4.24, while the cut-off for the time interference effect is 36.92.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline SCWT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Digit Cancellation Test (DCT)', 'SecondaryOutcomeDescription': 'In the DCT the patient is asked to cross out with a pencil, as quickly as possible, all numbers corresponding to those indicated at the top of each matrix. Line A serves as an example. The performance of the subject is counted from line I. Corrections of the barriers are not allowed. The task of the examiner is mark the point at which the subject has exceeded the maximum time of the test, but let the subject let the subject finish his task for each matrix. The maximum time for each matrix is 45 sec- and is considered from the moment the subject finishes the run in. If the subject takes less time than the maximum time, it will be indicated at the end of each matrix. The time cut-off for the test is 23.9.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline DCT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Trial Making Test (TMT)', 'SecondaryOutcomeDescription': 'The TMT measures flexibility of thinking on a visual-motor sequencing task. It consists of two parts, A and B, where 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.).\\n\\nResults for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.\\n\\nTrail A: Average 29 seconds, Deficient > 78 seconds, Rule of Thumb Most in 90 seconds Trail B: Average 75 seconds, Deficient > 273 seconds, Rule of Thumb Most in 3 minutes', 'SecondaryOutcomeTimeFrame': 'Change from Baseline TMT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Dual-Energy X-ray Absorptiometry (DEXA)', 'SecondaryOutcomeDescription': 'DEXA is an instrumental examination based on the principle of differential attenuation of an X-ray beam, at two energy levels, as it passes through tissues. This attenuation is recordable and correlated with the body composition of the subject being examined.\\n\\nThe device uses a coincident X-ray beam with no scattering in the environment. The radiation dose per single examination is minimal (1 mRem). There is therefore no risk to both patient and operator, and it is possible to repeat the examination at short intervals.\\n\\nDEXA allows for:\\n\\na weight and percentage assessment of lean mass and fat mass in different body districts. It is therefore possible to determine the areas of fat accumulation and quantify their weight in grams.\\na selective assessment in the different body districts of the state of bone mineralization.\\n\\nThe examination has a total duration of 30 minutes.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline DEXA at 4, 8 and 16 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAge greater than or equal to 5 years;\\nPatients with ischemic or haemorrhagic stroke outcomes documented through neuroimaging techniques (magnetic resonance or computed tomography);\\nLatency from the acute event between 1 and 6 months;\\nCognitive skills that allow you to carry out simple orders and understand the physiotherapist's instructions [assessed through the Token Test (score ≥ 26.5)];\\nAbility to walk independently or with little assistance;\\nAbility to understand and sign informed consent.\\n\\nExclusion Criteria:\\n\\nVitamin D intake greater than 3000 IU/day;\\nTherapy with Vitamin K antagonists;\\nConditions causing excess electrolytes in the blood;\\nDiagnosis of metabolic mineral storage disorders (eg, hemochromatosis, Wilson);\\nDialysis patients;\\nSystemic, neurological, cardiac pathologies that make walking risky or cause motor deficits;\\nOncological pathologies;\\nProblems of an orthopedic or postural nature;\\nPresence of plantar ulcers;\\nPartial or total amputation of segments of the foot;\\nInability to provide informed consent.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Silvia Giovannini, MD, phD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+390630154382', 'CentralContactEMail': 'silvia.giovannini@policlinicogemelli.it'}, {'CentralContactName': 'Letizia Castelli, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+390630154382', 'CentralContactEMail': 'letizia.castelli@policlinicogemelli.it'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Silvia Giovannini, MD, phD', 'OverallOfficialAffiliation': 'Fondazione Policlinico Universitario A. Gemelli, IRCCS', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fondazione Policlinico Universitario A. Gemelli IRCCS', 'LocationStatus': 'Recruiting', 'LocationCity': 'Roma', 'LocationState': 'RM', 'LocationZip': '00168', 'LocationCountry': 'Italy', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Silvia Giovannini, MD, phD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+390630154382', 'LocationContactEMail': 'silvia.giovannini@policlinicogemelli.it'}, {'LocationContactName': 'Letizia Castelli, MS', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+390630154382', 'LocationContactEMail': 'letizia.castelli@policlinicogemelli.it'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000005221', 'ConditionMeshTerm': 'Fatigue'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8054', 'ConditionBrowseLeafName': 'Fatigue', 'ConditionBrowseLeafAsFound': 'Fatigue', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 15, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00163007', 'OrgStudyIdInfo': {'OrgStudyId': '297'}, 'Organization': {'OrgFullName': 'Ostfold Hospital Trust', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutritional Therapy for Stroke Patients', 'OfficialTitle': 'Nutritional Therapy for Patients With Acute Stroke and With Poor Nutritional Status or at Risk of Poor Nutritional Status'}, 'StatusModule': {'StatusVerifiedDate': 'May 2009', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2008', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2008', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 9, 2005', 'StudyFirstSubmitQCDate': 'September 9, 2005', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 13, 2005', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 8, 2009', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 11, 2009', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'LeadSponsor': {'LeadSponsorName': 'Ostfold Hospital Trust', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Oslo', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Prospective, short-term studies in patients admitted for acute stroke have shown an increased risk of infections, bedsores, impaired functional outcome, slower rate of recovery, poorer rehabilitation potential and higher mortality in patients with a poor nutritional status. In hospitals without routine nutritional assessment and individual nutrition management plans, the risk of patients developing malnutrition may be increased. In this study, patients admitted for acute stroke are randomised into either receiving nutritional therapy derived from estimated individual nutritional intake and nutritional needs, or nutritional therapy based on routine care without routine assessment of nutritional status, intake, or needs. The primary outcome measure is the percentage of patients with weight loss ≥ 5 % at three month follow-up.', 'DetailedDescription': 'Prospective, short-term studies in patients admitted for acute stroke have shown an increased risk of infections, bedsores, impaired functional outcome, slower rate of recovery, poorer rehabilitation potential and higher mortality in patients with a poor nutritional status. Sixteen percent of stroke patients are already malnourished on admission to hospital. The incidence of dysphagia in patients with acute stroke ranges from 30 to 45%. Dysphagia increases the risk of developing poor nutritional status, and new cases of malnutrition develop during the hospital stay, even during the first week. In hospitals without routine nutritional assessment and individual nutrition management plans, the risk of patients developing malnutrition may be increased. In this study patients admitted for acute stroke are randomised into either receiving nutritional therapy derived from estimated individual nutritional intake and nutritional needs, or nutritional therapy based on routine care; without routine assessment of nutritional status, intake or needs. Nutritional therapy: enriched meals, sip-feedings or enteral feedings. Parameters of nutritional status: Weight, BMI, TSF thickness, mid upper arm circumference, body composition, s-albumin and s-transferrin. Estimation of nutritional intake: Daily registration of food and drink intake. Estimating functional status: Hand grip strength, Barthels ADL index and Scandinavian stroke scale. Estimating quality of life: EQ-5D.\\n\\nBefore the inclusion started we decided to use the percentage of patients with weight loss ≥ 5 % at 3 months follow-up as the primary outcome measure because this is correlated better to clinical outcomes as e.g. mortality and comorbidity. Secondary outcome measures were then defined as handgrip strength, quality of life, nutritional status, nutrient intake and length of hospital stay.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Malnutrition', 'Weight Loss', 'Dysphagia']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '125', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Nutritional support'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of patients with weight loss >=5 % at three month follow-up.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of life, handgrip strength and nutritional status at three months. Dietary intake in hospital. Length of hospital stay.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAcute stroke based on clinical symptoms\\n18 years old and above\\n< 7 days since debut of stroke symptoms and either body mass index (BMI) = or < 20\\nWeight loss > 5% in 3-6 months or there has been little or is likely to be no or very little nutritional intake for > 5 days\\n\\nExclusion Criteria:\\n\\nSubarachnoidal bleeding and planned operation\\nSevere dementia\\nReduced consciousness\\nImmobility\\nExpected short-time survival', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Truls Hauge, PhD', 'OverallOfficialAffiliation': 'Ullevaal University Hospital', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ostfold Hospital Trust', 'LocationCity': 'Fredrikstad', 'LocationZip': '1603', 'LocationCountry': 'Norway'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '20955603', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ha L, Hauge T, Iversen PO. Body composition in older acute stroke patients after treatment with individualized, nutritional supplementation while in hospital. BMC Geriatr. 2010 Oct 18;10:75. doi: 10.1186/1471-2318-10-75.'}, {'ReferencePMID': '20176418', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ha L, Hauge T, Spenning AB, Iversen PO. Individual, nutritional support prevents undernutrition, increases muscle strength and improves QoL among elderly at nutritional risk hospitalized for acute stroke: a randomized, controlled trial. Clin Nutr. 2010 Oct;29(5):567-73. doi: 10.1016/j.clnu.2010.01.011. Epub 2010 Feb 21.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}, {'ConditionMeshId': 'D000015431', 'ConditionMeshTerm': 'Weight Loss'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001836', 'ConditionAncestorTerm': 'Body Weight Changes'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17792', 'ConditionBrowseLeafName': 'Weight Loss', 'ConditionBrowseLeafAsFound': 'Weight Loss', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4805', 'ConditionBrowseLeafName': 'Body Weight Changes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 16, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02043574', 'OrgStudyIdInfo': {'OrgStudyId': 'N0944-W'}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Nutrition and Aerobic Exercise in Chronic Stroke', 'OfficialTitle': 'Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke', 'Acronym': 'NEXIS'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 17, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 29, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 6, 2014', 'StudyFirstSubmitQCDate': 'January 21, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 23, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'January 21, 2020', 'ResultsFirstSubmitQCDate': 'January 21, 2020', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'January 31, 2020', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 21, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 31, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'Strokes are very common in the United States and occur more in the elderly. The number of strokes is likely to double in the next 50 years. Many stroke survivors are sedentary and have a poor dietary intake, which results in abnormalities in fuel utilization (eg carbohydrate versus fat). This study will examine the effects of dietary modification and treadmill training on fuel utilization and physical function. We will study skeletal muscle oxidative stress in chronic stroke patients and the ability to employ dietary modification and exercise training to reverse these abnormalities in this ethnically diverse population.', 'DetailedDescription': 'In acute stroke settings, it is known that energy imbalance is associated with poorer rehabilitation and functional outcomes, and importantly, increased risk of institutionalization. However, nutrition and eating habits of chronic stroke rehabilitative care have received very little consideration, especially if the survivor is living in a free living environment. Studies have shown deficiencies in energy and protein intake versus recommendations in chronic stroke survivors. Perry et al. found ~7% of chronic stroke survivors were at moderate and ~5% at high nutritional risk. Although little is known regarding total daily energy expenditure and dietary intake in chronic stroke, energy and macronutrient imbalance may have a profound impact on stroke recovery and risk of development of chronic disease and recurrent stroke by altering substrate oxidation and result in systemic and tissue level oxidative stress. Conversely, cardiovascular disease risk increases with excess calorie and fat intake and two-thirds of stroke survivors are overweight or obese. In obese, non-stroke populations, energy dense, high fat meals are associated with increases in plasma oxidative stress markers. Oxidative stress can lead to mitochondrial damage and abnormal accumulation of metabolite intermediates and lipid accumulation in non-adipose tissues, which can impair heart function, increasing CVD and stroke recurrence risk.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Aerobic Exercise', 'Treadmill Test', 'Sedentary Lifestyle']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Subjects are randomized to either stretching or treadmill training.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '51', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stretching (Control)', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Six months of stretching', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stretching (control)']}}, {'ArmGroupLabel': 'Treadmill Exercise', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Six months of treadmill training', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Treadmill Exercise']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Treadmill Exercise', 'InterventionDescription': 'Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Treadmill Exercise']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Stretching (control)', 'InterventionDescription': 'Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stretching (Control)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The Change in Total Daily Energy Expenditure', 'PrimaryOutcomeDescription': 'Subjects will wear an accelerometer activity monitor on their belt for 5 to 7 days to determine caloric expenditure in daily activities.', 'PrimaryOutcomeTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'The Change in Substrate Oxidation', 'SecondaryOutcomeDescription': 'After a 12 hour fast, economy of hemiparetic gait will be measured using open circuit spirometry during a standard constant load submaximal effort treadmill walking task at a pre-established gait velocity (60% of self-selected floor walking velocity). This slower walking velocity is selected because untrained subjects with stroke usually cannot maintain their self-selected walking pace, precluding steady state measures of oxygen consumption that defines gait economy. We will calculate the change in respiratory exchange ratio from rest to the final 3 minutes of a 10-minute walk under steady state oxygen consumption conditions (RER at 60%VO2peak-RER at rest). Subjects not achieving a plateau in VO2 will be re-tested at a lower velocity on a different date to eliminate potential confounding effects of fatigue on testing.', 'SecondaryOutcomeTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)'}, {'SecondaryOutcomeMeasure': 'The Change in Circulating Nitrotyrosine', 'SecondaryOutcomeDescription': 'Plasma will be used to quantitate circulating nitrotyrosine concentrations', 'SecondaryOutcomeTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nVeteran\\nAdequate language and neurocognitive function to safely participate in informed consent, and exercise testing and training\\nUnder the care of a primary care medical provider.\\nAge greater than 20 years\\nBody mass index between 20 to 50 kg/m2\\nAlready completed all conventional inpatient and outpatient physical therapy.\\nIschemic or hemorrhagic stroke greater than or equal to 6 months prior.\\n\\nExclusion Criteria:\\n\\nAlready performing aerobic exercise 3 x / week.\\nIncreased alcohol consumption defined as greater than 2 oz. liquor or 2 times 4 oz. glasses of wine or 2 x 12 oz. cans of beer per day\\nCardiac history of: a) unstable angina, b) recent (less than 3 months prior to study entry) myocardial infarction, congestive heart failure (NYHA category II-IV); c) hemodynamically significant valvular dysfunction.\\nMuscle Biopsy Exclusion Criteria: a) anti-coagulation therapy with heparin, warfarin, or lovenox (anti-platelet therapy is permitted), b) bleeding disorder c) allergy to lidocaine\\nMedical History: a) recent hospitalization (less than 3 months prior to study entry) for severe medical disease, b) peripheral arterial disease with vascular claudication, c) orthopedic or chronic pain condition restricting exercise, d) pulmonary or renal failure, e) active cancer, f) untreated poorly controlled hypertension measured on at least 2 occasions (greater than 160/100) g) type I diabetes mellitus, untreated and / or poorly controlled diabetes with fasting blood glucose of greater than 170 and HbA1c greater than 10.0, h) medications: heparin, warfarin, lovenox, oral steroids i) currently pregnant.\\nNeurological history of: a) dementia with Mini-Mental Status Score less than 23 (less than 17 if education level at or below 8th grade), and diagnostic confirmation by neurologist or psychiatrist, b) severe receptive or global aphasia which confounds testing and training, operationally defined as unable to follow 2 point commands, c) neurologic disorder restricting exercise, such as Parkinsons Syndrome or myopathy, d) untreated major depression.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Monica C Serra, PhD', 'OverallOfficialAffiliation': 'South Texas Health Care System, San Antonio, TX', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21201', 'LocationCountry': 'United States'}, {'LocationFacility': 'South Texas Health Care System, San Antonio, TX', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78229', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Stretching (Control)', 'FlowGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Treadmill Exercise', 'FlowGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will occur 3 days/week and will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '25'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '26'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '19'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '20'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '6'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '6'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Stretching (Control)', 'BaselineGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Treadmill Exercise', 'BaselineGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will occur 3 days/week and will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '25'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '26'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '51'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '18'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '33'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '63', 'BaselineMeasurementSpread': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '61', 'BaselineMeasurementSpread': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '62', 'BaselineMeasurementSpread': '8'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '7'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '21'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '23'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '44'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '15'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '29'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '21'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '25'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '51'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'The Change in Total Daily Energy Expenditure', 'OutcomeMeasureDescription': 'Subjects will wear an accelerometer activity monitor on their belt for 5 to 7 days to determine caloric expenditure in daily activities.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'change in kcal/day', 'OutcomeMeasureTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Stretching (Control)', 'OutcomeGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Treadmill Exercise', 'OutcomeGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '20'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.52', 'OutcomeMeasurementSpread': '40.89'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '32.86', 'OutcomeMeasurementSpread': '54.60'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'The Change in Substrate Oxidation', 'OutcomeMeasureDescription': 'After a 12 hour fast, economy of hemiparetic gait will be measured using open circuit spirometry during a standard constant load submaximal effort treadmill walking task at a pre-established gait velocity (60% of self-selected floor walking velocity). This slower walking velocity is selected because untrained subjects with stroke usually cannot maintain their self-selected walking pace, precluding steady state measures of oxygen consumption that defines gait economy. We will calculate the change in respiratory exchange ratio from rest to the final 3 minutes of a 10-minute walk under steady state oxygen consumption conditions (RER at 60%VO2peak-RER at rest). Subjects not achieving a plateau in VO2 will be re-tested at a lower velocity on a different date to eliminate potential confounding effects of fatigue on testing.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'ratio change', 'OutcomeMeasureTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Stretching (Control)', 'OutcomeGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Treadmill Exercise', 'OutcomeGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '20'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.013', 'OutcomeMeasurementSpread': '0.072'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.083', 'OutcomeMeasurementSpread': '0.135'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'The Change in Circulating Nitrotyrosine', 'OutcomeMeasureDescription': 'Plasma will be used to quantitate circulating nitrotyrosine concentrations', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': '% change', 'OutcomeMeasureTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Stretching (Control)', 'OutcomeGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Treadmill Exercise', 'OutcomeGroupDescription': 'Six months of treadmill training Treadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '20'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-24.8', 'OutcomeMeasurementSpread': '21.7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-36.5', 'OutcomeMeasurementSpread': '30.8'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '6 months from baseline', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Stretching (Control)', 'EventGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '19', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '19', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '19'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Treadmill Exercise', 'EventGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '20', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '20', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '20'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Recurrent stroke', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '19'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '20'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Monica Serra', 'PointOfContactOrganization': 'South Texas Veterans Health Care System', 'PointOfContactEMail': 'monica.serra@va.gov', 'PointOfContactPhone': '210-617-5300', 'PointOfContactPhoneExt': '15313'}}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'April 16, 2019', 'LargeDocUploadDate': '01/13/2020 15:27', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1303', 'ConditionBrowseLeafName': 'Chronic Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 17, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05651321', 'OrgStudyIdInfo': {'OrgStudyId': 'ONSTaste2.0'}, 'Organization': {'OrgFullName': 'Peking Union Medical College Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements', 'OfficialTitle': \"A Series of Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements on Patients' Nutritional Strategies\"}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 5, 2022', 'StudyFirstSubmitQCDate': 'December 5, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 15, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 10, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 12, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Peking Union Medical College Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The goal of this observational study is to test the taste perception threshold and palatability interval of different populations and the difference in taste perception between tumor and stroke patients and healthy people by combining manual sensory evaluation and electronic bionic sensory and investigate the taste perception characteristics and demand of enteral nutrition preparations such as Fortimel in tumor and stroke patients, and the difference in taste perception of enteral nutrition preparations with healthy people by combining manual sensory evaluation and electronic bionic sensory. Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'DetailedDescription': 'Combining manual sensory evaluation and electronic bionic sensory, assessing the differences in taste perception between tumor and stroke patients and healthy individuals by measuring the basic taste perception threshold and palatability interval and analyzing facial expressions.\\nCombining manual sensory evaluation with electronic bionic senses and simultaneous facial expression analysis to assess the taste perception characteristics and needs of tumor and stroke patients for different flavors of enteral nutrition preparations.\\nEstablishing an information base of electronic tongue taste data, facial expression emotion and flavor data of nutritional preparations based on the electronic tongue and facial expression data of relevant assays obtained simultaneously during the above experiments.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer- and Cancer Treatment-Related Conditions', 'Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Crossover']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '108', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'stroke patients', 'ArmGroupDescription': 'Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Samples materials of basic taste stimuli and enteral nutrition preparations']}}, {'ArmGroupLabel': 'cancer patients', 'ArmGroupDescription': 'Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Samples materials of basic taste stimuli and enteral nutrition preparations']}}, {'ArmGroupLabel': 'healthy people', 'ArmGroupDescription': 'Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Samples materials of basic taste stimuli and enteral nutrition preparations']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Samples materials of basic taste stimuli and enteral nutrition preparations', 'InterventionDescription': 'Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['cancer patients', 'healthy people', 'stroke patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Taste perception threshold', 'PrimaryOutcomeDescription': 'materials using basic taste stimuli, i.e. reference substances tartaric/citric acid (acid), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), quercetin/alum (astringent) to prepare Different flavors and concentrations of solutions were prepared. By the \"three-point test\", pure water was used as a control to determine the concentration of the flavors caused by The \"discrimination threshold\" of the sensation was determined by the \"three-point test\" using pure water as a control.', 'PrimaryOutcomeTimeFrame': 'After initial screening and exclusion, subjects who met the inclusion criteria were ready to begin taste threshold testing.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nhealthy people aged 18-80 years old (including 18 and 80 years old), patients with specific diseases.\\nspecific diseases meet the clinical diagnosis criteria and are not in the clinical treatment period (such as radiotherapy or perioperative period)\\nnot wearing a denture and having good oral hygiene.\\nnormal vision or corrected vision, no hearing impairment, and no mental behavior disorder.\\nvoluntarily participate in this trial and sign the informed consent form.\\n\\nExclusion Criteria:\\n\\nsubjects who may be allergic to the ingredients of the tested food\\npersons who have an aversion to the food to be tasted or who do not consume the food for cultural, ethnic, or other reasons\\npregnant or lactating women.\\nexcessive smokers (>15 cigarettes/day) or heavy drinkers (>25g/day for men and >15g/day for women)\\nEating disorders (binge eating, anorexia, bulimia nervosa, etc.) and those who cannot eat through the mouth\\nthose who underwent ear, nose, and throat, transnasal intracranial occupancy, and oral surgery\\nThose who currently have severe abnormalities of the respiratory system, endocrine system, immune system, nervous system, circulatory system, digestive system, hematopoietic system, and nervous system, and those who have undergone bariatric surgery.\\ncurrently taking medications that affect the sense of taste\\nSubjects who are participating in other clinical trials.\\nother people who have been determined by the investigator to be unsuitable for participation in this trial, patients with conditions that reduce the likelihood of enrollment or complicate enrollment, such as the presence of conditions that predispose to missed visits.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Study subjects are healthy people, patients with specific diseases (after radiotherapy for tumors, stroke)', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Wei Chen, Doctor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86 13911006820', 'CentralContactEMail': 'chenw@pumch.cn'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wei Chen, Doctor', 'OverallOfficialAffiliation': 'Peking Union Medical College Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Dongcheng district，Peking union medical college hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationZip': '100010', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Wei Chen, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '010-69154095', 'LocationContactEMail': 'txchenwei@sina.com'}, {'LocationContactName': 'Xiaodong Shi', 'LocationContactRole': 'Contact', 'LocationContactPhone': '17888811579'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M5063', 'InterventionBrowseLeafName': 'Caffeine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14334', 'InterventionBrowseLeafName': 'Quercetin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21010', 'InterventionBrowseLeafName': 'Citric Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M1837', 'InterventionBrowseLeafName': 'Sodium Citrate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14343', 'InterventionBrowseLeafName': 'Quinine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M257697', 'InterventionBrowseLeafName': 'Aluminum sulfate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T370', 'InterventionBrowseLeafName': 'Caffeine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T41', 'InterventionBrowseLeafName': 'Quercetin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T382', 'InterventionBrowseLeafName': 'Citrate', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSSti', 'InterventionBrowseBranchName': 'Central Nervous System Stimulants'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnCoag', 'InterventionBrowseBranchName': 'Anticoagulants'}, {'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'MuRelCen', 'InterventionBrowseBranchName': 'Muscle Relaxants, Central'}, {'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}, {'InterventionBrowseBranchAbbrev': 'Fl', 'InterventionBrowseBranchName': 'Flavonoid'}]}}}}}, {'Rank': 18, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02982668', 'OrgStudyIdInfo': {'OrgStudyId': 'KY20162086-2'}, 'Organization': {'OrgFullName': 'Xijing Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Optimizing Early Enteral Nutrition in Severe Stroke', 'OfficialTitle': 'A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage', 'Acronym': 'OPENS'}, 'StatusModule': {'StatusVerifiedDate': 'December 2020', 'OverallStatus': 'Terminated', 'WhyStopped': 'Significantly higher mortality', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 27, 2016', 'StudyFirstSubmitQCDate': 'November 30, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 5, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 31, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 4, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Xijing Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Tang-Du Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Xi'an Central Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Xi'an Gaoxin Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Yan'an University Affiliated Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The PLA 940 hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Xi'an No.3 Hospital\", 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': \"The First Affiliated Hospital of Xi'an Medical University\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Yulin No.1 Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"The First People's Hospital of Xianyang\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Tongchuan Mining Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The PLA General Hospital of Xinjiang', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Tongchuan People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Yulin No.2 Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"First Affiliated Hospital Xi'an Jiaotong University\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Ankang Central Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this academic lead study is to explore the ideal nutritional support strategy for patient with acute severe stroke.', 'DetailedDescription': 'Of high mortality and morbidity, severe stroke is associated with devastating damages in neurologic, respiratory, circulatory and many other systems. The outcomes of patients with severe stroke depend largely on medical strategies on acute stage, especially on nutritional support management. Unfortunately, clinical evidence are sparse and the ideal initial feeding strategy remains disputable.\\n\\nThe IF-STROKE study aims to provide reliable data on the effects of modified full enteral feeding (target recruitment 200) and permissive underfeeding in patients with acute severe stroke (target recruitment 200) compared to full enteral feeding (target recruitment 200). Patients presenting with acute (<72h) severe stroke (GCS ≦ 12 or NIHSS ≧ 11) and dysphagia (defined by Water Swallowing Test) will be randomly assigned to full enteral feeding, modified full enteral feeding, or permissive underfeeding treatment for 7 days.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Severe Stroke', 'Acute Stroke', 'Dysphagia']}, 'KeywordList': {'Keyword': ['severe stroke', 'Acute Stroke', 'Enteral Feeding', 'Mortality', 'Disability', 'Clinical trial']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '306', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Full enteral feeding', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Initial enteral feeding']}}, {'ArmGroupLabel': 'Modified full enteral feeding', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Initial enteral feeding', 'Drug: metoclopramide or mosapride']}}, {'ArmGroupLabel': 'Permissive underfeeding', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Initial enteral feeding']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Initial enteral feeding', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Full enteral feeding', 'Modified full enteral feeding', 'Permissive underfeeding']}}, {'InterventionType': 'Drug', 'InterventionName': 'metoclopramide or mosapride', 'InterventionDescription': 'gastrointestinal (GI) motility improving', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Modified full enteral feeding']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rate of patients with death or major disability (modified Rankin scale score ≥3)', 'PrimaryOutcomeDescription': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'PrimaryOutcomeTimeFrame': '3 months after enrollment'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Mortality (rate of patients with death)', 'SecondaryOutcomeDescription': 'Rate of patients with death', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'The scores of National Institute of Health stroke scale', 'SecondaryOutcomeDescription': 'National Institute of Health stroke scale, with scores ranging from 0 (normal function) to 42 (functional impairment)) was used to evaluate the impairment caused by a stroke.', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'Glasgow Coma Scale', 'SecondaryOutcomeDescription': 'Glasgow Coma Scale, with scores ranging from 3 (no response) to 15 (normal response), was used to grade the conscious state.', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'modified Rankin scale', 'SecondaryOutcomeDescription': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'Barthel index', 'SecondaryOutcomeDescription': 'The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'modified Rankin scale', 'SecondaryOutcomeDescription': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'Barthel index', 'SecondaryOutcomeDescription': 'The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'The incidence of treatment intolerance', 'SecondaryOutcomeDescription': 'The intolerance including gastric retention, diarrhea, constipation, gastrointestinal hemorrhage', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'The incidence of serious adverse events', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'The incidence of adverse events That are related to treatment', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nSevere stroke occurred in 7 days.\\nGCS ≤12 or NIHSS≥11.\\nAny cases of profiles #3 through 5 in Water Swallowing Test or with disorder of consciousness.\\nPlan to receive enteral feeding for at least 7 days.\\nInformed consent.\\n\\nExclusion Criteria:\\n\\nGastrointestinal diseases before stroke, such as gastrointestinal resection, malabsorption,and irritable bowel syndrome.\\nBrain death.\\nComplicated with the disease which only have life expectancy < 6 months in over 50% patients.\\nAfter cardiac arrest.\\nReceived parenteral nutrition support.\\nPregnant woman.\\nConcurrent severe hepatic or renal dysfunction。\\nUnstable hemodynamics.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wen Jiang, PhD', 'OverallOfficialAffiliation': 'Department of Neurology, Xijing Hospital, Fourth Military Medical University', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Xijing Hospital', 'LocationCity': \"Xi'an\", 'LocationState': 'Shaanxi', 'LocationZip': '710032', 'LocationCountry': 'China'}, {'LocationFacility': 'Tangdu Hospital', 'LocationCity': \"Xi'an\", 'LocationState': 'Shaanxi', 'LocationZip': '710038', 'LocationCountry': 'China'}, {'LocationFacility': \"The First Affiliated Hospital of Xi'an Jiaotong University,\", 'LocationCity': \"Xi'an\", 'LocationState': 'Shaanxi', 'LocationZip': '710061', 'LocationCountry': 'China'}, {'LocationFacility': 'Yulin No.2 Hospital', 'LocationCity': 'Yunlin', 'LocationState': 'Shaanxi', 'LocationZip': '719000', 'LocationCountry': 'China'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24289189', 'ReferenceType': 'background', 'ReferenceCitation': 'Wirth R, Smoliner C, Jager M, Warnecke T, Leischker AH, Dziewas R; DGEM Steering Committee*. Guideline clinical nutrition in patients with stroke. Exp Transl Stroke Med. 2013 Dec 1;5(1):14. doi: 10.1186/2040-7378-5-14.'}, {'ReferencePMID': '26773077', 'ReferenceType': 'background', 'ReferenceCitation': 'McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, Gervasio JM, Sacks GS, Roberts PR, Compher C; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016 Feb;40(2):159-211. doi: 10.1177/0148607115621863. No abstract available. Erratum In: JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1200.'}, {'ReferencePMID': '12750536', 'ReferenceType': 'result', 'ReferenceCitation': 'FOOD Trial Collaboration. Poor nutritional status on admission predicts poor outcomes after stroke: observational data from the FOOD trial. Stroke. 2003 Jun;34(6):1450-6. doi: 10.1161/01.STR.0000074037.49197.8C. Epub 2003 May 15.'}, {'ReferencePMID': '20130154', 'ReferenceType': 'result', 'ReferenceCitation': 'Ukleja A. Altered GI motility in critically Ill patients: current understanding of pathophysiology, clinical impact, and diagnostic approach. Nutr Clin Pract. 2010 Feb;25(1):16-25. doi: 10.1177/0884533609357568.'}, {'ReferencePMID': '15733717', 'ReferenceType': 'result', 'ReferenceCitation': 'Dennis MS, Lewis SC, Warlow C; FOOD Trial Collaboration. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet. 2005 Feb 26-Mar 4;365(9461):764-72. doi: 10.1016/S0140-6736(05)17983-5.'}, {'ReferencePMID': '20971534', 'ReferenceType': 'result', 'ReferenceCitation': 'Heyland DK, Stephens KE, Day AG, McClave SA. The success of enteral nutrition and ICU-acquired infections: a multicenter observational study. Clin Nutr. 2011 Apr;30(2):148-55. doi: 10.1016/j.clnu.2010.09.011. Epub 2010 Oct 25.'}, {'ReferencePMID': '22673593', 'ReferenceType': 'result', 'ReferenceCitation': 'Jie B, Jiang ZM, Nolan MT, Zhu SN, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012 Oct;28(10):1022-7. doi: 10.1016/j.nut.2012.01.017. Epub 2012 Jun 5.'}, {'ReferencePMID': '22307571', 'ReferenceType': 'result', 'ReferenceCitation': 'National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, Morris A, Dong N, Rock P. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA. 2012 Feb 22;307(8):795-803. doi: 10.1001/jama.2012.137. Epub 2012 Feb 5.'}, {'ReferencePMID': '26398094', 'ReferenceType': 'result', 'ReferenceCitation': 'Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults. N Engl J Med. 2015 Sep 24;373(13):1281. doi: 10.1056/NEJMx150028. No abstract available.'}, {'ReferencePMID': '35219379', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zhao J, Yuan F, Song C, Yin R, Chang M, Zhang W, Zhang B, Yu L, Jia Y, Ma Y, Song Y, Wang C, Song C, Wang X, Shang L, Yang F, Jiang W; OPENS Trial Investigators. Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2022 Apr;21(4):319-328. doi: 10.1016/S1474-4422(22)00010-2. Epub 2022 Feb 24.'}, {'ReferencePMID': '30755171', 'ReferenceType': 'derived', 'ReferenceCitation': 'Yuan F, Yang F, Zhang W, Jia Y, Ma Y, Qu Y, Wang X, Huo K, Wang C, Yuan X, Song C, Zhang B, Jiang W; OPENS study group. Optimizing early enteral nutrition in severe stroke (OPENS): protocol for a multicentre randomized controlled trial. BMC Neurol. 2019 Feb 12;19(1):24. doi: 10.1186/s12883-019-1253-2.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000008787', 'InterventionMeshTerm': 'Metoclopramide'}, {'InterventionMeshId': 'C000062720', 'InterventionMeshTerm': 'Mosapride'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000932', 'InterventionAncestorTerm': 'Antiemetics'}, {'InterventionAncestorId': 'D000001337', 'InterventionAncestorTerm': 'Autonomic Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000005765', 'InterventionAncestorTerm': 'Gastrointestinal Agents'}, {'InterventionAncestorId': 'D000065127', 'InterventionAncestorTerm': 'Dopamine D2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000018492', 'InterventionAncestorTerm': 'Dopamine Antagonists'}, {'InterventionAncestorId': 'D000015259', 'InterventionAncestorTerm': 'Dopamine Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000017366', 'InterventionAncestorTerm': 'Serotonin Receptor Agonists'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M11450', 'InterventionBrowseLeafName': 'Metoclopramide', 'InterventionBrowseLeafAsFound': 'Pharmacokinetic Study', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M264835', 'InterventionBrowseLeafName': 'Mosapride', 'InterventionBrowseLeafAsFound': 'Shampoo', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M3941', 'InterventionBrowseLeafName': 'Antiemetics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8571', 'InterventionBrowseLeafName': 'Gastrointestinal Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7163', 'InterventionBrowseLeafName': 'Dopamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20286', 'InterventionBrowseLeafName': 'Dopamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M17652', 'InterventionBrowseLeafName': 'Dopamine Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20194', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M15202', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19338', 'InterventionBrowseLeafName': 'Serotonin Receptor Agonists', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'AnEm', 'InterventionBrowseBranchName': 'Antiemetics'}, {'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'CaAg', 'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}}}}}, {'Rank': 19, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01517542', 'OrgStudyIdInfo': {'OrgStudyId': '10-0014'}, 'Organization': {'OrgFullName': 'Hospital de Clinicas de Porto Alegre', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Effectiveness of Nutritional Counseling in Patients After Stroke', 'OfficialTitle': 'Evaluation on the Effectiveness of Nutritional Counseling on an Adapted DASH Diet in Patients After Stroke: a Randomized Clinical Trial'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Withdrawn', 'WhyStopped': 'low availability of professionals to recruit the participants', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2010', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 22, 2011', 'StudyFirstSubmitQCDate': 'January 24, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 25, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 9, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 16, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'SHEILA CRISTINA OURIQUES MARTINS', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Hospital de Clinicas de Porto Alegre'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Clinicas de Porto Alegre', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Stroke is the leading cause of disability worldwide and the leading cause of death in Brazil. It is estimated that about 18 million people will have a stroke in 2015 and approximately one third of these resulting in death. The factors most important modifiable risk for stroke include high blood pressure (hypertension), diabetes, smoking, dyslipidemia, sedentary lifestyle and obesity. Acting on these risk factors can be reduced by 88% the risk of another stroke. Healthy eating is among the changes in lifestyle that are recommended for prevention and treatment of one of the main risk factors for stroke. Studies show that the adoption of the DASH diet can significantly reduce blood pressure and the result is even more significant in hypertensive patients, making this diet a new alternative in the prevention and treatment of hypertension and consequently stroke. Compliance therapy is a determining factor for success in the treatment of chronic diseases. Adherence to long-term treatment in developed countries is around 50% and in developing countries the rates are even lower. The aim of this study is to evaluate the effectiveness of nutritional counseling in an adapted DASH style diet on body weight, glycemic control, blood pressure values and improved lipid profile compared to the usual diet without nutritional counseling in patients with stroke within the last 3 months. The hypothesis is that nutritional counseling with an adapted DASH style diet reduces cardiovascular risk factors compared with the usual diet without nutritional counseling in patients with stroke within 3 months. The stroke patients will be selected in the hospitalization or in the outpatient clinic of Hospital de Clínicas de Porto Alegre in a period up to 3 months after ischemic stroke. The patients will be randomized to one of the 2 groups. In the first visit they will be submitted to a social class and international physical activity questionnaire and they will be submitted to a food frequency questionnaire, measures of weight, height, waist circumference, hip and neck, blood pressure and cholesterol and glucose measurements at the baseline, 30 days and 3, 6, 9 and 12 months. The main endpoints will be the change in the body weight, blood glucose, blood pressure values and lipid profile.', 'DetailedDescription': 'The study will be followed by a evaluation of other endpoints: new stroke, myocardial infarction or cardiovascular death.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Cardiovascular Diseases']}, 'KeywordList': {'Keyword': ['diet', 'DASH', 'Stroke', 'Nutritional counseling']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Nutritional counseling', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nutritional Counseling']}}, {'ArmGroupLabel': 'Usual diet', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nutritional Counseling', 'InterventionDescription': '2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nutritional counseling']}, 'InterventionOtherNameList': {'InterventionOtherName': ['adherence', 'nutrition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline arterial blood pressure and 6 months', 'PrimaryOutcomeDescription': 'The patients will be randomized to one of the 2 groups (with nutritional counseling and no intervention - habitual diet). The main endpoint will be the change in the blood pressure values and adherence to treatment measured in 30 days and 3, 6, 9 and 12 months.', 'PrimaryOutcomeTimeFrame': '30 days and 3, 6, 9 and 12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in lipids from baseline', 'SecondaryOutcomeDescription': 'The patients will be randomized to one of the 2 groups (with nutritional counseling and no intervention - habitual diet). The secundary endpoint will be the change in the lipid profile and adherence to treatment measured in 30 days and 3, 6, 9 and 12 months.', 'SecondaryOutcomeTimeFrame': '30 days, 3, 6, 9 and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in the body weight', 'SecondaryOutcomeDescription': 'The patients will be randomized to one of the 2 groups (with nutritional counseling and no intervention - habitual diet). The secundary endpoint will be the change in the body weight measured in 30 days and 3, 6, 9 and 12 months.', 'SecondaryOutcomeTimeFrame': '30 days and 3, 6, 9 and 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIschemic Stroke up to 3 months\\nModified Rankin Score < 4\\n\\nExclusion Criteria:\\n\\nAphasia\\nEnteral diet\\nUnavailability to follow up the study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Sheila CO Martins, PI', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Vanessa A Piper, SI', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Márcia LF Chaves, SI', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Study Chair'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023', 'RemovedCountryList': {'RemovedCountry': ['Brazil']}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 20, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05640154', 'OrgStudyIdInfo': {'OrgStudyId': 'HPLgeriatric'}, 'Organization': {'OrgFullName': 'Assiut University', 'OrgClass': 'OTHER'}, 'BriefTitle': \"HPL Program for Geriatric Patients' at Risk for Stroke\", 'OfficialTitle': \"Health Promoting Lifestyle Program for Geriatric Patients' at Risk for Stroke\"}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Enrolling by invitation', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 16, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 1, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 28, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 3, 2022', 'StudyFirstSubmitQCDate': 'December 3, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 7, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 3, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 7, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'TA Shoulkamy', 'ResponsiblePartyInvestigatorTitle': 'principal investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Assiut University'}, 'LeadSponsor': {'LeadSponsorName': 'Assiut University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a highest reason of illness and death all over world. In 2017, stroke was the second greatest recurrent reason of mortality, after ischemic cardiac illness, and produced 6.2 million mortality all over world. The load of stroke does not only lie in the great mortality but the great morbidity also results in up to 50% of survivors being chronically disabled. Thus stroke is a disease of huge public health importance with economic and social consequences.', 'DetailedDescription': 'Patients with stroke with uncontrolled glucose levels have higher mortality and poor post stroke outcomes. Controlling diabetes and other associated risk factors are effective ways to prevent initial strokes as well as stroke recurrence. Diabetes increases ischemic stroke incidence in all age groups, individuals with diabetes are more likely to suffer from hypertension, myocardial infarction and high cholesterol than individuals without diabetes have been linked to a greater risk of stroke. Smoking is a major cause of cardiovascular disease and causes one of every four deaths from cardiovascular disease. Smoking can raise triglycerides (a type of fat in your blood), Lower \"good\" cholesterol (high-density lipoprotein), Make blood sticky and more likely to clot, which can block blood flow to the heart and brain, Damage cells that line the blood vessels, Increase the buildup of plaque (fat, cholesterol, calcium, and other substances) in blood vessels and cause thickening and narrowing of blood vessels.The idea of lifestyle includes a broad variety of subjects, containing substantial life, spiritual life and other issues. Physical activity, smoking, alcohol consumption, nutrition and other aspects to measure lifestyle used by Chinese scientists. Health promoting lifestyle (HPL) is defined as \"a multi-dimensional pattern of self-initiated actions and perceptions that serve to maintain or enhance the level of wellness, self-actualization, and fulfillment of the individual\". It assesses a personal well-being activity that involves physical activity, dieting, spiritual growth, interpersonal relationships, health responsibility, and stress management, and would lead to enhaning wellbeing condition'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Health-Related Behavior']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '170', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Educational program', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. they will receive the nursing educational program which will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).also they will receive health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: educational program']}}, {'ArmGroupLabel': 'control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. the will not receive educational program and life style promotion.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'educational program', 'InterventionDescription': 'The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Educational program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"the effect of implementing nursing educational program on Health Promoting Lifestyle for geriatric patients' at risk for stroke.\", 'PrimaryOutcomeDescription': 'by using tool II: It is a well-established instrument to assess personal lifestyle behaviors that promote health. It is composed of a 52-items questionnaire that is answered according to a 4-point Likert-type scale, with (Never (N) = 1, Sometimes (S) = 2, Often (O) = 3, Routinely (R) = 4). The total scale is 52-items and composed of six subscales to measure dimensions of health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management). The total score will be adjusted from 0 to 100 and can classify the result to good lifestyle behavior if the percent score 60% and more and bad lifestyle behavior if less than 60%.', 'PrimaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge 60 years and more\\nDiagnosed with hypertension, diabetes mellitus and cardiac diseases.\\nAble to communicate with health team, free from mental problems, and agreed to participate in the study were included.\\n\\nExclusion Criteria:\\n\\nunable to communicate with health team.\\nfree from mental problems.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '60 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Faculty of Nursing', 'LocationCity': 'Assiut', 'LocationCountry': 'Egypt'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 21, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04744324', 'OrgStudyIdInfo': {'OrgStudyId': 'SKH-20201006R'}, 'Organization': {'OrgFullName': 'National Taipei University of Nursing and Health Sciences', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Self-supporting Care Model in Home Environment for Patients With Stroke', 'OfficialTitle': 'Effects of Self-supporting Care Model on Activities of Daily Living for Patients With Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'April 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 3, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 28, 2023', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 28, 2023', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 3, 2021', 'StudyFirstSubmitQCDate': 'February 3, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 8, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 6, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 10, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'En-Chi Chiu', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'National Taipei University of Nursing and Health Sciences'}, 'LeadSponsor': {'LeadSponsorName': 'National Taipei University of Nursing and Health Sciences', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"The purpose of this study was to administer intervention based on self-supporting care model in home environment and to explore the effects of this intervention on stroke patients' activities of daily living, movement, cognition, nutritional status, and quality of life.\", 'DetailedDescription': 'Subjects were randomized to intervention group and control group. The experiment was designed as randomized cross-over control trial. The primary outcome included 8 measures: Barthel Index-based Supplementary Scales, Canadian Occupational Performance Measure, Fugl-Meyer Assessment, Balance Computerized Adaptive Testing, Mini Mental State Examination-2nd edition, Mini Nutritional Assessment, Stroke Impact Scale, and Stroke Self-Efficacy Questionnaire.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Activities of Daily Living']}, 'KeywordList': {'Keyword': ['Stroke', 'Self-supporting Care Model', 'Home Care Services']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Crossover Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '28', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Self-supporting Care Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Self-supporting Care in home', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Self-supporting Care']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Home Health Education', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Home health education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Self-supporting Care', 'InterventionDescription': 'Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Self-supporting Care Group']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Home health education', 'InterventionDescription': 'Individualized home health education', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Barthel Index -based Supplementary Scales', 'PrimaryOutcomeDescription': 'The Barthel Index-based Supplementary Scales assesses basic activities of daily living using three scales:actual performance, ability, and self-perceived difficulty. The score ranges the three scales (i.e., actual performance, ability, and self-perceived difficulty)is 0-20, 0-18, and 0-20, respectively. A higher score indicates better basic activities of daily living.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Canadian Occupational Performance Measure', 'PrimaryOutcomeDescription': 'The Canadian Occupational Performance Measure is to measure occupational performance though three areas: self-care, productivity, and leisure. Patients define important activities and classify them with a score of one to 10. A higher score indicates better occupational performance.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Fugl-Meyer Assessment', 'PrimaryOutcomeDescription': 'The Fugl-Meyer Assessment scale is to assess the sensorimotor impairment in individuals who have had stroke. The score ranges is 0 to 226. A higher score indicates better body function.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Balance computerized adaptive testing', 'PrimaryOutcomeDescription': 'The Balance computerized adaptive testing is to assess balance ability.The score ranges is 0 to 10. A higher score indicates better balance ability.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Mini Mental State Examination-2nd edition', 'PrimaryOutcomeDescription': 'The Mini Mental State Examination-2nd edition is to assess cognitive functions. The score ranges is 0 to 90. A higher score indicates better cognitive functions.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Mini Nutritional Assessment', 'PrimaryOutcomeDescription': 'The Mini Nutritional Assessment is a comprehensive nutritional assessment scale. The score range is 0 to 30 points. The higher the score, the lower the risk of malnutrition.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Stroke Impact Scale', 'PrimaryOutcomeDescription': 'The Stroke Impact Scale is to assess health-related quality of life: emotion, communication, memory and thinking, and social role function. The score ranges is 59 to 295. A lower score indicates the quality of life less affected by stroke.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Stroke Self-Efficacy Questionnaire', 'PrimaryOutcomeDescription': 'The Stroke Self-Efficacy Questionnaire is a self-report scale measuring self-efficacy judgments in specific domains of functioning post stroke. The score ranges is 0 to 130. A higher score indicates better self-efficacy.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nage > 20 years\\nDiagnosis of stroke\\nThe modified Rankin Scale : 2~4\\nKeep sitting for half an hour by himself/herself\\nFollow instructions\\nWilling to sign the subject's consent\\n\\nExclusion Criteria:\\n\\nDiagnosis of dementia\\nHistory of orthopedic diseases or peripheral nerve injury\\nreadmission because of stroke\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'En-Chi Chiu, PhD', 'OverallOfficialAffiliation': 'National Taipei University of Nursing and Health Sciences', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Shin Kong Wu Ho-Su Memorial Hospital', 'LocationCity': 'Taipei City', 'LocationState': 'Shihlin District', 'LocationZip': '111045', 'LocationCountry': 'Taiwan'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 22, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03945526', 'OrgStudyIdInfo': {'OrgStudyId': 'Neuronutrition'}, 'Organization': {'OrgFullName': 'Indonesia University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and NIHSS of Stroke Patients', 'OfficialTitle': 'Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and National Institute of Health Stroke Scale Score of Acute Ischemic Stroke Patients: A Randomized Trial'}, 'StatusModule': {'StatusVerifiedDate': 'May 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 23, 2010', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 9, 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 9, 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 8, 2019', 'StudyFirstSubmitQCDate': 'May 8, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 10, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 9, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 13, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Gabriella Nurahmani Putri', 'ResponsiblePartyInvestigatorTitle': 'Assistant Clinical Nutrition Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Indonesia University'}, 'LeadSponsor': {'LeadSponsorName': 'Indonesia University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is an interventional randomized, controlled trial in analyzing the effects of astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic stroke patients. According to published studies, it was hypothesized that acute ischemic stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and lower NIHSS score compared to the control group.', 'DetailedDescription': 'There were a total of 24 subjects, with 12 subjects in the intervention group and 12 subjects in the control group.The participants were divided into an interventional group and a control group. The interventional group was given astaxanthin supplementation 2 x 8mg per day for 7 days, while the control group was given placebo.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebral Stroke', 'Malondialdehyde', 'Oxidative Stress']}, 'KeywordList': {'Keyword': ['Astaxanthin', 'Antioxidant', 'Plasma Malondialdehyde', 'NIHSS score', 'Ischemic Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Astaxanthin and Placebo', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Astaxanthin', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Astaxanthin supplementation will be given at 2 x 8mg for 7 days.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Astaxanthine']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo Oral Tablet']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Astaxanthine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Astaxanthin']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Astaxanthine 8mg']}}, {'InterventionType': 'Drug', 'InterventionName': 'Placebo Oral Tablet', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Astaxanthine placebo']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Plasma Malondialdehyde Levels on Astaxanthine Treated Stroke Patients as Assessed by Wills Spectrophotometry', 'PrimaryOutcomeDescription': 'This method used Thiobarbituric acid reaction (TBAR) with substances such as malondialdehyde. The scale was 0.367 nmol/ml-0.707 nmol/ml. The value above 0.707nmol/ml would be the worse outcome, and value less than 0.367nmol/ml would be the best outcome. Bivariate analysis was used to analyze the results (T-test or the Mann-Whitney Test).', 'PrimaryOutcomeTimeFrame': '7 days'}, {'PrimaryOutcomeMeasure': 'National Institute of Health Stroke Scale on Astaxanthine Treated Stroke Patients', 'PrimaryOutcomeDescription': 'Score scale was 4-15, where less than 4 indicates mild neurologic deficit, 4-15 moderate neurologic deficit, and more than 15 severe neurologic deficit. They will be assessed before and after the trial to compare how each participant improved after given the intervention.', 'PrimaryOutcomeTimeFrame': '7 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n40-65 years old\\nHas acute ischemic stroke with an onset of less than 48 hours before hospital admission\\nNIHSS score of less than or equal to 15\\nCan consume food orally or enterally\\nHas given their consent to be a participant in the study\\n\\nExclusion Criteria:\\n\\nRenal failure\\nLiver failure\\nIs taking supplements other than his or her main stroke medications\\nHas taken antioxidant supplements in the last 3 months before stroke onset', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Salim Harris, SpS', 'OverallOfficialAffiliation': 'IDI', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Sri Sukmaniah, SpGK', 'OverallOfficialAffiliation': 'IDI', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Nutrition University of Indonesia', 'LocationCity': 'Jakarta', 'LocationZip': '10340', 'LocationCountry': 'Indonesia'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '12760178', 'ReferenceType': 'background', 'ReferenceCitation': 'Barber PA, Demchuk AM, Hirt L, Buchan AM. Biochemistry of ischemic stroke. Adv Neurol. 2003;92:151-64. No abstract available.'}, {'ReferencePMID': '19218497', 'ReferenceType': 'background', 'ReferenceCitation': 'Shen H, Kuo CC, Chou J, Delvolve A, Jackson SN, Post J, Woods AS, Hoffer BJ, Wang Y, Harvey BK. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009 Jun;23(6):1958-68. doi: 10.1096/fj.08-123281. Epub 2009 Feb 13.'}, {'ReferencePMID': '1497349', 'ReferenceType': 'background', 'ReferenceCitation': 'Palozza P, Krinsky NI. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch Biochem Biophys. 1992 Sep;297(2):291-5. doi: 10.1016/0003-9861(92)90675-m.'}, {'ReferencePMID': '15635162', 'ReferenceType': 'background', 'ReferenceCitation': 'Hussein G, Nakamura M, Zhao Q, Iguchi T, Goto H, Sankawa U, Watanabe H. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull. 2005 Jan;28(1):47-52. doi: 10.1248/bpb.28.47.'}, {'ReferencePMID': '9799909', 'ReferenceType': 'background', 'ReferenceCitation': 'Gariballa SE, Sinclair AJ. Assessment and treatment of nutritional status in stroke patients. Postgrad Med J. 1998 Jul;74(873):395-9. doi: 10.1136/pgmj.74.873.395.'}, {'ReferencePMID': '11509080', 'ReferenceType': 'background', 'ReferenceCitation': 'Demirkaya S, Topcuoglu MA, Aydin A, Ulas UH, Isimer AI, Vural O. Malondialdehyde, glutathione peroxidase and superoxide dismutase in peripheral blood erythrocytes of patients with acute cerebral ischemia. Eur J Neurol. 2001 Jan;8(1):43-51. doi: 10.1046/j.1468-1331.2001.00166.x.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 23, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03910855', 'OrgStudyIdInfo': {'OrgStudyId': '201711-00071'}, 'Organization': {'OrgFullName': 'Singapore General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Impact of Mindfulness on Psychological Well-being of Stroke Survivors and Their Caregivers', 'OfficialTitle': 'Investigating the Impact of Mindfulness on Psychological Well-being of Stroke Survivors and Their Caregivers: A Randomized Controlled Trial.', 'Acronym': 'SOMII'}, 'StatusModule': {'StatusVerifiedDate': 'June 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 15, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 15, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 12, 2019', 'StudyFirstSubmitQCDate': 'April 9, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 10, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 13, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 15, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Singapore General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will employ a randomized control design. Stroke survivors and family caregivers will be recruited for the study, and randomized either to receive mindfulness-based intervention or health education. Both programs consist of 4 2-hour sessions. Participants of the mindfulness-based intervention (MBI) will be taught and guided in practice of psychosocial interventions that are focused on (1) stress management and coping skills, (2), body awareness and movement, (3) feelings of empathy and compassion and (4) motivation for rehabilitation. Participants of the health education program (HEP) will learn and discuss topics related to self-care and post-stroke management. Measures will be administered prior to and on completion of the intervention, and at 3-month follow-up. They will be used to assess symptoms associated with depression, anxiety, stress, perceived quality of life and participant characteristics such as personality variables.', 'DetailedDescription': 'Stroke prevalence is 3-4% among Singaporeans above the age of 50, and will rise with our aging population. Stroke survivors face many concerns, including physical, psychological, cognitive and psychosocial consequences of stroke, as well as impaired functioning and quality of life. They often rely on their family for physical, cognitive and emotional support in order to perform daily functional activities. Dependence on family members has been shown to affect the physical, mental and emotional well-being of caregivers of stroke survivors. Research indicates that the long-term demands of caring for a stroke survivor puts a strain on caregivers who may not be able to provide the appropriate amount of care required to manage the needs of stroke survivors over time.\\n\\nMindfulness-based interventions (MBIs) are increasingly being offered as psychotherapeutic interventions for individuals who suffer from medical conditions such as stroke, and for their long-term family caregivers. Several review studies have shown that MBIs, specifically for long-term conditions, enhanced the ability to cope with physical difficulties, improved mental and emotional well-being as well as overall quality of life, promoting better health outcomes. A systematic review investigating the use of MBIs with stroke survivors found that psychological, physiological and psychosocial outcomes were improved, such as anxiety, depression, mental fatigue and overall quality of life (Lawrence et al., 2013).\\n\\nHowever, there are limited data for stroke survivors and their caregivers especially among Asians. Furthermore, there is little attention to study the interaction between participants characteristics and MBIs to determine whether there are any specific moderators that help to maximize the therapeutic outcomes of MBIs (Shaprio et al., 2011). Although there are growing number of studies correlating personality traits and dispositional mindfulness (Hanley, 2016; Giluk, 2009), little research has been done to examine personality traits as moderators to treatment outcome. Research focusing the the five-factor model of personality has demonstrated that the five personality traits have different strengths of correlation with the dispositional mindfulness. Among the traits, neuroticism displayed the strongest negative correlation with depositional mindfulness while conscientiousness displayed the strongest positive correlation with depositional mindfulness.\\n\\nThis study will be the first to examine the moderating effects of personality traits on the impact of mindfulness-based intervention in terms of depression, anxiety, stress and perceived quality of life of stroke survivors and their family caregivers. Furthermore, this study will evaluate and compare the impacts of mindfulness-based intervention and health education on the psychological well-being of both the participants. Findings will encourage the development of future strategies to understand the variability in treatment response and prognosis as well as to address individual differences with relevant psychotherapy skills.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Stress', 'Anxiety', 'Depression']}, 'KeywordList': {'Keyword': ['Mindfulness', 'Stroke Survivors', 'Caregivers']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Participants will be randomized to receive either a Mindfulness-based Intervention (MBI) or a Health Education Program (HEP). The intervention is for 4 weeks. Measures will be administered prior to and on completion of the intervention, and at 3-month follow-up.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '63', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Mindfulness Based Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Mindfulness Based Intervention']}}, {'ArmGroupLabel': 'Health Education Program', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Health Education Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Mindfulness Based Intervention', 'InterventionDescription': 'The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Mindfulness Based Intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Health Education Program', 'InterventionDescription': 'The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Health Education Program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cohen Perceived Stress Scale, PSS', 'PrimaryOutcomeDescription': 'A 10-item measure evaluating the perception of stress.', 'PrimaryOutcomeTimeFrame': 'An average of 1 Month'}, {'PrimaryOutcomeMeasure': 'Centre for Epidemiologic Studies Depression Scale (CES-D)', 'PrimaryOutcomeDescription': 'A 20-item measure for epidemiological research on depression.', 'PrimaryOutcomeTimeFrame': 'An average of 1 Week'}, {'PrimaryOutcomeMeasure': 'Stroke Specific Quality of Life Scale (SS-QOL)', 'PrimaryOutcomeDescription': 'A 49-item self-report questionnaire designed to measure the heath related quality of life specific to stroke survivors across 12 domains.', 'PrimaryOutcomeTimeFrame': 'An average of 1 month'}, {'PrimaryOutcomeMeasure': 'Stroke Impact Scale (SIS)', 'PrimaryOutcomeDescription': 'A 64-item questionnaire that assesses across 8 domains', 'PrimaryOutcomeTimeFrame': 'An average of 1 week'}, {'PrimaryOutcomeMeasure': 'Short-Form-36 (SF-36)', 'PrimaryOutcomeDescription': 'A 36-item self-report survey of health, including physical and mental health. Higher scaled scores reflect better quality of health.', 'PrimaryOutcomeTimeFrame': 'A range from 4 to 52 weeks'}, {'PrimaryOutcomeMeasure': 'The State-Trait Anxiety Inventory, STAI', 'PrimaryOutcomeDescription': 'The STAI is a commonly used measure of trait and state anxiety.', 'PrimaryOutcomeTimeFrame': 'State: Current state, Trait: An average of 1 month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Zarit Burden Inventory (ZBI)', 'SecondaryOutcomeDescription': 'A 22-item self-report questionnaire to measure for level of caregiver burden or stress.', 'SecondaryOutcomeTimeFrame': 'An average of 1 month'}, {'SecondaryOutcomeMeasure': 'The Big Five Personality Inventory, BFI', 'SecondaryOutcomeDescription': '44-item inventory that measures an individual on the Big Five Factors (dimensions) of personality.', 'SecondaryOutcomeTimeFrame': 'An average of 1 month'}, {'SecondaryOutcomeMeasure': 'Five Facet Mindfulness Questionnaire, FFMQ', 'SecondaryOutcomeDescription': 'This 39-item instrument is based on a factor analytic study of five independently developed mindfulness questionnaires.', 'SecondaryOutcomeTimeFrame': 'An average of 1 month'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nStroke survivors and/ or their\\nFamily Caregivers\\nComprehends and provides consent independently\\n\\nExclusion Criteria:\\n\\n-Cognitively impaired individuals with a MMSE score of less than 20, and a MoCA score of less than 23.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '21 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kinjal Doshi, PhD', 'OverallOfficialAffiliation': 'Singapore General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Singapore General Hospital', 'LocationCity': 'Singapore', 'LocationZip': '169608', 'LocationCountry': 'Singapore'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'Preliminary data to inform design of future studies.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6748', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6751', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4014', 'ConditionBrowseLeafName': 'Anxiety Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 24, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05162781', 'OrgStudyIdInfo': {'OrgStudyId': 'IRB-300008211'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01AG070049-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01AG070049-01A1'}]}, 'Organization': {'OrgFullName': 'University of Alabama at Birmingham', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke', 'OfficialTitle': 'Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'August 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 9, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 30, 2025', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 30, 2026', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 19, 2021', 'StudyFirstSubmitQCDate': 'December 6, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 17, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 11, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 15, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Gitendra Uswatte', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Alabama at Birmingham'}, 'LeadSponsor': {'LeadSponsorName': 'University of Alabama at Birmingham', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute on Aging (NIA)', 'CollaboratorClass': 'NIH'}, {'CollaboratorName': 'Posit Science', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will compare two approaches to cognitive rehabilitation in adults with stroke with persistent, mild to moderate, cognitive impairment. Both approaches will feature a web-based computer \"game\" that trains cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. This training is termed Speed of Processing Training (SOPT). One approach will add (A) in-lab training on everyday activities with important cognitive components and (B) procedures designed to transfer improvements in cognition from the treatment setting to everyday life. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will add (A) in-lab training on relaxation, healthy nutrition, and healthy sleep and (B) procedures designed to promote integration of these lifestyle changes into everyday life. This approach is termed Brain Fitness-Heath Education Lifestyle Program (BF-HELP).\\n\\nBoth CICT and BF-HELP will involve 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life; The set of the latter procedures is termed the Transfer Package. To accommodate the demands of participants\\' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. Family caregivers in both groups will also receive training on how to best support participants in their therapeutic program.\\n\\nThe study will also test if there is an advantage to placing follow-up phone calls after treatment ends. The purpose of the calls will be to support transition of any behavioral changes achieved during treatment into everyday life on a long-term basis.\\n\\nParticipants will be randomly assigned to the interventions.\\n\\nTesting will happen one month before treatment, one day before treatment, one day afterwards, and 6- and 12-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Cognitive Dysfunction']}, 'KeywordList': {'Keyword': ['stroke', 'cognitive dysfunction', 'cognitive processing speed', 'IADL']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Half of the participants will receive CICT, which consists of SOPT, IADL training in the lab, and a Transfer Package targeting IADL performance outside it. The other half will receive BF-HELP, which consists of SOPT, in-lab training on relaxation, nutrition, and sleep hygiene, and a Transfer Package targeting implementation of these lifestyle changes outside it. Half of the CICT group will receive 15 follow-up phone calls over the course of one year. The other CICT participants will receive none. The same will apply to the BF-HELP group. The phone calls will support integration of the behavioral changes targeted during treatment to everyday life afterwards.\\n\\nFor all participants, outcome testing will take place one month before treatment (Baseline 1), one day before treatment (Baseline 2 aka Pre-treatment), one day afterwards (Post-treatment), 6-months afterwards (6-month Follow-up), and 12-months afterwards (12-month follow-up). Randomization will take place after Baseline 2.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': 'Tester will be blinded to group assignment of participants.', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CICT with Follow-up Phone Calls', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Instrumental Activities of Daily Living In-lab Training', 'Behavioral: Cognitive Transfer Packagke', 'Behavioral: Family Caregiver Coaching', 'Behavioral: Follow-up Phone Calls']}}, {'ArmGroupLabel': 'CICT without Follow-up Phone Calls', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Instrumental Activities of Daily Living In-lab Training', 'Behavioral: Cognitive Transfer Packagke', 'Behavioral: Family Caregiver Coaching']}}, {'ArmGroupLabel': 'BF-HELP with Follow-up Phone Calls', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Family Caregiver Coaching', 'Behavioral: Follow-up Phone Calls', 'Behavioral: Healthy Lifestyle In-lab Training', 'Behavioral: Healthy Lifestyle Transfer Package']}}, {'ArmGroupLabel': 'BF-HELP without Follow-up Phone Calls', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Family Caregiver Coaching', 'Behavioral: Follow-up Phone Calls', 'Behavioral: Healthy Lifestyle In-lab Training', 'Behavioral: Healthy Lifestyle Transfer Package']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Speed of Processing Training', 'InterventionDescription': 'This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer \"game\", in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls', 'CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}, 'InterventionOtherNameList': {'InterventionOtherName': ['SOPT']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Instrumental Activities of Daily Living In-lab Training', 'InterventionDescription': 'The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}, 'InterventionOtherNameList': {'InterventionOtherName': ['IADL In-lab Training']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive Transfer Packagke', 'InterventionDescription': 'This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Family Caregiver Coaching', 'InterventionDescription': 'One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls', 'CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Follow-up Phone Calls', 'InterventionDescription': 'After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls', 'CICT with Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Healthy Lifestyle In-lab Training', 'InterventionDescription': 'This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Healthy Lifestyle Transfer Package', 'InterventionDescription': 'This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Quality of Life in Neurological Disorders Measures (Neuro-QOL), Cognitive Function Scale', 'PrimaryOutcomeDescription': 'The Neuro-QOL assesses function in daily life in several domains; it is a widely used, validated, transdiagnostic, self-report measure. The development and use of the Neuro-QOL is supported by the National Institutes of Health. The component of the Neuro-QOL that assessed cognitive function will be used here. Items are rated by respondents using a five-point scale: 1 = not at all, 5 = very much. Higher scores indicate better function.', 'PrimaryOutcomeTimeFrame': 'Change from Day 30 to Day 60, i.e., from Pre- to Post-treatment'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Primary Inclusion Criteria:\\n\\nstroke > 1 year previously\\nmild-to-moderate general cognitive impairment as determined by a Montreal Cognitive Assessment (MOCA) score between 10-26\\nsome impairment in performance of daily activities; this will be determined by a score of 3 or below on the Cognitive Task Activity Log (CTAL)\\n\\nAdditional Inclusion Criteria:\\n\\n40 years or older; no upper limit if medically stable\\nsufficiently fit, from both a physical and mental health perspective, to take part in study\\nadequate sight and hearing to complete UFOV test\\nadequate thinking skills, e.g., ability to follow directions, retain information, to complete UFOV and CTAL, as marked by judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\\nreside in the community (as opposed to a hospital or skilled nursing facility)\\nable to travel to laboratory on multiple occasions\\ncaregiver available\\n\\nExclusion Criteria:\\n\\ncognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse or due to another type of brain injury, such a traumatic brain injury, or a progressive brain disease, such as Alzheimer's Dementia\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Edward Taub, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '205-934-2471', 'CentralContactEMail': 'etaub@uab.edu'}, {'CentralContactName': 'Gitendra Uswatte, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '205-975-5089', 'CentralContactEMail': 'guswatte@uab.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Edward Taub, PhD', 'OverallOfficialAffiliation': 'University of Alabama at Birmingham', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Alabama at Birmingham', 'LocationStatus': 'Recruiting', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35294', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Staci McKay, BS', 'LocationContactRole': 'Contact', 'LocationContactPhone': '205-934-9768', 'LocationContactEMail': 'stacemc@uab.edu'}, {'LocationContactName': 'Edward Taub, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '205-934-2471', 'LocationContactEMail': 'etaub@uab.edu'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000060825', 'ConditionMeshTerm': 'Cognitive Dysfunction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafAsFound': 'Cognitive Dysfunction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5991', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21526', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4505', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14163', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M12168', 'InterventionBrowseLeafName': 'Nicotine', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 25, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05902767', 'OrgStudyIdInfo': {'OrgStudyId': 'NUT-me'}, 'Organization': {'OrgFullName': 'Monash University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nut Supplementation to Mitigate Post-stroke Cognitive Decline', 'OfficialTitle': 'Nut Supplementation to Mitigate Post-stroke Cognitive Decline (NUT-me): a Pilot Study', 'Acronym': 'NUT-me'}, 'StatusModule': {'StatusVerifiedDate': 'June 2023', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 30, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 30, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 18, 2023', 'StudyFirstSubmitQCDate': 'June 5, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 15, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 5, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 15, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Barbara R. Cardoso', 'ResponsiblePartyInvestigatorTitle': 'Senior Lecturer', 'ResponsiblePartyInvestigatorAffiliation': 'Monash University'}, 'LeadSponsor': {'LeadSponsorName': 'Monash University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a strong risk factor for dementia, with up to 80% of individuals having lower cognitive function 5 years after a stroke event. However, having a stroke does not need to result in declining cognition if effective strategies to reduce the risk of post stroke dementia are identified. Diets containing nuts can reduce the risk of both dementia and stroke but have not been tested in stroke survivors. Therefore, this pilot study aims to determine whether eating nuts regularly reduces post-stroke cognitive decline and dementia. The NUT-me pilot study will supplement the diet of stroke survivors with a mix of nuts containing walnuts, hazelnuts, almonds and Brazil nuts for 3 months and assess the effects on cognition and health markers. The researchers predict that regular nut consumption will contribute to preserving post-stroke cognitive function in comparison to patients who do not consume nuts. The results of this novel pilot study will be used to guide a larger trial and provide a simple dietary strategy that stroke survivors can adopt to reduce post-stroke cognitive decline.', 'DetailedDescription': \"This study will investigate the efficacy and feasibility of supplementing the habitual diet of stroke survivors with a supply of mixed nuts containing Brazil nut, walnuts, hazelnuts, and almonds to reduce post-stroke cognitive decline. The overall aim of this project will be achieved through the following objectives:\\n\\nExamine the feasibility through the assessment of compliance with the intervention and participants' perception of the study\\nInvestigate the efficacy of the intervention on cognitive decline, body composition and health outcomes (blood pressure, fasting glucose and insulin, and blood lipids) The investigators hypothesise that the inclusion of nuts is a simple dietary strategy that will slow post-stroke cognitive decline and that supplementation with nuts will improve body composition and health biomarkers of stroke survivors.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Dementia']}, 'KeywordList': {'Keyword': ['dementia', 'cognitive decline', 'nuts']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'The participants will be randomly assigned to one of the two study groups: Nuts of Control.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '10', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Nut Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive a supply of mixed nuts containing: 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nuts']}}, {'ArmGroupLabel': 'Control Group', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Participants will follow the same protocol as the Nut group regarding appointments and collection of information. At the visits, they will receive dietary counselling on how to follow the Australian Dietary Guidelines', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nuts', 'InterventionDescription': 'A mix of nuts containing 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.\\nDietary counselling on how to follow the Australian Dietary Guidelines', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nut Group']}}, {'InterventionType': 'Other', 'InterventionName': 'Control', 'InterventionDescription': '- Dietary counselling on how to follow the Australian Dietary Guidelines', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cognitive Function Composite Score', 'PrimaryOutcomeDescription': 'Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.', 'PrimaryOutcomeTimeFrame': '90 days'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Fluid Cognition Composite Score', 'SecondaryOutcomeDescription': 'Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Crystallized Cognition Composite Score', 'SecondaryOutcomeDescription': 'Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': '% body fat', 'SecondaryOutcomeDescription': 'Changes in % body fat measured using bioelectrical Impedance Analysis (BIA)', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Depressive symptoms', 'SecondaryOutcomeDescription': 'Changes in the presence of depressive symptoms assessed by Patient Health Questionnaire (PHQ-9). The score ranges from zero to 27, with higher scores indicating worse depressive symptoms.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'HOMA-IR', 'SecondaryOutcomeDescription': 'HOMA-IR is a measure of insulin resistance. It is calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Blood lipids', 'SecondaryOutcomeDescription': 'Changes in total cholesterol, LDL, HDL and triglycerides', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Inflammatory markers', 'SecondaryOutcomeDescription': 'Changes in the composite of the following inflammatory markers: IL-6, IL-1β, IL-8, IL-10, and IL-1ra', 'SecondaryOutcomeTimeFrame': '90 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIschaemic stroke (first or recurrent stroke) in the last 6 months\\nAble to attend 4 study visits over 3 months\\nMotivation and willingness to participate in the study protocol\\nNo prior neurological or psychiatric disease, including dementia\\nCan give informed consent and participate in cognitive testing\\n\\nExclusion Criteria:\\n\\nbe < 18 years;\\nhave allergy to nuts\\nhave premorbid modified Rankin scale (mRS)≥4, denoting no severe disability\\nincapable of giving consent\\nhave problems with mastication that preclude nut intake\\nhave habitual consumption of tree nuts (>2 servings/wk) in the previous 2 months\\nhave habitual consumption of alpha-linolenic acid supplements (fish oil, flaxseed oil, and/or soy lecithin)\\nhave dementia or psychiatric disease\\ndo not speak English', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Barbara R Cardoso, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+61499840472', 'CentralContactEMail': 'barbara.cardoso@monash.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Barbara R Cardoso, PhD', 'OverallOfficialAffiliation': 'Department of Nutrition, Dietetics and Food - Monash University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Nutrition, Dietetics and Food - Monash University', 'LocationCity': 'Melbourne', 'LocationState': 'Victoria', 'LocationZip': '3168', 'LocationCountry': 'Australia', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Barbara R Cardoso, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+61499840472', 'LocationContactEMail': 'barbara.cardoso@monash.edu'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'This is a small pilot study and the generated data will be used only by the Principal Investigator as preliminary data in grant applications and potentially one publication (yet to be decided).'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000003704', 'ConditionMeshTerm': 'Dementia'}, {'ConditionMeshId': 'D000060825', 'ConditionMeshTerm': 'Cognitive Dysfunction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafAsFound': 'Cognitive Decline', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6594', 'ConditionBrowseLeafName': 'Dementia', 'ConditionBrowseLeafAsFound': 'Dementia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21526', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4505', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14163', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5991', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T143', 'InterventionBrowseLeafName': 'English Walnut', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 26, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04387747', 'OrgStudyIdInfo': {'OrgStudyId': 'ıstPMRTRH-SRCPN'}, 'Organization': {'OrgFullName': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'Evaluation of Sarcopenia in Patients With Stroke', 'OfficialTitle': 'Evaluation Of Sarcopenia In Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'May 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 15, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 1, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 1, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 11, 2020', 'StudyFirstSubmitQCDate': 'May 13, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 14, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 26, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 30, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Tuğba Aydın', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is to investigate the prevalence of sarcopenia in stroke patients; to determine the relationship between sarcopenia and duration of stroke, age, gender, etiology of stroke, ambulation status, spasticity, nutrition and malnutrition', 'DetailedDescription': 'Sarcopenia was defined as a loss of skeletal muscle mass and decreased muscle strength. The purpose of this study was to investigate the prevalence of sarcopenia following stroke, to investigate the relationship between sarcopenia and duration of stroke, age, sex, etiology of stroke, ambulation status, spasticity, nutrition and malnutrition. Demographic characteristics, duration of stroke, sarcopenia presence (walking speed ≥ 0.8 m / s, SARC-F score ≥4, short physical performance battery score ≤ 8, thigh circumference <33cm (The data for Turkey) <31cm (European data)) were recorded. Hand grip strength (jamar) measured from the intact hand and TANITA BIA analysis were planned for all patients.\\n\\nAmbulation level with Functional Ambulation Classification (FAC), nutritional status with 24-hour dietary recall (24HR) method, diagnosis of malnutrition with Glim Criteria, spasticity with Modified Ashworth Scale, motor development for stroke patient Brunnstrom staging, screening for frailty with Frail questionnaire activity of daily living were evaluated with Barthel Index.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Sarcopenia', 'Stroke']}, 'KeywordList': {'Keyword': ['sarcopenia', 'stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '81', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'SARCOPENIA IN STROKE PATIENTS', 'InterventionDescription': 'Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Functional Ambulation Classification (FAC)', 'PrimaryOutcomeDescription': 'The Functional Ambulation Categories (FAC) is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device. FAC stage 0 indicates the non-functional ambulation, and stage 5 indicates the independent walking at each speed and on ground.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': '24-hour dietary recall (24HR) method', 'PrimaryOutcomeDescription': '24-hour dietary recall method consists of precisely recalling, describing and quantifying the intake of foods and beverages consumed during the day before the interview, from the first intake in the morning until the last foods or beverages consumed at night.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': 'Glim Criteria', 'PrimaryOutcomeDescription': 'The five criteria for malnutrition include non-volitional weight loss, low body mass index, and reduced muscle mass as phenotypic criteria, and reduced food intake/assimilation and inflammation/disease burden as etiologic criteria. It is proposed that the diagnosis of malnutrition be based upon the presence of at least one phenotypic criterion and one etiologic criterion.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': 'sarcopenia', 'PrimaryOutcomeDescription': 'The walking speed ≥0.8 m / s, SARC-F score ≥4, short physical performance battery score ≤ 8, thigh circumference <33cm.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': 'EQ-5D', 'PrimaryOutcomeDescription': 'EQ-5D-3L is used to evaluate the quality of life. This scale scores five health conditions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) through evaluation in 3 levels (no problems, some problems, extreme problems).', 'PrimaryOutcomeTimeFrame': '1 interview day'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Barthel index', 'SecondaryOutcomeDescription': 'The Barthel Index measures the activity limitations in patients with neuromuscular disease. The Barthel Index are assessed, including toileting, bathing, eating, dressing, continence, transfers, and ambulation. A client scoring 0 points would be dependent in all assessed activities of daily living, whereas a score of 100 would reflect independence in these activities.', 'SecondaryOutcomeTimeFrame': '1 interview day'}, {'SecondaryOutcomeMeasure': \"Brunnstrom's staging\", 'SecondaryOutcomeDescription': \"Brunnstrom's staging is used to evaluate the sequence of motor development and reorganization of the brain after stroke in six stages. Stage 1: Flaccidity; Stage 2: Spasticity Appears; Stage 3: Increased Spasticity; Stage 4: Decreased Spasticity; Stage 5: Spasticity Continues to Decrease; Stage 6: Spasticity Disappears and Coordination Reappears.\", 'SecondaryOutcomeTimeFrame': '1 interview day'}, {'SecondaryOutcomeMeasure': 'Modified Ashworth Scale', 'SecondaryOutcomeDescription': 'The Modified Ashworth scale (MAS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Scoring: 0: No increase in muscle tone; 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension; 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM; 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved; 3: Considerable increase in muscle tone, passive movement difficult; 4: Affected part(s) rigid in flexion or extension.', 'SecondaryOutcomeTimeFrame': '1 interview day'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with chronic stroke (Stroke duration > 3 months)\\nPatients with a FAC score > 3\\n\\nExclusion Criteria:\\n\\nPatients unable to cooperate\\nOther diseases that cause gait disorders such as neuromuscular disease, cardiopulmonary problems.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Inpatient stroke cases', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'TUGBA AYDIN, MD', 'OverallOfficialAffiliation': 'Istanbul Physical Medicine Rehabilitation Training & Research Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital', 'LocationCity': 'İstanbul', 'LocationZip': '34192', 'LocationCountry': 'Turkey'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25676847', 'ReferenceType': 'background', 'ReferenceCitation': 'Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10.'}, {'ReferencePMID': '27530769', 'ReferenceType': 'background', 'ReferenceCitation': 'Ryan AS, Ivey FM, Serra MC, Hartstein J, Hafer-Macko CE. Sarcopenia and Physical Function in Middle-Aged and Older Stroke Survivors. Arch Phys Med Rehabil. 2017 Mar;98(3):495-499. doi: 10.1016/j.apmr.2016.07.015. Epub 2016 Aug 13.'}, {'ReferencePMID': '34356039', 'ReferenceType': 'derived', 'ReferenceCitation': 'Aydin T, Kesiktas FN, Oren MM, Erdogan T, Ahisha YC, Kizilkurt T, Corum M, Karacan I, Ozturk S, Bahat G. Sarcopenia in patients following stroke: an overlooked problem. Int J Rehabil Res. 2021 Sep 1;44(3):269-275. doi: 10.1097/MRR.0000000000000487.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000055948', 'ConditionMeshTerm': 'Sarcopenia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009133', 'ConditionAncestorTerm': 'Muscular Atrophy'}, {'ConditionAncestorId': 'D000020879', 'ConditionAncestorTerm': 'Neuromuscular Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000001284', 'ConditionAncestorTerm': 'Atrophy'}, {'ConditionAncestorId': 'D000020763', 'ConditionAncestorTerm': 'Pathological Conditions, Anatomical'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafAsFound': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11780', 'ConditionBrowseLeafName': 'Muscular Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4279', 'ConditionBrowseLeafName': 'Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22309', 'ConditionBrowseLeafName': 'Neuromuscular Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22209', 'ConditionBrowseLeafName': 'Pathological Conditions, Anatomical', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 27, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05369637', 'OrgStudyIdInfo': {'OrgStudyId': '75/CES/JAS/2021'}, 'Organization': {'OrgFullName': 'Instituto de Saude Publica da Universidade do Porto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Multiple Interventions to Accelerate the Return to the Pre-event Level of Functioning After a TIA and Minor Stroke', 'OfficialTitle': 'Back to Normal - Multiple Non-pharmacological Interventions to Accelerate the Return to the Pre-event Level of Functioning After a Transient Ischemic Attack and Minor Stroke - a Pilot Randomized Controlled Trial'}, 'StatusModule': {'StatusVerifiedDate': 'May 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 11, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 2, 2022', 'StudyFirstSubmitQCDate': 'May 6, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 11, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 31, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 3, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Instituto de Saude Publica da Universidade do Porto', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The occurrence of a transient ischemic attack (TIA) or a minor stroke is frequently assumed as a temporary and non-disabling event. Nevertheless, patients can experience subtle but meaningful impairments, including a decreased performance in activities of daily living (ADLs), a high prevalence of depression, cognitive decline, physical deficits, hearing degeneration, with implications in returning to work, social relations and activities. Additionally, it has been described a higher risk of stroke among these patients, which highlights the importance of promoting secondary prevention, soon after these acute episodes. Therefore, this pilot randomized controlled trial (RCT) aims to evaluate the feasibility and the effectiveness of a three-month multidomain intervention program, composed of five non-pharmacological components which may contribute to accelerate the return to the pre-event level of functioning in patients with TIA and minor stroke. The results may guide future clinical practices and health policies aiming to reduce the overall burden of stroke.', 'DetailedDescription': 'This is pragmatic non-pharmacological RCT, which will include patients diagnosed with a TIA or a minor stroke recruited at the emergency or neurology departments of the Hospital Pedro Hispano, located in Matosinhos, Portugal (n=70). Those who accept to participate will be randomly allocated to 2 groups (1:1): (a) Intervention - will receive a combined approach of cognitive training, physical exercise, nutrition education and psychoeducation sessions, during three-months, as well as assessment/correction of hearing loss; (b) Control - participants will not be subject to any intervention. Both groups will receive the usual standard of care provided to these types of clinical diseases.\\n\\nData will be collected using different strategies. Trained interviewers will conduct face-to-face interviews, covering sociodemographic characteristics, lifestyles (including adherence to the mediterranean diet), health status, and will perform anthropometry and measure blood pressure as well as physical performance. The complete or partial recovery time of instrumental ADLs will be assessed using an adapted version of the Frenchay Activities Index. Disability and basic ADLs will be also evaluated (Modified Rankin Scale and Barthel Index, respectively). Cognitive function will be evaluated using the Montreal Cognitive Assessment and a self-administered web-based tool for remote longitudinal assessment (Brain on Track), if applicable. Symptoms of anxiety and depression, as well as quality of life, will be evaluated through self-administered instruments. Levels of glycated hemoglobin and 24-hour urinary sodium, potassium and creatinine excretions, as well as pH levels, will be also measured. All participants will be evaluated at 0 and 3 months after the beginning of the intervention. Electronic medical records will be assessed to obtain clinical data.\\n\\nFunctionality recovery will be defined as a primary outcome and additional information regarding the feasibility, outcomes and sample size requirements of such programs will also be assessed, which is crucial to implement a large-scale RCT.\\n\\nThis project was previously approved by the Local Ethics Committee and by the Data Protection Officer of the Institute of Public Health of the University of Porto. In this context, all procedures will be undertaken to guarantee compliance with ethical standards, as well as data protection and safety, considering national and international laws.\\n\\nThis study will be developed as part of the project \"Multiple Interventions to Prevent Cognitive Decline\" (MIND-Matosinhos).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Transient Ischemic Attack', 'Minor Stroke']}, 'KeywordList': {'Keyword': ['Transient Ischemic Attack', 'Minor Stroke', 'Non-Pharmacological Interventions', 'Activities of Daily Living', 'Randomized Controlled Trial']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '70', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Non-pharmacological Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in the intervention group will receive a multidomain non-pharmacological program, including cognitive training, physical exercise, nutrition education, psychoeducation, and diagnosis and correction of hearing impairment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive training', 'Behavioral: Physical exercise', 'Behavioral: Behavioral: Nutrition education', 'Behavioral: Psychoeducation', 'Other: Diagnosis and correction of hearing impairment']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Control group will receive the usual standard of care provided to these clinical diseases.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive training', 'InterventionDescription': 'This component will comprise the following activities:\\n\\ni. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Physical exercise', 'InterventionDescription': 'This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:\\n\\ni. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Behavioral: Nutrition education', 'InterventionDescription': 'This component will be based on the following activities:\\n\\ni. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Psychoeducation', 'InterventionDescription': 'This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Diagnosis and correction of hearing impairment', 'InterventionDescription': 'This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Time to recovery in each instrumental activity of daily living', 'PrimaryOutcomeDescription': 'Time to recovery in each instrumental activity of daily living measured by an adapted version of the Frenchay Activities Index.', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Recruitment timeframe', 'PrimaryOutcomeDescription': 'Proportion of participants recruited within the seven days post-onset of symptoms will be calculated as the number of participants recruited within the time frame divided by the total number of participants.', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Adherence to each component of the intervention', 'PrimaryOutcomeDescription': 'Proportion of adherence to each component of the intervention and to different intervention modalities (remote/in person), calculated as the number of sessions attended divided by the total number of sessions implemented. For remote cognitive training the outcome will be the absolute number of sessions.', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Dropout', 'PrimaryOutcomeDescription': 'Proportion of participants who dropped out of the study, calculated as the number of participants who dropped out after attending at least one session divided by the total number of participants who attended at least one session.', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Time of follow-up', 'SecondaryOutcomeDescription': 'Number of days between the first and the last session attended by the participant.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Complete assessment of participants', 'SecondaryOutcomeDescription': 'For each study outcome, proportion of participants with complete information, calculated at baseline and follow-up, as the number of participants with complete information divided by the total number of participants evaluated.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Implemented sessions', 'SecondaryOutcomeDescription': 'Proportion of sessions implemented, calculated as the number of sessions that the research team was able to implement divided by the total number of sessions planned.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Cognitive performance', 'SecondaryOutcomeDescription': \"Variation of participant's cognitive performance assessed using the Montreal Cognitive Assessment, between the baseline and the follow-up assessments. This scale varies from 0 (worst cognitive performance) to 30 points (best cognitive performance).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Memory complaints', 'SecondaryOutcomeDescription': 'Variation of the self-reported memory complaints, assessed using the Subjective Memory Complaints Scale, between the baseline and follow-up assessments. This scale varies from 0 (best score) to 21 points (worst score). Scores over three points indicate the presence of self-reported memory complaints.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Adherence to the Mediterranean diet', 'SecondaryOutcomeDescription': \"Variation of participant's self-reported adherence to the Mediterranean diet, assessed using the Mediterranean food pattern (MEDAS) scale, between the baseline and the follow-up assessments. This scale varies from 0 (lowest adherence to the Mediterranean diet) to 14 points (highest adherence to the Mediterranean diet). A score over 10 points indicates good adherence to the Mediterranean diet.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Anxiety and depression', 'SecondaryOutcomeDescription': 'Variation of the anxiety and depression scores, assessed using the Hospital Anxiety and Depression Scale (HADS), between the baseline and the follow-up assessments. This scale varies from 0 (best score) to 21 points (worst score).', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Reported quality of life', 'SecondaryOutcomeDescription': \"Variation of participant's quality of life, assessed using the EuroQol Group scale - 5 dimensions (EQ-5D) scale, between the baseline and the follow-up assessments. This scale is subdivided in two subscales: a) five multiple choice questions, with five response possibilities, which produce a score that varies from 5 (best score) to 25 points (worst score); b) visual analogic scale, that varies from 0 (worst score) to 100 (best score).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Handgrip strength', 'SecondaryOutcomeDescription': \"Variation of participant's handgrip strength, assessed using a dynamometer, between the baseline and the follow-up assessments.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Agility 1', 'SecondaryOutcomeDescription': \"Variation of participant's agility and balance, assessed using the Timed Up and Go Test scale, between the baseline and the follow-up assessments. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Agility 2', 'SecondaryOutcomeDescription': \"Variation of participant's agility and balance, assessed using the Unipedal Stance Test, between the baseline and the follow-up assessments. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Upper body strength', 'SecondaryOutcomeDescription': \"Variation of participant's upper body strength assessed using the 30-second arm curl test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Lower body strength', 'SecondaryOutcomeDescription': \"Variation of participant's lower body strength assessed using the 30-second chair stand test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Upper body flexibility', 'SecondaryOutcomeDescription': \"Variation of participant's upper body flexibility assessed using the back-scratch test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Lower body flexibility', 'SecondaryOutcomeDescription': \"Variation of participant's lower body flexibility assessed using the chair sit-and-reach test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Agility 3', 'SecondaryOutcomeDescription': \"Variation of participant's agility and dynamic balance assessed using the 8-foot distance test (2,44 meters), from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Aerobic endurance', 'SecondaryOutcomeDescription': \"Variation of participant's aerobic endurance assessed using the 2-minute step test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Lower limb function', 'SecondaryOutcomeDescription': \"Variation of participant's lower limb function, assessed using the Short Physical Performance Battery (SPPB), which tests 3 dimensions: standing balance, walking speed, and chair stands. Each component is scored between 0-4, total score from 0 (poor performance) to 12 (best performance).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Functional capacity to perform basic activities of daily living', 'SecondaryOutcomeDescription': \"Variation of participant's independence on performing basic activities of daily living, using the Barthel Index, which ranges from 0 to 20 and higher scores represent increased functionality and independence.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Disability', 'SecondaryOutcomeDescription': \"Variation of participant's disability assessed via modified Rankin Scale, with scores ranging from 0 (perfect health) to 6 (dead).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': '24-hour urinary sodium excretion', 'SecondaryOutcomeDescription': \"Variation of participant's urinary sodium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary salt intake.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': '24-hour urinary potassium excretion', 'SecondaryOutcomeDescription': \"Variation of participant's urinary potassium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary potassium intake.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Levels of glycated hemoglobin', 'SecondaryOutcomeDescription': \"Variation of participant's levels of glycated hemoglobin, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' blood sample and will be used to analyze glycemic control.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Body mass index', 'SecondaryOutcomeDescription': \"Variation of participant's body mass index between the baseline and the follow-up assessments.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Blood pressure', 'SecondaryOutcomeDescription': \"Variation of participant's systolic and diastolic blood pressure between the baseline and the follow-up assessments.\", 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAged 18-85 years old;\\nClinical diagnosis of transient ischemic stroke or minor stroke as defined by the National Institute of Health Stroke Scale score ≤3;\\nOnset of symptoms within the last seven days;\\nFirst-time stroke or TIA;\\nFour or more years of education;\\nDischarged home without the need for inpatient rehabilitation;\\nModified Rankin Scale 0 to 2, inclusive.\\n\\nExclusion Criteria:\\n\\nUnable to attend the face-to-face intervention sessions;\\nPrevious diagnosis of Dementia or severe disability;\\nContraindication for physical exercise;\\nSevere loss of hearing, vision, or communication skills;\\nFrailty, reduced life expectancy due to severe disease or need for regular treatments that compete with availability for intervention.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Ana Rute Costa, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+351 22 206 1820', 'CentralContactEMail': 'arcosta@ispup.up.pt'}, {'CentralContactName': 'Micaela Gonçalves, Bachelor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+351 22 206 1820', 'CentralContactEMail': 'esmeralda_micaela@hotmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Vítor Tedim Cruz, PhD', 'OverallOfficialAffiliation': 'Instituto de Saude Publica da Universidade do Porto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Instituto de Saúde Pública da Universidade do Porto', 'LocationStatus': 'Recruiting', 'LocationCity': 'Porto', 'LocationZip': '4050-600', 'LocationCountry': 'Portugal', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ana Rute Costa', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+351 22 206 1820'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000002546', 'ConditionMeshTerm': 'Ischemic Attack, Transient'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000002545', 'ConditionAncestorTerm': 'Brain Ischemia'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5485', 'ConditionBrowseLeafName': 'Ischemic Attack, Transient', 'ConditionBrowseLeafAsFound': 'Transient Ischemic Attack', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5484', 'ConditionBrowseLeafName': 'Brain Ischemia', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 28, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01777672', 'OrgStudyIdInfo': {'OrgStudyId': 'Marató-11'}, 'Organization': {'OrgFullName': 'Hospital de Mataró', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia', 'OfficialTitle': 'Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia (OD). A Randomized Controlled Trial.'}, 'StatusModule': {'StatusVerifiedDate': 'February 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2016', 'PrimaryCompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 21, 2013', 'StudyFirstSubmitQCDate': 'January 28, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 29, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 7, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 9, 2017', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Pere Clave', 'ResponsiblePartyInvestigatorTitle': 'MD, PhD', 'ResponsiblePartyInvestigatorAffiliation': 'Hospital de Mataró'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Mataró', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Oropharyngeal dysphagia (OD) is a major complaint among many patients with stroke and causes severe complications. There is no specific treatment for these patients. Impaired swallow response is caused by a delay in the timing of oropharyngeal reconfiguration with delayed airway protection. Swallow response is initiated by sensory afferent fibers in the oropharynx and cerebral cortex reaching the central swallowing pattern generator (CPG) in the medulla oblongata and brainstem motor nuclei. Hypothesis: Stimulation of pharyngeal sensory afferent fibers through TRPV1 receptors and electrical stimuli might enhance the stimulation of the CPG and speed the swallow response. Long-term treatment of OD will improve clinical outcome of stroke patients. Aim: To assess the effect of TRPV1 agonists (capsaicin) and that of sensorial pharyngeal electrical stimulation (intrapharyngeal and transcutaneous) on VFS signs and swallow response at 3, 6 and 12 months after treatment in stroke patients with established OD. To compare the clinical effect of classical rehabilitation strategies with that of these new afferent sensorial neurostimulation strategies in terms of nutritional status parameters, incidence of aspiration pneumonia and/or low respiratory tract infection, quality of life, and mortality. Methods: Clinical screening of OD with the volume-viscosity swallow test and assessment by VFS and quantitative measurements of swallow response. Randomized controlled trial assessing the effect of standard rehabilitation with that of afferent sensorial neurostimulation strategies.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Dysphagia', 'Aspiration', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '100', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Dietary and oral hygiene recommendations', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations']}}, {'ArmGroupLabel': 'oral TRPV1 agonist', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations', 'Dietary Supplement: oral TRPV1 agonist']}}, {'ArmGroupLabel': 'pharyngeal electrical stimulation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations', 'Device: pharyngeal electrical stimulation']}}, {'ArmGroupLabel': 'transcutaneous electrical stimulation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations', 'Device: transcutaneous electrical stimulation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Dietary and oral hygiene recommendations', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Dietary and oral hygiene recommendations', 'oral TRPV1 agonist', 'pharyngeal electrical stimulation', 'transcutaneous electrical stimulation']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'oral TRPV1 agonist', 'InterventionDescription': 'Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['oral TRPV1 agonist']}}, {'InterventionType': 'Device', 'InterventionName': 'pharyngeal electrical stimulation', 'InterventionDescription': 'Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pharyngeal electrical stimulation']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Electrodes (Gaeltec, Ltd, Dunvegan, Isle of Skye, UK.', 'Electrical stimulator (Grass Instruments Co, USA)']}}, {'InterventionType': 'Device', 'InterventionName': 'transcutaneous electrical stimulation', 'InterventionDescription': 'Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['transcutaneous electrical stimulation']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Intelect VitalStim, Chattanooga, USA)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To assess the efficacy and safety of new neuron-stimulation treatments for OD in patients with stroke and to explore their mechanism of action.', 'PrimaryOutcomeDescription': 'The efficacy of each treatment will be assessed by VFS in each patient after the treatment and at the end of the follow-up period, considering Rosenbek scale and measures of oropharyngeal swallow response including oropharyngeal reconfiguration, timing and extent of hyoid motion and bolus propulsion force of the tongue. Clinical outcome also evaluated are episodes of aspiration pneumonia and low respiratory tract infections, nutritional status, complications and clinical symptoms experimented during one year of follow-up and mortality rates and cause of death.\\n\\nParticipating clinicians will be instructed to register and describe all serious adverse events (SAE) occurred during the study and report them on a specific form within 24 hours. The guidelines for SAE reporting to the Ethical Committee and competent authorities will be followed.', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To determine the prevalence of OD and its complications in stroke patients over one year.', 'SecondaryOutcomeTimeFrame': '12 months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'To assess and compare one year health resource consumption between all study treatment groups.', 'OtherOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n- Person with persistent clinical signs or symptoms of OD according to V-VST and confirmed with VFS (PA scale level 3 or more) secondary to a stroke episode in the last 3 months.\\n\\nExclusion Criteria:\\n\\nPatient unconscious or in a coma\\nPatients diagnosed with transitory ischemic accident\\nlife expectancy less than 3 months\\nneurodegenerative disease', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Pere Pere, Doctor', 'OverallOfficialAffiliation': 'Hospital de Mataró, Gastrointestinal Physiology Laboratory', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital de Mataró', 'LocationCity': 'Mataró', 'LocationState': 'Barcelona', 'LocationZip': '08304', 'LocationCountry': 'Spain'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}, {'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Dysphagia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M5161', 'InterventionBrowseLeafName': 'Capsaicin', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Derm', 'InterventionBrowseBranchName': 'Dermatologic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 29, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03470506', 'OrgStudyIdInfo': {'OrgStudyId': '20154'}, 'Organization': {'OrgFullName': 'University of Virginia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Study of the Relationship of Gut Microbial Composition and Stroke Outcome', 'OfficialTitle': 'A Study of the Relationship of Gut Microbial Composition and Stroke Outcome', 'Acronym': 'GEMSTONE'}, 'StatusModule': {'StatusVerifiedDate': 'November 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 20, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 6, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 1, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 29, 2017', 'StudyFirstSubmitQCDate': 'March 16, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 20, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 17, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 19, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Virginia', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Colorado, Denver', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to investigate the relationship between gut microbiome (bacteria in the gut), inflammation and the injured brain. It has been established that bacteria in the gut play key roles in digestion, nutrition absorption and immune response of the entire body. Human intestinal bacteria composition in the gut has been associated with several stroke risk factors including obesity, insulin resistance, diabetes and hypertension. If we can establish a relationship between gastrointestinal microbial community composition and ischemic stroke outcomes could lead to dietary interventions in the future to improve recovery after a stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Fecal and blood samples will be collected. The biorepository will contain acute and convalescent samples: DNA (genetic and epigenetic), RNA (gene expression), serum/plasma (biomarker levels, proteomics), and fecal (microbiome) samples couple with clinical and research data.'}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Ischemic stroke', 'ArmGroupDescription': 'Diagnosed with an ischemic stroke by a Neurologist', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Stool Samples']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Stool Samples', 'InterventionDescription': 'Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ischemic stroke']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Measured differences in taxonomic make-up and the relative frequency of the gut microbial composition in relation to excellent vs. poor stroke outcome', 'PrimaryOutcomeDescription': 'The primary outcome in this case-comparison design of those with excellent vs. non-excellent ischemic stroke outcomes at 3 months as measured by the National Institutes of Health Stroke Scale (NIHSS) is the taxonomic make up of the gut microbial composition. In other words, comprehensive microbiota survey results from 16S rRNA gene sequencing from individuals with excellent outcomes versus all other outcomes at 3 months are the outcome.', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Cogstate cognitive correlates and post-stroke microbial composition', 'SecondaryOutcomeDescription': 'Descriptive analyses will be used to develop a preliminary understanding of microbiome composition in relation to measures of cognitive functioning as derived from Cogstate cognitive assessment results at baseline and 3 months post- ischemic stroke', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMen and women at least 18 years of age.\\nWilling and able to attend all study visits.\\nEnglish speaking.\\nMust have had a stroke that occurred within 48 hours of admission to the Stroke Unit as determined by a neurologist.\\n\\nExclusion Criteria:\\n\\nHistory of inflammatory bowel disease.\\nReceiving antibiotics within 30 days of entry into the study.\\nHistory of institutionalization for mental illness within the last year.\\nUnable to consent and does not have a surrogate available to consent on their behalf.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Community probability sample of adults who have suffered an ischemic stroke within 48 hours of admission to UVA', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sonya A Gunter, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '434-924-9664', 'CentralContactEMail': 'sag7bf@hscmail.mcc.virginia.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bradford Worrall, MD, MS', 'OverallOfficialAffiliation': 'University of Virginia', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Virginia Health System', 'LocationStatus': 'Enrolling by invitation', 'LocationCity': 'Charlottesville', 'LocationState': 'Virginia', 'LocationZip': '22908', 'LocationCountry': 'United States'}, {'LocationFacility': 'Inova Health System', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fairfax', 'LocationState': 'Virginia', 'LocationZip': '22031', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Robert Lipsky, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '571-472-0240', 'LocationContactEMail': 'robert.lipsky@inova.org'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 30, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03021252', 'OrgStudyIdInfo': {'OrgStudyId': 'PSM/RHB/NR21'}, 'Organization': {'OrgFullName': 'Parc de Salut Mar', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Respiratory Muscle Training in Stroke Swallowing Disorders', 'OfficialTitle': 'The RETORNUS-2 Study: Impact of Respiratory Muscle Training on Swallowing Disorders in Stroke Patients', 'Acronym': 'RETORNUS-2'}, 'StatusModule': {'StatusVerifiedDate': 'September 2019', 'OverallStatus': 'Terminated', 'WhyStopped': 'Because of the SARS-COV2 pandemic. Recruitment stopped at 48 patients', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 1, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 16, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 10, 2017', 'StudyFirstSubmitQCDate': 'January 11, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 13, 2017', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 18, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 22, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Parc de Salut Mar', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Instituto de Salud Carlos III', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Clinical randomized clinical trial to assess the effectiveness of incorporating inspiratory and expiratory muscle training (IEMT) in the rehabilitation of stroke patients with dysphagia in terms of functional outcomes, comorbidities, survival and quality of life.\\n\\nThis project also incorporates a longitudinal study to assess the clinical impact of dysphagia on body composition and nutritional status in stroke patients.', 'DetailedDescription': 'Stroke is a major cause of morbidity and mortality worldwide. Stroke can lead to varying degrees of oropharyngeal dysphagia (25-85% of patients) and respiratory muscle dysfunction associated with an increase in medical complications such as bronchoaspiration, malnutrition and death. Dysphagia is present in a significant proportion of patients admitted to Rehabilitation (up to 85% depending on series) in stroke. Standard swallow therapy consists of educational intervention aimed to improve self-management of dysphagia and protect the airway, oral exercises to improve lingual praxis, and compensatory techniques based on videofluoroscopic findings. Recent studies suggest that IEMT can improve swallowing efficacy and reduce eventual bronchoaspiration events.\\n\\nNutritional status appears in 9-67% of patients with acute and subacute stroke and has an impact on functional outcomes and provides information about the risk of hospitalization and death. Stroke patients are at risk of developing malnutrition because of neurologic impairments related to feeding (chewing, deglutition and self-feeding) that can result in a poor food intake. To date, there is only few studies on prevalence and influence of malnutrition in stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Swallowing Disorder', 'Stroke', 'Respiratory Muscle Training', 'Malnutrition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'High intensity IEMT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Inspiratory and expiratory muscle training + standard swallow therapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: High intensity IEMT']}}, {'ArmGroupLabel': 'Sham IEMT', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Sham inspiratory and expiratory muscle training + standard swallow therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Sham IEMT']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'High intensity IEMT', 'InterventionDescription': 'Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['High intensity IEMT']}}, {'InterventionType': 'Device', 'InterventionName': 'Sham IEMT', 'InterventionDescription': '5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sham IEMT']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in respiratory muscle strength', 'PrimaryOutcomeDescription': 'Respiratory muscle strength is assessed through maximal inspiratory and expiratory pressures (PImax and PEmax, respectively) using a pressure transducer connected to a digital register system. The PImax is measured at mouth during a maximum effort from residual volume against occluded airway. To determine the PEmax, the patients will perform a maximum expiratory effort from total lung capacity (TLC) in the face of the occluded airway. A specific and validated respiratory pressures manometer will be used (Micro RPM, Cardinalhealth, Kent, UK).', 'PrimaryOutcomeTimeFrame': 'Baseline and weekly during 8 weeks'}, {'PrimaryOutcomeMeasure': 'Change in dysphagia severity', 'PrimaryOutcomeDescription': 'Dysphagia severity is assessed with the Penetration-Aspiration Scale: scores of 1-2 indicate normal swallowing; 3-5, penetration; >6, aspiration.', 'PrimaryOutcomeTimeFrame': 'Baseline, 8 weeks, 6 months post-stroke'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in tongue strength', 'SecondaryOutcomeDescription': 'Lingual Force (IOPI system): maximum isometric tongue pressure defined as the highest of the three peak isometric tongue pressure scores.', 'SecondaryOutcomeTimeFrame': 'Baseline and weekly during 8 weeks'}, {'SecondaryOutcomeMeasure': 'Change in fat-free mass', 'SecondaryOutcomeDescription': 'Fat-free mass measured by electrical bioimpedance in kilograms and expressed as normal, low or high values according to normal values for the reference population', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months and 6 months post-stroke'}, {'SecondaryOutcomeMeasure': 'Malnutrition at 6 months', 'SecondaryOutcomeDescription': 'Malnutrition criteria of the European Society of Clinical Nutrition and Metabolism (ESPEN)', 'SecondaryOutcomeTimeFrame': 'Baseline and 6 months post-stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFirst-ever Ischemic or haemorrhagic stroke\\nTime since stroke onset: 1 month\\nDysphagia confirmed by videofluoroscopic study with a score >3 in the 8-point Penetration Aspiration Scale.\\nMini-mental State Exploration > 24)\\n\\nExclusion Criteria:\\n\\nAphasia\\nHistory of cardiopulmonary disease; neurologic condition other than stroke and metabolic disease\\nMedical treatment with potential effect on muscle structure and function', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anna Guillén-Solà, MD, PhD', 'OverallOfficialAffiliation': 'Fundació IMIM - Parc de Salut Mar', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Hospital de l'Esperança\", 'LocationCity': 'Barcelona', 'LocationState': 'Catalonia', 'LocationZip': '08024', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Physical Medicine & Rehabilitation Dpt. Parc de Salut Mar.', 'LocationCity': 'Barcelona', 'LocationZip': '08024', 'LocationCountry': 'Spain'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '16269630', 'ReferenceType': 'background', 'ReferenceCitation': 'Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005 Dec;36(12):2756-63. doi: 10.1161/01.STR.0000190056.76543.eb. Epub 2005 Nov 3.'}, {'ReferencePMID': '27271373', 'ReferenceType': 'background', 'ReferenceCitation': 'Guillen-Sola A, Messagi Sartor M, Bofill Soler N, Duarte E, Barrera MC, Marco E. Respiratory muscle strength training and neuromuscular electrical stimulation in subacute dysphagic stroke patients: a randomized controlled trial. Clin Rehabil. 2017 Jun;31(6):761-771. doi: 10.1177/0269215516652446. Epub 2016 Jun 7.'}, {'ReferencePMID': '26180145', 'ReferenceType': 'background', 'ReferenceCitation': 'Messaggi-Sartor M, Guillen-Sola A, Depolo M, Duarte E, Rodriguez DA, Barrera MC, Barreiro E, Escalada F, Orozco-Levi M, Marco E. Inspiratory and expiratory muscle training in subacute stroke: A randomized clinical trial. Neurology. 2015 Aug 18;85(7):564-72. doi: 10.1212/WNL.0000000000001827. Epub 2015 Jul 15.'}, {'ReferencePMID': '25503549', 'ReferenceType': 'background', 'ReferenceCitation': 'Kulnik ST, Birring SS, Moxham J, Rafferty GF, Kalra L. Does respiratory muscle training improve cough flow in acute stroke? Pilot randomized controlled trial. Stroke. 2015 Feb;46(2):447-53. doi: 10.1161/STROKEAHA.114.007110. Epub 2014 Dec 11.'}, {'ReferencePMID': '22732970', 'ReferenceType': 'background', 'ReferenceCitation': 'Burgos R, Sarto B, Elio I, Planas M, Forga M, Canton A, Trallero R, Munoz MJ, Perez D, Bonada A, Salo E, Lecha M, Enrich G, Salas-Salvado J; Group for the Study of Malnutrition in Hospitals in Catalonia. Prevalence of malnutrition and its etiological factors in hospitals. Nutr Hosp. 2012 Mar-Apr;27(2):469-76. doi: 10.1590/S0212-16112012000200018.'}, {'ReferencePMID': '34172071', 'ReferenceType': 'derived', 'ReferenceCitation': 'Guillen-Sola A, Messaggi-Sartor M, Ramirez-Fuentes C, Marco E, Duarte E. The Retornus-2 study: impact of respiratory muscle training in subacute stroke patients with dysphagia, study protocol of a double-blind randomized controlled trial. Trials. 2021 Jun 25;22(1):416. doi: 10.1186/s13063-021-05353-y.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}, {'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}, {'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Swallowing Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}]}}}}}, {'Rank': 31, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03394339', 'OrgStudyIdInfo': {'OrgStudyId': 'CIHR-FRU VEG & CVD 2017'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Meta-analysis of Fruit and Vegetable Sources and Cardiovascular Outcomes', 'OfficialTitle': 'Relation of Fruit and Vegetable Sources With Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies.'}, 'StatusModule': {'StatusVerifiedDate': 'October 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 1, 2018', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 1, 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 3, 2018', 'StudyFirstSubmitQCDate': 'January 8, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 9, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 11, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John Sievenpiper', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Fruit and vegetables are a cornerstone of healthy dietary patterns and dietary guidelines worldwide. The supporting evidence, however, is largely derived from observational studies of protective associations with cardiovascular disease (CVD) in health-conscious populations or from randomized trials of the effect of specific fruit or vegetable derived nutrients on CVD risk factors. A growing body of literature has influenced a shift away from a focus on single nutrients to a focus on whole foods and dietary patterns. To what extent fruit and vegetables should contribute to dietary patterns for cardiovascular health and whether specific types of fruit or vegetables should be recommended is unclear. Although previous systematic reviews and meta-analyses have elucidated the association between the intake of total and some specific fruit and vegetables with cardiovascular outcomes, a comprehensive synthesis comparing the certainty of the evidence for the different types of fruit and vegetables in relation to a range of cardiovascular outcomes has yet to be completed. We propose to conduct a systematic review and meta-analysis of the available prospective cohort studies using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the association between different types of fruit and vegetables and different cardiovascular outcomes that include CVD, coronary heart disease [CHD], and stroke incidence and mortality.', 'DetailedDescription': 'Background:\\n\\nA high intake of fruit and vegetables is a common trait among healthy dietary patterns and a cornerstone of nutrition interventions for cardiovascular disease (CVD) prevention. There is an international consensus that at least 5 servings per day of fruit and vegetables is beneficial to overall population health (WHO, 2003). This guidance, however, is largely founded on observational studies showing protective associations of high intakes of fruit and vegetables with CVD in health-conscious individuals (Reddy and Katan, 2004). Recommendations to consume specific types of fruit and vegetables, such as citrus fruit and green leafy vegetables, have been established mainly on the association of isolated nutrients with CVD risk reduction in observational studies or the effect of isolated nutrients on CVD risk factors in small randomized trials (Katamay et al., 2007). Given its prominence in dietary guidelines, there is a need to determine the extent of CVD risk reduction that may be attributed to the consumption of fruit and vegetables. As guidelines are shifting away from a focus on single nutrients to a focus on whole foods and dietary patterns and achieving adequate intakes continue to be a challenge worldwide and (Hall et al., 2009), there is also an advantage in establishing which types of fruit and vegetables are associated with the greatest protection in CVD incidence and mortality per serving. Although several systematic reviews and meta-analyses of prospective cohort studies have demonstrated protective associations between the intake of total fruit and vegetables and CVD risk (Aune et al., 2017; Zhan et al., 2017; Gan et al., 2015; Wang et al, 2014; Hu et al., 2007; He et al., 2007; Dauchet et al., 2006), few have focused on specific fruit and vegetables or explored a range of cardiovascular outcomes which may have different etiologies. Several large prospective cohort studies have recently been published which may strengthen the certainty of the evidence by increasing the number of observations for the relationship between different fruit and vegetables exposures and different cardiovascular outcomes. We propose to build and expand on the exiting systematic reviews and meta-analyses by conducting a comprehensive synthesis of prospective cohort studies comparing the certainty of the evidence for the different types of fruit and vegetables in relation to a range of cardiovascular outcomes.\\n\\nObjective:\\n\\nTo conduct a systematic review and meta-analysis of the available prospective cohort studies using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the association between different types of fruit and vegetables and different cardiovascular outcomes including CVD, CHD, and stroke incidence and mortality.\\n\\nDesign:\\n\\nThe conduct of the proposed systematic review and meta-analysis will follow the Cochrane handbook for systematic reviews of interventions and the GRADE handbook for grading the certainty of the evidence and the strength of recommendations using the GRADE approach. The reporting will follow the Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.\\n\\nData Sources:\\n\\nMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) will be searched using relevant search terms. Search of databases will be supplemented by manual searches of bibliographies.\\n\\nStudy Selection:\\n\\nProspective cohort studies exploring the relation of fruit and/or vegetable intake to incident cardiovascular disease for a minimum follow-up time of 1 year will be included.\\n\\nData extraction:\\n\\nTwo independent reviewers will extract relevant information including study design, sample size, subject characteristics, exposure form (i.e. total fruit and vegetables, citrus fruit, green leafy vegetables, etc.), duration/person-years of follow-up, adjustments of models and risk ratios for clinical outcomes derived from clinical event data across quantiles of exposure. Any disagreements will be reconciled by consensus with arbitration by the Principal Investigator.\\n\\nRisk of bias:\\n\\nRisk of bias (ROB) will be assessed by two independent reviewers using the Newcastle-Ottawa Scale (NOS). Up to 9 points can be awarded based on cohort selection (max 4 points), the comparability of cohort design and analysis (max 4 points), and adequacy of the outcome measures (max 3 points). Studies that receive ≥6 points will be considered as higher quality. Again, any disagreements will be reconciled by consensus with arbitration by the Principal Investigator.\\n\\nOutcomes:\\n\\nWe will assess 6 outcomes: CVD incidence and mortality, CHD incidence and mortality, and stroke incidence and mortality.\\n\\nData Synthesis:\\n\\nWe will pool the natural log-transformed relative risks for the 6 cardiovascular outcomes using the inverse variance method with random effects models with data expressed as risk ratios (RR) with 95% confidence intervals (CIs). Analyses will be conducted by extreme quantiles analyses, comparing the highest with the lowest (reference) level of exposure. Data will also be scaled to allow for per serving/day analyses. Between-study heterogeneity will be assessed by the Cochran Q test and quantified by the I2 statistic with significance at P<0.1. An I2≥50% and P<0.1 will be considered as evidence of substantial heterogeneity. Sensitivity analyses and a priori subgroup analyses will be undertaken to explore sources of heterogeneity. Sensitivity analyses will include the systematic removal of included cohorts with the recalculation of summary estimates. A priori subgroup analyses will be conducted when ≥10 cohort comparisons are available by age, sex, location of cohort, follow-up duration, dietary assessment tool, risk of bias (NOS score). A separate subgroup analysis will also be conducted by each domain of risk of bias by NOS. Meta-regression analyses will assess the significance of categorical and continuous subgroups analyses. Dose-response analyses will be undertaken using random-effects generalized least squares trend estimation models (GLST) to assess linear relationships and spline curve modeling (the MKSPLINE procedure) to assess non-linear relationships. If ≥10 cohort comparisons are available, then publication bias will be assessed by visual inspection of funnel plots and formal testing with the Egger and Begg tests at a significance level of p≤ 0.10. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.\\n\\nGrading the Evidence:\\n\\nThe Grading of Recommendations Assessment, Development and Evaluation (GRADE) method will be used to assess the overall certainty of the evidence for each of the cardiovascular outcomes. This system grades the evidence as \"high quality\", \"moderate quality\", \"low quality\", or \"very low quality\". Observational studies including prospective cohort studies start at a \"low quality\" and then can be downgraded or upgraded based on established criteria. Criteria to downgrade will include study limitations (weight of studies show risk of bias by NOS), inconsistency (substantial unexplained inter-study heterogeneity, I2>50%, P<0.10), indirectness (presence of factors relating to the population, exposures, and outcomes that limit generalizability), imprecision (95% CI are wide or cross a minimally important difference of 5% [RR 0.95- 1.05]), and publication bias (significant evidence of publication bias or small-study effects). Criteria to upgrade will include a large magnitude effect (RR>2 or RR<0.5 in the absence of plausible confounders), a dose-response gradient, and attenuation by plausible confounding effects.\\n\\nKnowledge translation plan:\\n\\nThe results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, physical activity, lifestyle modification, obesity, diabetes, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined.\\n\\nSignificance:\\n\\nThe study will aid in establishing a stronger evidence-base to determine the extent to which a high fruit and vegetable intake may be associated with reduction in incident CVD. It may also bring to light categories of fruits and/or vegetables that could provide additional benefit in CVD prevention.\\n\\nReferences:\\n\\nWorld Health Organization. (2003). Fruit and Vegetable Promotion Initiative - report of the meeting. Geneva.\\n\\nReddy KS and Katan MB. (2004). Diet, nutrition and the prevention of hypertension and cardiovascular disease. Public Health Nutrition. 7(1A): 167-186\\n\\nKatamay SW, Esslinger KA, Vigneault M, et al. (2007) Nutrition Reviews. 65(4): 155-166.\\n\\nHall JN, Moore S, Harper SB, et al. (2009). Global variability in fruit and vegetable consumption. American Journal of Preventative Medicine. 36:402-409\\n\\nAune D, Giovannucci E, Boffetta P, et al. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality - a systematic review and dose-response meta-analysis of prospective studies. International Journal of Epidemiology. 1-28\\n\\nZhan J, Liu Y, Cai L, et al. (2017). Fruit and vegetable consumption and risk of cardiovascular disease: A meta-anaylsis of prospective cohort studies. Critical Reviews in Food Science and Nutrition. 57(8):1650-1663\\n\\nGan Y, Tong X, Liqing L, et al. (2015). Consumption of fruit and vegetable and risk of coronary heart disease: A meta-analysis of prospective cohort studies. International Journal of Cardiology. 183: 129-137\\n\\nWang X, Ouyang Y, Liu J, et al. (2014). Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. British Medical Journal. 349\\n\\nHu D, Hunag J, Wang Y, et al. (2014). Fruits and vegetables consumption and risk of stroke: A meta-analysis of prospective cohort studies. Stroke. 45: 1613-1619\\n\\nHe FG, Nowson CA, Lucas M et al. (2007). Increased consumption of fruit and vegetables is related to reduced risk of coronary heart disease: meta-analysis of cohort studies. Journal of Human Hypertension. 21:717-728\\n\\nHe FJ, Nowson CA and MacGregor GA. (2006). Fruit and vegetable consumption and stroke: a meta-analysis of cohort studies. Lancet: 367:320-326.\\n\\nDauchet L, Amouyel P, Hereberg S, et al. (2006). Fruit and vegetable consumption and risk of coronary heart disease: A meta-analyses of cohort studies. The Journal of Nutrition. 136: 2588-2593.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['CHD - Coronary Heart Disease', 'CVD - Cerebrovascular Disease', 'Stroke']}, 'KeywordList': {'Keyword': ['Systematic review and meta-anaylsis', 'Evidence-based nutrition (EBN)', 'Dietary guidelines', 'Fruit', 'Vegetables']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Anticipated'}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cardiovascular disease (CVD)', 'PrimaryOutcomeDescription': 'Risk ratios for CVD incidence and mortality', 'PrimaryOutcomeTimeFrame': '1 year follow-up'}, {'PrimaryOutcomeMeasure': 'Coronary heat disease (CHD)', 'PrimaryOutcomeDescription': 'Risk ratios for CHD incidence and mortality', 'PrimaryOutcomeTimeFrame': '1 year follow-up'}, {'PrimaryOutcomeMeasure': 'Stroke', 'PrimaryOutcomeDescription': 'Rsk ratios for stroke incidence and mortality', 'PrimaryOutcomeTimeFrame': '1 year follow-up'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nProspective cohort studies or case-cohort studies\\nDuration >= 1 year\\nAssessment of the exposure of fruit and/or vegetables\\nAscertainment of viable data by level of exposure\\n\\nExclusion Criteria:\\n\\nEcological, cross-sectional, and retrospective observational studies, clinical trials, and non-human studies\\nDuration < 1 year\\nNo assessment of exposures of fruit or vegetables\\nNo ascertainment viable clinical outcome data by level of exposure', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Varied', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'John Sievenpiper, MD, PhD, FRCPC', 'OverallOfficialAffiliation': \"Department of Nutritional Sciences, Faculty of Medicine, University of Toronto and Clinical Nutrition and Risk Factor Modification Centre and Toronto 3D Knowledge Institute and Clinical Trials Unit, St. Michael's Hospital\", 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Sonia Blanco Mejia, MD', 'OverallOfficialAffiliation': \"Clinical Nutrition and Risk Factor Modifcation Centre and Toronto 3D Knowledge Institute and Clinical Trials Unit, St. Michael's Hosptial\", 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': \"The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital\", 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5C 2T2', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33000670', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zurbau A, Au-Yeung F, Blanco Mejia S, Khan TA, Vuksan V, Jovanovski E, Leiter LA, Kendall CWC, Jenkins DJA, Sievenpiper JL. Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc. 2020 Oct 20;9(19):e017728. doi: 10.1161/JAHA.120.017728. Epub 2020 Oct 1.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'All data will be available in the publication'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002561', 'ConditionMeshTerm': 'Cerebrovascular Disorders'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}, {'ConditionMeshId': 'D000003327', 'ConditionMeshTerm': 'Coronary Disease'}, {'ConditionMeshId': 'D000003324', 'ConditionMeshTerm': 'Coronary Artery Disease'}, {'ConditionMeshId': 'D000017202', 'ConditionMeshTerm': 'Myocardial Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000001161', 'ConditionAncestorTerm': 'Arteriosclerosis'}, {'ConditionAncestorId': 'D000001157', 'ConditionAncestorTerm': 'Arterial Occlusive Diseases'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6239', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafAsFound': 'CHD - Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4159', 'ConditionBrowseLeafName': 'Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4155', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 32, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03937934', 'OrgStudyIdInfo': {'OrgStudyId': '18-006630'}, 'Organization': {'OrgFullName': 'Mayo Clinic', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Study Title: Food Rx', 'OfficialTitle': 'Study Title: Food Rx'}, 'StatusModule': {'StatusVerifiedDate': 'June 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 20, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 20, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 20, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 30, 2019', 'StudyFirstSubmitQCDate': 'May 1, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 6, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 5, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 9, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Erin C. Westfall', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Mayo Clinic'}, 'LeadSponsor': {'LeadSponsorName': 'Mayo Clinic', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Researchers are trying to determine if subjects with lack of access to healthy food and a long term health problem, are helped by a weekly box of healthy groceries and nutrition education.', 'DetailedDescription': \"Participants that have a chronic preventable disease and food insecurity will be offered enrollment in the study. Once all participants are enrolled, they will be given weekly boxes of food which includes materials for a nutritious recipe and extra fruit and vegetables for a total of 6 weeks. The SNAP-Ed Educator and SHIP Public health coordinator will be present at food pick up to answer questions about the boxes, food preparation, etc. They will be given the option of participating in grocery store and farmer's market tours, as well as sign up for text messaging of nutrition information and recipes. At the end of 6 weeks, they will be asked to participate in a focus group. At baseline, 3 months and 6 months, they will be asked to complete a survey on lifestyle behaviors and food choices.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes', 'High Blood Pressure', 'Obesity', 'Hypertension', 'Heart Diseases', 'Stroke', 'TIA', 'Osteoarthritis', 'Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Subjects with long term health condition', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Nutrition Education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Nutrition Education', 'InterventionDescription': 'Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Subjects with long term health condition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in the number of self-reported fruits per day', 'PrimaryOutcomeDescription': 'Number of self-reported fruits per day', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'PrimaryOutcomeMeasure': 'Change in the number of self-reported vegetables per day', 'PrimaryOutcomeDescription': 'Number of self-reported vegetables per day', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'PrimaryOutcomeMeasure': 'Change in number of days a week and minutes per day participants participate in physical activity and sedentary activity', 'PrimaryOutcomeDescription': 'Measured using self-reported Food Rx Pilot survey', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in A1c', 'SecondaryOutcomeDescription': 'Identified through chart review', 'SecondaryOutcomeTimeFrame': '6 months and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in BMI kg/m2 (weight in kg, height in meters)', 'SecondaryOutcomeDescription': 'Identified through chart review', 'SecondaryOutcomeTimeFrame': '6 months and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in Systolic and/or Diastolic Hypertension mmHg', 'SecondaryOutcomeDescription': 'Identified through chart review', 'SecondaryOutcomeTimeFrame': '6 months and 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult patients that have been identified as having food insecurity based on a two question screening tool, AND\\nAlso has one of more of the following chronic diseases:\\nHypertension,\\nHeart disease,\\nStroke/TIA,\\nDM 2,\\nCancer/history of cancer,\\nobesity\\nosteoarthritis\\n\\nExclusion Criteria:\\n\\nPregnant women\\nChildren', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Erin Westfall, DO', 'OverallOfficialAffiliation': 'Mayo Clinic', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Mayo Clinic Health System', 'LocationCity': 'Mankato', 'LocationState': 'Minnesota', 'LocationZip': '56001', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Mayo Clinic Clinical Trials', 'SeeAlsoLinkURL': 'https://www.mayo.edu/research/clinical-trials'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12616', 'ConditionBrowseLeafName': 'Osteoarthritis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9714', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'High Blood Pressure', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}}}}, {'Rank': 33, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01146132', 'OrgStudyIdInfo': {'OrgStudyId': 'CRP-Santé'}, 'Organization': {'OrgFullName': 'Public Research Centre Health, Luxembourg', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutrition and Physical Activity in Patients With Cerebrovascular Disease', 'OfficialTitle': 'Nutrition and Physical Activity in Patients With Cerebrovascular Disease', 'Acronym': 'ALVINA'}, 'StatusModule': {'StatusVerifiedDate': 'October 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 15, 2010', 'StudyFirstSubmitQCDate': 'June 16, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 17, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 4, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 5, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Manon Gantenbein', 'ResponsiblePartyInvestigatorTitle': 'Clinical Research Coordinator', 'ResponsiblePartyInvestigatorAffiliation': 'Public Research Centre Health, Luxembourg'}, 'LeadSponsor': {'LeadSponsorName': 'Manon Gantenbein', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Centre Hospitalier du Luxembourg', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The study will provide evidence of eating habits and physical activity in cerebrovascular patients in Luxembourg and of the degree to which these habits may be changed acutely (after one month) and in the long run (after 4 months) by intensive counselling. Furthermore the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition, and on surrogate parameters for stroke will be assessed.', 'DetailedDescription': 'Quality of life in the elderly and their families is severely affected by stroke and cognitive dysfunction caused by atherosclerosis of the brain supplying arteries. Nutrition, namely a Mediterranean-style diet, nuts, soybean products, whole grain products, dark chocolate, fish oil and avoidance of salt, and regular physical activity play a major role in the prevention of these diseases. Data are available on cardiac patients, however little is known on cerebrovascular patients. The role of red wine in the protection of cerebrovascular disease is discussed; it may be simply an epiphenomenon of otherwise healthy lifestyle in the population with a regularly low alcohol consumption not properly corrected for in epidemiological studies. No prospective randomised data is available.\\n\\nWe intend to perform a prospective randomised study on nutrition and physical activity in 100 patients with chronic cerebrovascular disease (i.e. patients with atherosclerotic stenosis, at least 20% of a brain supplying artery as demonstrated by carotid ultrasound and without an acute stroke/TIA). The study consists of three parts:\\n\\n(1) Assessment of eating and physical activity habits in these patients and correlation with indicators of cerebrocardiovascular disease (cerebral perfusion as measured by transcranial Doppler sonography, pulsatility of the transcranial and extracranial Doppler signal, elasticity of the carotid artery, ankle-brachial index, cognitive functioning) and risk factors of cerebrovascular disease (blood pressure and blood pressure amplitude assessed by 24 h ambulatory blood pressure measurement; HDL, LDL, triglycerides, Lp(a), glucose, HbA1c, homocysteine, and fibrinogen; waist-hip ratio and BMI).\\n\\n2) Half of these patients will be randomised to intensive counselling concerning healthy eating and physical activity habits during the first month once a week. All the 100 patients will be reassessed after one month and after 4 months with the above mentioned parameters.\\n\\n3) In a double cross-over design half of the patients allocated to intensive counselling (i.e. n=25) and half of the patients without intensive counselling (n=25) will be allocated to 0,2 l of red wine daily (men) or 0,1l of red wine daily (women), respectively. The remaining 50 patients will be advised to avoid red wine for the time of the study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebrovascular Disorders']}, 'KeywordList': {'Keyword': ['Nutrition', 'Physical activity', 'Cerebrovascular disease', 'wine consumption', 'BMI', 'Pulse transit time', 'transcranial Doppler sonography']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '119', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Luxembourg diet + wine', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Luxembourg variant of the mediterranean Diet, physical activity with wine consumption', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine']}}, {'ArmGroupLabel': 'conventional + wine', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'conventional Diet with red wine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Conventional diet +/- wine']}}, {'ArmGroupLabel': 'conventional', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'conventional diet without wine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Conventional diet +/- wine']}}, {'ArmGroupLabel': 'Luxembourg diet', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Luxembourg variant of the mediterranean Diet, physical activity with wine consumption', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Conventional diet +/- wine', 'InterventionDescription': 'usual eating habits', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['conventional', 'conventional + wine']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Luxembourg variant of Mediterranean diet + physical activity +/- wine', 'InterventionDescription': 'Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as \"Luxembourg variant of the Mediterranean diet\"', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Luxembourg diet', 'Luxembourg diet + wine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Differences in mean systolic blood pressure in the two diet/sport arms', 'PrimaryOutcomeDescription': 'Assess the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition and on surrogate parameters for cerebrovascular disease.', 'PrimaryOutcomeTimeFrame': '4 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Effects on cerebrovascular health profile', 'SecondaryOutcomeDescription': 'Assess effects on cerebrocardiovascular health profile, cognitive function and ultrasound parameters.', 'SecondaryOutcomeTimeFrame': '4 months'}, {'SecondaryOutcomeMeasure': 'Assessment of genetic marker and/or genetic modifications.', 'SecondaryOutcomeDescription': 'The genetic analyses will investigate:\\n\\nA) Profiles of inflammatory, anti-inflammatory cytokines B) Genes related to risk of stroke C) Chromosome regions related to atherosclerosis D) Genetic polymorphism in inflammation\\n\\nGenes to be analyzed: FABP2, MTP1, ApoE, ApoA1, PPAR gamma Pro 12 Ala, TNF alpha, Paraoxonase 1, ADH, Kinesin-like protein (KIF) 6 Trp719Arg (rs20455), SNP, 5 (component of complement 5) 2416A> G variant (rs17611), sCAMs (sICAM-1, sVCAM-1, sPSEL et sESEL), (C3, C4) Complement and CRP, P-selectin and its ligand, P-selectin glycoprotein ligand 1', 'SecondaryOutcomeTimeFrame': 'Baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIn- and outpatients of the Neurology Department of the CHL and their family members\\nCarotid atherosclerosis assessed by B-mode ultrasound of at least 20% lumen reduction\\nNo acute stroke/TIA/amaurosis fugax (at least 3 months ago)\\nTemporal ultrasound window suitable for recording of the middle cerebral artery\\nAbility to give informed consent\\n\\nExclusion Criteria:\\n\\nNo signed informed consent\\npatient not able to give informed consent', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Dirk Droste, Pr, MD', 'OverallOfficialAffiliation': 'Centre Hospitalier du Luxembourg', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'CHL', 'LocationCity': 'Luxembourg', 'LocationZip': '1210', 'LocationCountry': 'Luxembourg'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24228901', 'ReferenceType': 'derived', 'ReferenceCitation': 'Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, Gilson G, Chioti A. A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial. Nutr J. 2013 Nov 15;12(1):147. doi: 10.1186/1475-2891-12-147.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002561', 'ConditionMeshTerm': 'Cerebrovascular Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M11139', 'InterventionBrowseLeafName': 'Mechlorethamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T294', 'InterventionBrowseLeafName': 'Soy Bean', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T143', 'InterventionBrowseLeafName': 'English Walnut', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}]}}}}}, {'Rank': 34, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03431402', 'OrgStudyIdInfo': {'OrgStudyId': 'KasrELAiniH critical care dep.'}, 'Organization': {'OrgFullName': 'Kasr El Aini Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke', 'OfficialTitle': 'Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'March 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 1, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 1, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 1, 2018', 'StudyFirstSubmitQCDate': 'February 10, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 13, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 13, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 14, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Tamer Salah aldin Fahmy', 'ResponsiblePartyInvestigatorTitle': 'Professor of critical care medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Kasr El Aini Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Kasr El Aini Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Background and Rationale:\\n\\nCerebrovascular disease is always ranked at the top causes of death and most of hospitalized acute stroke patients have ischemic stroke [1].\\n\\nAlthough the mortality rate of acute ischemic stroke is less than that of hemorrhagic stroke [1], it still results in patient disabilities and complications that often lead to significant costs to individuals, families, and society.\\n\\nTraditional treatment for acute ischemic stroke includes thrombolytic therapy by injecting tissue plasminogen activator (t-PA) within three hours after onset of symptoms [2], antiplatelets and/or anticoagulant agents administered within the first 48 hours. Clinically, the narrow time window of thrombolytic therapy and coexisting contraindications limit the use of t-PA [2]. Thus, searching for an effective supplemental treatment for acute ischemic stroke is imperative.\\n\\nHyperbaric oxygen therapy (HBOT) is valuable in treating acute carbon monoxide poisoning [3,4], air or gas embolism [5], facilitating wound healing [6] and has been used as an adjuvant treatment for many neurological disorders that need further study as concussion [7] , stroke [8,9], cerebral palsy [ 10],traumatic brain injury [ 11], cerebral air embolism [12], Autism [13] and multiple sclerosis [14].\\n\\nIndications of hyperbaric oxygen therapy recommended by undersea and hyperbaric medical society (UHMS) [15] are 1.air or gas embolism [5], 2.carbon monoxide poisoning [3,4], 3.clostridial myositis and myonecrosis [16], 4.crush injury, compartment syndrome and other acute traumatic ischemias [17], 5.decompression sickness [18], 6.arterial insufficiencies [19], 7.severe anemia [20], 8.intracranial abscess [21], 9.necrotizing soft tissue infections [22],10. refractory osteomyelitis [23], 11.delayed radiation injury [24], 12.compromised grafts and flaps [25], 13.acute thermal burn injury [26] and 14.idiopathic sudden sensorineural hearing loss [27].\\n\\nKnown mechanisms of HBOT-induced neuroprotection include enhancing neuronal viability via increased tissue oxygen delivery to the area of diminished blood flow, reducing brain edema, and improving metabolism after ischemia [28,29]. Furthermore, a recent study performed on a rat suggested that upregulation of the expression of glial derived neurotrophic factor (GDNF) and nerve growth factor (NGF) might underlie the effect of HBOT [30].\\n\\nThe effectiveness of use of Hyperbaric oxygen therapy in human ischemic stroke is still controversial that need further evaluation.', 'DetailedDescription': 'Study Methods:\\n\\nStudy Population A 60 adult (aged >18 years) patients were included with a diagnosis of acute thromboembolic ischemic stroke within 48 hours after onset, according to clinical picture and imaging findings by brain computed tomography (CT) without evidence of hemorrhage, upon admission to the hospital and no patient received thrombolytic therapy.\\n\\nInclusion criteria:\\n\\nGroup one, HBOT group (n = 30): thirty adult patients with acute ischemic stroke will receive conventional medical treatment ( as antiplatelet but not thrombolytic therapy) with 10 sessions of adjunctive hyperbaric oxygen therapy (HBOT) within 3-5 days after the onset of stroke .\\n\\nCompared with Group two, control group(n = 30): thirty adult patients with acute ischemic stroke will receive conventional medical treatment alone.\\n\\nThe baseline clinical characteristics were similar in both groups.\\n\\nExclusion criteria:\\n\\nPatient with cerebral hemorrhage\\nPatient received thrombolytic therapy\\nEmphysema with carbon dioxide retention\\nPneumothorax\\nSeizure disorder\\nUncontrolled high fever\\n\\nDemographic Characteristics:\\n\\nAdults more than 18 years, Any gender. All patients upon admission to the hospital will provide:\\n\\nComplete history taking:Age, Gender, Smoking, Alcohol consumption, Past history: diabetes mellitus , hypertension , Chronic obstructive pulmonary disease, Epilepsy or cardiovascular disease.\\n\\nNeurological assessment use NIHSS score Blood tests:Complete blood count , Coagulation profile, Fasting blood sugar., Renal function test (Urea and creatinine).\\n\\nCT brain\\n\\nChest x-ray :\\n\\nElectrocardiogram (ECG):'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Acute stroke receive hyperbaric oxygen', 'ArmGroupType': 'Other', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Hyperbaric oxygen']}}, {'ArmGroupLabel': 'Acute stroke receive only conventional treatment', 'ArmGroupType': 'No Intervention'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Hyperbaric oxygen', 'InterventionDescription': '- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Acute stroke receive hyperbaric oxygen']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in national institute of health stroke score before and after treatment with hyperbaric oxygen therapy', 'PrimaryOutcomeDescription': 'The national institute of health stroke score (NIHSS) is a 15 item neurologic examination that provides a quantitative measure of stroke-related neurologic deficit. (Maximum score of 42) \"Mild\" disease was defined as score of 0-14, \"moderate\" as 15-28, and \"severe\" as 29-42.\\n\\nAs pretreatment evaluation, all patients will be evaluated by national institute of health stroke score within 48 hours after admission.\\n\\nAs posttreatment evaluation, patients in the hyperbaric oxygen therapy group were evaluated by national institute of health stroke score after 10 sessions of hyperbaric oxygen therapy.\\n\\nThe control group was evaluated with national institute of health stroke score 10 days after stroke onset.\\n\\nOne month after treatment, all patients were evaluated again using the national institute of health stroke score.', 'PrimaryOutcomeTimeFrame': '2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hospital mortality', 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'Hospital length of stay', 'SecondaryOutcomeTimeFrame': '2 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\nAdult patients with acute ischemic stroke\\nGlasgow coma scale more than 10\\n\\nExclusion criteria:\\n\\nPatient with cerebral hemorrhage\\nPatient received thrombolytic therapy\\nEmphysema with carbon dioxide (CO2) retention\\nPneumothorax\\nSeizure disorder', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Ibrahim Shehata, MSC', 'CentralContactRole': 'Contact', 'CentralContactPhone': '001011946001', 'CentralContactEMail': 'shehata772@gmail.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ibrahim Shehata Hussin', 'LocationStatus': 'Recruiting', 'LocationCity': 'Cairo', 'LocationCountry': 'Egypt', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ibrahim Shehata, MSC', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'shehata772@gmail.com'}, {'LocationContactName': 'Shereen Elgengeehy, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Tamer Fahmy, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Mahmoud Kenawi, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'waleed Farouk, MD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 35, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05461911', 'OrgStudyIdInfo': {'OrgStudyId': 'DECUBISON'}, 'Organization': {'OrgFullName': 'Enrollme.ru, LLC', 'OrgClass': 'NETWORK'}, 'BriefTitle': 'Study to Assess the Clinical Efficacy of the Specialized Enteral Tube Nutrition Composition Nutrison Advanced Cubison as a Part of Complex Pressure Ulcers (PU) Therapy', 'OfficialTitle': 'Prospective Multicenter Randomized Controlled Low-interventional Post-registration Study to Assess the Clinical Efficacy of the Specialized Enteral Tube Nutrition Composition Nutrison Advanced Cubison as a Part of Complex Pressure Ulcers (PU) Therapy Versus Standard Enteral Tube Nutrition Products'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 1, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 1, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 1, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 12, 2022', 'StudyFirstSubmitQCDate': 'July 14, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 18, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 14, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 18, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Enrollme.ru, LLC', 'LeadSponsorClass': 'NETWORK'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Danone Nutricia', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'A large number of studies are devoted to studying the effect of patient nutrition on the occurrence and treatment of pressure ulcers. Several studies, including the US National Long-term Treatment of Pressure Ulcers Study, have shown that weight loss and malnutrition were associated with a higher risk of pressure ulcers.\\n\\nOne of the successful products specially created for the treatment of pressure ulcers and taking into account the results of research is the high-protein, energy-rich, ready-to-use enteral tube feeding food product Nutrison Advanced Cubison. It is a complete enteral nutritional supplement with an innovative nutrient composition for patients with chronic wounds, including pressure ulcers, or at increased risk of developing them.\\n\\nTaking into account the available data, it seems expedient to continue studying the unique combination of nutrients that make up the study food product Nutrison Advanced Cubison in order to develop the most effective nutritional protocols for patients at risk for the treatment and prevention of pressure ulcers.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pressure Ulcer ( Stage 2-3)']}, 'KeywordList': {'Keyword': ['Stroke', 'Traumatic Brain Injury']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'The Study Group', 'ArmGroupDescription': '30 adult patients aged 30-75 years to receive a specialized tube feeding product Nutrison Advanced Cubison (20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Nutrison Advanced Cubison']}}, {'ArmGroupLabel': 'The Control Group', 'ArmGroupDescription': '30 patients aged 30-75 years to receive a standard (available in the clinic) tube feeding product (energetically similar to the product in group 1) with a standard content of arginine, vitamins and minerals from calculating the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Nutrison Advanced Cubison', 'InterventionDescription': '(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['The Study Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes in the area of pressure ulcers in both groups during the study', 'PrimaryOutcomeTimeFrame': 'up to 4 weeks'}, {'PrimaryOutcomeMeasure': 'The proportion of patients in both groups with a decrease in the area of the pressure ulcer by 20% or more by the date of completion of observations', 'PrimaryOutcomeTimeFrame': 'up to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Changes in the Pressure Ulcer Scale for Healing values in both groups during the study', 'PrimaryOutcomeDescription': 'Pressure Ulcer Scale for Healing (PUSH) is a common tool to monitor pressure healing over time. The PUSH Tool monitors three parameters: surface area of the wound, wound exudate and type of wound tissue. Minimum value is 0, maximum value is 17. The bigger scale is the worse', 'PrimaryOutcomeTimeFrame': 'up to 4 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Duration of treatment for pressure ulcers in study patients', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Frequency and duration of infectious complications of pressure ulcers in study patients', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of the blood albumin at the beginning and at the end of observations', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of the blood lymphocytes at the beginning and at the end of observations', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of the C-reactive protein at the beginning and at the end of observations', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients diagnosed with stroke / TBI and who are on tube feeding\\nPresence of pressure ulcers of 2-3 stages\\nInformed voluntary consent to medical intervention is formalized in accordance with the requirements of the Federal Law of 21.11.2011 N 323-FZ \"On the basics of protecting the health of citizens in the Russian Federation.\"\\n\\nExclusion Criteria:\\n\\nHemodynamically unstable patients\\nSevere renal impairment (GFR <30 ml / min)\\nModerate or severe liver failure (Child-Pugh Class B or C)\\nOncological diseases (lasting more than 5 years)\\nHypersensitivity to any component of the test food mixture\\nInclusion in clinical interventional research\\nUncertainty of the investigator about the willingness or ability of the subject to comply with the protocol requirements\\nAny other medical or non-medical reasons that, in the opinion of the physician, may prevent the patient from participating in the study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '79 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': '60 patients hospitalized with strokes or traumatic brain injury, who are on tube feeding and with the presence of pressure ulcers of 2-3 stages identified at baseline or during hospital stay', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mikhail Getman, Dr', 'OverallOfficialAffiliation': 'Enrollme.ru, LLC', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'GAUZ Bryansk city hospital №1', 'LocationCity': 'Bryansk', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'GBUZ GKB named after VV Vinogradov DZM', 'LocationCity': 'Moscow', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Hospital named after V.D. Seredavin', 'LocationCity': 'Samara', 'LocationCountry': 'Russian Federation'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003668', 'ConditionMeshTerm': 'Pressure Ulcer'}, {'ConditionMeshId': 'D000014456', 'ConditionMeshTerm': 'Ulcer'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000012883', 'ConditionAncestorTerm': 'Skin Ulcer'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M16896', 'ConditionBrowseLeafName': 'Ulcer', 'ConditionBrowseLeafAsFound': 'Ulcer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4897', 'ConditionBrowseLeafName': 'Brain Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M628', 'ConditionBrowseLeafName': 'Brain Injuries, Traumatic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6560', 'ConditionBrowseLeafName': 'Pressure Ulcer', 'ConditionBrowseLeafAsFound': 'Pressure Ulcer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15376', 'ConditionBrowseLeafName': 'Skin Ulcer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15364', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M4203', 'InterventionBrowseLeafName': 'Ascorbic Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M17458', 'InterventionBrowseLeafName': 'Zinc', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T477', 'InterventionBrowseLeafName': 'Vitamin C', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T437', 'InterventionBrowseLeafName': 'Ascorbic Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T1', 'InterventionBrowseLeafName': 'Arginine', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}, {'InterventionBrowseBranchAbbrev': 'AA', 'InterventionBrowseBranchName': 'Amino Acids'}]}}}}}, {'Rank': 36, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03096015', 'OrgStudyIdInfo': {'OrgStudyId': '3174E'}, 'Organization': {'OrgFullName': 'Boston University Charles River Campus', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Intensive Interdisciplinary Treatment Program for Individuals With Stroke-Induced Aphasia', 'OfficialTitle': 'Intensive Interdisciplinary Treatment Program for Individuals With Stroke-Induced Aphasia'}, 'StatusModule': {'StatusVerifiedDate': 'March 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2013', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 21, 2017', 'StudyFirstSubmitQCDate': 'March 24, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 30, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 30, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Elizabeth Hoover', 'ResponsiblePartyInvestigatorTitle': 'Clinical Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Boston University Charles River Campus'}, 'LeadSponsor': {'LeadSponsorName': 'Boston University Charles River Campus', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'An intensive, interdisciplinary treatment program was administered during the summer as part of regular clinic services in the Aphasia Resource Center (ARC) at Sargent College. This program was run program as described for three years. Not more than six native English speakers with mild or moderate profiles of aphasia and multidisciplinary rehabilitation needs (OT,PT, SLP and nutrition) were recruited from the Boston community to participate in an intensive interdisciplinary treatment program for four weeks during the month of June 2013. The program consists of approximately six hours of interdisciplinary treatment each day, five days per week over a four-week interval. Treatment is individualized using current evidence-based treatment approaches, which are commonly accepted protocols in clinical practice and will be administered by clinical faculty and staff from Speech-Language and Hearing Sciences, Occupational Therapy (OT), Physical Therapy (PT), the Center for Neurorehabilitation and Nutrition. Segments of these types of treatments are available for a small fee as part of our service in the Aphasia Resource Center; however, this comprehensive, interdisciplinary program is not available of this research study.\\n\\nApproximately 30 hours of therapy per week are provided -- 6 hours per day over 5 days consisting of Speech-language Pathology, Physical Therapy, Occupational Therapy, and Nutrition Counseling.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Aphasia']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignInterventionModelDescription': 'Within-subjects Group design', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '19', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intensive Treatment for Aphasia', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Intensive Comprehensive Aphasia Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Intensive Comprehensive Aphasia Program', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intensive Treatment for Aphasia']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Stroke Impact Scale (to assess change)', 'PrimaryOutcomeDescription': 'QoL indicator for stroke survivors', 'PrimaryOutcomeTimeFrame': '1 month pre intervention, immediately prior to intervention, the week post intervention, 3 months after intervention was completed'}, {'PrimaryOutcomeMeasure': 'Canadian Occupational Performance Measure (to assess change)', 'PrimaryOutcomeDescription': 'Measures participation and satisfaction in meaningful activities', 'PrimaryOutcomeTimeFrame': '1 month pre intervention, immediately prior to intervention, the week post intervention, 3 months after intervention was completed'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Goal Attainment Scaling (to assess change)', 'SecondaryOutcomeDescription': 'Measures attainment of individualized/personal community-based goals', 'SecondaryOutcomeTimeFrame': '1 month pre intervention, immediately prior to intervention, the week post intervention, 3 months after intervention was completed'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nClinical diagnosis of mild or moderate profile of aphasia secondary to a single stroke, as diagnosed by a certified speech-language pathologist.\\nMust be able to demonstrate auditory comprehension at a level that is functional for conversation.\\nMust demonstrate mobility or sensory deficits as a result of the stroke.\\nMust demonstrate cardiac/nutritional needs.\\nMust be able to ambulate without the physical assistance of another person for at least 500 feet.\\nMust be able to negotiate elevator and stairs independently\\nMust be able to manage bathroom needs without assistance.\\nMust be more than twelve months post-onset of stroke.\\nMust be between 18 and 75 years of age.\\nMust be native speakers of English\\nMust have 8th grade level of education or higher.\\nMust have adequate vision for functional reading\\nMust have adequate hearing for conversation\\n\\nExclusion Criteria:\\n\\nSubjects who meet the above inclusion criteria, but who are also bilingual, and/or have concomitant neurological disease will be excluded from the study.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001037', 'ConditionMeshTerm': 'Aphasia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000013064', 'ConditionAncestorTerm': 'Speech Disorders'}, {'ConditionAncestorId': 'D000007806', 'ConditionAncestorTerm': 'Language Disorders'}, {'ConditionAncestorId': 'D000003147', 'ConditionAncestorTerm': 'Communication Disorders'}, {'ConditionAncestorId': 'D000019954', 'ConditionAncestorTerm': 'Neurobehavioral Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4042', 'ConditionBrowseLeafName': 'Aphasia', 'ConditionBrowseLeafAsFound': 'Aphasia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15554', 'ConditionBrowseLeafName': 'Speech Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10513', 'ConditionBrowseLeafName': 'Language Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6064', 'ConditionBrowseLeafName': 'Communication Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21516', 'ConditionBrowseLeafName': 'Neurobehavioral Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 37, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05503420', 'OrgStudyIdInfo': {'OrgStudyId': 'UW21-522'}, 'Organization': {'OrgFullName': 'The University of Hong Kong', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Masticatory Muscles Training Exercises on the Masticatory Performance and Rehabilitation of Stroke Patients', 'OfficialTitle': 'Randomized Controlled Trial on Effects of Masticatory Muscles Training Exercises on the Masticatory Performance and Rehabilitation of Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 1, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 14, 2022', 'StudyFirstSubmitQCDate': 'August 14, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 16, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 14, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 16, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The University of Hong Kong', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Stroke is one of the top causes of death and morbidity of adults, especially the older population in the economically developed countries. People who survives from stroke attack usually suffer from a wide range of impairments and often have poor chewing ability even when they are physically well enough to be discharged from hospital. Aim of this proposed study is to investigate the effects of providing masticatory muscles training exercises on the masticatory performance, nutrition intake and general health conditions of stroke rehabilitation patients. Around 100 stroke patients undergoing rehabilitation in the rehabilitation centre in Tung Wah Eastern Hospital, Hong Kong, will be recruited and allocated randomly into one of two study groups: Group 1 will be provided with an oral device for chewing muscles exercises and training exercises on chewing (the intervention group); and Group 2 will just follow the current stroke rehabilitation programme which does not have any training in chewing (a negative control group). A video on the chewing muscles exercises will be produced and placed online for the participants in Group 1 to view on demand. Data from the participants in both groups will be collected at four time points: at baseline before provision of the interventions, and at around 1, 3 and 6 months after the intervention. Each participant will be interviewed by a trained interviewer and undergo a clinical examination. The information collected will include the participant's oral health status such as numbers of decayed teeth and occluding tooth pairs, and their masticatory performance measured both objectively by chewing on a colour-changeable gum and subjectively by a chewing function questionnaire. Their type of stroke (ischemic or hemorrhagic) and general health conditions such as physical function status and nutrition intake will be recorded. The masticatory performance and general health conditions of the two groups of study participants at baseline and follow-up evaluations will be compared to assess if the masticatory muscles training exercises can improve the rehabilitation outcomes. It is anticipated that this proposed randomized trial will provide high-level clinical evidence to support the introduction of masticatory muscles training exercises into the rehabilitation programme of stroke patients and to inform how the exercises will benefit the patients, such as improving their chewing ability and general health conditions.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Mastication']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '96', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'exerciser', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will be asked to use a masticatory muscle training exerciser twice daily, 10 minutes each time, and also perform active range of motion for 4 minutes each time.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Masticatory muscle training exerciser']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants in this group will receive the normal stroke rehabilitation training in the centre without additional provision of masticatory muscles training exercises.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Masticatory muscle training exerciser', 'InterventionDescription': 'In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['exerciser']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'masticatory performance', 'PrimaryOutcomeDescription': 'colour of a color-changeable gum after chewing for 90 seconds measured in a* value', 'PrimaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\naged 30 years or above, first-time stroke patient within 20 days post-stroke and medical status being stable\\n\\nExclusion Criteria:\\n\\nunable to follow basic instructions, unable to communicate clearly, being bed-ridden, dysphagic (on nasogastric tube) and not having any natural teeth in either of the jaws', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'The University of Hong Kong', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hong Kong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Edward Lo', 'LocationContactRole': 'Contact', 'LocationContactPhone': '852-28590292', 'LocationContactEMail': 'edward-lo@hku.hk'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M15320', 'InterventionBrowseLeafName': 'Silicon', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 38, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04289766', 'OrgStudyIdInfo': {'OrgStudyId': 'REC/00654 Irum Farooq'}, 'Organization': {'OrgFullName': 'Riphah International University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Focal Muscle Vibration on Upper Limb Function in Subacute Post-stroke Patients', 'OfficialTitle': 'Effects of Focal Muscle Vibration on Upper Limb Function in Subacute Post-stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'April 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 26, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 20, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 20, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 27, 2020', 'StudyFirstSubmitQCDate': 'February 27, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 28, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 20, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 21, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Riphah International University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is the second leading cause of death, accounting for 11.13 % of total deaths, and the main cause of disability worldwide. The major type of stroke is ischemic, which occurs in about 87% of all stroke cases Stroke has different risk factors, which can be grouped into modifiable and non-modifiable risk factors. Major risk factors for stroke include age, history of cerebrovascular event, smoking, alcohol consumption, physical inactivity, hypertension, diabetes mellitus, cardiovascular diseases, obesity, metabolic syndrome, diet, nutrition, and genetic risk factors. Many new technique used for rehabilitation after stroke includes Constraint-Induced Movement Therapy for Arm or Leg Paralysis, Mirror Therapy for Hand Recovery, Harness the Relentless Force etc. Segmental muscle vibration (SMV) is also a new technique and effective to decrease the hyper-toned muscles spasticity but still less work done on it. SMV with different frequencies have different effects for both flaccid and spastic patients of all 3 stages of stroke. In our study we will work with 60hz and 120hz frequencies to reduce the spasticity of upper limb and improves their functional level.', 'DetailedDescription': 'Evidence strongly suggest that a period of pure sensory stimulation can affect motor corticoids activity excitability.\\n\\nIn 2019 segmental muscle vibration(SMV) used to improve upper extremity functional ability post stroke and concluded that patients in both groups improved significantly after treatment in Barthel index (BI), elbow Range of Motion (ROM) and elbow muscle strength. However muscle tone in elbow joint of hemiplegic upper extremity improved significantly after only in the experimental group. They suggested that with routine physiotherapy with extended exposure SMV will results in significant reduced spasticity and better improved Activities Of Daily Livings (ADLs).\\n\\nIn 2019 a work done with SMV to improve gate performance in patients with foot drop after chronic stroke. Results of this study revealed moderate improvement in mean gate speed, normal side swing velocity, bilateral stride length and normal-side toe off in experimental group. Further studies needed to evaluate the optimal and minimum SMV dosage.\\n\\nAnother study conducted in 2019 to see Results show that processing speed, inhibitory control and attention improved following SMV. But working memory between groups and also not show a association between executive functions course and fall risk, so they suggest further work to examine effects of vibration therapy on executive functions.\\n\\nIn 2014 another therapist highlight the potential use of SMV to modulate electromyographic (EMG) for reaching movement in chronic stroke patients but needs to be confirmed by larger control perspective trials of SMV.\\n\\nIn 2019 combined work done with repetitive focal muscle vibration with physiotherapy to improve the motor function even in very acute phase of stroke and finds it a valid complementary non pharmacological therapy In 2019 another study suggest that Whole Body Vibration (WBV) and Upper and Lower Cycle (ULC) effective upper for upper extremity motor function and grip strength in sub-acute stroke.\\n\\nIn 2019 a study reported the risk factors (vibration injury to hands vascular components, intermediate blanching neurological components and lower back pain for drivers of work machines) and benefits (improvement in bone health and neuromuscular function). So is a room for research to design a balanced WBV protocol.\\n\\nA study in 2018 did a meta-analysis and compare the effects of WBV in stroke patients and concludes that it is a safe therapeutic method for improving symptoms.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke, Subacute']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '106', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Conventional Treatment', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Conventional Treatment includes exercises limbs', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Conventional Treatment']}}, {'ArmGroupLabel': 'Focal Muscle Vibration (120Hz)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.\\nConventional Treatment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Focal Muscle Vibration (120Hz)']}}, {'ArmGroupLabel': 'Focal Muscle Vibration (60Hz)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.\\nConventional Treatment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Focal Muscle Vibration (60Hz)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Conventional Treatment', 'InterventionDescription': 'These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Conventional Treatment']}}, {'InterventionType': 'Other', 'InterventionName': 'Focal Muscle Vibration (120Hz)', 'InterventionDescription': 'These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Focal Muscle Vibration (120Hz)']}}, {'InterventionType': 'Other', 'InterventionName': 'Focal Muscle Vibration (60Hz)', 'InterventionDescription': 'These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Focal Muscle Vibration (60Hz)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Fugl Meyer Scale (FMS)', 'PrimaryOutcomeDescription': \"Changes from the Baseline this scale was measured\\n\\nFugl Meyer Assessment is the utmost extensively used and approved clinical scale for assessment of sensorimotor loss in post stroke patients.This scale is comprised of five domains and there are 155 items in total:\\n\\nMotor functioning (in the upper and lower extremities)\\nSensory functioning (evaluates light touch on two surfaces of the arm and leg, and position sense for 8 joints)\\nBalance (contains 7 tests, 3 seated and 4 standing)\\nJoint range of motion (8 joints)\\nJoint pain 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.\\n\\nMAS detecting the changes in muscle tone in patients with stroke.. It's a 6 point scale. 0=no muscle tone, 4= affected parts rigid flexion or extension.Its reliability is 0.567.\", 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 8 Weeks'}, {'PrimaryOutcomeMeasure': 'Motor Assessment Scale (MAS)', 'PrimaryOutcomeDescription': 'Changes from the Baseline this scale was measured\\n\\n. The Motor Assessment Scale (MAS) is used to assess everyday motor function in patients with stroke. 8 items assess 8 areas of motor function\\nPatients perform each task 3 times, only the best performance is recorded\\nItems (with the exception of the general tonus item*) are assessed using a 7-point scale (0 to 6)\\nA score of 6 indicates optimal motor behavior\\nItem scores (with the exception of the general tonus item) are summed to provide an overall score (out of 48 points)\\nCompleting a higher-level item suggests successful performance on lower-level items and thus lower-items can be skipped. For the general tonus item, the score is based on continuous observations throughout the assessment. A score of 4 on this item indicates a consistently normal response, a score > 4 indicates persistent hyper-tonus, and a score < 4 indicates various degrees of hypo-tonus', 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 8 Weeks'}, {'PrimaryOutcomeMeasure': 'Modified Ashworth Scale', 'PrimaryOutcomeDescription': \"Changes from the Baseline this scale was measured\\n\\nModified Ashworth Scale' scores exhibited better reliability when measuring upper extremities than lower[11]. The scale is as below:\\n0 No increase in muscle tone\\n1 Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension\\n1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM\\n2 More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved\\n3 Considerable increase in muscle tone, passive movement difficult\\n4 Affected part(s) rigid in flexion or extension\", 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 8 Weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHemiplegic affected side spastic <3 on the Ashworth scale.\\nHistory of stroke should be > 6 weeks and <12 weeks.\\n\\nExclusion Criteria:\\n\\nIndividuals with the other neurological deficit\\nDiabetic ulcer, infection or amputation of limb\\nSerious cardiovascular disease or unstable angina\\nSerious orthopedic problem\\nChronic medical problems', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '35 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Imran Amjad, Phd', 'OverallOfficialAffiliation': 'Riphah International University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Railway General Hospital', 'LocationCity': 'Rawalpindi', 'LocationState': 'Punjab', 'LocationZip': '44000', 'LocationCountry': 'Pakistan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30762754', 'ReferenceType': 'background', 'ReferenceCitation': 'Annino G, Alashram AR, Alghwiri AA, Romagnoli C, Messina G, Tancredi V, Padua E, Mercuri NB. Effect of segmental muscle vibration on upper extremity functional ability poststroke: A randomized controlled trial. Medicine (Baltimore). 2019 Feb;98(7):e14444. doi: 10.1097/MD.0000000000014444.'}, {'ReferencePMID': '19855076', 'ReferenceType': 'background', 'ReferenceCitation': 'Paoloni M, Mangone M, Scettri P, Procaccianti R, Cometa A, Santilli V. Segmental muscle vibration improves walking in chronic stroke patients with foot drop: a randomized controlled trial. Neurorehabil Neural Repair. 2010 Mar-Apr;24(3):254-62. doi: 10.1177/1545968309349940. Epub 2009 Oct 23.'}, {'ReferencePMID': '16680616', 'ReferenceType': 'background', 'ReferenceCitation': 'Smith L, Brouwer B. Effectiveness of muscle vibration in modulating corticospinal excitability. J Rehabil Res Dev. 2005 Nov-Dec;42(6):787-94. doi: 10.1682/jrrd.2005.02.0041.'}, {'ReferencePMID': '25227540', 'ReferenceType': 'background', 'ReferenceCitation': 'Paoloni M, Tavernese E, Fini M, Sale P, Franceschini M, Santilli V, Mangone M. Segmental muscle vibration modifies muscle activation during reaching in chronic stroke: A pilot study. NeuroRehabilitation. 2014;35(3):405-14. doi: 10.3233/NRE-141131.'}, {'ReferencePMID': '30873102', 'ReferenceType': 'background', 'ReferenceCitation': 'Toscano M, Celletti C, Vigano A, Altarocca A, Giuliani G, Jannini TB, Mastria G, Ruggiero M, Maestrini I, Vicenzini E, Altieri M, Camerota F, Di Piero V. Short-Term Effects of Focal Muscle Vibration on Motor Recovery After Acute Stroke: A Pilot Randomized Sham-Controlled Study. Front Neurol. 2019 Feb 19;10:115. doi: 10.3389/fneur.2019.00115. eCollection 2019.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 39, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02207023', 'OrgStudyIdInfo': {'OrgStudyId': 'H13-03353'}, 'Organization': {'OrgFullName': 'University of British Columbia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Healthy Lifestyles After Stroke - Stroke Coach', 'OfficialTitle': 'A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study', 'Acronym': 'StrokeCoach'}, 'StatusModule': {'StatusVerifiedDate': 'March 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 31, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 28, 2014', 'StudyFirstSubmitQCDate': 'July 30, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 1, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 5, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 8, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Janice Eng', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'University of British Columbia'}, 'LeadSponsor': {'LeadSponsorName': 'University of British Columbia', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Heart and Stroke Foundation of Canada', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to examine the efficacy of a lifestyle modification telehealth program on health-related behaviours in community-dwelling individuals living with stroke.', 'DetailedDescription': 'Participants recruited in this study will be randomly assigned to either the Healthy Lifestyle Training Program, or Attention Control Memory Training Program.\\n\\nIndividuals in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. Individuals in the Memory Training Program will each receive 7 memory coaching telephone sessions (30-60 minutes) with a trained memory training coach over a 6 month period. 100 evaluable subjects will be recruited (124 to accommodate for 20% dropout).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Apoplexy', 'Cerebral Stroke', 'Cerebrovascular Accident', 'Cerebrovascular Accident, Acute', 'Cerebrovascular Apoplexy', 'Cerebrovascular Stroke', 'CVA', 'Stroke, Acute', 'Vascular Accident, Brain']}, 'KeywordList': {'Keyword': ['Stroke', 'Telehealth', 'Rehabilitation', 'Stroke Coach', 'Randomized controlled trial', 'Lifestyle behaviours', 'Secondary prevention', 'Chronic disease self-management']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '126', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Memory Training Program', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.'}, {'ArmGroupLabel': 'Healthy Lifestyle Training Program', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Healthy Lifestyle Training Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Healthy Lifestyle Training Program', 'InterventionDescription': 'Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Lifestyle Training Program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Global measure of lifestyle behavior (Health Promoting Lifestyle Profile II)', 'PrimaryOutcomeDescription': 'The 52-item Health Promoting Lifestyle Profile II provides a composite score of lifestyle, in the areas of: health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, and stress management.', 'PrimaryOutcomeTimeFrame': 'End of program (6 months)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Daily walking physical activity', 'SecondaryOutcomeDescription': 'Study participants will wear the activity monitor over the 7 days following each assessment period (baseline, 6 months, 12 months)', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Dietary behavior (26 items SmartDiet Questionnaire)', 'SecondaryOutcomeDescription': 'The SmartDiet Canadian Version Questionnaire was developed to assess fiber and fat intake. This questionnaire has 26 questions about diet and lifestyle. Most questions list foods in 3 or 4 categories according to fat or fiber content.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Medication adherence (8-item Morisky Medication Adherence Scale)', 'SecondaryOutcomeDescription': 'The Morisky Medication Adherence Scale assesses habits in taking medication and barriers that may hinder medication adherence.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Depressive symptoms (20-item Centre for Epidemiological Studies-Depression [CES-D] Scale)', 'SecondaryOutcomeDescription': 'This scale assess the frequency with which participants experience depression symptoms, such as restless sleep, poor appetite, and feeling lonely, during the past week.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Cognition (Montreal Cognitive Assessment [MoCA])', 'SecondaryOutcomeDescription': 'The MoCA is a screening instrument to assess for cognitive impairment.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Cardiovascular risk factors (resting blood pressure, lipid, and glucose profiles, C-Reactive Protein, Homocysteine).', 'SecondaryOutcomeDescription': 'These risk factors will be assessed using hospital lab services.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Body composition (Body Mass Index, waist circumference)', 'SecondaryOutcomeDescription': 'The Body Mass Index is a measure of body fat based on weight and height. Waist circumference will be measured using a tape measure around the waist at the height of the umbilicus.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Health-related quality of life (SF-36)', 'SecondaryOutcomeDescription': \"The SF-36 is a generic health status measure that was designed to be applied to all health conditions and assess health concepts, which represent basic human values and are relevant to a person's functional status and well-being.\", 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Health and Social Services Utilization (Health and Social Service Utilization Inventory)', 'SecondaryOutcomeDescription': 'The Health and Social Services Utilization inventory collects data regarding health services used, medications, and out of pocket health costs.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Global measure of lifestyle behavior (Health Promoting Lifestyle Profile II)', 'SecondaryOutcomeDescription': 'The 52-item Health Promoting Lifestyle Profile II provides a composite score of lifestyle, in the areas of: health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, and stress management.', 'SecondaryOutcomeTimeFrame': '6 months after the program ends (12 months from baseline)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHas experienced a stroke in the last 12 months\\n50 years of age or older\\nLiving in the community with phone access\\nMild to moderate stroke severity (i.e., modified Rankin Scale score ranging from 1 to 4)\\nAble to communicate in English\\n\\nExclusion Criteria:\\n\\nStroke of non-vascular origin\\nActively engaged in formal stroke rehabilitation services\\nUncontrolled arrhythmias\\nSignificant musculoskeletal or other neurological condition\\nSevere aphasia or dysarthria\\nNot medically stable\\nPain or co-morbidities which would preclude activity\\nLiving in long-term residential care\\nCognitive impairment, dependent in activities of daily living, and no caregiver participation', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Janice Eng, PhD', 'OverallOfficialAffiliation': 'University of British Columbia', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Royal Columbian Hospital', 'LocationCity': 'New Westminster', 'LocationState': 'British Columbia', 'LocationZip': 'V3L 3W7', 'LocationCountry': 'Canada'}, {'LocationFacility': 'University Hospital of Northern BC', 'LocationCity': 'Prince George', 'LocationState': 'British Columbia', 'LocationZip': 'V2M 1S2', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Surrey Memorial Hospital', 'LocationCity': 'Surrey', 'LocationState': 'British Columbia', 'LocationZip': 'V3V 1Z2', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Holy Family Hospital', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5P 3L6', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Vancouver General Hospital', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 1M9', 'LocationCountry': 'Canada'}, {'LocationFacility': 'GF Strong Rehabilitation Centre', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 2G9', 'LocationCountry': 'Canada'}, {'LocationFacility': \"St. Paul's Hospital\", 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V6Z 1Y6', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33949270', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sakakibara BM, Lear SA, Barr SI, Goldsmith CH, Schneeberg A, Silverberg ND, Yao J, Eng JJ. Telehealth coaching to improve self-management for secondary prevention after stroke: A randomized controlled trial of Stroke Coach. Int J Stroke. 2022 Apr;17(4):455-464. doi: 10.1177/17474930211017699. Epub 2021 May 27.'}, {'ReferencePMID': '28869405', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sakakibara BM, Lear SA, Barr SI, Benavente O, Goldsmith CH, Silverberg ND, Yao J, Eng JJ. A telehealth intervention to promote healthy lifestyles after stroke: The Stroke Coach protocol. Int J Stroke. 2018 Feb;13(2):217-222. doi: 10.1177/1747493017729266. Epub 2017 Sep 4.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Accident', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11997', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5837', 'ConditionBrowseLeafName': 'Chronic Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1303', 'ConditionBrowseLeafName': 'Chronic Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 40, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03969563', 'OrgStudyIdInfo': {'OrgStudyId': 'D2951-R'}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Mindfulness-Based Stress Reduction to Improve Neuropsychological Functioning in Acquired Brain Injury', 'OfficialTitle': 'Mindfulness-Based Stress Reduction to Improve Neuropsychological Functioning in Acquired Brain Injury'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 6, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 5, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 22, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 29, 2019', 'StudyFirstSubmitQCDate': 'May 29, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 31, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 9, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 13, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': \"Thousands of Veterans suffer a stroke every year, and these individuals often suffer emotional and cognitive changes that negatively affect their quality of life as well as their ability to recover. In addition to traditional rehabilitation such as physical and occupational therapy, a number of alternative treatments are now being studied for their ability to enhance patients' recovery following stroke. One of these treatments, Mindfulness-Based Stress Reduction or MBSR, involves an 8-week course that teaches individuals strategies such as breathing techniques, meditation, and movement therapy. The current study proposes to teach MBSR to a group of Veterans with a history of stroke to determine whether this type of intervention has beneficial effects on psychological and cognitive functioning. The investigators hope to find that MBSR is a useful, additional intervention that can improve Veterans' well-being and quality of life as they recover from stroke.\", 'DetailedDescription': \"Stroke affects approximately 800,000 Americans every year, including thousands of Veterans, and is a leading cause of disability in the US. While many stroke patients receive rehabilitation during the acute and post-acute phases of stroke, many individuals suffer chronic deficits and have few options for continued treatment. A number of low-cost, alternative treatments are now being tested for their usefulness in treating neuropsychological deficits in chronic stroke patients. One of the best studied of these treatments is Mindfulness-Based Stress Reduction (MBSR), which involves an 8-week course led by a trained instructor. MBSR teaches individuals strategies for coping with their injury, such as meditation, breathing techniques, and yoga. A handful of preliminary studies have shown that MBSR is effective in reducing symptoms of anxiety and depression in stroke patients, as well as enhancing performance on cognitive tasks. However, only a single randomized controlled trial of MBSR in stroke has been published to date, and that study suffered from a number of weaknesses such as the lack of an active control group. Moreover, no previous study has assessed the usefulness of MBSR for stroke in a Veteran population. Therefore, the current study proposes to undertake a rigorous, randomized controlled trial of MBSR in Veterans with a history of stroke, using an active control group, blinded examiners, and a 6-month follow-up session to determine whether the benefits of MBSR are long-lasting. For the study, 120 Veterans with a history of chronic stroke will be recruited: 60 participants will be randomly assigned to the MBSR intervention, and 60 participants will be assigned to a Brain Health class that is matched to the MBSR intervention with respect to the instructor, number of hours of instruction, homework activities, and class size. A blinded examiner will complete a neuropsychological assessment of patients' emotional and cognitive status at three time points: 1) prior to the intervention, 2) following the intervention, and 3) six months later. Evaluation of the MBSR intervention will test for improvements in anxiety and depressive symptomatology following the intervention, relative to the Brain Health group, as well as improvements on a cognitive test battery. It is predicted that improvements associated with the MBSR intervention will still be present at the 6-month follow-up assessment as well. The final objective of the current proposal is to determine whether the site of a patient's stroke plays a role in their ability to benefit from MBSR. Previous research has suggested that left prefrontal cortex plays a critical role underlying the effects of MBSR. Thus, it is predicted that involvement of this brain region will modulate the observed effects. Such information could be used to target those Veterans who can most benefit from the proposed intervention. If shown to be effective, MBSR could provide a low-cost, non-invasive rehabilitative treatment for Veterans with acquired brain injury that can improve their neuropsychological functioning and general sense of well-being.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['stroke', 'MBSR', 'meditation', 'mindfulness', 'yoga']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Participants are assigned to either the MBSR or Brain Health education class, in parallel for the duration of the study.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': \"The neuropsychologist doing the assessments pre- and post-intervention will not be aware of the participant's group assignment.\", 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '109', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'MBSR', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Mindfulness-based Stress Reduction']}}, {'ArmGroupLabel': 'Brain Health Education', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': '8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brain Health Education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Mindfulness-based Stress Reduction', 'InterventionDescription': '8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['MBSR']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MBSR']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Brain Health Education', 'InterventionDescription': '8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Brain Health Education']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Beck Anxiety Inventory', 'PrimaryOutcomeDescription': 'The primary psychological outcome measure is the Beck Anxiety Inventory to measure changes in subjective symptoms of anxiety from pre- to post-intervention. The range is 0 to 63, with 0 being no/minimal anxiety and 63 being severe anxiety. A lower score post-intervention indicates improvement on this measure.', 'PrimaryOutcomeTimeFrame': '10 weeks'}, {'PrimaryOutcomeMeasure': 'Working Memory Score on the Repeatable Battery for the Assessment of Neuropsychological Status', 'PrimaryOutcomeDescription': \"The primary cognitive outcome measure is the Repeatable Battery for the Assessment of Neuropsychological Status working memory score, which tests participants' ability to hold information in mind for several seconds. Raw scores will be converted to normative percentiles, which can range from 1-99th percentile. A higher percentile post-intervention indicates improvement on this measure.\", 'PrimaryOutcomeTimeFrame': '10 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Beck Depression Inventory', 'SecondaryOutcomeDescription': 'The secondary psychological outcome measure is a change in depression scores from pre- to post-intervention. The range is 0 to 63, with 0 being no/minimal depression and 63 being severe depression. A lower score post-intervention indicates improvement on this measure.', 'SecondaryOutcomeTimeFrame': '10 weeks'}, {'SecondaryOutcomeMeasure': 'Attention Score on the Repeatable Battery for the Assessment of Neuropsychological Status', 'SecondaryOutcomeDescription': \"The secondary cognitive outcome score is the Repeatable Battery for the Assessment of Neuropsychological Status attention score, which tests participants' ability to stay focused on a stimulus and respond with minimal distraction. Raw scores will be converted to normative percentiles, which can range from 1-99th percentile. A higher percentile post-intervention indicates improvement on this measure.\", 'SecondaryOutcomeTimeFrame': '10 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nhistory of a single, chronic right or left hemisphere stroke\\n\\ndefined here as > 3 months post-onset so that residual symptoms have stabilized)\\nnative English proficiency\\n\\nat least mild level of depression\\n\\n14 on Beck Depression Inventory-II94,95\\n\\nand/or mild anxiety\\n\\n8 on the Beck Anxiety Inventory27\\n\\nlanguage within normal limits\\n\\nWestern Aphasia Battery score > 93.7104\\nscores already available in the investigators' stroke patient database so that language deficits will not interfere with the intervention\\n\\nExclusion Criteria:\\n\\na pre-morbid neurologic history or history of schizophrenia spectrum and other psychotic disorders\\n\\nincluding depressive disorders with psychotic features\\nbipolar disorders (to avoid potential confounds in neuropsychological testing)\\nMini-Mental State Examination score <19 (suggesting moderate to severe cognitive impairment that is a contraindication in effectively participating in the MBSR intervention52)\\nrecent substance abuse/dependence disorder (< 1 year)\\nacutely suicidal\\nconcurrent involvement in another rehabilitation program\\nsignificant visual or hearing disabilities that would preclude participating in the program\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Juliana V. Baldo, PhD', 'OverallOfficialAffiliation': 'VA Northern California Health Care System, Mather, CA', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'VA Northern California Health Care System, Mather, CA', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95655-4200', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'ICF', 'LargeDocHasProtocol': 'No', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'Yes', 'LargeDocLabel': 'Informed Consent Form', 'LargeDocDate': 'August 18, 2021', 'LargeDocUploadDate': '03/09/2023 16:47', 'LargeDocFilename': 'ICF_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001930', 'ConditionMeshTerm': 'Brain Injuries'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000006259', 'ConditionAncestorTerm': 'Craniocerebral Trauma'}, {'ConditionAncestorId': 'D000020196', 'ConditionAncestorTerm': 'Trauma, Nervous System'}, {'ConditionAncestorId': 'D000014947', 'ConditionAncestorTerm': 'Wounds and Injuries'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4897', 'ConditionBrowseLeafName': 'Brain Injuries', 'ConditionBrowseLeafAsFound': 'Brain Injury', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17375', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9039', 'ConditionBrowseLeafName': 'Craniocerebral Trauma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21713', 'ConditionBrowseLeafName': 'Trauma, Nervous System', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}]}}}}}, {'Rank': 41, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03701815', 'OrgStudyIdInfo': {'OrgStudyId': 'KRU001'}, 'Organization': {'OrgFullName': 'VA Palo Alto Health Care System', 'OrgClass': 'FED'}, 'BriefTitle': 'Effect of Lifestyle Changes on BDNF Level After Stroke', 'OfficialTitle': 'Assessing the Effect of Multi-disciplinary Lifestyle Medicine Intervention on Brain-derived Neurotrophic Factor Levels Following Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'October 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 19, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 11, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 28, 2019', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 27, 2018', 'StudyFirstSubmitQCDate': 'October 8, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 10, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 8, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 10, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jeffrey Krauss', 'ResponsiblePartyInvestigatorTitle': 'Staff Physician', 'ResponsiblePartyInvestigatorAffiliation': 'VA Palo Alto Health Care System'}, 'LeadSponsor': {'LeadSponsorName': 'VA Palo Alto Health Care System', 'LeadSponsorClass': 'FED'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Stanford University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Spaulding Rehabilitation Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is a pilot study to determine whether a lifestyle medicine intervention following stroke may increase levels of Brain-Derived Neurotrophic Factor (BDNF).', 'DetailedDescription': 'This is a substudy of the study entitled \"Assessing a Multi-Disciplinary Lifestyle Medicine Intervention Following Stroke,\" specifically looking at the effects of lifestyle change on brain-derived neurotrophic factor (BDNF). BDNF has emerged as a key facilitator of neuroplasticity to improve motor learning and rehabilitation after stroke. Aerobic exercise has been shown to increase levels of BDNF in multiple parts of the central nervous system and therefore may facilitate neuroplasticity and motor recovery. While BDNF levels appear to be increased for up to 1 hour following a bout of aerobic exercise, it is unclear whether regular aerobic exercise over weeks to months can increase baseline BDNF levels in humans following stroke.\\n\\nAn single nucleotide polymorphism exists on the BDNF gene in 30-50% of the human population that results in an amino acid change from valine (val) to methionine (met) at position 66 (val66met) of the precursor peptide proBDNF. The presence of the met allele results in a 25% reduction in activity-dependent secretion of BDNF in the CNS.\\n\\nThe Wellness in Rehabilitation program at the VA Palo Alto Health Care System is a lifestyle medicine intervention for patients following stroke. It is a 12-week program involving weekly meetings that include exercise (particularly aerobic exercise), nutrition, stress management, education, and group support. Participants are encouraged to perform healthy lifestyle behaviors (i.e. exercise) daily at home, and a health coach calls each patient weekly to support the behavior change process.\\n\\nParticipants in the Wellness in Rehabilitation program who elect to participate in the research study will have blood drawn at baseline, week 6, and week 12. Blood draws will be performed in the morning prior to exercise, and week 6 will additionally include a blood draw within 30 minutes of completing a bout of aerobic exercise. Following completion of the study, plasma BDNF levels (measured as nanograms per milliliter) will then be measured at all 4 time points (baseline, week 6 pre-exercise, week 6 post-exercise, and week 12). In addition, BDNF genotype will be measured using the baseline sample. Participants will also complete bike or treadmill exercise testing at baseline and week 12 to determine pre- and post-program cardiovascular fitness levels (measured as VO2 max and estimated metabolic equivalents), and will also complete a 6-minute walk test. They will be asked to record their exercise daily and will additionally complete the Physical Activity Scale for Individuals with Physical Disabilities at baseline and week 12 time points.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['brain-derived neurotrophic factor', 'exercise', 'BDNF', 'lifestyle medicine']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '12', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Post-stroke', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients will receive a 12-week lifestyle medicine program.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Wellness in Rehabilitation program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Wellness in Rehabilitation program', 'InterventionDescription': 'The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Post-stroke']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Lifestyle Medicine program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'BDNF level - Final', 'PrimaryOutcomeDescription': 'Plasma BDNF protein levels, expressed in nanograms per milliliter, measured prior to any exercise upon completion of intervention.', 'PrimaryOutcomeTimeFrame': 'Week 12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'BDNF level - Post-exercise', 'SecondaryOutcomeDescription': 'Plasma BDNF protein levels, expressed in nanograms per milliliter, measured immediately following bout of aerobic exercise.', 'SecondaryOutcomeTimeFrame': 'Week 6'}, {'SecondaryOutcomeMeasure': 'BDNF Genotype', 'SecondaryOutcomeDescription': 'Genotyping of venous blood samples to determine ValVal, MetMet, and ValMet distribution.', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'Cardiovascular Fitness - VO2 max', 'SecondaryOutcomeDescription': 'Measured as VO2 max (ml/kg/min).', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Cardiovascular Fitness - METs', 'SecondaryOutcomeDescription': 'Measured as estimated metabolic equivalents (kcal/kg/hour).', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': '6-minute Walk Test', 'SecondaryOutcomeDescription': 'Total distance walked 6 minutes on a flat surface.', 'SecondaryOutcomeTimeFrame': 'Week 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHistory of prior stroke (ischemic or hemorrhagic) or transient ischemic attack\\nAbility to ambulate at least 10 feet with minimal to moderate assistance\\nAbility to travel to intervention site on a weekly basis.\\n\\nExclusion Criteria:\\n\\nCerebral aneurysm\\nConcurrent pregnancy\\nSerious terminal illnesses (e.g. end stage renal disease, heart failure (class IV), cirrhosis (class C), metastatic cancer)\\nAny injury or illness preventing participation in regular aerobic exercise\\nModerate-severe dementia or cognitive decline', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jeffrey Krauss, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '6504935000', 'CentralContactPhoneExt': '65525', 'CentralContactEMail': 'jkrauss@stanford.edu'}, {'CentralContactName': 'Windy McNerney, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '6504935000', 'CentralContactEMail': 'windymc@stanford.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey Krauss, MD', 'OverallOfficialAffiliation': 'VA Palo Alto Health Care System, Stanford University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'VA Palo Alto Health Care System', 'LocationStatus': 'Recruiting', 'LocationCity': 'Palo Alto', 'LocationState': 'California', 'LocationZip': '94304', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jeffrey Krauss, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '650-493-5000', 'LocationContactPhoneExt': '65525', 'LocationContactEMail': 'jeffrey.krauss@va.gov'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 42, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03728400', 'OrgStudyIdInfo': {'OrgStudyId': 'DENUTRITION USINV'}, 'Organization': {'OrgFullName': 'Groupe Hospitalier Paris Saint Joseph', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Follow-up of Malnutrition Screening in USINV', 'OfficialTitle': 'Follow-up of Malnutrition Screening in Neurovascular Intensive Care Unit', 'Acronym': 'DENUTRITION'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 29, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 30, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 31, 2018', 'StudyFirstSubmitQCDate': 'October 31, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 2, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 6, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 7, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Groupe Hospitalier Paris Saint Joseph', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This aim of the study is to set up a procedure for screening for undernutrition in the neurovascular intensive care unit. This screening procedure follows a specific work concerning undernutrition in thrombolyzed patients (NCT03303820). This work was motivated by the fact that, despite a high frequency of undernutrition in the hospital (at least 30% of patients), undernutrition in neurovascular unit is studied very little. A cohort of thrombolysed patients in 2014 was studied retrospectively. Patients malnourished at the entrance had a non-significant, less good recovery of their stroke (+ 1 Rankin score point at 3 months in malnourished patients at the entrance).', 'DetailedDescription': 'The main objective of this project is to assess, prospectively, the frequency of undernutrition at the entrance to the neurovascular intensive care unit and to evaluate the implementation of the undernutrition screening procedure.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '66', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients in neurovascular intensive care', 'ArmGroupDescription': \"During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.\"}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'frequency of undernutrition at the entrance', 'PrimaryOutcomeDescription': 'The primary endpoint is the number of patients who have had an assessment of their nutritional status, that is, for whom undernutrition is detected according to the terms proposed in the undernutrition screening procedure: search for previous quantified weight loss, input BMI, albuminemia.', 'PrimaryOutcomeTimeFrame': 'Day 1'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Modified Rankin scale', 'SecondaryOutcomeDescription': 'The Rankin score will be performed in post stroke consultation, 3 months after inclusion. Rankin scale: 0 no symptoms, 1 No significant disability. Able to carry out all usual activities, despite some symptoms, 2 Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 Moderate disability. Requires some help, but able to walk unassisted, 4 Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 Severe disability. Requires constant nursing care and attention, bedridden, incontinent', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Recurrence rate of ischemic or haemorrhagic stroke', 'SecondaryOutcomeDescription': 'The recurrence of stroke will be collected during the post stroke consultation, 3 months after inclusion.', 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatient whose age ≥ 70 years\\nPatient hospitalized in Neurovascular Intensive care Unit following a stroke (infarction or cerebral hematoma)\\nFrancophone patient\\n\\nExclusion Criteria:\\n\\nPatient hospitalized in Neurovascular Intensive care Unit following a transient ischemic attack\\nPatient whose age ≤ 70 years\\nPatient hospitalized in Neurovascular Intensive care Unit for another reason than neurovascular disease\\nPatient opposing the use of his data', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '70 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'Patients hospitalized in Neurovascular Intensive care Unit following a stroke', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marie P BRUANDET, MD', 'OverallOfficialAffiliation': 'Groupe Hospitalier Paris Saint Joseph', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Groupe Hospitalier Paris Saint-Joseph', 'LocationCity': 'Paris', 'LocationZip': '75014', 'LocationCountry': 'France'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}}, {'Rank': 43, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03798418', 'OrgStudyIdInfo': {'OrgStudyId': 'CCH-170208'}, 'Organization': {'OrgFullName': 'Changhua Christian Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases', 'OfficialTitle': 'Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases - Effects of Therapeutic Exercise and Nutrition Intervention'}, 'StatusModule': {'StatusVerifiedDate': 'October 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 1, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2022', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2022', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 28, 2018', 'StudyFirstSubmitQCDate': 'January 9, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 10, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 30, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 1, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ta-Sen Wei,MD', 'ResponsiblePartyInvestigatorTitle': 'Director, Physical Medical and Rehabilitation, Principal Investigator, Clinical Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Changhua Christian Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Changhua Christian Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The objective of this study is to investigate the effects of therapeutic exercise and nutrition intervention for sarcopenia and risk of falls in patients with major chronic diseases. The outcomes will be analyzed regarding muscle strength, quality, and volume, etc., balance and gait, bone density, body composition, fall and quality of life after the intervention.', 'DetailedDescription': 'The main common chronic diseases in the elderly such as stroke, osteoporosis, chronic kidney disease and cancer, have been regarded as the fall high-risk patients. These patients are considered to be at risk for sarcopenia due to decreased exercise, nutritional status, and other reasons. Sarcopenia can be diagnosed and intervened effectively to delay the vicious cycle of health. Past studies have pointed out that in addition to drug intervention, treatment for sarcopenia must be accompanied by appropriate exercise and nutritional intervention (such as protein supplements, vitamin D) in order to achieve the best prevention and treatment.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Osteoporosis', 'Chronic Kidney Diseases', 'Cancer']}, 'KeywordList': {'Keyword': ['Sarcopenia', 'stroke', 'osteoporosis', 'chronic kidney disease', 'cancer', 'balance and gait', 'fall']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '186', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'exercise group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'elastic band strengthening exercise', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: elastic band strengthening exercise']}}, {'ArmGroupLabel': 'exercise combine diet counseling group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'elastic band strengthening exercise combined diet counseling.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: elastic band strengthening exercise', 'Dietary Supplement: diet counseling']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'elastic band strengthening exercise', 'InterventionDescription': '2-3days per week(150min per week)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['exercise combine diet counseling group', 'exercise group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['thera-band strengthening exercise']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'diet counseling', 'InterventionDescription': 'each patients in this group will receive4-5times diet counseling', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['exercise combine diet counseling group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['nutrition counseling']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change of walking speed', 'PrimaryOutcomeDescription': 'distance: 6m, patients can walk with foor orthosis and assistive devices', 'PrimaryOutcomeTimeFrame': 'baseline: before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of grip force', 'PrimaryOutcomeDescription': 'Use a grip force meter (kg) to test both hands for test 3 times', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of postural sway displacement', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure the postural sway displacement (mm)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of postural sway velocity', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure the postural sway velocity (mm/s)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of postural sway area', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure the postural sway area (mm^2)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of step time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: step time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of stance time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: stance time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of swing time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: swing time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of single support time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: single support time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of double support time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: double support time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of step length', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: step distance (mm)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of stance length', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: stance distance (mm)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle thickness', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: thickness (mm). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle fiber length', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: fiber length (mm). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle fiber orientation angle', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: fiber orientation angle (degrees). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle cross section area', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: cross-sectional area (mm^2).\\n\\nTarget muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of physiological cost index (PCI)', 'PrimaryOutcomeDescription': 'Heart rate (HR: beats/min) and walking speed (m/s) have been previously shown to be linearly related to oxygen uptake at sub-maximal exercise levels. Combination of these two parameters yields a single value in beats per meter, the physiological cost index (PCI). This is calculated as Working HR - Resting HR (beats/min) / Walking speed (m/s)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of international Quality of Life Assessment Short Form -36 (SF-36)', 'PrimaryOutcomeDescription': 'including 8 health concepts: (1) physical functioning, (2) role limitations because of physical health problems; (3) bodily pain, (4) social functioning, (5) general mental health (psychological distress and psychological wellbeing), (6) role limitations because of emotional problems, (7) vitality (energy/fatigue), (8) general health perceptions.\\n\\nScoring: answers to each question are scored which are then summed and transformed to a 0 - 100 scale.\\n\\nThe lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of amplitude of Muscle activity', 'PrimaryOutcomeDescription': 'use electromyography to measure the muscles activity in microvolts (uv) included quadriceps, hamstrings, tibialis anterior, gastrocnemius during subject walking in self-selected speed in 6 meters.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change of concentration of CRP (C-Reactive Protein)', 'SecondaryOutcomeDescription': 'The concentration of CRP in the blood test. CRP is used mainly as a marker of inflammation.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of ALB (Serum albumin)', 'SecondaryOutcomeDescription': 'The concentration of ALB in the blood test. Albumin is the most important contributor to the maintenance of plasma colloid oncotic pressure; deficiency results in edema.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Glomerular Filtration Rate (GFR)', 'SecondaryOutcomeDescription': \"The concentration of GFR in the blood test. The glomerular filtration rate is the best test to measure the patient's level of kidney function and determine the stage of kidney disease. It can calculate it from the results of the blood creatinine test.\", 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Hemoglobin (Hb)', 'SecondaryOutcomeDescription': 'The concentration of Hb in the blood test.', 'SecondaryOutcomeTimeFrame': 'Time Frame: before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Glucose SPOT', 'SecondaryOutcomeDescription': 'The concentration of Glucose SPOT in the blood test. TheSpot glucose measurement in epidermal interstitial fluid appears to be a promising alternative to capillary blood glucose estimation', 'SecondaryOutcomeTimeFrame': 'Time Frame: before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Cholesterol', 'SecondaryOutcomeDescription': 'The concentration of Cholesterol in the blood test.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Triglyceride', 'SecondaryOutcomeDescription': 'The concentration of Triglyceride in the blood test.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Transferrin', 'SecondaryOutcomeDescription': 'The concentration of Transferrin in the blood test.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Berg balance test (BBS)', 'SecondaryOutcomeDescription': 'including 14 items which are scored on a 5 points scale (0-4). The degree of success in achieving each task is given a score of zero (unable) to four (independent), and the final measure is the sum of all of the scores.\\n\\nThe item scores are summed, minimum score =0, maximum score = 56', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Fugl-Meyer Assessment (FMA)', 'SecondaryOutcomeDescription': 'Items are scored on a 3-point ordinal scale (0 = cannot perform; 1 = performs partially; 2 = performs fully) Maximum Score = 226 points The 5 domains assessed include, Motor function (UE maximum score = 66; LE maximum score = 34), Sensory function (maximum score = 24), Balance (maximum score = 14), Joint range of motion (maximum score = 44), Joint pain (maximum score = 44)', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Body Mass Index (BMI)', 'SecondaryOutcomeDescription': '(body weight) kg/(height) m*(height)m', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Mini-mental state examination (MMSE)', 'SecondaryOutcomeDescription': 'It is an 11-question measure that tests five areas of cognitive function:\\n\\norientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Modified Ashworth scale (MAS)', 'SecondaryOutcomeDescription': 'measures resistance during passive soft-tissue stretching, the score is ranged from 0-4 0: No increase in muscle tone\\n\\nSlight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM\\nMore marked increase in muscle tone through most of the ROM, but affected part(s) easily moved\\nConsiderable increase in muscle tone, passive movement difficult\\nAffected part(s) rigid in flexion or extension', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Muscle tone', 'SecondaryOutcomeDescription': 'measure the muscle tone (kg/m) under muscle resting. Target muscles are quadricep, hamstring, anterior tibialis, gastrocnemius.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n55-85 years old\\n3-6 months after onset\\nwalk independently for at least 10m\\n\\nExclusion Criteria:\\n\\nlower limb Brunnstrom stage >5\\ncombine other neuropathy diseases\\nsignificant deformity of lower limb include: Modified Ashworth scale(MAS) >3; contracture, fracture, chronic joint pain.\\njoint arthroplasty\\nunstable vital sign\\ncan not cooperate study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Tasen Wei, Doctor', 'OverallOfficialAffiliation': 'Changhua Christian Hospital', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Changhua Christian Hospital', 'LocationCity': 'Changhua', 'LocationZip': '500', 'LocationCountry': 'Taiwan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24785098', 'ReferenceType': 'background', 'ReferenceCitation': 'Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. 2014 Oct;33(5):737-48. doi: 10.1016/j.clnu.2014.03.007. Epub 2014 Mar 29.'}, {'ReferencePMID': '11518445', 'ReferenceType': 'background', 'ReferenceCitation': 'Stapleton T, Ashburn A, Stack E. A pilot study of attention deficits, balance control and falls in the subacute stage following stroke. Clin Rehabil. 2001 Aug;15(4):437-44. doi: 10.1191/026921501678310243.'}, {'ReferencePMID': '11833018', 'ReferenceType': 'background', 'ReferenceCitation': 'Hyndman D, Ashburn A, Stack E. Fall events among people with stroke living in the community: circumstances of falls and characteristics of fallers. Arch Phys Med Rehabil. 2002 Feb;83(2):165-70. doi: 10.1053/apmr.2002.28030.'}, {'ReferencePMID': '25852886', 'ReferenceType': 'background', 'ReferenceCitation': 'Kutner NG, Zhang R, Huang Y, Wasse H. Falls among hemodialysis patients: potential opportunities for prevention? Clin Kidney J. 2014 Jun;7(3):257-63. doi: 10.1093/ckj/sfu034. Epub 2014 Apr 15.'}, {'ReferencePMID': '17699348', 'ReferenceType': 'background', 'ReferenceCitation': 'Cook WL, Tomlinson G, Donaldson M, Markowitz SN, Naglie G, Sobolev B, Jassal SV. Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol. 2006 Nov;1(6):1197-204. doi: 10.2215/CJN.01650506. Epub 2006 Aug 30.'}, {'ReferencePMID': '24415363', 'ReferenceType': 'background', 'ReferenceCitation': 'Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Barnes CA, Gourin CG, Der-Torossian H. Cancer cachexia update in head and neck cancer: Definitions and diagnostic features. Head Neck. 2015 Apr;37(4):594-604. doi: 10.1002/hed.23599. Epub 2014 Mar 25.'}, {'ReferencePMID': '19588334', 'ReferenceType': 'background', 'ReferenceCitation': 'Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD002759. doi: 10.1002/14651858.CD002759.pub2.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'only for research'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010024', 'ConditionMeshTerm': 'Osteoporosis'}, {'ConditionMeshId': 'D000055948', 'ConditionMeshTerm': 'Sarcopenia'}, {'ConditionMeshId': 'D000007674', 'ConditionMeshTerm': 'Kidney Diseases'}, {'ConditionMeshId': 'D000051436', 'ConditionMeshTerm': 'Renal Insufficiency, Chronic'}, {'ConditionMeshId': 'D000002908', 'ConditionMeshTerm': 'Chronic Disease'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}, {'ConditionAncestorId': 'D000052776', 'ConditionAncestorTerm': 'Female Urogenital Diseases'}, {'ConditionAncestorId': 'D000005261', 'ConditionAncestorTerm': 'Female Urogenital Diseases and Pregnancy Complications'}, {'ConditionAncestorId': 'D000091642', 'ConditionAncestorTerm': 'Urogenital Diseases'}, {'ConditionAncestorId': 'D000052801', 'ConditionAncestorTerm': 'Male Urogenital Diseases'}, {'ConditionAncestorId': 'D000051437', 'ConditionAncestorTerm': 'Renal Insufficiency'}, {'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000001851', 'ConditionAncestorTerm': 'Bone Diseases, Metabolic'}, {'ConditionAncestorId': 'D000001847', 'ConditionAncestorTerm': 'Bone Diseases'}, {'ConditionAncestorId': 'D000009140', 'ConditionAncestorTerm': 'Musculoskeletal Diseases'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000009133', 'ConditionAncestorTerm': 'Muscular Atrophy'}, {'ConditionAncestorId': 'D000020879', 'ConditionAncestorTerm': 'Neuromuscular Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000001284', 'ConditionAncestorTerm': 'Atrophy'}, {'ConditionAncestorId': 'D000020763', 'ConditionAncestorTerm': 'Pathological Conditions, Anatomical'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10388', 'ConditionBrowseLeafName': 'Kidney Diseases', 'ConditionBrowseLeafAsFound': 'Kidney Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5837', 'ConditionBrowseLeafName': 'Chronic Disease', 'ConditionBrowseLeafAsFound': 'Chronic Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafAsFound': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12637', 'ConditionBrowseLeafName': 'Osteoporosis', 'ConditionBrowseLeafAsFound': 'Osteoporosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M26407', 'ConditionBrowseLeafName': 'Renal Insufficiency, Chronic', 'ConditionBrowseLeafAsFound': 'Chronic Kidney Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M26408', 'ConditionBrowseLeafName': 'Renal Insufficiency', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17009', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2876', 'ConditionBrowseLeafName': 'Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26783', 'ConditionBrowseLeafName': 'Female Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13817', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8089', 'ConditionBrowseLeafName': 'Female Urogenital Diseases and Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26785', 'ConditionBrowseLeafName': 'Male Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22390', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4816', 'ConditionBrowseLeafName': 'Bone Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4820', 'ConditionBrowseLeafName': 'Bone Diseases, Metabolic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11787', 'ConditionBrowseLeafName': 'Musculoskeletal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11780', 'ConditionBrowseLeafName': 'Muscular Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4279', 'ConditionBrowseLeafName': 'Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22309', 'ConditionBrowseLeafName': 'Neuromuscular Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22209', 'ConditionBrowseLeafName': 'Pathological Conditions, Anatomical', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1303', 'ConditionBrowseLeafName': 'Chronic Graft Versus Host Disease', 'ConditionBrowseLeafAsFound': 'Chronic', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 44, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04956471', 'OrgStudyIdInfo': {'OrgStudyId': 'M2019312'}, 'Organization': {'OrgFullName': 'Peking University Third Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Guideline - Based Nursing Plan for Dysphagia After Stroke', 'OfficialTitle': 'Guideline - Based Nursing Plan for Dysphagia After Stroke: Current Status and Influencing Factors'}, 'StatusModule': {'StatusVerifiedDate': 'July 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 1, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 1, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 1, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 27, 2021', 'StudyFirstSubmitQCDate': 'July 7, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 9, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 7, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 9, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Peking University Third Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Research purposes:1, investigate the nursing management is the head nurse for swallowing disorder after stroke care management status; Compared with the existing research, the difference between guidelines and evidence-based nursing plan and the analysis of the influencing factors.2, the investigation nursing personnel for swallowing disorder after stroke nursing implementation status; Compare the difference between its and department management requirements and to analyze its influencing factors.3 patients with swallowing disorder after stroke or their caregivers for swallowing disorder after stroke care needs of semi-structured interviews.', 'DetailedDescription': 'Research purposes:1, investigate the nursing management is the head nurse for swallowing disorder after stroke care management status; Compared with the existing research, the difference between guidelines and evidence-based nursing plan and the analysis of the influencing factors.2, the investigation nursing personnel for swallowing disorder after stroke nursing implementation status; Compare the difference between its and department management requirements and to analyze its influencing factors.3 patients with swallowing disorder after stroke or their caregivers for swallowing disorder after stroke care needs of semi-structured interviews.Study design.This subject adopts the mixed methods research design, the three parts to complete. Research focuses on the 3 armour hospital for ten. The first part first USES the literature analysis method, systematic review of swallowing disorder after stroke related guidelines and research. According to the guidelines and involved in the study of swallowing disorder after stroke care issues related to design the head nurse questionnaire, then cross-sectional investigation understand swallowing disorder after stroke clinical nursing management present situation in our country. According to the regional distribution plans to choose 10 3 armour hospital survey, about 15 head nurse.The second part first USES the literature analysis method, systematic review of swallowing disorder after stroke related guidelines and research. According to the guidelines and involved in the study of brain 4 cross-sectional survey) 108%Understanding of the brain in our country。Hospital survey,About 250 nurses. The third part USES the qualitative research in the design of phenomenological research methods, through face-to-face semi-structured interviews, collect data, understand the needs of patients and their caregivers, guide the nursing measures of existing. Selection of founding of neurology ward patients as the research and interview object, about 20 cases need to sample.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '20', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'hospitalized patients with swallowing disorder after stroke,.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: interview']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'interview', 'InterventionDescription': 'A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['hospitalized patients with swallowing disorder after stroke,.']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '1 swallowing disorder after stroke care management present situation investigation', 'PrimaryOutcomeDescription': 'The first part of swallowing disorder after stroke care management present situation investigation; Investigation includes general information and management status. A data includes gender, age, working years, job position, cultural degree, whether to have participated in related training. Current conditions including room management specification, nurse training, swallowing dysfunction screening and evaluation management, nutrition, management of complications.', 'PrimaryOutcomeTimeFrame': 'One year after recruitment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\nCerebral apoplexy diagnosed by CT or MRI;\\nDrinking water from depression > grade 3;\\nBe clear and able to communicate;\\nVolunteer for the study.\\n\\nExclusion criteria:\\n\\nIf you have serious basic diseases such as cardiovascular and cerebrovascular diseases, you cannot cooperate with the examination.\\nThe patient refused to accept the investigator.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': '15 cases.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Baohua Li', 'OverallOfficialAffiliation': 'Peking Yniversity Third Hospital Medical', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Peking Yniversity Third Hospital', 'LocationCity': 'Beijing', 'LocationCountry': 'China'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}]}}}}}, {'Rank': 45, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04295044', 'OrgStudyIdInfo': {'OrgStudyId': 'CORPG6G0191'}, 'Organization': {'OrgFullName': 'Chang Gung Memorial Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of High Protein Diet in Stroke Patients With Low Muscle Mass', 'OfficialTitle': 'Effect of High Protein Diet in Stroke Patients With Low Muscle Mass'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 15, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 3, 2020', 'StudyFirstSubmitQCDate': 'March 3, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 4, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 28, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 30, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Chang Gung Memorial Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Our prior studies demonstrated that dehydration was a predictor for poor outcome in stroke and Blood urea nitrogen/Cr ratio-based saline hydration therapy in patients with acute ischemic stroke may increase the rate of favorable clinical outcome with functional independence at 3 months after stroke. However, dehydration is likely to be only a part of representation in poor nutrition status and physical fragility for a stroke patient.\\n\\nOur prior study found that acute stroke patients admitted to neurological intensive care unit with low urinary creatinine excretion rate (CER), a marker of muscle mass, was associated with poor outcome at 6 months after stroke. An animal study suggested inadequate food and water intake determine mortality following stroke in mice and nutritional support reduced the 14-day mortality rate from 59% to 15%. A study also showed that high protein intake was associated with a better outcome in previous cardiovascular events.\\n\\nWe will calculate CER based on published equation. Based on our prior study, acute stroke patients with their CER<1500 mg/day will be enrolled. A randomized controlled trial will be conducted and patients will be randomly assigned to high protein diet or normal protein diet for at least 2 weeks. We plan to enroll 300 patients, with 150 patients in ach group, during 3-year study period. We will consult dietitians for arrangement of their diet. We assume that patients receiving high protein diet will have higher opportunity to walk independently (modified Rankin Scale 0-1) at 3 month after stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke', 'Diet, Healthy', 'Muscle Loss']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '110', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'High protein diet', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'received high protein diet, prescribed by dietitian', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: high protein diet']}}, {'ArmGroupLabel': 'Normal protein diet', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'received normal protein diet, prescribed by dietitian', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: normal protein diet']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'high protein diet', 'InterventionDescription': 'receive 1.8g protein/kg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['High protein diet']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'normal protein diet', 'InterventionDescription': 'receive 1g protein/kg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Normal protein diet']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'modified Rankin Scale 0-1', 'PrimaryOutcomeDescription': 'No significant disability', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'modified Rankin Scale 0-2', 'SecondaryOutcomeDescription': 'Slight disability', 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nacute ischemic stroke during hospitalization\\neGFR >30\\nurine albumin creatinine ratio < 30 mg/g\\nurinary creatinine excretion rate (CER) < 1500g/day\\n\\nExclusion Criteria:\\n\\nchronic kidney disease stage 4 or 5 (i.e. eGFR < 30)\\nproteinuria (protein 1+ or more in urine routine)\\nknown impairment of functional status (mRS ≥ 2) prior to the index stroke\\nrefuse to participate in this study.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Chang Gung Memorial Hospital, Chiayi Branch', 'LocationCity': 'Chiayi City', 'LocationZip': '613', 'LocationCountry': 'Taiwan'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 46, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05845372', 'OrgStudyIdInfo': {'OrgStudyId': 'NFEC-2023-040'}, 'Organization': {'OrgFullName': 'Nanfang Hospital, Southern Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy', 'OfficialTitle': 'Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy: a Prospective, Multicenter, Observational Cohort Study'}, 'StatusModule': {'StatusVerifiedDate': 'April 2023', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 1, 2027', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 1, 2027', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 26, 2023', 'StudyFirstSubmitQCDate': 'April 26, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 6, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 6, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Nanfang Hospital, Southern Medical University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'The Fourth Affiliated Hospital of Guangzhou Medical University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The Affiliated Hospital of Inner Mongolia Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Second Affiliated Hospital of Wenzhou Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Second Affiliated Hospital of Guangxi Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Fujian Medical University Union Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Huizhou Municipal Central Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Haikou People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Kashgar 1st People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Ganzhou City People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Guangdong Provincial Hospital of Traditional Chinese Medicine', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Huadu District People's Hospital of Guangzhou\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Dongguan donghua hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Sinopharm North Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Heyuan people's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Hainan People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Hainan Traditional Chinese Medicine Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Second Hospital University of South China', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Dongguan People's Hospital\", 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': \"Yueyang People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.\", 'DetailedDescription': 'Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.\\n\\nHowever, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Ischemic Stroke']}, 'KeywordList': {'Keyword': ['Acute Ischemic Stroke', 'Stress Ulcer Bleeding', 'Mechanical Thrombectomy']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '2592', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stress Ulcer Prophylaxis', 'ArmGroupDescription': 'Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.'}, {'ArmGroupLabel': 'Control Group', 'ArmGroupDescription': 'Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '90-day mortality after onset', 'PrimaryOutcomeDescription': 'Proportion of enrolled patients who died 90 days after onset of disease.', 'PrimaryOutcomeTimeFrame': '90-day after onset'}, {'PrimaryOutcomeMeasure': 'Incidence of stroke-associated pneumonia', 'PrimaryOutcomeDescription': 'Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset', 'PrimaryOutcomeTimeFrame': 'within 7-day of onset'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Incidence of clinically significant bleeding', 'SecondaryOutcomeDescription': 'One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d(（1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U.', 'SecondaryOutcomeTimeFrame': 'within 7-day of onset'}, {'SecondaryOutcomeMeasure': 'Incidence of stress ulcer bleeding', 'SecondaryOutcomeDescription': 'Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood', 'SecondaryOutcomeTimeFrame': '7-day after onset'}, {'SecondaryOutcomeMeasure': 'Incidence of unfavorable functional prognosis at 90 days after onset', 'SecondaryOutcomeDescription': 'Incidence of unfavorable functional prognosis at 90 days after onset', 'SecondaryOutcomeTimeFrame': '90-day after onset'}, {'SecondaryOutcomeMeasure': '90-day mRS score change', 'SecondaryOutcomeDescription': 'Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria', 'SecondaryOutcomeTimeFrame': '90-day after onset'}, {'SecondaryOutcomeMeasure': 'Incidence of early neurological deterioration', 'SecondaryOutcomeDescription': 'Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4', 'SecondaryOutcomeTimeFrame': 'within 72 hours after onset'}, {'SecondaryOutcomeMeasure': '1-year post-onset mortality', 'SecondaryOutcomeDescription': 'Mortality at 1 year after onset in patients who were eligible for inclusion criteria', 'SecondaryOutcomeTimeFrame': '1 year after onset'}, {'SecondaryOutcomeMeasure': 'Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset', 'SecondaryOutcomeDescription': 'Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria', 'SecondaryOutcomeTimeFrame': '1 year after onset'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge ≥18 years.\\nWithin 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the \"China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018\".\\nMeet the indications for mechanical thrombectomy in the \"Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022\".\\nTreated with mechanical thrombectomy.\\nNIHSS score ≥ 6 at onset of illness.\\nSign an informed notice.\\n\\nExclusion Criteria:\\n\\nAllergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure.\\n\\nHave participated in other interventional clinical studies (affecting the outcome of this cohort study).\\n\\nParticipants who were judged by the investigator to be unsuitable for participation in this study.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Suyue Pan, M.D., Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '13556184981', 'CentralContactEMail': 'pansuyue@smu.edu.cn'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Suyue Pan', 'OverallOfficialAffiliation': 'Department of Neurology, Nanfang Hospital,Southern Medical University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fujian Medical University Union Hospital', 'LocationCity': 'Fuzhou', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shenggen Chen, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13459480275'}]}}, {'LocationFacility': 'Dongguan donghua hospital', 'LocationCity': 'Dongguan', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lingyu Sun', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13829203368'}]}}, {'LocationFacility': \"Dongguan People's Hospital\", 'LocationCity': 'Dongguan', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhu Shi, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13669825459'}]}}, {'LocationFacility': 'Guangdong Provincial Hospital of Traditional Chinese Medicine', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lixin Wang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13922793886'}]}}, {'LocationFacility': \"Huadu District People's Hospital of Guangzhou\", 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Guangning Li, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13926239656'}]}}, {'LocationFacility': 'Nanfang Hospital of Southern Medical University', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Suyue Pan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13556184981'}]}}, {'LocationFacility': 'The Fourth Affiliated Hospital of Guangzhou Medical University', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China'}, {'LocationFacility': \"Heyuan people's Hospital\", 'LocationCity': 'Heyuan', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Minzhen Zhu', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15007622318'}]}}, {'LocationFacility': 'Huizhou Municipal Central Hospital', 'LocationCity': 'Huizhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lizhi Wang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13802872076'}]}}, {'LocationFacility': \"Haikou People's Hospital\", 'LocationCity': 'Haikou', 'LocationState': 'Hainan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Guoshuai Yang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13876006248'}]}}, {'LocationFacility': \"Hainan Provincial People's Hospital\", 'LocationCity': 'Haikou', 'LocationState': 'Hainan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Fan Zhang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '17389897580'}]}}, {'LocationFacility': 'Hainan Traditional Chinese Medicine Hospital', 'LocationCity': 'Haikou', 'LocationState': 'Hainan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yong Gu, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15521280288'}]}}, {'LocationFacility': 'The First Hospital of Changsha', 'LocationCity': 'Changsha', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xu Peng, M.D。', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15802507292'}]}}, {'LocationFacility': 'The Second Hospital University of South China', 'LocationCity': 'Hengyang', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yanhong Hu, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13265004191'}]}}, {'LocationFacility': \"Yueyang People's Hospital\", 'LocationCity': 'Yueyang', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yuan Zhou, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15107309796'}]}}, {'LocationFacility': 'Sinopharm North Hospital', 'LocationCity': 'Baotou', 'LocationState': 'Inner Mongolia', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lifei Xing, M.D', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15354919958'}]}}, {'LocationFacility': 'The Affiliated Hospital of Inner Mongolia Medical University', 'LocationCity': 'Hohhot', 'LocationState': 'Inner Mongolia', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lihua Sun, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18686292585'}]}}, {'LocationFacility': \"Ganzhou City People's Hospital\", 'LocationCity': 'Ganzhou', 'LocationState': 'Jiangxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhaohui Lai', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13879729792'}]}}, {'LocationFacility': 'Second Affiliated Hospital of Wenzhou Medical University', 'LocationCity': 'Wenzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Saijun Zhou, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13857746659'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020521', 'ConditionAncestorTerm': 'Stroke'}, {'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M16896', 'ConditionBrowseLeafName': 'Ulcer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9246', 'ConditionBrowseLeafName': 'Hemorrhage', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Acute Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 47, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04492644', 'OrgStudyIdInfo': {'OrgStudyId': 'CMUH108-REC3-110'}, 'Organization': {'OrgFullName': 'China Medical University Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Correlation Among Nutrition, Muscle Strength, Masticatory and Swallow Ability of Inpatient Elders', 'OfficialTitle': 'The Correlation Among Nutrition, Muscle Strength, Masticatory and Swallow Ability of Inpatient Elders', 'Acronym': 'NMM'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 28, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 3, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 3, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 28, 2020', 'StudyFirstSubmitQCDate': 'July 29, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 30, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 29, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Yin-Hwa Shih', 'ResponsiblePartyInvestigatorTitle': 'Assistant professor', 'ResponsiblePartyInvestigatorAffiliation': 'China Medical University Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'China Medical University Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'China Medical University, China', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The masticatory performance would affect the nutritional status of elderly people. the prevalence of undernutrition among elderly inpatients is %20-50%. Previous related studies investigate the masticatory performance with special chewing gum and self-reported questionnaires. This study observes the correlation of masticatory muscles sEMG, nutritional status, and handgrip force among elderly inpatients.', 'DetailedDescription': 'In this cross-sectional study, we enrolled 120 seniors aged 65 and above who are newly admitted to the Asian University Hospital. Within 24 hours they admitted to the hospital, we collected the Mini Nutritional Assessment scores, surface electromyography data, handgrip strength, self-assessment swallowing ability score, and clinical objective data. We performed the statistics for independent t-test, Pearson correlation analysis, and binary logistic regression with SPSS 23 software.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Malnutrition; Moderate']}, 'KeywordList': {'Keyword': ['the elder inpatient,', 'nutritional assessment', 'handgrip strength', 'masticatory electromyography']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'elderly inpatients', 'ArmGroupDescription': 'Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: No intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'No intervention', 'InterventionDescription': 'No intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['elderly inpatients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'masticatory muscle surface EMG', 'PrimaryOutcomeDescription': 'The sEMG examinations were conducted with a Zebris EMG Bluetooth muscle activity recording system', 'PrimaryOutcomeTimeFrame': 'Data were collected after the participants signed the informed consent form within 24 hours admitted to hospital.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Nutritional status', 'SecondaryOutcomeDescription': 'Nutritional status was measured by the Mini Nutritional Assessment (MNA).', 'SecondaryOutcomeTimeFrame': 'Data were collected after the participants signed the informed consent form within 24 hours admitted to hospital.'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Handgrip force', 'OtherOutcomeDescription': 'Left and right handgrip forces were measured by a Jamar® Hydraulic Hand Dynamometer', 'OtherOutcomeTimeFrame': 'Data were collected after the participants signed the informed consent form within 24 hours admitted to hospital.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nnew elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious\\n\\nExclusion Criteria:\\n\\nElderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '65 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'We enrolled 120 elderly inpatients in Asia University Hospital, Taiwan. We included new elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yin-Hwa Shih, Ph.D.', 'OverallOfficialAffiliation': 'Asia University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Asia University', 'LocationCity': 'Taichung', 'LocationZip': '404', 'LocationCountry': 'Taiwan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28673255', 'ReferenceType': 'result', 'ReferenceCitation': 'Alzahrani SH, Alamri SH. Prevalence of malnutrition and associated factors among hospitalized elderly patients in King Abdulaziz University Hospital, Jeddah, Saudi Arabia. BMC Geriatr. 2017 Jul 3;17(1):136. doi: 10.1186/s12877-017-0527-z.'}, {'ReferencePMID': '19089202', 'ReferenceType': 'result', 'ReferenceCitation': 'Berretin-Felix G, Nary Filho H, Padovani CR, Trindade Junior AS, Machado WM. Electromyographic evaluation of mastication and swallowing in elderly individuals with mandibular fixed implant-supported prostheses. J Appl Oral Sci. 2008 Mar-Apr;16(2):116-21. doi: 10.1590/s1678-77572008000200007.'}, {'ReferencePMID': '31747030', 'ReferenceType': 'result', 'ReferenceCitation': 'Gomes F, Baumgartner A, Bounoure L, Bally M, Deutz NE, Greenwald JL, Stanga Z, Mueller B, Schuetz P. Association of Nutritional Support With Clinical Outcomes Among Medical Inpatients Who Are Malnourished or at Nutritional Risk: An Updated Systematic Review and Meta-analysis. JAMA Netw Open. 2019 Nov 1;2(11):e1915138. doi: 10.1001/jamanetworkopen.2019.15138.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 48, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02807012', 'OrgStudyIdInfo': {'OrgStudyId': '16-0181'}, 'Organization': {'OrgFullName': 'Hospital de Clinicas de Porto Alegre', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nursing Home Care Intervention Post Stroke', 'OfficialTitle': 'Nursing Home Care Educational Intervention for Family Caregivers of Older Adults Post Stroke', 'Acronym': 'SHARE'}, 'StatusModule': {'StatusVerifiedDate': 'March 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 3, 2016', 'StudyFirstSubmitQCDate': 'June 16, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 21, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 8, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 12, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Clinicas de Porto Alegre', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"Associated with the worsening of functional capacity of older adult and the lack of guidance on how to care of them after stroke, the family caregiver starts to fell burden related to the care, and the quality of life was affected by that burden. Besides that, the older adult began to use more frequently health services and had more hospitalizations by preventable conditionals with adequate care.\\n\\nThe aim of this study is to evaluate the effectiveness of educational interventions of care at home provide by nurses to family caregivers of older adult with stroke after hospital discharge, compared with usual care guidelines or no guidance, in one month follow up. The family caregivers of older adults post stroke with the first functional sequel from the Clinical Hospital of Porto Alegre (HCPA) will participate in the study.\\n\\nThe intervention will involve the systematic monitoring of nurses through home visits (HVs) during one month. Thus, will instrumentalize the family caregiver to care of older adult with stoke according the protocol developed in a research group and the needs of care of them. The control group won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.\", 'DetailedDescription': \"Associated with the worsening of functional capacity of older adult and the lack of guidance on how to care of them after stroke, the family caregiver starts to fell burden related to the care and the quality of life was affected by that burden. Besides that, the older adult began to use more frequently health services and had more hospitalizations by preventable conditionals with adequate care.\\n\\nThe aim of this study is to evaluate the effectiveness of educational interventions of care at home provide by nurses to family caregivers of older adult with stroke after hospital discharge, compared with usual care guidelines or no guidance, in one month follow up. The family caregivers of older adults post stroke with the first functional sequel from the Clinical Hospital of Porto Alegre (HCPA) will participate in the study. The randomization will be through the randomization list created by web page randomization.com.\\n\\nThe intervention will involve systematic monitoring of nurses through home visits (HVs) during one month. Thus, will instrumentalize the family caregiver to care of older adult with stoke according the protocol developed in a research group and the needs of care of them. The control group won't receive the HVs and could have or not the usual care guidelines provide by health services that have access.\\n\\nWill be collect the identification, social and demographics data of the older adults and the caregivers at the moment of hospital discharge. Therefore, will be collect the clinical data of the older adults. After discharge and at the older adult's home, will be realized the first home visit (1ª HV) to all older adults and caregivers included in the study and will be applied to the family caregiver the Caregiver Burden Scale and the instrument WHOQOL-BREF that analyse the quality of life. Also, will be applied the Measure of Functional Independence (MIF) to identify the independence level of the older adults and the needs of care. In this moment, will be randomized by an extern member of research group through telephone contact. After this first HV, the older adults and caregivers included in the intervention group will received more three HVs, until 14, 21 and 30 days after discharge, respectively, by a pair of interventional nurses.\\n\\nThe control group won't receive the home visits by nurses, but could have or not the usual care guidelines provide by health services that have access.\\n\\nAll older adults and caregivers included in the study will received a fifth HV until 60 days after discharge. In this last HV will be applied to family caregiver the Caregiver Burden Scale and the instrument WHOQOL-BREF. In addition, will be applied a questionnaire related older adult's utilization of health services and rehospitalizations during this time and the MIF.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Home care services', 'Nursing', 'Clinical trial', 'Geriatric nursing', 'Family caregiver', 'Aged']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '82', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Nursing educational intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nursing educational intervention']}}, {'ArmGroupLabel': 'Usual care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': \"The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.\"}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nursing educational intervention', 'InterventionDescription': 'The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.\\n\\nThe control group could have ou not the usual care guidelines provide by health services that have access.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nursing educational intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"The family caregiver's burden of care analyzed by Caregiver Burden Scale\", 'PrimaryOutcomeDescription': 'The family caregiver burden of care will be analyzed by Caregiver Burden Scale.', 'PrimaryOutcomeTimeFrame': '2 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"The family caregiver's quality of life analyzed by instrument WHOQOL-BREF\", 'SecondaryOutcomeDescription': 'The family caregiver quality of life will be analyzed by instrument WHOQOL-BREF.', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': \"The elderly's functional capacity\", 'SecondaryOutcomeDescription': 'The elderly functional capacity will be analyzed by the instrument Measure of Functional Independence', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': \"The elderly's health service utilization\", 'SecondaryOutcomeDescription': 'The elderly health service utilization will be assessed by an questionnaire developed for this study. The answers will be yes or not and analyzed quantitatively.', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': \"The elderly's rehospitalization\", 'SecondaryOutcomeDescription': 'The elderly rehospitalization will be assessed by an questionnaire developed for this study. The answers will be yes or not and analyzed quantitatively.', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': 'The quality of life of family caregiver with 60 years old or older analyzed by instrument WHOQOL-OLD', 'SecondaryOutcomeDescription': 'The family caregiver quality of life will be analyzed by instrument WHOQOL-OLD', 'SecondaryOutcomeTimeFrame': '2 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nFamily caregivers of older adults from the Special Care Unit - stroke (SCU-Stroke) at the moment of discharge;\\nOlder adults with diagnosis of stroke with the first sequel identified by minimum score of 2 points from the ranking scale;\\nOlder adults who live until 20 kilometers from HCPA;\\nCaregiver will be a family member with consanguineous relationship or not;\\nCaregiver will be responsible for the most part of the older adult's care;\\nCaregiver without payment;\\nCaregiver with 18 year old or more.\\n\\nExclusion Criteria:\\n\\nOlder adults who live in a Long Term Care Services;\\nOlder adults who will be included in a governmental program for Home Care Service;\\nCaregivers who don't accept receive the HV by nurses.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Lisiane MG Paskulin, PhD', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital de Clínicas de Porto Alegre', 'LocationCity': 'Porto Alegre', 'LocationState': 'Rio Grande Do Sul', 'LocationZip': '90035-903', 'LocationCountry': 'Brazil'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '34813082', 'ReferenceType': 'derived', 'ReferenceCitation': 'Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021 Nov 23;11(11):CD001919. doi: 10.1002/14651858.CD001919.pub4.'}, {'ReferencePMID': '32602588', 'ReferenceType': 'derived', 'ReferenceCitation': 'Day CB, Bierhals CCBK, Mocellin D, Predebon ML, Santos NO, Dal Pizzol FLF, Fuhrmann AC, Aires M, Paskulin LMG. Nursing Home Care Intervention Post Stroke (SHARE) 1 year effect on the burden of family caregivers for older adults in Brazil: A randomized controlled trial. Health Soc Care Community. 2021 Jan;29(1):56-65. doi: 10.1111/hsc.13068. Epub 2020 Jun 30.'}, {'ReferencePMID': '31800798', 'ReferenceType': 'derived', 'ReferenceCitation': 'Bierhals CCBK, Day CB, Mocellin D, Santos NOD, Predebon ML, Pizzol FLFD, Fuhrmann AC, Medeiros GG, Aires M, Paskulin LMG. Use of health services by elderly people post-stroke: a randomized controlled trial. Rev Gaucha Enferm. 2019 Dec 2;41(spe):e20190138. doi: 10.1590/1983-1447.2020.20190138. eCollection 2020. English, Portuguese.'}, {'ReferencePMID': '29426361', 'ReferenceType': 'derived', 'ReferenceCitation': 'Day CB, Bierhals CCBK, Santos NOD, Mocellin D, Predebon ML, Dal Pizzol FLF, Paskulin LMG. Nursing home care educational intervention for family caregivers of older adults post stroke (SHARE): study protocol for a randomised trial. Trials. 2018 Feb 9;19(1):96. doi: 10.1186/s13063-018-2454-5.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 49, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05651945', 'OrgStudyIdInfo': {'OrgStudyId': 'Pro2022-0785'}, 'Organization': {'OrgFullName': 'Hackensack Meridian Health', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)', 'OfficialTitle': 'Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors', 'Acronym': 'SRP-CROSS'}, 'StatusModule': {'StatusVerifiedDate': 'May 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 20, 2023', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 20, 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 20, 2031', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 7, 2022', 'StudyFirstSubmitQCDate': 'December 7, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 15, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 18, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Hackensack Meridian Health', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'The Cardiovascular Institute of New Jersey at Rutgers Robert Wood Johnson Medical School', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study examines the effectiveness of the cardiac rehabilitation program for stroke patients. The study will examine if patients with stroke, who receive cardiac rehabilitation in addition to their standard of care treatments, demonstrate improved recovery of function. It will also examine if these patients have reduced hospital readmission, reduced rate of recurrent stroke, and mortality.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Cerebrovascular Accident']}, 'KeywordList': {'Keyword': ['cardiac rehabilitation', 'stroke', 'stroke rehabilitation', 'stroke recovery', 'exercise', 'cardiovascular disease', 'cardiovascular function', 'cognitive function', 'physical function', 'neurorehabilitation', 'transition of care post stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '112', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cardiac rehabilitation group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Traditional medically supervised center-based cardiac rehabilitation program; including 36 sessions (30-50 minutes) of a progressive exercise program and educational sessions for cardiovascular disease (CVD) risk factors.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Cardiac rehabilitation program']}}, {'ArmGroupLabel': 'Standard of care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Depending on functional deficits, conventional rehabilitation therapies can include physical therapy, occupational therapy, and/or speech therapy sessions with 2-3 visits per week. Participants will receive their standard of care therapies as prescribed by their treating physicians.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Cardiac rehabilitation program', 'InterventionDescription': 'The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cardiac rehabilitation group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '6-Minute Walk Test (6MWT)', 'PrimaryOutcomeDescription': 'Mean change in 6MWT score from baseline (30 days post-stroke) to 120 days post-stroke.', 'PrimaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'MET-min - (Metabolic Equivalent of Task - minutes)', 'SecondaryOutcomeDescription': 'Mean change in MET-min score from baseline (30 days post-stroke) to 120 days post-stroke.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}, {'SecondaryOutcomeMeasure': 'AM-PAC - (Activity Measure for Post Acute Care)', 'SecondaryOutcomeDescription': 'Mean change in AM-PAC score from baseline (30 days post-stroke) to 120 days post-stroke. AM-PAC is a questionnaire that evaluates functional outcomes across three domains: basic mobility, daily activity, and applied cognitive. Standardized scores range from -11.95 to 104.9 for basic mobility, from -2.73 to 115.4 for daily activities, and from 6.84 to 68.28 for applied cognition with higher scores representing a better function.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}, {'SecondaryOutcomeMeasure': 'MoCA - (Montreal Cognitive Assessment)', 'SecondaryOutcomeDescription': 'Mean change in MoCA score from baseline (30 days post-stroke) to 120 days post-stroke. MoCA is a 16-item test assessing multiple cognitive domains with a score range from 0-30 with higher scores representing a better function.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}, {'SecondaryOutcomeMeasure': 'SS-QOL - (Stroke specific Quality of Life)', 'SecondaryOutcomeDescription': 'Mean change in SS-QOL score from baseline (30 days post-stroke) to 120 days post-stroke. SS-QOL is a self-reported questionnaire containing 49 item questions covering 12 domains with a score range of 49-245 with higher scores representing better function.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke'}, {'SecondaryOutcomeMeasure': 'PHQ-9 - (Patient Health Questionnaire -9)', 'SecondaryOutcomeDescription': 'Mean change in PHQ-9 score from baseline (30 days post-stroke) to 120 days post-stroke. The PHQ-9 is a self-administered questionnaire designed to diagnose and evaluate depression with a score range 0-27.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke'}, {'SecondaryOutcomeMeasure': 'All-cause hospital readmission', 'SecondaryOutcomeDescription': 'All-cause hospital readmission rates at 1-year post-stroke', 'SecondaryOutcomeTimeFrame': '1-year post-stroke'}, {'SecondaryOutcomeMeasure': 'Recurrent stroke rate', 'SecondaryOutcomeDescription': 'Recurrent stroke rates at 1-year post stroke', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'All-cause mortality rate', 'SecondaryOutcomeDescription': 'All-cause mortality rates at 1-year post stroke', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'AM-PAC - (Activity Measure for Post Acute Care)', 'SecondaryOutcomeDescription': 'Mean change in AM-PAC score from baseline (30 days post stroke) to 1-year post stroke. AM-PAC is a questionnaire that evaluates functional outcomes across three domains: basic mobility, daily activity, and applied cognitive. Standardized scores range from -11.95 to 104.9 for basic mobility, from -2.73 to 115.4 for daily activities, and from 6.84 to 68.28 for applied cognition with higher scores representing a better function.', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'SS-QOL - (Stroke specific Quality of Life)', 'SecondaryOutcomeDescription': 'Mean change in SS-QOL score from baseline (30 days post stroke) to 1-year post stroke. SS-QOL is a self-reported questionnaire containing 49 item questions covering 12 domains with a score range of 49-245 with higher scores representing better function.', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'mRS - (Modified Rankin Scale)', 'SecondaryOutcomeDescription': 'Mean change in mRS score from baseline (30 days post stroke) to 120 days post stroke. The mRS is a questionnaire to assess the level of disability and functional independence in daily activities with reference to pre-stroke activities. The scale is scored 0-6 where 0 indicates lack of symptoms and the score 6 indicates death.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post stroke) to 120 days post stroke'}, {'SecondaryOutcomeMeasure': 'Picture Your Plate (PYP)', 'SecondaryOutcomeDescription': 'Mean change in PYP score from baseline (30 days post stroke) to 120 days post stroke. Picture Your Plate is a brief 48-question dietary assessment questionnaire with a total score ranging from 0 to 96 with higher scores representing an unhealthy diet.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post stroke) to 120 days post stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18 years or older\\nStroke diagnosis (ischemic or hemorrhagic) / radiologic evidence of acute stroke\\nMedically cleared by a cardiologist for participation in the cardiac rehabilitation program with no contraindications to cardiac rehabilitation per American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) guidelines\\nAbility to stand and walk with or without an assistive device for 10 feet safely, with or without assistance from another person\\nAbility to transfer on/off the recumbent bike with or without an assistive device safely, with or without assistance from another person\\nAbility to follow simple commands and communicate pain or distress\\nAdmission to an Inpatient Rehabilitation Facility post-stroke\\nSigned informed consent form\\n\\nExclusion Criteria:\\n\\nPresence of subarachnoid hemorrhage, intracranial aneurysm, intracranial hemangioma, or arteriovenous malformation\\nMedical disorders that preclude participation in the study as determined by the Principal Investigator.\\nInability to have baseline assessment within 45 days post-stroke diagnosis\\nPatient considered unable to comply with study requirements\\nKnown terminal illness with life expectancy less than 1 year\\nCompliant diagnosis eligible for traditional cardiac rehabilitation covered by insurance\\nUnable to understand/speak English', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Hayk Petrosyan, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '732-321-7000', 'CentralContactPhoneExt': '65979', 'CentralContactEMail': 'hayk.petrosyan@hmhn.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Sara J Cuccurullo, MD', 'OverallOfficialAffiliation': 'Hackensack Meridian Health - JFK Johnson Rehabilitation Institute', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Talya K Fleming, MD', 'OverallOfficialAffiliation': 'Hackensack Meridian Health - JFK Johnson Rehabilitation Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hackensack Meridian Health - JFK Johnson Rehabilitation Institute', 'LocationStatus': 'Recruiting', 'LocationCity': 'Edison', 'LocationState': 'New Jersey', 'LocationZip': '08820', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hayk Petrosyan, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '732-321-7000', 'LocationContactPhoneExt': '65979', 'LocationContactEMail': 'hayk.petrosyan@hmhn.org'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26764059', 'ReferenceType': 'background', 'ReferenceCitation': 'Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016 Jan 5;67(1):1-12. doi: 10.1016/j.jacc.2015.10.044.'}, {'ReferencePMID': '24846875', 'ReferenceType': 'background', 'ReferenceCitation': 'Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, MacKay-Lyons M, Macko RF, Mead GE, Roth EJ, Shaughnessy M, Tang A; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Aug;45(8):2532-53. doi: 10.1161/STR.0000000000000022. Epub 2014 May 20.'}, {'ReferencePMID': '31634208', 'ReferenceType': 'background', 'ReferenceCitation': 'Cuccurullo SJ, Fleming TK, Kostis WJ, Greiss C, Gizzi MS, Eckert A, Ray AR, Scarpati R, Cosgrove NM, Beavers T, Cabrera J, Sargsyan D, Kostis JB. Impact of a Stroke Recovery Program Integrating Modified Cardiac Rehabilitation on All-Cause Mortality, Cardiovascular Performance and Functional Performance. Am J Phys Med Rehabil. 2019 Nov;98(11):953-963. doi: 10.1097/PHM.0000000000001214.'}, {'ReferencePMID': '33657031', 'ReferenceType': 'background', 'ReferenceCitation': 'Cuccurullo SJ, Fleming TK, Kostis JB, Greiss C, Eckert A, Ray AR, Scarpati R, Zinonos S, Gizzi M, Cosgrove NM, Cabrera J, Oh-Park M, Kostis WJ. Impact of Modified Cardiac Rehabilitation Within a Stroke Recovery Program on All-Cause Hospital Readmissions. Am J Phys Med Rehabil. 2022 Jan 1;101(1):40-47. doi: 10.1097/PHM.0000000000001738.'}, {'ReferencePMID': '26112254', 'ReferenceType': 'background', 'ReferenceCitation': 'English C, Healy GN, Coates A, Lewis L, Olds T, Bernhardt J. Sitting and Activity Time in People With Stroke. Phys Ther. 2016 Feb;96(2):193-201. doi: 10.2522/ptj.20140522. Epub 2015 Jun 25.'}, {'ReferencePMID': '28444348', 'ReferenceType': 'background', 'ReferenceCitation': 'Fini NA, Holland AE, Keating J, Simek J, Bernhardt J. How Physically Active Are People Following Stroke? Systematic Review and Quantitative Synthesis. Phys Ther. 2017 Jul 1;97(7):707-717. doi: 10.1093/ptj/pzx038.'}, {'ReferencePMID': '21885867', 'ReferenceType': 'background', 'ReferenceCitation': 'Globas C, Becker C, Cerny J, Lam JM, Lindemann U, Forrester LW, Macko RF, Luft AR. Chronic stroke survivors benefit from high-intensity aerobic treadmill exercise: a randomized control trial. Neurorehabil Neural Repair. 2012 Jan;26(1):85-95. doi: 10.1177/1545968311418675. Epub 2011 Sep 1.'}, {'ReferencePMID': '21576654', 'ReferenceType': 'background', 'ReferenceCitation': 'Goel K, Lennon RJ, Tilbury RT, Squires RW, Thomas RJ. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation. 2011 May 31;123(21):2344-52. doi: 10.1161/CIRCULATIONAHA.110.983536. Epub 2011 May 16.'}, {'ReferencePMID': '31596465', 'ReferenceType': 'background', 'ReferenceCitation': 'MacKay-Lyons M, Billinger SA, Eng JJ, Dromerick A, Giacomantonio N, Hafer-Macko C, Macko R, Nguyen E, Prior P, Suskin N, Tang A, Thornton M, Unsworth K. Aerobic Exercise Recommendations to Optimize Best Practices in Care After Stroke: AEROBICS 2019 Update. Phys Ther. 2020 Jan 23;100(1):149-156. doi: 10.1093/ptj/pzz153.'}, {'ReferencePMID': '32868656', 'ReferenceType': 'background', 'ReferenceCitation': 'Marzolini S. Including Patients With Stroke in Cardiac Rehabilitation: BARRIERS AND FACILITATORS. J Cardiopulm Rehabil Prev. 2020 Sep;40(5):294-301. doi: 10.1097/HCR.0000000000000540.'}, {'ReferencePMID': '27425176', 'ReferenceType': 'background', 'ReferenceCitation': 'Marzolini S, Danells C, Oh PI, Jagroop D, Brooks D. Feasibility and Effects of Cardiac Rehabilitation for Individuals after Transient Ischemic Attack. J Stroke Cerebrovasc Dis. 2016 Oct;25(10):2453-63. doi: 10.1016/j.jstrokecerebrovasdis.2016.06.018. Epub 2016 Jul 11.'}, {'ReferencePMID': '31588512', 'ReferenceType': 'background', 'ReferenceCitation': 'Marzolini S, Fong K, Jagroop D, Neirinckx J, Liu J, Reyes R, Grace SL, Oh P, Colella TJF. Eligibility, Enrollment, and Completion of Exercise-Based Cardiac Rehabilitation Following Stroke Rehabilitation: What Are the Barriers? Phys Ther. 2020 Jan 23;100(1):44-56. doi: 10.1093/ptj/pzz149.'}, {'ReferencePMID': '26673558', 'ReferenceType': 'background', 'ReferenceCitation': 'Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360. doi: 10.1161/CIR.0000000000000350. Epub 2015 Dec 16. No abstract available. Erratum In: Circulation. 2016 Apr 12;133(15):e599.'}, {'ReferencePMID': '34978528', 'ReferenceType': 'background', 'ReferenceCitation': 'Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2020. NCHS Data Brief. 2021 Dec;(427):1-8.'}, {'ReferencePMID': '23428993', 'ReferenceType': 'background', 'ReferenceCitation': 'Pang MY, Charlesworth SA, Lau RW, Chung RC. Using aerobic exercise to improve health outcomes and quality of life in stroke: evidence-based exercise prescription recommendations. Cerebrovasc Dis. 2013;35(1):7-22. doi: 10.1159/000346075. Epub 2013 Feb 14.'}, {'ReferencePMID': '21940961', 'ReferenceType': 'background', 'ReferenceCitation': \"Prior PL, Hachinski V, Unsworth K, Chan R, Mytka S, O'Callaghan C, Suskin N. Comprehensive cardiac rehabilitation for secondary prevention after transient ischemic attack or mild stroke: I: feasibility and risk factors. Stroke. 2011 Nov;42(11):3207-13. doi: 10.1161/STROKEAHA.111.620187. Epub 2011 Sep 22.\"}, {'ReferencePMID': '30191075', 'ReferenceType': 'background', 'ReferenceCitation': 'Prior PL, Suskin N. Exercise for stroke prevention. Stroke Vasc Neurol. 2018 Jun 26;3(2):59-68. doi: 10.1136/svn-2018-000155. eCollection 2018 Jun.'}, {'ReferencePMID': '31409176', 'ReferenceType': 'background', 'ReferenceCitation': 'Regan EW, Handlery R, Beets MW, Fritz SL. Are Aerobic Programs Similar in Design to Cardiac Rehabilitation Beneficial for Survivors of Stroke? A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019 Aug 20;8(16):e012761. doi: 10.1161/JAHA.119.012761. Epub 2019 Aug 14.'}, {'ReferencePMID': '33499647', 'ReferenceType': 'background', 'ReferenceCitation': 'Regan EW, Handlery R, Stewart JC, Pearson JL, Wilcox S, Fritz S. Integrating Survivors of Stroke Into Exercise-Based Cardiac Rehabilitation Improves Endurance and Functional Strength. J Am Heart Assoc. 2021 Feb 2;10(3):e017907. doi: 10.1161/JAHA.120.017907. Epub 2021 Jan 27.'}, {'ReferencePMID': '26903147', 'ReferenceType': 'background', 'ReferenceCitation': 'Sandberg K, Kleist M, Falk L, Enthoven P. Effects of Twice-Weekly Intense Aerobic Exercise in Early Subacute Stroke: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2016 Aug;97(8):1244-53. doi: 10.1016/j.apmr.2016.01.030. Epub 2016 Feb 20.'}, {'ReferencePMID': '22019548', 'ReferenceType': 'background', 'ReferenceCitation': 'Towfighi A, Markovic D, Ovbiagele B. Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA. J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):146-51. doi: 10.1136/jnnp-2011-300743. Epub 2011 Oct 21.'}, {'ReferencePMID': '29169967', 'ReferenceType': 'background', 'ReferenceCitation': 'Turan TN, Al Kasab S, Nizam A, Lynn MJ, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane BF, Montgomery J, Chimowitz MI; SAMMPRIS Investigators. Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial. J Stroke Cerebrovasc Dis. 2018 Mar;27(3):801-805. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.017. Epub 2017 Nov 21.'}, {'ReferencePMID': '28284834', 'ReferenceType': 'background', 'ReferenceCitation': 'Vanroy C, Feys H, Swinnen A, Vanlandewijck Y, Truijen S, Vissers D, Michielsen M, Wouters K, Cras P. Effectiveness of Active Cycling in Subacute Stroke Rehabilitation: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2017 Aug;98(8):1576-1585.e5. doi: 10.1016/j.apmr.2017.02.004. Epub 2017 Mar 8.'}, {'ReferencePMID': '33501848', 'ReferenceType': 'background', 'ReferenceCitation': 'Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4202', 'ConditionBrowseLeafName': 'Oculocerebral Syndrome With Hypopigmentation', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 50, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02432521', 'OrgStudyIdInfo': {'OrgStudyId': '35583814.1.0000.0068_CAAE'}, 'Organization': {'OrgFullName': 'University of Sao Paulo General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Predictors of Treatment Response of Motor Sequels After a Stroke', 'OfficialTitle': 'Predictors of Treatment Response of Motor Sequels After a Cerebrovascular Accident'}, 'StatusModule': {'StatusVerifiedDate': 'July 2017', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2017', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 16, 2015', 'StudyFirstSubmitQCDate': 'April 28, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 4, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 3, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 5, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Linamara Rizzo Battistella, MD PhD', 'ResponsiblePartyInvestigatorTitle': 'Full Professor, Medical School of the University of Sao Paulo, Post Graduate Program in Medical Sciences of the Medical School of the University of Sao Paulo', 'ResponsiblePartyInvestigatorAffiliation': 'University of Sao Paulo General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'University of Sao Paulo General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The cerebrovascular accident (CVA) is currently the leading cause of death in Brazil and it is estimated that there are about 62 million stroke survivors worldwide. Thus, the stroke sequels are a major public health problem not only in Brazil but in the world, with existing treatments often insufficient for complete recovery. Thus this study aims to identify predictors of different responses from rehabilitation therapy through the evaluation of clinical and neurophysiological data performed before and after treatment. For the neurophysiological study will be used the association of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS). This last one will be performed in the baseline and after a single Transcranial direct current stimulation (tDCS) session, aiming to leverage the ability of those technics to analyze the cerebral plasticity. As a secondary objective: 1) Identify specific features of brain plasticity involved in recovery from stroke and discuss the possible implications of these findings in the therapeutic approach; 2) Search possible electrophysiological markers that can be used as surrogate outcome of stroke of motor sequel.', 'DetailedDescription': 'The cerebrovascular accident (CVA) is currently the leading cause of death in Brazil and it is estimated that there are about 62 million stroke survivors worldwide. Thus, the stroke sequels are a major public health problem not only in Brazil but in the world, with existing treatments often insufficient for complete recovery. Thus, the search for new treatments is necessary, as well as the need to optimize and individualize the existing treatments. Several approaches are being used in order to find predictors of the recovery of patients after the stroke, highlighting the most recent studies using magnetic resonance imaging (MRI) with tractography. However these studies have important limitations such as high cost, but mainly the low capacity of this technique to quantify brain plasticity known to play an important role in the recovery of stroke sequelae. Thus, techniques to measure brain plasticity theory offer the best potential to predict the resilience of post stroke injury, among which stands out transcranial magnetic stimulation (TMS).\\n\\nTMS is a noninvasive brain stimulation techniques suitable for measuring the motor cortex excitability which in turn is used as an indirect measure of brain plasticity. Another interesting approach is the combination of TMS with the study of neuronal function through the electroencephalogram (EEG). The EEG under the stroke, has also been suggested as sequelae recovery predictor, however in this scenario the association of these findings with TMS has not yet been explored. Thus this study aims to identify predictors of different responses from rehabilitation therapy through the evaluation of clinical and neurophysiological data performed before and after treatment. For the neurophysiological study will be used the association of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS). This last one will be performed in the baseline and after a single Transcranial direct current stimulation (tDCS) session, aiming to leverage the ability of those technics to analyze the cerebral plasticity.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebrovascular Accident']}, 'KeywordList': {'Keyword': ['stroke', 'transcranial magnetic stimulation (TMS)', 'Electroencephalography (EEG)', 'Cerebrovascular Accident', 'Brain Vascular Accident']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Ecologic or Community']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '49', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Conventional rehabilitation program from IMREA', 'InterventionDescription': 'The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in motor cortex excitability as measured by Transcranial magnetic stimulation (TMS)', 'PrimaryOutcomeDescription': 'A noninvasive brain stimulation techniques suitable for measuring the motor cortex excitability', 'PrimaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'PrimaryOutcomeMeasure': 'Change in spontaneous electrical brain activity as assessed by Electroencephalogram (EEG)', 'PrimaryOutcomeDescription': \"The record of the brain's spontaneous electrical activity\", 'PrimaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'cinematic variables analyzed with robotic', 'SecondaryOutcomeDescription': 'speed, acceleration, articular angulation, time-to-point, task execution time, target displacement', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Mini-mental State Examination', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Visual Analog Scale of Pain', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Verbal fluency test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Boston naming test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Hamilton Rating scale of depression', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'The Kinesthetic and visual imagery questionnaire (KVIQ)', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'National Institutes of Health Stroke Scale (NIHSS)', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Stroke Impact Scale (SIS)', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Von Frey test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Functional Independence Measure', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Epworth Sleepiness Scale', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Fugl-Meyer Assessment', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Medical Research Council Scale', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Modified Ashworth Scale', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Finger Tapping', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Jebsen-Taylor Hand Function Test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Purdue Pegboard test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nClinical and radiological diagnosis (Functional magnetic Resonance (FMR) and/or Computerized tomography (TC) ) of the stroke;\\nMore than one month from the date of the stroke;\\nClinical stability;\\nSigned and dated informed consent form.\\n\\nExclusion Criteria:\\n\\nDisturbs that forbid the adherence in treatment;\\nSubjects already undergoing in other researches;\\nPregnant women;\\nLesions that could affect the proposed therapy;\\nThe occurence of lesion or muscle,joint pain that could forbid the therapy;\\nDestabilization of the clinical comorbidities.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients of hemiplegia ambulatory from the Institute of Physical Medicine and Rehabilitation (IMREA) from the Clinics Hospital (HC) of the Medical School of the University of Sao Paulo (USP)', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Linamara Battistella, Md PhD', 'OverallOfficialAffiliation': 'Head Professor, Medical School of the University of Sao Paulo, pos graduation program at the Medical Science of the Medical School of the University of Sao Paulo', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Centro de Pesquisa Clínica do Instituto de Medicina e Reabilitação do HCFMUSP', 'LocationCity': 'Sao Paulo', 'LocationZip': '05716-150', 'LocationCountry': 'Brazil'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23319486', 'ReferenceType': 'background', 'ReferenceCitation': 'Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology. 2013 Jan 15;80(3 Suppl 2):S5-12. doi: 10.1212/WNL.0b013e3182762397.'}, {'ReferencePMID': '21035399', 'ReferenceType': 'background', 'ReferenceCitation': 'Stinear C. Prediction of recovery of motor function after stroke. Lancet Neurol. 2010 Dec;9(12):1228-1232. doi: 10.1016/S1474-4422(10)70247-7. Epub 2010 Oct 27.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Accident', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 51, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01463878', 'OrgStudyIdInfo': {'OrgStudyId': 'ANUS1014'}, 'Organization': {'OrgFullName': 'Eastern Virginia Medical School', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study', 'OfficialTitle': 'Enteral Nutrition and Glycemic Variability NICU Study', 'Acronym': 'ANUS1014'}, 'StatusModule': {'StatusVerifiedDate': 'October 2012', 'OverallStatus': 'Terminated', 'WhyStopped': 'Unlikely to show statistical significance and slow recruitment.', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2011'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'October 24, 2011', 'StudyFirstSubmitQCDate': 'November 1, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 2, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 22, 2012', 'ResultsFirstSubmitQCDate': 'August 28, 2012', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'September 28, 2012', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 3, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 5, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Paul Marik', 'ResponsiblePartyInvestigatorTitle': 'Chief of Pulmnary and Critical Care Medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Eastern Virginia Medical School'}, 'LeadSponsor': {'LeadSponsorName': 'Eastern Virginia Medical School', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Primary Objective:\\n\\nTo determine the effects of a diabetes specific enteral formula compared to a standard formula supplemented with protein (isocaloric and isonitrogenous) on the mean blood glucose and glycemic variability in a homogenous group of critically ill patients in a neurological ICU. Blood glucose will be recorded every minute using a continuous blood glucose monitor. The primary end points will be the difference between the mean blood glucose levels and the glucose variability between the control and intervention groups for the time period that the patient is in the ICU and receiving tube feeds and for up to a maximum of 14 days.\\n\\nSecondary Objectives:\\n\\nTo determine the effects of the diabetes specific versus standard tube feeds on the change in muscle thickness and volume measured by 2-dimensional ultrasound imaging during the patients ICU stay.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Subarachnoid Hemorrhage', 'Intracranial Hemorrhage', 'Ischemic Strokes', 'Subdural Hematoma']}, 'KeywordList': {'Keyword': ['glycemic control', 'glycemic variability', 'mean blood glucose level']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 4']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '14', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Glycerna', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Glycerna']}}, {'ArmGroupLabel': 'Control - Jevity', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Jevity - Control Diet']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Glycerna', 'InterventionDescription': 'Diabetes specific formula', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Glycerna']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Jevity - Control Diet', 'InterventionDescription': 'Control Diet', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control - Jevity']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Glycemic Variability', 'PrimaryOutcomeDescription': 'The patients blood glucose levels will be monitored with a continuous blood glucose monitor which records the calibrated blood glucose level every minute. The mean blood glucose over the patients entire ICU stay (up to 14 days) as well as the mathematical variation (fluctuation) in blood glucose levels will be calculated. The degree of glycemic variation will be assessed by a number of mathematical formula, including mean amplitude of glycemic excursions (MAGE). These parameters will be compared between the control and intervention groups.', 'PrimaryOutcomeTimeFrame': 'Entire ICU stay. Up to 14 days in the ICU (average about 7 days)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quadriceps Muscle Volume', 'SecondaryOutcomeDescription': 'The quadriceps muscle volume will be estimated by 2-dimensional ultrasound imaging at enrollment and at the end of the study period (when the patient is being transferred from the ICU or no longer receiving tube feeds). The change in muscle mass during the ICU stay will be compared between the control and intervention groups.', 'SecondaryOutcomeTimeFrame': 'First versus last measurment in ICU. Up to 14 days (average 7 days)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients aged between 18 and 89 years old\\nPatients with critical illness including ischemic or hemorrhagic stroke, epidural/subdural bleeds and subarachnoid hemorrhage\\nPatients who are expected to stay in the ICU for at least 5 days\\nHyperglycemia is not an inclusion criteria\\n\\nExclusion Criteria:\\n\\nPatients who have received or will be treated with systemic corticosteroids.\\nPatients who will be receiving high doses of propofol (>40 cc/hr)\\nPatients with type 1 Diabetes\\nPatients with sepsis or acute trauma\\nPatients with an expected stay in the ICU of less than 4 days\\nPatients who are unable to receive enteral nutrition or who have medical conditions precluding nutrition by the enteral route including allergies to formula components\\nPregnant and lactating patients\\nPatients with prior history of gastroparesis\\nPatients with acute kidney failure (creatinine > 2.5mg/dl)\\nPatients with acute liver failure (bilirubin > 2.0 mg/dl)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '89 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Paul e Marik, MD', 'OverallOfficialAffiliation': 'EVMS', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Sentara Norfolk General Hospital', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23507', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowRecruitmentDetails': '18 patients were consented and only 14 enrolled. 4 dropped out as failed to meet the inclusion criteria after consent; were bale to take food by mouth', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Glycerna', 'FlowGroupDescription': 'Diabetic specific formula'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Control - Jevity', 'FlowGroupDescription': 'The control arm of the study. Patients to receive Jevity'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '9'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '9'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'no longer met criteria for tube feed', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '2'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '2'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Glycerna', 'BaselineGroupDescription': 'Diabetic specific formula'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Control - Jevity', 'BaselineGroupDescription': 'The control arm of the study. Patients to receive Jevity'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '9'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '9'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '18'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '3'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '15'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '72', 'BaselineMeasurementSpread': '12'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '74', 'BaselineMeasurementSpread': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '73', 'BaselineMeasurementSpread': '11'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '9'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '18'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Glycemic Variability', 'OutcomeMeasureDescription': 'The patients blood glucose levels will be monitored with a continuous blood glucose monitor which records the calibrated blood glucose level every minute. The mean blood glucose over the patients entire ICU stay (up to 14 days) as well as the mathematical variation (fluctuation) in blood glucose levels will be calculated. The degree of glycemic variation will be assessed by a number of mathematical formula, including mean amplitude of glycemic excursions (MAGE). These parameters will be compared between the control and intervention groups.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'mg/dl (MAGE)', 'OutcomeMeasureTimeFrame': 'Entire ICU stay. Up to 14 days in the ICU (average about 7 days)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Glycerna', 'OutcomeGroupDescription': 'Diabetic specific formula'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Control - Jevity', 'OutcomeGroupDescription': 'The control arm of the study. Patients to receive Jevity'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '7'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '7'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '168', 'OutcomeMeasurementSpread': '40'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '166', 'OutcomeMeasurementSpread': '41'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Quadriceps Muscle Volume', 'OutcomeMeasureDescription': 'The quadriceps muscle volume will be estimated by 2-dimensional ultrasound imaging at enrollment and at the end of the study period (when the patient is being transferred from the ICU or no longer receiving tube feeds). The change in muscle mass during the ICU stay will be compared between the control and intervention groups.', 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': 'First versus last measurment in ICU. Up to 14 days (average 7 days)'}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '1', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Glycerna', 'EventGroupDescription': 'Diabetic specific formula', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '7', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '7'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Control - Jevity', 'EventGroupDescription': 'The control arm of the study. Patients to receive Jevity', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '7', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '7'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr Paul Marik', 'PointOfContactOrganization': 'Eastern Virginia Medical School', 'PointOfContactEMail': 'marikpe@evms.edu', 'PointOfContactPhone': '757-446-8910'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000013345', 'ConditionMeshTerm': 'Subarachnoid Hemorrhage'}, {'ConditionMeshId': 'D000020300', 'ConditionMeshTerm': 'Intracranial Hemorrhages'}, {'ConditionMeshId': 'D000006408', 'ConditionMeshTerm': 'Hematoma, Subdural'}, {'ConditionMeshId': 'D000006470', 'ConditionMeshTerm': 'Hemorrhage'}, {'ConditionMeshId': 'D000006406', 'ConditionMeshTerm': 'Hematoma'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000020521', 'ConditionAncestorTerm': 'Stroke'}, {'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000020198', 'ConditionAncestorTerm': 'Intracranial Hemorrhage, Traumatic'}, {'ConditionAncestorId': 'D000006259', 'ConditionAncestorTerm': 'Craniocerebral Trauma'}, {'ConditionAncestorId': 'D000020196', 'ConditionAncestorTerm': 'Trauma, Nervous System'}, {'ConditionAncestorId': 'D000014947', 'ConditionAncestorTerm': 'Wounds and Injuries'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M9246', 'ConditionBrowseLeafName': 'Hemorrhage', 'ConditionBrowseLeafAsFound': 'Hemorrhage', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9183', 'ConditionBrowseLeafName': 'Hematoma', 'ConditionBrowseLeafAsFound': 'Hematoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15825', 'ConditionBrowseLeafName': 'Subarachnoid Hemorrhage', 'ConditionBrowseLeafAsFound': 'Subarachnoid Hemorrhage', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21803', 'ConditionBrowseLeafName': 'Intracranial Hemorrhages', 'ConditionBrowseLeafAsFound': 'Intracranial Hemorrhage', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9185', 'ConditionBrowseLeafName': 'Hematoma, Subdural', 'ConditionBrowseLeafAsFound': 'Subdural Hematoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21715', 'ConditionBrowseLeafName': 'Intracranial Hemorrhage, Traumatic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17375', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9039', 'ConditionBrowseLeafName': 'Craniocerebral Trauma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21713', 'ConditionBrowseLeafName': 'Trauma, Nervous System', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}]}}}}}, {'Rank': 52, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04011787', 'OrgStudyIdInfo': {'OrgStudyId': '1437'}, 'Organization': {'OrgFullName': 'University Hospitals of North Midlands NHS Trust', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Relative Effectiveness of BOLUS Versus Continuous Nasogastric Feeding After Stroke: a Proof of Principal Study', 'OfficialTitle': 'The Relative Effectiveness of BOLUS Versus Continuous Nasogastric Feeding After Stroke: a Proof of Principal Study', 'Acronym': 'BOLUS'}, 'StatusModule': {'StatusVerifiedDate': 'May 2022', 'OverallStatus': 'Withdrawn', 'WhyStopped': 'Funding withdrawn for the study', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 1, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 12, 2019', 'StudyFirstSubmitQCDate': 'July 4, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 8, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 19, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 26, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University Hospitals of North Midlands NHS Trust', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Patients with severe strokes are often unable to be take oral diet food and fluids safely because they cannot swallow effectively. Therefore, patients need to be fed via a tube placed through the nose into the stomach (nasogastric tube). Tube feeding can be given by the intermittent (bolus) method, whereby the feed is given over a short time (15 to 30 minutes), or by the continuous feeding method, where the feed is given continuously over 10-16 hours. Nasogastric feeding can be complicated by vomiting or reflux of the feed into the oesophagus causing aspiration of gastric contents into the lung and pneumonia. Nasogastric feeds can be given continuously or as bolus feeds. Healthy people eating normally take their diet in discrete meals. The human digestive system is adapted to intermittent food intake and is likely to work best if food is provided in this pattern, but the larger volume of the feed by this method may cause vomiting and aspiration. It is unclear which method is better for allowing normal digestive processes and reducing pneumonia due to aspirated feeds. There are no trials comparing these two feeding methods in patients with acute stroke. The aim of this small study is to determine if a trial comparing the two treatment approaches is feasible in patients with acute stroke, and to collect information on the effects on feed tolerance and digestion.\\n\\nIn this study we will compare the effect of the bolus and intermittent nasogastric tube feeding on digestion and feed tolerance in 20 patients who need nasogastric feeding within 36 hours of a stroke. Patients will be randomly allocated to be given the feeds either by the bolus or by the continuous method for 7 days. During this time they will be examined every day. The study will examine how effectively food is digested by measuring the amount of feed given and the metabolic responses of the body by looking at changes in the level of blood sugar and digestive hormones. The investigators will also monitor complications such as vomiting, diarrhoea, and pneumonia. Patients will be randomly allocated to be given the feeds either by the bolus or by the continuous method for 7 days.\\n\\nThis will provide information which will allow the investigators to design a larger definitive study to conclusively prove which method is more appropriate.', 'DetailedDescription': \"Patients admitted to the acute stroke unit at University Hospitals of North Midlands NHS Trust and who require nasogastric (NG) feeding will be eligible for recruitment, patients will be screened and assessed for eligibility on the stroke unit by a member of the local research team, confirmed by a medical practitioner.\\n\\nConsent- Informed consent will be sought from patients after full oral and written information about the nature and purpose of the study, potential risks and benefits, alternative treatments, and the right to refuse and to withdraw at any time. In cases where the patient lacks the capacity to give fully informed consent, the patient will be informed as much as he/she is able to understand with the option to refuse, and fully informed consent will be sought from a consultee. The oral and written information will be provided to the consultee including the same information as would be given to the patient. If the patient has capacity to consent for themselves, but unable to sign because of impairments; verbal consent, witnessed and signed by an independent observer, will be documented. Where the patient has capacity to consent for themselves, but only able to make a mark on the paper rather than sign as required, the same procedure will be followed. Confirmation of consent will be sought in patients who are recruited with consent from a consultee, but regain capacity prior to the end of the trial.\\n\\nDue to the nature of the study, patients or their consultee will have to decide within a few hours of admission to hospital. They will be given the opportunity to discuss the study with a relative or friend. Participants or their consultee will be free to withdraw from the trial at any time without giving reasons and without prejudicing further treatment.\\n\\nAn age-matched healthy control group will be recruited from patients' relatives and friends to provide a normal baseline for the metabolic response to normal feeding.\\n\\nThe original signed consent form will be filed in the case report form. One copy will be given to the patient or consultee, another copy will be sent to the trial coordinating centre and another will be filed in the patients' notes.\\n\\nThe participant information sheets, and consent forms, will not be available in other languages. If needed, the usual hospital interpreter and translator services will be available to assist with discussion of the trial.\\n\\nIf a participant is able to consent for the study but later becomes incapacitated, the original consent will endure the loss of capacity as long as the trial has not significantly altered since the original consent was given.\\n\\nRandomisation- Participants will be randomized into the intervention or control groups using a computerized random number generator. The randomization procedure will be conducted by an independent statistician at Keele University. Sealed and numbered opaque envelopes containing the allocated intervention will be kept in the research office on the acute stroke ward. For each randomisation the envelope with the lowest number will be used. The envelopes will be selected and opened by the research nurse following consent and baseline assessment. An email containing the Participant ID and the number of the envelope will be sent to the Principal Investigator. A copy of the original randomisation codes will be kept independently by the sponsor in the Trial Master File. Assessments-\\n\\nA daily log of symptoms and signs of feed intolerance and pneumonia will be taken for 7 days.\\nA venous blood sample for a full blood count and C-reactive Protein will be taken on day 1, 3, and 7.\\nA Chest x-Ray will be conducted on day 7 to confirm/exclude evidence of pneumonia.\\nGlucose level measurements will be taken every 10 minutes for each participant for 5 days following randomisation, using a sensor inserted into the subcutaneous tissue by the trained research nurse.\\nDaily for 5 days following randomisation fasting venous plasma glucose, apart from the day that the hormonal profile is collected, samples are to be taken by the research nurse and processed by the pathology department.\\nAll participants, including healthy controls, will have a hormonal profile in response to feeding will be taken on day 4, post randomisation. The continuous feed, the bolus feed or, in the non-stroke control group, a calorific drink that is equivalent calories to the Naso-Gastric feed (e.g. Ensure plus) will be given as the first meal in the morning after an overnight fast. Venous plasma glucose and insulin levels will be checked both fasting, immediately after the meal, and every 30 minutes in response to NG feed for 4 hours after the meal (total of 10 sets of samples per subject, each set comprising 2ml clotted sample and 1ml fluoride oxalate sample). For patients who are on NG feeding, the sample collection will similarly start at -30 and 0 minute before the NG feed (either bolus or continuous feed) and then every 30 minutes for 4 hours (total of 10 samples). The venous plasma glucose sample collected for the hormonal profile will also be used for the daily fasting venous plasma glucose sample (see above). We will primarily calculate the time averaged mean insulin and glucose responses computed as incremental AUCs (above baseline), divided by the time interval (hours). Values at each individual time point will be compared directly. The investigators will also collect data on total glycaemic exposure (glucose AUC 0-240) and the insulinogenic index (ΔI30/ΔG30) as an index of β-cell response.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Dysphagia']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': '20 patients will be randomised to two arms with a control group of a further 10 patients', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'bolus NGT feeding', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: bolus NGT feeding', 'Diagnostic Test: Continuous Glucose Monitoring', 'Diagnostic Test: Metabolic Profile', 'Radiation: Chest X-ray']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Continuous NGT feeding (standard care)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Continuous NGT feeding', 'Diagnostic Test: Metabolic Profile', 'Radiation: Chest X-ray']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'bolus NGT feeding', 'InterventionDescription': 'Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Continuous NGT feeding', 'InterventionDescription': 'Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'Continuous Glucose Monitoring', 'InterventionDescription': 'Both participant groups will have continuous glucose monitoring performed for 5 days while in the study', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'Metabolic Profile', 'InterventionDescription': 'Bloods will be taken to assess all patients metabolic profile', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control', 'Intervention']}}, {'InterventionType': 'Radiation', 'InterventionName': 'Chest X-ray', 'InterventionDescription': 'A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control', 'Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Feed tolerance', 'PrimaryOutcomeDescription': 'Total of 7 points. 7/7 full tolerance, 0/7 severe intolerance. This is based on Nutrition, Vomiting, Diarrhoea, Bloating, Abdominal pain, Pneumonia and raised inflammatory markers', 'PrimaryOutcomeTimeFrame': '7 days'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Number of glucose excursions above 7mmol/L', 'SecondaryOutcomeDescription': 'Number of glucose excursions above 7mmol/L', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'mean glucose levels', 'SecondaryOutcomeDescription': 'mean glucose levels', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'glucose centiles', 'SecondaryOutcomeDescription': '10th, 25th, 50th, 75th, 90th', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'total area under curve (AUC)', 'SecondaryOutcomeDescription': 'total area under the curve (AUC) measured in mmol', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'diurnal AUC', 'SecondaryOutcomeDescription': 'diurnal AUC', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'nocturnal AUC', 'SecondaryOutcomeDescription': 'nocturnal AUC', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'average duration of specific glucose readings', 'SecondaryOutcomeDescription': 'e.g. <4-7.9mmol/l, 7-11mmol/l and >11mmol/l', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'average hourly change', 'SecondaryOutcomeDescription': 'change in glucose levels from one hour to the next', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'inter-day variability', 'SecondaryOutcomeDescription': 'change in glucose levels between days', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'largest amplitude of glycaemic excursions', 'SecondaryOutcomeDescription': 'largest rise in glucose levels', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'mean amplitude of glycaemic excursions', 'SecondaryOutcomeDescription': 'average of glucose levels', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'postprandial amplitude of glycaemic excursions', 'SecondaryOutcomeDescription': 'glucose changes after meal', 'SecondaryOutcomeTimeFrame': '7 days'}, {'SecondaryOutcomeMeasure': 'the time-averaged mean insulin and glucose responses', 'SecondaryOutcomeDescription': 'computed as incremental AUCs (above baseline), divided by the time interval (hours)', 'SecondaryOutcomeTimeFrame': '5 hours'}, {'SecondaryOutcomeMeasure': 'total glycaemic exposure', 'SecondaryOutcomeDescription': 'glucose AUC 0-240', 'SecondaryOutcomeTimeFrame': '5 hours'}, {'SecondaryOutcomeMeasure': 'the insulinogenic index', 'SecondaryOutcomeDescription': 'relationship between insulin and glucose levels at 30 minutes', 'SecondaryOutcomeTimeFrame': '5 hours'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge >=18 years\\nWithin 36 h hospital admission with acute ischaemic or haemorrhagic stroke\\nDysphagia requiring nasogastric tube (NGT) feeding (assessed by failed sip test)\\n\\nExclusion Criteria:\\n\\nMoribund, receiving palliative care\\nClinical diagnosis of pneumonia\\nPre-existing gastric motility problems\\nInability to obtain consent from the patients or their representative', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Fahmy Hanna', 'OverallOfficialAffiliation': 'Consultant', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University Hospitals of North Midlands NHS Trust', 'LocationCity': 'Stoke-on-Trent', 'LocationState': 'Staffordshire', 'LocationZip': 'ST4 6QG', 'LocationCountry': 'United Kingdom'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': \"The participants' clinicians clinical team and members of the research team on the delegation log will access the data. Representatives of the sponsor (UHNM) and representatives the regulatory authorities will have access to personal data for monitoring and audit purposes only.\"}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}]}}}}}, {'Rank': 53, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05614882', 'OrgStudyIdInfo': {'OrgStudyId': '2000033911'}, 'Organization': {'OrgFullName': 'Yale University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'New Model of Stroke Education', 'OfficialTitle': 'New Model of Stroke Education'}, 'StatusModule': {'StatusVerifiedDate': 'November 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 2027', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 4, 2022', 'StudyFirstSubmitQCDate': 'November 4, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 14, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 18, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 23, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Yale University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'NIH (pending)', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The main goal of this study is to reorganize how stroke educational materials are given to patients from written delivery of information to using verbal delivery of information. Another goal is to compare post stroke behavior and medication compliance in participants receiving the new verbal model of stroke education vs. those receiving the current written stroke education.\\n\\nThe main question[s] it aims to answer are:\\n\\nDoes the current delivery of stroke education provide the necessary knowledge base for patients who have suffered a stroke as measured by a stroke questionnaire?\\nDoes verbal education provide better understanding for patients post-stroke?\\nAre patients more likely to be compliant with medications and followup visits with their medical team after receiving verbal education? Participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL). Individuals in both literacy groups will be randomized into receiving verbal or written stroke education. All participants will be tested with the stroke knowledge assessment to measure learning after education.\\n\\nResearchers will compare written to verbal education to see if verbal results in more stroke education and compliance.', 'DetailedDescription': \"The primary objective of this study is to restructure the current model of stroke education using verbal delivery of information that is accessible and understood by individuals of different cultural backgrounds and various literacy levels. Participants in this study will be provided with a new model of stroke education through verbal communication to educate them on factors related to stroke using vocabulary that is more familiar and understood by individuals with lower literacy levels. The current delivery of stroke information is carried out through a model that involves mainly written communication. Data will be collected to better understand the efficacy of the current written model of stroke education compared to the new verbal education and determine which of the two methods of delivering information is more compatible with the literacy levels of the community served by Yale New Haven Hospital.\\n\\nThe second part of the study, participants' electronic medical record (EMR) will be reviewed at 1, 3, 6 and 12 months post stroke to evaluate the attendance post stroke follow up visits, post stroke blood pressure readings and overall medication compliance.\\n\\nParticipants in this study will be based from a convenience sample from the Rehabilitation and Wellness Center in Milford, Connecticut. Participants will be admitted post-stroke after being diagnosed with stroke of mild to moderate severity.\\n\\nAll the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.\\n\\nAssessments will be completed during the participants inpatient stay. A run in pilot study of 20 anticipated participants will be carried out prior to the larger study. The larger study was registered in anticipation of NIH funding.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Individuals in this study will be based from a convenience sample from the Rehabilitation and Wellness Center in Milford, Connecticut. Participants will be admitted post-stroke after being diagnosed with stroke of mild to moderate severity. Individuals will be over 18 years of age with no history of prior stroke who are able to read basic information, having no more than a mild aphasia with intact language comprehension skills who speak English or Spanish (assessment materials are available in these two languages).\\n\\nAll the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization. Anticipated enrollment of 20 for pilot and 200 for larger study.', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '220', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Written Stroke Education', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this arm will be given the current written standard of care for stroke education. Assessments will be completed during the participants inpatient stay.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Written Stroke Education']}}, {'ArmGroupLabel': 'Verbal Stroke Education', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this arm will be given the experimental verbal stroke education. Assessments will be completed during the participants inpatient stay.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Verbal Stroke Education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Written Stroke Education', 'InterventionDescription': 'The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Written Stroke Education']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Verbal Stroke Education', 'InterventionDescription': 'Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Verbal Stroke Education']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Stroke Knowledge Test (SKT)', 'PrimaryOutcomeDescription': 'SKT is a 20 question assessment to determine if written or verbal delivery of post stroke education was more successful in educating participants. The assessment is scored as a percentage of correct questions out of a total of 20 questions. Higher scores indicate more educated on stroke.', 'PrimaryOutcomeTimeFrame': '1 day post intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Count of post stroke follow up visits attended', 'SecondaryOutcomeDescription': 'Electronic medical records will be reviewed at 1, 3, 6 and 12 months post discharge to evaluate if participants had post stroke follow up visits with their care providers (recorded as yes/no). This will demonstrate which method is more likely to support patients in gathering information that is needed to manage their chronic conditions, maintaining compliance and decrease their chance of stroke recurrence.', 'SecondaryOutcomeTimeFrame': 'Month 1 up to Month 12 post discharge'}, {'SecondaryOutcomeMeasure': 'Count of post stroke blood pressure readings above 130/80 mmHG systolic', 'SecondaryOutcomeDescription': 'Electronic medical records will be reviewed at 1, 3, 6 and 12 months post discharge to monitor how many post stroke blood pressure readings are above 130/80 mmHG systolic.This will demonstrate which method is more likely to support patients in gathering information that is needed to manage their chronic conditions, maintaining compliance and decrease their chance of stroke recurrence.', 'SecondaryOutcomeTimeFrame': 'Month 1 up to Month 12 post discharge'}, {'SecondaryOutcomeMeasure': 'Medical compliance measured by count of prescriptions filled', 'SecondaryOutcomeDescription': 'Electronic medical records will be reviewed at 1, 3, 6 and 12 months post discharge to count the number of prescriptions filled that were ordered by the provider. Medical compliance will be assessed by the number of prescriptions filled. This will demonstrate which method is more likely to support patients in gathering information that is needed to manage their chronic conditions, maintaining compliance and decrease their chance of stroke recurrence.', 'SecondaryOutcomeTimeFrame': 'Month 1 up to Month 12 post discharge'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMale or female ≥18 years of age at time of stroke.\\nDocumentation of a stroke diagnosis as evidenced by one or more clinical features consistent with deficits in physical mobility, mild deficits in language\\n\\nExclusion Criteria:\\n\\nDocumented history of stroke\\nDocumented cognitive deficits\\nIndividuals <18 years of age\\nIndividuals who are unable to provide consent\\nThose who are pregnant will be excluded from this sample (pregnancy tests are typically completed on admission, for applicable individuals).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Necolle Morgado-Vega, DO', 'CentralContactRole': 'Contact', 'CentralContactPhone': '203-843-5733', 'CentralContactEMail': 'necolle.morgado-vega@yale.edu'}, {'CentralContactName': 'Jacqueline Brown, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '203-479-4708', 'CentralContactEMail': 'jbrown@newhaven.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Necolle Morgado-Vega, MD', 'OverallOfficialAffiliation': 'Yale University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'YNHH Rehabilitation & Wellness Center', 'LocationCity': 'Milford', 'LocationState': 'Connecticut', 'LocationZip': '06460', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 54, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02159014', 'OrgStudyIdInfo': {'OrgStudyId': 'DanceFit Prime'}, 'Organization': {'OrgFullName': 'North Essex Partnership NHS Foundation Trust', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study', 'OfficialTitle': 'DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention to Reduce the Risk of Heart Disease, Stroke, Diabetes, and Dementia in Inactive Adults, in Primary Care Settings - A Feasibility Study', 'Acronym': 'DanceFit'}, 'StatusModule': {'StatusVerifiedDate': 'October 2015', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 3, 2014', 'StudyFirstSubmitQCDate': 'June 6, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 9, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 13, 2015', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 14, 2015', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr Thomas Dannhauser', 'ResponsiblePartyInvestigatorTitle': 'Chief Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'North Essex Partnership NHS Foundation Trust'}, 'LeadSponsor': {'LeadSponsorName': 'North Essex Partnership NHS Foundation Trust', 'LeadSponsorClass': 'OTHER_GOV'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'West Essex Clinical Commissioning Group', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'School for Social Entrepreneurs London and Lloyds TSB', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'University College, London', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Regular physical activity improves physical and mental health and reduces the risk of heart disease, stroke, cancer, diabetes, obesity and premature death from any cause. Unfortunately the majority of adults are not active enough to reap these benefits. People who are inactive and at high risk of stroke, heart disease, diabetes and dementia, and who may benefit from increased activity can be identified in primary care by combining standard risk tools. These high risk patients can be offered physical activity programmes that are designed to increase longterm adherence. Aerobic dance is an activity that combines physical, social and cognitive stimulation and allows easily adjusted intensity levels to meet individual needs. Engagement in an activity program also provides opportunities to offer advice on healthy nutrition and associated meal preparation skills. Information technology can be used to increase activity participation. Video materials can be produced to guide activity participation at home, thereby increasing overall activity participation. The investigators propose a feasibility study of a multimodal dance-based physical activity and nutrition intervention aimed at patients at high risk of stroke, heart disease, diabetes and dementia, in primary care settings.', 'DetailedDescription': 'Regular physical activity improves physical and mental health and reduces the risk of heart disease, stroke, cancer, diabetes, dementia, obesity and premature death from any cause (Department of Health & Prevention., 2004). Unfortunately the majority of adults are not active enough to reap these benefits (Chaudhury & Roth, 2006). Specific psychological techniques can be used to overcome the known barriers to increased activity. People who are inactive can be identified in primary care through the use of standard risk tools. Similarly, standard risk tools can identify people at high risk of stroke, heart disease and diabetes, and people at risk from dementia are identified by a diagnosis of mild cognitive impairment. Combining these clinical indicators can identify people who are inactive and at highest risk who may therefore benefit most from activity interventions. These high risk patients can be offered physical activity programmes that are designed to increase longterm adherence. Aerobic dance is an activity that combines physical, social and cognitive stimulation and allows easily adjusted intensity levels to meet individual needs. Engagement in an activity program also provides opportunities to offer advice on healthy nutrition and associated meal preparation skills. Information technology can be used to increase activity participation. Video materials can be produced to guide activity participation at home, thereby increasing overall activity participation.\\n\\nTRIAL DESIGN The investigators plan a longitudinal study where participants will be followed up for a total of 24 weeks. Outcome measures will be collected at three time points that separates two phases. Phase 1 consists of the group based weekly intervention plus access to online material and Phase 2 consists of only access to the online material. The time points are: baseline (Time 0), 12 weeks post intervention (Time 1) and 24 weeks post intervention (Time 2). Outcomes measured at time 1 will be used to determine the effects of Phase 1 immediately following participation, and measure at 24 weeks (Time 2) to determine the outcomes 12 weeks after the end of the group based intervention intervention and therefore the longer term effects with support from online material only. Participants will therefore serve as their own controls during Phase 2 for comparison with Phase 1. In other words the investigators will compare the results for each participant following Phase 1 with their results following Phase 2 to determine the effects of removing the group facilitation.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cardiac Diseases', 'Stroke', 'Diabetes Mellitus', 'Dementia', 'Mild Cognitive Impairment']}, 'KeywordList': {'Keyword': ['Physical activity intervention', 'Aerobic dance', 'Nutritional intervention', 'Online participation', 'Primary Care settings', 'General Practice Physical Activity Questionnaire GPPAQ', 'Qrisk2', 'QDS Diabetes']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '40', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Phase 1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Facilitated group-based aerobic dance', 'Behavioral: Online, video prompted, individual aerobic dance', 'Behavioral: Facilitated group-based nutritional intervention']}}, {'ArmGroupLabel': 'Phase 2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Self-paced online aerobic dance activity', 'Behavioral: Individual self-paced nutritional intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Facilitated group-based aerobic dance', 'InterventionDescription': 'Physical activity facilitated by instructor', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Phase 1']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Online, video prompted, individual aerobic dance', 'InterventionDescription': 'Supported online activity intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Phase 1']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Facilitated group-based nutritional intervention', 'InterventionDescription': 'Education, skill training, access and use of NHS Change4Life Eat Well web resource', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Phase 1']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Self-paced online aerobic dance activity', 'InterventionDescription': 'Self paced physical activity', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Phase 2']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Individual self-paced nutritional intervention', 'InterventionDescription': 'Individual use of online nutritional advice resources.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Phase 2']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Recruitment and retention rates', 'PrimaryOutcomeTimeFrame': '24 weeks'}, {'PrimaryOutcomeMeasure': 'Activity adherence rates', 'PrimaryOutcomeTimeFrame': '24 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Level of physical activity participation', 'SecondaryOutcomeDescription': 'Assessed using the General Practice Physical Activity Questionnaire (GPPAQ)', 'SecondaryOutcomeTimeFrame': '24 weeks'}, {'SecondaryOutcomeMeasure': '10 year risk of cardiac or cerebral ischaemic event', 'SecondaryOutcomeDescription': 'Assessed using the QRISK2 for CVD / Stroke', 'SecondaryOutcomeTimeFrame': '24 weeks'}, {'SecondaryOutcomeMeasure': '10 year risk of developing diabetes mellitus', 'SecondaryOutcomeDescription': 'Assessed using the QDS Diabetes risk tool', 'SecondaryOutcomeTimeFrame': '24 weeks'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Depressive and anxiety symptoms', 'OtherOutcomeDescription': 'Assessed on the Hospital Anxiety and Depression Scale (HADS)', 'OtherOutcomeTimeFrame': '24 weeks'}, {'OtherOutcomeMeasure': 'Change in cardiovascular fitness.', 'OtherOutcomeDescription': 'Assessed on the Modified Siconolfi Step Test', 'OtherOutcomeTimeFrame': '24 weeks'}, {'OtherOutcomeMeasure': 'Change in body composition', 'OtherOutcomeDescription': 'Assessed by measuring body fat percentage', 'OtherOutcomeTimeFrame': '24 weeks'}, {'OtherOutcomeMeasure': 'Life quality', 'OtherOutcomeDescription': 'Assessed on the World Health Organization Quality of Life (WHOQOL-BREF) tool.', 'OtherOutcomeTimeFrame': '24 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMale or female patients identified as Inactive/Moderately Inactive on the GPPAQ and at high risk due the presence of one or more of the following additional risk factors:\\n\\n20% or higher 10 year risk of stroke or heart attack by using QRISK2 for stroke (Hippisley-Cox, Coupland, Vinogradova, et al, 2008).\\n20% or higher 10-year risk of type 2 diabetes on the QDS measure (Hippisley-Cox, Coupland, Robson, et al, 2009).\\nDiagnosis of mild cognitive impairment from a memory clinic.\\nDiagnosed transient ischaemic cardiac or cerebral event (stable ischaemic heart disease, transient ischaemic attack).\\nAged 17 years or older.\\nAt low risk from serious adverse effects from increased physical activity as indicated by performance on the revised Physical Activity Readiness Questionnaire (PAR-Q)(Thomas, Reading & Shephard, 1992).\\nParticipants should have a suitable exercise space available at home for safe participation in the online component.\\nParticipants with access to the internet at home, and where it has been determined following a home visit by the research team that they can access the online material and safely participate.\\n\\nExclusion Criteria:\\n\\nBlood pressure above 160/100 mmHg.\\nBody mass index over 40 kg/m2.\\nMusculoskeletal or other medical problems preventing safe participation in regular moderate intensity exercise (65-77% of predicted maximum heart rate). This will include a resting tachycardia (heart rate above 100 bpm) and history of myocardial infarction, unstable angina or transient cerebral ischemia within the last month, severe osteoporosis, uncontrolled diabetes, febrile illness and destabilising arrythmias.\\nParticipants with modifiable exclusion criteria will be reconsidered after successful management. Patients will be referred for medical /cardiological review and management prior to commencing exercise if indicated by the PAR-Q and the intervention will be guided by the PARmed-X (Chisholm, Stewart & Crooks, 1987).\\nParticipants taking medications affecting heart rate will need to be on a stable dosing regimen for 3 months prior to commencing in order to control for potential spurious results on fitness measures caused by these treatments.\\nParticipants who do not have the necessary space, internet connection or computer equipment to allow them to participate safely using the online material.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '17 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Thomas M Dannhauser, PhD', 'OverallOfficialAffiliation': 'North Essex Partnership Foundation NHS Trust, University College London', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Chigwell Medical Centre', 'LocationCity': 'Chigwell', 'LocationState': 'Essex', 'LocationZip': 'IG6 2TA', 'LocationCountry': 'United Kingdom'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24886353', 'ReferenceType': 'background', 'ReferenceCitation': 'Dannhauser TM, Cleverley M, Whitfield TJ, Fletcher BC, Stevens T, Walker Z. A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairment--ThinkingFit: pilot and feasibility study for a randomized controlled trial. BMC Psychiatry. 2014 May 5;14:129. doi: 10.1186/1471-244X-14-129.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003704', 'ConditionMeshTerm': 'Dementia'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}, {'ConditionMeshId': 'D000060825', 'ConditionMeshTerm': 'Cognitive Dysfunction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafAsFound': 'Mild Cognitive Impairment', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Cardiac Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6594', 'ConditionBrowseLeafName': 'Dementia', 'ConditionBrowseLeafAsFound': 'Dementia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21526', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4505', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14163', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5991', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}}}}, {'Rank': 55, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04553237', 'OrgStudyIdInfo': {'OrgStudyId': 'PCAT'}, 'Organization': {'OrgFullName': 'Groupe Hospitalier Paris Saint Joseph', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Clinical Prognosis After Stroke in Nonagenarian Patients Treated With Thrombolysis or Mechanical Thrombectomy', 'OfficialTitle': 'Clinical Prognosis After Stroke in Nonagenarian Patients Treated With Thrombolysis or Mechanical Thrombectomy', 'Acronym': 'PCAT'}, 'StatusModule': {'StatusVerifiedDate': 'April 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 11, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 31, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 26, 2023', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 11, 2020', 'StudyFirstSubmitQCDate': 'September 11, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 17, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 27, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Groupe Hospitalier Paris Saint Joseph', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a significant cause of death and disability in France and internationally. The incidence of stroke increases with age, equal for both sexes. Of all strokes, 50% of cases occur in patients over 75 years of age. This advanced age leads to a high risk of mortality, long hospitalization, causing neurological sequelae in most cases.\\n\\nNeurological handicap in the elderly is due to a high rate of comorbidity, reduced neuronal plasticity, nutritional status, and the short time to convert the penumbra area to ischemia.\\n\\nCurrently the standard treatment for the acute phase of HF is thrombolysis or thrombectomy.\\n\\nThe principle of thrombolysis is based on the use of a thrombolytic drug (Actylise®). It is a tissue plasminogen activator (t-PA) that will cause lysis and dissolution of clots blocking the artery. Thrombolysis is recommended until 4:30 a.m. after the onset of symptoms in the absence of contraindication.\\n\\nMechanical thrombectomy consists of removing the blood clot by introducing a probe into the artery having a proximal carotid or sylvic occlusion in its M1 portion or in the vertebro-basilar territory of an indeterminate schedule of less than 24 hours or determined from 6 hours to 24 hours having a radio-clinical mismatch, according to the DAWN study. The results of this study were analyzed according to age, NIHSS score and lesion volume on perfusion scanner or MRI (RAPID software). The interim analysis at 31 months on 206 randomized patients (107 thrombectomies versus 99 medical treatments alone) showed a clear superiority of the thrombectomy, leading to the premature end of the study, over the handicap at 3 months with more than 35 % of independent patients.\\n\\nIn most of the randomized studies, patients over 90 years of age have been excluded or are under-represented. This lack of data therefore does not make it possible to determine the effectiveness of thrombolysis or thrombectomy treatments in these patients.\\n\\nA recent meta-analysis has shown that the functional recovery in these patients treated by thrombectomy is superior to those of the same age without thrombectomies. According to American studies, the advanced age of a patient is not a contraindication to this treatment.\\n\\nPatients affected by a cerebral infarction represent 40 to 50% of hospitalizations in the neurology department of the Groupe Hospitalier Paris Saint-Joseph. In the intensive care of the neuro-vascular unit, the patient is received as quickly as possible to decide whether he can benefit from an extreme emergency treatment (intravenous thrombolysis or thrombectomy).\\n\\nThe present study should show that the clinical course after treatment in patients over 90 years of age is substantially comparable to younger patients, and that age is not a contraindication to treatment in the acute phase of stroke in the elderly.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '111', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients over 90 years old'}, {'ArmGroupLabel': 'Patients between 70 and 89 years of age.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Management of stroke between two groups of patients.', 'PrimaryOutcomeDescription': 'This outcome corresponds to the comparaison of functional recovery at D90 after a stroke as measured by the Modified Rankin scale for measuring the degree of disability or dependence in the daily activities of patients.\\n\\n0 - No symptoms.\\n\\n- No significant disability. Able to carry out all usual activities, despite some symptoms.\\n- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\\n- Moderate disability. Requires some help, but able to walk unassisted.\\n- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\\n- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\\n- Dead.', 'PrimaryOutcomeTimeFrame': 'Day 90'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Symptomatic hemorrhagic changes', 'SecondaryOutcomeDescription': 'This outcome corresponds to the rate of patients with hemorrhagic transformation.', 'SecondaryOutcomeTimeFrame': 'Day 90'}, {'SecondaryOutcomeMeasure': 'Intra-hospital mortality', 'SecondaryOutcomeDescription': 'This outcome corresponds to the rate of patients with in-hospital mortality.', 'SecondaryOutcomeTimeFrame': 'Day 90'}, {'SecondaryOutcomeMeasure': 'Other complications', 'SecondaryOutcomeDescription': 'This outcome corresponds to the rate of patients presenting others complications during hospitalisation.', 'SecondaryOutcomeTimeFrame': 'Day 90'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatient over 70 years old\\nPatient treated in the neurology department of Paris Saint-Joseph hospital for a stroke between 2017 and 2019\\nPatient treated by thrombolysis less than 4:30 after the onset of symptoms and / or by mechanical thrombectomy less than 24 hours.\\nFrench-speaking patient\\n\\nExclusion Criteria:\\n\\nPatient under guardianship or curatorship\\nPatient deprived of liberty\\nPatient under legal protection\\nPatient objecting to the use of their data for this research', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '70 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'Patients treated for stroke in the neurology department within the Groupe Hospitalier Paris Saint Joseph, between January 01, 2017 and December 31, 2019, i.e. 122 patients.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'IOANA BABICIU, MD', 'OverallOfficialAffiliation': 'Groupe Hospitalier Paris Saint Joseph', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Groupe Hospitalier Paris Saint-Joseph', 'LocationCity': 'Paris', 'LocationZip': '75014', 'LocationCountry': 'France'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '29235985', 'ReferenceType': 'result', 'ReferenceCitation': 'Murphy SL, Xu J, Kochanek KD, Curtin SC, Arias E. Deaths: Final Data for 2015. Natl Vital Stat Rep. 2017 Nov;66(6):1-75.'}, {'ReferencePMID': '29367334', 'ReferenceType': 'result', 'ReferenceCitation': 'Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Erratum In: Stroke. 2018 Mar;49(3):e138. Stroke. 2018 Apr 18;:'}, {'ReferencePMID': '27733282', 'ReferenceType': 'result', 'ReferenceCitation': 'GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. Erratum In: Lancet. 2017 Jan 7;389(10064):e1.'}, {'ReferencePMID': '18556583', 'ReferenceType': 'result', 'ReferenceCitation': 'Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, Black S; Stroke Outcome Research Canada (SORCan) Working Group. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke. 2008 Aug;39(8):2310-7. doi: 10.1161/STROKEAHA.107.511402. Epub 2008 Jun 12.'}, {'ReferencePMID': '25358699', 'ReferenceType': 'result', 'ReferenceCitation': 'Castonguay AC, Zaidat OO, Novakovic R, Nguyen TN, Taqi MA, Gupta R, Sun CH, Martin C, Holloway WE, Mueller-Kronast N, E English J, Linfante I, Dabus G, Malisch TW, Marden FA, Bozorgchami H, Xavier A, Rai AT, Froehler MT, Badruddin A, Abraham MG, Janardhan V, Shaltoni H, Yoo AJ, Abou-Chebl A, Chen PR, Britz GW, Kaushal R, Nanda A, A Issa M, Nogueira RG. Influence of age on clinical and revascularization outcomes in the North American Solitaire Stent-Retriever Acute Stroke Registry. Stroke. 2014 Dec;45(12):3631-6. doi: 10.1161/STROKEAHA.114.006487. Epub 2014 Oct 30.'}, {'ReferencePMID': '22744644', 'ReferenceType': 'result', 'ReferenceCitation': 'Chandra RV, Leslie-Mazwi TM, Oh DC, Chaudhry ZA, Mehta BP, Rost NS, Rabinov JD, Hirsch JA, Gonzalez RG, Schwamm LH, Yoo AJ. Elderly patients are at higher risk for poor outcomes after intra-arterial therapy. Stroke. 2012 Sep;43(9):2356-61. doi: 10.1161/STROKEAHA.112.650713. Epub 2012 Jun 28.'}, {'ReferencePMID': '9873157', 'ReferenceType': 'result', 'ReferenceCitation': 'Sharma JC, Fletcher S, Vassallo M. Strokes in the elderly - higher acute and 3-month mortality - an explanation. Cerebrovasc Dis. 1999 Jan-Feb;9(1):2-9. doi: 10.1159/000015889.'}, {'ReferencePMID': '30949120', 'ReferenceType': 'result', 'ReferenceCitation': 'Sharobeam A, Cordato DJ, Manning N, Cheung A, Wenderoth J, Cappelen-Smith C. Functional Outcomes at 90 Days in Octogenarians Undergoing Thrombectomy for Acute Ischemic Stroke: A Prospective Cohort Study and Meta-Analysis. Front Neurol. 2019 Mar 20;10:254. doi: 10.3389/fneur.2019.00254. eCollection 2019.'}, {'ReferencePMID': '26445678', 'ReferenceType': 'result', 'ReferenceCitation': 'To CY, Rajamand S, Mehra R, Falatko S, Badr Y, Richards B, Qahwash O, Fessler RD. Outcome of mechanical thrombectomy in the very elderly for the treatment of acute ischemic stroke: the real world experience. Acta Radiol Open. 2015 Sep 10;4(9):2058460115599423. doi: 10.1177/2058460115599423. eCollection 2015 Sep.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 56, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01753024', 'OrgStudyIdInfo': {'OrgStudyId': 'STPH-ICU-001'}, 'Organization': {'OrgFullName': \"Shanghai 10th People's Hospital\", 'OrgClass': 'OTHER'}, 'BriefTitle': 'Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients', 'OfficialTitle': 'The Incidence of Pancreatic Exocrine Insufficiency and the Benefits of Pancreatic Enzyme Supplementation in Critically Ill Adult Patients'}, 'StatusModule': {'StatusVerifiedDate': 'September 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 16, 2012', 'StudyFirstSubmitQCDate': 'December 16, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 20, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 4, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 6, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Sheng Wang MD PhD', 'ResponsiblePartyInvestigatorTitle': 'Associate professor', 'ResponsiblePartyInvestigatorAffiliation': \"Shanghai 10th People's Hospital\"}, 'LeadSponsor': {'LeadSponsorName': \"Shanghai 10th People's Hospital\", 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Tongji Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University\", 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Malnutrition is a frequent problem in critically ill patients that is associated with detrimental clinical outcomes. To provide adequate nutritional support, current studies focused mostly on the choice of delivery timing, formula selection and the route of administration, little attention was paid to malnutrition related to exocrine pancreatic insufficiency (EPI).\\n\\nIn fact, malnutrition is also a major consequence of pancreatic exocrine insufficiency and pancreatic damage is commonly observed in critically ill patients without prior pancreatic diseases. Hence, EPI associated malnutrition should be concerned due to the high prevalence of pancreatic damage in critically ill patients.\\n\\nThe aims of this study is to evaluate the incidence of EPI in critically ill adult patients and explore its potential risk factors. Moreover, the efficacy of pancreatic enzyme supplementation therapy on malnutrition in ICU patients with specific clinical characteristics will be investigated.', 'DetailedDescription': \"Critically ill patients who is able to receive early enteral nutrition and estimated to stay in ICU at least four days are considered to enroll into this study. Exclusion criteria are age under 18 or over 80 years, pregnancy or breastfeeding, known exocrine pancreatic insufficiency due to pancreatitis, unresectable pancreatic cancer, cystic fibrosis, celiac disease, Zollinger-Ellison syndrome, pancreatectomy, gastrectomy and medications of somatostatin or aprotinin that directly influence pancreatic exocrine function.\\n\\nInformed consent documents are signed by immediate family members of the recruited patients. All study procedures are performed in accordance with the institutional guidelines for the conduct of research on human beings and approved by the Human Ethics Committee of Shanghai Tenth People's Hospital.\\n\\nOnce the enrolled patients are admitted to the ICU, they are inserted either a nasogastric tube or a nasojejunal tube guided by electronic gastroscope according to the expected feeding time, and the position of feeding tubes is confirmed by plain abdominal radiograph. Enteral nutrition will be initiated at a rate of 25 ml/h within 24h of admission, and the infusion rate increases steadily until the prescribed nutritional requirements are achieved within 3 days. Daily nutritional requirements are calculated mainly based on the patient's body mass index.\\n\\nDuring the study, the details of each patient such as age, sex, BMI, admission diagnosis, and Acute Physiology and Chronic Health Evaluation II score are collected. All clinical characteristics that may cause pancreatic damage, including shock (systolic blood pressure < 90 mmHg), tissue hypoxia (serum lactate > 2 mmol/L), respiratory failure (PaO2 < 60 mmHg), anemia (hemoglobin < 90 g/L), obesity (BMI > 30 kg/m2), biliary sludge (total bilirubin > 17.5 μmol/L), hypertriglyceridemia (> 1.7 mmol/L), sepsis, cardiac arrest, cardiopulmonary bypass (CPB), severe head injury, acute stroke, post-neurosurgery, diabetes, inflammatory bowel disease (IBS), mechanical ventilation and continuous renal replacement therapy (CRRT) are recorded prospectively. Medications such as propofol, valproate, metronidazole and morphine-derived drugs, which are applied for more than 24 h and might induce pancreatic damage, are also documented. Arterial blood samples are taken 3 days after admission to determine biochemical parameters. Stool samples are collected 3-5 days after the beginning of enteral nutrition and frozen at -20℃ until analysis. Some patients will undergo CT scanning and magnetic resonance cholangio-pancreatography (MRCP)to acquire histological evidence of exocrine pancreatic insufficiency.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Critical Illness', 'Sepsis', 'Diabetes', 'Cardiac Arrest', 'Acute Renal Failure', 'Shock']}, 'KeywordList': {'Keyword': ['exocrine pancreatic insufficiency', 'fecal elastase-1', 'amylase', 'lipase', 'critical illness', 'enteral nutrition', 'malnutrition', 'sepsis', 'diabetes', 'hyperlactacidemia', 'hemodialysis', 'mechanical ventilation']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '2 Weeks', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Blood samples: lactate, hemoglobin, total bilirubin, trypsin, Vit D, etc. Stool samples: 24h fecal fat; fetal elastase-1; Fecal chymotrypsin. Nutrition status: BMI, weight loss, biomarkers such as albumin and prealbumin, etc.\\n\\nRadiological assessments: MRCP & CT scanning.'}, 'EnrollmentInfo': {'EnrollmentCount': '362', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Sepsis-PEST', 'ArmGroupDescription': 'septic patients with enteral nutrition and pancreatic enzyme supplementation therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'Sepsis-NPEST', 'ArmGroupDescription': 'Septic patients with enteral nutrition only', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'DM-PEST', 'ArmGroupDescription': 'Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'DM-NPEST', 'ArmGroupDescription': 'Diabetic patients with enteral nutrition only', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'PCAS-PEST', 'ArmGroupDescription': 'Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'PCAS-NPEST', 'ArmGroupDescription': 'Patients suffering from cardiac arrest receive enteral nutrition only', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'ARF-PEST', 'ArmGroupDescription': 'Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}, {'ArmGroupLabel': 'ARF-NPEST', 'ArmGroupDescription': 'Patients with acute renal failure receive enteral nutrition only', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Enteral nutrition (EN)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Enteral nutrition (EN)', 'InterventionDescription': 'All patients enrolled in this study must carry out nutritional support by enteral nutrition', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['ARF-NPEST', 'ARF-PEST', 'DM-NPEST', 'DM-PEST', 'PCAS-NPEST', 'PCAS-PEST', 'Sepsis-NPEST', 'Sepsis-PEST']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Screening and risk factors of exocrine pancreatic insufficiency in critically ill adult patients receiving enteral nutrition', 'PrimaryOutcomeDescription': 'The incidence of exocrine pancreatic insufficiency will be evaluated that is based on hyperamylasemia, hyperlipasemia and fecal elastase-1 concentrations. multivariate logistic regression analyses are used to estimate the correlations between exocrine pancreatic insufficiency and clinical events and characteristics, which include APACHE II score, shock, hyperlactacidemia, respiratory failure, anemia, obesity, biliary sludge, hypertriglyceridemia, sepsis, cardiac arrest, cardiopulmonary bypass, severe head injury, acute stroke, post-neurosurgery, diabetes, inflammatory bowel disease, mechanical ventilation, continuous renal replacement therapy and medications such as propofol, valproate, metronidazole and morphine-derived drugs', 'PrimaryOutcomeTimeFrame': 'From 2012-1 to 2012-12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Effects of pancreatic enzyme supplementation on nutritional status and clinical outcomes in critically ill patients with sepsis', 'SecondaryOutcomeDescription': 'The incidence of exocrine pancreatic insufficiency and the nutritional status are evaluated by fecal elastase-1 concentrations before pancreatic enzyme supplementation therapy is applied.\\n\\nPatients are assigned into two groups randomly, the control group is only receiving enteral nutrition without the addition of pancreatic enzyme(CREON), and the PEST group is given both enteral nutrition and pancreatic enzyme supplementation therapy at the same time.\\n\\nFollowing two weeks of corresponding treatments, the nutritional status and clinical outcomes are documented in both groups for statistical analysis.', 'SecondaryOutcomeTimeFrame': 'From 2013-1 to 2014-12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria: All critically ill patients who are able to receive early enteral nutrition and estimated to stay in ICU at least four days\\n\\nExclusion Criteria: age under 18 or over 80 years, pregnancy or breastfeeding, known exocrine pancreatic insufficiency due to pancreatitis, unresectable pancreatic cancer, cystic fibrosis, celiac disease, Zollinger-Ellison syndrome, pancreatectomy, gastrectomy and medications of somatostatin or aprotinin that directly influence pancreatic exocrine function', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'All critically ill patients who are able to receive early enteral nutrition and estimated to stay in ICU at least four days', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Sheng Wang, MD, PhD', 'OverallOfficialAffiliation': \"Shanghai 10th People's Hospital\", 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Yu G Zhuang, MD, MSc', 'OverallOfficialAffiliation': \"Shanghai 10th People's Hospital\", 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Li J Ma, MD, MSc', 'OverallOfficialAffiliation': \"Shanghai 10th People's Hospital\", 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Tongji Hospital', 'LocationCity': 'Shanghai', 'LocationState': 'Shanghai', 'LocationZip': '200065', 'LocationCountry': 'China'}, {'LocationFacility': \"Shanghai Tenth People's Hospital\", 'LocationCity': 'Shanghai', 'LocationState': 'Shanghai', 'LocationZip': '200072', 'LocationCountry': 'China'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22273174', 'ReferenceType': 'background', 'ReferenceCitation': 'Larger E, Philippe MF, Barbot-Trystram L, Radu A, Rotariu M, Nobecourt E, Boitard C. Pancreatic exocrine function in patients with diabetes. Diabet Med. 2012 Aug;29(8):1047-54. doi: 10.1111/j.1464-5491.2012.03597.x.'}, {'ReferencePMID': '22111014', 'ReferenceType': 'background', 'ReferenceCitation': 'Teichmann J, Riemann JF, Lange U. Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1. ISRN Gastroenterol. 2011;2011:951686. doi: 10.5402/2011/951686. Epub 2011 Nov 3.'}, {'ReferencePMID': '21799412', 'ReferenceType': 'background', 'ReferenceCitation': 'Wier HA, Kuhn RJ. Pancreatic enzyme supplementation. Curr Opin Pediatr. 2011 Oct;23(5):541-4. doi: 10.1097/MOP.0b013e32834a1b33.'}, {'ReferencePMID': '21629239', 'ReferenceType': 'background', 'ReferenceCitation': 'Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011 May 31;8(7):405-15. doi: 10.1038/nrgastro.2011.91.'}, {'ReferencePMID': '21508176', 'ReferenceType': 'background', 'ReferenceCitation': 'Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin Pract. 2011 Jun;26(3):349-51. doi: 10.1177/0884533611405537. Epub 2011 Apr 20.'}, {'ReferencePMID': '21323992', 'ReferenceType': 'background', 'ReferenceCitation': 'Dominguez-Munoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol. 2011 Mar;26 Suppl 2:12-6. doi: 10.1111/j.1440-1746.2010.06600.x.'}, {'ReferencePMID': '21086085', 'ReferenceType': 'background', 'ReferenceCitation': 'Kuhn RJ, Gelrud A, Munck A, Caras S. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. Adv Ther. 2010 Dec;27(12):895-916. doi: 10.1007/s12325-010-0085-7. Epub 2010 Nov 15. Erratum In: Adv Ther. 2011 Jul;28(7):602.'}, {'ReferencePMID': '21084049', 'ReferenceType': 'background', 'ReferenceCitation': 'Griesche-Philippi J, Otto J, Schworer H, Maisonneuve P, Lankisch PG. Exocrine pancreatic function in patients with end-stage renal disease. Clin Nephrol. 2010 Dec;74(6):457-64. doi: 10.5414/cnp74457.'}, {'ReferencePMID': '20495627', 'ReferenceType': 'background', 'ReferenceCitation': 'Ockenga J. Importance of nutritional management in diseases with exocrine pancreatic insufficiency. HPB (Oxford). 2009 Dec;11 Suppl 3(Suppl 3):11-5. doi: 10.1111/j.1477-2574.2009.00134.x.'}, {'ReferencePMID': '19202388', 'ReferenceType': 'background', 'ReferenceCitation': 'Hardt PD, Mayer K, Ewald N. Exocrine pancreatic involvement in critically ill patients. Curr Opin Clin Nutr Metab Care. 2009 Mar;12(2):168-74. doi: 10.1097/MCO.0b013e328322437e.'}, {'ReferencePMID': '18306065', 'ReferenceType': 'background', 'ReferenceCitation': 'Senkal M, Ceylan B, Deska T, Marpe B, Geier B. Exocrine pancreas disfunction in severely traumatised patients and early enteral nutrition. Ulus Travma Acil Cerrahi Derg. 2008 Jan;14(1):34-9.'}, {'ReferencePMID': '17497124', 'ReferenceType': 'background', 'ReferenceCitation': 'Denz C, Siegel L, Lehmann KJ, Dagorn JC, Fiedler F. Is hyperlipasemia in critically ill patients of clinical importance? An observational CT study. Intensive Care Med. 2007 Sep;33(9):1633-6. doi: 10.1007/s00134-007-0668-1. Epub 2007 May 12.'}, {'ReferencePMID': '17438451', 'ReferenceType': 'background', 'ReferenceCitation': 'Nys M, Venneman I, Deby-Dupont G, Preiser JC, Vanbelle S, Albert A, Camus G, Damas P, Larbuisson R, Lamy M. Pancreatic cellular injury after cardiac surgery with cardiopulmonary bypass: frequency, time course and risk factors. Shock. 2007 May;27(5):474-81. doi: 10.1097/shk.0b013e31802b65f8.'}, {'ReferencePMID': '15653954', 'ReferenceType': 'background', 'ReferenceCitation': 'Serrano N. Increased lipase plasma levels in ICU patients: when are they critical? Chest. 2005 Jan;127(1):7-10. doi: 10.1378/chest.127.1.7. No abstract available.'}, {'ReferencePMID': '23924602', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wang S, Ma L, Zhuang Y, Jiang B, Zhang X. Screening and risk factors of exocrine pancreatic insufficiency in critically ill adult patients receiving enteral nutrition. Crit Care. 2013 Aug 7;17(4):R171. doi: 10.1186/cc12850.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010188', 'ConditionMeshTerm': 'Exocrine Pancreatic Insufficiency'}, {'ConditionMeshId': 'D000058186', 'ConditionMeshTerm': 'Acute Kidney Injury'}, {'ConditionMeshId': 'D000016638', 'ConditionMeshTerm': 'Critical Illness'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000051437', 'ConditionAncestorTerm': 'Renal Insufficiency'}, {'ConditionAncestorId': 'D000007674', 'ConditionAncestorTerm': 'Kidney Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}, {'ConditionAncestorId': 'D000052776', 'ConditionAncestorTerm': 'Female Urogenital Diseases'}, {'ConditionAncestorId': 'D000005261', 'ConditionAncestorTerm': 'Female Urogenital Diseases and Pregnancy Complications'}, {'ConditionAncestorId': 'D000091642', 'ConditionAncestorTerm': 'Urogenital Diseases'}, {'ConditionAncestorId': 'D000052801', 'ConditionAncestorTerm': 'Male Urogenital Diseases'}, {'ConditionAncestorId': 'D000010182', 'ConditionAncestorTerm': 'Pancreatic Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M20554', 'ConditionBrowseLeafName': 'Sepsis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16559', 'ConditionBrowseLeafName': 'Toxemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9101', 'ConditionBrowseLeafName': 'Heart Arrest', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28688', 'ConditionBrowseLeafName': 'Acute Kidney Injury', 'ConditionBrowseLeafAsFound': 'Acute Renal Failure', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18700', 'ConditionBrowseLeafName': 'Critical Illness', 'ConditionBrowseLeafAsFound': 'Critical Illness', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26408', 'ConditionBrowseLeafName': 'Renal Insufficiency', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15267', 'ConditionBrowseLeafName': 'Shock', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12798', 'ConditionBrowseLeafName': 'Exocrine Pancreatic Insufficiency', 'ConditionBrowseLeafAsFound': 'Pancreatic Exocrine Insufficiency', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M30335', 'ConditionBrowseLeafName': 'Hyperlactatemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22390', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10388', 'ConditionBrowseLeafName': 'Kidney Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17009', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2876', 'ConditionBrowseLeafName': 'Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26783', 'ConditionBrowseLeafName': 'Female Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13817', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8089', 'ConditionBrowseLeafName': 'Female Urogenital Diseases and Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26785', 'ConditionBrowseLeafName': 'Male Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12792', 'ConditionBrowseLeafName': 'Pancreatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Infections'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 57, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02852941', 'OrgStudyIdInfo': {'OrgStudyId': 'C.I/KTx/2016/07'}, 'Organization': {'OrgFullName': 'Medical University of Warsaw', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Assessment of Volumetric Hemodynamic Parameters and Nutritional Status in Stable Renal Transplant Recipients', 'OfficialTitle': 'Assessment of Volumetric Hemodynamic Parameters and Nutritional Status in Stable Renal Transplant Recipients'}, 'StatusModule': {'StatusVerifiedDate': 'September 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2016'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 27, 2016', 'StudyFirstSubmitQCDate': 'August 1, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 2, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 12, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 13, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Łukasz Czyżewski', 'ResponsiblePartyInvestigatorTitle': 'PhD', 'ResponsiblePartyInvestigatorAffiliation': 'Medical University of Warsaw'}, 'LeadSponsor': {'LeadSponsorName': 'Medical University of Warsaw', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Changes in volumetric hemodynamic parameters and fluid overload (Cardiac Index,Stroke Volume, Thoracic Fluid Content, Systemic Vascular Resistance) were measured using a impedance cardiography (ICG) (CardioScreen 1000 - Haemodynamic Measurement System, Medis. Ilmenau) in stable renal transplant recipients Nutritional status was measured by Tanita 418 Monitor.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cardiac Output, Low', 'High Blood Pressure']}, 'KeywordList': {'Keyword': ['Impedance', 'Kidney Transplantation']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '80', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients after kidney transplantation', 'ArmGroupDescription': 'The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: CardioScreen 1000', 'Device: Tanita 418- Bioelectrical impedance analysis']}}, {'ArmGroupLabel': 'Healthy subjects', 'ArmGroupDescription': 'Medical staff: medical doctors, nurses', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: CardioScreen 1000', 'Device: Tanita 418- Bioelectrical impedance analysis']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'CardioScreen 1000', 'InterventionDescription': 'Haemodynamic Measurement System, Medis Impedance cardiography (ICG)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy subjects', 'Patients after kidney transplantation']}}, {'InterventionType': 'Device', 'InterventionName': 'Tanita 418- Bioelectrical impedance analysis', 'InterventionDescription': 'The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy subjects', 'Patients after kidney transplantation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Assessment of cardiac index in Stable Renal Transplant Recipients', 'PrimaryOutcomeDescription': 'Measurement of cardiac index (l/min/m2)', 'PrimaryOutcomeTimeFrame': '1 day'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Assessment of Nutritional Status in Stable Renal Transplant Recipients', 'SecondaryOutcomeDescription': 'Measurement of amount of fat tissue (%)', 'SecondaryOutcomeTimeFrame': '1 day'}, {'SecondaryOutcomeMeasure': 'Assessment of Systemic Vascular Resistance Index in Stable Renal Transplant Recipients', 'SecondaryOutcomeDescription': 'Measurement of Systemic Vascular Resistance Index (dynes-sec/cm-5/m2)', 'SecondaryOutcomeTimeFrame': '1 day'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ngive voluntary consent to participate in the study\\nfunctioning graft longer than 3 months to 10 years\\nno clinical cardiovascular disease during the 6 months preceding entry\\nstable graft function- glomerular filtration rate > 30 ml/min/1.73 m2, creatinine concentration <2.5 mg/dl\\nmedical staff (medical doctors, nurses)\\n\\nExclusion Criteria:\\n\\nnot meet the above criteria\\nepisode of illness (for example: infection)\\npregnancy', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'A total of 100 consecutive patients admitted to routine visin in Transplant Centre and 30 healthy subjects were included in this study.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Medical University of Warsaw', 'LocationCity': 'Warsaw', 'LocationState': 'Mazovian', 'LocationZip': '02-091', 'LocationCountry': 'Poland'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26871855', 'ReferenceType': 'background', 'ReferenceCitation': 'Czyzewski L, Wyzgal J, Czyzewska E, Kurowski A, Sierdzinski J, Truszewski Z, Szarpak L. Assessment of Arterial Stiffness, Volume, and Nutritional Status in Stable Renal Transplant Recipients. Medicine (Baltimore). 2016 Feb;95(6):e2819. doi: 10.1097/MD.0000000000002819.'}, {'ReferencePMID': '25365639', 'ReferenceType': 'background', 'ReferenceCitation': 'Czyzewski L, Sanko-Resmer J, Wyzgal J, Kurowski A. Comparative analysis of hypertension and its causes among renal replacement therapy patients. Ann Transplant. 2014 Nov 3;19:556-68. doi: 10.12659/AOT.891248.'}, {'ReferencePMID': '24770703', 'ReferenceType': 'background', 'ReferenceCitation': 'Czyzewski L, Wyzgal J, Kolek A. Evaluation of selected risk factors of cardiovascular diseases among patients after kidney transplantation, with particular focus on the role of 24-hour automatic blood pressure measurement in the diagnosis of hypertension: an introductory report. Ann Transplant. 2014 Apr 28;19:188-98. doi: 10.12659/AOT.890189.'}, {'ReferencePMID': '25382249', 'ReferenceType': 'background', 'ReferenceCitation': 'Czyzewski L, Sanko-Resmer J, Wyzgal J, Kurowski A. Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. Ann Transplant. 2014 Nov 9;19:576-85. doi: 10.12659/AOT.891265.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}, {'ConditionMeshId': 'D000002303', 'ConditionMeshTerm': 'Cardiac Output, Low'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M9714', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'High Blood Pressure', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5249', 'ConditionBrowseLeafName': 'Cardiac Output, Low', 'ConditionBrowseLeafAsFound': 'Cardiac Output, Low', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 58, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02347995', 'OrgStudyIdInfo': {'OrgStudyId': 'N1461-R'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'HP-00062067', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Baltimore VAMC'}]}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Resistive Training Combined With Nutritional Therapy After Stroke', 'OfficialTitle': 'Resistive Training Combined With Nutritional Therapy After Stroke', 'Acronym': 'REPS'}, 'StatusModule': {'StatusVerifiedDate': 'July 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 24, 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 1, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'October 1, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 8, 2015', 'StudyFirstSubmitQCDate': 'January 22, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 28, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 19, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 20, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Baltimore VA Medical Center', 'CollaboratorClass': 'FED'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke survivors experience severe muscle wasting during the chronic phase of recovery, with implications for strength, function and general health. Although resistive exercise training effectively combats this problem, it is unknown whether sub-optimal protein intake limits the observed gains in skeletal muscle growth. Skeletal muscle adaptations may occur when resistive training (RT) is combined with nutritional therapy in the form of post- exercise protein consumption. This study would be the first to directly compare RT+protein supplementation to RT+placebo (same calories as protein supplement) in those with chronic hemiparesis caused by stroke, providing evidence-based rationale for combination therapy in the clinical care of this population.', 'DetailedDescription': \"The VA research team has played a prominent role in documenting the significant skeletal muscle atrophy that accompanies chronic hemiparesis after disabling stroke. Muscle volume is reduced by 24% in paretic vs. non-paretic legs, having significant implications for strength, function, fitness, metabolism and general health. The investigators' previous work establishes progressive, high-intensity resistive training (RT) as an effective rehabilitation strategy for older stroke survivors, producing thigh muscle hypertrophy on both the paretic and non-paretic sides. Protein supplementation can significantly augment gains in muscle mass after RT in healthy populations, but no experiments have yet been conducted in stroke. New preliminary data from the investigators' group indicates that stroke participants consume 20% less protein than the recommended daily amount for older individuals (0.80 vs. 1.0 g/kg/day) suggesting that relative gains in skeletal muscle could be significantly better in the presence of adequate protein intake. New data also indicates that leg muscle mass predicts resting metabolic rate (RMR) in stroke, implying that a combined nutrition and RT therapy aimed at maximizing muscle gains would translate into improved energy balance, a key factor in rehabilitation success. A better understanding of the true potential for aggressive RT interventions to address stroke-related atrophy and related problems for maximum benefit awaits clinical trials directly comparing RT with and without nutritional therapy. The investigators propose to conduct a 12-week randomized placebo controlled clinical trial comparing the effects of RT+ protein supplementation at 1.2 g/kg/day (RT+PRO) vs. RT+isocaloric placebo (RT+PLA) on body composition, hypertrophy, strength, functional mobility and energy expenditure in chronic stroke.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Exercise', 'Protein', 'Nutrition', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Resistive Training', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Participants will drink a placebo beverage after each resistance training session.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}}, {'ArmGroupLabel': 'Resistive Training + Protein', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will drink 30 grams of whey protein after each resistance training session.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Protein']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Protein', 'InterventionDescription': 'This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Resistive Training + Protein']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo', 'InterventionDescription': 'This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Resistive Training']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in thigh muscle area', 'PrimaryOutcomeDescription': 'muscle area in cm2', 'PrimaryOutcomeTimeFrame': 'Measured at baseline and after the 3 month intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in muscle strength', 'SecondaryOutcomeDescription': 'strength', 'SecondaryOutcomeTimeFrame': 'Measured at baseline and after the 3 month intervention'}, {'SecondaryOutcomeMeasure': 'Change in functional mobility (6 min walk distance)', 'SecondaryOutcomeDescription': '6 min walk distance', 'SecondaryOutcomeTimeFrame': 'Measured at baseline and after the 3 month intervention'}, {'SecondaryOutcomeMeasure': 'Change in myostatin messenger RNA (mRNA) level', 'SecondaryOutcomeDescription': 'myostatin mRNA (AU)', 'SecondaryOutcomeTimeFrame': 'Measured at baseline and after the 3 month intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nStroke > 3 months prior\\nCompletion of all regular post-stroke physical therapy\\nAdequate language and neurocognitive function to participate in testing and training and to provide informed consent\\nAble to walk 10 meters without human assistance\\n\\nExclusion Criteria:\\n\\nRegular structured resistive exercise (>2x/week)\\nAlcohol consumption >3oz. liquor, 3 x 4oz. glasses of wine, or 3 x 12oz beers/day, by self report\\nNeurological history of: a) dementia by clinical evaluation, b) severe receptive or global aphasia, which confounds testing and training, operationally defined as unable to follow 2 point commands, c) untreated major depression by clinical interview\\nMedical History: a) recent hospitalization (less than 3 months prior to study entry) for severe medical disease, b) orthopedic or chronic pain condition restricting exercise, c) pulmonary or renal failure, d) active cancer, e) untreated poorly controlled hypertension measured on at least 2 occasions (greater than 190/100) f) untreated and / or poorly controlled diabetes with fasting blood glucose of greater than 170 and HbA1c greater than 10.0, g) medications: oral steroids, h) currently pregnant\\nCardiac history of: a) unstable angina, b) recent (less than 3 months prior to study entry) myocardial infarction, congestive heart failure (NYHA category II-IV); c) hemodynamically significant valvular dysfunction\\nAny medical condition that, in the opinion of the Investigator, might interfere with the subject's participation in the study, poses any added risk for the subject, or confounds the assessment of the subject\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Lynda C Robey', 'CentralContactRole': 'Contact', 'CentralContactPhone': '(410) 605-7000', 'CentralContactPhoneExt': '5446', 'CentralContactEMail': 'lynda.robey@va.gov'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Alice S. Ryan, PhD', 'OverallOfficialAffiliation': 'Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD', 'LocationStatus': 'Recruiting', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21201', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lynda C Robey', 'LocationContactRole': 'Contact', 'LocationContactPhone': '410-605-7000', 'LocationContactPhoneExt': '5446', 'LocationContactEMail': 'lynda.robey@va.gov'}, {'LocationContactName': 'Alice S. Ryan, PhD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '35192798', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ryan AS, Novitskaya M, Treuth AL. Predictive Equations Overestimate Resting Metabolic Rate in Survivors of Chronic Stroke. Arch Phys Med Rehabil. 2022 Jul;103(7):1352-1359. doi: 10.1016/j.apmr.2022.01.155. Epub 2022 Feb 19.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T435', 'InterventionBrowseLeafName': 'Whey Protein', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 59, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03485820', 'OrgStudyIdInfo': {'OrgStudyId': '201705047'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01HD092398-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01HD092398-01'}]}, 'Organization': {'OrgFullName': 'Washington University School of Medicine', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Novel Transition Program to Reduce Disability After Stroke', 'OfficialTitle': 'COMPASS: A Novel Transition Program to Reduce Disability After Stroke', 'Acronym': 'COMPASS'}, 'StatusModule': {'StatusVerifiedDate': 'July 2023', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 20, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 26, 2018', 'StudyFirstSubmitQCDate': 'March 26, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 2, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 19, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Washington University School of Medicine', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study evaluates a program designed to help individuals transition home from inpatient rehabilitation following an ischemic or hemorrhagic stroke. Half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.', 'DetailedDescription': \"A gap in care exists at the point of transition from inpatient rehabilitation (IR) to home, when survivors encounter new environmental barriers due to the cognitive and sensorimotor sequelae of stroke. Resolving these barriers and improving independence in the community have potential to significantly improve stroke survivors' long-term morbidity. The proposed study investigates the efficacy and safety of a novel enhanced rehabilitation-transition program to reduce environmental barriers and improve daily activity performance and community participation.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke', 'Hemorrhagic Stroke']}, 'KeywordList': {'Keyword': ['environmental modifications', 'activity performance']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Single-blind, parallel-group, randomized controlled trial', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '185', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'COMPASS', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: COMPASS']}}, {'ArmGroupLabel': 'Education program', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'An OT practitioner will deliver the program in accordance with \"Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home.\" Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stroke education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'COMPASS', 'InterventionDescription': \"The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['COMPASS']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Stroke education', 'InterventionDescription': 'The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Education program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reintegration to Normal Living Index (RNLI)', 'PrimaryOutcomeDescription': \"The RNLI is a disability-related quality-of life-instrument that will be used to measure participants' satisfaction with their home and community participation and has been validated on a population of community-dwelling individuals with chronic conditions.\", 'PrimaryOutcomeTimeFrame': '12 months post-stroke'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Stroke Impact Scale (SIS)', 'SecondaryOutcomeDescription': \"The SIS is a health-related quality of life (HRQoL) measure that quantifies the impact of stroke on a client's life, via questionnaire. 59 items are measured across 8 domains, including: strength, hand function, mobility, Activities of Daily Living and Instrumental Activities of Daily Living (ADLs/IADLs), emotion, memory, communication, and participation.\", 'SecondaryOutcomeTimeFrame': '12 months post-stroke'}, {'SecondaryOutcomeMeasure': 'In-Home Occupational Performance Evaluation (I-HOPE)', 'SecondaryOutcomeDescription': 'The I-HOPE will be used to measure current activity patterns of participants, identify activities that are difficult but important to them, and identify the environmental barriers that influence those activities (person-environment fit).', 'SecondaryOutcomeTimeFrame': '12 months post-stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\naged ≥50 years\\nacute ischemic or hemorrhagic stroke diagnosis\\nindependent ADLs prior to stroke (premorbid Modified Rankin Scale Score ≤2)\\nplan to discharge to home\\n\\nExclusion Criteria:\\n\\nsevere terminal systemic disease that limits life expectancy to < 6 months\\nprevious disorder (e.g. dementia) that makes interpretation of the self-rated scales difficult or Short Blessed Test (SBT) score of 10 or less (indicating significant cognitive impairment)\\nmoderate to severe Aphasia as determined by the NIHSS Best Language rating of 2 or more\\nreside in congregate living facility.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Susan Stark, PhD', 'OverallOfficialAffiliation': 'Washington University School of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Washington University School of Medicine', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63108', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '31577356', 'ReferenceType': 'derived', 'ReferenceCitation': 'Somerville E, Minor B, Keglovits M, Yan Y, Stark S. Effect of a Novel Transition Program on Disability After Stroke: A Trial Protocol. JAMA Netw Open. 2019 Oct 2;2(10):e1912356. doi: 10.1001/jamanetworkopen.2019.12356.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000083302', 'ConditionMeshTerm': 'Hemorrhagic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2405', 'ConditionBrowseLeafName': 'Hemorrhagic Stroke', 'ConditionBrowseLeafAsFound': 'Hemorrhagic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21550', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 60, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05228561', 'OrgStudyIdInfo': {'OrgStudyId': 'EgeUniversity-ETURHAN-001'}, 'Organization': {'OrgFullName': 'Ege University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Effect of Mobile Application Supported Diabetes Education On Type 2 Diabetes Self-Management And Blood Sugar Level', 'OfficialTitle': 'The Effect of Mobile Application Supported Diabetes Education On Type 2 Diabetes Self-Management And Blood Sugar In Newly Diagnosed Type 2 Diabetes Patients'}, 'StatusModule': {'StatusVerifiedDate': 'January 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 15, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 15, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 15, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 30, 2021', 'StudyFirstSubmitQCDate': 'January 27, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 8, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 27, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 8, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'EMRE TURHAN', 'ResponsiblePartyInvestigatorTitle': 'Graduate Student', 'ResponsiblePartyInvestigatorAffiliation': 'Ege University'}, 'LeadSponsor': {'LeadSponsorName': 'Ege University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Diabetes is one of the biggest public health problems of the 21st century. Type 2 diabetes mellitus accounts for more than 90% of all diabetes cases and is the most common type of diabetes. Type 2 diabetes, in which genetic and environmental factors play a role,It is a metabolic disorder in which insulin resistance, decrease in insulin secretion and incretin hormone deficiency are effective in its physiopathology, characterized by polydipsia, polyphagia and polyuria, where the organism cannot adequately benefit from carbohydrates, fats and proteins due to insulin deficiency or defects in the effect of insulin, which requires continuous medical care.\\n\\nDiabetes is a major cause of blindness, end-stage renal disease, coronary artery disease, stroke and inferior extremity amputations. These complications due to diabetes impair the patient's quality of life and impose social, financial and emotional burdens on both the patient and their family.\\n\\nDiabetes education should be provided by healthcare professionals in order to ensure that diabetes patients knowledge and skills to prevent complications and provide better self management and self-care.\\n\\nHowever, The fact that individuals do not have time to spare for face-to-face health education, the possibility of accessing information in the web environment repeatedly and the lower cost of education in the web environment compared to classical education increases the importance of web-based health education. The widespread use of mobile technologies in recent years has led to the development of new mobile applications related to diabetes.\\n\\nThe disquisition proposal the investigators prepared was created to investigate the effect of mobile application supported diabetes and nutrition education on type 2 diabetes self-management and blood sugar in newly diagnosed type 2 diabetes patients.\\n\\nIn this context, with the development of a mobile application prepared in visual, text and video format to provide diabetes education, the monitoring of blood parameters before and after diabetes education, and the implementation of the Type 2 Diabetes Self-Management Scale, (which consists of 19 items developed in 2020), and type 2 diabetes self-management and the effect on blood sugar will be examined. This study will provide answers to questions about the effectiveness of diabetes education given to Type 2 Diabetes patients via mobile applications on diabetes self-management and blood parameters.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes Mellitus, Type 2', 'Education', 'Mobile Applications', 'Self-Management']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '140', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Control Group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'After the physician involved in the study asks the participants for their biochemical tests (FBC, HbA1C, LDL-C, HDL-C, Total K, Triglyceride), the outpatient dietitian will give routine nutrition education to the participants. In addition, a data collection form including socio-demographic information, health history, nutrition history and height, weight, waist circumference measurements will be made and filled by the thesis student.'}, {'ArmGroupLabel': 'Study Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The software developed for this research will be downloaded to the phones of the participants in the intervention group. With this software prepared, written and visual information (pictures, mini-videos) will be given to participants every day for 3 months on diabetes, self-management of diabetes and nutrition. Whether the participants read the messages or not will also be monitored through this software. At the end of 3 months, the participants in the intervention and control groups will be invited again, and their biochemical parameters and self-management status will be measured according to the diabetes self-management scale. Data will be collected through face-to-face interviews in the outpatient clinic, and weight will be measured with the bioelectrical impedance analyzer in the outpatient clinic, height will be measured with a height meter fixed to the wall, and waist circumference will be measured with a non-stretchable measuring tape.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Mobile Application Supported Nutrition and Diabetes Education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Mobile Application Supported Nutrition and Diabetes Education', 'InterventionDescription': 'With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Study Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The effect of mobile application supported diabetes education on type 2 diabetes self-management.', 'PrimaryOutcomeDescription': 'Type 2 diabetes self-management scores of the participants in the study group and control group will be compared.\\n\\nFor this comparison, the \"Type 2 Diabetes Self-Management Scale\" consisting of 3 sub-titles (Healthy Lifestyle Behaviors, Blood Sugar Management, Health Services Use) and 19 items developed in 2020 will be applied.\\n\\n(Scoring: Always 5, Often 4, Sometimes 3, Rarely 2, Never 1 point). Those with higher scores will be considered to show better self-management. This scale will first be administered to the participants when they are diagnosed with type 2 diabetes in the hospital.\\n\\nParticipants will be given diabetes and nutrition education for 3 months, and the Type 2 Diabetes Self-Management Scale will be repeated by inviting them to the hospital for control.\\n\\nThen, the participants will be taken into a 3-month follow-up process and at the end of the process, they will be invited to the hospital for control and the Type 2 Diabetes Self-Management Scale will be repeated.', 'PrimaryOutcomeTimeFrame': '6 Month'}, {'PrimaryOutcomeMeasure': 'The effect of mobile application supported diabetes education on blood sugar', 'PrimaryOutcomeDescription': 'The physician participating in the study will measure the Fasting Blood Sugar (mg/dl) values of the participants.\\n\\nWhen the participants are diagnosed with type 2 diabetes, their Fasting Blood Sugar (mg/dl) values will be measured and a 3-month diabetes education will be given. At the end of this diabetes training, the participants will be invited to the hospital for control and their Fasting Blood Sugar (mg/dl) values will be measured again.\\n\\nThen, the participants will be taken to the 3-month follow-up process and at the end of the process, the participants will be invited to the hospital for control and their Fasting Blood Sugar (mg/dl) values will be measured again.\\n\\nAt the end of the research, the effects of mobile application supported diabetes education on fasting blood sugar (mg/dl) will be compared with the routine diabetes education given in the hospital.', 'PrimaryOutcomeTimeFrame': '6 Months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nNewly diagnosed type 2 diabetes patients in the endocrinology and metabolism outpatient clinic of Ege University Medical Faculty Hospital.\\nPatients with Type 2 DM, between the ages of 18-64, using smart phones and having regular internet will be included in the study.\\n\\nExclusion Criteria:\\n\\nThose who receive regular messages every day will be checked, and those who do not open/read more than 25% of the messages in total will be excluded.\\ntype 1 diabetes or gestational diabetes', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '64 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27388988', 'ReferenceType': 'background', 'ReferenceCitation': 'Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016 Oct;12(10):616-22. doi: 10.1038/nrendo.2016.105. Epub 2016 Jul 8.'}, {'ReferencePMID': '12196426', 'ReferenceType': 'background', 'ReferenceCitation': 'Satman I, Yilmaz T, Sengul A, Salman S, Salman F, Uygur S, Bastar I, Tutuncu Y, Sargin M, Dinccag N, Karsidag K, Kalaca S, Ozcan C, King H. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care. 2002 Sep;25(9):1551-6. doi: 10.2337/diacare.25.9.1551.'}, {'ReferencePMID': '23407904', 'ReferenceType': 'background', 'ReferenceCitation': 'Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J; TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013 Feb;28(2):169-80. doi: 10.1007/s10654-013-9771-5. Epub 2013 Feb 14.'}, {'ReferencePMID': '28539866', 'ReferenceType': 'background', 'ReferenceCitation': 'Sami W, Ansari T, Butt NS, Hamid MRA. Effect of diet on type 2 diabetes mellitus: A review. Int J Health Sci (Qassim). 2017 Apr-Jun;11(2):65-71.'}, {'ReferencePMID': '20557415', 'ReferenceType': 'background', 'ReferenceCitation': 'Millar A, Cauch-Dudek K, Shah BR. The impact of diabetes education on blood glucose self-monitoring among older adults. J Eval Clin Pract. 2010 Aug;16(4):790-3. doi: 10.1111/j.1365-2753.2009.01195.x. Epub 2010 Jun 14.'}, {'ReferencePMID': '32513817', 'ReferenceType': 'background', 'ReferenceCitation': 'Powers MA, Bardsley JK, Cypress M, Funnell MM, Harms D, Hess-Fischl A, Hooks B, Isaacs D, Mandel ED, Maryniuk MD, Norton A, Rinker J, Siminerio LM, Uelmen S. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care. 2020 Jul;43(7):1636-1649. doi: 10.2337/dci20-0023. Epub 2020 Jun 8. No abstract available.'}, {'ReferencePMID': '21979293', 'ReferenceType': 'background', 'ReferenceCitation': 'Chomutare T, Fernandez-Luque L, Arsand E, Hartvigsen G. Features of mobile diabetes applications: review of the literature and analysis of current applications compared against evidence-based guidelines. J Med Internet Res. 2011 Sep 22;13(3):e65. doi: 10.2196/jmir.1874.'}, {'ReferencePMID': '23439183', 'ReferenceType': 'background', 'ReferenceCitation': 'El-Gayar O, Timsina P, Nawar N, Eid W. Mobile applications for diabetes self-management: status and potential. J Diabetes Sci Technol. 2013 Jan 1;7(1):247-62. doi: 10.1177/193229681300700130.'}, {'ReferencePMID': '30291098', 'ReferenceType': 'background', 'ReferenceCitation': 'Kelly L, Jenkinson C, Morley D. Experiences of Using Web-Based and Mobile Technologies to Support Self-Management of Type 2 Diabetes: Qualitative Study. JMIR Diabetes. 2018 May 11;3(2):e9. doi: 10.2196/diabetes.9743.'}, {'ReferencePMID': '12087014', 'ReferenceType': 'background', 'ReferenceCitation': 'Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002 Jul;25(7):1159-71. doi: 10.2337/diacare.25.7.1159.'}, {'ReferencePMID': '24676274', 'ReferenceType': 'background', 'ReferenceCitation': 'Calderon JL, Shaheen M, Hays RD, Fleming ES, Norris KC, Baker RS. Improving Diabetes Health Literacy by Animation. Diabetes Educ. 2014 May;40(3):361-372. doi: 10.1177/0145721714527518. Epub 2014 Mar 27.'}, {'ReferencePMID': '31311727', 'ReferenceType': 'background', 'ReferenceCitation': 'Abrar EA, Yusuf S, Sjattar EL, Rachmawaty R. Development and evaluation educational videos of diabetic foot care in traditional languages to enhance knowledge of patients diagnosed with diabetes and risk for diabetic foot ulcers. Prim Care Diabetes. 2020 Apr;14(2):104-110. doi: 10.1016/j.pcd.2019.06.005. Epub 2019 Jul 13.'}, {'ReferencePMID': '24357209', 'ReferenceType': 'background', 'ReferenceCitation': 'American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014. No abstract available.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Diabetes Atlas-Tenth Edition', 'SeeAlsoLinkURL': 'https://diabetesatlas.org/atlas/tenth-edition/'}, {'SeeAlsoLinkLabel': 'Diabetes Self-Management Support', 'SeeAlsoLinkURL': 'https://diabetesjournals.org/spectrum/article/20/4/221/70090/From-DSME-to-DSMS-Developing-Empowerment-Based'}, {'SeeAlsoLinkLabel': 'Diabetes Self-Management Education and Support (DSMES)', 'SeeAlsoLinkURL': 'https://www.cdc.gov/diabetes/dsmes-toolkit/standards/index.html'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000003924', 'ConditionMeshTerm': 'Diabetes Mellitus, Type 2'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafAsFound': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 61, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04135872', 'OrgStudyIdInfo': {'OrgStudyId': 'DongguanPeopleHospital'}, 'Organization': {'OrgFullName': \"Dongguan People's Hospital\", 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'Hypoalbuminemia in Mild Acute Stroke and Cognitive Impariment Post-stroke', 'OfficialTitle': 'Relationship Between Baseline Serum Albumin Level and Cognitive Impariment in Mild Acute Ischemic Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'October 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 30, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'October 21, 2019', 'StudyFirstSubmitQCDate': 'October 21, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 23, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 22, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 24, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Zhu Shi', 'ResponsiblePartyInvestigatorTitle': 'Deputy Director of Neurology', 'ResponsiblePartyInvestigatorAffiliation': \"Dongguan People's Hospital\"}, 'LeadSponsor': {'LeadSponsorName': \"Dongguan People's Hospital\", 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This registration enrolled patients with acute ischemic stroke within 72 hours after stroke ictus. Patients was identified as first-ever stroke based on past medical histrory. Admission CT was conducted to exclude hemorrhagic stroke, but not those bleeding transformation after ischemia injury. Baseline characteristics, including demographics, vascular risk factors, lab tests and neuroimagings were collected. Patients were followed up for cognitive assessments.', 'DetailedDescription': 'This is a perspective stroke registry cohort study. Stroke patients were included if ：(1) acute first-ever ischemic stroke and admitted within 72 hours after onset; (2) clinical stroke diagnosis was confirmed with positive diffusion-weighted magnetic resonance imaging (DW-MRI), those with isolated posterior circulations infarcts were exclude ; (3) presented with mild stroke severity ( admission NIHSS score ≤5); (4) age between 40 and 80 years.\\n\\nClinical data including demographic characteristics, risk factors, and baseline NIHSS score were assessed and collected using a standardized table by experienced neurologists. Lab tests were performed with fasting venous blood samples within 18 hours of admission.\\n\\nPatients were followed up for 6 months. The cognitive functions were assessed using the Chinese version of Montreal Cognitive Assessment (MoCA).\\n\\nContributing factors to post-stroke cognitive impariment (PSCI) were determined by comparing clinical data between PSCI and non-PSCI groups. All potential confounders were introduced into the multivariate regression models.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cognitive Impairment', 'Stroke', 'Albumin; Double']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'Yes', 'TargetDuration': '6 Months', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'fasting venous blood samples'}, 'EnrollmentInfo': {'EnrollmentCount': '435', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'hypoalbuminemia', 'ArmGroupDescription': 'hypoalbuminemia was classified as serum albumin level (SAL) <35g/L', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: strengthened nuitritional treatment']}}, {'ArmGroupLabel': 'normal albumin level', 'ArmGroupDescription': 'patients with serum albumin level (SAL) of 35g/L or higher'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'strengthened nuitritional treatment', 'InterventionDescription': 'improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['hypoalbuminemia']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'PSCI', 'PrimaryOutcomeDescription': 'Patients with a MoCA score of <24 were categorized as having PSCI', 'PrimaryOutcomeTimeFrame': '6 months post-stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nacute first-ever ischemic stroke and admitted within 72 hours after onset;\\nclinical stroke diagnosis was confirmed with positive diffusion-weighted magnetic resonance imaging (DW-MRI), those with isolated posterior circulations infarcts were exclude ;\\npresented with mild stroke severity ( admission NIHSS score ≤5);\\nage between 40 and 80 years.\\n\\nExclusion Criteria:\\n\\nPatients with index cognitive impairment or under current anti-dementia or psychiatric medication;\\npatients with large infarcts (≥1/3 middle cerebral artery territory);\\npatients with severe language or physical disability that impede neuropsychological testing;\\npatients with recurrent transient ischemic attack (TIA)/stroke during follow-up;\\ncoexisting serious conditions known to impair cognitive function', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': \"Patients were continuously enrolled from a perspective stroke registry between January 1, 2017 and June 31, 2018, in Dongguan People's Hospital, Guangdong, China.\", 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'zhu shi', 'OverallOfficialAffiliation': 'dongguan peoples hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Dongguan Peoples' Hospital\", 'LocationCity': 'Dongguan', 'LocationState': 'Guangdong', 'LocationZip': '523029', 'LocationCountry': 'China'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': \"The final decision to release IPD is still pending because of the ongoing census among all paticipants's decision.\"}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24087', 'ConditionBrowseLeafName': 'Hypoalbuminemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 62, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05901675', 'OrgStudyIdInfo': {'OrgStudyId': 'Pro00120848'}, 'Organization': {'OrgFullName': 'Medical University of South Carolina', 'OrgClass': 'OTHER'}, 'BriefTitle': 'EMPOWER: Effects of Weight Loss and Exercise Post-stroke', 'OfficialTitle': 'Enhancing Mobility and Psychosocial Function in Stroke Survivors Who Are Overweight Via Weight Loss and ExeRcise (EMPOWER): A Feasibility Trial.', 'Acronym': 'EMP'}, 'StatusModule': {'StatusVerifiedDate': 'June 2023', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 5, 2023', 'StudyFirstSubmitQCDate': 'June 5, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 13, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 14, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 18, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ewan Williams', 'ResponsiblePartyInvestigatorTitle': 'Assistant Professor-Faculty', 'ResponsiblePartyInvestigatorAffiliation': 'Medical University of South Carolina'}, 'LeadSponsor': {'LeadSponsorName': 'Medical University of South Carolina', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The prevalence of obesity among U.S. adults is ~40% and is projected to climb. It is well documented that obesity is associated with increased levels of disability as well as risk for numerous adverse health-related outcomes; including occurrence of stroke and all-cause mortality. Obesity is highly prevalent in stroke survivors (~30-45% of stroke survivors have BMI>30) and is associated with reductions in physical function and increased disability. Furthermore, neurological sequelae following stroke result in a myriad of residual impairments that contribute to significant reductions in physical activity, which further increase the risk for obesity. The alarmingly high (and increasing) rates of obesity amongst stroke survivors represents an area of critical clinical need and, despite an abundance of information regarding weight loss approaches in neurologically healthy individuals, there is a lack of information regarding the impact of intentional weight loss on overweight and obese survivors of stroke. Thus, the purpose of this study it investigate the effect of varying weight loss approaches on physical function and psychosocial outcomes in chronic stroke survivors.', 'DetailedDescription': 'With a surviving cohort of nearly 7 million individuals, stroke is the leading cause of long-term disability in the United States. Of the ~795,000 new strokes occurring in the U.S. each year, approximately two-thirds of survivors will have some degree of long term disability, and less than half will progress to independent community ambulation. Even among those who do achieve independent ambulation, significant residual deficits persist, with more than 60% of persons post-stroke reporting limitations in mobility related to walking. Concurrently, obesity is highly prevalent in stroke survivors (~30-45% of stroke survivors have BMI>30) and is associated with increased levels of disability as well as risk for numerous adverse health-related outcomes; including re-occurrence of stroke and all-cause mortality.8 The neurological sequelae following stroke result in a myriad of residual impairments that contribute to significant reductions in physical activity, which further increase the risk for obesity. The alarmingly high (and increasing) rates of obesity amongst stroke survivors represents an area of critical clinical need and, despite an abundance of information regarding weight loss approaches in neurologically healthy individuals, there is a lack of information regarding the impact of intentional weight loss on obese survivors of stroke.\\n\\nThe proposed approach is an opportunity to address the all-to-common problem of post-stroke obesity. In an effort to reduce the long-term risk for disability and development or worsening of comorbid conditions, we propose the Enhancing Mobility and Psychosocial function in Obese Chronic Stroke Survivors via Weight loss and ExeRcise (EMPOWER) pilot trial. This trial leverages a 15-week multidisciplinary approach to weight loss, via an existing lifestyle and weight management program at MUSC Weight Management Center. We will study the effects of this weight loss program delivered with or without concurrent supervised exercise training as the catalyst by which remediation of physical and psychosocial impairments promote enhanced recovery. Intentional weight loss in individuals who are obese (non-stroke) has been repeatedly shown to increase functional capacity, reduce risk of cardiovascular event and improve health related quality of life. However, a knowledge gap currently exists related to the efficacy of weight loss strategies for stroke survivors who are obese. Several lines of evidence suggest the potential impact of successful treatment for obesity following stroke, including: a) pathophysiological consequences of obesity, b) epidemiological evidence that obesity increases disability and reduces quality of life following stroke and c) well-established benefits of weight loss in neurologically health individuals. In response, we seek to create an environment suitable for stroke survivors who are obese to participate in and realize the benefits from a comprehensive lifestyle and weight management program. The proposed lifestyle management program incorporates a highly structured dietary caloric restriction intervention, consisting primarily of meal replacements, integrated with education and behavior modification strategies. In addition, the proposed exercise training program has demonstrated efficacy for improving post-stroke functional performance. It is our expectation that results of the proposed pilot trial will catalyze change in post-stroke rehabilitation and recovery care for local stroke survivors who are obese, as well as the ~800,000 stroke survivors/year worldwide, thereby reducing the global burden of post-stroke disability.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Obesity', 'Stroke']}, 'KeywordList': {'Keyword': ['Weight Loss', 'Exercise']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Participants will undergo the intervention within one arm alone.', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '30', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'DIET', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Focus-15 is a 15-week lifestyle change program developed and delivered by the Weight Management Center at the Medical University of South Carolina.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Lifestyle Management Program']}}, {'ArmGroupLabel': 'DIET+Exercise', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'As above with, the addition of supervised exercise. The investigators developed an innovative rehabilitation approach, Post-stroke Optimization of Walking using Explosive Resistance (POWER) training; a high-velocity, high-intensity lower extremity resistance training intervention that improves post-stroke muscular and locomotor function. POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Lifestyle Management Program', 'Other: Post-stroke Optimization of Walking using Explosive Resistance']}}, {'ArmGroupLabel': 'Wait-list Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants will undergo pre-, post- and follow-up testing but will not partake in any intervention during the same timeframe as those listed in the other arms. Participants will have the opportunity to be enrolled in one of the other arms once they have completed the WLC group timeframe.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Lifestyle Management Program', 'InterventionDescription': 'The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DIET', 'DIET+Exercise']}}, {'InterventionType': 'Other', 'InterventionName': 'Post-stroke Optimization of Walking using Explosive Resistance', 'InterventionDescription': 'POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['DIET+Exercise']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Physical Function', 'PrimaryOutcomeDescription': 'Participating in a lifestyle management program (DIET or DIET+Ex) will improve performance on the six-minute walk test (6MWT) compared to those in the waitlist control and DIET groups.', 'PrimaryOutcomeTimeFrame': '15 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Psychosocial Outcomes', 'SecondaryOutcomeDescription': 'Participating in a lifestyle management program (DIET+Ex or DIET) will improve across multiple domains of psychosocial function specific to post-stroke sequelae (vs. WLC + DIET), as indicated by total score on the Stroke Impact Scale (SIS).', 'SecondaryOutcomeTimeFrame': '15 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nage 35-85\\nstroke at least 6-months prior\\nresidual paresis in the lower extremity (Fugl-Meyer LE motor score <34)\\nability to walk without assistance and without an AFO during testing and training at speeds ranging from 0.2-0.8 m/s\\nbody mass index (BMI) greater than 25\\nprovision of informed consent. All subjects who meet criteria for training must complete an exercise tolerance test and be cleared for participation by the study physician.\\n\\nExclusion Criteria:\\n\\nunable to ambulate at least 150 feet prior to stroke, or experienced intermittent claudication while walking\\nhistory of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's\\nhistory of COPD or oxygen dependence\\npreexisting neurological disorders, dementia or previous stroke\\nhistory of major head trauma\\nlegal blindness or severe visual impairment\\nhistory of psychosis or other Axis I disorder that is primary\\nlife expectancy <1 yr\\nsevere arthritis or other problems that limit passive ROM\\nhistory of DVT or pulmonary embolism within 6 months\\nuncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions\\nsevere hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest\\nhistory of seizures or currently prescribed anti-seizure medications\\ncurrent enrollment in a clinical trial to enhance motor recovery\\npersons with child-bearing potential.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '35 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'College of Health Professions', 'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationZip': '29425', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ewan R Williams, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '843-792-3477', 'LocationContactEMail': 'williaew@musc.edu'}, {'LocationContactName': 'Chris Gregory, PhD, PT', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000015431', 'ConditionMeshTerm': 'Weight Loss'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001836', 'ConditionAncestorTerm': 'Body Weight Changes'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17792', 'ConditionBrowseLeafName': 'Weight Loss', 'ConditionBrowseLeafAsFound': 'Weight Loss', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M25876', 'ConditionBrowseLeafName': 'Overweight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4805', 'ConditionBrowseLeafName': 'Body Weight Changes', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 63, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04020666', 'OrgStudyIdInfo': {'OrgStudyId': '2016261'}, 'Organization': {'OrgFullName': 'The Second Hospital of Hebei Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism', 'OfficialTitle': 'Effects of Urinary Kallidinogenase on NIHSS Score, mRS Score, and Fasting Glucose Levels in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism: a Prospective Cohort Study'}, 'StatusModule': {'StatusVerifiedDate': 'December 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 2, 2019', 'StudyFirstSubmitQCDate': 'July 15, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 16, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 15, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 16, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The Second Hospital of Hebei Medical University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Urinary kallidinogenase may assist recovery acute ischemic stroke. This study evaluated the impact of urinary kallidinogenase on NIHSS score, modified Rankin scale (mRS) score and fasting glucose levels in patients with AIS combined with diabetes mellitus and impaired fasting glucose.', 'DetailedDescription': 'Patients with AIS and abnormal glucose metabolism were enrolled in this prospective cohort study and divided into two groups. The HUK group were treated with urinary kallidinogenase and standard treatment, the control group received standard treatment. NIHSS scores, mRS scores and fasting blood glucose were evaluated and compared.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Ischemic Stroke', 'Abnormal Glucose Metabolism']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '113', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'HUK group', 'ArmGroupDescription': 'On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Urinary Kallidinogenase']}}, {'ArmGroupLabel': 'control group', 'ArmGroupDescription': 'The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Urinary Kallidinogenase', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['HUK group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Kai Li Kang']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'NIHSS Score at 90 Days', 'PrimaryOutcomeDescription': 'Comparison of NIHSS score between the control and HUK group at 90 days', 'PrimaryOutcomeTimeFrame': 'at 90 days after admission'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'NIHSS Score at 10 Days、30 Days', 'SecondaryOutcomeDescription': 'Comparison of NIHSS score between the control and HUK group at 10days、30days.', 'SecondaryOutcomeTimeFrame': 'at 10 days, 30 days after admission'}, {'SecondaryOutcomeMeasure': 'Factors related to Non-General Recovery (90-day NIHSS was reduced by <90%)', 'SecondaryOutcomeDescription': 'Based on NIHSS score，multivariate analysis was performed to evaluate the factors related to non-general recovery (90-day NIHSS was reduced by <90%) for all patients.\\n\\nEvaluation of NIHSS score: General recovery was when NIHSS score was reduced by 90%-100%; Non-general recovery referred to when NIHSS score was reduced by <90%.', 'SecondaryOutcomeTimeFrame': 'at 90 days after admission'}, {'SecondaryOutcomeMeasure': 'mRS Score', 'SecondaryOutcomeDescription': 'The mRS score of 10 days after admission was taken as the baseline.Comparison of mRS score between the control and HUK group at 30days、90days.\\n\\nBased on mRS，multivariate analysis was also performed to evaluate the factors related to poor curative effect (90-day mRS ≥3) for all patients.\\n\\nEvaluation of mRS score: mRS score of 0-2 points referred to a good curative effect, and 3-5 points referred to a poor curative effect.', 'SecondaryOutcomeTimeFrame': '10 days, 30 days, and 90 days after admission'}, {'SecondaryOutcomeMeasure': 'fasting glucose levels', 'SecondaryOutcomeDescription': 'Comparison of the change in fasting glucose levels between the control and HUK group at admission and 10days.', 'SecondaryOutcomeTimeFrame': 'at admission and 10 days after admission'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAged 18-75 years (male or female)\\nPatients were admitted to hospital within 72h of stroke onset\\nDiagnosis of acute ischemic stroke according to the criteria stated in the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China (2010), and patients were confirmed as acute ischemic cerebrovascular disease by head computed tomography (CT) or magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI)\\nNIHSS score ranged from 3-21 points\\nPatients were previously diagnosed with type 2 diabetes, in which they were in line with the 2006 WHO diagnostic criteria for diabetes, or they had fasting blood glucose of 6.1-6.9mmol/L and glycosylated hemoglobin (HbA1C) of>6.1%\\nPatients could cooperate with the test and evaluation of relevant indicators in the trial.\\n\\nExclusion criteria:\\n\\nPregnant or lactating women\\nPatients with severe heart, liver and kidney dysfunction\\nPatients with a history of cerebrovascular disease and who still suffered from serious neurological dysfunction that had an influence on the trial\\nPatients with physical disabilities, joint deformities or muscle lesions\\nPatients were confirmed with intracranial hemorrhage by CT\\nPatients were allergic to the study drug\\nPatients suffering from severe systemic infection\\nPatients who had participated in other clinical trials within 1 month\\nFor any reason, the researchers believed that the subject was unlikely to complete the study (such as cerebral infarction caused by cerebral embolism, intracranial arteritis, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and moyamoya disease; patients undergoing thrombolysis or thrombectomy after admission; patients and their families were unable to cooperate with follow-up.)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with AIS combined with diabetes mellitus and impaired fasting glucose who was meets the Inclusion and Exclusion Criteria were enrolled in this prospective cohort study and divided into two groups.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Xiaopeng Wang, MD', 'OverallOfficialAffiliation': 'The Second Hospital of Hebei Medical University', 'OverallOfficialRole': 'Principal Investigator'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000002544', 'ConditionMeshTerm': 'Cerebral Infarction'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000020520', 'ConditionAncestorTerm': 'Brain Infarction'}, {'ConditionAncestorId': 'D000002545', 'ConditionAncestorTerm': 'Brain Ischemia'}, {'ConditionAncestorId': 'D000007238', 'ConditionAncestorTerm': 'Infarction'}, {'ConditionAncestorId': 'D000009336', 'ConditionAncestorTerm': 'Necrosis'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11600', 'ConditionBrowseLeafName': 'Mitral Valve Insufficiency', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5483', 'ConditionBrowseLeafName': 'Cerebral Infarction', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9972', 'ConditionBrowseLeafName': 'Infarction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21995', 'ConditionBrowseLeafName': 'Brain Infarction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5484', 'ConditionBrowseLeafName': 'Brain Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11974', 'ConditionBrowseLeafName': 'Necrosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000007610', 'InterventionMeshTerm': 'Kallikreins'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000003029', 'InterventionAncestorTerm': 'Coagulants'}, {'InterventionAncestorId': 'D000005303', 'InterventionAncestorTerm': 'Fertility Agents, Male'}, {'InterventionAncestorId': 'D000005299', 'InterventionAncestorTerm': 'Fertility Agents'}, {'InterventionAncestorId': 'D000012102', 'InterventionAncestorTerm': 'Reproductive Control Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M10328', 'InterventionBrowseLeafName': 'Kallikreins', 'InterventionBrowseLeafAsFound': 'IFRT', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M5949', 'InterventionBrowseLeafName': 'Coagulants', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Coag', 'InterventionBrowseBranchName': 'Coagulants'}, {'InterventionBrowseBranchAbbrev': 'Repr', 'InterventionBrowseBranchName': 'Reproductive Control Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 64, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05080699', 'OrgStudyIdInfo': {'OrgStudyId': '20-012322'}, 'Organization': {'OrgFullName': 'Mayo Clinic', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluating Benefit of Peptide Based Diet in Obese HEN Patients', 'OfficialTitle': 'Effect of Hypocaloric, High-protein Enteral Formula on Body Weight and Health Outcomes in Obese HEN Patients: A Pilot Study'}, 'StatusModule': {'StatusVerifiedDate': 'May 2023', 'OverallStatus': 'Enrolling by invitation', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 25, 2023', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 4, 2021', 'StudyFirstSubmitQCDate': 'October 4, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 18, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 2, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 3, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Manpreet S. Mundi', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Mayo Clinic'}, 'LeadSponsor': {'LeadSponsorName': 'Mayo Clinic', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to assess the effects of a low energy, high protein tube feeding formula on body weight in tube fed patients who are obese. It will also assess study formula tolerance as well as impact of the study formula on lean body mass, blood pressure, blood sugar and lipids.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Obesity']}, 'KeywordList': {'Keyword': ['Tube feeding', 'Obesity', 'Body mass']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '12', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Peptamen Intense in obese home enteral nutrition patients after stroke', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Peptamen Intense VHP, Nestlé Health Science, Switzerland']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Peptamen Intense VHP, Nestlé Health Science, Switzerland', 'InterventionDescription': 'An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Peptamen Intense in obese home enteral nutrition patients after stroke']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in body weight', 'PrimaryOutcomeDescription': 'Change in body weight, measured in kg', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in lean body mass', 'SecondaryOutcomeDescription': 'Change in lean body mass, measured as the difference between total body weight and body fat weight reported in percentage', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in systolic and diastolic blood pressure', 'SecondaryOutcomeDescription': 'Change in systolic and diastolic blood pressure, measured in mmHg', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in HbA1c', 'SecondaryOutcomeDescription': 'Change in hemoglobin A1c, measured in percentage', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in c-peptide', 'SecondaryOutcomeDescription': 'Change in c-peptide serum levels, measured in ng/mL', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in total cholesterol', 'SecondaryOutcomeDescription': 'Change in total cholesterol, measured in milligrams (mg) of cholesterol per deciliter (dL) of blood.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in HDL', 'SecondaryOutcomeDescription': 'Change in HDL, measured in milligrams (mg) of HDL per deciliter (dL) of blood.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in LDL', 'SecondaryOutcomeDescription': 'Change in LDL, measured in milligrams (mg) of LDL per deciliter (dL) of blood.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in triglycerides', 'SecondaryOutcomeDescription': 'Change in triglycerides, measured in milligrams (mg) of triglycerides per deciliter (dL) of blood.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in percent goal calories provided with enteral nutrition', 'SecondaryOutcomeDescription': 'Change in percent goal calories provided with enteral nutrition , measured percent of calorie provided with enteral nutrition from the estimated goal.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in percent goal proteins provided with enteral nutrition', 'SecondaryOutcomeDescription': 'Change in percent goal proteins provided with enteral nutrition , measured percent of protein provided with enteral nutrition from the estimated goal.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in tube feeding tolerance', 'SecondaryOutcomeDescription': 'Change in tolerance to tube feeding, measured by follow up questionnaire about symptoms of GI intolerance; namely, diarrhea, constipation, abdominal(stomach/tummy/belly) pain or discomfort, nausea and vomiting. The scale used will asses the frequency of these symptoms using the following terms: not at all, rarely, sometimes, often, and very often with not at all being least frequent and very often being most frequent presence of the concerning symptom.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in hand grip strength', 'SecondaryOutcomeDescription': 'Change in hand grip strength, measured by dynamometer.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in diabetes medications', 'SecondaryOutcomeDescription': 'Change in diabetes medications, measured by capturing any change in diabetes medications (when applicable) in terms of new medications added, or discontinuation or change in doses of current medications.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}, {'SecondaryOutcomeMeasure': 'Change in anti-hypertensive medications', 'SecondaryOutcomeDescription': 'Change in hypertension medications, measured by capturing any change in hypertension medications (when applicable) in terms of new medications added, or discontinuation or change in doses of current medications.', 'SecondaryOutcomeTimeFrame': 'Baseline, 12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHome Enteral Nutrition (HEN) patient receiving at least 90% of energy needs from enteral nutrition.\\nBMI > 30.\\nHistory of stroke.\\nWeight stable over the past month.\\n\\nExclusion Criteria:\\n\\nDiagnosis of cancer undergoing active treatment (chemotherapy, radiation, immunotherapy).\\nLife expectancy of less than 6 months.\\nStage IV or higher kidney disease (GFR < 30).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Manpreet Mundi, MD', 'OverallOfficialAffiliation': 'Mayo Clinic', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Mayo Clinic in Rochester', 'LocationCity': 'Rochester', 'LocationState': 'Minnesota', 'LocationZip': '55905', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Mayo Clinic Clinical Trials', 'SeeAlsoLinkURL': 'https://www.mayo.edu/research/clinical-trials'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009765', 'ConditionMeshTerm': 'Obesity'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000050177', 'ConditionAncestorTerm': 'Overweight'}, {'ConditionAncestorId': 'D000044343', 'ConditionAncestorTerm': 'Overnutrition'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafAsFound': 'Obesity', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25876', 'ConditionBrowseLeafName': 'Overweight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24997', 'ConditionBrowseLeafName': 'Overnutrition', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T435', 'InterventionBrowseLeafName': 'Whey Protein', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}]}}}}}, {'Rank': 65, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03913286', 'OrgStudyIdInfo': {'OrgStudyId': '17D.459'}, 'Organization': {'OrgFullName': 'Thomas Jefferson University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Neuromotor Prosthetic to Treat Stroke-Related Paresis', 'OfficialTitle': 'Neuromotor Prosthetic to Treat Stroke-Related Paresis', 'Acronym': 'Cortimo'}, 'StatusModule': {'StatusVerifiedDate': 'March 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 1, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 1, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 7, 2019', 'StudyFirstSubmitQCDate': 'April 11, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 12, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 2, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 17, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Thomas Jefferson University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of the research is to develop a new medical device prototype to restore functional movement of an arm made weak due to a chronic stroke', 'DetailedDescription': 'Microelectrode arrays implanted into the brain will decode signals to drive motors on the powered brace worn on the arm so that the patient can \"power steer\" his or her own arm. The ultimate goal is to create a fully implantable medical device that will restore movement in all parts of the body affected by a stroke. Independent movement will have functional benefits (e.g., being able to lift a fork to eat) and health benefits (e.g., decreasing the frequency of skin infections and preventing the formation of painful joint contractures).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke, Complication', 'Stroke', 'Stroke Sequelae', 'Hemiparesis', 'Arm Paralysis']}, 'KeywordList': {'Keyword': ['neuroprosthetic', 'neuroprosthesis', 'brain-computer', 'brain-machine', 'microelectrode', 'Utah array', 'orthosis', 'brain computer interface', 'assistive device', 'Neurorehabilitation', 'neurotechnology']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Device Feasibility', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The participant will be implanted with the Blackrock Microsystems MultiPort system.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Cortimo']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Cortimo', 'InterventionDescription': 'The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MyoPro powered orthotic brace', 'Blackrock Microsystems MultiPort']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from Baseline Fugl-Meyer Motor Impairment Score at 4 months', 'PrimaryOutcomeDescription': 'The Fugl-Meyer assessment (FMA) is a stroke specific index for estimating the performance of motor function. Total scores of FMA-Upper limb range from 0-66.\\n\\nFrom: Fugl-Meyer et al. The post-stroke hemiplegic patient: a method for evaluation of physical performance. Scand. J. Rehabil. Med., 1975.', 'PrimaryOutcomeTimeFrame': '4 months'}, {'PrimaryOutcomeMeasure': 'Change from Baseline Action Research Arm Test (ARAT) score at 4 months', 'PrimaryOutcomeDescription': 'The Action Research Arm Test (ARAT) measures specific changes in the arm function in people who sustained cerebral damage resulting in arm weakness. The ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch and gross movements. Each sub scale has items ordered according to ascending difficulty: 0- can not perform any part of the test, 1- performs the test partially, 2- completes the test, but takes abnormally long time, 3- performs the test normally. The sum of all subscales are added to compute the total score. The total score ranges between 0 to 57. The higher score is considered to be better outcome.\\n\\nFrom: Yozbatiran et al. A standardized approach to performing the action research arm test. Neurorehabil. Neural Repair, 2008.', 'PrimaryOutcomeTimeFrame': '4 months'}, {'PrimaryOutcomeMeasure': 'Change from Baseline Motricity Index score at 4 months', 'PrimaryOutcomeDescription': 'The Motricity Index measures strength in the arms and legs after stroke. The weighted score is based on the ordinal 6 point scale of Medical Research Council to measure maximal isometric muscle strength.\\n\\nFrom: Collin and Wade. Assessing motor impairment after stroke: A pilot reliability study. J. Neurol. Neurosurg. Psychiatry, 1990.', 'PrimaryOutcomeTimeFrame': '4 months'}, {'PrimaryOutcomeMeasure': 'Change from Baseline ADL, Hand and Recovery Scales within Stroke Impact Scale, at 4 months', 'PrimaryOutcomeDescription': \"The Stroke Impact Scales assess how having a stroke impacts a person's life. The scale has 8 subscales which ask questions regarding a person's physical limitations, memory and thinking, emotions and mood, ability to communicate, daily activities, mobility at home and in the community, use of hand most affected by stroke, and ability to participate in meaningful life activities. Each subscale item is rated on a scale from 5-1 (5= None of the time, 4=a little of the time, 3=Some of the time, 2=Most of the time, 1=All of the time). ADL = activities of daily living.\\n\\nFrom: Duncan et al. The Stroke Impact Scale Version 2.0 : Evaluation of Reliability, Validity, and Sensitivity to Change. Stroke, 1999.\", 'PrimaryOutcomeTimeFrame': '4 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from Baseline Braden skin health score at 4 months', 'SecondaryOutcomeDescription': 'The Braden scale predicts pressure sore risk. The Braden score consists of 6 categories: sensory perception, moisture, activity, mobility, nutrition and friction. The score ranges from 6-23 with lower scores indicating a higher risk.\\n\\nFrom: Bergstrom et al. The Braden Scale for Predicting Pressure Sore Risk. Nurs. Res. 36(4): 205-210. 1987.', 'SecondaryOutcomeTimeFrame': '4 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMust be 18 years or older.\\nClinical diagnosis of stroke (hemorrhagic or ischemic, cortical or subcortical), confirmed by brain computer tomography or magnetic resonance imaging, that occurred six or more months prior to enrollment\\nMust have arm weakness due to stroke.\\nParticipant is willing to comply with all follow-up evaluations at the specified times.\\nParticipant is able to provide informed consent prior to enrollment in the study.\\nThe participant is fluent in English.\\n> 24 on the Mini Mental Status Examination\\nMedically stable.\\nPassive flexion of shoulder in weakened upper extremity with range of > 30 degrees or more\\nPassive abduction of shoulder in weakened upper extremity with range of > 20 degrees or more\\nParticipant must have a caregiver willing to participate in the study who will help provide care for the surgical site.\\nMust be willing to live at hospital or at nearby hotel for 90-day duration when implantable components were present.\\n\\nPlateaued post-stroke recovery with complete or incomplete hemiplegia due to stroke in one upper limb, as measured on two serial occasions (at least one month apart) without improvement, by the following standardized functional assessments of the weaker upper extremity, at their worst:\\n\\nManual Muscle Testing scores of 0/5 (no movement) or 1/5 (palpable contraction in muscle, without movement) in the biceps (elbow flexion), triceps (elbow extension), wrist flexors, wrist extensors or intrinsic hand muscles\\nMild to plegia according to Medical Research Council Scale for Muscle Strength\\nFugl-Meyer Motor Impairment Score of 38 or lower\\nAction Research Arm Test (ARAT) score of 35 or lower\\nMotricity Index score of 55 or lower\\nNo joint contracture or severe spasticity in affected upper limb precluding the operation of the MyoPro orthotic device.\\nSufficient sitting balance to participate with robotic brace activities.\\nNo condition (e.g., severe arthritis, central pain) that would interfere with administration of motor function tests, ability to understand verbal commands and cooperate with test procedures.\\n\\nExclusion Criteria:\\n\\nNo medical condition requiring active anti-coagulation with a medication such as heparin, warfarin or rivaroxaban (note that anti-platelet agents such as aspirin or clopidogrel are acceptable)\\nNo active wound healing or skin breakdown issues.\\nNo history of poorly controlled autonomic dysreflexia.\\nVisual impairment such that extended viewing of a computer monitor would be challenging even with ordinary corrective lenses\\nChronic oral or intravenous steroids or immunosuppressive therapy\\nA score of 23 or lower on Folstein's Mini-Mental Status Examination\\nOrthopedic conditions of either arm that would affect performance on study\\nUntreated psychiatric disturbances that would affect motivation and trial participation\\nMedical contraindications for general anesthesia, craniotomy, or surgery.\\nDiagnosis of acute myocardial infarction or cardiac arrest within previous 6 months.\\nDementia\\nOther implantable devices such as heart/brain pacemakers\\nParticipants who rely on ventilators\\n\\nCo-morbid conditions that would interfere with study activities or response to treatment, which may include:\\n\\nLife expectancy < 3 years\\nSevere chronic pulmonary disease\\nSeizure within three months prior to enrollment\\nHistory of uncontrolled seizures\\nLocal, systemic acute or chronic infectious illness\\nLife threatening cardiac arrhythmias\\nSevere collagen vascular disorder\\nKidney failure or other major organ system failures History of a neurological ablation procedure.\\nLabeled contraindication for MRI.\\nHistory of HIV infection or ongoing chronic infection (such as tuberculosis).\\nPregnant or of child-bearing potential and are not taking acceptable methods of contraception.\\nParticipation in another investigational device or medication trial\\nExcessive pain in the paretic upper extremity (> 5 on a 10-point visual analog scale)\\nExcessive spasticity at the paretic elbow, wrist, or digits as defined as a score of > 2 on the Modified Ashworth Spasticity Scale\\nParticipating in any experimental rehabilitation or drug studies\\nModerate to severe apraxia (< 2.5 on the Alexander scale)\\nReceived phenol injections to any portion of the paretic upper extremity within the past 12 months\\nOther conditions or circumstances that, in the opinion of the investigators, would preclude safe and/or effective participation, including severe skin conditions, and/or other sequelae that may be contraindicated for arm orthosis use as well as personal circumstance\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mijail Serruya, MD, PhD', 'OverallOfficialAffiliation': 'Dr.', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Thomas Jefferson University', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19107', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'The individual participant data are available. The individual participant data comprises those that underlie the results reported in the first article describing outcome measures after deidentification. Other documents available are the Study Protocol and the Analytic Code.', 'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol', 'Analytic Code']}, 'IPDSharingTimeFrame': 'The data will be available beginning 3 months and ending 5 years following publication of the first manuscript summarizing outcome measure results.', 'IPDSharingAccessCriteria': 'The data is available to researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to Mijail.Serruya@jefferson.edu . To gain access, data requestors will need to sign a data access agreement. Data will be available for 5 years at a third-party website:', 'IPDSharingURL': 'https://doi.org/10.5281/zenodo.5885015'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000010243', 'ConditionMeshTerm': 'Paralysis'}, {'ConditionMeshId': 'D000010291', 'ConditionMeshTerm': 'Paresis'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12894', 'ConditionBrowseLeafName': 'Paresis', 'ConditionBrowseLeafAsFound': 'Paresis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20634', 'ConditionBrowseLeafName': 'Muscle Weakness', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12847', 'ConditionBrowseLeafName': 'Paralysis', 'ConditionBrowseLeafAsFound': 'Paralysis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}]}}}}}, {'Rank': 66, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00681434', 'OrgStudyIdInfo': {'OrgStudyId': '2006-0234'}, 'Organization': {'OrgFullName': 'University of Illinois at Chicago', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Bilateral Training Versus Unilateral Training in Stroke', 'OfficialTitle': 'Bilateral Training for Upper Extremity Hemiparesis in Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'August 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2007', 'PrimaryCompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 19, 2008', 'StudyFirstSubmitQCDate': 'May 19, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 21, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 1, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 4, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyOldNameTitle': 'Daniel M. Corcos, PhD', 'ResponsiblePartyOldOrganization': 'University of Illinois at Chicago'}, 'LeadSponsor': {'LeadSponsorName': 'University of Illinois at Chicago', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Shirley Ryan AbilityLab', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'This randomized, single-blind study compares the effectiveness of bilateral training to unilateral training for individuals with moderate hemiparesis. We hypothesize that bilateral training will be superior to unilateral in the proximal extremity but not the distal one.', 'DetailedDescription': 'Upper extremity hemiparesis is the most common post-stroke disability. Longitudinal studies have indicated that 30 to 66 percent of stroke survivors do not have full arm function six months post-stroke. Bilateral arm training has been investigated as a potential rehabilitation intervention for individuals not eligible for constraint induced movement therapy.\\n\\nThis training study included 24 hours of treatment over eight weeks. The protocol consisted of reaching activities with rhythmic auditory cueing emphasizing the proximal arm. Subjects assigned to the bilateral group performed bilateral symmetrical activities while subjects in the unilateral group performed the same activity with the affected arm only. The Motor Assessment Scale-Upper Limb Item and the Motor Status Scale are used as primary outcome measures. The Reaching Performance Scale and strength measures are secondary outcome measures. Assessments are administered pre-/ and post-training by a blind rater.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Hemiparesis']}, 'KeywordList': {'Keyword': ['stroke', 'upper extremity', 'hemiparesis']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'bilateral training', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: bilateral upper extremity training']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Unilateral training', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Unilateral upper extremity training']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'bilateral upper extremity training', 'InterventionDescription': 'Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Unilateral upper extremity training', 'InterventionDescription': 'Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Motor Assessment Scale', 'PrimaryOutcomeTimeFrame': 'pre and post (week one and week 8)'}, {'PrimaryOutcomeMeasure': 'Motor Status Scale', 'PrimaryOutcomeTimeFrame': 'pre and post, Week 0 and Week eight'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Reaching Performance Scale', 'SecondaryOutcomeTimeFrame': 'pre and post training (Week 0 and week 8)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\ncortical or subcortical stroke\\nchronic condition (at least six months prior)\\nability to follow 2-step commands\\nability to give consent\\n\\nExclusion Criteria:\\n\\nlesion in brain stem or cerebellum\\nvisual field cut\\nneglect\\nuncontrolled hypertension\\nangina\\nCOPD', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mary E Stoykov, PhD', 'OverallOfficialAffiliation': 'University of Illinois at Chicago Department of Kinesiology and Nutrition', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Daniel M Corcos, PhD', 'OverallOfficialAffiliation': 'University of Illinois at Chicago Department of Kinesiology and Nutrition', 'OverallOfficialRole': 'Study Chair'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19531608', 'ReferenceType': 'result', 'ReferenceCitation': 'Stoykov ME, Lewis GN, Corcos DM. Comparison of bilateral and unilateral training for upper extremity hemiparesis in stroke. Neurorehabil Neural Repair. 2009 Nov;23(9):945-53. doi: 10.1177/1545968309338190. Epub 2009 Jun 16.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000010291', 'ConditionMeshTerm': 'Paresis'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12894', 'ConditionBrowseLeafName': 'Paresis', 'ConditionBrowseLeafAsFound': 'Hemiparesis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20634', 'ConditionBrowseLeafName': 'Muscle Weakness', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}]}}}}}, {'Rank': 67, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00342654', 'OrgStudyIdInfo': {'OrgStudyId': '999999031'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'OH99-C-N031'}]}, 'Organization': {'OrgFullName': 'National Institutes of Health Clinical Center (CC)', 'OrgClass': 'NIH'}, 'BriefTitle': 'Nutrition Intervention Trials in Linxian Follow-up Study', 'OfficialTitle': 'Nutritional Intervention Trials in Linxian China- Continued Follow-up'}, 'StatusModule': {'StatusVerifiedDate': 'April 10, 2023', 'OverallStatus': 'Enrolling by invitation', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 20, 1999', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 1, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 1, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 19, 2006', 'StudyFirstSubmitQCDate': 'June 19, 2006', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 21, 2006', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 16, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 17, 2023', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'National Cancer Institute (NCI)', 'LeadSponsorClass': 'NIH'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Two large, nutritional intervention trials were conducted in Linxian, China between 1985-1991. These trials tested the effect of multiple vitamins and minerals in the prevention of esophageal cancer in a population with the highest known rate for this disease in the world. Results from the trials showed that Beta-carotene + Vitamin E + selenium reduced total mortality, total cancer mortality, and stomach cancer incidence and mortality. Multivitamins/minerals also showed reduction in premalignant lesions. Preliminary follow-up data obtained for the time period after cessation of intervention in 1991 suggests that the observed benefit for total and cancer mortality is reduced but that the benefit for stomach cancer remains.\\n\\nThe objectives of the follow-up study are: (1) to continue to determine cancer incidence and all causes of mortality in trial participants after intervention to permit examination of potential effects of the interventions on total and cause-specific mortality and cancer incidence in the post-intervention period; (2) to conduct a cross-sectional nutritional survey in a subsample of living trial participants to evaluate their nutritional status, asses the validity of dietary questionnaires, and relate neurologic status to vitamin B12 plasma levels; (3) to collect a blood sample from all living trial participants to permit further etiologic investigations of genetic and environmental hypotheses; and (4) to perform nested case-control studies of selected genetic and environmental hypotheses.\\n\\nTo accomplish the objectives of the follow-up study, we will: (1) determine updated vital status and cancer status data on all trial participants via monthly checks of village doctor records and quarterly checks of the Linxian Cancer Registry; conduct a Vital/Cancer Status Interview Survey among all (n-34,000 trial participants (or their surrogates); identify, collect, and store all available diagnostic materials for trial participants identified as having developed cancer or died with cancer during the follow-up period; (2) conduct a Nutritional Survey on a subsample (n-1000) of living trial participants that will include (a) a physical exam and brief medical history, (b) a neurologic history, (c) a cognitive function exam, (d) a hair/mouth skin exam, (e) a neurological exam, (f) a nutritional questionnaire, and (g) collection of a blood sample for hematologic/biochemical analyses; (3) conduct a Blood Collection Survey of all living trial participants (n-23,000) to obtain (a) a physical exam and brief medical history and (b) a single 10-ml blood sample for separation and preservation as WBCs (both viable and nonviable), RBCs, and plasma for genetic (e.g., xenobiotic polymorphisms) and environmental (e.g., plasma ascorbic acid) hypothesis testing; and (4) perform Nested Case-Control Studies of selected genetic and environmental hypothesis related to the etiology and prevention of esophageal cancer and stroke. These will be done using serum from the new cancer and stroke cases (-2500) and controls (-2500) previously identified from 1991-1996, as well as using new cancer and stroke cases and controls for the period 1996-2004 (-9000).\\n\\nThe followup for endpoints will continue monthly for an additional 5 years (through the year 2003). The Nutritional Survey and Blood Collection Survey will be conducted in the spring of 1999. The Nested Case-Control studies will be performed annually beginning in 2000, and the Vital/Cancer Interview Survey will be conducted in the Spring of 2001....', 'DetailedDescription': 'Two large, nutritional intervention trials were conducted in Linxian, China between 1985-1991. These trials tested the effect of multiple vitamins and minerals in the prevention of esophageal cancer in a population with the highest known rate for this disease in the world. Results from the trials showed that Beta-carotene + Vitamin E + selenium reduced total mortality, total cancer mortality, and stomach cancer incidence and mortality. Multivitamins/minerals also showed reduction in premalignant lesions. Preliminary follow-up data obtained for the time period after cessation of intervention in 1991 suggests that the observed benefit for total and cancer mortality is reduced but that the benefit for stomach cancer remains.\\n\\nThe objectives of the follow-up study are: (1) to continue to determine cancer incidence and all causes of mortality in trial participants after intervention to permit examination of potential effects of the interventions on total and cause-specific mortality and cancer incidence in the post-intervention period; (2) to conduct a cross-sectional nutritional survey in a subsample of living trial participants to evaluate their nutritional status, asses the validity of dietary questionnaires, and relate neurologic status to vitamin B12 plasma levels; (3) to collect a blood sample from all living trial participants to permit further etiologic investigations of genetic and environmental hypotheses; and (4) to perform nested case-control studies of selected genetic and environmental hypotheses.\\n\\nTo accomplish the objectives of the follow-up study, we will: (1) determine updated vital status and cancer status data on all trial participants via monthly checks of village doctor records and quarterly checks of the Linxian Cancer Registry; conduct a Vital/Cancer Status Interview Survey among all (n approximately 34,000 trial participants (or their surrogates); identify, collect, and store all available diagnostic materials for trial participants identified as having developed cancer or died with cancer during the follow-up period; (2) conduct a Nutritional Survey on a subsample (n approximately 1000) of living trial participants that will include (a) a physical exam and brief medical history, (b) a neurologic history, (c) a cognitive function exam, (d) a hair/mouth skin exam, (e) a neurological exam, (f) a nutritional questionnaire, and (g) collection of a blood sample for hematologic/ biochemical analyses; (3) conduct a Blood Collection Survey of all living trial participants (n approximately 23,000) to obtain (a) a physical exam and brief medical history and (b) a single 10-ml blood sample for separation and preservation as WBCs (both viable and nonviable), RBCs, and plasma for genetic (e.g., xenobiotic polymorphisms) and environmental (e.g., plasma ascorbic acid) hypothesis testing; and (4) perform Nested Case-Control Studies of selected genetic and environmental hypothesis related to the etiology and prevention of esophageal cancer and stroke. These will be done using serum from the new cancer and stroke cases (approximately 2500) and controls (approximately 2500) previously identified from 1991-1996, as well as using new cancer and stroke cases and controls for the period 1996-2004 (approximately 9000).\\n\\nThe followup for endpoints will continue monthly for an additional 5 years (through the year 2003). The Nutritional Survey and Blood Collection Survey will be conducted in the spring of 1999. The Nested Case-Control studies will be performed annually beginning in 2000, and the Vital/Cancer Interview Survey will be conducted in the Spring of 2001.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Esophageal Cancer', 'Gastric Cancer']}, 'KeywordList': {'Keyword': ['Epidemiology', 'Cancer', 'Environment', 'Genetics', 'Nutrition', 'Natural History']}}, 'DesignModule': {'StudyType': 'Observational', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Other']}}, 'EnrollmentInfo': {'EnrollmentCount': '34000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupDescription': 'Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Determine cancer incidence and all causes of mortality in trial participants in the post-intervention period and conduct studies ofselected genetic and environmental hypotheses related to the etiology and prevention of esophageal cancer and s...', 'PrimaryOutcomeDescription': 'analysis is ongoing', 'PrimaryOutcomeTimeFrame': 'Ongoing'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'No eligibility criteria listed.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '100 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991. These trials tested the effect of multiple vitamins and minerals in the prevention of esophageal cancer in a population with the highest known rate for this disease in the world.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Christian Abnet, Ph.D.', 'OverallOfficialAffiliation': 'National Cancer Institute (NCI)', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'LocationCity': 'Beijing', 'LocationCountry': 'China'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25845708', 'ReferenceType': 'background', 'ReferenceCitation': 'Murphy G, Freedman ND, Michel A, Fan JH, Taylor PR, Pawlita M, Qiao YL, Zhang H, Yu K, Abnet CC, Dawsey SM. Prospective study of Helicobacter pylori antigens and gastric noncardia cancer risk in the nutrition intervention trial cohort. Int J Cancer. 2015 Oct 15;137(8):1938-46. doi: 10.1002/ijc.29543. Epub 2015 May 5.'}, {'ReferencePMID': '20729852', 'ReferenceType': 'background', 'ReferenceCitation': 'Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, Lee MP, Ding T, Qiao YL, Gao YT, Koh WP, Xiang YB, Tang ZZ, Fan JH, Wang C, Wheeler W, Gail MH, Yeager M, Yuenger J, Hutchinson A, Jacobs KB, Giffen CA, Burdett L, Fraumeni JF Jr, Tucker MA, Chow WH, Goldstein AM, Chanock SJ, Taylor PR. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 2010 Sep;42(9):764-7. doi: 10.1038/ng.649. Epub 2010 Aug 22.'}, {'ReferencePMID': '19318634', 'ReferenceType': 'background', 'ReferenceCitation': 'Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, Johnson LL, Gail MH, Dong ZW, Yu B, Mark SD, Taylor PR. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst. 2009 Apr 1;101(7):507-18. doi: 10.1093/jnci/djp037. Epub 2009 Mar 24. Erratum In: J Natl Cancer Inst. 2010 Jan 20;102(2):140.'}, {'ReferencePMID': '29691288', 'ReferenceType': 'derived', 'ReferenceCitation': 'Fan JH, Wang JB, Wang SM, Abnet CC, Qiao YL, Taylor PR. Longitudinal change in blood pressure is associated with cardiovascular disease mortality in a Chinese cohort. Heart. 2018 Nov;104(21):1764-1771. doi: 10.1136/heartjnl-2017-312850. Epub 2018 Apr 24.'}, {'ReferencePMID': '29617851', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wang SM, Taylor PR, Fan JH, Pfeiffer RM, Gail MH, Liang H, Murphy GA, Dawsey SM, Qiao YL, Abnet CC. Effects of Nutrition Intervention on Total and Cancer Mortality: 25-Year Post-trial Follow-up of the 5.25-Year Linxian Nutrition Intervention Trial. J Natl Cancer Inst. 2018 Nov 1;110(11):1229-1238. doi: 10.1093/jnci/djy043.'}, {'ReferencePMID': '28594442', 'ReferenceType': 'derived', 'ReferenceCitation': 'Fan JH, Wang JB, Wang SM, Abnet CC, Qiao YL, Taylor PR. Body mass index and risk of gastric cancer: A 30-year follow-up study in the Linxian general population trial cohort. Cancer Sci. 2017 Aug;108(8):1667-1672. doi: 10.1111/cas.13292. Epub 2017 Jun 30.'}, {'ReferencePMID': '25613115', 'ReferenceType': 'derived', 'ReferenceCitation': 'Chen W, Wang JB, Abnet CC, Dawsey SM, Fan JH, Yin LY, Yin J, Taylor PR, Qiao YL, Freedman ND. Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):386-92. doi: 10.1158/1055-9965.EPI-14-1038. Epub 2015 Jan 22.'}, {'ReferencePMID': '23712839', 'ReferenceType': 'derived', 'ReferenceCitation': 'Wang JB, Abnet CC, Fan JH, Qiao YL, Taylor PR. The randomized Linxian Dysplasia Nutrition Intervention Trial after 26 years of follow-up: no effect of multivitamin supplementation on mortality. JAMA Intern Med. 2013 Jul 8;173(13):1259-61. doi: 10.1001/jamainternmed.2013.6066. No abstract available.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023', 'RemovedCountryList': {'RemovedCountry': ['United States']}}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M15754', 'ConditionBrowseLeafName': 'Stomach Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7778', 'ConditionBrowseLeafName': 'Esophageal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5486', 'ConditionBrowseLeafName': 'Stomach Cancer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2141', 'ConditionBrowseLeafName': 'Esophageal Cancer', 'ConditionBrowseLeafAsFound': 'Esophageal Cancer', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 68, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05505201', 'OrgStudyIdInfo': {'OrgStudyId': '2022-TDU-TIPF-0004'}, 'Organization': {'OrgFullName': 'Izmir Katip Celebi University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effectiveness of Transcranial Magnetic Stimulation in Subacute Stroke Patients With Severe Upper Limb Paresis', 'OfficialTitle': 'Effectiveness of Add-on Inhibitory Repetitive Transcranial Magnetic Stimulation Over the Contralesional Primary Motor Cortex in Subacute Stroke Patients With Severe Upper Limb Motor Impairment'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 11, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2025', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2025', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 11, 2022', 'StudyFirstSubmitQCDate': 'August 16, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 17, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 14, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 15, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'ilker şengül', 'ResponsiblePartyInvestigatorTitle': 'Principal investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Izmir Katip Celebi University'}, 'LeadSponsor': {'LeadSponsorName': 'Izmir Katip Celebi University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'There has been A-level evidence for the effectiveness of inhibitory rTMS of the contralesional M1 hand region in stroke patients in the acute stage. However, it has been reported to be ineffective in the chronic stage. In addition, it has been reported that the patient group benefiting from rTMS is mostly those with moderate to mild motor impairment. In contrast, a recent randomized controlled study has reported that ipsilesional excitatory rTMS or contra-lesional inhibitory rTMS may also have positive effects in stroke patients with severe upper limb motor impairment. The aim of this study is to investigate the effect of inhibitory repetitive transcranial magnetic stimulation applied to the contralesional primary motor cortex, by using the rTMS parameters specified in the current recommendation guide, on motor function, activities of daily living, and quality of life in subacute stroke patients with severe upper limb motor impairment.', 'DetailedDescription': 'The level of stroke-related upper limb motor impairment varies widely among individuals, from mild to severe. Because of this heterogeneity, rehabilitation interventions are tailored individually. In recent years, many studies have been published on the effectiveness of add-on non-invasive neuromodulation methods such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation in the treatment of stroke-related upper limb motor impairment. There has been A-level evidence for the effectiveness of inhibitory rTMS of the contralesional M1 hand region in stroke patients in the acute stage. However, it has been reported to be ineffective in the chronic stage. In addition, it has been reported that the patient group benefiting from rTMS is mostly those with moderate to mild motor impairment. It has been reported that contra-lesional hemisphere inactivation impairs paretic upper extremity performance in severely infarcted animals. In humans, contra-lesional hemisphere inactivation has been reported to slow down the reaction time. In contrast, a recent randomized controlled study has reported that ipsilesional excitatory rTMS or contralesional inhibitory rTMS may have positive effects in stroke patients with severe upper limb motor impairment. However, the literature on rTMS in post-stroke rehabilitation is highly heterogeneous in terms of frequency, session duration, location, patient characteristics, and outcome scales, and this ambiguity makes it difficult to adapt rTMS to the clinical practice. In this regard, future studies are needed to determine whether rTMS provides an additional benefit to traditional/task-specific rehabilitation approaches in stroke patients with severe upper limb paresis. The aim of this study is to investigate the effect of inhibitory repetitive transcranial magnetic stimulation applied to the contralesional primary motor cortex, by using the rTMS parameters specified in the current recommendation guide, on motor function, activities of daily living, and quality of life in subacute stroke patients with severe upper limb motor impairment.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke Rehabilitation']}, 'KeywordList': {'Keyword': ['Stroke', 'Upper limb impairment', 'Repetitive transcranial magnetic stimulation']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Active stimulation group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Fifteen sessions of inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. 120% of the resting motor threshold will be used in the stimulation. One session of stimulation will last for a total of 30 minutes and a total of 1800 pulses in the form of 1 Hz stimulation.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Repetitive transcranial magnetic stimulation']}}, {'ArmGroupLabel': 'Sham stimulation group', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Fifteen sessions of sham repetitive transcranial magnetic stimulation (rTMS) treatment will be applied to the contralesional primary motor cortex (hand region). The application will be performed with Neurosoft-Neuro MS / D device. The probe of the device will be held in an upright position and stimulation will be performed at the 10% of the resting motor threshold.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Sham Repetitive transcranial magnetic stimulation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Repetitive transcranial magnetic stimulation', 'InterventionDescription': 'Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Active stimulation group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Neuro Soft']}}, {'InterventionType': 'Device', 'InterventionName': 'Sham Repetitive transcranial magnetic stimulation', 'InterventionDescription': 'Sham Repetitive transcranial magnetic stimulation', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sham stimulation group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline in the Fugl-Meyer Assessment for Upper Extremity', 'PrimaryOutcomeDescription': 'The Fugl-Meyer Assessment for upper extremity (FMA-UE) is a widely used scale for motor recovery of the upper limb after stroke. FMA-UE comprises four domains (shoulder-arm, wrist, hand, and coordination-speed) developed to measure the severity of motor impairment from synergy to isolated voluntary movement. Scoring is based on direct observation of performance. Each item is scored on a three-point ordinal scale between 0 and 2 (0=cannot perform; 1=partially performs; 2=performs fully) according to performance. The score for an individual range between 0 and 66. The higher the score, the lower the motor impairment.', 'PrimaryOutcomeTimeFrame': '(1) Baseline, (2) At the end of the last session of the intervention (immediately after the 15th session, each session is 1 day), and (3) 4 weeks after the last session of the intervention)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from baseline in the Modified Barthel Index for Activities of Daily Living', 'SecondaryOutcomeDescription': \"The Modified Barthel Index assesses the activity of daily living based on performance. It comprises 10 domains, including nutrition, dressing, self-care, toilet use, bladder care, bowel care, transfer, mobility, climbing stairs, and bathing. Scoring is performed over 100 points. The level of independence is determined by the level of the patient's need for physical or verbal help. High scores mean that the level of independence is higher. The patient is allowed to use assistive devices.\", 'SecondaryOutcomeTimeFrame': '(1) Baseline, (2) At the end of the last session of the intervention (immediately after the 15th session, each session is 1 day), and (3) 4 weeks after the last session of the intervention)'}, {'SecondaryOutcomeMeasure': 'Change from baseline in the Stroke-Specific Quality of Life Scale', 'SecondaryOutcomeDescription': 'The stroke-Specific Quality of Life Scale assesses the quality of life in stroke patients. It consists of 12 domains and 49 items: mobility, energy, upper extremity function, work/productivity, mood, self-care, social role, family role, vision, language, thinking, and personality. Each item is evaluated on a 5-point Likert scale. The total score ranges from 49 to 245. Higher scores show a better quality of life.', 'SecondaryOutcomeTimeFrame': '(1) Baseline, (2) At the end of the last session of the intervention (immediately after the 15th session, each session is 1 day), and (3) 4 weeks after the last session of the intervention)'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Change from baseline in the Modified Ashworth Scale', 'OtherOutcomeDescription': 'The Modified Ashworth Scale is a scale that clinically evaluates the presence and severity of muscle tone increase. It is an ordinal scale that evaluates spasticity at six levels between 0 and 4 (0, 1, 1+, 2, 3, 4). The severity of spasticity increases as the score increases. Score 0 indicates no increase in muscle tone, while score 4 indicates that the affected part is rigid. Six levels between 0 and 5 (0, 1, 2, 3, 4, 5) will be used in statistical analysis. The score of 1+ will be treated as 2, 2 as 3, 3 as 4 and 4 as 5.', 'OtherOutcomeTimeFrame': '(1) Baseline, (2) At the end of the last session of the intervention (immediately after the 15th session, each session is 1 day), and (3) 4 weeks after the last session of the intervention)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPresence of subcortical ischemic stroke affecting the middle cerebral artery territory, which has been confirmed by imaging methods\\nHaving a stroke for the first time\\nPresence of subacute stroke (< 6 months)\\nMini-mental test score ≥ 24\\nSevere upper limb motor impairment (The Fugl-Meyer Assessment Scale - Upper Extremity motor impairment score ≤ 19/60, excluding reflex assessments)\\nLack of motor evoked potential (MEP) recording from the first dorsal interosseous muscle of the paretic extremity with single-pulse transcranial magnetic stimulation of the ipsilesional primary motor cortex (hand region)\\n\\nExclusion Criteria:\\n\\nTo have a clinical condition (metallic implant, cardiac pace, pregnancy, breastfeeding, claustrophobia, epilepsy, head trauma, cranial operation history) that will constitute a contraindication to transcranial magnetic stimulation\\nHistory of psychiatric illness such as major depression/personality disorder\\nHistory of convulsion or epilepsy or taking medication for epilepsy\\nCognitive impairment\\nPregnancy or breastfeeding\\nAlcohol or drug addiction\\nPreviously treated with transcranial magnetic stimulation\\nModerate or mild upper extremity motor impairment (The Fugl-Meyer Assessment Scale - Upper Extremity score > 19/60, excluding reflex assessments)\\nPresence of neglect', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'İlker Şengül, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0905337333698', 'CentralContactEMail': 'ilkrsngl@gmail.com'}, {'CentralContactName': 'Nazrin Aghazade, M.D.', 'CentralContactRole': 'Contact'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'İlker Şengül, M.D.', 'OverallOfficialAffiliation': 'İzmir Katip çelebi University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'İlker Şengül', 'LocationStatus': 'Recruiting', 'LocationCity': 'İzmir', 'LocationZip': '35360', 'LocationCountry': 'Turkey', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'İlker Şengül, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '05337333698', 'LocationContactEMail': 'ilkrsngl@gmail.com'}, {'LocationContactName': 'M.D.', 'LocationContactRole': 'Contact'}, {'LocationContactName': 'İlker Şengül, M.D.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Nazrin Aghazade, M.D.', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '16890483', 'ReferenceType': 'background', 'ReferenceCitation': 'Fitzgerald PB, Fountain S, Daskalakis ZJ. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clin Neurophysiol. 2006 Dec;117(12):2584-96. doi: 10.1016/j.clinph.2006.06.712. Epub 2006 Aug 4.'}, {'ReferencePMID': '31901449', 'ReferenceType': 'background', 'ReferenceCitation': 'Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020 Feb;131(2):474-528. doi: 10.1016/j.clinph.2019.11.002. Epub 2020 Jan 1. Erratum In: Clin Neurophysiol. 2020 May;131(5):1168-1169.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Ko MH, Jeong YC, Seo JH, Kim YH. The after-effect of sub-threshold 10 Hz repetitive transcranial magnetic stimulation on motor cortical excitability. J Korean Acad Rehabil Med 2006;30:436-40.'}, {'ReferencePMID': '22238412', 'ReferenceType': 'background', 'ReferenceCitation': 'Avenanti A, Coccia M, Ladavas E, Provinciali L, Ceravolo MG. Low-frequency rTMS promotes use-dependent motor plasticity in chronic stroke: a randomized trial. Neurology. 2012 Jan 24;78(4):256-64. doi: 10.1212/WNL.0b013e3182436558. Epub 2012 Jan 11.'}, {'ReferencePMID': '19780802', 'ReferenceType': 'background', 'ReferenceCitation': 'Khedr EM, Abdel-Fadeil MR, Farghali A, Qaid M. Role of 1 and 3 Hz repetitive transcranial magnetic stimulation on motor function recovery after acute ischaemic stroke. Eur J Neurol. 2009 Dec;16(12):1323-30. doi: 10.1111/j.1468-1331.2009.02746.x. Epub 2009 Sep 23.'}, {'ReferencePMID': '15911819', 'ReferenceType': 'background', 'ReferenceCitation': 'Mansur CG, Fregni F, Boggio PS, Riberto M, Gallucci-Neto J, Santos CM, Wagner T, Rigonatti SP, Marcolin MA, Pascual-Leone A. A sham stimulation-controlled trial of rTMS of the unaffected hemisphere in stroke patients. Neurology. 2005 May 24;64(10):1802-4. doi: 10.1212/01.WNL.0000161839.38079.92.'}, {'ReferencePMID': '18541794', 'ReferenceType': 'background', 'ReferenceCitation': 'Nowak DA, Grefkes C, Dafotakis M, Eickhoff S, Kust J, Karbe H, Fink GR. Effects of low-frequency repetitive transcranial magnetic stimulation of the contralesional primary motor cortex on movement kinematics and neural activity in subcortical stroke. Arch Neurol. 2008 Jun;65(6):741-7. doi: 10.1001/archneur.65.6.741.'}, {'ReferencePMID': '15787705', 'ReferenceType': 'background', 'ReferenceCitation': 'Biernaskie J, Szymanska A, Windle V, Corbett D. Bi-hemispheric contribution to functional motor recovery of the affected forelimb following focal ischemic brain injury in rats. Eur J Neurosci. 2005 Feb;21(4):989-99. doi: 10.1111/j.1460-9568.2005.03899.x.'}, {'ReferencePMID': '12376621', 'ReferenceType': 'background', 'ReferenceCitation': 'Johansen-Berg H, Rushworth MF, Bogdanovic MD, Kischka U, Wimalaratna S, Matthews PM. The role of ipsilateral premotor cortex in hand movement after stroke. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14518-23. doi: 10.1073/pnas.222536799. Epub 2002 Oct 10.'}, {'ReferencePMID': '36744269', 'ReferenceType': 'background', 'ReferenceCitation': 'Kim JS, Kim DH, Kim HJ, Jung KJ, Hong J, Kim DY. Effect of Repetitive Transcranial Magnetic Stimulation in Post-stroke Patients with Severe Upper-Limb Motor Impairment. Brain Neurorehabil. 2019 Oct 24;13(1):e3. doi: 10.12786/bn.2020.13.e3. eCollection 2020 Mar.'}, {'ReferencePMID': '33410386', 'ReferenceType': 'background', 'ReferenceCitation': 'Edwards JD, Black SE, Boe S, Boyd L, Chaves A, Chen R, Dukelow S, Fung J, Kirton A, Meltzer J, Moussavi Z, Neva J, Paquette C, Ploughman M, Pooyania S, Rajji TK, Roig M, Tremblay F, Thiel A. Canadian Platform for Trials in Noninvasive Brain Stimulation (CanStim) Consensus Recommendations for Repetitive Transcranial Magnetic Stimulation in Upper Extremity Motor Stroke Rehabilitation Trials. Neurorehabil Neural Repair. 2021 Feb;35(2):103-116. doi: 10.1177/1545968320981960.'}, {'ReferencePMID': '23529144', 'ReferenceType': 'background', 'ReferenceCitation': 'Woodbury ML, Velozo CA, Richards LG, Duncan PW. Rasch analysis staging methodology to classify upper extremity movement impairment after stroke. Arch Phys Med Rehabil. 2013 Aug;94(8):1527-33. doi: 10.1016/j.apmr.2013.03.007. Epub 2013 Mar 22.'}, {'ReferencePMID': '1135616', 'ReferenceType': 'background', 'ReferenceCitation': 'Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med. 1975;7(1):13-31.'}, {'ReferencePMID': '12234086', 'ReferenceType': 'background', 'ReferenceCitation': 'Gladstone DJ, Danells CJ, Black SE. The fugl-meyer assessment of motor recovery after stroke: a critical review of its measurement properties. Neurorehabil Neural Repair. 2002 Sep;16(3):232-40. doi: 10.1177/154596802401105171.'}, {'ReferencePMID': '3809245', 'ReferenceType': 'background', 'ReferenceCitation': 'Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7. doi: 10.1093/ptj/67.2.206.'}, {'ReferencePMID': '14258950', 'ReferenceType': 'background', 'ReferenceCitation': 'MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61-5. No abstract available.'}, {'ReferencePMID': '2760661', 'ReferenceType': 'background', 'ReferenceCitation': 'Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703-9. doi: 10.1016/0895-4356(89)90065-6.'}, {'ReferencePMID': '10853723', 'ReferenceType': 'background', 'ReferenceCitation': 'Kucukdeveci AA, Yavuzer G, Tennant A, Suldur N, Sonel B, Arasil T. Adaptation of the modified Barthel Index for use in physical medicine and rehabilitation in Turkey. Scand J Rehabil Med. 2000 Jun;32(2):87-92.'}, {'ReferencePMID': '10390308', 'ReferenceType': 'background', 'ReferenceCitation': 'Williams LS, Weinberger M, Harris LE, Clark DO, Biller J. Development of a stroke-specific quality of life scale. Stroke. 1999 Jul;30(7):1362-9. doi: 10.1161/01.str.30.7.1362.'}, {'ReferencePMID': '22591101', 'ReferenceType': 'background', 'ReferenceCitation': 'Hakverdioglu Yont G, Khorshid L. Turkish version of the Stroke-Specific Quality of Life Scale. Int Nurs Rev. 2012 Jun;59(2):274-80. doi: 10.1111/j.1466-7657.2011.00962.x. Epub 2011 Nov 23.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12894', 'ConditionBrowseLeafName': 'Paresis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20634', 'ConditionBrowseLeafName': 'Muscle Weakness', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}]}}}}}, {'Rank': 69, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01924247', 'OrgStudyIdInfo': {'OrgStudyId': '090/13'}, 'Organization': {'OrgFullName': 'Insel Gruppe AG, University Hospital Bern', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims', 'OfficialTitle': 'Prospective Randomized Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims With Minor or no Residual Deficits'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2013', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 31, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 31, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 9, 2013', 'StudyFirstSubmitQCDate': 'August 14, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 16, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'March 13, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 14, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Insel Gruppe AG, University Hospital Bern', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Schweizerische Herzstiftung', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Background:\\n\\nStroke represents one of the major health problems worldwide, particularly in transitional and industrialized countries. Stroke has a remarkable socioeconomic impact, especially in the ageing population, and therefore stroke prevention is important. Secondary preventive measures and rehabilitation are essential for reduction of recurrent events. However, to date appropriate secondary preventive programs for patients surviving a stroke with minor or no residual deficits have been poorly studied.\\n\\nSpecific aims/projects:\\n\\nThe aim of this study is to validate the effects of an outpatient secondary prevention program on vascular risk factors, adherence to vascular-protective medication, exercise capacity and health related quality of life.\\n\\nWorking Hypothesis:\\n\\nThe outpatient rehabilitation program results in a significant short (3 months) and long-term (1 year) improvement of vascular risk factors, neurological functions, exercise capacity, adherence to vasoprotective medication and health related quality of life.\\n\\nExperimental design/Methods:\\n\\nThis is a prospective, randomized clinical trial. At least 100 patients will be randomized either to the interventional group or to a group which is treated only by the family physician. All patients will be assessed at baseline, at 3 months and 1 year. The primary outcome is the number of reached cardiovascular health goals (6 metrics) between the interventional group and the group which is treated only by the family physician.\\n\\nExpected value of the proposed project:\\n\\nThe study has the potential to show that an outpatient rehabilitation program significantly improves vascular risk factors, adherence to medication, enhances quality of life and eventually reduces recurrent strokes and other vascular events. If this is confirmed, introducing outpatient rehabilitation programs will have a major socioeconomic impact.', 'DetailedDescription': 'Background\\n\\nStroke represents one of the major health problems worldwide, particularly in transitional and industrialized countries. Stroke ranks first as cause of handicap in adults, second as cause of dementia, third as cause of death and is a frequent cause of epilepsy, depression, falls and acute hospital admissions. Stroke has a remarkable socioeconomic impact, especially in the ageing population, and therefore stroke prevention is important.\\n\\nStroke begets stroke. Persons who have suffered a stroke are at high risk of suffering additional strokes. Therefore, prevention in these persons should be part of their medical management. However, secondary stroke prevention is complex due to the numerous risk factors and includes pharmacological interventions and non-pharmacological means for risk factor reduction. Up to 90% of the stroke risk is attributable to vascular risk factors. Therefore, appropriate use of all proven measures of risk factor reduction could prevent up to 90% of all strokes. This includes smoking cessation, control of hypertension and diabetes, anticoagulants or antiplatelet agents and lipid lowering drugs, a healthy lifestyle with regular physical activity, healthy normocaloric diet, moderate or no alcohol consumption, low-normal body weight and avoidance of distress. Importantly, effective stroke prevention can only be achieved by the reduction of several or all vascular risk factors.\\n\\nSecondary preventive measures and rehabilitation are essential for reduction of recurrent events. Furthermore, moderate to severely handicapped patients should receive in- and outpatient rehabilitation adapted to their individual deficits. The concept of secondary prevention through cardiac rehabilitation is an accepted treatment modality in patients after myocardial infarction or aortocoronary bypass surgery. However, appropriate secondary preventive programs for patients surviving a stroke with minor or no residual deficits are lacking. Therefore, the investigators developed a structured 12 week hospital based out-patient program for stroke patients with minor or no residual deficits based on the already existing format of cardiac rehabilitation to optimize secondary stroke prevention, relieve symptoms, improve neurological functioning, and improve health related quality of life.\\n\\nIn a prospective interventional single center cohort pilot study with 105 patients (that is submitted for publication), the investigators showed that a 12 week outpatient rehabilitation program resulted in a considerable improvement of vascular risk factors, neurological functions, and enhanced health related quality of life (see attached abstract).\\n\\nThe aim of this additional study is to validate the effects of this outpatient program in a prospective, randomized clinical trial with crossover design.\\n\\nObjective\\n\\nThe aim of this study is to validate the effects of an outpatient secondary prevention program on vascular risk factors, adherence to vascular-protective medication, exercise capacity and health related quality of life.\\n\\nMethods\\n\\nThis is a prospective, randomized clinical trial. At least 100 patients with minor stroke or transient ischemic attack treated in the University Hospital of Bern will be randomized either to the interventional group or to a group which is treated only by the family physician. All patients will be assessed at baseline, at 3 months and 1 year. The primary outcome is the number of reached cardiovascular health goals (6 metrics: smoking, physical exercise capacity, Mediterranean diet compliance, LDL-Cholesterol, Blood pressure, fasting plasma glucose) between the interventional group and the group which is treated only by the family physician. After inclusion of 100 patients in the study, a study independent statistician will perform a power analysis and the final number of patients to be included will be adapted.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebrovascular Disorders', 'Stroke', 'Prevention']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '109', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Interventional Arm', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Interventional Arm', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Outpatient secondary prevention program']}}, {'ArmGroupLabel': 'Control Arm', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Control Arm: Standard treatment by family physician', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Standard treatment by family physician']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Outpatient secondary prevention program', 'InterventionDescription': 'The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Interventional Arm']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Standard treatment by family physician', 'InterventionDescription': 'Standard treatment by family physician.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control Arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Improvement of a combined endpoint of physical exercise capacity, blood pressure, LDL-cholesterol, HDL-cholesterol, mediterranean diet compliance, and smoking status', 'PrimaryOutcomeDescription': 'The primary endpoint is a combined endpoint of improvement of physical exercise capacity, blood pressure, LDL-cholesterol, HDL-cholesterol, mediterranean diet compliance, and smoking status between the interventional arm and the control arm.', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Comparison of neurological function', 'SecondaryOutcomeDescription': 'NIHSS, mRS, 9-Hole-Peg-Test, Functional gait assessment', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Comparison of inflammation marker', 'SecondaryOutcomeDescription': 'C-reactive protein (CRP)', 'SecondaryOutcomeTimeFrame': 'at 3 months'}, {'SecondaryOutcomeMeasure': 'Comparison of adherence to prescribed medication', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Rate of new diagnosed overseen neurological deficits', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Comparison of quality-of-life questionnaires', 'SecondaryOutcomeDescription': 'SF 36, DS 14, HADS, Jenkins 4-Items Quest, Fatigue Skala für Motorik und Kognition, EUROQUAL, Stroke Specific Quality of Life, PH Q-9, WHOQQL Bref, Mediterranean Diet Compliance Questionnaire, SWISSPAQ', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Comparison of the primary outcome measures between the interventional arm and the control arm', 'SecondaryOutcomeTimeFrame': 'at 3 months, at 12 months'}, {'SecondaryOutcomeMeasure': 'Comparison of drop-out rate between the interventional arm and the control arm', 'SecondaryOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with ischemic stroke and TIA\\nInclusion in the first 60 days after stroke\\nAge between 18 and 75 years\\nMinor or no residual neurological deficits (mRS 0-1)\\nWritten consent by the patient\\n\\nExclusion Criteria\\n\\nSevere congestive heart failure (NYHA IV)\\nEvidence of disabling stroke or dementia as measured by modified Rankin Scale score of ≥3 or a MOCA score < 26\\nAny medical condition which disables a patient to participate physical exercise training', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Simon Jung, MD', 'OverallOfficialAffiliation': 'Department of Neurology, University Hospital of Bern, 3010 Bern, Switzerland', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Neurology, Bern University Hospital', 'LocationCity': 'Bern', 'LocationZip': '3010', 'LocationCountry': 'Switzerland'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000002561', 'ConditionMeshTerm': 'Cerebrovascular Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11997', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 70, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03854981', 'OrgStudyIdInfo': {'OrgStudyId': '18316'}, 'Organization': {'OrgFullName': 'University of Virginia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Pre-operative Exercise and Nutrition Therapy on Cardio-metabolic Health in Patients Undergoing Bariatric Surgery', 'OfficialTitle': 'Role of Pre-operative Exercise and Nutrition Therapy on Insulin Resistance and Vascular Health in Patients Undergoing Bariatric Surgery'}, 'StatusModule': {'StatusVerifiedDate': 'February 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 11, 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 22, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 24, 2019', 'StudyFirstSubmitQCDate': 'February 23, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 26, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 23, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 26, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Steven K. Malin, PhD', 'ResponsiblePartyInvestigatorTitle': 'Assistant Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Virginia'}, 'LeadSponsor': {'LeadSponsorName': 'University of Virginia', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Obesity is a major health concern that has been associated with an estimated 2.8 million deaths worldwide each year. The number of individuals considered obese with a Body Mass Index (BMI) above 30 kg/m2 has grown to more than 500 million. The increased morbidity and mortality associated with obesity stems from a long list of comorbidities, including hypertension, coronary artery disease, stroke, cancer, and type 2 diabetes (T2D). Bariatric surgery is an emerging intervention that has been used frequently to induce weight loss for obese individuals and it has been shown to improve glycemic control and insulin resistance in people at risk for type 2 diabetes. Surgery may also lead to healthy improvements in inflammation, immune cells and vascular health. It is already known that exercise and weight loss from lifestyle modification can improve glycemic control, insulin resistance, inflammation, and arterial stiffness. However, no work has been done to examine a combination of bariatric surgery and pre-surgery exercise. Recent work by the team has evidence demonstrating that health status pre-surgery has an impact on post-surgery outcomes. Such findings suggest that improvements in health status from exercise before surgery may improve surgery outcomes as well as surgery-induced health outcomes. To date, no study has systematically examined the role of exercise on the prevalence of surgery complications or on post-surgery weight loss, glycemic control, and insulin resistance. Moreover, no work currently exists on exercise, with or without bariatric surgery on adipose tissue derived inflammation. Therefore, the purpose of this study is to investigate the effect of pre-surgery lifestyle intervention with exercise on bariatric surgery outcomes. To test this objective, subjects will participate in a match paired study, based on BMI. Subjects will undergo testing of blood chemistry and related measures of health before (pre-test) and after (post) intervention. Then all subjects will receive bariatric surgery. Post surgery outcomes will be assessed by examining surgery operating time, changes in blood chemistry, adipose tissue biopsies and other measures indicative of glucose and vascular health. After this surgery, subjects will return for testing about 30d later.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Bariatric Surgery Candidate']}, 'KeywordList': {'Keyword': ['Insulin Resistance', 'Cardiovascular Risk', 'Inflammation', 'Exercise', 'Diet']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '12', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Standard Care', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Standard Care']}}, {'ArmGroupLabel': 'Exercise + Standard Care', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': \"Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Exercise', 'Procedure: Standard Care']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Exercise', 'InterventionDescription': 'Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Exercise + Standard Care']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Standard Care', 'InterventionDescription': 'Standard preoperative care of bariatric surgery', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Exercise + Standard Care', 'Standard Care']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Insulin Resistance', 'PrimaryOutcomeDescription': 'Mixed Meal Tolerance Test', 'PrimaryOutcomeTimeFrame': 'Through Study Completion, up to about 8 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Augmentation Index in %', 'SecondaryOutcomeDescription': 'Arterial Stiffness', 'SecondaryOutcomeTimeFrame': 'Through Study Completion, up to about 8 weeks'}, {'SecondaryOutcomeMeasure': 'Changes in Blood lipids in mg/dl', 'SecondaryOutcomeDescription': 'Cholesterol and triglycerides', 'SecondaryOutcomeTimeFrame': 'Through Study Completion, up to about 8 weeks'}, {'SecondaryOutcomeMeasure': 'Length of Stay Post Surgery in minutes', 'SecondaryOutcomeDescription': 'Recovery from surgery', 'SecondaryOutcomeTimeFrame': 'Up to 1 week'}, {'SecondaryOutcomeMeasure': 'Operating time in minutes', 'SecondaryOutcomeDescription': 'Length of Surgery', 'SecondaryOutcomeTimeFrame': 'Surgical Procedure'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Changes in blood glucose in mg/dl', 'OtherOutcomeDescription': 'For the Mixed Meal Tolerance Test', 'OtherOutcomeTimeFrame': 'Through Study Completion, up to about 8 weeks'}, {'OtherOutcomeMeasure': 'Changes in blood pressure in mmHg', 'OtherOutcomeDescription': 'At the Mixed Meal Tolerance Test', 'OtherOutcomeTimeFrame': 'Through Study Completion, up to about 8 weeks'}, {'OtherOutcomeMeasure': 'Body weight and height will be combined to determine BMI in kg/m^2', 'OtherOutcomeDescription': 'At the Mixed Meal tolerance Test', 'OtherOutcomeTimeFrame': 'Through Study Completion, up to about 8 weeks'}, {'OtherOutcomeMeasure': 'Concentration of adiponectin in pg/mg', 'OtherOutcomeDescription': 'From adipose biopsy', 'OtherOutcomeTimeFrame': 'Surgical Procedure'}, {'OtherOutcomeMeasure': 'Concentration of leptin in pg/mg', 'OtherOutcomeDescription': 'From adipose biopsy', 'OtherOutcomeTimeFrame': 'Surgical Procedure'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMales and Females, 18-70 years of age\\nBMI >30 and <70 kg/m2\\nSedentary (Not currently participating in exercise training: >30 min. of physical activity per day, >3 days/week)\\nHCT for women > 36%, Men >38%\\nNon-pregnant (women).-self reported\\nSmoker (if bariatric surgery patient) or non-smoker (enrolled for the dietary portion of the study)\\nHas the ability/willingness to participate in the study and agree to any of the arms involved in the study.\\nNo prior surgical procedure for obesity with the exception of a laparoscopic adjustable gastric banding (LAGB) under the condition that the band had not been adjusted in less than or equal to 1 year\\n\\nExclusion Criteria:\\n\\nCurrently participating in exercise training: >30 min. of physical activity per day, >2 days/week)\\nCigarette smoking (presently or in the past 6 months), drug or alcohol abuse\\nPregnancy or breastfeeding\\nHistory of congestive heart failure, ischemic heart disease, severe pulmonary disease.\\nHistory of cancer (within 5 years)\\nDiagnosed as insulin-dependent diabetes.\\nChange in psychotropic medication dosage in past six weeks\\nAST or ALT > 3 times normal range\\nCurrently involved in any active weight loss treatment program (other than self-directed attempt at calorie restricting diet) or lean patients (BMI <29 kg/m2).\\nCurrent purging behavior occurring > once a week over the past six weeks (self-induced vomiting for weight control purposes, laxative or diuretic abuse)\\nRevisional bariatric procedures including a RYGB reversal to a SG or a LAGB revision to a SG or RYGB if the band has been adjusted in greater than or equal to 1 year.\\nActive psychotic illness, including bipolar affective disorders.\\nEvidence of current suicidality or homicidality\\nConditions associated with significant cognitive dysfunction (e.g. dementia) or medical instability that puts the participant at risk\\nContraindication to exercise (severe/uncontrolled CVD; inability to walk 2 blocks, bone or joint problems )\\nAllergy to \"caine\" family drugs (e.g. lidocaine).\\nCurrently taking active weight suppression medication (e.g. phentermine,bupropion SR, topiramate).\\nOn medication known to cause substantial weight gain (e.g. atypical antipsychotics such as olanzapine, sodium valproate, steroid therapy). This would not include medications commonly used in this population that usually result in only mild weight loss (e.g. SSRIs).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Steven K Malin', 'OverallOfficialAffiliation': 'University of Virginia', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26627222', 'ReferenceType': 'background', 'ReferenceCitation': 'Malin SK, Kashyap SR. Differences in Weight Loss and Gut Hormones: Rouen-Y Gastric Bypass and Sleeve Gastrectomy Surgery. Curr Obes Rep. 2015 Jun;4(2):279-86. doi: 10.1007/s13679-015-0151-1.'}, {'ReferencePMID': '25132119', 'ReferenceType': 'background', 'ReferenceCitation': 'Malin SK, Bena J, Abood B, Pothier CE, Bhatt DL, Nissen S, Brethauer SA, Schauer PR, Kirwan JP, Kashyap SR. Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery. Diabetes Obes Metab. 2014 Dec;16(12):1230-8. doi: 10.1111/dom.12376. Epub 2014 Sep 14.'}, {'ReferencePMID': '23196991', 'ReferenceType': 'background', 'ReferenceCitation': 'Shada AL, Hallowell PT, Schirmer BD, Smith PW. Aerobic exercise is associated with improved weight loss after laparoscopic adjustable gastric banding. Obes Surg. 2013 May;23(5):608-12. doi: 10.1007/s11695-012-0826-6.'}, {'ReferencePMID': '25437877', 'ReferenceType': 'background', 'ReferenceCitation': 'Coen PM, Tanner CJ, Helbling NL, Dubis GS, Hames KC, Xie H, Eid GM, Stefanovic-Racic M, Toledo FG, Jakicic JM, Houmard JA, Goodpaster BH. Clinical trial demonstrates exercise following bariatric surgery improves insulin sensitivity. J Clin Invest. 2015 Jan;125(1):248-57. doi: 10.1172/JCI78016. Epub 2014 Dec 1.'}, {'ReferencePMID': '25651277', 'ReferenceType': 'background', 'ReferenceCitation': 'Khanna V, Malin SK, Bena J, Abood B, Pothier CE, Bhatt DL, Nissen S, Watanabe R, Brethauer SA, Schauer PR, Kirwan JP, Kashyap SR. Adults with long-duration type 2 diabetes have blunted glycemic and beta-cell function improvements after bariatric surgery. Obesity (Silver Spring). 2015 Mar;23(3):523-6. doi: 10.1002/oby.21021. Epub 2015 Feb 3.'}, {'ReferencePMID': '23529939', 'ReferenceType': 'background', 'ReferenceCitation': 'Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013 Mar;21 Suppl 1(0 1):S1-27. doi: 10.1002/oby.20461.'}, {'ReferencePMID': '23036993', 'ReferenceType': 'background', 'ReferenceCitation': 'Malin SK, Niemi N, Solomon TP, Haus JM, Kelly KR, Filion J, Rocco M, Kashyap SR, Barkoukis H, Kirwan JP. Exercise training with weight loss and either a high- or low-glycemic index diet reduces metabolic syndrome severity in older adults. Ann Nutr Metab. 2012;61(2):135-41. doi: 10.1159/000342084.'}, {'ReferencePMID': '24064339', 'ReferenceType': 'background', 'ReferenceCitation': 'Malin SK, Haus JM, Solomon TP, Blaszczak A, Kashyap SR, Kirwan JP. Insulin sensitivity and metabolic flexibility following exercise training among different obese insulin-resistant phenotypes. Am J Physiol Endocrinol Metab. 2013 Nov 15;305(10):E1292-8. doi: 10.1152/ajpendo.00441.2013. Epub 2013 Sep 24.'}, {'ReferencePMID': '24355497', 'ReferenceType': 'background', 'ReferenceCitation': 'Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014 Apr;63(4):250-9. doi: 10.1016/j.jjcc.2013.11.006. Epub 2013 Dec 16.'}, {'ReferencePMID': '15616203', 'ReferenceType': 'background', 'ReferenceCitation': 'Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004 Dec 23;351(26):2683-93. doi: 10.1056/NEJMoa035622.'}, {'ReferencePMID': '14530719', 'ReferenceType': 'background', 'ReferenceCitation': 'Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003 Oct;238(4):467-84; discussion 84-5. doi: 10.1097/01.sla.0000089851.41115.1b.'}, {'ReferencePMID': '24283920', 'ReferenceType': 'background', 'ReferenceCitation': 'Malin SK, Finnegan S, Fealy CE, Filion J, Rocco MB, Kirwan JP. beta-Cell dysfunction is associated with metabolic syndrome severity in adults. Metab Syndr Relat Disord. 2014 Mar;12(2):79-85. doi: 10.1089/met.2013.0083. Epub 2013 Nov 27.'}, {'ReferencePMID': '24383875', 'ReferenceType': 'background', 'ReferenceCitation': 'Liu B, Kuang L, Liu J. Bariatric surgery relieves type 2 diabetes and modulates inflammatory factors and coronary endothelium eNOS/iNOS expression in db/db mice. Can J Physiol Pharmacol. 2014 Jan;92(1):70-7. doi: 10.1139/cjpp-2013-0034. Epub 2013 Oct 21.'}, {'ReferencePMID': '19164269', 'ReferenceType': 'background', 'ReferenceCitation': 'Yassine HN, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults--a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009 Jan;64(1):90-5. doi: 10.1093/gerona/gln032. Epub 2009 Jan 20.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000007333', 'ConditionMeshTerm': 'Insulin Resistance'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000006946', 'ConditionAncestorTerm': 'Hyperinsulinism'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M9983', 'ConditionBrowseLeafName': 'Inflammation', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10060', 'ConditionBrowseLeafName': 'Insulin Resistance', 'ConditionBrowseLeafAsFound': 'Insulin Resistance', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9687', 'ConditionBrowseLeafName': 'Hyperinsulinism', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M10055', 'InterventionBrowseLeafName': 'Insulin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M173072', 'InterventionBrowseLeafName': 'Insulin, Globin Zinc', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Hypo', 'InterventionBrowseBranchName': 'Hypoglycemic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 71, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00604669', 'OrgStudyIdInfo': {'OrgStudyId': 'IRB00004573'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'e4573', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Assigned Emory IRB number'}]}, 'Organization': {'OrgFullName': 'Emory University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients', 'OfficialTitle': 'Total Parenteral Nutrition(TPN)-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients'}, 'StatusModule': {'StatusVerifiedDate': 'November 2013', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2007'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2009', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 17, 2008', 'StudyFirstSubmitQCDate': 'January 29, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 30, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'December 8, 2008', 'ResultsFirstSubmitQCDate': 'March 15, 2010', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'April 7, 2010', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 20, 2013', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 13, 2013', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Guillermo Umpierrez', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Emory University'}, 'LeadSponsor': {'LeadSponsorName': 'Emory University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'A growing body of evidence suggests hyperglycemia is associated with adverse outcomes in patients with and without diabetes. Observational studies document an association between hyperglycemia and poor clinical outcomes in cardiothoracic surgery, elective surgery, myocardial infarction, stroke. Randomized studies indicate glycemic control is associated with improved outcomes in diabetic patients with critically illness. Hyperglycemia is a recognized and common complication of patients receiving total parenteral nutrition (TPN). Few studies in the literature have looked into the impact of TPN-associated inhospital complications and mortality. Accordingly, this study aims to evaluate the impact of hyperglycemia on clinical outcome (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay, and mortality) in patients receiving TPN. We will perform a retrospective chart review of all patients treated with TPN from 1/01/06 to 12/31/06 at Grady Memorial Hospital. We hypothesize that patients receiving TPN who develop hyperglycemia experience higher morbidity (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay) and mortality compared to TPN patients with euglycemia. The results of this study will help us to formulate a prospective randomized clinical trial on the management of TPN-associated hyperglycemia in hospitalized patients.\\n\\nThis study aims to evaluate the impact of hyperglycemia on clinical outcome (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay, in hospital mortality) in patients receiving total parenteral nutrition. We will perform a retrospective chart review of all patients admitted to the hospital receiving TPN from 1/01/06 to 12/31/06 at Grady Memorial Hospital. The results of this study will help us to formulate a prospective randomized clinical trial on the management of TPN-associated hyperglycemia in hospitalized patients.', 'DetailedDescription': 'Hypotheses:\\n\\nWe hypothesize that patients receiving TPN who develop hyperglycemia experience higher morbidity (infections, systemic sepsis, cardiac complications, acute renal failure, length of stay) and mortality compared to TPN patients with euglycemia.\\n\\nSpecific Aim:\\n\\nTo determine the impact of hyperglycemia on clinical outcome (infection, systemic sepsis, cardiac complications, acute renal failure, length of stay, mortality) in patients receiving total parenteral nutrition.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Hyperglycemia']}, 'KeywordList': {'Keyword': ['Diabetes', 'Nutrition/Dietics', 'clinical outcomes', 'total parenteral nutrition']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '170', 'EnrollmentType': 'Actual'}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Mortality', 'PrimaryOutcomeDescription': 'Mortality rate of those with hyperglycemia while on TPN duing the period of 1/01/06 to 12/31/06.', 'PrimaryOutcomeTimeFrame': 'at the end of the chart review of all patients'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria: Perform a retrospective chart analysis of all patients receiving TPN at Grady Memorial Hospital during the period of 1/01/06 to 12/31/06.\\n\\nExclusion criteria: None except for charts without adequate data sufficient for chart review.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'All patients receiving TPN at Grady Memorial Hospital during the period of 1/01/06 to 12/31/06.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Guillermo Umpierrez, MD', 'OverallOfficialAffiliation': 'Emory University SOM', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Grady Memorial Hospital', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30303', 'LocationCountry': 'United States'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowPreAssignmentDetails': 'Nothing to disclose.', 'FlowRecruitmentDetails': '170 charts reviewed', 'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Those Exposed to TPN'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '170'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '163'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'lack of information in chart', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '7'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Those Exposed to TPN'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '163'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '120'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '39'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '60', 'BaselineMeasurementSpread': '17'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '57'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '106'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '163'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Mortality', 'OutcomeMeasureDescription': 'Mortality rate of those with hyperglycemia while on TPN duing the period of 1/01/06 to 12/31/06.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'mortality rate', 'OutcomeMeasureTimeFrame': 'at the end of the chart review of all patients', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Those Exposed to TPN'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '163'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '36'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Those Exposed to TPN', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '0', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '0'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Guillermo Umpierrez', 'PointOfContactOrganization': 'Emory University', 'PointOfContactEMail': 'geumpie@emory.edu', 'PointOfContactPhone': '404-778-1665'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006943', 'ConditionMeshTerm': 'Hyperglycemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9684', 'ConditionBrowseLeafName': 'Hyperglycemia', 'ConditionBrowseLeafAsFound': 'Hyperglycemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 72, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00747279', 'OrgStudyIdInfo': {'OrgStudyId': 'HSD001'}, 'Organization': {'OrgFullName': 'Hospital Sao Domingos', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke', 'OfficialTitle': 'Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'September 2008', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2007'}, 'StudyFirstSubmitDate': 'September 4, 2008', 'StudyFirstSubmitQCDate': 'September 4, 2008', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 5, 2008', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 8, 2008', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 9, 2008', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'LeadSponsor': {'LeadSponsorName': 'Hospital Sao Domingos', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this prospective randomized controlled trial was to compare intensive insulin therapy with a carbohydrate restrictive strategy in patients with acute ischemic stroke evaluating the outcome through the Glasgow Outcome Scale Extended, hospital mortality and NIHSS during the ICU stay.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Ischemic Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 4']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '70', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Carbohydrate restrictive strategy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Carbohydrate restrictive strategy']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Intensive insulin therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Intensive insulin therapy']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Carbohydrate restrictive strategy', 'InterventionDescription': 'Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Drug', 'InterventionName': 'Intensive insulin therapy', 'InterventionDescription': 'Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Neurological outcome through the Glasgow Outcome Scale Extended', 'PrimaryOutcomeTimeFrame': 'At least 4 months after hospital discharge'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'NIHSS during ICU stay', 'SecondaryOutcomeTimeFrame': 'ICU stay'}, {'SecondaryOutcomeMeasure': 'Hospital mortality', 'SecondaryOutcomeTimeFrame': 'Hospital stay'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult patients with acute ischemic stroke defined as: Abrupt onset of focal neurologic deficit\\nNo evidence of intracranial hemorrhage at non-contrasted CT scan.\\n\\nExclusion Criteria:\\n\\nAge below 18\\nPregnancy', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'JOSE R AZEVEDO, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '55 98 32275735', 'CentralContactEMail': 'jrazevedo@elo.com.br'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital Sao Domingos', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sao Luis', 'LocationState': 'MA', 'LocationZip': '65060-642', 'LocationCountry': 'Brazil', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'JOSE R AZEVEDO, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '55 98 32275735', 'LocationContactEMail': 'jrazevedo@elo.com.br'}, {'LocationContactName': 'JOSE R AZEVEDO, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000002544', 'ConditionMeshTerm': 'Cerebral Infarction'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000020520', 'ConditionAncestorTerm': 'Brain Infarction'}, {'ConditionAncestorId': 'D000002545', 'ConditionAncestorTerm': 'Brain Ischemia'}, {'ConditionAncestorId': 'D000007238', 'ConditionAncestorTerm': 'Infarction'}, {'ConditionAncestorId': 'D000009336', 'ConditionAncestorTerm': 'Necrosis'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5483', 'ConditionBrowseLeafName': 'Cerebral Infarction', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9972', 'ConditionBrowseLeafName': 'Infarction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21995', 'ConditionBrowseLeafName': 'Brain Infarction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5484', 'ConditionBrowseLeafName': 'Brain Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11974', 'ConditionBrowseLeafName': 'Necrosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000007328', 'InterventionMeshTerm': 'Insulin'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000007004', 'InterventionAncestorTerm': 'Hypoglycemic Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21550', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M10055', 'InterventionBrowseLeafName': 'Insulin', 'InterventionBrowseLeafAsFound': 'Efficacy', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M173072', 'InterventionBrowseLeafName': 'Insulin, Globin Zinc', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M4544', 'InterventionBrowseLeafName': 'Benzocaine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9744', 'InterventionBrowseLeafName': 'Hypoglycemic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T433', 'InterventionBrowseLeafName': 'Tannic Acid', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Hypo', 'InterventionBrowseBranchName': 'Hypoglycemic Agents'}, {'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}]}}}}}, {'Rank': 73, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03218020', 'OrgStudyIdInfo': {'OrgStudyId': 'DKFZ Study_ID 905'}, 'Organization': {'OrgFullName': 'German Cancer Research Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Red Meat, Increased Iron Load and CVD Risk', 'OfficialTitle': 'Red Meat Consumption and Risk of Cardiovascular Diseases - is Increased Iron Load a Possible Link?'}, 'StatusModule': {'StatusVerifiedDate': 'July 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 1994', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2009', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2009', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 13, 2017', 'StudyFirstSubmitQCDate': 'July 13, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 14, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 14, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 18, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'German Cancer Research Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Increased iron load could be a risk factor for cardiovascular diseases (CVD). Red meat consumption affects iron status and has also been shown to be related to increased CVD risk. The investigators hypothesized that risk associations between red meat intake and cardiovascular disease risk can to some degree be explained by higher iron load among individuals with higher meat intake. Thus, the investigators evaluate associations between red meat consumption, iron status, and CVD risk in a large-scale population based study, the European Prospective Investigation into Cancer and Nutrition (EPIC) - Heidelberg.', 'DetailedDescription': 'The present study part of the the European Prospective Investigation into Cancer and Nutrition (EPIC) - Heidelberg, a large-scale observational cohort study located at the German Cancer Research Center, Heidelberg, Germany. The study started between 1994 and 1998, when 25 540 adults from the local general population were recruited. Study participants are being followed-up by active and passive procedures. The main aim of the study is to evaluate associations between diet, lifestyle as well as metabolism and risks of major chronic diseases (cancer, cardiovascular diseases, diabetes).\\n\\nHere, the investigators register a project from within EPIC-Heidelberg on prediagnostic iron status as a potential mediator of associations between pre-diagnostic red meat consumption and cardiovascular disease risk. For this particular project, an embedded case-cohort set-up was chosen, i.e. iron status markers (primary marker: serum ferritin; secondary markers: serum transferrin, serum iron) were measured in baseline blood samples from a random subcohort (n=2738) and all validated incident cases of myocardial infarction (n=556), stroke (n=513), and CVD death (n=327) that occured until the closure date of the present study (12-31-2009).\\n\\nStatistical analyses follow four steps to assess whether iron status may mediate associations between red meat consumption and CVD risk, as proposed by Wittenbecher et al. (Am J Clin Nutr, 2015: www.ncbi.nlm.nih.gov/pubmed/25948672):\\n\\nMultivariable Cox regression analyses on red meat consumption and CVD risk, assuming a significant positive association\\nMultivariable linear regression analyses on red meat consumption and iron status, assuming a significant positive association\\nMultivariable Cox regression analyses on iron status and CVD risk, assuming a significant positive association\\nMultivariable Cox regression analyses on red meat consumption and CVD risk, additionally adjusting for iron status, assuming that the association will be attenuated by adjustment for iron status'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Myocardial Infarction', 'Stroke', 'Cardiovascular Mortality']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'Serum samples from baseline examinations stored in the biobank of the study.'}, 'EnrollmentInfo': {'EnrollmentCount': '25540', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Random Subcohort', 'ArmGroupDescription': 'Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: No intervention assigned, this is an observational study.']}}, {'ArmGroupLabel': 'Incident CVD Cases', 'ArmGroupDescription': 'Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: No intervention assigned, this is an observational study.']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'No intervention assigned, this is an observational study.', 'InterventionDescription': 'No intervention assigned, this is an observational study.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Incident CVD Cases', 'Random Subcohort']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Myocardial infraction', 'PrimaryOutcomeDescription': 'Incident cases of primary myocardial infarction according to clinical records', 'PrimaryOutcomeTimeFrame': '1994 - 2009'}, {'PrimaryOutcomeMeasure': 'Stroke', 'PrimaryOutcomeDescription': 'Incident cases of primary stroke according to clinical records', 'PrimaryOutcomeTimeFrame': '1994 - 2009'}, {'PrimaryOutcomeMeasure': 'Cardiovascular death', 'PrimaryOutcomeDescription': 'Incident cases of cardiovascular death according to death certificates', 'PrimaryOutcomeTimeFrame': '1994 - 2009'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nGeneral population, age 35-65 years\\n\\nExclusion Criteria:\\n\\nPrevalent myocardial infraction or stroke', 'Gender': 'All', 'MinimumAge': '35 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'EPIC-Heidelberg was launched as part of EPIC-Europe between 1994 and 1998, when 13 611 female and 11 929 male participants aged 35 to 65 years were recruited from the local general population.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Rudolf Kaaks, Prof.', 'OverallOfficialAffiliation': 'German Cancer Research Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'German Cancer Research Center', 'LocationCity': 'Heidelberg', 'LocationZip': '69120', 'LocationCountry': 'Germany'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009203', 'ConditionMeshTerm': 'Myocardial Infarction'}, {'ConditionMeshId': 'D000007238', 'ConditionMeshTerm': 'Infarction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000007511', 'ConditionAncestorTerm': 'Ischemia'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000009336', 'ConditionAncestorTerm': 'Necrosis'}, {'ConditionAncestorId': 'D000017202', 'ConditionAncestorTerm': 'Myocardial Ischemia'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11845', 'ConditionBrowseLeafName': 'Myocardial Infarction', 'ConditionBrowseLeafAsFound': 'Myocardial Infarction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9972', 'ConditionBrowseLeafName': 'Infarction', 'ConditionBrowseLeafAsFound': 'Infarction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11974', 'ConditionBrowseLeafName': 'Necrosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M10223', 'InterventionBrowseLeafName': 'Iron', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 74, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02858518', 'OrgStudyIdInfo': {'OrgStudyId': '1408020'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '2014-A01664-43', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'ANSM'}]}, 'Organization': {'OrgFullName': 'Centre Hospitalier Universitaire de Saint Etienne', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?', 'OfficialTitle': 'Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?', 'Acronym': 'PREDIC-AGE'}, 'StatusModule': {'StatusVerifiedDate': 'August 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 1, 2016', 'StudyFirstSubmitQCDate': 'August 3, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 8, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 20, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 23, 2017', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Centre Hospitalier Universitaire de Saint Etienne', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'Atrial fibrillation (AF) is a rhythmic cardiac activity disorder disturbing hemodynamic blood flow. It is a public health problem with 600,000 to 1 million people involved in France which 2/3 are aged over 75 years. a FA untreated exposes the patient to a significant risk of embolism responsible for a rate stroke (stroke) ischemic estimated at 85%. The anticoagulant standard treatment helps prevent the occurrence of this complication.\\n\\nHowever, oral anticoagulation also exposes patients to an increased risk of bleeding. The bleeding risk can be assessed using scales: several being proposed (HEMORR2HAGES, HAS-BLED, ATRIA and scores Shireman and Charlson ...).\\n\\nmoreover, in geriatric hospital care, every patient has a \"standardized geriatric assessment\" to assess and quantify functional capacity, autonomy, cognitive abilities, nutritional status, psychological state and its environment social.\\n\\nThus, the objective of the investigators study was to determine the frequency of each item of each bleeding risk assessment score and geriatric assessment in patients 80 and older hospitalized geriatric ward in the department and with anticoagulant.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Atrial Fibrillation', 'Gerontology']}, 'KeywordList': {'Keyword': ['anticoagulant']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples Without DNA', 'BioSpecDescription': 'classical blood sample : NFS, ionograms, CRP, TSH, albumin, vitamin D, Calcium and coagulation factors + tube for genetic study'}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with atrial fibrillation with anticoagulant treatment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: questionnaires']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'questionnaires', 'InterventionDescription': 'scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with atrial fibrillation with anticoagulant treatment']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'scale : HEMORR2HAGES', 'PrimaryOutcomeDescription': 'hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...', 'PrimaryOutcomeTimeFrame': 'at baseline'}, {'PrimaryOutcomeMeasure': 'scale : HAS-Bled', 'PrimaryOutcomeDescription': 'arterial hypertension, renal function, liver function, cerebrovascular accident...', 'PrimaryOutcomeTimeFrame': 'at baseline'}, {'PrimaryOutcomeMeasure': 'scale : ATRIA', 'PrimaryOutcomeDescription': 'anemia, serious kidney diseases, hypertension, antecedent...', 'PrimaryOutcomeTimeFrame': 'at baseline'}, {'PrimaryOutcomeMeasure': 'scale : shireman', 'PrimaryOutcomeDescription': 'gender, age, hemorrhage, diabetes, anemia...', 'PrimaryOutcomeTimeFrame': 'at baseline'}, {'PrimaryOutcomeMeasure': 'scale charlson', 'PrimaryOutcomeDescription': 'age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer', 'PrimaryOutcomeTimeFrame': 'at baseline'}, {'PrimaryOutcomeMeasure': 'scale : standardised geriatric assessment', 'PrimaryOutcomeDescription': 'comorbidities, cognition, mobility, pain, nutrition, living environment...', 'PrimaryOutcomeTimeFrame': 'at baseline'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Occurrence of major bleeding event or not major', 'SecondaryOutcomeTimeFrame': 'at baseline and 6 months'}, {'SecondaryOutcomeMeasure': 'genotyping', 'SecondaryOutcomeDescription': 'CYP2C9', 'SecondaryOutcomeTimeFrame': 'at baseline'}, {'SecondaryOutcomeMeasure': 'genotyping', 'SecondaryOutcomeDescription': 'VKCRC1', 'SecondaryOutcomeTimeFrame': 'at baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nhospitalisation in geriatric unit\\nAtrial fibrillation treated by anticoagulant treatment (AVK or oral anticoagulation)\\nsigned inform consent\\n\\nExclusion Criteria:\\n\\nestimated lifetime less than 6 months\\nunder guardianship or curatorship\\nwithout support person', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '80 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'patients seniors with atrial fibrillation with anticoagulant treatment', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Emilie CRAWFORD-ACHOUR, MD', 'OverallOfficialAffiliation': 'CHU de SAINT-ETIENNE', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'CH de FEURS', 'LocationCity': 'Feurs', 'LocationZip': '42110', 'LocationCountry': 'France'}, {'LocationFacility': 'CH de FIRMINY', 'LocationCity': 'Firminy', 'LocationZip': '42700', 'LocationCountry': 'France'}, {'LocationFacility': 'CH de ROANNE', 'LocationCity': 'Roanne', 'LocationZip': '42300', 'LocationCountry': 'France'}, {'LocationFacility': 'CH de SAINT-CHAMOND', 'LocationCity': 'Saint-chamond', 'LocationZip': '42400', 'LocationCountry': 'France'}, {'LocationFacility': 'CHU de SAINT-ETIENNE', 'LocationCity': 'Saint-etienne', 'LocationZip': '42000', 'LocationCountry': 'France'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001281', 'ConditionMeshTerm': 'Atrial Fibrillation'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001145', 'ConditionAncestorTerm': 'Arrhythmias, Cardiac'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M4276', 'ConditionBrowseLeafName': 'Atrial Fibrillation', 'ConditionBrowseLeafAsFound': 'Atrial Fibrillation', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9246', 'ConditionBrowseLeafName': 'Hemorrhage', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4143', 'ConditionBrowseLeafName': 'Arrhythmias, Cardiac', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M10800', 'InterventionBrowseLeafName': 'Liver Extracts', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3934', 'InterventionBrowseLeafName': 'Anticoagulants', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Hemat', 'InterventionBrowseBranchName': 'Hematinics'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnCoag', 'InterventionBrowseBranchName': 'Anticoagulants'}]}}}}}, {'Rank': 75, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03692234', 'OrgStudyIdInfo': {'OrgStudyId': 'Homoarginine in Stroke'}, 'Organization': {'OrgFullName': 'Universitätsklinikum Hamburg-Eppendorf', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Homoarginine Supplementation in Patients After Stroke', 'OfficialTitle': 'Homoarginine in Stroke (HiS) Study', 'Acronym': 'HiS'}, 'StatusModule': {'StatusVerifiedDate': 'June 2021', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 22, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'August 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 18, 2018', 'StudyFirstSubmitQCDate': 'September 28, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 2, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 30, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 2, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Universitätsklinikum Hamburg-Eppendorf', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study represents a follow-up of the previous study \"Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects\" (NCT02675660). This study will evaluate the applicability of an oral formulation of L-homoarginine to normalize homoarginine blood levels in patients with acute ischemic stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Deficiency; Diet']}, 'KeywordList': {'Keyword': ['homoarginine']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'randomized double-blind placebo controlled', 'DesignPrimaryPurpose': 'Basic Science', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '500', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'placebo', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'placebo capsules containing lactose - oral once weekly administration for six month', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: placebo']}}, {'ArmGroupLabel': 'homoarginine', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': '125 mg L-homoarginine supplement - oral once weekly administration for six month', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: 125 mg L-homoarginine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': '125 mg L-homoarginine', 'InterventionDescription': 'capsules for oral supplementation', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['homoarginine']}}, {'InterventionType': 'Other', 'InterventionName': 'placebo', 'InterventionDescription': 'capsules for oral supplementation', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['placebo']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Homoarginine serum concentration', 'PrimaryOutcomeDescription': 'Normalization of homoarginine serum concentration to levels >2.1 umol/L.', 'PrimaryOutcomeTimeFrame': 'six month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Intima-media thickness', 'SecondaryOutcomeDescription': 'Intima-media thickness (IMT) measured at both common carotid arteries using an edge detection system. Plaques are defined as protrusion of ≥1.5 mm in common, internal and external carotid artery.', 'SecondaryOutcomeTimeFrame': 'six month'}, {'SecondaryOutcomeMeasure': 'National Institute of Health Stroke Scale', 'SecondaryOutcomeDescription': 'National Institute of Health Stroke Scale (NIHSS) will be assessed by a neurologist. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 (normal) and 4 (maximum impairment). The maximum possible score is 42, with the minimum score being a 0.', 'SecondaryOutcomeTimeFrame': 'six month'}, {'SecondaryOutcomeMeasure': 'Modified Ranking Scale', 'SecondaryOutcomeDescription': 'Modified Ranking Scale (mRS) is a scale for measuring the degree of disability of a stroke patients. The scale runs from 0 (perfect health) to 6 (death).', 'SecondaryOutcomeTimeFrame': 'six month'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nischemic stroke (CT or MRI), high-risk transient ischemic attack (ABCD2-score >= 4) or acute central retinal artery occlusion\\nserum homoarginine </= 2.1 umol/L\\nsigned informed consent\\n\\nExclusion Criteria:\\n\\nno acute stroke\\nserum homoarginine > 2.1 umol/L\\nheart failure (NYHA > 1)\\nchronic kidney disease (GFR <60 mL/min)\\nnot competent\\npregnancy, lactation\\nno or withdrawn signed informed consent', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Chi-un Choe, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+49407410', 'CentralContactPhoneExt': '22389', 'CentralContactEMail': 'cchoe@uke.de'}, {'CentralContactName': 'Edzard Schwedhelm, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+49407410', 'CentralContactPhoneExt': '54891', 'CentralContactEMail': 'schwedhelm@uke.de'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University Medical Center Hamburg', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hamburg', 'LocationZip': '20246', 'LocationCountry': 'Germany', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chi-un Che, MD', 'LocationContactRole': 'Contact'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27434056', 'ReferenceType': 'background', 'ReferenceCitation': 'Atzler D, Schonhoff M, Cordts K, Ortland I, Hoppe J, Hummel FC, Gerloff C, Jaehde U, Jagodzinski A, Boger RH, Choe CU, Schwedhelm E. Oral supplementation with L-homoarginine in young volunteers. Br J Clin Pharmacol. 2016 Dec;82(6):1477-1485. doi: 10.1111/bcp.13068. Epub 2016 Sep 20.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Deficiency; Diet', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}}, {'Rank': 76, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03610828', 'OrgStudyIdInfo': {'OrgStudyId': 'DNSG-Vegetarian diets (cohort)'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Meta-analysis of Vegetarian Diets and Incident Cardiovascular Outcomes', 'OfficialTitle': 'Relation of Vegetarian Diets With Incident Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies'}, 'StatusModule': {'StatusVerifiedDate': 'July 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 1, 2018', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 1, 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 16, 2018', 'StudyFirstSubmitQCDate': 'July 25, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 1, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 25, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 1, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John Sievenpiper', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Vegetarian and vegan diets have been shown to reduce cardiometabolic risk factors for chronic diseases, such as cardiovascular disease and diabetes, and have been associated with decreased risk of these chronic diseases. The role of vegetarian and/or vegan dietary patterns and incident cardiovascular outcomes still remains unclear. To address these uncertainties, the investigators propose to conduct a systematic review and meta-analysis of the totality of evidence from prospective cohort studies to distinguish the association of vegetarian and/or vegan dietary patterns on the prevention and management of cardiovascular diseases. This proposed knowledge synthesis was commissioned by the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) and will be used to inform clinical practice and dietary guidelines, help improve health outcomes, and guide future research design.', 'DetailedDescription': \"Background: Cardiovascular disease (CVD) is the number 1 cause of death worldwide, representing 31% of all deaths. Vegetarian and/or vegan dietary patterns have been shown in prospective cohort and cross-sectional studies to be associated with lower coronary heart disease and ischemic heart disease risk. Evidence from randomized controlled trials also suggest that vegetarian and vegan diets may be beneficial for cardiovascular disease risk factors, such as LDL cholesterol, weight, blood pressure and type 2 diabetes (glycemic control). Moreover, evidence from meta-analyses of prospective cohort studies have shown that diets high in red and processed meat consumption are associated with an increased incidence of stroke and cardiovascular mortality. The evidence for a vegetarian dietary pattern is promising for prevention and management of cardiovascular diseases, however, not all CVD guidelines recommend following a vegetarian and/or vegan dietary pattern for the prevention and management of these diseases, or the guidelines grade the evidence as low quality.\\n\\nNeed for proposed research: High quality systematic reviews and meta-analyses of prospective cohort studies represent evidence to support dietary guidelines and public health policy development. As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, there is a need for systematic reviews and meta-analyses comparing the role of vegetarian/vegan diets in the prevention and management of cardiovascular diseases.\\n\\nObjective: The investigators will conduct a systematic reviews and meta-analysis to assess vegan/vegetarian diets with cardiovascular disease outcomes (cardiovascular disease (CVD), coronary heart disease (CHD) and stroke incidence and mortality) in prospective cohort studies.\\n\\nDesign: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.\\n\\nData sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials databases will be searched using appropriate search terms supplemented by hand searches of references of included studies.\\n\\nData extraction: Two or more investigators will independently extract relevant data and assess risk of bias using the Newcastle-Ottawa Scale (NOS) for observational studies. Risk ratios, odds ratios and hazard ratios for clinical outcomes will be extracted or derived from clinical event data across exposure to either vegetarian or non-vegetarian diets. All disagreements will be resolved by consensus.\\n\\nOutcomes: Six outcomes will be assessed: CVD incidence and mortality, coronary heart disease (CHD) incidence and mortality, stroke incidence and mortality\\n\\nData synthesis: The natural log-transformed relative risks or hazard ratios of clinical outcomes comparing the exposure to the reference group from each cohort will be pooled using the generic inverse variance method with random effects models. Heterogeneity will be assessed by Cochrane's Q and quantified by I2. Sensitivity analyses and a priori subgroup analyses will be undertaken to explore sources of heterogeneity including the effect of the cohorts, sex, type of vegetarian diet, underlying disease status, follow-up (<10-years, >=10-years), level of adjustment of models, quality of the studies (NOS), and validation of the dietary assessment instruments. Significant unexplained heterogeneity will be investigated by additional post hoc subgroup analyses. Meta-regression analyses will assess the significance of subgroups analyses. Publication bias will be assessed by the inspection of funnel plots and using Begg's and Egger's tests.\\n\\nEvidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).\\n\\nKnowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, cardiovascular diseases and diabetes. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.\\n\\nSignificance: The proposed project will aid in knowledge translation related to the role of vegetarian/vegan diets in the prevention and management of cardiovascular diseases, strengthening the evidence-base for guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cardiovascular Diseases', 'Coronary Heart Disease', 'Stroke', 'Mortality']}, 'KeywordList': {'Keyword': ['Vegetarian Diet', 'Vegan Diet', 'Systematic Reviews and Meta-Analysis', 'Clinical practice guidelines', 'Prospective cohort studies', 'Cardiovascular disease', 'Coronary heart disease', 'Stroke', 'Cardiovascular mortality', 'Coronary heart disease mortality', 'Stroke mortality']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Vegetarian or Vegan Diets', 'InterventionDescription': 'Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cardiovascular disease incidence', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Cardiovascular disease mortality', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Coronary heart disease incidence', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Coronary heart disease mortality', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Stroke incidence', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Stroke mortality', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nProspective cohorts studies\\nDuration >=1 year\\nAssessment of the exposure of vegetarian or vegan diet\\nAscertainment of viable data by level of exposure\\n\\nExclusion Criteria:\\n\\nEcological, cross-sectional, retrospective observational studies, clinical trials and non-human studies\\nDuration < 1 year\\nNo assessment of exposure of vegetarian/vegan diet\\nNo ascertainment viable clinical outcome data by level of exposure', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Healthy volunteers or those at risk for cardiovascular disease', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'John Sievenpiper, PhD, MD', 'OverallOfficialAffiliation': 'University of Toronto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital\", 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5C 2T2', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28728684', 'ReferenceType': 'background', 'ReferenceCitation': 'Satija A, Bhupathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett W, Rexrode KM, Rimm EB, Hu FB. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol. 2017 Jul 25;70(4):411-422. doi: 10.1016/j.jacc.2017.05.047.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'World Health Organization. (2017). Cardiovascular Diseases. Obtained from: http://www.who.int/mediacentre/factsheets/fs317/en/'}, {'ReferencePMID': '26853923', 'ReferenceType': 'background', 'ReferenceCitation': 'Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2017 Nov 22;57(17):3640-3649. doi: 10.1080/10408398.2016.1138447.'}, {'ReferencePMID': '16873779', 'ReferenceType': 'background', 'ReferenceCitation': 'Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Jaster B, Seidl K, Green AA, Talpers S. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1777-83. doi: 10.2337/dc06-0606.'}, {'ReferencePMID': '19339401', 'ReferenceType': 'background', 'ReferenceCitation': 'Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green A, Ferdowsian H. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009 May;89(5):1588S-1596S. doi: 10.3945/ajcn.2009.26736H. Epub 2009 Apr 1.'}, {'ReferencePMID': '23695207', 'ReferenceType': 'background', 'ReferenceCitation': 'Mishra S, Xu J, Agarwal U, Gonzales J, Levin S, Barnard ND. A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: the GEICO study. Eur J Clin Nutr. 2013 Jul;67(7):718-24. doi: 10.1038/ejcn.2013.92. Epub 2013 May 22.'}, {'ReferencePMID': '26143683', 'ReferenceType': 'background', 'ReferenceCitation': 'Wang X, Lin X, Ouyang YY, Liu J, Zhao G, Pan A, Hu FB. Red and processed meat consumption and mortality: dose-response meta-analysis of prospective cohort studies. Public Health Nutr. 2016 Apr;19(5):893-905. doi: 10.1017/S1368980015002062. Epub 2015 Jul 6.'}, {'ReferencePMID': '26935118', 'ReferenceType': 'background', 'ReferenceCitation': 'Yang C, Pan L, Sun C, Xi Y, Wang L, Li D. Red Meat Consumption and the Risk of Stroke: A Dose-Response Meta-analysis of Prospective Cohort Studies. J Stroke Cerebrovasc Dis. 2016 May;25(5):1177-1186. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.040. Epub 2016 Feb 27.'}, {'ReferencePMID': '25535808', 'ReferenceType': 'background', 'ReferenceCitation': 'Coutts SB, Wein TH, Lindsay MP, Buck B, Cote R, Ellis P, Foley N, Hill MD, Jaspers S, Jin AY, Kwiatkowski B, MacPhail C, McNamara-Morse D, McMurtry MS, Mysak T, Pipe A, Silver K, Smith EE, Gubitz G; Heart, and Stroke Foundation Canada Canadian Stroke Best Practices Advisory Committee. Canadian Stroke Best Practice Recommendations: secondary prevention of stroke guidelines, update 2014. Int J Stroke. 2015 Apr;10(3):282-91. doi: 10.1111/ijs.12439. Epub 2014 Dec 23.'}, {'ReferencePMID': '27712954', 'ReferenceType': 'background', 'ReferenceCitation': 'Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J Jr, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GB, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. Epub 2016 Jul 25.'}, {'ReferencePMID': '31263700', 'ReferenceType': 'derived', 'ReferenceCitation': 'Glenn AJ, Viguiliouk E, Seider M, Boucher BA, Khan TA, Blanco Mejia S, Jenkins DJA, Kahleova H, Rahelic D, Salas-Salvado J, Kendall CWC, Sievenpiper JL. Relation of Vegetarian Dietary Patterns With Major Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Front Nutr. 2019 Jun 13;6:80. doi: 10.3389/fnut.2019.00080. eCollection 2019.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}, {'ConditionMeshId': 'D000003327', 'ConditionMeshTerm': 'Coronary Disease'}, {'ConditionMeshId': 'D000003324', 'ConditionMeshTerm': 'Coronary Artery Disease'}, {'ConditionMeshId': 'D000017202', 'ConditionMeshTerm': 'Myocardial Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000001161', 'ConditionAncestorTerm': 'Arteriosclerosis'}, {'ConditionAncestorId': 'D000001157', 'ConditionAncestorTerm': 'Arterial Occlusive Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6239', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4159', 'ConditionBrowseLeafName': 'Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4155', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 77, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04337255', 'OrgStudyIdInfo': {'OrgStudyId': '18052104-IRB01'}, 'Organization': {'OrgFullName': 'Rush University Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients', 'OfficialTitle': 'MIND Diet and Dementia Prevention in Ischemic Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'June 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 14, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2026', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 12, 2019', 'StudyFirstSubmitQCDate': 'April 4, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 7, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 26, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 28, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Neelum T. Aggarwal, MD', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Rush University Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Rush University Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Chicago', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Advocate Hospital System', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'National Institute on Aging (NIA)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"To test the effects of a 2- to 3-year intervention of the MIND diet versus usual post-stroke care on cognitive decline, the characteristic feature of dementia, and on brain biomarkers of Alzheimer's Disease (AD) and vascular disease in a Phase Ill randomized controlled trial of 500 patients hospitalized for acute ischemic stroke, aged 55 years or older, and without dementia who are discharged home following hospitalization.\", 'DetailedDescription': 'The Mediterranean-DASH diet intervention for Neurodegenerative Delay (MIND in Stroke patients is designed to test the effects of a 2-3 year intervention of a hybrid of the Mediterranean and DASH diets, called MIND on 500 older patients, without dementia who are hospitalized for acute stroke who are discharged home following hospitalization. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetable and berries as well as food component servings that reflect the nutrition dementia evidence. In this study we will test the effects of a 2- to 3-year intervention of the MIND diet (3 months of delivered meals followed by dietary and general stroke health counseling) versus usual post-stroke care (3 months delivered self-selected meals followed by general stroke health counseling) on change on cognitive outcomes over 24 to 36 months. Biological effects of the MIND diet will be assessed by measurement of brain macro and microstructural integrity in 300 trial participants randomly selected participants. Other biochemical markers will be assessed in the entire group of 500 participants including: plasma Abeta42/beta40, brain derived neurotropic factor (BDNF) and plasma markers of oxidative stress and inflammation. The trial will examine potential effect mediators and modifiers by a number of cardiovascular risk factors, AD biomarkers and biological mechanisms. The proposed study has 3 recruitment sites, Rush University Medical Center, University of Chicago, and Advocate Christ Hospital all located in Chicago.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cognitive Decline', 'Dementia, Vascular', 'Alzheimer Disease', 'Dementia', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'MIND diet intervention', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': 'Single ( Outcomes assessor)', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '500', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'MIND DIET intervention', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Allocation and blinding 3 year intervention of MIND Diet + counseling', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Behavioral Dietary intervention ( MIND Diet)']}}, {'ArmGroupLabel': 'Usual care diet intervention', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': '3 year Intervention of usual care diet + counseling', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Behavioral Usual Care Diet Intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Behavioral Dietary intervention ( MIND Diet)', 'InterventionDescription': 'The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['MIND DIET intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Behavioral Usual Care Diet Intervention', 'InterventionDescription': 'The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Usual care diet intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in global cognitive score', 'PrimaryOutcomeDescription': '3-year change in global cognitive score. The global cognitive score is a composite score, based on the average of z scores of the 19 individual tests scores, with a mean of 0 and standard deviation of 1. Higher scores reflect high global cognitive function.', 'PrimaryOutcomeTimeFrame': '3-years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in brain MRI derived markers of macro and micro structural integrity (cubic Centimeters), total brain volume, hippocampal volume and white matter hyperintensity volume ( cubic centimeters)', 'SecondaryOutcomeDescription': '300 participants total ( 150 in each treatment group)', 'SecondaryOutcomeTimeFrame': '3-years'}, {'SecondaryOutcomeMeasure': 'Change in 5 individual cognitive domains', 'SecondaryOutcomeDescription': 'Change in 5 individual domains that include executive functioning, perceptual speed, episodic memory, semantic and working memory. Each domain is made up of atleast 2 cognitive tests that are z scored and averaged for that domain. Higher scores on each domain reflects higher cognition in that domain.', 'SecondaryOutcomeTimeFrame': '3-years'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria\\nMen and women, 55 years of age - inclusive- or older\\nAcute stroke as defined by an acute focal neurological deficit in combination with one of the following: acute ischemic infarct (stroke) as documented by either a DWl positive lesion on MR imaging or a new lesion on a delayed CT scan\\nWritten informed consent by patient prior to study participation\\nWillingness to complete all assessments and participate in follow-up\\nWilling to participate and give informed consent\\nAdequate Visual and auditory acuity to undergo neuropsychological testing\\nExclusion criteria\\nCDR>=0.5\\nNuts, berries, olive oil, or fish allergies\\nUse of medications to treat Alzheimer's disease or Parkinson's disease\\nAphasia\\nConditions of psychosis or bipolar disorder judged by study investigators to potentially interfere with study compliance over 3 years\\nReport of alcohol or substance abuse within six months, or heavy alcohol consumption (>2 drinks/d women; >3 drinks/d men)\\nUnstable or recent onset of cardiovascular disease, such as myocardial infarction within six months or presence of congestive heart failure (Stages II-IV)\\nCancer treatment <= 5 years except non-melanoma skin cancer , basal cell skin cancer (this criterion may be waived at the site PI's discretion)\\nIllness that might be associated with weight change, such as a history of stomach or gastrointestinal conditions (Inflammatory Bowel Disease, Crohn's Disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, etc.)\\nHistory of liver disease, HIV or Hepatitis C\\nAn intracerebral hemorrhage as documented on CT or MRI\\nPre- hospitalization diagnosis of dementia or mild cognitive impairment\\nPatients presenting one of the following diseases: cerebral venous thrombosis, traumatic cerebral hemorrhage, intracerebral hemorrhage because of a known or image-guided assumed vascular malformation, pure meningeal or intraventricular hemorrhage\\nPatients presenting a malignant disease with life expectancy < 3 years\\nResidence in a nursing home and thus going back to nursing home upon discharge\\nParticipation in an ongoing investigational drug study\\nException to these guidelines will be rare but may be considered on a case by case basis at the discretion of the PI's\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Neelum T Aggarwal, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '312 942 2338', 'CentralContactEMail': 'neelum_t_aggarwal@rush.edu'}, {'CentralContactName': 'Christy C Tangney, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '3129425995', 'CentralContactEMail': 'ctangney@rush.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Neelum T Aggarwal, MD.', 'OverallOfficialAffiliation': 'Rush University Medical Center', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Christy Tangney, PhD', 'OverallOfficialAffiliation': 'Rush University Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Rush University Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60612', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26086182', 'ReferenceType': 'result', 'ReferenceCitation': 'Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, Aggarwal NT. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015 Sep;11(9):1015-22. doi: 10.1016/j.jalz.2015.04.011. Epub 2015 Jun 15.'}, {'ReferencePMID': '25681666', 'ReferenceType': 'result', 'ReferenceCitation': \"Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015 Sep;11(9):1007-14. doi: 10.1016/j.jalz.2014.11.009. Epub 2015 Feb 11.\"}, {'ReferencePMID': '31686099', 'ReferenceType': 'result', 'ReferenceCitation': 'Cherian L, Wang Y, Fakuda K, Leurgans S, Aggarwal N, Morris M. Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) Diet Slows Cognitive Decline After Stroke. J Prev Alzheimers Dis. 2019;6(4):267-273. doi: 10.14283/jpad.2019.28.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'Electronic data will be made available after trial completion', 'IPDSharingInfoTypeList': {'IPDSharingInfoType': ['Study Protocol', 'Statistical Analysis Plan (SAP)', 'Informed Consent Form (ICF)', 'Clinical Study Report (CSR)', 'Analytic Code']}, 'IPDSharingTimeFrame': '6 months following publication of results', 'IPDSharingAccessCriteria': 'Review & Approval by the Publications and Presentation Committee'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000000544', 'ConditionMeshTerm': 'Alzheimer Disease'}, {'ConditionMeshId': 'D000003704', 'ConditionMeshTerm': 'Dementia'}, {'ConditionMeshId': 'D000015140', 'ConditionMeshTerm': 'Dementia, Vascular'}, {'ConditionMeshId': 'D000060825', 'ConditionMeshTerm': 'Cognitive Dysfunction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000024801', 'ConditionAncestorTerm': 'Tauopathies'}, {'ConditionAncestorId': 'D000019636', 'ConditionAncestorTerm': 'Neurodegenerative Diseases'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}, {'ConditionAncestorId': 'D000002537', 'ConditionAncestorTerm': 'Intracranial Arteriosclerosis'}, {'ConditionAncestorId': 'D000020765', 'ConditionAncestorTerm': 'Intracranial Arterial Diseases'}, {'ConditionAncestorId': 'D000056784', 'ConditionAncestorTerm': 'Leukoencephalopathies'}, {'ConditionAncestorId': 'D000001161', 'ConditionAncestorTerm': 'Arteriosclerosis'}, {'ConditionAncestorId': 'D000001157', 'ConditionAncestorTerm': 'Arterial Occlusive Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafAsFound': 'Cognitive Decline', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3575', 'ConditionBrowseLeafName': 'Alzheimer Disease', 'ConditionBrowseLeafAsFound': \"Alzheimer's Disease\", 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6594', 'ConditionBrowseLeafName': 'Dementia', 'ConditionBrowseLeafAsFound': 'Dementia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17551', 'ConditionBrowseLeafName': 'Dementia, Vascular', 'ConditionBrowseLeafAsFound': 'Dementia, Vascular', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22692', 'ConditionBrowseLeafName': 'Tauopathies', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21248', 'ConditionBrowseLeafName': 'Neurodegenerative Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21526', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4505', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14163', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5991', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4159', 'ConditionBrowseLeafName': 'Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5476', 'ConditionBrowseLeafName': 'Intracranial Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22211', 'ConditionBrowseLeafName': 'Intracranial Arterial Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28281', 'ConditionBrowseLeafName': 'Leukoencephalopathies', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4155', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2192', 'ConditionBrowseLeafName': 'Familial Alzheimer Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 78, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02108613', 'OrgStudyIdInfo': {'OrgStudyId': '084902'}, 'Organization': {'OrgFullName': 'British Columbia Cancer Agency', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Living Well on Androgen Deprivation Therapy', 'OfficialTitle': 'Living Well on Androgen Deprivation Therapy: A Comprehensive Approach to Prostate Cancer Survivorship'}, 'StatusModule': {'StatusVerifiedDate': 'April 2014', 'OverallStatus': 'Withdrawn', 'WhyStopped': 'It was deemed not enough funding and the initial funding returned and study withdrawn (never opened and no recruitment happened.', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2015', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'March 2017', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 7, 2014', 'StudyFirstSubmitQCDate': 'April 7, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 9, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 23, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 29, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'British Columbia Cancer Agency', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'The Prostate Centre - Vancouver Island and the Gulf Islands', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Approximately half of men treated for prostate cancer will be offered hormone deprivation therapy during their cancer experience. The secondary effects of this treatment can result in osteoporosis, cardiovascular disease, stroke, diabetes, and diminished sexual health. To promote healthy lifestyle choices for couples and maintain their intimacy and emotional health we propose the Living Well, an innovative program that combines nutrition, physical activity, and sexual health initiatives in one integrated service. This project will be piloted at the Vancouver Island Centre with an expected 100 patients over 1 year. Over a six month period both the experimental and control groups will have access to a workbook (designed for men with prostate cancer and on hormone deprivation therapy) and sexual health counseling. The experimental group will also have access to an exercise and a nutritional program and support by volunteers to keep motivated. Assessment will look at quality of life, physical factors, and biomarkers associated with secondary disease.', 'DetailedDescription': 'Purpose:\\n\\nThe overarching goal of the Living Well project is to maintain or improve quality of life for people with prostate cancer on androgen deprivation therapy (ADT) and their partners by providing the couples with the tools to promote confidence and motivation to remain both physically and psychosocially healthy and intimate. The primary objective is to determine the effect of our comprehensive community-based survivorship program on psychosocial health of people with PCa on ADT and their partners. Secondarily we intend to explore the impact of the program on biomarkers associated with the metabolic syndrome often observed in men on ADT, the program\\'s operational and perceived (by patients and partners) impact of the program.\\n\\nHypothesis:\\n\\nThe intervention group will show a larger magnitude of improvement on measures of QOL, fatigue, and intimacy, ultimately leading to increased benefit when compared to the control group.\\nWe believe through the engagement of peer volunteers that compliance and adherence to positive lifestyle changes will be higher on the intervention group when compared to the control group.\\n\\nJustification:\\n\\nADT has offered people with prostate cancer (PCa) improved curative outcomes when combined with local radiation therapy and has been fundamental in controlling disease for those with a biochemical recurrence or metastatic disease. Due to its effectiveness, ADT is offered to up to 50% of people with PCa.\\n\\nADT reduces the occurrence of metastases by lowering testosterone levels. Unfortunately, decreased testosterone can lead to hot flashes, diminished libido, erectile dysfunction, depression, diminished muscle strength, reduced bone mineral density, increased fat mass, and increased cholesterol levels. This conglomerate of secondary effects can lead to osteoporosis, cardiovascular disease, stroke, and diabetes. Poor lifestyle habits can further aggravate these secondary effects of ADT therapy. Being overweight may increase the risk of mortality from PCa. However, the increase in vascular disease and diabetes seems to be more strongly correlated with death than the cancer itself. Those with pre-existing cardiac problems and receiving ADT, have a 75% chance of dying from cardiovascular disease rather than PCa.\\n\\nThere is growing evidence that healthy lifestyle practices that include a healthy diet and regular physical activity can improve the overall prognosis of PCa patients and diminish the negative effects of ADT. Many cancer survivors are motivated to seek information about food choices and physical activity to improve their response to treatment and quality of life. Recent research has shown that a preemptive educational program built around a book, the \"Androgen Deprivation Therapy: An Essential Guide for Prostate Cancer Patients and Their Loved Ones\", or the \"Workbook\" for short, which addresses all issues of life style management, can be effective in helping patients and their families in overcoming the challenges of ADT.\\n\\nThe Workbook was created by a national team of PCa experts (the ADT Working Group) and is endorsed by the Canadian Urological Association. The Workbook addresses the well-established, physical and emotional adverse effects of ADT. Although not all ADT side effects directly reduce a patient\\'s survival, they may greatly impact a patient and his partner\\'s QoL. Important aspects explored in the Workbook include the psychosocial effects of ADT, exercise needs, and the nutritional recommendations for men on ADT. Previous research indicates that the effectiveness of the Workbook is enhanced when distributed to patients prior to the start of ADT, before side effects manifest. The Workbook\\'s effectiveness is also enhanced when combined with motivational sessions led by trained educators.\\n\\nGiven that people with PCa on ADT and their partners generally struggle with aspects of their sexual health, nutrition, and physical activity concurrently, we propose for the first time to test a comprehensive PCa survivorship approach, the Living Well program, which addresses concerns related to all three components. This is a community-based program designed for PCa patients prior to starting on ADT and will also be extended to their partners. The program will make extensive use of the ADT Workbook and will be primarily delivered using existing resources.\\n\\nObjectives:\\n\\nThe primary outcomes are:\\n\\nQuality of Life\\nFatigue\\n\\nSecondary outcome is\\n\\n- Intimacy\\n\\nWe will also explore:\\n\\nEffects on biomarkers associated with the metabolic syndrome secondary to ADT *\\nEffects on erectile dysfunction, PSA and testosterone levels*\\nThe perceptions of patients and partners about the impact of the program on their psychosocial health\\nOperational impact\\n\\nNote: *Patient\\'s health records will be checked to obtain annual blood measures of cholesterol, glucose, lipoprotein, PSA, testosterone levels and for responses to the Sexual Health Inventory for Men - SHIM, all part of usual care.\\n\\nResearch Method:\\n\\nWe propose a prospective randomized control trial. Over twelve months, a sample of 100 English-speaking people, who are scheduled to start androgen deprivation therapy or have started within the last 7 days for prostate cancer at will be recruited for the study. Every two consented participants (and their partners if available) will be randomized. Therefore, one patient/partner will receive the intervention and one is placed in the control group. Both arms will receive the workbook and sexual counseling. The experimental group will also have access to an exercise and a nutrition program, with all three components supported by peer volunteers. Over the course of one month we predict eight patient/partners will be consented (four control, four intervention). Every four participants (and their partners if available) randomized to the intervention will form a group that will proceed through the program.\\n\\nPotential participants will be identified and invited by physicians. The Research Intern will consent participants. After consenting the participant will be instructed to bring their signed PAR-Q+ (24, 25) and consent form to the Introductory Meeting at the Prostate Centre. The research intern will also access participant\\'s medical records to collect demographic information (cancer stage and treatment, co-morbidities, age) before they start the program.Participant\\'s partners will also be invited to participate in the program The control group will attend the Introductory meeting and two sexual health counseling sessions .The intervention group will attend the Introductory meeting, the two sexual health meetings plus the exercise component (eight weekly exercise sessions) and the nutrition component (four monthly nutrition sessions) over a period of 6 months. A peer volunteer will be assigned to each intervention couple and will provide support during the intervention to help maintain participant\\'s adherence to physical activity and healthy eating goals.Both intervention and control groups will provide measurements at each sexual health session (body-mass index -BMI, waist circumference, grip strength, blood pressure and heart rate) , describe their medical history and current medications. Both groups will attend follow-up measurement sessions at 12 and 24 months after baseline. Participants and their partners will fill out separate questionnaires at baseline, 6 months and at the two follow-up measurement sessions Participants and their partners will be interviewed at baseline, six, twelve, and twenty-four months. Interviews will be conducted until saturation at baseline (expected n=10) and the same couples will be interviewed again at the other time points. During these interviews qualitative data will be collected and transcribed for analysis. Questions related to their current physical activity experience, nutritional habits and barriers to maintaining a healthy diet and regular physical activity routine will be asked. In addition interviews with intervention participants will ask questions related to participants\\' satisfaction with the timing, quality, relevance & usefulness of topics discussed during the physical activity and nutrition sessions, motivation provided by instructors and peer volunteers and overall feedback about the program.\\n\\nStatistical Analysis:\\n\\nThe Statistical Package for the Social Sciences (SPSS) version 14.0 (SPSS Inc., Chicago, IL) will be used for the statistical analysis. Significance will be set at P = 0.05 (two-tailed). Descriptive statistics [mean ± standard deviation (SD)] will be calculated for all characteristics. Differences between groups will be examined using Mann-Whitney U-test or Kruskal-Wallis test. A sample size calculation was based on the Quality of Life primary outcome measured by the FACT-P questionnaire (36). Change in quality of life will be determined by calculating change scores between different time-points. Considering mean score difference of 5, at the 5% level (2-tailed) and 80% power, a sample size of 41 should yield significant statistical differences. Based on our clinical and research experience with this population, we estimate recruiting about 50 patients per group in 12 months. Qualitative data will be systematically organized and sorted using ATLAS.ti 6.2 and analyzed through thematic analysis.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Prostate Cancer']}, 'KeywordList': {'Keyword': ['Androgen deprivation therapy', 'Supportive care', 'Quality of life']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Exercise Sessions', 'Behavioral: Nutrition Education', 'Behavioral: Peer Support Volunteer']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'The control group will receive sexual health counseling.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Exercise Sessions', 'InterventionDescription': '8 weeks of weekly exercise classes taught by a certified exercise physiologist.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Nutrition Education', 'InterventionDescription': 'Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Peer Support Volunteer', 'InterventionDescription': 'Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"Change from baseline in participant's quality of life on the Functional Assessment of Chronic Illnesses Therapy (FACT-P)\", 'PrimaryOutcomeDescription': 'Functional Assessment of Chronic Illnesses Therapy is a quality of life questionnaire for patients.with prostate cancer.', 'PrimaryOutcomeTimeFrame': 'Baseline, 6 months, 12 months and 24 months'}, {'PrimaryOutcomeMeasure': \"Change from baseline in patient's partner quality of life on the Quality of Life Scale (QOLS)\", 'PrimaryOutcomeDescription': 'The Quality of Life Scale is a quality of life questionnaire that will be used for participants partners.', 'PrimaryOutcomeTimeFrame': 'Baseline, 6 months,12 months, 24 months'}, {'PrimaryOutcomeMeasure': 'Change from baseline in fatigue on the Functional Assessment of Chronic Illnesses Therapy- Fatigue (FACIT-fatigue)', 'PrimaryOutcomeDescription': 'The Functional Assessment of Chronic Illnesses Therapy is a measure of fatigue. This outcome will be tested for both participants and their partners.', 'PrimaryOutcomeTimeFrame': 'Baseline, 6 months, 12 months, 24 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change from baseline in intimacy on the Dyadic Adjustment Scale (DAS)', 'SecondaryOutcomeDescription': 'The Dyadic Adjustment Scale is to measure intimacy. Both participants and their partners will complete this measure.', 'SecondaryOutcomeTimeFrame': 'Baseline, 6 months, 12 months, 24 months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Change from baseline in Body-Mass Index', 'OtherOutcomeDescription': \"Patient's weight and height will be measured at each meeting with the nurse. Body-Mass index [mass(kg)/height (m)2] will be calculated at each time point\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months and 24 months'}, {'OtherOutcomeMeasure': 'Change from baseline in waist circumference', 'OtherOutcomeDescription': \"Patient's waist circumference will be measured at each meeting with the nurse.\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months, siz months, 12 months and 24 months'}, {'OtherOutcomeMeasure': 'Change from baseline in grip strength', 'OtherOutcomeDescription': \"Patient's grip strength will be measured at each meeting with the nurse.\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months and 24 months'}, {'OtherOutcomeMeasure': 'Changes from baseline in systolic blood pressure', 'OtherOutcomeDescription': \"Patient's blood pressure will be measured at each meeting with the nurse.\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months and 24 months'}, {'OtherOutcomeMeasure': 'Change from baseline on blood levels of cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), total glucose (TG), fasting glucose and glycated hemoglobin (HbA1)', 'OtherOutcomeDescription': \"Blood measures will be obtained from patient's health records. Blood measures obtained within 12 months prior to starting the program will be used as baseline. Monitoring of these parameters are part of the standard of care.\", 'OtherOutcomeTimeFrame': 'Baseline, 12 and 24 months'}, {'OtherOutcomeMeasure': 'Change in erectile dysfunction from baseline on the Sexual Health Inventory for Men (SHIM)', 'OtherOutcomeDescription': \"SHIM results will be obtained from patient's health records. Monitoring erectile dysfunction using this tool is part of the usual care.\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months and 24 months'}, {'OtherOutcomeMeasure': \"Perceptions of patients and partners about the impact of the program on their psychosocial health assessed though qualitative interviews and program's meetings\", 'OtherOutcomeDescription': \"Interviews will be conducted until saturation at baseline (expected n=10) and the same couples will be interviewed again at the other time points. During these interviews qualitative data will be collected and transcribed for analysis. Questions related to their current physical activity experience, nutritional habits and barriers to maintaining a healthy diet and regular physical activity routine will be asked. In addition interviews with intervention participants will ask questions related to participants' satisfaction with the timing, quality, relevance & usefulness of topics discussed during the physical activity and nutrition sessions, motivation provided by instructors and peer volunteers and overall feedback about the program.\", 'OtherOutcomeTimeFrame': 'Baseline, 6 months, 12 months, 24 months'}, {'OtherOutcomeMeasure': 'Operational impact of the program assessed though interviews with participants, peer-support volunteers, and health care providers and program documentation', 'OtherOutcomeDescription': \"• Operational impact - assessed though interviews with participants, peer-support volunteers, and health care providers, as well as any documentation related to the availability of space and personnel to conduct the program. Finally, direct costs of the program (ie. average salaries of qualified exercise professionals, materials, fitness equipment, etc.) will be obtained from available government economic data and project's expenditures.\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months and 6 months'}, {'OtherOutcomeMeasure': 'Change from baseline on blood levels of Prostate-specific antigen (PSA) and testosterone', 'OtherOutcomeDescription': \"Blood measures will be obtained from patient's health records. Blood measures obtained within 12 months prior to starting the program will be used as baseline. Monitoring of these parameters are part of the standard of care.\", 'OtherOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months, 24 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAll prostate cancer patients registered with BCCA-VIC or referred by an urologist that are prescribed to receive androgen deprivation in their care plan (not currently on hormone therapy)\\nMust provide written, informed consent\\nMust be able to understand, speak, read and write English, and have the cognitive capacity to complete written questionnaires\\nMust be deemed ready to become more physically active, as determined by the PAR-Q+ and, if required, screened by a Canadian Society for Exercise Physiology Certified Exercise Physiologist® (CSEP-CEP) or medical doctor.\\nMust be willing and able to attend the introductory meeting with the Prostate Centre nurse (baseline measurement recordings), 8 weeks of supervised exercise, 4 monthly nutrition meetings, two sexual health meetings (which includes measurement recording sessions at 6 months), and follow up at 12 and 24 months\\nMust have access to a telephone\\nMust be able to commit to the full 6 month intervention period of the study (i.e. no scheduled, extended absences) and follow up at 12 and 24 months. This does not preclude any participants from withdrawing from the study at any point.\\nMust have greater than 12 months life expectancy\\n\\nExclusion Criteria:\\n\\nPrior invasive malignancy (except non-melanomatous skin cancer) or superficial bladder cancer unless disease free for a minimum of 5 years [for example, carcinoma in situ of the oral cavity is permissible]\\nPrevious hormone therapy within the past 5 years\\nParticipants who do not meet the following PAR-Q+(26, 27) criteria will be excluded from the study:\\nMust not have a YES response to Q2 on pg1: Do you feel pain in your chest at rest, during your daily activities of living, OR when you do physical activity?\\nMust not have a YES response to Q7 on pg 1: Has your doctor ever said that you should only do medically supervised physical activity?\\nMust not have YES response to any sub-questions on pages 2-3 related to musculoskeletal conditions, diabetes, heart disease, mental health problems or learning difficulties, pulmonary conditions, spinal cord injury, stroke unless clearance is provided by a CSEP-CEP . A CSEP-CEP will only provide clearance to a positive response if upon further query it is determined that the participant is asymptomatic and the benefits of light to moderate intensity exercise outweigh any foreseeable health and injury risks. In such cases where the CSEP-CEP makes a professional determination that the foreseeable risks may outweigh the benefits of exercise or the participant does not know the necessary details of his or her own medical condition, then the participant will need to obtain clearance via the physician referral letter.\\nPARQ+ form must be signed and dated within 6 months of entry into study\\nMore than 80 years of age', 'HealthyVolunteers': 'No', 'Gender': 'Male', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jennifer Goulart, MD', 'OverallOfficialAffiliation': 'British Columbia Cancer Agency', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Satnam Sidhu, RD', 'OverallOfficialAffiliation': 'British Columbia Cancer Agency', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'BC Cancer Agency', 'LocationCity': 'Victoria', 'LocationState': 'British Columbia', 'LocationZip': 'V*R 6V5', 'LocationCountry': 'Canada'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000011471', 'ConditionMeshTerm': 'Prostatic Neoplasms'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000005832', 'ConditionAncestorTerm': 'Genital Diseases, Male'}, {'ConditionAncestorId': 'D000091662', 'ConditionAncestorTerm': 'Genital Diseases'}, {'ConditionAncestorId': 'D000091642', 'ConditionAncestorTerm': 'Urogenital Diseases'}, {'ConditionAncestorId': 'D000011469', 'ConditionAncestorTerm': 'Prostatic Diseases'}, {'ConditionAncestorId': 'D000052801', 'ConditionAncestorTerm': 'Male Urogenital Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M14025', 'ConditionBrowseLeafName': 'Prostatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Prostate Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8636', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17005', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2877', 'ConditionBrowseLeafName': 'Genital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8634', 'ConditionBrowseLeafName': 'Genital Diseases, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2876', 'ConditionBrowseLeafName': 'Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14023', 'ConditionBrowseLeafName': 'Prostatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26785', 'ConditionBrowseLeafName': 'Male Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6034', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3749', 'InterventionBrowseLeafName': 'Androgens', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 79, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01601704', 'OrgStudyIdInfo': {'OrgStudyId': 'NB-CVOT'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'The Light Study', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Takeda'}, {'SecondaryId': 'U1111-1162-4981', 'SecondaryIdType': 'Registry Identifier', 'SecondaryIdDomain': 'WHO'}]}, 'Organization': {'OrgFullName': 'Orexigen Therapeutics, Inc', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)', 'OfficialTitle': 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR'}, 'StatusModule': {'StatusVerifiedDate': 'April 2016', 'OverallStatus': 'Terminated', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 14, 2012', 'StudyFirstSubmitQCDate': 'May 16, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 18, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'December 11, 2016', 'ResultsFirstSubmitQCDate': 'February 24, 2017', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'February 27, 2017', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 27, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Orexigen Therapeutics, Inc', 'LeadSponsorClass': 'INDUSTRY'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Obesity', 'Overweight']}, 'KeywordList': {'Keyword': ['Body Weight', 'Bupropion', 'Cardiovascular Diseases', 'Diabetes Mellitus', 'Diabetes Mellitus, Type 2', 'Endocrine System Diseases', 'Glucose Metabolism Disorders', 'Heart Diseases', 'Metabolic Diseases', 'Narcotic Antagonists', 'Naltrexone', 'Nutrition Disorders', 'Obesity', 'Overnutrition', 'Overweight']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '8910', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'NB32', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: NB32', 'Behavioral: Weight Management Program']}}, {'ArmGroupLabel': 'PBO', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: PBO', 'Behavioral: Weight Management Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'NB32', 'InterventionDescription': 'Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['NB32']}, 'InterventionOtherNameList': {'InterventionOtherName': ['CONTRAVE']}}, {'InterventionType': 'Drug', 'InterventionName': 'PBO', 'InterventionDescription': 'Placebo. Administered in addition to the weight management program.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['PBO']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Weight Management Program', 'InterventionDescription': \"A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['NB32', 'PBO']}, 'InterventionOtherNameList': {'InterventionOtherName': ['WeightMate (Tm)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)', 'PrimaryOutcomeDescription': 'The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed.', 'PrimaryOutcomeTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization', 'SecondaryOutcomeDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'SecondaryOutcomeTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke)', 'SecondaryOutcomeDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'SecondaryOutcomeTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal)', 'SecondaryOutcomeDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'SecondaryOutcomeTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal)', 'SecondaryOutcomeDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'SecondaryOutcomeTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n≥50 years of age (women) or ≥45 years of age (men)\\nBody mass index (BMI) ≥27 kg/m2 and ≤50 kg/m2\\nWaist circumference ≥88 cm (women) or ≥102 cm (men)\\n\\nAt increased risk of adverse cardiovascular outcomes:\\n\\nCardiovascular disease (confirmed diagnosis or at high likelihood of cardiovascular disease) with at least one of the following:\\n\\nHistory of documented myocardial infarction >3 months prior to screening\\nHistory of coronary revascularization\\nHistory of carotid or peripheral revascularization\\nAngina with ischemic changes (resting ECG), ECG changes on a graded exercise test (GXT), or positive cardiac imaging study\\nAnkle brachial index <0.9 (by simple palpation) within prior 2 years\\n≥50% stenosis of a coronary, carotid, or lower extremity artery within prior 2 years\\n\\nAND/OR\\n\\nType 2 diabetes mellitus with at least 2 of the following:\\n\\nHypertension (controlled with or without pharmacotherapy at <145/95 mm Hg)\\nDyslipidemia requiring pharmacotherapy\\nDocumented low HDL cholesterol (<50 mg/dL in women or <40 mg/dL in men) within prior 12 months\\nCurrent tobacco smoker\\n\\nExclusion Criteria:\\n\\nMyocardial infarction within 3 months prior to screening\\nAngina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading scheme\\nClinical history of cerebrovascular disease (stroke)\\nHistory of tachyarrhythmia other than sinus tachycardia\\nPlanned bariatric surgery, cardiac surgery, or coronary angioplasty\\nHistory of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the subject to seizures\\nHistory of mania or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary)\\nAny condition with life expectancy anticipated to be less than 4 years (e.g., congestive heart failure NYHA Class 3 or 4)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '45 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Medical Director Clinical Science', 'OverallOfficialAffiliation': 'Takeda', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationCountry': 'United States'}, {'LocationCity': 'Dothan', 'LocationState': 'Alabama', 'LocationCountry': 'United States'}, {'LocationCity': 'Mobile', 'LocationState': 'Alabama', 'LocationCountry': 'United States'}, {'LocationCity': 'Scottsboro', 'LocationState': 'Alabama', 'LocationCountry': 'United States'}, {'LocationCity': 'Chandler', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Mesa', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Peoria', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Scottsdale', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Tuscson', 'LocationState': 'Arizona', 'LocationCountry': 'United States'}, {'LocationCity': 'Little Rock', 'LocationState': 'Arkansas', 'LocationCountry': 'United States'}, {'LocationCity': 'Anaheim', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Carmichael', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Escondido', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Fresno', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Harbor City', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Huntington Beach', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'La Jolla', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Lomita', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Paramount', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Pasadena', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Riverside', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Santa Rosa', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Spring Valley', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Thousand Oaks', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Torrance', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'West Hills', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationCity': 'Colorado Springs', 'LocationState': 'Colorado', 'LocationCountry': 'United States'}, {'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationCountry': 'United States'}, {'LocationCity': 'Golden', 'LocationState': 'Colorado', 'LocationCountry': 'United States'}, {'LocationCity': 'Wheat Ridge', 'LocationState': 'Colorado', 'LocationCountry': 'United States'}, {'LocationCity': 'Norwalk', 'LocationState': 'Connecticut', 'LocationCountry': 'United States'}, {'LocationCity': 'Stamford', 'LocationState': 'Connecticut', 'LocationCountry': 'United States'}, {'LocationCity': 'Wilmington', 'LocationState': 'Delaware', 'LocationCountry': 'United States'}, {'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationCountry': 'United States'}, {'LocationCity': 'Boynton Beach', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Brooksville', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Clearwater', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Deland', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Delray Beach', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Gainesville', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Jacksonville Beach', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Melbourne', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'New Port Richey', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'New Smyrna Beach', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Oakland Park', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Orlando', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Palm Harbor', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Pembroke Pines', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Pensacola', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Pinellas Park', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Saint Petersburg', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Vero beach', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Wellington', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Winter Haven', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Austell', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Columbus', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Lawrenceville', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Riverdale', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Savannah', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Stockbridge', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationCity': 'Honolulu', 'LocationState': 'Hawaii', 'LocationCountry': 'United States'}, {'LocationCity': 'Meridian', 'LocationState': 'Idaho', 'LocationCountry': 'United States'}, {'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationCountry': 'United States'}, {'LocationCity': 'Gurnee', 'LocationState': 'Illinois', 'LocationCountry': 'United States'}, {'LocationCity': 'Melrose Park', 'LocationState': 'Illinois', 'LocationCountry': 'United States'}, {'LocationCity': 'Bloomington', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Brownsburg', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Elwood', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Evansville', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Hammond', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'South Bend', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Valparaiso', 'LocationState': 'Indiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Ames', 'LocationState': 'Iowa', 'LocationCountry': 'United States'}, {'LocationCity': 'Council Bluffs', 'LocationState': 'Iowa', 'LocationCountry': 'United States'}, {'LocationCity': 'Des Moines', 'LocationState': 'Iowa', 'LocationCountry': 'United States'}, {'LocationCity': 'West Des Moines', 'LocationState': 'Iowa', 'LocationCountry': 'United States'}, {'LocationCity': 'Overland Park', 'LocationState': 'Kansas', 'LocationCountry': 'United States'}, {'LocationCity': 'Wichita', 'LocationState': 'Kansas', 'LocationCountry': 'United States'}, {'LocationCity': 'Crestview Hills', 'LocationState': 'Kentucky', 'LocationCountry': 'United States'}, {'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationCountry': 'United States'}, {'LocationCity': 'Mount Sterling', 'LocationState': 'Kentucky', 'LocationCountry': 'United States'}, {'LocationCity': 'Alexandria', 'LocationState': 'Louisiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Baton Rouge', 'LocationState': 'Louisiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Monroe', 'LocationState': 'Louisiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Natchitoches', 'LocationState': 'Louisiana', 'LocationCountry': 'United States'}, {'LocationCity': 'Auburn', 'LocationState': 'Maine', 'LocationCountry': 'United States'}, {'LocationCity': 'Bangor', 'LocationState': 'Maine', 'LocationCountry': 'United States'}, {'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationCountry': 'United States'}, {'LocationCity': 'Columbia', 'LocationState': 'Maryland', 'LocationCountry': 'United States'}, {'LocationCity': 'Elkridge', 'LocationState': 'Maryland', 'LocationCountry': 'United States'}, {'LocationCity': 'Lutherville', 'LocationState': 'Maryland', 'LocationCountry': 'United States'}, {'LocationCity': 'Salisbury', 'LocationState': 'Maryland', 'LocationCountry': 'United States'}, {'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationCountry': 'United States'}, {'LocationCity': 'Brockton', 'LocationState': 'Massachusetts', 'LocationCountry': 'United States'}, {'LocationCity': 'Fall River', 'LocationState': 'Massachusetts', 'LocationCountry': 'United States'}, {'LocationCity': 'Haverhill', 'LocationState': 'Massachusetts', 'LocationCountry': 'United States'}, {'LocationCity': 'Methuen', 'LocationState': 'Massachusetts', 'LocationCountry': 'United States'}, {'LocationCity': 'Bingham Farms', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Dearbon', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Kalamazoo', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Midland', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Saginaw', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Southfield', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Stevensville', 'LocationState': 'Michigan', 'LocationCountry': 'United States'}, {'LocationCity': 'Edina', 'LocationState': 'Minnesota', 'LocationCountry': 'United States'}, {'LocationCity': 'Rochester', 'LocationState': 'Minnesota', 'LocationCountry': 'United States'}, {'LocationCity': 'Jackson', 'LocationState': 'Mississippi', 'LocationCountry': 'United States'}, {'LocationCity': 'Olive Branch', 'LocationState': 'Mississippi', 'LocationCountry': 'United States'}, {'LocationCity': 'Tupelo', 'LocationState': 'Mississippi', 'LocationCountry': 'United States'}, {'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationCountry': 'United States'}, {'LocationCity': 'Butte', 'LocationState': 'Montana', 'LocationCountry': 'United States'}, {'LocationCity': 'Missoula', 'LocationState': 'Montana', 'LocationCountry': 'United States'}, {'LocationCity': 'Fremont', 'LocationState': 'Nebraska', 'LocationCountry': 'United States'}, {'LocationCity': 'Grand Island', 'LocationState': 'Nebraska', 'LocationCountry': 'United States'}, {'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationCountry': 'United States'}, {'LocationCity': 'Henderson', 'LocationState': 'Nevada', 'LocationCountry': 'United States'}, {'LocationCity': 'Las Vegas', 'LocationState': 'Nevada', 'LocationCountry': 'United States'}, {'LocationCity': 'Reno', 'LocationState': 'Nevada', 'LocationCountry': 'United States'}, {'LocationCity': 'Sparks', 'LocationState': 'Nevada', 'LocationCountry': 'United States'}, {'LocationCity': 'Belvidere', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationCity': 'Edison', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationCity': 'Elizabeth', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationCity': 'Elmer', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationCity': 'Linden', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationCity': 'Ridgewood', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationCity': 'Albuquerque', 'LocationState': 'New Mexico', 'LocationCountry': 'United States'}, {'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'Endwell', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'New Hyde Park', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'New York', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'Staten Island', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'Syracuse', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'Williamsville', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationCity': 'Cary', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Charlotte', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Elizabeth City', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Greensboro', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Greenville', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Hickory', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Morganton', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Raleigh', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Salisbury', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Wilmington', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Winston-Salem', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Akron', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Beachwood', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Cincinnati', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Delaware', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Kettering', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Marion', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Mentor', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Willoughby Hills', 'LocationState': 'Ohio', 'LocationCountry': 'United States'}, {'LocationCity': 'Oklahoma City', 'LocationState': 'Oklahoma', 'LocationCountry': 'United States'}, {'LocationCity': 'Medford', 'LocationState': 'Oregon', 'LocationCountry': 'United States'}, {'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationCountry': 'United States'}, {'LocationCity': 'Altoona', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Bensalem', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Danville', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Duncansville', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Ephrata', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Jersey Shore', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Lancaster', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Lansdale', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Norristown', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Scottdale', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Sellersville', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'State College', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'West Reading', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Wilkes-Barre', 'LocationState': 'Pennsylvania', 'LocationCountry': 'United States'}, {'LocationCity': 'Anderson', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Columbia', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Greenville', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Greer', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Hodges', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Laurens', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Mount Pleasant', 'LocationState': 'South Carolina', 'LocationCountry': 'United States'}, {'LocationCity': 'Rapid City', 'LocationState': 'South Dakota', 'LocationCountry': 'United States'}, {'LocationCity': 'Bristol', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Chattanooga', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Germantown', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Jackson', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Kingsport', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Knoxville', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Memphis', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationCity': 'Beaumont', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Corpus Christi', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Hurst', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Lake Jackson', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'McKinney', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Schertz', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Tomball', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Waco', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationCity': 'Bountiful', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'Draper', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'Murray', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'Ogden', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'Orem', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'Salt Lake City', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'West Jordan', 'LocationState': 'Utah', 'LocationCountry': 'United States'}, {'LocationCity': 'Alexandria', 'LocationState': 'Virginia', 'LocationCountry': 'United States'}, {'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationCountry': 'United States'}, {'LocationCity': 'Richmond', 'LocationState': 'Virginia', 'LocationCountry': 'United States'}, {'LocationCity': 'Winchester', 'LocationState': 'Virginia', 'LocationCountry': 'United States'}, {'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationCountry': 'United States'}, {'LocationCity': 'Spokane', 'LocationState': 'Washington', 'LocationCountry': 'United States'}, {'LocationCity': 'Tacoma', 'LocationState': 'Washington', 'LocationCountry': 'United States'}, {'LocationCity': 'Walla Walla', 'LocationState': 'Washington', 'LocationCountry': 'United States'}, {'LocationCity': 'Green Bay', 'LocationState': 'Wisconsin', 'LocationCountry': 'United States'}, {'LocationCity': 'Kenosha', 'LocationState': 'Wisconsin', 'LocationCountry': 'United States'}, {'LocationCity': 'Madison', 'LocationState': 'Wisconsin', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26954408', 'ReferenceType': 'derived', 'ReferenceCitation': 'Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 8;315(10):990-1004. doi: 10.1001/jama.2016.1558.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'NB32', 'FlowGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Placebo', 'FlowGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowMilestoneComment': 'Represents number of participants randomized', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4456'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '4454'}]}}, {'FlowMilestoneType': 'Treated', 'FlowMilestoneComment': 'Represents number of participants included in the ITT analysis', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4455'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '4450'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowMilestoneComment': 'Completed indicates treated participants. Represents number of participants in the ITT analysis.', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4455'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '4450'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '1'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '4'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Randomized but not dispensed study med', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'NB32', 'BaselineGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Placebo', 'BaselineGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '4455'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '4450'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '8905'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2973'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3053'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '6026'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1482'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1397'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2879'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '61.1', 'BaselineMeasurementSpread': '7.27'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '60.9', 'BaselineMeasurementSpread': '7.38'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '61.0', 'BaselineMeasurementSpread': '7.33'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2437'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2419'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4856'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2018'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2031'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4049'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '279'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '291'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '570'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4174'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4156'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8330'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '5'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '20'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '31'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '27'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '46'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '12'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '656'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '648'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1304'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3738'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3698'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '7436'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': 'NA', 'BaselineMeasurementComment': 'Selection of multiple race categories was not permissible by the participants. Participants advised to select the most appropriate category.'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': 'NA', 'BaselineMeasurementComment': 'Selection of multiple race categories was not permissible by the participants. Participants advised to select the most appropriate category.'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': 'NA', 'BaselineMeasurementComment': 'Total not calculated because data are not available (NA) in one or more arms.'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '25'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '51'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '76'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4455'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4450'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8905'}]}}]}}]}}, {'BaselineMeasureTitle': 'Weight', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'kilogram', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '105.6', 'BaselineMeasurementSpread': '19.09'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '106.3', 'BaselineMeasurementSpread': '19.18'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '106.0', 'BaselineMeasurementSpread': '19.14'}]}}]}}]}}, {'BaselineMeasureTitle': 'Body Mass Index (BMI)', 'BaselineMeasurePopulationDescription': 'BMI was calculated at the site. Data are missing for 3 participants for whom the site did not calculate BMI, although weight and height were measured.', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'kg/m^2', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4452'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8902'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '37.2', 'BaselineMeasurementSpread': '5.26'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '37.4', 'BaselineMeasurementSpread': '5.44'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '37.3', 'BaselineMeasurementSpread': '5.35'}]}}]}}]}}, {'BaselineMeasureTitle': 'Cardiovascular (CV) risk group', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'CV disease without T2DM (type 2 diabetes mellitus)', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '670'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '646'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1316'}]}}]}}, {'BaselineClassTitle': 'CV disease with T2DM', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '745'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '801'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1546'}]}}]}}, {'BaselineClassTitle': 'T2DM without CV disease', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3039'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3002'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '6041'}]}}]}}]}}, {'BaselineMeasureTitle': 'Hypertension', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4162'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4117'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8279'}]}}]}}, {'BaselineClassTitle': 'No', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '293'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '333'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '626'}]}}]}}]}}, {'BaselineMeasureTitle': 'Dyslipidemia', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4100'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4070'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8170'}]}}]}}, {'BaselineClassTitle': 'No', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '355'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '380'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '735'}]}}]}}]}}, {'BaselineMeasureTitle': 'History of Depression', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Yes', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1031'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '995'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2026'}]}}]}}, {'BaselineClassTitle': 'No', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3424'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3455'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '6879'}]}}]}}]}}, {'BaselineMeasureTitle': 'Baseline Antidepressant Medication Use', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '4455'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '4450'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '8905'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1042'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1015'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2057'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)', 'OutcomeMeasureDescription': 'The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed.', 'OutcomeMeasurePopulationDescription': 'Intent-to-treat (ITT) population is defined as subjects who undergo randomization into the Treatment Period (TP) and are dispensed study medication. Treatment refers to the treatment assigned during TP randomization rather than the actual treatment received. ITT population is the primary analysis population for the primary and secondary endpoints.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'NB32', 'OutcomeGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4455'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '4450'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '90'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '102'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Non-Inferiority or Equivalence', 'OutcomeAnalysisNonInferiorityComment': 'At the pre-planned 50% interim analysis, a non-inferiority analysis was conducted based on the estimated hazard ratio (NB32/Placebo) for the time to the first confirmed occurrence of MACE. The upper-bound of the 99.7% confidence interval for the hazard ratio was compared to 1.4, the non-inferiority margin.', 'OutcomeAnalysisParamType': 'Cox Proportional Hazard', 'OutcomeAnalysisParamValue': '0.88', 'OutcomeAnalysisCIPctValue': '99.7', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.57', 'OutcomeAnalysisCIUpperLimit': '1.34', 'OutcomeAnalysisEstimateComment': 'Hazard ratio is based on CPH model with treatment as a factor.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization', 'OutcomeMeasureDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'OutcomeMeasurePopulationDescription': 'Intent-to-treat (ITT) population is defined as subjects who undergo randomization into the Treatment Period (TP) and are dispensed study medication. Treatment refers to the treatment assigned during TP randomization rather than the actual treatment received. ITT population is the primary analysis population for the primary and secondary endpoints.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'NB32', 'OutcomeGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4455'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '4450'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '133'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '142'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Cox Proportional Hazard', 'OutcomeAnalysisParamValue': '0.93', 'OutcomeAnalysisCIPctValue': '99.7', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.66', 'OutcomeAnalysisCIUpperLimit': '1.33', 'OutcomeAnalysisEstimateComment': 'Hazard ratio is based on CPH model with treatment as a factor.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke)', 'OutcomeMeasureDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'OutcomeMeasurePopulationDescription': 'Intent-to-treat (ITT) population is defined as subjects who undergo randomization into the Treatment Period (TP) and are dispensed study medication. Treatment refers to the treatment assigned during TP randomization rather than the actual treatment received. ITT population is the primary analysis population for the primary and secondary endpoints.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'NB32', 'OutcomeGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4455'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '4450'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '17'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '34'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Cox Proportional Hazard', 'OutcomeAnalysisParamValue': '0.50', 'OutcomeAnalysisCIPctValue': '99.7', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.21', 'OutcomeAnalysisCIUpperLimit': '1.19', 'OutcomeAnalysisEstimateComment': 'Hazard ratio is based on CPH model with treatment as a factor.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal)', 'OutcomeMeasureDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'OutcomeMeasurePopulationDescription': 'Intent-to-treat (ITT) population is defined as subjects who undergo randomization into the Treatment Period (TP) and are dispensed study medication. Treatment refers to the treatment assigned during TP randomization rather than the actual treatment received. ITT population is the primary analysis population for the primary and secondary endpoints.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'NB32', 'OutcomeGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4455'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '4450'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '55'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '57'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Cox Proportional Hazard', 'OutcomeAnalysisParamValue': '0.96', 'OutcomeAnalysisCIPctValue': '99.7', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.55', 'OutcomeAnalysisCIUpperLimit': '1.67', 'OutcomeAnalysisEstimateComment': 'Hazard ratio is based on CPH model with treatment as a factor.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal)', 'OutcomeMeasureDescription': 'Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures.', 'OutcomeMeasurePopulationDescription': 'Intent-to-treat (ITT) population is defined as subjects who undergo randomization into the Treatment Period (TP) and are dispensed study medication. Treatment refers to the treatment assigned during TP randomization rather than the actual treatment received. ITT population is the primary analysis population for the primary and secondary endpoints.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'NB32', 'OutcomeGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Placebo', 'OutcomeGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\"}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4455'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '4450'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '22'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '21'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Cox Proportional Hazard', 'OutcomeAnalysisParamValue': '1.04', 'OutcomeAnalysisCIPctValue': '99.7', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.43', 'OutcomeAnalysisCIUpperLimit': '2.55', 'OutcomeAnalysisEstimateComment': 'Hazard ratio is based on CPH model with treatment as a factor.'}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': 'Treatment-emergent serious adverse events and treatment-emergent adverse events leading to study medication discontinuation are defined as those events with onset coincident with treatment period randomization starting at Visit 3 (Day 1) and through end of study or 30 days after discontinuation of study medication (whichever one is earlier).', 'EventsDescription': 'Safety data is based on all available data at the time of database lock, which occurred after the pre-planned 50% interim analysis.', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'NB32', 'EventGroupDescription': \"NB32: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\", 'EventGroupSeriousNumAffected': '463', 'EventGroupSeriousNumAtRisk': '4455', 'EventGroupOtherNumAffected': '1157', 'EventGroupOtherNumAtRisk': '4455'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Placebo', 'EventGroupDescription': \"Administered in addition to the weight management program.\\n\\nWeight Management Program: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.\", 'EventGroupSeriousNumAffected': '386', 'EventGroupSeriousNumAtRisk': '4450', 'EventGroupOtherNumAffected': '282', 'EventGroupOtherNumAtRisk': '4450'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Anaemia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Haemorrhagic anaemia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Iron deficiency anaemia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lymphadenopathy', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Accelerated idioventricular rhythm', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acute coronary syndrome', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '6', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acute myocardial infarction', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '11', 'SeriousEventStatsNumAffected': '11', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '7', 'SeriousEventStatsNumAffected': '7', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Angina pectoris', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '17', 'SeriousEventStatsNumAffected': '17', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '15', 'SeriousEventStatsNumAffected': '15', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Angina unstable', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '25', 'SeriousEventStatsNumAffected': '22', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '16', 'SeriousEventStatsNumAffected': '15', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Aortic valve disease', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Arrhythmia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Arteriosclerosis coronary artery', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Atrial fibrillation', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '12', 'SeriousEventStatsNumAffected': '12', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '15', 'SeriousEventStatsNumAffected': '15', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Atrial flutter', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Atrial tachycardia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Atrial thrombosis', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Atrioventricular block', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Atrioventricular block complete', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cardiac arrest', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cardiac failure', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cardiac failure acute', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cardiac failure congestive', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '16', 'SeriousEventStatsNumAffected': '13', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '11', 'SeriousEventStatsNumAffected': '8', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cardio-respiratory arrest', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Chronotropic incompetence', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Congestive cardiomyopathy', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Coronary artery disease', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '22', 'SeriousEventStatsNumAffected': '21', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '21', 'SeriousEventStatsNumAffected': '21', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Coronary artery occlusion', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Coronary artery stenosis', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ischaemic cardiomyopathy', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Myocardial infarction', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '14', 'SeriousEventStatsNumAffected': '14', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '13', 'SeriousEventStatsNumAffected': '13', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Myocardial ischaemia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Palpitations', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pericardial effusion', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Sick sinus syndrome', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Supraventricular tachycardia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Tachycardia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ventricular fibrillation', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ventricular tachycardia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Haemorrhagic arteriovenous malformation', 'SeriousEventOrganSystem': 'Congenital, familial and genetic disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Porphyria acute', 'SeriousEventOrganSystem': 'Congenital, familial and genetic disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Vertigo', 'SeriousEventOrganSystem': 'Ear and labyrinth disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Adrenal insufficiency', 'SeriousEventOrganSystem': 'Endocrine disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Goitre', 'SeriousEventOrganSystem': 'Endocrine disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hyperparathyroidism', 'SeriousEventOrganSystem': 'Endocrine disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal adhesions', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal hernia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal hernia obstructive', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal pain', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal pain lower', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal pain upper', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal strangulated hernia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Colitis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Colitis ischaemic', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Constipation', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': \"Crohn's disease\", 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Diverticulum intestinal haemorrhagic', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Duodenal ulcer haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Duodenitis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Enteritis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastric ulcer haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastritis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastrointestinal haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastrointestinal ulcer', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastrointestinal ulcer haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastrooesophageal reflux disease', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Haematochezia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hiatus hernia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hiatus hernia, obstructive', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Impaired gastric emptying', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Inguinal hernia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Intestinal perforation', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Large intestine polyp', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lower gastrointestinal haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Nausea', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Obstruction gastric', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Oesophageal spasm', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Oesophagitis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Oesophagitis haemorrhagic', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pancreatitis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pancreatitis acute', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Peptic ulcer', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Retroperitoneal haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Small intestinal obstruction', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '10', 'SeriousEventStatsNumAffected': '9', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Umbilical hernia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Umbilical hernia, obstructive', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Upper gastrointestinal haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Vomiting', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Asthenia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Chest discomfort', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Chest pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '15', 'SeriousEventStatsNumAffected': '15', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '9', 'SeriousEventStatsNumAffected': '9', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cyst', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Death', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Device dislocation', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Device malfunction', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Fat tissue increased', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ischaemic ulcer', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Non-cardiac chest pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '22', 'SeriousEventStatsNumAffected': '22', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '13', 'SeriousEventStatsNumAffected': '13', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pyrexia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Sudden cardiac death', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Surgical failure', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Systemic inflammatory response syndrome', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Unevaluable event', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bile duct stone', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Biliary colic', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Biliary dyskinesia', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cholecystitis', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cholecystitis acute', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cholecystitis chronic', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cholelithiasis', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Drug-induced liver injury', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gallbladder disorder', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gallbladder polyp', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hepatic cyst', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Anaphylactic reaction', 'SeriousEventOrganSystem': 'Immune system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypersensitivity', 'SeriousEventOrganSystem': 'Immune system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abdominal wall abscess', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abscess', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Abscess limb', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Appendicitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Appendicitis perforated', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Arthritis bacterial', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bronchitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bursitis infective staphylococcal', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cellulitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '17', 'SeriousEventStatsNumAffected': '16', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '8', 'SeriousEventStatsNumAffected': '8', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cellulitis of male external genital organ', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cellulitis staphylococcal', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Clostridium difficile colitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Clostridium difficile infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Colonic abscess', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Diverticulitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '7', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Escherichia bacteraemia', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastroenteritis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastroenteritis bacterial', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastroenteritis viral', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Human ehrlichiosis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Infected bites', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Influenza', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Intervertebral discitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lobar pneumonia', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lung infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Osteomyelitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Perirectal abscess', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pharyngeal abscess', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pneumonia', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '13', 'SeriousEventStatsNumAffected': '12', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '10', 'SeriousEventStatsNumAffected': '10', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pneumonia staphylococcal', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pyelonephritis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Sepsis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Septic shock', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Staphylococcal infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Upper respiratory tract infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Urinary tract infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Urinary tract infection bacterial', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Urosepsis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Wound abscess', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acetabulum fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ankle fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cervical vertebral fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Concussion', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Craniocerebral injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cystitis radiation', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Fall', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Femoral neck fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Femur fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastrointestinal stoma complication', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gun shot wound', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Head injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hip fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Humerus fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Incisional hernia', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Joint dislocation', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Joint injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lower limb fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Meniscus injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Multiple injuries', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Postoperative ileus', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Postoperative respiratory failure', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Procedural pain', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Radius fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Rib fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Road traffic accident', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Skull fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spinal column injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spinal cord injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spinal fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Subdural haematoma', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Tendon rupture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Thermal burn', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ulna fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Upper limb fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Wound dehiscence', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Wrist fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Anticoagulation drug level below therapeutic', 'SeriousEventOrganSystem': 'Investigations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Blood potassium decreased', 'SeriousEventOrganSystem': 'Investigations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Blood potassium increased', 'SeriousEventOrganSystem': 'Investigations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Blood pressure increased', 'SeriousEventOrganSystem': 'Investigations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Thyroid function test abnormal', 'SeriousEventOrganSystem': 'Investigations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Troponin increased', 'SeriousEventOrganSystem': 'Investigations', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Alkalosis hypochloraemic', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Dehydration', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '6', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Diabetes mellitus inadequate control', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Fluid overload', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hyperglycaemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypoglycaemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypokalaemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hyponatraemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Metabolic acidosis', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Obesity', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Arthralgia', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Arthritis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Back pain', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bursitis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cervical spinal stenosis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Exostosis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Intervertebral disc compression', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Intervertebral disc degeneration', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Intervertebral disc disorder', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Intervertebral disc protrusion', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lumbar spinal stenosis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '9', 'SeriousEventStatsNumAffected': '8', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Musculoskeletal chest pain', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Musculoskeletal pain', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Neck pain', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Osteoarthritis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '42', 'SeriousEventStatsNumAffected': '40', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '44', 'SeriousEventStatsNumAffected': '41', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Osteoarthropathy', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Osteonecrosis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pain in extremity', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Resorption bone increased', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Rheumatoid arthritis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Rotator cuff syndrome', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spinal column stenosis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spinal ligament ossification', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spinal osteoarthritis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spondylolisthesis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Synovial cyst', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Vertebral osteophyte', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acute myeloid leukaemia', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Adenocarcinoma gastric', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Adenocarcinoma pancreas', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Adenoma benign', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'B-cell lymphoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'B-cell unclassifiable lymphoma high grade', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Basal cell carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Benign lung neoplasm', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bladder cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bladder transitional cell carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': \"Bowen's disease\", 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Breast cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '6', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cholangiocarcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Clear cell renal cell carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Colon adenoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Colon cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Colon cancer metastatic', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Endometrial adenocarcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Endometrial cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Glioblastoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Glioblastoma multiforme', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Invasive ductal breast carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Leukaemia', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lung adenocarcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lung neoplasm malignant', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Malignant melanoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Malignant melanoma in situ', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Mesothelioma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Metastases to liver', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Metastases to spleen', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Metastatic neoplasm', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Metastatic squamous cell carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': \"Non-Hodgkin's lymphoma\", 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Oesophageal adenocarcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Oesophageal cancer metastatic', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ovarian cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ovarian granulosa cell tumour', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pancreatic carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Phaeochromocytoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Prostate cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '6', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Prostate cancer stage II', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Renal cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Renal cell carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Squamous cell carcinoma of skin', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Thymoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Thyroid neoplasm', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Tongue neoplasm malignant stage unspecified', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Tonsil cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Uterine cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Uterine leiomyoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Aphasia', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Brain stem stroke', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Carotid artery disease', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Carotid artery occlusion', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Carotid artery stenosis', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cerebellar haemorrhage', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cerebral infarction', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cerebrovascular accident', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '7', 'SeriousEventStatsNumAffected': '7', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '5', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Complicated migraine', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Convulsion', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Dementia with Lewy bodies', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Diabetic hyperosmolar coma', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Dizziness', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Encephalopathy', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Haemorrhage intracranial', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Headache', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hemiparesis', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hydrocephalus', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypoaesthesia', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ischaemic stroke', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lacunar infarction', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Lumbar radiculopathy', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Metabolic encephalopathy', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Nerve root compression', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Normal pressure hydrocephalus', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Paraesthesia', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Presyncope', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Spondylitic myelopathy', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Subarachnoid haemorrhage', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Syncope', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '7', 'SeriousEventStatsNumAffected': '7', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '6', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Transient ischaemic attack', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'VIIth nerve paralysis', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Alcohol withdrawal syndrome', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bipolar disorder', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Delirium', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Depression', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hallucination', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Major depression', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Mental status changes', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Suicidal ideation', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acute prerenal failure', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Haematuria', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Nephrolithiasis', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Nephrosclerosis', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Obstructive uropathy', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Renal failure', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Renal failure acute', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '8', 'SeriousEventStatsNumAffected': '8', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '11', 'SeriousEventStatsNumAffected': '11', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Renal failure chronic', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Urinary retention', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Benign prostatic hyperplasia', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Cystocele', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Endometrial hyperplasia', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Ovarian mass', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pelvic prolapse', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Rectocele', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Uterine prolapse', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Uterovaginal prolapse', 'SeriousEventOrganSystem': 'Reproductive system and breast disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acute pulmonary oedema', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Acute respiratory failure', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Asthma', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Bronchospasm', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Chronic obstructive pulmonary disease', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '10', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Dyspnoea', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Dyspnoea exertional', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypoxia', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pleural effusion', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pleurisy', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pleuritic pain', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pneumothorax', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pulmonary embolism', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '7', 'SeriousEventStatsNumAffected': '6', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pulmonary haemorrhage', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pulmonary hypertension', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Pulmonary thrombosis', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Respiratory distress', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Respiratory failure', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '5', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Angioedema', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Skin ulcer', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Subcutaneous emphysema', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Gastrectomy', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hip surgery', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Accelerated hypertension', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Aortic aneurysm', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Aortic stenosis', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Arterial occlusive disease', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Deep vein thrombosis', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Haematoma', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypertensive crisis', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Hypotension', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Iliac artery occlusion', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Orthostatic hypotension', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Peripheral artery thrombosis', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Peripheral ischaemia', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Peripheral vascular disorder', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}, {'SeriousEventTerm': 'Subclavian artery stenosis', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 15.0', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '4455'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '4450'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Angina pectoris', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Atrial fibrillation', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Bradycardia', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Cardiac discomfort', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Cardiac failure congestive', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Cardiac flutter', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Extrasystoles', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Palpitations', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '20', 'OtherEventStatsNumAffected': '20', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Tachycardia', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hearing impaired', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Tinnitus', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Vertigo', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '11', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Vertigo positional', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Blepharospasm', 'OtherEventOrganSystem': 'Eye disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Diplopia', 'OtherEventOrganSystem': 'Eye disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Vision blurred', 'OtherEventOrganSystem': 'Eye disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Visual acuity reduced', 'OtherEventOrganSystem': 'Eye disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abdominal discomfort', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '27', 'OtherEventStatsNumAffected': '27', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abdominal distension', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abdominal pain', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '18', 'OtherEventStatsNumAffected': '18', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abdominal pain lower', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abdominal pain upper', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '18', 'OtherEventStatsNumAffected': '18', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Bowel movement irregularity', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Coeliac disease', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Colitis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Constipation', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '129', 'OtherEventStatsNumAffected': '129', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '15', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Diarrhoea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '35', 'OtherEventStatsNumAffected': '35', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '21', 'OtherEventStatsNumAffected': '21', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Diverticulum', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dry mouth', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '21', 'OtherEventStatsNumAffected': '21', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dyspepsia', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dysphagia', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Epigastric discomfort', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Eructation', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Faecal incontinence', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Flatulence', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Frequent bowel movements', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Gastritis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Gastrointestinal hypermotility', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Gastrooesophageal reflux disease', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Haematemesis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Haematochezia', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Haemorrhoids', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hypoaesthesia oral', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Intestinal obstruction', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Irritable bowel syndrome', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Lip swelling', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '346', 'OtherEventStatsNumAffected': '346', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '21', 'OtherEventStatsNumAffected': '21', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Oesophageal rupture', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pancreatitis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Retching', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Stomatitis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Upper gastrointestinal haemorrhage', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Vomiting', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '89', 'OtherEventStatsNumAffected': '89', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Vomiting projectile', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Asthenia', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Chest discomfort', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Chest pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Drug intolerance', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Feeling abnormal', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Feeling cold', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Feeling jittery', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '16', 'OtherEventStatsNumAffected': '16', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Feeling of body temperature change', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Gait disturbance', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Generalised oedema', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Influenza like illness', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Local swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Mucosal dryness', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Non-cardiac chest pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Oedema peripheral', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Cholelithiasis', 'OtherEventOrganSystem': 'Hepatobiliary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hepatic cirrhosis', 'OtherEventOrganSystem': 'Hepatobiliary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Drug hypersensitivity', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hypersensitivity', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Acute sinusitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Bronchitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Bronchopneumonia', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Diverticulitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Gastroenteritis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Helicobacter infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Impetigo', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Influenza', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pharyngitis streptococcal', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pneumonia', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Sinusitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Upper respiratory tract infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Urinary tract infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Viral infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Ankle fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Foot fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Humerus fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Joint injury', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Ligament rupture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Lower limb fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Meniscus injury', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Muscle injury', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Muscle strain', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Procedural pain', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Rib fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Tendon injury', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Tendon rupture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Upper limb fracture', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Alanine aminotransferase increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Aspartate aminotransferase increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Blood creatinine increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Blood glucose decreased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Blood glucose increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Blood pressure increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '20', 'OtherEventStatsNumAffected': '20', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '14', 'OtherEventStatsNumAffected': '14', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Blood pressure systolic increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Grip strength decreased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Heart rate increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hepatic enzyme increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'International normalised ratio increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Prostatic specific antigen increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Weight increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Decreased appetite', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Diabetes mellitus', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Gout', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hyperphagia', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hypoglycaemia', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Increased appetite', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Arthralgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Arthritis', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Back pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '11', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Intervertebral disc degeneration', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Intervertebral disc protrusion', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Muscle spasms', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Muscle twitching', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Muscular weakness', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Musculoskeletal chest pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Musculoskeletal pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Musculoskeletal stiffness', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Neck pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Osteoporosis', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pain in extremity', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Polymyalgia rheumatica', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Rotator cuff syndrome', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Benign breast neoplasm', 'OtherEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Breast cancer', 'OtherEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Malignant melanoma', 'OtherEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Altered state of consciousness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Amnesia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Balance disorder', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Burning sensation', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Carpal tunnel syndrome', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Disturbance in attention', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '67', 'OtherEventStatsNumAffected': '64', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dizziness postural', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dysgeusia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '16', 'OtherEventStatsNumAffected': '16', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dysgraphia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dyskinesia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Essential tremor', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '51', 'OtherEventStatsNumAffected': '51', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '15', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hypoaesthesia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Lethargy', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Memory impairment', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Migraine', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Multiple sclerosis', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Muscle contractions involuntary', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Nerve compression', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Neurodegenerative disorder', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Paraesthesia', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': \"Parkinson's disease\", 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Restless legs syndrome', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Sciatica', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Somnolence', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Spinal meningeal cyst', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Tremor', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '81', 'OtherEventStatsNumAffected': '80', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'VIIth nerve paralysis', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abnormal behaviour', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Abnormal dreams', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Affect lability', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Agitation', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Anger', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Anxiety', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '26', 'OtherEventStatsNumAffected': '26', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Apathy', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Aversion', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Bruxism', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Confusional state', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Depression', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Disorientation', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Fear', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hallucination', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hallucination, auditory', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hallucination, visual', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Insomnia', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '38', 'OtherEventStatsNumAffected': '38', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '16', 'OtherEventStatsNumAffected': '16', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Irritability', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Libido decreased', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Major depression', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Mental disorder', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Middle insomnia', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Mood altered', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Mood swings', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Nervousness', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Nightmare', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Obsessive-compulsive disorder', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Panic attack', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Paranoia', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Personality change', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Psychomotor retardation', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Restlessness', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Sleep disorder', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Sleep talking', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Sleep terror', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Suicidal ideation', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dysuria', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Glomerulosclerosis', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Haematuria', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Nephrolithiasis', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pollakiuria', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Renal colic', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Renal failure chronic', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Renal impairment', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Urinary hesitation', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Benign prostatic hyperplasia', 'OtherEventOrganSystem': 'Reproductive system and breast disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Ejaculation disorder', 'OtherEventOrganSystem': 'Reproductive system and breast disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Erectile dysfunction', 'OtherEventOrganSystem': 'Reproductive system and breast disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Vaginal prolapse', 'OtherEventOrganSystem': 'Reproductive system and breast disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Asthma', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Choking sensation', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dysphonia', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dyspnoea', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dyspnoea exertional', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Epistaxis', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Nasal discomfort', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Oropharyngeal pain', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Paranasal sinus hypersecretion', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pleural effusion', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pleurisy', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pulmonary fibrosis', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Sinus congestion', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Wheezing', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Alopecia', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Angioedema', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dermatitis', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Dermatitis contact', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Drug eruption', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hyperhidrosis', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Night sweats', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pruritus', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Pruritus generalised', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Skin irritation', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Skin reaction', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Swelling face', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Urticaria', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Cardioversion', 'OtherEventOrganSystem': 'Surgical and medical procedures', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Knee arthroplasty', 'OtherEventOrganSystem': 'Surgical and medical procedures', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Flushing', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hot flush', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hypertension', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '25', 'OtherEventStatsNumAffected': '25', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '11', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Hypotension', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4450'}]}}, {'OtherEventTerm': 'Labile blood pressure', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 15.0', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '4455'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '4450'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictionType': 'OTHER', 'AgreementRestrictiveAgreement': 'Yes', 'AgreementOtherDetails': \"If not already published by Sponsor as part of a multi-center publication, 24 months after conclusion, abandonment or termination of the study or notification that there will be no such multi-center publication, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 90 days to review and comment on the proposed publication. Sponsor may delay publication for up to an additional 6-month period to file for patent protection.\"}, 'PointOfContact': {'PointOfContactTitle': 'Global Head of Development', 'PointOfContactOrganization': 'Orexigen Therapeutics, Inc.', 'PointOfContactEMail': 'MedInfo@Orexigen.com', 'PointOfContactPhone': '858-875-8600'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000050177', 'ConditionMeshTerm': 'Overweight'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044343', 'ConditionAncestorTerm': 'Overnutrition'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25876', 'ConditionBrowseLeafName': 'Overweight', 'ConditionBrowseLeafAsFound': 'Overweight', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24997', 'ConditionBrowseLeafName': 'Overnutrition', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'C000591595', 'InterventionMeshTerm': 'Bupropion hydrochloride, naltrexone hydrochoride drug combination'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000019440', 'InterventionAncestorTerm': 'Anti-Obesity Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M18703', 'InterventionBrowseLeafName': 'Bupropion', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M11935', 'InterventionBrowseLeafName': 'Narcotics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M11912', 'InterventionBrowseLeafName': 'Naltrexone', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M11933', 'InterventionBrowseLeafName': 'Narcotic Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M243018', 'InterventionBrowseLeafName': 'Bupropion hydrochloride, naltrexone hydrochoride drug combination', 'InterventionBrowseLeafAsFound': 'Distortions', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M21086', 'InterventionBrowseLeafName': 'Anti-Obesity Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T217', 'InterventionBrowseLeafName': 'Mace', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T240', 'InterventionBrowseLeafName': 'Nutmeg', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PsychDr', 'InterventionBrowseBranchName': 'Psychotropic Drugs'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'AlcDet', 'InterventionBrowseBranchName': 'Alcohol Deterrents'}, {'InterventionBrowseBranchAbbrev': 'NarcAntag', 'InterventionBrowseBranchName': 'Narcotic Antagonists'}, {'InterventionBrowseBranchAbbrev': 'AnObAg', 'InterventionBrowseBranchName': 'Anti-Obesity Agents'}, {'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}]}}}}}, {'Rank': 80, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01466907', 'OrgStudyIdInfo': {'OrgStudyId': 'MaStrokeFup0809'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'UMASNL', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Regional Ethical Review Board DNr 520/2007'}]}, 'Organization': {'OrgFullName': 'Skane University Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Secondary Prevention and Health Promotion After Stroke', 'OfficialTitle': 'Secondary Prevention and Health Promotion After Stroke A Nurse-led Randomized Controlled Open Trial'}, 'StatusModule': {'StatusVerifiedDate': 'January 2014', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2008'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 4, 2011', 'StudyFirstSubmitQCDate': 'November 4, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 8, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 22, 2014', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 23, 2014', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ann-Cathrin Jonsson', 'ResponsiblePartyInvestigatorTitle': 'Ass. Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Skane University Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Skane University Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study was to examine to what extent a one year population of stroke patients at a university hospital had well regulated risk factors and health problems one year after stroke, and if a structured nurse-led previous follow-up in the intervention group including referrals if needed could influence health outcome and risk factors one year after stroke.', 'DetailedDescription': \"The follow-up protocol was categorized into Risk factors, Patients' self-reports, and Other health problems. Referral was sent to a physician if medical interventions were needed regarding risk factors measured above the limits as stated in the follow-up protocol in accordance with guidelines,and/or if any self-reported health problems were stated by the patients, or had been detected by the Specialist Nurse. Primary outcome was comparison between the intervention group and control group at one year after stroke regarding proportion of regulated risk factors, and self-reports on health outcome. Results of the two follow-ups of the intervention group were also compared.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['complication', 'depression', 'follow-up', 'intervention', 'nurse-led', 'outcome', 'secondary prevention', 'stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '597', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intervention group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Secondary prevention, supportive counselling']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Standard care until one year follow-up']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Secondary prevention, supportive counselling', 'InterventionDescription': \"Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.\", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention group']}}, {'InterventionType': 'Other', 'InterventionName': 'Standard care until one year follow-up', 'InterventionDescription': 'No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Risk factors and health outcome compared between intervention group and control group', 'PrimaryOutcomeDescription': \"Outcome for both groups after one year was measured as the proportion of risk factors sufficiently treated, the patients' self-reports on health outcome and comparison between the intervention group and the control group.\", 'PrimaryOutcomeTimeFrame': 'Baseline to one year after stroke for both groups.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Risk factors and health outcome at two follow-ups.', 'SecondaryOutcomeDescription': 'Comparison of health outcome at three months and one year after stroke in the intervention group.', 'SecondaryOutcomeTimeFrame': 'Baseline to one year after stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nWHO criteria for definition of stroke Signed consent\\n\\nExclusion Criteria:\\n\\nOther diagnosis causing neurological symptoms', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Ann-Cathrin Jönsson, PhD', 'OverallOfficialAffiliation': 'Department of Health Sciences, Lund University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Skåne University Hospital', 'LocationCity': 'Malmö', 'LocationZip': '205 02', 'LocationCountry': 'Sweden'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6748', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6751', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11997', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 81, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04127994', 'OrgStudyIdInfo': {'OrgStudyId': '2100'}, 'Organization': {'OrgFullName': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Glycemic Variability Comparing Two vs Six Meals in Type 2 Diabetes', 'OfficialTitle': 'Effect on Glycemic Variability, Weight and Oxidative Stress Markers FGF 21 in a Low Calorie Diet of Three Meals Compared With a Conventional Low Calorie Plan of Six Meals in Patients With Type 2 Diabetes With Overweight or Obesity'}, 'StatusModule': {'StatusVerifiedDate': 'October 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 17, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 12, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 11, 2019', 'StudyFirstSubmitQCDate': 'October 12, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 16, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 12, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 16, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Miguel Ángel Gómez Sámano', 'ResponsiblePartyInvestigatorTitle': 'MD', 'ResponsiblePartyInvestigatorAffiliation': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran'}, 'LeadSponsor': {'LeadSponsorName': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'L.N. Adrián Romero Villaseñor', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'L.N. Aurora Ramos Flores', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'L.N. Mariana Galindo Guzmán', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Dr. Daniel Cuevas Ramos', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Dr. Adrian Soto Mota', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Dr. Francisco J. Gómez Pérez', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Dr. Alfonso Gulias Herrero', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Lucía Palacios Baez', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Gerardo Saavedra Jiménez', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Hector Donaldo Espinosa Salazar', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Issa Lill Santiago Falfán', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Cristina Aurora Tlapanco Beltrán', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Horacio Correa Carranza', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Alejandra Dominguez Sanchez', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The frequency of meals is a very important aspect of nutrition, with profound effects on human health and in life expectancy. Excessive energy consumption is totally associated with a significant increase in the incidence of chronic diseases including diabetes. That is why nutritional therapy is recommended for all people with diabetes mellitus type 1 and 2 as an effective complement to your medical treatment. For overweight or obese type 2 diabetic patients, a low-calorie diet along with healthy eating patterns are recommended for weight loss. Similarly, modest body weight decrease may provide clinical benefits in patients, such as improved blood glucose, blood pressure, lipid profile, and others. Data about the role of nutritional habits and energy density being important precursors of obesity and diabetes are well known. On the other hand, data regarding frequency and timing of meals and how these factors relate to corporal weight are not totally understood.', 'DetailedDescription': \"In general, hypocaloric plans for patients with type 2 diabetes mellitus are consumed in five or six small meals per day. Eating more often is presumed to reduce hunger and thus energy consumption. However, the effects of meal frequency on human health and longevity are unclear.\\n\\nTherefore, this study will be carried out in which the differences in the impact of nutritional therapy between a hypocaloric conventional 6 times meal versus a 3-meal low-calorie plan will be demonstrated.\\n\\nThe procedures will be as follows:\\n\\n50 patients with DM2 from the Institute's Diabetes Clinic who are overweight or obese and between 40 and 70 years of age and who are found to have oral hypoglycemic agents, HbA1c less than 9% and less than 10 years old will be recruited of evolution.\\n\\nClinical evaluation:\\n\\nA complete medical history and physical examination will be performed in order to confirm the presence of the inclusion criteria and rule out the presence of exclusion criteria. An anthropometric and body composition assessment (waist and hip circumference, height, weight and percentage of fat) as well as blood pressure measurement will be made. A history of coronary heart disease, menopausal status and use of hormone therapy, smoking, alcohol consumption and physical activity (through a questionnaire of physical activity validated in the Mexican population) will be conducted.\\n\\nNutritional assessment:\\n\\nPatients will be divided into 2 groups without any distinction.\\n\\nThe first group of 25 patients will undergo a caloric restriction with a caloric restriction of 15% of their usual daily intake with a 40% macronutrient distribution in Carbohydrates, 20% Protein and 40% Lipids in three times of (TC6) over a period of 12 weeks in which the following variables will be measured: (Weight, Glucose Variability: Monitor, HbA1c, blood glucose, Lipid Profile, Oxidative stress, FGF-21, Blood Pressure and Hunger-Satiety Levels.)\\n\\nAt the first visit, the clinical evaluation will be elaborated, which consists of a complete physical examination in which vital signs will be measured, neck and head examination, examination of the thorax and abdomen, exploration of upper and lower extremities. As well as a complete nutritional assessment that includes; Assessment of body composition using bioimpedance with body composition analyzer jawon iOi 353, Reminder of food consumption of 72hrs to collect information on the diet of each patient. Based on the information collected will proceed to prescribe the individualized TC6 plan and will be given a 24/7 reminder format to be filled by the patient for a week, in addition to giving the indication to perform home glucose measurement once a day In random scheme.\\n\\nTo evaluate attachment to the nutritional plan, the patient will be cited 15 days later to perform daily consumption assessment using the 24/7 reminder format filled out by the patient and a 72hrs reminder performed through an interview. Likewise, levels of Hunger-Satiety will be measured with the tables of the institute Joslin validated for Mexican population.\\n\\nIf the patient adheres to the diet, blood samples will be taken for the measurement of the variables (HbA1C, Glucose, Lipid Profile, Insulin, FGF-21) and after that place the Medtronic model Ipro2 continuous glucose monitor with In order to monitor the patient's blood glucose for 7 days.\\n\\nAt the end of the 7 days, the patient will be asked to remove the sensor and re-evaluate dietary attachment.\\n\\nThe TC6 plan will be continued for 6 weeks, and at the end of this period the patient will be recalled to re-perform blood samples to measure the variables (HbA1C, Glucose, Lipid Profile, Insulin, FGF-21) Blood pressure and levels of Hunger-Satiety.\\n\\nThe TC6 regimen will be continued for a further 6 weeks. At the end of the period the patient will be asked to re-perform blood samples to measure the variables (HbA1C, Glucose, Lipid Profile, Insulin, FGF-21), Weight, Blood Pressure and Hunger-Satiety levels.\\n\\nThe second group of 25 patients will undergo a caloric restriction with a caloric restriction of 15% of their usual daily intake, with a 40% macronutrient distribution in Carbohydrates, 20% Protein and 40% Lipids in three times of (TC3) over a period of 12 weeks in which the following variables (Weight, Glucose Variability: Monitor, HbA1c, blood glucose, Lipid Profile, Oxidative, FGF-21, Blood Pressure and Hunger-Satiety levels are measured.) At the first visit, the clinical evaluation will be elaborated, which consists of a complete physical examination in which vital signs will be measured, neck and head examination, examination of the thorax and abdomen, exploration of upper and lower extremities. As well as a complete nutritional evaluation that includes, assessment of body composition using bioimpedance with jawon iOi 353 body composition analyzer, food consumption reminder of 72hrs to collect information on each patient's diet. Based on the information collected will proceed to prescribe the individualized TC3 plan and will be given a 24/7 reminder format to be filled by the patient for a week, in addition to giving the indication to perform home glucose measurement once a day in random scheme.\\n\\nTo evaluate attachment to the nutritional plan, the patient will be cited 15 days later to perform daily consumption assessment using the 24/7 reminder format filled out by the patient and a 72hrs reminder performed through an interview. Likewise, levels of Hunger-Satiety will be measured with the tables of the institute Joslin validated for Mexican population.\\n\\nIf the patient adheres to the diet, blood samples will be taken for the measurement of the variables (HbA1C, Glucose, Lipid Profile, Insulin, FGF-21) and after that place the Medtronic model Ipro2 continuous glucose monitor with in order to monitor the patient's blood glucose for 7 days.\\n\\nAt the end of the 7 days, the patient will be asked to remove the sensor and re-evaluate dietary attachment.\\n\\nThe TC3 plan will be continued for 6 weeks, and at the end of this period the patient will be recalled to re-perform blood samples to measure the variables (HbA1C, Glucose, Lipid Profile, Insulin, FGF-21) Blood pressure and levels of Hunger-Satiety. The TC3 regimen will be continued for a further 6 weeks. At the end of the period the patient will be asked to re-perform blood samples to measure the variables (HbA1C, Glucose, Lipid Profile, Insulin, FGF-21), Weight, Blood Pressure and Hunger-Satiety levels.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes Mellitus Type 2', 'Overweight and Obesity', 'Meal Time']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Crossover Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': '3 meals', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.\\n\\nWe will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Comparing 3 versus 6 meals in type 2 diabetes patients']}}, {'ArmGroupLabel': '6 meals', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.\\n\\nWe will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Comparing 3 versus 6 meals in type 2 diabetes patients']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Comparing 3 versus 6 meals in type 2 diabetes patients', 'InterventionDescription': 'We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['3 meals', '6 meals']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Impact of 3 stroke diet in glycemic variability compared to a 6 stroke diet', 'PrimaryOutcomeDescription': 'Patients from both groups (3 stroke and 6 stroke diet) will be monitored for 7 days using iPro™ CGM system (Medtronic). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit) comparing glycemic variability between them. Mean difference of glycaemic variability (MAGE) calculated in mmol/L.', 'PrimaryOutcomeTimeFrame': '12 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in Hba1c levels compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of HbA1c represented in %', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in fasting glucose levels compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of fasting glucose represented in mg/dL', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in triglycerides levels compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of triglycerides represented in mg/dL', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in cholesterol levels compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of cholesterol levels represented in mg/dL', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in FGF-21 levels compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of FGF-21 levels represented in pg/ml.', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in systolic and diastolic blood pressure compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of systolic and diastolic blood pressure represented in mmHg', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in satiety compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of satiety will be estimated using hunger-satiety questionnaire', 'SecondaryOutcomeTimeFrame': '12 weeks'}, {'SecondaryOutcomeMeasure': 'Impact of 3 stroke diet in weight loss compared to a 6 stroke diet', 'SecondaryOutcomeDescription': 'Mean difference of weight represented in kilograms', 'SecondaryOutcomeTimeFrame': '12 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nOral hypoglycemic agents\\nHbA1c <9%\\nLess than 10 years of evolution\\nDiabetes Mellitus type 2\\nOverweight or obese\\nAge 40-70 years\\nBMI ≥25 to < 40 kg/m\\n\\nExclusion Criteria:\\n\\nObesity 3rd grade\\nDM 1\\nHospitalization in the last 3 months\\n>10 years of evolution\\nHbA1c >9%\\nPregnancy', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Miguel Angel Gómez Sámano, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '55 54870900', 'CentralContactPhoneExt': '2405', 'CentralContactEMail': 'miguelangelgomezsamano@gmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Miguel Angel Gómez Sámano, MD', 'OverallOfficialAffiliation': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ''\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Ciudad de mexico', 'LocationZip': '14080', 'LocationCountry': 'Mexico', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Miguel Ángel Gómez Sámano, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '55 54870900', 'LocationContactPhoneExt': '2405', 'LocationContactEMail': 'miguelangelgomezsamano@gmail.com'}, {'LocationContactName': 'Miguel Angel Gómez Sámano, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Daniel Cuévas Ramos, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Francisco Javier Gómez Pérez, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Horacio Correa Carranza, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Alejandra Domínguez Sánchez, MD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'ICF', 'LargeDocHasProtocol': 'No', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'Yes', 'LargeDocLabel': 'Informed Consent Form', 'LargeDocDate': 'April 3, 2019', 'LargeDocUploadDate': '10/10/2019 13:16', 'LargeDocFilename': 'ICF_000.pdf'}, {'LargeDocTypeAbbrev': 'Prot', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol', 'LargeDocDate': 'January 13, 2017', 'LargeDocUploadDate': '10/10/2019 23:38', 'LargeDocFilename': 'Prot_001.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000009765', 'ConditionMeshTerm': 'Obesity'}, {'ConditionMeshId': 'D000050177', 'ConditionMeshTerm': 'Overweight'}, {'ConditionMeshId': 'D000003924', 'ConditionMeshTerm': 'Diabetes Mellitus, Type 2'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000044343', 'ConditionAncestorTerm': 'Overnutrition'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafAsFound': 'Obesity', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M25876', 'ConditionBrowseLeafName': 'Overweight', 'ConditionBrowseLeafAsFound': 'Overweight', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafAsFound': 'Diabetes Mellitus Type 2', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24997', 'ConditionBrowseLeafName': 'Overnutrition', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}}}}, {'Rank': 82, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04347863', 'OrgStudyIdInfo': {'OrgStudyId': '106-E-29'}, 'Organization': {'OrgFullName': 'Taiwan Adventist Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Investigating Program of Food Preparation on Diet Improvement for Patients With Stroke', 'OfficialTitle': 'Investigating Program of Food Preparation on Diet Improvement for Patients With Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'April 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 19, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 28, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 28, 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 13, 2020', 'StudyFirstSubmitQCDate': 'April 13, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 15, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 13, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 15, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Taiwan Adventist Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is a randomized controlled behavioral intervention trial to assess the efficacy of investigating program of food preparation on diet improve patients with stroke.', 'DetailedDescription': 'This is a randomized controlled behavioral intervention trial to assess the efficacy of investigating program of food preparation on diet improve patients with stroke. Subjects will be randomized to intervention group and control group.The primary outcome included seven measures, Functional oral intake scale, Mini Nutritional Assessment, Council on Nutrition Appetite Questionnaire, Dietary Well-Being Scale, Swallowing Quality of Life questionnaire, WHO Quality of Life-BREF and Eating Assessment Tool-10.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Dysphagia, Late Effect of Stroke']}, 'KeywordList': {'Keyword': ['Food preparation', 'Dietary well-being', 'Quality of life', 'Dysphagia', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '22', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Experimental group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Group swallowing disorder diet preparation program', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Group swallowing disorder diet preparation program']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'No Intervention'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Group swallowing disorder diet preparation program', 'InterventionDescription': 'This program included food properties, select food, type of cooking, using thickener and tasting', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Experimental group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes of the Eating Assessment Tool-10', 'PrimaryOutcomeDescription': 'Eating Assessment Tool-10 assesses ability of swallowing by myself. The total scare ranges from 0-40. A higher level indicates better ability of swallowing. Changes of the Eating Assessment Tool-10 will be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}, {'PrimaryOutcomeMeasure': 'Changes of the Functional Oral Intake Scale', 'PrimaryOutcomeDescription': 'Functional Oral Intake Scale assesses ability of swallowing. The total level ranges from 1-7. A higher level indicates better ability of swallowing. Changes of the Functional Oral Intake Scale will be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}, {'PrimaryOutcomeMeasure': 'Changes of the Mini Nutritional Assessment', 'PrimaryOutcomeDescription': 'Mini Nutritional Assessment assesses comprehensive nutritional. The total score ranges from 0-30. A higher score indicates better nutrition status. Changes of the Mini Nutritional Assessment will be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}, {'PrimaryOutcomeMeasure': 'Changes of the Council on Nutrition Appetite Questionnaire', 'PrimaryOutcomeDescription': 'Council on Nutrition Appetite Questionnaire assesses appetite.The total score ranges from 8-40. A higher score indicates better appetite. Changes of the Council on Nutrition Appetite Questionnaire will be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}, {'PrimaryOutcomeMeasure': 'Changes of the Dietary Well-Being Scale', 'PrimaryOutcomeDescription': 'Dietary Well-Being Scale assesses dietary well-being. The total scare ranges from 21-126. A higher score indicates better dietary well-being. Changes of the Dietary Well-Being Scale well be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}, {'PrimaryOutcomeMeasure': 'Changes of the Swallowing Quality of Life questionnaire', 'PrimaryOutcomeDescription': 'Swallowing Quality of Life questionnaire assesses quality of life about swallowing.The total score ranges from 44-220. A higher score indicates better quality of life about swallowing. Changes of the Swallowing Quality of Life questionnaire well be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}, {'PrimaryOutcomeMeasure': 'Changes of the WHO Quality of Life-BREF', 'PrimaryOutcomeDescription': 'WHO Quality of Life-BREF assesses quality of life. The total score ranges from 28-140. A higher score indicates better quality of life. Changes of the WHO Quality of Life-BREF well be assessed before and after intervention.', 'PrimaryOutcomeTimeFrame': '6 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nDiagnosis is stroke\\nEAT-10 ≥ 3\\nAged > 20 years\\nCapability of following instructions\\nWilling to participants to the study\\n\\nExclusion Criteria:\\n\\nNon-stroke neurological diseases ( ex: traumatic brain injury, brain tumor, neurodegenerative disease and Parkinson's disease )\\nDysphagia by neck injury or surgery\\nDuring the study, he/she was hospitalized again due to disease.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'En-Chi Chiu, PhD', 'OverallOfficialAffiliation': 'National Taipei University of Nursing and Health Sciences', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'National Taipei University of Nursing and Health Sciences', 'LocationCity': 'Taipei City', 'LocationState': 'Beitou Dist', 'LocationZip': '12303', 'LocationCountry': 'Taiwan'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}, {'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Dysphagia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T6034', 'ConditionBrowseLeafName': 'Quality of Life', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 83, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02470078', 'OrgStudyIdInfo': {'OrgStudyId': '2014-155'}, 'Organization': {'OrgFullName': 'University Hospital Muenster', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke', 'OfficialTitle': 'Randomised Controlled Trial of Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 3, 2015', 'StudyFirstSubmitQCDate': 'June 11, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 12, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 5, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 7, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University Hospital Muenster', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to evaluate whether pharyngeal electrical stimulation in addition to standard care can enhance swallowing recovery in severely dysphagic stroke patients post extubation compared to sham treatment plus standard care.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Dysphagia']}, 'KeywordList': {'Keyword': ['extubation']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Pharyngeal electrical stimulation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Phagenyx-Catheter, Phagenesis Limited, UK.']}}, {'ArmGroupLabel': 'Sham stimulation', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Sham stimulation once daily for 10 minutes on three consecutive days.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Sham stimulation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Phagenyx-Catheter, Phagenesis Limited, UK.', 'InterventionDescription': 'Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Pharyngeal electrical stimulation']}}, {'InterventionType': 'Device', 'InterventionName': 'Sham stimulation', 'InterventionDescription': 'The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sham stimulation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Reintubation rate', 'PrimaryOutcomeDescription': 'Need for reintubation within 120 hours from extubation', 'PrimaryOutcomeTimeFrame': '120 hours'}, {'PrimaryOutcomeMeasure': 'Pneumonia rate', 'PrimaryOutcomeDescription': 'Incidence of aspiration pneumonia within 120 hours from extubation', 'PrimaryOutcomeTimeFrame': '120 hours'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Length of stay', 'SecondaryOutcomeDescription': 'Length of stay on the intensive care unit', 'SecondaryOutcomeTimeFrame': 'Participants will be followed for the duration of stay on the intensive care unit, an expected average of 3 weeks'}, {'SecondaryOutcomeMeasure': 'Time until oral nutrition', 'SecondaryOutcomeDescription': 'Time span from extubation until consumption of an completely oral diet is safely possible', 'SecondaryOutcomeTimeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 4 weeks'}, {'SecondaryOutcomeMeasure': 'PEG tube placement', 'SecondaryOutcomeDescription': 'Number of participants needing percutaneous endogastric tube placement due to persistent severe dysphagia', 'SecondaryOutcomeTimeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 5 weeks.'}, {'SecondaryOutcomeMeasure': 'Swallowing function', 'SecondaryOutcomeDescription': 'Salient semiquantitative parameters of swallowing function (leaking, penetration, aspiration, residues, delayed triggering of swallow reflex) as assessed by a standardized fiberoptic endoscopic evaluation protocol after three days of treatment', 'SecondaryOutcomeTimeFrame': 'after 3 days of treatment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n- severe dysphagia post extubation due to acute stroke\\n\\nExclusion Criteria:\\n\\npreexisting dysphagia\\ncomorbidities that can possibly cause dysphagia\\npsychiatric comorbidities\\npacemaker or other implanted electronic devices', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Rainer Dziewas, MD', 'OverallOfficialAffiliation': 'University Hospital Münster', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Neurology, University of Muenster', 'LocationCity': 'Muenster', 'LocationZip': '48129', 'LocationCountry': 'Germany'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}, {'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Dysphagia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 84, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05494138', 'OrgStudyIdInfo': {'OrgStudyId': '4-2022-0645'}, 'Organization': {'OrgFullName': 'Yonsei University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutriomics and Artificial Intelligence Nutrition Obesity Cohort', 'OfficialTitle': 'Nutriomics and Artificial Intelligence Nutrition Obesity Cohort'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 15, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 31, 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'August 31, 2041', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 7, 2022', 'StudyFirstSubmitQCDate': 'August 7, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 9, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 7, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Yonsei University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to establish a prospective cohort. From registration to the 5th year, basic investigation, specific examinations for cardiovascular and metabolic disease, basic blood tests, collection of human material samples, and clinical event follow-up are conducted yearly. The obese group will be examined yearly, and telephone follow-up will be conducted if necessary. The control group will participate in the baseline survey once enrollment and clinical event follow-up by phone will be conducted annually thereafter. From the 6th year, only clinical event follow-up will be conducted.', 'DetailedDescription': 'The obese group will enroll 500 people within 1 year of study initiation and follow-up annually. The control group will enroll 30 patients a year for 5 years.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Obesity']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '650', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'The obese group', 'ArmGroupDescription': 'Obese patients (BMI ≥25 kg/m2) with chronic diseases such as cardiovascular disease, hypertension, diabetes, and metabolic syndrome. More than 10% of the patients in the obese group will be patients with a BMI ≥30.'}, {'ArmGroupLabel': 'The control group', 'ArmGroupDescription': 'Adults with BMI 18.5~24.9 kg/m2.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Differences of nutriomics according to obesity phenotypes', 'PrimaryOutcomeDescription': 'Cross-sectional analysis of nutriomics of normal control group and obese patients', 'PrimaryOutcomeTimeFrame': 'At five years of study'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Clinical events', 'SecondaryOutcomeDescription': 'A composite of all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, revascularization of coronary artery, and heart failure hospitalization', 'SecondaryOutcomeTimeFrame': 'three years, four years, five years, etc'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria for the obese group\\n\\nAdults 19 years of age or older\\nObese patients with chronic diseases such as cardiovascular disease, hypertension, diabetes, and metabolic syndrome (BMI ≥ 25 kg/m2, [BMI ≥ 30 kg/m2, including 10% or more])\\n\\nInclusion criteria for the control group\\n\\nAdults 19 years of age or older\\nThose with BMI 18.5~24.9 kg/m2\\n\\nExclusion criteria for the obese group\\n\\nSerious non-cardiovascular disease with life expectancy less than 6 months\\nPregnant or suspected of being pregnant or are lactating\\nPatients within 3 months of organ transplantation\\nPatients currently being treated for acute transplant rejection\\nPatients treated for acute coronary syndrome (myocardial infarction, unstable angina) and discharged within 6 months\\nPatients with acute cerebral infarction within 6 months of being hospitalized and discharged\\nType 1 Diabetes\\nPatients taking steroids, female hormones\\nThose who have difficulty using smartphones\\n\\nExclusion criteria for the control group\\n\\nSerious non-cardiovascular disease with life expectancy less than 6 months\\nPregnant or suspected of being pregnant or are lactating\\nPersons who are continuously taking medications prescribed by a doctor due to chronic diseases excluding hypertension and dyslipidemia\\nWithin 5 years of diagnosis of malignant tumor\\nThose who have difficulty using smartphones', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '19 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'The obese group will be selected from patients who visit the department of cardiology or endocrinology for the management of chronic diseases. The control group will be selected from among those who voluntarily participate in the epidemiological study of normal participants.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sungha Park', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+82-2-2228-8455', 'CentralContactEMail': 'shpark0530@yuhs.ac'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Sungha Park', 'OverallOfficialAffiliation': 'Division of Cardiology, Severance Hospital, Yonsei University College of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Yonsei University Health System, Severance Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Seoul', 'LocationCountry': 'Korea, Republic of', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sungha Park', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+82-2-2228-8455', 'LocationContactEMail': 'shpark0530@yuhs.ac'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'When there is a request for data sharing from other researchers, the principal investigator will review it and decide whether to share it or not.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000009765', 'ConditionMeshTerm': 'Obesity'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000050177', 'ConditionAncestorTerm': 'Overweight'}, {'ConditionAncestorId': 'D000044343', 'ConditionAncestorTerm': 'Overnutrition'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafAsFound': 'Obesity', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M25876', 'ConditionBrowseLeafName': 'Overweight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24997', 'ConditionBrowseLeafName': 'Overnutrition', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 85, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02863887', 'OrgStudyIdInfo': {'OrgStudyId': 'PBRC 2016-018'}, 'Organization': {'OrgFullName': 'Pennington Biomedical Research Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Lifestyle Changes Through Exercise and Nutrition', 'OfficialTitle': 'The Lifestyle Changes Through Exercise and Nutrition (LEAN) Project', 'Acronym': 'LEAN'}, 'StatusModule': {'StatusVerifiedDate': 'June 2018', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 23, 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 23, 2017', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 7, 2016', 'StudyFirstSubmitQCDate': 'August 8, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 11, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'June 4, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 6, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Robert L. Newton, Jr.', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Pennington Biomedical Research Center'}, 'LeadSponsor': {'LeadSponsorName': 'Pennington Biomedical Research Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The goal of The LEAN project intervention is to promote weight loss, healthy dietary habits, increased physical activity, improved blood glucose and cholesterol, and weight related quality of life in obese African American adults through a sustainable, technology enhanced, church-based program.', 'DetailedDescription': 'The LEAN Project is a community-based weight loss program that is delivered through churches serving lower-income, obese, African American adults. The intervention will involve training community health coaches to deliver the intervention. These community health coaches will be individuals who are members of the church and who are willing to be trained on how to deliver behaviorally-based, empirically proven, lifestyle change interventions. These community health coaches will be trained by the staff at Pennington Biomedical, who have experience training and delivering these types of interventions. The community health coaches will deliver the intervention through their respective church after being trained. Weekly text messages will be sent to participants in order to supplement the intervention sessions and provide support. The primary aim is to determine if the trained community health coach church-based intervention will result in significant weight loss. Secondary aims will assess blood glucose, cholesterol, physical activity, food intake, and weight related quality of life.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Obesity', 'Diabetes']}, 'KeywordList': {'Keyword': ['Weight Loss', 'African American', 'Community Based', 'Mobile technology', 'Translational science']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Crossover Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '97', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Weight loss intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Weight loss intervention']}}, {'ArmGroupLabel': 'Delayed Treatment Control Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Weight loss intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Weight loss intervention', 'InterventionDescription': 'The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Delayed Treatment Control Group', 'Weight loss intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percent weight loss', 'PrimaryOutcomeDescription': 'Percent weight loss will be calculated at 6 and 12 months.', 'PrimaryOutcomeTimeFrame': 'Month 6 and Year 1'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Body Fat Percentage', 'SecondaryOutcomeDescription': \"The participant's body fat percentage is measured using the portable Tanita Body Composition Analyzer (SC-240).\", 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Blood Glucose', 'SecondaryOutcomeDescription': 'The Alere Cholestech LDX® Analyzer is engineered to provide accurate, actionable, and readily accessible glucose testing results. The Cholestech uses fingerstick sampling and small sample size (40μL) that makes results less time consuming and easy to obtain.', 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Blood Pressure', 'SecondaryOutcomeDescription': 'Blood pressure will be measured using an automatic blood pressure cuff (Omeron, Model BP710 or similar). Participants will rest for approximately 5 minutes prior to blood pressure measurement to ensure accurate at rest reading.', 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Food Intake', 'SecondaryOutcomeDescription': 'The National Cancer Institute (NCI) fat screener estimates the percentage of energy from fat by asking patients to report the frequency of consuming specific foods over the past 12 months. A standard 7-item fruit and vegetable screener developed by the NCI and National 5 a Day Program grantees asks how often fruit and vegetables were consumed in the past month.', 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Physical activity', 'SecondaryOutcomeDescription': 'The International Physical Activity Questionnaire (IPAQ) questionnaire is a self-report measure of physical activity. The metabolic equivalent task (MET) minutes in each domain of leisure time activity, that is, sedentary, light, moderate, and vigorous intensity, will be calculated. The IPAQ has been shown to be a reliable and valid measure of physical activity and has been sensitive to changes in physical activity resulting from intervention programs.', 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Quality of Life', 'SecondaryOutcomeDescription': \". Each participant's quality of life will be assessed using the Impact of Weight on Quality of Life Survey.\", 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Satisfaction Questionnaire', 'SecondaryOutcomeDescription': \"Each participant's satisfaction with the different elements of the study, including the community health coaches, the intervention, and the text messages, will be measured using a questionnaire developed by the investigators.\", 'SecondaryOutcomeTimeFrame': 'Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Blood Cholesterol', 'SecondaryOutcomeDescription': 'The Alere Cholestech LDX® Analyzer is engineered to provide accurate, actionable, and readily accessible cholesterol testing results. The Cholestech uses fingerstick sampling and small sample size (40μL) that makes results less time consuming and easy to obtain.', 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}, {'SecondaryOutcomeMeasure': 'Change in Pulse', 'SecondaryOutcomeDescription': 'Pulse will be measured using an automatic blood pressure cuff (Omeron, Model BP710 or similar). Participants will rest for approximately 5 minutes prior to pulse measurement to ensure accurate at rest reading.', 'SecondaryOutcomeTimeFrame': 'Screening, Month 6 and Year 1'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nself-identify as African American\\na member of a participating church\\nage 18-75 years old\\nBMI > 30\\nown a mobile phone with text message capabilities\\nat risk for diabetes (diagnosed nuclear family member or gestational diabetes) or diagnosed with type 2 diabetes\\nwilling to provide written informed consent\\nwilling to change diet, physical activity and weight\\nable to participate in face-face counselling sessions as scheduled\\nlow to moderate cardiovascular disease risk\\n\\nExclusion Criteria:\\n\\ncurrently participating in a weight loss program\\ncurrently using weight loss medication or have lost weight (>10 lbs in last year)\\nplanning to move from the area within the next year\\ngiven birth within the past year, are currently pregnant or plan to become pregnant within the next year\\nplanning to have bariatric surgery within 2 years\\nhistory of major depression, suicidal behavior or eating disorder\\nhospitalization for a mental disorder or substance abuse in the last year\\nhave cancer or had cancer within the past 5 years.\\nserious heart problems such as arrhythmias, cardiomyopathy, congestive heart failure\\nstroke or heart attack in the last six months\\nhigh blood pressure [systolic ≥160, or diastolic ≥100]\\nchronic inflammatory conditions, including but not limited to severe arthritis, lupus, or inflammatory bowel disease\\ndiseases that are life threatening or that can interfere with or be aggravated by exercise or weight loss\\nunwilling or unable to provide informed consent\\nphysician's or principal investigator's decision to exclude\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Robert L Newton, Jr., PhD', 'OverallOfficialAffiliation': 'Pennington Biomedical Research Center', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Pennington Biomedical Research Center', 'LocationCity': 'Baton Rouge', 'LocationState': 'Louisiana', 'LocationZip': '70808', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33677781', 'ReferenceType': 'derived', 'ReferenceCitation': 'Nguyen T, Irwin ML, Dewan AT, Cartmel B, Harrigan M, Ferrucci LM, Sanft T, Li F, Lu L, Salinas YD. Examining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention. Breast Cancer Res Treat. 2021 Jun;187(2):487-497. doi: 10.1007/s10549-021-06151-5. Epub 2021 Mar 6.'}, {'ReferencePMID': '30143478', 'ReferenceType': 'derived', 'ReferenceCitation': 'Newton RL Jr, Carter LA, Johnson W, Zhang D, Larrivee S, Kennedy BM, Harris M, Hsia DS. A Church-Based Weight Loss Intervention in African American Adults using Text Messages (LEAN Study): Cluster Randomized Controlled Trial. J Med Internet Res. 2018 Aug 24;20(8):e256. doi: 10.2196/jmir.9816.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17792', 'ConditionBrowseLeafName': 'Weight Loss', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}}}}, {'Rank': 86, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00116558', 'OrgStudyIdInfo': {'OrgStudyId': 'R01NS045087', 'OrgStudyIdType': 'U.S. NIH Grant/Contract', 'OrgStudyIdLink': 'https://reporter.nih.gov/quickSearch/R01NS045087'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'R01NS045087', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/R01NS045087'}]}, 'Organization': {'OrgFullName': 'University of Kentucky', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation', 'OfficialTitle': 'Early Treatment of Amyotrophic Lateral Sclerosis With Nutrition and Non-Invasive Positive Pressure Ventilation'}, 'StatusModule': {'StatusVerifiedDate': 'July 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 1, 2004', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 2012', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 2012', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 29, 2005', 'StudyFirstSubmitQCDate': 'June 29, 2005', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 30, 2005', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'March 15, 2010', 'ResultsFirstSubmitQCDate': 'July 11, 2019', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'July 31, 2019', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 11, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 31, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Edward Kasaraskis', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'University of Kentucky'}, 'LeadSponsor': {'LeadSponsorName': 'Edward Kasaraskis', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'Yes', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS.', 'DetailedDescription': \"Studies to date indicate that percutaneous endoscopic gastrostomy (PEG)-insertion of a feeding tube in the stomach-and non-invasive positive pressure ventilation (NIPPV)-mechanically assisted or generated breaths delivered through a tightly fitting nasal or facial mask-improve survival in amyotrophic lateral sclerosis (ALS), even when introduced late in the disease.\\n\\nDr. Kasarskis and his research team believe early intervention with these treatments may improve patients outcome even further. However, many issues regarding the early use of these treatments prevent the design of a phase III clinical trial to test this hypothesis. Common to both NIPPV and nutrition is a lack of a reliable indicator of early respiratory or nutritional insufficiency. With respect to nutrition, reliable and cost effective methods are needed to determine a patient's energy (i.e. caloric) requirements at different stages of the illness to establish a basis for recommending PEG on the adequacy of energy intake. For NIPPV, factors that influence acceptance and tolerability of this therapy, and measurements of early respiratory dysfunction need to be identified.\\n\\nThe purposes of this trial are to develop and validate strategies to improve tolerability of NIPPV, identify factors that influence acceptance of NIPPV, and evaluate measures of early respiratory failure, other than percentage of forced vital capacity (FVC). Researchers will also develop and validate methods to determine energy balance in and evaluate the nutritional status of patients with ALS that will be applicable to a multi-center phase III study of nutrition and NIPPV.\\n\\nThe study will be conducted at 11 other sites across the country. Some study sites will focus on the nutritional aspects of the trial while the other sites will focus on NIPPV treatment. A total of 220 patients will be studied over 2 years.\\n\\nEnrollment will end on June 30, 2007. The last patient was followed clinically until June 30, 2008. The study remained open for sample analysis, data analysis, and assessment of vital status until the completion of funding on November 30, 2009.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Amyotrophic Lateral Sclerosis']}, 'KeywordList': {'Keyword': ['amyotrophic lateral sclerosis', 'ALS', \"Lou Gehrig's disease\", 'nutrition', 'NIPPV', 'non-invasive positive pressure ventilation', 'percutaneous endoscopic gastrostomy', 'PEG']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '153', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Early NIPPV Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants with >80% predicted forced vital capacity (FVC).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Early NIPPV']}}, {'ArmGroupLabel': 'Standard of Care NIPPV', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants with 50-74% predicted forced vital capacity (FVC).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Standard NIPPV']}}, {'ArmGroupLabel': 'Standard of Care NIPPV and Nutritional Monitoring', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Standard NIPPV']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Early NIPPV', 'InterventionDescription': 'Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Early NIPPV Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['BiPAP (Bilevel Positive Airway Pressure)']}}, {'InterventionType': 'Device', 'InterventionName': 'Standard NIPPV', 'InterventionDescription': 'Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard of Care NIPPV', 'Standard of Care NIPPV and Nutritional Monitoring']}, 'InterventionOtherNameList': {'InterventionOtherName': ['BiPAP (Bilevel Positive Airway Pressure)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.', 'PrimaryOutcomeDescription': 'Percentage of patients attempting to use NIPPV therapy within six weeks of initial offer.', 'PrimaryOutcomeTimeFrame': '6 weeks'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Patient Survival With Early Versus Standard of Care NIPPV Treatment', 'OtherOutcomeDescription': 'Duration of patient survival', 'OtherOutcomeTimeFrame': 'one year'}, {'OtherOutcomeMeasure': 'Compliance With NIPPV Treatment', 'OtherOutcomeDescription': 'Number of hours of NIPPV use per month', 'OtherOutcomeTimeFrame': 'one month'}, {'OtherOutcomeMeasure': 'Total Daily Energy Expediture (TDEE) of ALS Patients', 'OtherOutcomeDescription': 'Total daily energy expenditure (TDEE) with be measured using the dual labeled water (DLW) method', 'OtherOutcomeTimeFrame': 'Duration of study (approximately 1 year)'}, {'OtherOutcomeMeasure': 'Tolerance of NIPPV Treatment', 'OtherOutcomeDescription': 'Percent of patients achieving tolerance (>4hr/night NIPPV after 2-3 week titration period) determined by actual usage data.', 'OtherOutcomeTimeFrame': 'one month'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nWilling and able to give informed consent.\\nIf women of childbearing age, must be non-lactating and surgically sterile or using an effective method of birth control (double-barrier or oral contraception) and have a negative pregnancy test.\\nMinorities: All races and ethnic backgrounds.\\nDisease inclusion: Clinically possible/definite/probable, or laboratory supported probable, sporadic or familial ALS according to the revised Escorial criteria.\\nOnset of progressive weakness within 60 months prior to study.\\nWilling to return for visits as scheduled and adhere to protocol requirements.\\n\\nFVC Criteria\\n\\nNIPPV Arm: Best-sitting FVC between 50% and 95% of predicted normal.\\nNutrition Arm: Best-sitting FVC >50% of predicted normal.\\n\\nExclusion Criteria:\\n\\nUntreated or unstable hyper or hypothyroidism, untreated or unstable asthma, unstable angina, advanced liver or renal disease, advanced cancer, untreated diabetes or chronic obstructive pulmonary disease (COPD).\\nDiagnosis of other motor neuron or other neurological disorder that mimics ALS.\\nDiagnosis of other neurodegenerative disease (i.e., Parkinson's disease, Alzheimer's disease, etc.)\\nInflammatory bowel disease or malabsorption syndrome.\\nUse of NIPPV, mechanical ventilation, or tracheostomy at the time of consent.\\nInability to adhere to study visit schedule or lack of reliable caretaker if participant requires one.\\nPregnant or lactating woman.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Edward Kasarskis, MD, PhD', 'OverallOfficialAffiliation': 'University of Kentucky', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Colorado', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80262', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Miami', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33136', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Kentucky', 'LocationCity': 'Lexington', 'LocationState': 'Kentucky', 'LocationZip': '40536', 'LocationCountry': 'United States'}, {'LocationFacility': 'Henry Ford Hospital', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48202', 'LocationCountry': 'United States'}, {'LocationFacility': 'Beth Israel', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10003', 'LocationCountry': 'United States'}, {'LocationFacility': 'Columbia University', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States'}, {'LocationFacility': 'SUNY', 'LocationCity': 'Syracuse', 'LocationState': 'New York', 'LocationZip': '13210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pennsylvania State University', 'LocationCity': 'Hershey', 'LocationState': 'Pennsylvania', 'LocationZip': '17033', 'LocationCountry': 'United States'}, {'LocationFacility': 'Drexel University', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19103', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Texas-San Antonio', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78229', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Utah', 'LocationCity': 'Salt Lake City', 'LocationState': 'Utah', 'LocationZip': '84132', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Vermont', 'LocationCity': 'Burlington', 'LocationState': 'Vermont', 'LocationZip': '54505', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24522445', 'ReferenceType': 'background', 'ReferenceCitation': 'Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.'}, {'ReferencePMID': '29243507', 'ReferenceType': 'background', 'ReferenceCitation': 'Scagnelli CN, Howard DB, Bromberg MB, Kasarskis EJ, Matthews DE, Mitsumoto HM, Simmons Z, Tandan R; ALS Nutrition-NIPPV Study Group. Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):220-231. doi: 10.1080/21678421.2017.1413117. Epub 2017 Dec 15.'}, {'ReferencePMID': '21271789', 'ReferenceType': 'result', 'ReferenceCitation': 'Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, Kryscio RJ; ALS Nutrition/NIPPV Study Group. The ALS Nutrition/NIPPV Study: design, feasibility, and initial results. Amyotroph Lateral Scler. 2011 Jan;12(1):17-25. doi: 10.3109/17482968.2010.515225.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Standard of Care NIPPV and Nutritional Monitoring', 'FlowGroupDescription': 'Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Standard of Care NIPPV', 'FlowGroupDescription': 'Participants with 50-74% predicted forced vital capacity (FVC).'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': 'Early NIPPV', 'FlowGroupDescription': 'Participants with >80% predicted forced vital capacity (FVC).'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '80'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '26'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '47'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '49'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '11'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '14'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '31'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '15'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '33'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Death', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '11'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '3'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '17'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '12'}]}}, {'FlowDropWithdrawType': 'disease progression', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '7'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '18'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Standard of Care NIPPV and Nutritional Monitoring', 'BaselineGroupDescription': 'Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Standard of Care NIPPV', 'BaselineGroupDescription': 'Participants with 50-74% predicted forced vital capacity (FVC).'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Early NIPPV Intervention', 'BaselineGroupDescription': 'Participants with >80% predicted forced vital capacity (FVC).'}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '80'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '26'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '47'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '153'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '59.0', 'BaselineMeasurementSpread': '11.7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '60.8', 'BaselineMeasurementSpread': '11.4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '56.2', 'BaselineMeasurementSpread': '11.2'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '58.6', 'BaselineMeasurementSpread': '11.6'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '28'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '55'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '52'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '30'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '98'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '80'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '47'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '153'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.', 'OutcomeMeasureDescription': 'Percentage of patients attempting to use NIPPV therapy within six weeks of initial offer.', 'OutcomeMeasurePopulationDescription': 'Data were not obtained from the \"Standard of Care NIPPV and Nutritional Monitoring\" arm.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': '6 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard of Care NIPPV and Nutritional Monitoring', 'OutcomeGroupDescription': 'Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Standard of Care NIPPV', 'OutcomeGroupDescription': 'Participants with 50-74% predicted forced vital capacity (FVC).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Early NIPPV Intervention', 'OutcomeGroupDescription': 'Participants with >80% predicted forced vital capacity (FVC).'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '26'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '47'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '23'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '35'}]}}]}}]}}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Patient Survival With Early Versus Standard of Care NIPPV Treatment', 'OutcomeMeasureDescription': 'Duration of patient survival', 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': 'one year', 'OutcomeMeasureDenomUnitsSelected': 'Participants'}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Compliance With NIPPV Treatment', 'OutcomeMeasureDescription': 'Number of hours of NIPPV use per month', 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': 'one month', 'OutcomeMeasureDenomUnitsSelected': 'Participants'}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Total Daily Energy Expediture (TDEE) of ALS Patients', 'OutcomeMeasureDescription': 'Total daily energy expenditure (TDEE) with be measured using the dual labeled water (DLW) method', 'OutcomeMeasureReportingStatus': 'Not Posted', 'OutcomeMeasureTimeFrame': 'Duration of study (approximately 1 year)', 'OutcomeMeasureDenomUnitsSelected': 'Participants'}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Tolerance of NIPPV Treatment', 'OutcomeMeasureDescription': 'Percent of patients achieving tolerance (>4hr/night NIPPV after 2-3 week titration period) determined by actual usage data.', 'OutcomeMeasurePopulationDescription': 'No data were collected for the \"Standard of Care NIIPPV and Nutritional Monitoring\" arm.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'one month', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard of Care NIPPV and Nutritional Monitoring', 'OutcomeGroupDescription': 'Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Standard of Care NIPPV', 'OutcomeGroupDescription': 'Participants with 50-74% predicted forced vital capacity (FVC).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Early NIPPV', 'OutcomeGroupDescription': 'Participants with >80% predicted forced vital capacity (FVC).'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '23'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '35'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '11'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '14'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '1', 'EventsTimeFrame': '3 years, 4 months', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Combined Arms', 'EventGroupDescription': 'Sincere efforts were made to locate per arm data, but these data are no longer available. All adverse events are reported as one arm/group.', 'EventGroupDeathsNumAffected': '19', 'EventGroupDeathsNumAtRisk': '153', 'EventGroupSeriousNumAffected': '42', 'EventGroupSeriousNumAtRisk': '153', 'EventGroupOtherNumAffected': '62', 'EventGroupOtherNumAtRisk': '153'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'ALS Progression', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 5/5/2007 5/25/2007 Status: Resolved Reason for Qualifying: Are other conditions which represent significant hazards Intensity: Moderate Relationship to study: Unrelated Description: Treatment and Evaluation of ALS Progression', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Aspiration', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 5/11/2008 5/12/2008 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Mild Relationship to study: Unrelated Description: Aspiration', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Aspiration Pneumonia', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 6/10/2007 6/19/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Presumed Aspiration Pneumonia', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Bladder malignancy/UTI', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 8/22/2007 9/5/2007 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Possible bladder malignancy and UTI', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Blood Clot', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 8/21/2005 9/1/2005 Status:Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to study: Unrelated Description: Blood Clot Behind right knee', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Cardiac Arrest', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 4/4/2006 4/4/2006 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to Study: Unrelated Description: Cardiac Arrest', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Colonic Bleed', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 1/15/2007 1/29/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship: Unrelated Description: Left Colonic Bleed', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Concussion', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 2/7/2007 2/7/2007 Status: Resolved Reason for Qualifying: Life-threatening Intensity: Moderate Relationship to Study: Unrelated Description: Concussion as result of Automobile Accident', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Death', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 6/2/2006 6/2/2006 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to Study: Unrelated Description: No Information Given', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '14', 'SeriousEventStatsNumAffected': '14', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Difficulty Breathing', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 5/21/2007 5/27/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Difficulty breathing due to Sialorrhea', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Dislodged PEG Tube', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 6/30/2007 Status: Continuing at discontinuation Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Dislodged PEG Tube and Respiratory Distress', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Distended Abdomen', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 8/24/2005 8/29/2005 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Distended Abdomen', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Dysphagia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 3/11/2008 3/11/2008 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Dysphagia', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Dyspnea', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 4/9/2007 Status: Continuing at discontinuation Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Increased Dyspnea', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Failure to Thrive', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 7/23/2007 8/10/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Diagnosed as failure to thrive', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Hip Fracture', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 4/25/2006 5/4/2006 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to study: Unrelated Description: Left Hip Fracture Resulting From Fall', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Hypokalemia, hypomagnesia, and antythmia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 12/15/2007 12/17/2007 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Hypokalemia, hypomagnesia, and antythmia', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 10/3/2007 10/11/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Severe infection', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Irregular Heartbeat', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 1/18/2008 2/17/2008 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Irregular Heartbeat', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Laceration', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 9/9/2007 11/4/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Debridement and Closure of Laceration', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Liver Cancer Diagnosis', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 11/4/2005 Status: Continuing at discontinuation Reason for Qualifying: Are other conditions which represent significant hazards Intensity: Severe Relationship to Study: Unrelated Description: Liver Cancer Diagnosis', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Loculated right pleural effusion', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 7/27/2007 8/2/2007 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Loculated right pleural effusion and possible Pneumonia', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Myocardial Infarction', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 8/30/2007 8/31/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Apparent Myocardial Infarction', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'PEG Procedure Complications', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 5/11/2006 5/12/2006 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to study: Unrelated Description: Complications from PEG Procedure', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Peg Replacement', 'SeriousEventOrganSystem': 'Surgical and medical procedures', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 3/14/2008 3/18/2008 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Mild Relationship to study: Unrelated Description: PEG replacement', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Pneumonia', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 3/6/2008 3/19/2008 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Pneumonia', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Pulmonary Emboli and pneumonia', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 9/3/2006 10/5/2006 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Pulmonary emboli and pneumonia', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Respiratory Complications', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 10/7/2006 10/7/2006 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to study: Unrelated Description: Respiratory Complications', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Respiratory Failure', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 9/28/2007 9/28/2007 Status: Resolved Reason for qualifying: Requiring or prolonging Hospitalization Intensity: Severe Relationship to study: Unrelated Description: continued respiratory decline', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Sepsis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 10/3/2007 10/11/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Severe Sepsis around PEG Tube', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Shortness of Breath', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 10/2/2006 Status: Continuing at discontinuation Reason for Qualifying: Are other conditions which represent significant hazards Intensity: Severe Relationship: Unrelated Description: Shortness of breath', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Subarachroid Hemmorrhage and Contusion', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 3/14/2007 3/16/2007 Status: Resolved Reason for Qualifying: Resulting in death Severe Relationship to Study: Unrelated Description: Sub-arachnoid Haemmorrhage and Contusion Resulting from fall', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Subdural Hematoma', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 6/11/2007 6/11/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Subdural Hematoma from fall', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}, {'SeriousEventTerm': 'Transitional Cell Carcinoma', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventNotes': 'Dates: 9/6/2007 9/23/2007 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to study: Unrelated Description Small bowel obstruction, transitional cell carcinoma', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '153'}]}}]}, 'OtherEventList': {'OtherEvent': [{'OtherEventTerm': 'Abdominal Distension', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/20/2007 Status: Unresolved at 48 Weeks Description: Abdominal distension Intensity: moderate Relationship to study: possible', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Abnormal Lab', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 5/2/2006 8/21/2006 Status: Resolved Description: Abnormal Lab Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Allergy', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 4/17/2007 4/22/2007 Status: Ended Description: Allergy Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Ankle Sprain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 9/6/2006 Status: Ended Description: Ankle Sprain Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Arthritis', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/27/2007 Status: Unresolved at 48 Weeks Description: Arthritis Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Back Pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates:: 6/3/2006 Status: Unresolved at 48 weeks Description: Back Pain Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Blister', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 4/1/2008 Status: Unresolved at 48 Weeks Description: Blister Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Blood Clot', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/28/2008 Status: Unresolved at 48 Weeks Description: Blood Clot Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Bronchitis', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/20/2008 2/10/2008 Status: Ended Description: Bronchitis Intensity: moderate Relationship to study: possible', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Bruise', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 5/11/2006 5/11/2006 Status:Ended Description: Bruise Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Burning Sensation', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 7/23/2007 Status: Continuing Description: PAIN Burning Sensation Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Cold', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 8/9/2007 8/15/2007 Status: Ended Description: Cold Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Colon Polyp', 'OtherEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/1/2006 2/1/2006 Status: Ended Description: Colon Polyp Intensity: mild Relationship: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Concussion', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/6/2006 2/6/2006 Status: Ended Description: Concussion Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Congestion', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 7/21/2006 7/31/2006 Status: Resolved Description: Congestion Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Conjunctivitis', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 7/3/2007 7/8/2007 Status: Ended Description: Conjunctivitis Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Constipation', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/1/2006 6/1/2006 Status: Resolved Description: Constipation Intensity: moderate Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Contusion', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 7/4/2007 7/4/2007 Status: Ended Description: Contusion Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Cough', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 9/7/2006 Status: Ended Description: Cough Intensity: moderate Relationship: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Decreased Rectal Tone', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 6/4/2007 Status: Continuing Description: Decreased Rectal Tone Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Dehydration', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/5/2008 Description: Dehydration Intensity: mild Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Dental', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 4/17/2006 Status: Ended Description: Dental Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Dermatitis', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/1/2008 Status: Unresolved at 48 Weeks Description: Dermatitis Intensity: mild Relationship to study: possible', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Diarrhea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/10/2007 2/10/2007 Status: Ended Description: Diarrhea Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Diverticulitis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/15/2006 11/14/2006 Status: Resolved Description: Diverticulitis Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/15/2006 Status: Ended Description: Dizziness Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Dry Eye', 'OtherEventOrganSystem': 'Eye disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/15/2007 Description:Dry Eye Intensity: mild Relationship to study: probable', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Dysphagia', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 6/15/2006 Status: Unresolved at 48 Weeks Description: Dysphagia Intensity: mild Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Ear Infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/1/2006 10/26/2006 Status: Resolved Description: Ear Infection Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Edema', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/24/2006 Status: Unresolved at 48 Weeks Description: Edema Intensity: mild Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Fall', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 4/13/2007 4/13/2007 Status: Ended Description: Fall Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/1/2005 Status: Unresolved at Discontinuation Description: Fatigue Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Fracture', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/18/2007 3/29/2007 Status: Resolved Description: Fracture Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Gastritis', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 9/25/2006 10/2/2006 Status: Ended Description: Gastritis Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Hallucination', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 9/13/2006 9/16/2006 Status: Ended Description: Hallucination Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/18/2006 3/1/2006 Status: Ended Description: Headache Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Hypercarbia', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/6/2006 Status: Continuing Description: Hypercarbia Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Hypertension', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/11/2008 Status: Unresolved at 48 Weeks Description: Hypertension Intensity: mild Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Hypotension', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/4/2006 11/4/2006 Status: Ended Description: Hypotension Intensity: mild Relationship to Study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/26/2007 11/4/2007 Status: Ended Description: Infection Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Knee Sprain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 6/30/2007 7/13/2007 Status: Ended Description: Knee Sprain Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Laceration', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/5/2007 2/5/2007 Status: Ended Description: Laceration Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Lesion', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/30/2007 5/7/2007 Status: Ended Description: Lesion Intensity: mild Relationship to study: definite', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Nosebleed', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/1/2007 Status: Continuing Description: Nosebleed Intensity: mild Relationship to study: probable', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Osteopenia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 9/4/2006 Status: Unresolved at 48 Weeks Description: Osteopenia Intensity: mild Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'PEG', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 6/29/2006 7/1/2006 Status: Ended Description: PEG Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/20/2006 12/18/2006 Status: Resolved Description: Pain Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Pneumonia', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/1/2007 Status: Unresolved at 48 Weeks Description: Pneumonia Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Post Nasal Drip', 'OtherEventOrganSystem': 'Immune system disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/31/2006 Status: Unresolved at 48 Weeks Description: Post Nasal Drip Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Pressure Sores', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/28/2006 11/30/2006 Status: Resolved Description: Pressure Sores Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'RADS', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/17/2007 4/30/2007 Status: Ended Description: RADS Intensity: mild Relationship: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 8/15/2005 Status: Unresolved at 48 Weeks Description: Rash Intensity: mild Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Shortness of breath', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/25/2007 2/25/2007 Status: Ended Description: Shortness of Breath Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Shoulder Pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/23/2006 1/25/2006 Status: Ended Description: Shoulder Pain Intensity: severe Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Sialorrhea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/10/2006 Status: Unresolved at 48 Weeks Description: Sialorrhea Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Sinus Infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 4/1/2007 4/7/2007 Status: Ended Description: Sinus Infection Severity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Sore Throat', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/12/2006 Status: Unresolved at 48 Weeks Description: Sore Throat Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Spasm (Respiratory)', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 1/19/2007 1/19/2007 Status: Resolved Description: Spasm Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Stomach Upset', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 4/29/2006 5/1/2006 Status: Ended Description: Stomach Upset Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'UTI', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 3/14/2006 3/24/2006 Status: Ended Description: UTI Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Urgent Bowel Movements', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/1/2006 Status: Unresolved at Discontinuation Description: Urgent Bowel Movements Intensity: mild Relationship to study: possible', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Urinary Frequency', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 6/11/2007 6/24/2007 Status: Ended Description: Urinary Frequency Intensity: moderate Relationship to study: not likely', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Vomiting', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 10/18/2005 10/18/2005 Status: Ended Description: Vomiting Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Weakness', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 2/1/2006 Status: Unresolved at Discontinuation Description: Weakness Intensity: mild Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Weight Loss', 'OtherEventOrganSystem': 'General disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 8/8/2005 3/13/2006 Status: Ended Description: Weight Loss Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}, {'OtherEventTerm': 'Wheezing', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Dates: 11/6/2006 Status: Resolved Description: Wheezing Intensity: moderate Relationship to study: not related', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '153'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Edward J. Kasarskis, M.D., Ph.D.', 'PointOfContactOrganization': 'University of Kentucky', 'PointOfContactEMail': 'ejkas@uky.edu', 'PointOfContactPhone': '859-218-5061'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000016472', 'ConditionMeshTerm': 'Motor Neuron Disease'}, {'ConditionMeshId': 'D000000690', 'ConditionMeshTerm': 'Amyotrophic Lateral Sclerosis'}, {'ConditionMeshId': 'D000012598', 'ConditionMeshTerm': 'Sclerosis'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000019636', 'ConditionAncestorTerm': 'Neurodegenerative Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000009468', 'ConditionAncestorTerm': 'Neuromuscular Diseases'}, {'ConditionAncestorId': 'D000013118', 'ConditionAncestorTerm': 'Spinal Cord Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000057177', 'ConditionAncestorTerm': 'TDP-43 Proteinopathies'}, {'ConditionAncestorId': 'D000057165', 'ConditionAncestorTerm': 'Proteostasis Deficiencies'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M18569', 'ConditionBrowseLeafName': 'Motor Neuron Disease', 'ConditionBrowseLeafAsFound': 'Lateral Sclerosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3714', 'ConditionBrowseLeafName': 'Amyotrophic Lateral Sclerosis', 'ConditionBrowseLeafAsFound': 'Amyotrophic Lateral Sclerosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15105', 'ConditionBrowseLeafName': 'Sclerosis', 'ConditionBrowseLeafAsFound': 'Sclerosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21248', 'ConditionBrowseLeafName': 'Neurodegenerative Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12101', 'ConditionBrowseLeafName': 'Neuromuscular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15605', 'ConditionBrowseLeafName': 'Spinal Cord Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28449', 'ConditionBrowseLeafName': 'TDP-43 Proteinopathies', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28437', 'ConditionBrowseLeafName': 'Proteostasis Deficiencies', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T349', 'ConditionBrowseLeafName': 'Amyotrophic Lateral Sclerosis', 'ConditionBrowseLeafAsFound': 'Amyotrophic Lateral Sclerosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T4699', 'ConditionBrowseLeafName': 'Primary Lateral Sclerosis', 'ConditionBrowseLeafAsFound': 'Lateral Sclerosis', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 87, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05422729', 'OrgStudyIdInfo': {'OrgStudyId': '05200218'}, 'Organization': {'OrgFullName': 'Food and Health Bureau, Hong Kong', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'mHealth-supported Coach', 'OfficialTitle': 'A Multidisciplinary-led Personalised mHealth-supported Coach for Reducing Midlife Stroke Risk'}, 'StatusModule': {'StatusVerifiedDate': 'June 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 5, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 4, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 8, 2022', 'StudyFirstSubmitQCDate': 'June 13, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 16, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 13, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 16, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Helen YL Chan', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor (Dr)', 'ResponsiblePartyInvestigatorAffiliation': 'Chinese University of Hong Kong'}, 'LeadSponsor': {'LeadSponsorName': 'Food and Health Bureau, Hong Kong', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'A randomised controlled trial to evaluate the effects of a personalised mHealth-supported coach programme in the middle-aged group with stroke risk.', 'DetailedDescription': 'Aim: To evaluate the effects of a personalised mHealth-supported coach programme on the adoption of health-promoting behaviours in the middle-aged group, in comparison with usual care.\\n\\nDesign: A 24-month prospective two-arm, parallel-group, single-blinded, repeated-measure randomised controlled trial will be conducted.\\n\\nParticipants: People who aged between 40 and 64, mentally competent, have a non-laboratory INTERHEART risk score (IHRS) of 10 or higher, communicable in Chinese and free from stroke and transient ischemic attack (TIA) or other cardiovascular disease will be eligible to the study. A total of 164 participants will be recruited through a district community centre and randomly assigned on 1:1 ratio to the intervention group or the control group.\\n\\nIntervention: A theory-based mHealth-supported coach programme, including individual consultation sessions and a mobile application with a virtual sharing platform, is developed by a multidisciplinary team for the intervention group over three months, whereas the control group receives usual care.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Heart Disease Risk Factors']}, 'KeywordList': {'Keyword': ['Primary Health Care']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '164', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Personalised mHeatlh-supported coaching programme', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Three monthly individual consultation session, supported with a specific mobile application.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: mHealth-supported coaching']}}, {'ArmGroupLabel': 'Traditional in-person health coaching programme', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Three monthly individual consultation sessions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Conventional Health coaching']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'mHealth-supported coaching', 'InterventionDescription': 'The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Personalised mHeatlh-supported coaching programme']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Conventional Health coaching', 'InterventionDescription': 'Three individual consultation sessions delivered by a nurse.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Traditional in-person health coaching programme']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Health-promoting behaviours', 'PrimaryOutcomeDescription': 'Four subscales, including health responsibility, nutrition, physical activity and stress management, of the Health Promoting Lifestyle Profile II. The possible score range from 34 to 136, with a higher score meaning healthier lifestyles were adopted.', 'PrimaryOutcomeTimeFrame': '3-month post-allocation'}, {'PrimaryOutcomeMeasure': 'Health-promoting behaviours', 'PrimaryOutcomeDescription': 'Four subscales, including health responsibility, nutrition, physical activity and stress management, of the Health Promoting Lifestyle Profile II. The possible score range from 34 to 136, with a higher score meaning healthier lifestyles were adopted.', 'PrimaryOutcomeTimeFrame': '6-month post-allocation'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Self-efficacy of adopting health-promoting behaviours', 'SecondaryOutcomeDescription': 'The adapted version of the Diabetes Mellitus Type II Self Efficacy Scale will be used. Participants will rate their level of confidence in various behaviours, in diet control, weight control and lifestyle management, by using a five-point Likert scale. The possible scores ranged from 7 to 35, with a higher score meaning a higher level of self-efficacy.', 'SecondaryOutcomeTimeFrame': '3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Self-efficacy', 'SecondaryOutcomeDescription': 'The adapted version of the Diabetes Mellitus Type II Self Efficacy Scale will be used. Participants will rate their level of confidence in various behaviours, in diet control, weight control and lifestyle management, by using a five-point Likert scale. The possible scores ranged from 7 to 35, with a higher score meaning a higher level of self-efficacy.', 'SecondaryOutcomeTimeFrame': '6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'INTERHEART risk score', 'SecondaryOutcomeDescription': 'The score was calculated based on the weighted sum of nine risk factors, including age, sex, lifestyles and psychosocial wellbeing, which were significantly related to cardiovasuclar diseases. The possible score range was 0 - 48, in which a higher score corresponds to higher risk.', 'SecondaryOutcomeTimeFrame': '3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'INTERHEART risk score', 'SecondaryOutcomeDescription': 'The score was calculated based on the weighted sum of nine risk factors, including age, sex, lifestyles and psychosocial wellbeing, which were significantly related to cardiovasuclar diseases. The possible score range was 0 - 48, in which a higher score corresponds to higher risk.', 'SecondaryOutcomeTimeFrame': '6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'automatic retinal image analysis', 'SecondaryOutcomeDescription': 'Retinal fundus image will be obtained from both eyes of the participant using a non-mydriatic digital retinal camera (Canon CR-2 AF, U.S.A., Inc). Stroke risk estimation will be determined through fractural analysis, statistical texture analysis and high-order spectra analysis based on the retinal vessel parameters. The ARIA-stroke algorithm developed using R and Matlab software has a sensitivity and a specificity of 94.7% and 100%, respectively. The value between 0.5 and 0.7 is considered as moderate risk, while high risk is considered at 0.7 or higher.', 'SecondaryOutcomeTimeFrame': '3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'automatic retinal image analysis (ARIA)', 'SecondaryOutcomeDescription': 'Retinal fundus image will be obtained from both eyes of the participant using a non-mydriatic digital retinal camera (Canon CR-2 AF, U.S.A., Inc). Stroke risk estimation will be determined through fractural analysis, statistical texture analysis and high-order spectra analysis based on the retinal vessel parameters. The ARIA-stroke algorithm developed using R and Matlab software has a sensitivity and a specificity of 94.7% and 100%, respectively. The value between 0.5 and 0.7 is considered as moderate risk, while high risk is considered at 0.7 or higher.', 'SecondaryOutcomeTimeFrame': '6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Psychological distress', 'SecondaryOutcomeDescription': 'The Depression Anxiety Stress Scale (DASS-21)includes 21 items, with 7 in each subscale: depression, anxiety and stress. Participants will rate their level of agreement with the statements on a 4-point Likert scale, from 0 (not apply to me at all) to 3 (applied to me very much). The potential scores range from 0 to 63, with a higher score means higher level of distress experienced.', 'SecondaryOutcomeTimeFrame': '3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Psychological distress', 'SecondaryOutcomeDescription': 'The Depression Anxiety Stress Scale (DASS-21)includes 21 items, with 7 in each subscale: depression, anxiety and stress. Participants will rate their level of agreement with the statements on a 4-point Likert scale, from 0 (not apply to me at all) to 3 (applied to me very much). The potential scores range from 0 to 63, with a higher score means higher level of distress experienced.', 'SecondaryOutcomeTimeFrame': '6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Blood pressure', 'SecondaryOutcomeDescription': 'Blood pressure measurement will be carried out, after 10 min of rest, on the left arm in a sitting posture by using an electronic sphygmomanometer.', 'SecondaryOutcomeTimeFrame': 'Between baseline and 3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Blood pressure', 'SecondaryOutcomeDescription': 'Blood pressure measurement will be carried out, after 10 min of rest, on the left arm in a sitting posture by using an electronic sphygmomanometer.', 'SecondaryOutcomeTimeFrame': 'Between 3-month and 6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Body mass index (BMI)', 'SecondaryOutcomeDescription': 'BMI will be calculated by dividing the weight (in kilogram) by the height (in meter) squared. The height will be measured using a stadiometer, and body weight will be measured using an electronic scale.', 'SecondaryOutcomeTimeFrame': 'Between baseline and 3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Body mass index(BMI)', 'SecondaryOutcomeDescription': 'BMI will be calculated by dividing the weight (in kilogram) by the height (in meter) squared. The height will be measured using a stadiometer, and body weight will be measured using an electronic scale.', 'SecondaryOutcomeTimeFrame': 'Between 3-month and 6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Waist-hip ratio (WHR)', 'SecondaryOutcomeDescription': 'WHR will be used for determining body fat distribution. Waist circumference will be measured at the mid-point between the lowest rib and the iliac crest, whereas hip circumference will be measured at the widest level over the great trochanters. The two measurements will be measured to the nearest 0.1 cm by using a measuring tape.', 'SecondaryOutcomeTimeFrame': 'Between baseline and 3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Waist-hip ratio (WHR)', 'SecondaryOutcomeDescription': 'WHR will be used for determining body fat distribution. Waist circumference will be measured at the mid-point between the lowest rib and the iliac crest, whereas hip circumference will be measured at the widest level over the great trochanters. The two measurements will be measured to the nearest 0.1 cm by using a measuring tape.', 'SecondaryOutcomeTimeFrame': 'Between 3-month and 6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Fasting blood glucose', 'SecondaryOutcomeDescription': 'Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.', 'SecondaryOutcomeTimeFrame': 'Between baseline and 3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Fasting blood glucose', 'SecondaryOutcomeDescription': 'Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.', 'SecondaryOutcomeTimeFrame': 'Between 3-month and 6-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Blood lipid profile', 'SecondaryOutcomeDescription': 'The profile includes ncluding triglyceride, total Cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C). Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.', 'SecondaryOutcomeTimeFrame': 'Between baseline and 3-month post-allocation'}, {'SecondaryOutcomeMeasure': 'Change in Blood lipid profile', 'SecondaryOutcomeDescription': 'The profile includes ncluding triglyceride, total Cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C). Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.', 'SecondaryOutcomeTimeFrame': 'Between 3-month and 6-month post-allocation'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nChinese ethnic\\nable to read Chinese and communicate in Cantonese/Mandarin\\nwith non-laboratory IHRS score 10 or higher\\n\\nExclusion Criteria:\\n\\nmentally incompetent\\npreviously diagnosed with stroke, TIA, MI, coronary heart disease, heart failure or atrial fibrillation\\nwith eye or retinal disease\\nwith terminal disease with an expected life expectancy less than six months\\nbeing pregnant\\nhave enrolled in other lifestyle-based or exercise-based projects\\ndo have mobile devices or internet service to access the mobile application', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '64 Years', 'StdAgeList': {'StdAge': ['Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Helen Y Chan, Ph.D', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+85239438099', 'CentralContactEMail': 'helencyl@cuhk.edu.hk'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Helen Y Chan, Ph.D', 'OverallOfficialAffiliation': 'Chinese University of Hong Kong', 'OverallOfficialRole': 'Principal Investigator'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}]}}}}}, {'Rank': 88, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02814604', 'OrgStudyIdInfo': {'OrgStudyId': '499174'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'FoodFLIP: Testing the Effectiveness of a Food Information App to Promote the Selection of Healthier Foods', 'OfficialTitle': 'FoodFLIP: Testing the Effectiveness of a Food Information App to Promote the Selection of Healthier Foods'}, 'StatusModule': {'StatusVerifiedDate': 'November 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 23, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'January 30, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 24, 2016', 'StudyFirstSubmitQCDate': 'June 22, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 28, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 4, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 9, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': \"Mary L'Abbe\", 'ResponsiblePartyInvestigatorTitle': 'Earle W. McHenry Professor and Chair', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Heart and Stroke Foundation of Canada', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Dietitians of Canada', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"There is a lot of confusion when it comes to understanding nutrition information on food packages, thus making it difficult for consumers to choose healthy products. In today's busy and fast-paced shopping environment, mobile digital technology (for example, Smartphone applications) can help consumers make 'healthier' food choices when they are shopping. This study aims to test the effectiveness of a traffic light front-of-pack system, the Health Star Rating System (HSR or Star System), and the proposed sodium, saturated fat and sugar warning labels proposed by Health Canada. The study will also experimentally test the use of a Smartphone application (app), FoodFlip, to help educate consumers on these systems on food packages to explore the impact of a learning effect on the efficacy of the labelling systems.\", 'DetailedDescription': 'The rising rate of obesity and diet-related chronic diseases illustrate that Canadians\\' eating habits need to change. Equipping Canadians with information and tools to enable healthy food choices that decrease risk for disease is imperative. While the Nutrition Facts table (NFt) is the most standardized and complete form of nutrition labelling, studies have shown that consumers are confused about serving size, nutrient quantities, and the interpretation of the % Daily Value. Thus, expert groups have proposed the introduction of interpretive front-of-pack (FOP) nutrition rating systems (e.g. traffic light labelling or star ratings) that also help consumers understand the significance of the levels of nutrients in relation to the \"healthiness\" of a food. One of the main barriers to the introduction of such a system is the absence of high quality studies that objectively measure the impact of nutrition information on actual food purchases. This is a consequence of both the practical challenges associated with designing and conducting such studies in \\'real-world\\' settings, and the lack of food industry support to quantitatively examine or publish the potential for enhanced nutrition labels to modify consumer food choices. With the growing burden of diet-related disease, there is an urgent need for robust evidence to evaluate the potential for additional interpretive nutrition labelling systems to modify and improve food purchasing patterns. Given the relative ubiquity of mobile digital technologies, our Canadian Smartphone application (FoodFLIP) provides us with an unprecedented opportunity to examine and improve consumers\\' diets.\\n\\nThis study will investigate whether a traffic light, a health star rating or a high-in warning label FOP system can help consumers identify and purchase healthier foods.\\n\\nObjective 1: To evaluate the effects of three FOP systems in helping consumers characterize healthfulness and nutritional content of food items.\\n\\nObjective 2: To determine which of the three FOP systems support healthier food choices and are preferred by Canadian consumers.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Consumer Behavior', 'Diet, Food, and Nutrition']}, 'KeywordList': {'Keyword': ['Front-of-Pack Labelling', 'Star rating system', 'Traffic light rating system', 'Consumer Behavior', 'Health Literacy', 'Mobile Apps', 'Nutrition Labeling', 'Healthy food choices', 'High-in Warning Labels']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '2008', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Traffic Light', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.\\n\\nIntervention: Device:Smartphone, Behavioural: Nutrition Rating Systems', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nutrition Rating Systems']}}, {'ArmGroupLabel': 'Health Star Rating System', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall \"healthy\" rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.\\n\\nIntervention: Device:Smartphone, Behavioural: Nutrition Rating Systems', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nutrition Rating Systems']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': \"Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.\"}, {'ArmGroupLabel': 'High-in Warning Label', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': \"Participants in this group will download an app which features the nutrition information of the selected product in a 'high-in' warning label format (i.e. stop signs for each of saturated fat, sugar, and sodium; according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.\\n\\nIntervention: Device:Smartphone, Behavioural: Nutrition Rating Systems\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nutrition Rating Systems']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nutrition Rating Systems', 'InterventionDescription': 'Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Health Star Rating System', 'High-in Warning Label', 'Traffic Light']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Device: Smartphone']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The accurate characterization of healthfulness and nutritional content of foods as indicated by each intervention group will be compared.', 'PrimaryOutcomeDescription': 'In the first series of experimental tasks, participants will be exposed to an image of a food package with the assigned FOP nutrition information and NFt. Participants will be asked to rate the products on how likely they would be to purchase the product, overall healthiness, and the relative amount of specific nutrients in the product (e.g., if the product contains a little or a lot of sodium) using a Likert scale. In the second series of tasks, participants will be shown 5 similar products side by side (5 breakfast cereals, 5 yogurts and 5 pasta dinners). Participants will be asked to rank the products from MOST HEALTHY to LEAST HEALTHY, and which product they would select if they were trying to consume a low sodium, low energy or high fibre diet.', 'PrimaryOutcomeTimeFrame': '6 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'A qualitative assessment of the functionality and usability of the smartphone app (FoodFLIP) will be assessed through questionnaires on a 5-point Likert Scale (the percentage of users finding the app easy to use/easy to understand etc).', 'SecondaryOutcomeDescription': 'The functionality and usability of the smartphone app is assessed through questionnaires (e.g easy to use, easy to understand etc). Responses on these questionnaires are scaled using a five-point Likert-scale and scores for each question are recorded separately to assess the usability of the smartphone app (e.g 1 least liked to 5 most liked).', 'SecondaryOutcomeTimeFrame': '6 weeks'}, {'SecondaryOutcomeMeasure': 'The health claims with or without additional labelling elements influence perceptions of healthiness and purchasing intentions will be compared between each FOP system.', 'SecondaryOutcomeDescription': 'Participants will be randomized to see products with symbolic and textual health and/or nutrition claims. Participants will first be shown an image with or without claims for 10 seconds (this is slightly longer than the average time an individual spends viewing a product in a food store when making a purchasing decision). The image will then be removed from the screen, and participants will be asked to recall the presence and content of the claim. The image will then be returned to the screen and participants will be asked to rate how healthy the product is and to rate how likely they would be to purchase the product.', 'SecondaryOutcomeTimeFrame': '6 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nShop at a supermarket owned by one of the largest four national retailers at least twice a month. This includes Loblaws, Sobeys, Metro or Safeway\\nOwn a smartphone (iPhone version 3 or later or android)\\nAre 18 years or over and provide informed consent to participate\\nReside in Canada, excluding Northern Territories', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': \"Mary R L'Abbe, Ph.D.\", 'OverallOfficialAffiliation': 'University of Toronto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Toronto', 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5S3E2', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '14972060', 'ReferenceType': 'background', 'ReferenceCitation': 'Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004 Feb;7(1A):187-200. doi: 10.1079/phn2003588.'}, {'ReferencePMID': '24669982', 'ReferenceType': 'background', 'ReferenceCitation': \"Emrich TE, Qi Y, Mendoza JE, Lou W, Cohen JE, L'abbe MR. Consumer perceptions of the Nutrition Facts table and front-of-pack nutrition rating systems. Appl Physiol Nutr Metab. 2014 Apr;39(4):417-24. doi: 10.1139/apnm-2013-0304. Epub 2013 Oct 24.\"}, {'ReferenceType': 'background', 'ReferenceCitation': 'The Standing Committee on Health. Healthy Weights for Healthy Kids. 2007'}, {'ReferencePMID': '22585907', 'ReferenceType': 'background', 'ReferenceCitation': 'McGuire S. Institute of Medicine. 2012. Front-of-Package Nutrition Rating Systems and Symbols: Promoting Healthier Choices. Washington, DC: The National Academies Press. Adv Nutr. 2012 May 1;3(3):332-3. doi: 10.3945/an.112.001933. No abstract available.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}}}}, {'Rank': 89, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03555734', 'OrgStudyIdInfo': {'OrgStudyId': 'DNSG-Pulses'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Umbrella Review and Updated Systematic Review and Meta-analysis of Pulses/Legumes and Incident Cardiometabolic Diseases', 'OfficialTitle': 'Association Between Pulses/Legumes and Cardiometabolic Disease Outcomes: An Umbrella Review and Updated Systematic Review and Meta-analysis of Prospective Cohort Studies'}, 'StatusModule': {'StatusVerifiedDate': 'June 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 21, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 31, 2018', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 31, 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 24, 2018', 'StudyFirstSubmitQCDate': 'June 12, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 13, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 12, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 13, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John Sievenpiper', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor, MD, PhD, FRCPC', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'European Foundation for the Study of Diabetes', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The European Association for the Study of Diabetes (EASD) guidelines have not made any specific recommendations regarding dietary pulses. To update the recommendations, the Diabetes and Nutrition Study Group (DNSG) of the EASD commissioned an umbrella review and updated systematic review and meta-analysis using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to summarize the available evidence from prospective cohort studies of the association between dietary pulses/legumes and cardiometabolic disease outcomes (incident cardiovascular diseases, diabetes, hypertension and overweight/obesity).', 'DetailedDescription': \"Background: Dietary pulses, the edible dried seeds of legumes, are high in fiber, plant protein, and various micronutrients and low in fat and glycemic index (GI), have shown a wide range of health benefits for the prevention and management of type 2 diabetes and cardiovascular disease. However, dietary pulses are not well recognized for these advantages. Recommendations for dietary pulse intake vary across chronic disease guidelines. In specific, the European Association for the Study of Diabetes (EASD) guidelines for nutrition therapy have not made any specific recommendations regarding dietary pulses. The present umbrella review and updated systematic review and meta-analysis using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was thus commissioned by the Diabetes and Nutrition Study Group (DNSG) of the EASD to summarize the available evidence from prospective cohort studies of the association between dietary pulses/legumes and cardiometabolic disease outcomes (incident cardiovascular diseases, diabetes, hypertension and overweight/obesity).\\n\\nNeed for proposed research: High quality systematic reviews and meta-analyses represent the highest level of evidence to support dietary guidelines and public health policy development. As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, there is a need for a systematic review and meta-analysis assessing the pooled association between dietary pulses/legumes and cardiometabolic disease outcomes.\\n\\nObjective: The investigators will conduct an umbrella review and updated systematic review and meta-analysis to summarize the association between dietary pulses/legumes and cardiometabolic disease outcomes in prospective cohort studies.\\n\\nDesign: The umbrella review will consist of a literature search of the most recent and/or comprehensive systematic reviews and meta-analyses published in this area. The included systematic reviews and meta-analyses will be updated conducting a systematic search for prospective cohort studies published after the census dates of the included systematic reviews and meta-analyses. The planning and conduct of the updated systematic review and meta-analysis will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.\\n\\nData sources:\\n\\nThe umbrella review will consist of searching PubMed databases using appropriate search terms to identify the most recent and/or comprehensive systematic reviews and meta-analyses published in this area. The updated systematic review and meta-analysis will consist of searching MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials after the census dates of the included systematic reviews and meta-analyses from the umbrella review using appropriate search terms supplemented by manual searches of references of included studies. Authors will be contacted for applicable missing data.\\n\\nStudy selection:\\n\\nThe umbrella review will include the most recent and/or comprehensive systematic reviews and meta-analyses of prospective cohort studies assessing the association between pulse/legume intake and cardiometabolic diseases outcomes (cardiovascular diseases, diabetes, hypertension, overweight/obesity). The updated systematic review and meta-analysis will include prospective cohort studies ≥1 year assessing the association between pulse/legume intake and cardiometabolic diseases outcomes (cardiovascular diseases, diabetes, hypertension, overweight/obesity) published since the last census dates of the included systematic reviews and meta-analyses from the umbrella review.\\n\\nData extraction: Data from prospective cohort studies in the most recent and/or comprehensive systematic reviews and meta-analyses will be included in the updated systematic review and meta-analysis. For newly identified prospective cohort studies, two or more investigators will independently extract relevant data and assess risk of bias using the Newcastle-Ottawa Scale (NOS) for observational studies. Risk ratios, odds ratios and hazard ratios for clinical outcomes will be extracted or derived from clinical event data across quantiles of exposure. All disagreements will be resolved by consensus.\\n\\nOutcomes: The primary outcome of the systematic review and meta-analysis will be incident cardiovascular disease. Secondary outcomes will include incident coronary heart disease, stroke, diabetes, hypertension and overweight/obesity.\\n\\nData synthesis: The natural log-transformed relative risks of outcomes comparing the exposure to the reference group from each cohort will be pooled using the generic inverse variance method with random effects models and expressed as risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity will be assessed by Cochran Q statistic and quantified by I2. The significance level will be set at p<0.10 and an I2≥ 50% will be considered evidence of substantial heterogeneity. To explore sources of heterogeneity, the investigators will conduct sensitivity analyses, in which each study is systematically removed with recalculation of the summary estimates. If there are ≥10 studies, then the investigators will also explore sources of heterogeneity by a priori subgroup analyses (cohorts, sex, health status, follow-up [<10-years, ≥10-years], dose, level of adjustment of models, quality of the studies (NOS), and validation of the dietary assessment instruments). Meta-regression analyses will be used to assess the significance of categorical and continuous subgroups analyses. If there are ≥10 studies available, publication bias will be assessed by the visual inspection of funnel plots and formal testing using Begg's and Egger's tests. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.\\n\\nEvidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.\\n\\nKnowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.\\n\\nSignificance: The proposed project will aid in knowledge translation related to the role of dietary pulses in cardiometabolic disease risk, strengthening the evidence-base for guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cardiovascular Diseases', 'Coronary Heart Disease', 'Stroke', 'Diabetes Mellitus, Type 2', 'Hypertension', 'Obesity']}, 'KeywordList': {'Keyword': ['Pulses (beans, chickpeas, lentils, dry peas)', 'Legumes', 'Cardiovascular disease', 'Coronary heart disease', 'Stroke', 'Diabetes', 'Hypertension', 'Obesity', 'Prospective cohort studies', 'Umbrella review', 'Systematic review and meta-analysis']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Dietary pulses or legumes', 'InterventionDescription': 'Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cardiovascular disease (CVD)', 'PrimaryOutcomeDescription': 'Risk ratios for CVD incidence and mortality', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Coronary heat disease (CHD)', 'SecondaryOutcomeDescription': 'Risk ratios for CHD incidence and mortality', 'SecondaryOutcomeTimeFrame': 'Up to 20 years'}, {'SecondaryOutcomeMeasure': 'Stroke', 'SecondaryOutcomeDescription': 'Risk ratios for stroke incidence and mortality', 'SecondaryOutcomeTimeFrame': 'Up to 20 years'}, {'SecondaryOutcomeMeasure': 'Diabetes', 'SecondaryOutcomeDescription': 'Risk ratios for diabetes incidence and mortality', 'SecondaryOutcomeTimeFrame': 'Up to 20 years'}, {'SecondaryOutcomeMeasure': 'Hypertension', 'SecondaryOutcomeDescription': 'Risk ratios for hypertension incidence and mortality', 'SecondaryOutcomeTimeFrame': 'Up to 20 years'}, {'SecondaryOutcomeMeasure': 'Obesity', 'SecondaryOutcomeDescription': 'Risk ratios for obesity incidence and mortality', 'SecondaryOutcomeTimeFrame': 'Up to 20 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nUmbrella review:\\n\\nSystematic reviews and meta-analyses of prospective cohort studies assessing the relationship of dietary pulses or legumes with incident cardiometabolic diseases (cardiovascular diseases, diabetes, and hypertension).\\n\\nUpdated systematic review and meta-analysis:\\n\\nProspective cohorts studies\\nFollow-up duration >=1 year\\nAssessment of the exposure of pulses or legumes\\nAscertainment of viable data by level of exposure (cardiovascular diseases, diabetes, and hypertension).\\n\\nExclusion Criteria:\\n\\nUmbrella review:\\n\\nNot a systematic review and meta-analysis of prospective cohort studies that assess' the relationship of dietary pulses or legumes with incident cardiometabolic diseases\\n\\nUpdated systematic review and meta-analysis:\\n\\nEcological, cross-sectional, retrospective observational studies, clinical trials and non-human studies\\nDuration <1 year\\nNo assessment of the exposure of pulses or legumes\\nNo ascertainment of viable data by level of exposure\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Healthy volunteers or those at risk for cardiometabolic diseases', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'John Sievenpiper, MD, PhD', 'OverallOfficialAffiliation': 'University of Toronto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital\", 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5C 2T2', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '19394480', 'ReferenceType': 'background', 'ReferenceCitation': 'Mitchell DC, Lawrence FR, Hartman TJ, Curran JM. Consumption of dry beans, peas, and lentils could improve diet quality in the US population. J Am Diet Assoc. 2009 May;109(5):909-13. doi: 10.1016/j.jada.2009.02.029.'}, {'ReferencePMID': '22916812', 'ReferenceType': 'background', 'ReferenceCitation': 'Mudryj AN, Yu N, Hartman TJ, Mitchell DC, Lawrence FR, Aukema HM. Pulse consumption in Canadian adults influences nutrient intakes. Br J Nutr. 2012 Aug;108 Suppl 1:S27-36. doi: 10.1017/S0007114512000724.'}, {'ReferencePMID': '24710915', 'ReferenceType': 'background', 'ReferenceCitation': 'Ha V, Sievenpiper JL, de Souza RJ, Jayalath VH, Mirrahimi A, Agarwal A, Chiavaroli L, Mejia SB, Sacks FM, Di Buono M, Bernstein AM, Leiter LA, Kris-Etherton PM, Vuksan V, Bazinet RP, Josse RG, Beyene J, Kendall CW, Jenkins DJ. Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials. CMAJ. 2014 May 13;186(8):E252-62. doi: 10.1503/cmaj.131727. Epub 2014 Apr 7.'}, {'ReferencePMID': '24014659', 'ReferenceType': 'background', 'ReferenceCitation': 'Jayalath VH, de Souza RJ, Sievenpiper JL, Ha V, Chiavaroli L, Mirrahimi A, Di Buono M, Bernstein AM, Leiter LA, Kris-Etherton PM, Vuksan V, Beyene J, Kendall CW, Jenkins DJ. Effect of dietary pulses on blood pressure: a systematic review and meta-analysis of controlled feeding trials. Am J Hypertens. 2014 Jan;27(1):56-64. doi: 10.1093/ajh/hpt155. Epub 2013 Sep 7.'}, {'ReferencePMID': '27030531', 'ReferenceType': 'background', 'ReferenceCitation': 'Kim SJ, de Souza RJ, Choo VL, Ha V, Cozma AI, Chiavaroli L, Mirrahimi A, Blanco Mejia S, Di Buono M, Bernstein AM, Leiter LA, Kris-Etherton PM, Vuksan V, Beyene J, Kendall CW, Jenkins DJ, Sievenpiper JL. Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2016 May;103(5):1213-23. doi: 10.3945/ajcn.115.124677. Epub 2016 Mar 30.'}, {'ReferencePMID': '24820437', 'ReferenceType': 'background', 'ReferenceCitation': 'Li SS, Kendall CW, de Souza RJ, Jayalath VH, Cozma AI, Ha V, Mirrahimi A, Chiavaroli L, Augustin LS, Blanco Mejia S, Leiter LA, Beyene J, Jenkins DJ, Sievenpiper JL. Dietary pulses, satiety and food intake: a systematic review and meta-analysis of acute feeding trials. Obesity (Silver Spring). 2014 Aug;22(8):1773-80. doi: 10.1002/oby.20782. Epub 2014 May 13.'}, {'ReferencePMID': '19526214', 'ReferenceType': 'background', 'ReferenceCitation': 'Sievenpiper JL, Kendall CW, Esfahani A, Wong JM, Carleton AJ, Jiang HY, Bazinet RP, Vidgen E, Jenkins DJ. Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia. 2009 Aug;52(8):1479-95. doi: 10.1007/s00125-009-1395-7. Epub 2009 Jun 13.'}, {'ReferencePMID': '15853122', 'ReferenceType': 'background', 'ReferenceCitation': 'Mann JI, De Leeuw I, Hermansen K, Karamanos B, Karlstrom B, Katsilambros N, Riccardi G, Rivellese AA, Rizkalla S, Slama G, Toeller M, Uusitupa M, Vessby B; Diabetes and Nutrition Study Group (DNSG) of the European Association. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis. 2004 Dec;14(6):373-94. doi: 10.1016/s0939-4753(04)80028-0. No abstract available.'}, {'ReferencePMID': '27222591', 'ReferenceType': 'background', 'ReferenceCitation': 'Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23. No abstract available.'}, {'ReferencePMID': '27712954', 'ReferenceType': 'background', 'ReferenceCitation': 'Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J Jr, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GB, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. Epub 2016 Jul 25.'}, {'ReferencePMID': '29650114', 'ReferenceType': 'background', 'ReferenceCitation': 'Diabetes Canada Clinical Practice Guidelines Expert Committee; Sievenpiper JL, Chan CB, Dworatzek PD, Freeze C, Williams SL. Nutrition Therapy. Can J Diabetes. 2018 Apr;42 Suppl 1:S64-S79. doi: 10.1016/j.jcjd.2017.10.009. No abstract available. Erratum In: Can J Diabetes. 2019 Mar;43(2):153.'}, {'ReferencePMID': '29222375', 'ReferenceType': 'background', 'ReferenceCitation': 'American Diabetes Association. 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S38-S50. doi: 10.2337/dc18-S004.'}, {'ReferencePMID': '31728500', 'ReferenceType': 'derived', 'ReferenceCitation': 'Viguiliouk E, Glenn AJ, Nishi SK, Chiavaroli L, Seider M, Khan T, Bonaccio M, Iacoviello L, Mejia SB, Jenkins DJA, Kendall CWC, Kahleova H, Rahelic D, Salas-Salvado J, Sievenpiper JL. Associations between Dietary Pulses Alone or with Other Legumes and Cardiometabolic Disease Outcomes: An Umbrella Review and Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Adv Nutr. 2019 Nov 1;10(Suppl_4):S308-S319. doi: 10.1093/advances/nmz113.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}, {'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}, {'ConditionMeshId': 'D000003327', 'ConditionMeshTerm': 'Coronary Disease'}, {'ConditionMeshId': 'D000003324', 'ConditionMeshTerm': 'Coronary Artery Disease'}, {'ConditionMeshId': 'D000017202', 'ConditionMeshTerm': 'Myocardial Ischemia'}, {'ConditionMeshId': 'D000003924', 'ConditionMeshTerm': 'Diabetes Mellitus, Type 2'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000003920', 'ConditionAncestorTerm': 'Diabetes Mellitus'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000001161', 'ConditionAncestorTerm': 'Arteriosclerosis'}, {'ConditionAncestorId': 'D000001157', 'ConditionAncestorTerm': 'Arterial Occlusive Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6239', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9714', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafAsFound': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4159', 'ConditionBrowseLeafName': 'Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4155', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T294', 'InterventionBrowseLeafName': 'Soy Bean', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 90, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03449784', 'OrgStudyIdInfo': {'OrgStudyId': 'RECHMPL18_0104'}, 'Organization': {'OrgFullName': 'University Hospital, Montpellier', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias', 'OfficialTitle': 'Observatory of Patients With Dyslipidemia Hospitalized in Endocrinology-Diabetology-Nutrition Unit: Observational Study', 'Acronym': 'OBDYSLIP'}, 'StatusModule': {'StatusVerifiedDate': 'June 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2012', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 1, 2040', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'May 1, 2041', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 22, 2018', 'StudyFirstSubmitQCDate': 'February 22, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 28, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 29, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 5, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University Hospital, Montpellier', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University Hospital, Toulouse', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years in Europe, and is also increasingly common in developing countries. In the European Union, the economic cost of CVD represents annually €192 billion in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. LDL-cholesterol (LDL-C) is one of the major risk factors for CVD, through its role in the development of atherosclerosis. The efficacy of statins has been demonstrated by a considerable amount of literature not only in lowering LDL cholesterol levels but also in reducing cardiovascular events, both in diabetes and non-diabetes patients. Guidelines for the management of dyslipidemia have emerged from different countries. Thereby, in 2016 the French Society of Endocrinology (SFE) and the New French Society of Atherosclerosis (NSFA) published a consensus statement on the management of dyslipidemias integrating features from European recommendations and in 2017 the Haute Autorité de Santé updated the French guidelines. However, LDL-C goal attainment has rarely been assessed specifically in diabetes population, in which CVD is of particular importance. This study aimed to assess the rate of dyslipidaemias in a population of patient hospitalized in Endocrinology-Diabetology-Nutrition unit.\\n\\nThis observational study was carried in the Diabetes-Nutrition unit of the University Hospital of Montpellier - France. All consecutive patients admitted to that unit during the study period were assessed for eligibility. Data on age, sex, tobacco smoking, body mass index, hypertension (treatment of previously diagnosed hypertension or blood values > 140/90 mmHg), presence and type of CVD (coronary artery disease, stroke and transient ischemic attack, peripheral arterial disease), were collected at admission. LDL-C, HDL-C and triglycerides levels calculated with the Friedewald formula, and glomerular filtration rate calculated according to the CKD-EPI formula were obtained from blood samples taken within 24 hours of hospitalization admission. Information on the name and daily dose of lipid lowering drugs (statins, fibrate, ezetimibe …) at admission was documented. Cardiovascular risk level and LDL-C target values were defined according to 2011 and 2016 ESC guidelines and 2017 French guidelines.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Patient With Dyslipidemia']}, 'KeywordList': {'Keyword': ['dyslipidemia', 'lipid-lowering therapy', 'cardiovascular risk', 'diabetes', 'low-density lipoprotein cholesterol']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '977', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with dyslipidemia non achieving LDL-C target', 'ArmGroupDescription': 'patients with dyslipidemia non achieving LDL-C target', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Detection of patients with dyslipidemia']}}, {'ArmGroupLabel': 'patients with dyslipidemia achieving LDL-C target', 'ArmGroupDescription': 'patients with dyslipidemia achieving LDL-C target', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Detection of patients with dyslipidemia']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Detection of patients with dyslipidemia', 'InterventionDescription': 'Detection of patients with dyslipidemia', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with dyslipidemia achieving LDL-C target', 'patients with dyslipidemia non achieving LDL-C target']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'number with dyslipidemia', 'PrimaryOutcomeDescription': 'number of patient with dyslipidemia', 'PrimaryOutcomeTimeFrame': '1 day'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'number of patient not achieving LDL-C target according to cardiovascular risk', 'SecondaryOutcomeDescription': 'number of patient not achieving LDL-C target according to cardiovascular risk', 'SecondaryOutcomeTimeFrame': '1 day'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\n- Patients aged above 18 years old, admitted to the department during the study period and hospitalized for at least 24 hours, blood samples taken within 24 hours of hospitalization admission (LDL-C, triglycerides)\\n\\nExclusion criteria:\\n\\n- Patients with elevated triglycerides (>4.5 mmol/L or >400 mg/dL)', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Study population was composed of patient hospitalized in Diabetes-Nutrition unit of Montpellier University hospital.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Cyril BREUKER, PharmD,Phd', 'CentralContactRole': 'Contact', 'CentralContactPhone': '467337121', 'CentralContactPhoneExt': '33', 'CentralContactEMail': 'c-breuker@chu-montpellier.fr'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Cyril BREUKER', 'OverallOfficialAffiliation': 'University Hospital, Montpellier', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Uhmontpellier', 'LocationStatus': 'Recruiting', 'LocationCity': 'Montpellier', 'LocationZip': '34295', 'LocationCountry': 'France', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'cyril BREUKER', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'c-breuker@chu-montpellier.fr'}, {'LocationContactName': 'P Goudry', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'A Avignon', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'A Sultan', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'P Cestac', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'B Sallerin', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30041785', 'ReferenceType': 'derived', 'ReferenceCitation': 'Breuker C, Clement F, Mura T, Macioce V, Castet-Nicolas A, Audurier Y, Boegner C, Morcrette E, Jalabert A, Villiet M, Avignon A, Sultan A. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Int J Cardiol. 2018 Oct 1;268:195-199. doi: 10.1016/j.ijcard.2018.04.068.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'NC'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000050171', 'ConditionMeshTerm': 'Dyslipidemias'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000052439', 'ConditionAncestorTerm': 'Lipid Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25871', 'ConditionBrowseLeafName': 'Dyslipidemias', 'ConditionBrowseLeafAsFound': 'Dyslipidemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26719', 'ConditionBrowseLeafName': 'Lipid Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 91, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00063674', 'OrgStudyIdInfo': {'OrgStudyId': 'T2DPPG (completed)'}, 'Organization': {'OrgFullName': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'OrgClass': 'NIH'}, 'BriefTitle': 'Type 2 Diabetes Primary Prevention for At Risk Girls'}, 'StatusModule': {'StatusVerifiedDate': 'January 2010', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2003'}, 'StudyFirstSubmitDate': 'July 2, 2003', 'StudyFirstSubmitQCDate': 'July 2, 2003', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 3, 2003', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 12, 2010', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 13, 2010', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'LeadSponsor': {'LeadSponsorName': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'LeadSponsorClass': 'NIH'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Purpose: To evaluate two approaches to prevent obesity and type 2 diabetes in young girls.\\n\\nThe Need: We are experiencing an epidemic of childhood obesity. Rates of obesity have doubled to tripled in the past two decades, with the highest rates among poor and ethnic minority girls. Type 2 diabetes (what used to be called adult-onset diabetes) is now showing up in overweight children, and more children are manifesting precursors of heart disease and stroke.\\n\\nOur Two Approaches:\\n\\nA state-of-the-art nutrition education program with monthly newsletters mailed to girls and their parents and quarterly evening lectures/educational events at school sites, including cooking demonstrations and games to improve nutrition and increase physical activity.\\nAfter-school dance classes held five days per week all year long at school sites from the time school lets out until 6PM. Dance classes will include a 1-1.5 hour supervised homework study hall each day, and emphasize both traditional ethnic dances and popular dance.\\n\\nParticipants: Second, third and fourth grade girls and their families will be eligible to participate. All activities are free of charge. To be able to perform a valid evaluation, to be able to accommodate all girls at their own school, and to be fair about which girls receive which program, families who wish to participate will be randomly selected to participate in either one program or the other (nutrition education or dance classes). Each family will participate for two years.\\n\\nEvaluation: Trained Stanford staff will perform all evaluation procedures with participating families in their own homes at the beginning and every six months. Families will be compensated for their participation.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Obesity', 'Diabetes Mellitus', 'Prediabetic State']}, 'KeywordList': {'Keyword': ['exercise', 'eating', 'dance', 'health education', 'obesity prevention', 'diabetes prevention', 'children']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single'}}, 'EnrollmentInfo': {'EnrollmentCount': '240', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Nutrition Education'}, {'InterventionType': 'Behavioral', 'InterventionName': 'After-school dance class'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Second-, third- and fourth-grade girls, aged 7-10 years of age enrolled in one of the participating schools will be eligible. Our goal is to be as inclusive as possible. However, girls will not be eligible to participate if they:\\n\\nhave been diagnosed with a chronic illness that affects their growth and/or weight (e.g., type 1 diabetes, hypothyroidism, inflammatory bowel disease)\\nare taking medications potentially affecting their growth and/or weight (e.g., methylphenidate HCl, systemic steroids)\\nhave Asthma (not exclusionary alone) but have taken systemic steroids (oral, intravenous, or intramuscular) for a period of more than 21 days in the past year\\nhave a condition that limits their participation in physical activity enough that they are not able to participate in Physical Education at school (e.g., significant structural heart disease)\\nare pregnant\\nare unable to complete the informed consent process.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '7 Years', 'MaximumAge': '10 Years', 'StdAgeList': {'StdAge': ['Child']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Stanford University School of Medicine', 'LocationCity': 'Palo Alto', 'LocationState': 'California', 'LocationZip': '94304', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000011236', 'ConditionMeshTerm': 'Prediabetic State'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000003920', 'ConditionAncestorTerm': 'Diabetes Mellitus'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13807', 'ConditionBrowseLeafName': 'Prediabetic State', 'ConditionBrowseLeafAsFound': 'Prediabetic State', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}}}}, {'Rank': 92, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04327713', 'OrgStudyIdInfo': {'OrgStudyId': 'DNSG-Fish oil'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Meta-analysis of Fish Oil Supplementation and Cardiovascular Outcomes in Diabetes', 'OfficialTitle': 'Systematic Review and Meta-analysis of Randomized Controlled Trials of the Effect of Fish Oil Supplementation on Cardiovascular Outcomes in Diabetes'}, 'StatusModule': {'StatusVerifiedDate': 'November 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 28, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 28, 2020', 'StudyFirstSubmitQCDate': 'March 28, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 31, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 2, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 4, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John Sievenpiper', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD)', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Diabetes Canada', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'Fish oil contains a large amount of long-chain omega-3 polyunsaturated fatty acids, which are considered an important component of a healthy diet. As many patients do not eat fish, supplementation with fish oil is a common strategy to provide sufficient amounts of these particular fatty acids in daily life. Fish oil supplementation has been investigated for decades for its cardio-protective effects and its ability to lower serum triglycerides. People with diabetes mellitus have an increased risk for cardiovascular events and show alterations in lipids with high triglycerides. Whether there is a benefit of fish oil supplementation in this high risk group remains unclear with major international diabetes associations recommending against the use of fish oil supplements. The European Association for the Study of Diabetes (EASD) has not made any recommendations about the use of fish oils in people with diabetes since 2004. To inform the update of the EASD clinical practice guidelines for nutrition therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned the proposed systematic review and meta-analysis of randomized controlled trials of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes and use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of the evidence.', 'DetailedDescription': \"Background: Cardiovascular disease (CVD) accounts for a large proportion of annual deaths around the world. In both the general population as well as in high-risk subgroups, achieving a healthy diet is one approach to lower the risk for CVD. Fish oil supplements have been widely investigated for cardiovascular indications, showing consistent reductions in triglycerides with variable effects on other intermediate risk factors (glycemia, blood pressure, inflammation) which have not translated into reductions in patient-important clinical outcomes. Recent systematic reviews and meta-analyses of the available randomized trials have failed to show a meaningful cardiovascular benefit of fish oil supplementation. It is unclear whether this lack of benefit holds across all groups, especially groups with a high triglyceride phenotype and at high cardiovascular risk such as those with diabetes. No systematic review and meta-analysis has specifically synthesized the evidence of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes. On the basis of several recent large cardiovascular outcomes trials in people with diabetes or that included subgroups of people with diabetes, the 2019 American Diabetes Association and 2018 Diabetes Canada clinical practice guidelines recommended against the use of fish oil supplementation for cardiovascular risk reduction in people with diabetes. The European Association for the Study of Diabetes (EASD) have made a similar recommendation but have not updated their clinical practice guidelines since 2004. To inform the update of the EASD clinical practice guidelines for nutrition therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a series of evidence syntheses. The proposed systematic review and meta-analysis of randomized controlled trials will assess the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes and use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of the evidence.\\n\\nNeed for proposed research: There is an urgent need for a synthesis of the evidence of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes to inform the update of the EASD clinical practice guidelines for nutrition therapy. High quality systematic reviews and meta-analyses of randomized controlled trials with assessment of the certainty of the evidence using GRADE provide the strongest form of evidence synthesis to support clinical practice guidelines and public health policy development.\\n\\nObjective: To inform the update of the European Association for the Study of Diabetes (EASD) clinical practice guidelines for nutrition therapy, the investigators will conduct a systematic review and meta-analysis of randomized controlled trials of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes and use the GRADE approach to assess the certainty of the evidence.\\n\\nDesign: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.\\n\\nData sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials databases will be searched using appropriate search terms supplemented by hand searches of references of included studies.\\n\\nStudy selection: Randomized controlled trials conducted in humans with a follow-up duration ≥ 52 weeks investigating the effect of fish oil supplementation compared to placebo on cardiovascular outcomes will be included. Eligible studies will be conducted in people with diabetes or contain data from a subgroup of people with diabetes. Studies that are not randomized, have a shorter duration (<52 weeks), use multi-modal interventions that do not allow for the isolation of the effect of fish oil supplementation, provide fish oil in the form of a prescription pharmaceutical drug (e.g. icopsant ethyl), lack a suitable control group/comparator, are not conducted in people with diabetes, and/or do not report viable cardiovascular outcomes data will be excluded.\\n\\nData extraction: Two investigators will independently extract relevant data and assess risk of bias using the Cochrane Risk of Bias tool Version 2. Events and total participants in intervention group and control groups will be extracted. When avaialble, risk ratios, odds ratios and hazard ratios for clinical outcomes will be extracted or derived from clinical event data across exposure to either fish oil supplementation or placebo. All disagreements will be resolved by consensus. Corresponding authors of relevant publications will be asked for additional data if needed.\\n\\nOutcomes: The primary outcome will be total CVD incidence. Secondary outcomes will be major adverse cardiovascular events (MACE), CVD mortality, all-cause mortality, coronary heart disease (CHD) incidence, CHD mortality, MI incidence, stroke incidence, and arrhythmia.\\n\\nData synthesis: Risk ratios of clinical outcomes using total events and number of people in intervention and control groups will be calculated for each RCT. Reported relative ratio measures will be used for studies not reporting raw numbers and hazard ratio and odds ratios will be considered equivalent to risk ratios.\\n\\nData will be pooled using the Mantel-Haenszel method with random effects models. Results will be reported as pooled risk ratios with 95% confidence intervals (95% CI). Heterogeneity will be assessed by the Cochrane Q statistic and quantified by the I2 statistic with I2>50% and P(Q) <0.1 considered evidence of substantial heterogeneity.\\n\\nIf there are ≥10 trials, a priori subgroup analyses will be undertaken to explore sources of heterogeneity including sex, age, type of diabetes (type 1 or type 2 diabetes), prevention type (primary, secondary), intervention type (supplements, supplemented foods, dietary advice), comparator, study design, follow-up duration,baseline glycemic control, risk of bias, funding source. Significant unexplained heterogeneity will be investigated by additional post hoc subgroup analyses. Meta-regression analyses will assess the significance of subgroups analyses.\\n\\nSensitivity analysis will be performed by removing one study at a time. A study will be considered influential if it changes the direction or significance of effect and/or heterogeneity.\\n\\nIf there are ≥10 trials, publication bias will be assessed by the inspection of funnel plots and using Begg's and Egger's tests. If publication bias is suspected, we will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.\\n\\nEvidence Assessment: The certainty of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.\\n\\nKnowledge translation plan: The results will be disseminated through talks or posters at regional, national, and international scientific meetings and publication in high impact factor journals. We will target public health and scientific communities interested in nutrition, cardiovascular diseases and diabetes. Their feedback will be incorporated in order to improve the public health message and to define key areas for future research.\\n\\nApplicant/Co-applicant: Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.\\n\\nSignificance: The proposed project will aid in knowledge translation related to the role of fish oil supplementation in the prevention of cardiovascular diseases in the high-risk group of T2DM patients, strengthening the evidence-base for guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Type2 Diabetes', 'Heart Failure', 'Myocardial Infarction', 'Stroke', 'Arrhythmia', 'Cardiovascular Diseases']}, 'KeywordList': {'Keyword': ['fish oil supplementation', 'Cardiovascular disease', 'stroke', 'myocardial infarction', 'diabetes', 'coronary heart disease', 'systematic review', 'meta-analysis']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'fish oil supplementation', 'ArmGroupDescription': 'fish oil supplementation, usually capsules with a defined content of EPA and DHA\\n\\ndosage and duration of intervention differ between the included studies of our meta-analysis', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: fish oil supplement']}}, {'ArmGroupLabel': 'placebo supplementation', 'ArmGroupDescription': 'placebo supplementation, usually capsules with a defined content of non-fish oil or other components\\n\\ncontent, dosage and duration of intervention differ between the included studies of our meta-analysis', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: fish oil supplement']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'fish oil supplement', 'InterventionDescription': 'daily fish oil supplement vs. placebo', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['fish oil supplementation', 'placebo supplementation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Total cardiovascular disease (CVD) incidence', 'PrimaryOutcomeDescription': 'Risk ratio of fatal and non-fatal CVD events', 'PrimaryOutcomeTimeFrame': 'at least 1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Major adverse cardiovascular events (MACE)', 'SecondaryOutcomeDescription': 'Risk ratio of MACE', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'CVD mortality', 'SecondaryOutcomeDescription': 'Risk ratio of fatal CVD events', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'All-cause mortality', 'SecondaryOutcomeDescription': 'Risk ratio of all-cause mortality', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'Coronary heart disease (CHD) incidence', 'SecondaryOutcomeDescription': 'Risk ratio of fatal and non-fatal CHD events', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'Coronary heart disease (CHD) mortality', 'SecondaryOutcomeDescription': 'Risk ratio of fatal CHD events', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'Myocardial infarction (MI) incidence', 'SecondaryOutcomeDescription': 'Risk ratio of fatal and non-fatal MI events', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'Stroke incidence', 'SecondaryOutcomeDescription': 'Risk ratio of fatal and non-fatal stroke events', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}, {'SecondaryOutcomeMeasure': 'Arrhythmia incidence', 'SecondaryOutcomeDescription': 'Risk ratio of fatal and non-fatal arrhythmia events', 'SecondaryOutcomeTimeFrame': 'at least 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nRandomized controlled trials\\nParticipants with diabetes\\nFollow-up duration ≥ 52 weeks\\nIntervention involves fish oil supplementation using supplements, supplemented foods, or dietary advice\\nControl group\\nAscertainment of at least one cardiovascular outcome\\n\\nExclusion Criteria:\\n\\nNon-randomized studies\\nParticipants without diabetes\\nFollow-up duration <52 weeks\\nMulti-modal interventions\\nInterventions of fish oils in the form of a prescription pharmaceutical drug (e.g. icosapent ethyl)\\nLack of a suitable control group (e.g. fish oil containing comparator)\\nNo viable cardiovascular outcome data.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'People with type 2 diabetes mellitus', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'John L Sievenpiper, MD,PhD,FRCPC', 'OverallOfficialAffiliation': 'University of Toronto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital\", 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5C 2T2', 'LocationCountry': 'Canada'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': \"We don't have access to individual participant data, as we are conducting a systematic review and meta-analysis.\"}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}, {'ConditionMeshId': 'D000009203', 'ConditionMeshTerm': 'Myocardial Infarction'}, {'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000007238', 'ConditionMeshTerm': 'Infarction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000007511', 'ConditionAncestorTerm': 'Ischemia'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000009336', 'ConditionAncestorTerm': 'Necrosis'}, {'ConditionAncestorId': 'D000017202', 'ConditionAncestorTerm': 'Myocardial Ischemia'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6239', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9111', 'ConditionBrowseLeafName': 'Heart Failure', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4143', 'ConditionBrowseLeafName': 'Arrhythmias, Cardiac', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11845', 'ConditionBrowseLeafName': 'Myocardial Infarction', 'ConditionBrowseLeafAsFound': 'Myocardial Infarction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9972', 'ConditionBrowseLeafName': 'Infarction', 'ConditionBrowseLeafAsFound': 'Infarction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11974', 'ConditionBrowseLeafName': 'Necrosis', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 93, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05355831', 'OrgStudyIdInfo': {'OrgStudyId': 'H-20036199'}, 'Organization': {'OrgFullName': 'Herlev Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation', 'OfficialTitle': 'Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation', 'Acronym': 'PRACTISE'}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 28, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 26, 2022', 'StudyFirstSubmitQCDate': 'April 26, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 2, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 13, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 15, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Christina Kruuse', 'ResponsiblePartyInvestigatorTitle': 'Study Principal Investigator, Consultant Neurologist, Dept. Neurology, Herlev Hospital', 'ResponsiblePartyInvestigatorAffiliation': 'Herlev Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Christina Kruuse', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Danish Research Centre for Magnetic Resonance', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Novo Nordic Foundation', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Copenhagen', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Lundbeck Foundation', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined.', 'DetailedDescription': 'Approximately two thirds of stroke patients have reduced motor function which have a large impact on both activities of daily living and quality of life. Only 12-34% achieve full motor recovery.\\n\\nThere is a growing interest in using non-invasive brain stimulation (NIBS) techniques to supplement neurorehabilitation. NIBS can modulate cortical excitability and is a powerful tool for motor rehabilitation post-stroke. Application Transcranial Direct Current Stimulation (TDCS) is currently emerging as a tool used in neurorehabilitaiton. Prior studies have shown that TDCS-stimulation prior to physical training may significantly improve of motor function post-stroke. However, up to 50% of the participants recieving active TDCS show no response to stimulation.\\n\\nA one-size-fits-all approach to TDCS in stroke rehabilitation may not be optimal and a more precise and individualized targeting is warranted to stimulate functionally relevant areas.\\n\\nIn this study TDCS will be personalized for stroke patients with upper-extremity paresis using individual functional and structural Magnetic Resonance Imaging (MRI) and an electric field modelling pipeline developed at Danish Research Centre for Magnetic Resonance (DRMCR). Based on these measures the electric current induced by TDCS will individually target the area with residual neural activity during movement. The effect of personalized TDCS will be assessed by clinical measures of motor improvement. Sub-studies furthermore assess if the functional reorganization of motor networks is affected by personalized TDCS by application of functional magnetic resonance (fMRI) and.\\n\\nThe study will have 3 phases:\\n\\nPersonalization: The stimulation profile of each patient will be individualized using structural MRI a pipeline for simulation based on MRI (SimNIBS) to make individual anatomical head models in order to estimate the best montage and current dosage. Further, task-based fMRI will be used to estimate residual motor activity location. The target current is set in the area displaying the highest residual motor activity in sensorimotor areas.\\nIntervention: Four weeks upper extremity training program of specialized supervised physiotherapeutic training 3 times per week. Each training session consists of 2x 20 minutes of training with concurrent personalized TDCS stimulation or montage of equipment but no stimulation (sham). Each bloc of 20 minutes training is separated by a small break of 5-10 minutes. Both patient, therapist and investigator will be blinded to the stimulation mode (activ TDCS or sham)\\nFollow-up: Immediately after the 4 weeks of intervention and 12 weeks after intervention has ended, follow-up with clinical examination and brain MRI will be done.\\n\\nAd baseline Transcranial Magnetic Stimulation (TMS) will be done as well to assess corticospinal integrity as well as estimation of intracortical inhibition.\\n\\nHypothesis:\\n\\nThe main hypothesis is that personalized ipsi-lesional anodal TDCS during specialized individualized arm-training will lead to significantly greater improvements in upper-extremity motor function compared to sham.\\n\\nSubstudy with healthy controls:\\n\\nA cohort of 20 healthy age- and sex matched controls will be recruited for one session of MRI and TMS identical to the procedure of the patients at baseline as well as the same questionnaires (Protocol amendment approved by the local Ethics Committee the 10th October 2022).\\n\\nThese data will be analyzed in a substudy for normative comparison between the stroke patients and healthy age- and sex-matched controls.\\n\\nHypothesis - Healthy Controls:\\n\\nStroke patients will exhibit a higher laterality index measured by fMRI and a stronger degree of interhemispheric inhibition at baseline compared to healthy controls measued by task-related fMRI and by TMS iSP and SICI.\\n\\nThe degree of interhemispheric inhibition in stroke patients will normalize during recovery and be similar to normal controls at the last follow-up after 12 weeks.\\n\\nFurther, the degree of normalization of the interhemispheric inhibition in stroke patients will be proportional to degree of improvement of the upper-extremity measured by UE-FMA.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke', 'Upper Extremity Hemiparesis']}, 'KeywordList': {'Keyword': ['non-invasive brain stimulation', 'transcranial direct current stimulation', 'effective connectivity', 'functional connectivity', 'Fugl-Meyer Assessment', 'Functional Magnetic Resonance Imaging']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Quadruple', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Active Transcranial Direct Current Stimulation', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Anodal TDCS 1mV for 2x 20 minutes.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Active Transcranial Direct Current Stimulation']}}, {'ArmGroupLabel': 'Sham stimulation', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': '2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Sham stimulation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Active Transcranial Direct Current Stimulation', 'InterventionDescription': 'See arm/group description', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Active Transcranial Direct Current Stimulation']}}, {'InterventionType': 'Device', 'InterventionName': 'Sham stimulation', 'InterventionDescription': 'See arm/group description', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sham stimulation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Upper-extremity motor outcome', 'PrimaryOutcomeDescription': 'Difference in change in Upper-extremity Fugl-Meyer Assessment (UE-FMA) score. Range 0-66.', 'PrimaryOutcomeTimeFrame': 'From baseline to four months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Upper-extremity function', 'SecondaryOutcomeDescription': 'Difference in change in Action Reach Arm Test (ARAT) score. Range 0-57. High scores mean a better outcome.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Stroke severity', 'SecondaryOutcomeDescription': 'Difference in change in National Health Institutes Stroke Scale (NIHSS). Range 0-42. High scores mean a better outcome.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Stroke disability', 'SecondaryOutcomeDescription': 'Difference in change in Modified Rankin Scale (mRS). Range 0-6. Lower scores mean a better outcome.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'ADL performance', 'SecondaryOutcomeDescription': \"Difference in change in Bartel's 20-item Index (BI-20). Range 0-100. Higher scores mean better outcome.\", 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Gait speed', 'SecondaryOutcomeDescription': 'Difference in change in 10 Meter Walk Test (10MWT) in minutes:sec.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Physical Activity', 'SecondaryOutcomeDescription': 'Difference in change in Physical Activity Scale 2.0 (PAS2). The answers will be translated into a Metabolic Equivalent of Task (MET)-score. The higher MET-score the higher level of activity.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Montreal Cognitive Assessment', 'SecondaryOutcomeDescription': 'Difference in change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Symbol Digit Modalities Test', 'SecondaryOutcomeDescription': 'Difference in change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Health-related quality of life', 'SecondaryOutcomeDescription': 'Difference in change in EQ-5D-5L score. Range 1 to 20, a high score means low health-related quality of life. Includes a 0-100 visual analogue scale for overall percieved quality of life.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Becks Depression Inventory (BDI)', 'SecondaryOutcomeDescription': 'Difference in change in BDI-II score. Score range 0-63. Higher score means increased risk of depression.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Fatigue Severity Scale (FSS)', 'SecondaryOutcomeDescription': 'Difference in change in FSS score. Score range 0-7. Higher score means increased fatigue severity.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'WHO-5 Well-Beeing Index', 'SecondaryOutcomeDescription': 'Difference in change in WHO-5 score. Score range 0-100. Higher score means better quality of life.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'Biomarker of inflammation and exercise', 'SecondaryOutcomeDescription': 'Difference in change in serum level Cathepsin-B (unit mikro gram/L)', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'MRI - Cerebral bloodflow', 'SecondaryOutcomeDescription': 'Change in cerebral blood flow measured with arterial spin labeling (ASL) during rest', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'fMRI - Effective connectivity', 'SecondaryOutcomeDescription': 'Change in activation patterns measured with blood-oxygen-level dependent (BOLD) during both single and bimanual task.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'fMRI - Interhemispheric inhibition', 'SecondaryOutcomeDescription': 'Change in activation pattern measured by blood-oxygen-level dependent (BOLD) during both single and bimanual task.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'fMRI - Laterality Index', 'SecondaryOutcomeDescription': 'Change in activation pattern for hemispheric dominance measured by the ratio of active fMRI voxels in each hemisphere.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'MRI - Corticospinal integrity', 'SecondaryOutcomeDescription': 'Change in corticospinal integrity measured by diffusion MRI.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}, {'SecondaryOutcomeMeasure': 'MRI - Infarct lesion load', 'SecondaryOutcomeDescription': 'Difference in change in size of infarct lesion meaured by structural MRI.', 'SecondaryOutcomeTimeFrame': 'From baseline to four months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Brain Derived Neutrotrophic Factor (BDNF) genetic polymorphism', 'OtherOutcomeDescription': 'Determination of BDNF genetic variant - either Val66Met variant or wildtype.', 'OtherOutcomeTimeFrame': 'Baseline'}, {'OtherOutcomeMeasure': 'Feasibility of intervention', 'OtherOutcomeDescription': 'Completion of intervention in the active vs. control group', 'OtherOutcomeTimeFrame': 'From baseline to four months'}, {'OtherOutcomeMeasure': 'TMS - motor evoked potential', 'OtherOutcomeDescription': 'Determination of existence of a MEP-response by TMS as an indicator of cortico-spinal tract integrity. Prognostic marker of motor recovery.', 'OtherOutcomeTimeFrame': 'Baseline'}, {'OtherOutcomeMeasure': 'TMS - Ipsilateral silent period (iSP)', 'OtherOutcomeDescription': 'Determination of degree of interhemispheric inhibition unaffected vs. affected hemisphere', 'OtherOutcomeTimeFrame': 'Baseline'}, {'OtherOutcomeMeasure': 'TMS - Short latency intracortical inhibition (SICI)', 'OtherOutcomeDescription': 'Determination of degree of interhemispheric inhibition unaffected vs. affected hemisphere', 'OtherOutcomeTimeFrame': 'Baseline'}, {'OtherOutcomeMeasure': 'TMS - cortico-motor conduction time (CMCT)', 'OtherOutcomeDescription': 'Determination of conduction time from stimulation of cortical neurons to response measured in a peripheral muscle (FDI)', 'OtherOutcomeTimeFrame': 'Baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Patients - Inclusion Criteria:\\n\\nAge >18 years\\nIschemic stroke confirmed by clinical and imaging criteria\\nHemiparesis including reduced upper-extremity function\\nLocation of stroke either cortically involving middle cerebral artery or the anterior cerebral artery circulation or subcortical (involving thalamus, basal ganglia).\\nNIHSS score >2 and <8\\nModified Rankin Scale (mRS) ≤ 3\\nIndex of stroke within 4 weeks of inclusion\\nSigned informed consent\\n\\nPatients - Exclusion Criteria:\\n\\n>50% stenosis of extra- or intracranial artery as well as vascular malformations or aneurisms detected by brain CT-angiography.\\nExclusively ischemic stroke in spine, pons, brainstem, medulla or cerebellum.\\nHistory of seizures, epilepsy, anxiety, dementia alcohol- or drug abuse.\\nPrior serious head injury or neurosurgery\\nFrequent severe headaches or migraine.\\nPregnancy or breastfeeding\\nCurrent use of neuro-receptor/transmitter modulating medication, or medication interfering with seizure threshold (such as antiepileptic medication, some antidepressants, anxiety medication, antihistamines, stimulant drugs for attention deficit hyperactivity disorder).\\nPacemaker, implantable cardiac device unit (ICD-unit), metal fragments or other materials implanted not compatible with MRI (see appendix B).\\nClaustrophobia\\nPrior adverse effect to TDCS or Transcranial Magnetic Stimulation.\\nNot able to provide informed consent.\\nTerminally ill or short life expectancy.\\n\\nHealthy controls - Inclusion criteria:\\n\\nAge between >18 years (matched to patients)\\nSex and age matched to patients\\nAble bodied\\nHave the ability to comply with all requirements of the study protocol, as determined by the investigator\\nNo history of stroke or dementia\\nEligible for MRI and TMS\\n\\nHealthy controls - Exclusion Criteria:\\n\\nHistory of neurologic disease\\nHistory of cerebral haemorrhage or brain damage\\nPregnancy\\nPacemaker or other implanted electronic devices\\nClaustrophobia\\nPsychiatric disorder\\nEpilepsy or close relatives suffering from epilepsy\\nMigraine\\nAny contraindication to MRI or TMS', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Christina Krusse, MD, Prof', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+4538681233', 'CentralContactEMail': 'christina.kruuse@regionh.dk'}, {'CentralContactName': 'Mia Kolmos, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+4538681375', 'CentralContactEMail': 'mia.kolmos@regionh.dk'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Christina Kruuse, MD, Prof', 'OverallOfficialAffiliation': 'Herlev Gentofte Hospital, Department of Neurology', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Copenhagen University Department of Nutrition and Exercise', 'LocationStatus': 'Recruiting', 'LocationCity': 'Copenhagen', 'LocationZip': '2200', 'LocationCountry': 'Denmark', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Anke Karabanov, MSc, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+4535328039', 'LocationContactEMail': 'anke@nexs.ku.dk'}, {'LocationContactName': 'Anke Karabanov, MSc, PhD', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'Department of Neurology, Herlev Gentofte Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Herlev', 'LocationZip': '2730', 'LocationCountry': 'Denmark', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Christina Kruuse, MD, Prof', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+4538681233'}, {'LocationContactName': 'Mia Kolmos, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+4538681375', 'LocationContactEMail': 'mia.kolmos@regionh.dk'}, {'LocationContactName': 'Christina Kruuse, MD, Prof', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Mia Kolmos, MD', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'Danish Research Centre for Magnetic Resonance', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hvidovre', 'LocationZip': '2650', 'LocationCountry': 'Denmark', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hartwig R Siebner, MD, Prof', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+4538626541', 'LocationContactEMail': 'hartwig.roman.siebner@regionh.dk'}, {'LocationContactName': 'Axel Thielscher, MSc, Prof', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+4538623326', 'LocationContactEMail': 'axelt@drcmr.dk'}, {'LocationContactName': 'Hartwig R Siebner, MD, Prof', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Axel Thielscher, MSc, Prof', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Marie Louise Liu, MD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes', 'IPDSharingDescription': 'IPD can be accessed upon reasonable request and after evaluation from the investigator.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000010291', 'ConditionMeshTerm': 'Paresis'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12894', 'ConditionBrowseLeafName': 'Paresis', 'ConditionBrowseLeafAsFound': 'Hemiparesis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20634', 'ConditionBrowseLeafName': 'Muscle Weakness', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}]}}}}}, {'Rank': 94, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02702375', 'OrgStudyIdInfo': {'OrgStudyId': 'CIHR-Sugars 2015'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases', 'OfficialTitle': 'Relation of Important Food Sources of Sugars With Incident Cardiometabolic Disease: A Series of Systematic Reviews and Meta-analyses to Inform Guidelines, Public Health Policy, and Future Research Design'}, 'StatusModule': {'StatusVerifiedDate': 'May 2016', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2018', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 2, 2016', 'StudyFirstSubmitQCDate': 'March 2, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 8, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 22, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 24, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John Sievenpiper', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': \"The Physicians' Services Incorporated Foundation\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Canadian Diabetes Association', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'There is an urgent need for stronger evidence to support recommendations for the role of sugars in diabetes and related cardiometabolic diseases. Although large prospective cohort studies have shown a significant positive association of fructose-containing sugars-sweetened beverages with incident obesity, diabetes, heart disease, and stroke, these associations do not appear to hold true for total fructose-containing sugars and other important sources of free fructose-containing sugars such as pure fruit juice, yogurt, or even cakes and sweets. As dietary guidelines have moved away from macronutrient centric recommendations towards more food and dietary-pattern based recommendations, this inconsistency in the data has not been appreciated. There remains a focus on free sugars, in the absence of sufficient information on the role of different food sources of fructose-containing sugars in diabetes and related cardiometabolic diseases. A systematic review and meta-analysis of prospective cohort studies is considered to be the \"Gold Standard\" of evidence. To provide evidence-based guidance to support the development of public health policy in relation sugars and the primary prevention of diabetes, we will conduct a series of systematic reviews and meta-analyses of the relation of food sources of fructose-containing sugars with incident type 2 diabetes and related cardiometabolic diseases in prospective cohort studies.', 'DetailedDescription': 'Background: Sugars have emerged as one of the most important public health targets. Attention has focused on the special role of fructose based on its unique biochemical, metabolic, and endocrine responses. These mechanisms, however, have failed to translate into clinically meaningful effects in calorie-matched comparisons with other sources of carbohydrate. Sugars-sweetened beverage (SSBs) appear to be the special case. Whereas large prospective cohort studies have shown a consistent relation of SSBs with incident obesity, diabetes, metabolic syndrome (MetS), hypertension, coronary heart disease (CHD), stroke, and gout, associations have not been shown when modeling total sugars (with the exception of gout) or other food sources of added/free sugars such as pure fruit juices, yogurt, or even sweets. In the absence of a clear signal for sugars alone, it is unclear whether the associations seen for SSBs hold for other important food sources of sugars.\\n\\nNeed for a review: As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, the lack of high quality syntheses and translation of the role of different food sources of sugars in cardiometabolic diseases represents an urgent call for stronger evidence to support guidelines development.\\n\\nObjectives: To build on our previous work, we will conduct a series of systematic reviews and meta-analyses to compare important food sources of added/free sugars (SSBs, pure fruit juice, yogurt, sweets, cereals, etc). in their relation with incident cardiometabolic diseases.\\n\\nDesign: Our proposed series of systematic reviews and meta-analyses will follow the same successful protocol we used for our previous CIHR-funded knowledge synthesis of fructose and cardiometabolic risk (clinicaltrials.gov, NCT01363791). The knowledge syntheses will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).\\n\\nData sources: MEDLINE, EMBASE, and The Cochrane library will be searched.\\n\\nStudy selection: We will include cohorts assessing the relation of different food sources of fructose-containing sugars (SSBs, pure fruit juice, yogurt, sweets, cereals, etc) with incident type 2 diabetes, MetS, hypertension, CHD, stroke, and gout.\\n\\nData extraction: Two investigators will independently extract relevant data and assess risk of bias.\\n\\nOutcomes: We will assess 6 outcomes: type 2 diabetes, MetS, hypertension, CHD, stroke, and gout.\\n\\nData synthesis: Risk ratios will be pooled using the generic inverse variance method for each food source of fructose-containing sugars. Random-effects models will be used even in the absence of statistically significant between-study heterogeneity, as they yield more conservative summary effect estimates in the presence of residual heterogeneity. Fixed-effects models will only be used where there is <5 included studies. Paired analyses will be applied for crossover trials. Heterogeneity will be assessed by the Cochran Q statistic and quantified by the I2 statistic. To explore sources of heterogeneity, the investigators will conduct sensitivity analyses, in which each study is systematically removed. If there are >=10 studies, then the investigators will also explore sources of heterogeneity by a priori subgroup analyses (follow-up, adjustments, exposure assessment, dose, outcome ascertainment, risk of bias). Meta-regression analyses will assess the significance of categorical and continuous subgroups analyses. When >=10 studies are available, publication bias will be investigated by inspection of funnel plots and formal testing using the Egger and Begg tests. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.\\n\\nEvidence Assessment: The strength of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).\\n\\nKnowledge translation plan: We will follow the Ottawa model. Results will be disseminated through presentations at scientific meetings and publication in high impact journals. Webcasts and social media posts on YouTube videos, Facebook, twitter and LinkedIn will also be used. Target adopters will include clinicians, allied health professionals, policy makers, industry, researchers, and patient groups.\\n\\nSignificance: The proposed project will aid in knowledge translation related to the health effects of food sources of sugars, informing evidence-based guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes Mellitus, Type 2', 'Metabolic Syndrome X', 'Hypertension', 'Cardiovascular Diseases', 'Stroke', 'Gout']}, 'KeywordList': {'Keyword': ['Systematic review and meta-analysis', 'Evidence-based medicine (EBM)', 'Evidence-based nutrition (EBN)', 'Clinical practice guidelines', 'Prospective cohort studies', 'Dietary sugars', 'Fructose', 'Sucrose', 'High fructose corn syrup', 'HFCS', 'Cohort studies', 'Prospective studies', 'Diabetes Mellitus', 'Metabolic syndrome', 'Coronary heart disease', 'Stroke', 'Hypertension', 'Gout']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Fructose-containing Sugars', 'InterventionOtherNameList': {'InterventionOtherName': ['fructose, sucrose, high-fructose corn syrup (HFCS)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Type 2 diabetes', 'PrimaryOutcomeDescription': 'Incident type 2 diabetes', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Metabolic syndrome', 'PrimaryOutcomeDescription': 'Incident metabolic syndrome', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Hypertension', 'PrimaryOutcomeDescription': 'Incident cases of hypertension and those with high blood pressure', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Coronary heart disease', 'PrimaryOutcomeDescription': 'Incident coronary heart disease or coronary artery disease', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Stroke', 'PrimaryOutcomeDescription': 'Incident stroke', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}, {'PrimaryOutcomeMeasure': 'Gout', 'PrimaryOutcomeDescription': 'Incident gout', 'PrimaryOutcomeTimeFrame': 'Up to 20 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Prospective cohort studies\\n\\nInclusion Criteria\\n\\nProspective cohort studies or case-cohort studies\\nDuration >= 1 year\\nAssessment of the exposure of fructose-containing sugars or important food sources\\nAscertainment of viable data by level of exposure\\n\\nExclusion Criteria:\\n\\nEcological, cross-sectional, and retrospective observational studies, clinical trials, and non-human studies\\nDuration < 1 year\\nNo assessment of exposures of fructose-containing sugars or important food sources\\nNo ascertainment viable clinical outcome data by level of exposure', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'All individuals, both children and adults, regardless of health status.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'JOHN L SIEVENPIPER, MD, PHD, FRCPC', 'OverallOfficialAffiliation': 'University of Toronto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Micheal's Hospital\", 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5C 2T2', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24370846', 'ReferenceType': 'background', 'ReferenceCitation': 'Sievenpiper JL, de Souza RJ, Cozma AI, Chiavaroli L, Ha V, Mirrahimi A. Fructose vs. glucose and metabolism: do the metabolic differences matter? Curr Opin Lipidol. 2014 Feb;25(1):8-19. doi: 10.1097/MOL.0000000000000042.'}, {'ReferencePMID': '22354959', 'ReferenceType': 'background', 'ReferenceCitation': \"Sievenpiper JL, Chiavaroli L, de Souza RJ, Mirrahimi A, Cozma AI, Ha V, Wang DD, Yu ME, Carleton AJ, Beyene J, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. 'Catalytic' doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. Br J Nutr. 2012 Aug;108(3):418-23. doi: 10.1017/S000711451200013X. Epub 2012 Feb 21.\"}, {'ReferencePMID': '25144126', 'ReferenceType': 'background', 'ReferenceCitation': 'Jayalath VH, Sievenpiper JL, de Souza RJ, Ha V, Mirrahimi A, Santaren ID, Blanco Mejia S, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ. Total fructose intake and risk of hypertension: a systematic review and meta-analysis of prospective cohorts. J Am Coll Nutr. 2014;33(4):328-39. doi: 10.1080/07315724.2014.916237. Epub 2014 Aug 21.'}, {'ReferencePMID': '23316283', 'ReferenceType': 'background', 'ReferenceCitation': 'Mirrahimi A, de Souza RJ, Chiavaroli L, Sievenpiper JL, Beyene J, Hanley AJ, Augustin LS, Kendall CW, Jenkins DJ. Associations of glycemic index and load with coronary heart disease events: a systematic review and meta-analysis of prospective cohorts. J Am Heart Assoc. 2012 Oct;1(5):e000752. doi: 10.1161/JAHA.112.000752. Epub 2012 Oct 25.'}, {'ReferencePMID': '31826724', 'ReferenceType': 'derived', 'ReferenceCitation': 'Liu Q, Ayoub-Charette S, Khan TA, Au-Yeung F, Blanco Mejia S, de Souza RJ, Wolever TMS, Leiter LA, Kendall CWC, Sievenpiper JL. Important Food Sources of Fructose-Containing Sugars and Incident Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc. 2019 Dec 17;8(24):e010977. doi: 10.1161/JAHA.118.010977. Epub 2019 Dec 12.'}, {'ReferencePMID': '31061018', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ayoub-Charette S, Liu Q, Khan TA, Au-Yeung F, Blanco Mejia S, de Souza RJ, Wolever TM, Leiter LA, Kendall C, Sievenpiper JL. Important food sources of fructose-containing sugars and incident gout: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2019 May 5;9(5):e024171. doi: 10.1136/bmjopen-2018-024171.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}, {'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}, {'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000024821', 'ConditionMeshTerm': 'Metabolic Syndrome'}, {'ConditionMeshId': 'D000003924', 'ConditionMeshTerm': 'Diabetes Mellitus, Type 2'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000007333', 'ConditionAncestorTerm': 'Insulin Resistance'}, {'ConditionAncestorId': 'D000006946', 'ConditionAncestorTerm': 'Hyperinsulinism'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16045', 'ConditionBrowseLeafName': 'Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6239', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9714', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6809', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafAsFound': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22695', 'ConditionBrowseLeafName': 'Metabolic Syndrome', 'ConditionBrowseLeafAsFound': 'Metabolic Syndrome', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19506', 'ConditionBrowseLeafName': 'Microvascular Angina', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8867', 'ConditionBrowseLeafName': 'Gout', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7552', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10060', 'ConditionBrowseLeafName': 'Insulin Resistance', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9687', 'ConditionBrowseLeafName': 'Hyperinsulinism', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T69', 'ConditionBrowseLeafName': 'Abdominal Obesity Metabolic Syndrome', 'ConditionBrowseLeafAsFound': 'Metabolic Syndrome X', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC16', 'ConditionBrowseBranchName': 'Diseases and Abnormalities at or Before Birth'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 95, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02444715', 'OrgStudyIdInfo': {'OrgStudyId': 'CAPSYS-201205/08-1'}, 'Organization': {'OrgFullName': 'Luxembourg Institute of Science and Technology', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Computer-Aided Prevention System', 'OfficialTitle': 'Study on Improved Prevention Methods for Cerebro-cardiovascular Diseases Based on a Computer-aided Prevention System', 'Acronym': 'CAPSYS'}, 'StatusModule': {'StatusVerifiedDate': 'January 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 2014', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'August 2014', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 12, 2015', 'StudyFirstSubmitQCDate': 'May 13, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 14, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'June 8, 2015', 'ResultsFirstSubmitQCDate': 'July 27, 2015', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'August 24, 2015', 'ResultsFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'January 20, 2016', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 18, 2016', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Lübomira Spassova', 'ResponsiblePartyInvestigatorTitle': 'Dr.-Ing.', 'ResponsiblePartyInvestigatorAffiliation': 'Luxembourg Institute of Science and Technology'}, 'LeadSponsor': {'LeadSponsorName': 'Lübomira Spassova', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Centre Hospitalier du Luxembourg', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"Stroke is one of the most frequent and life-threatening diseases in Europe. About four stroke events occur per day in Luxembourg alone, and about 30% of these patients are affected by recurrent stroke within the following five years. Thus, new methods of primary and secondary prevention are needed to better control lifestyle-related risk factors.\\n\\nThe development and maintenance of a healthy lifestyle (smoking cessation, healthy nutrition, moderate physical exercises etc.) is a major objective concerning the primary and secondary prevention of cerebro- and cardiovascular diseases. CAPSYS is a computer-based lifestyle coaching system developed by researchers from the Public Research Centre (CRP) Henri Tudor in Luxembourg in collaboration with neurologists from the Centre Hospitalier de Luxembourg (CHL), which aims at supporting patients in performing appropriate behavior changes in order to minimize their individual risk factors. Patients can access CAPSYS by dialing a local-rate telephone number and answer to a set of previously known questions concerning their current nutrition, physical activity, blood pressure, smoking etc. In an interactive voice response approach, questions are issued by the system in natural language using text-to-speech, and the patient can provide the required values using the phone keypad. Based on the gathered values for each patient, the system automatically generates personalized verbal feedback at runtime and presents it to the patient during the phone dialog. Depending on the individual development of the patient's risk factors, the system feedback can contain advice for improvement, praise for healthy behavior and motivation to pursue a certain goal.\\n\\nThe user acceptance and effectiveness of the CAPSYS system is evaluated in a six-month randomized controlled study with participants recruited at CHL's neurology department.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebrovascular Diseases', 'Stroke', 'Cardiovascular Diseases', 'CVD Risk Factors']}, 'KeywordList': {'Keyword': ['Lifestyle coaching', 'Phone-based system', 'CVD prevention', 'Patient-centered decision support']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '94', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Standard care (SC)', 'ArmGroupType': 'Active Comparator', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Standard care']}}, {'ArmGroupLabel': 'Interventional care (IC)', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CAPSYS']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Standard care', 'InterventionDescription': 'Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard care (SC)']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'CAPSYS', 'InterventionDescription': 'In addition to the usual care, patients are asked to call the CAPSYS system twice a week.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Interventional care (IC)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Systolic Blood Pressure', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}, {'PrimaryOutcomeMeasure': 'Change in HDL Level', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}, {'PrimaryOutcomeMeasure': 'Change in LDL Level', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}, {'PrimaryOutcomeMeasure': 'Change in Triglyceride Level', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}, {'PrimaryOutcomeMeasure': 'Change in HbA1c Level', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}, {'PrimaryOutcomeMeasure': 'Change in Glycaemia Level', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}, {'PrimaryOutcomeMeasure': 'Change in BMI Value', 'PrimaryOutcomeTimeFrame': 'baseline and 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in Fruits and Vegetables Consumption', 'SecondaryOutcomeDescription': 'Self-reported weekly portions of fruits and vegetables consumption\\n\\n(During the recruiting interview, participants were instructed in estimating the size of a portion of fruits or vegetables and they were provided an information booklet on this topic.)', 'SecondaryOutcomeTimeFrame': 'baseline and 6 months'}, {'SecondaryOutcomeMeasure': 'Change in Whole Grain Food Consumption', 'SecondaryOutcomeDescription': 'Self-reported weekly portions of whole grain food consumption\\n\\n(During the recruiting interview, participants were instructed in estimating the size of a portion of whole grain food and they were provided an information booklet on this topic.)', 'SecondaryOutcomeTimeFrame': 'baseline and 6 months'}, {'SecondaryOutcomeMeasure': 'Change in Sweets Consumption', 'SecondaryOutcomeDescription': 'Self-reported weekly portions of sweets consumption\\n\\n(During the recruiting interview, participants were instructed in estimating the size of a portion of sweets and they were provided an information booklet on this topic.)', 'SecondaryOutcomeTimeFrame': 'baseline and 6 months'}, {'SecondaryOutcomeMeasure': 'Change in Duration of Physical Activity', 'SecondaryOutcomeDescription': 'Self-reported weekly duration of physical activity of medium or high intensity', 'SecondaryOutcomeTimeFrame': 'baseline and 6 months'}, {'SecondaryOutcomeMeasure': 'Change in Quality of Life', 'SecondaryOutcomeDescription': 'The QoL was measured using the standardised EQ-5D-5L instrument provided by the EuroQol Group.\\n\\nIn this context, the health value was specified by the participants on a subjective scale ranging from 0 (\"The worst health you can imagine\") to 100 (\"The best health you can imagine\").', 'SecondaryOutcomeTimeFrame': 'baseline and 6 months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Usability: SUS Score', 'OtherOutcomeDescription': 'The usability of the intervention was assessed based on the standardised System Usability Scale (SUS).\\n\\nSUS scores were not collected in the SC group because the SC participants were not using CAPSYS and hence were not able to assess its usability.\\n\\nThe System Usability Scale (SUS) provides a \"quick and dirty\", reliable tool for measuring the usability. It consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Originally created by John Brooke in 1986, it allows to evaluate a wide variety of products and services, including hardware, software, mobile devices, websites and applications.\\n\\nThe total SUS score computed based on the responses provided to each of the 10 items can range from 0 (worst) to 100 (best). Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average.', 'OtherOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAt high risk of stroke:\\n\\nAlready suffered a stroke or Transient Ischemic Attack (TIA) or\\n\\nAt least two risk factors for stroke:\\n\\nHigh blood pressure\\nOverweight\\nLow physical activity\\nSmoking\\nUnhealthy diet\\n\\nExclusion Criteria:\\n\\nInability to fill out or to understand the informed consent\\nNo signed informed consent\\nDementia', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Lübomira Spassova, Dr.-Ing.', 'OverallOfficialAffiliation': 'Luxembourg Institute of Science and Technology', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Debora Vittore', 'OverallOfficialAffiliation': 'Centre Hospitalier de Luxembourg (CHL)', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Dirk W Droste, Prof. Dr.', 'OverallOfficialAffiliation': 'Centre Hospitalier de Luxembourg (CHL)', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Norbert Rösch, Prof. Dr.', 'OverallOfficialAffiliation': 'University of Applied Sciences Kaiserslautern', 'OverallOfficialRole': 'Study Director'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23823433', 'ReferenceType': 'background', 'ReferenceCitation': 'Spassova L, Vittore D, Droste D, Rosch N. Automated lifestyle coaching for cerebro-cardiovascular disease prevention. Stud Health Technol Inform. 2013;190:234-6.'}, {'ReferencePMID': '34813082', 'ReferenceType': 'derived', 'ReferenceCitation': 'Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021 Nov 23;11(11):CD001919. doi: 10.1002/14651858.CD001919.pub4.'}, {'ReferencePMID': '26861865', 'ReferenceType': 'derived', 'ReferenceCitation': 'Spassova L, Vittore D, Droste DW, Rosch N. Randomised controlled trial to evaluate the efficacy and usability of a computerised phone-based lifestyle coaching system for primary and secondary prevention of stroke. BMC Neurol. 2016 Feb 9;16:22. doi: 10.1186/s12883-016-0540-4.'}]}}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Standard Care (SC)', 'FlowGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Interventional Care (IC)', 'FlowGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '46'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '48'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '36'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '32'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '10'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '16'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Standard Care (SC)', 'BaselineGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Interventional Care (IC)', 'BaselineGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '46'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '48'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '94'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '59.6', 'BaselineMeasurementSpread': '12.1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '60.7', 'BaselineMeasurementSpread': '11.3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '60.2', 'BaselineMeasurementSpread': '11.6'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '31'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '29'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '34'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '63'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in Systolic Blood Pressure', 'OutcomeMeasurePopulationDescription': 'Blood pressure data is missing for 4 of the 36 SC and 4 of the 32 IC participants who provided final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'mmHg', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '32'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '28'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.19', 'OutcomeMeasurementSpread': '21.34'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-9', 'OutcomeMeasurementSpread': '21.37'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.96', 'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.03', 'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in HDL Level', 'OutcomeMeasurePopulationDescription': 'For participants who did not provide final questionnaires, data was retrieved from medical records. HDL data is missing for 5 of the 46 SC and 11 of the 48 IC participants who started the study.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'mg/dl', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '41'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '37'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1', 'OutcomeMeasurementLowerLimit': '-5', 'OutcomeMeasurementUpperLimit': '7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-2', 'OutcomeMeasurementLowerLimit': '-7', 'OutcomeMeasurementUpperLimit': '4'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.53', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.44', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in LDL Level', 'OutcomeMeasurePopulationDescription': 'For participants who did not provide final questionnaires, data was retrieved from medical records. LDL data is missing for 5 of the 46 SC and 11 of the 48 IC participants who started the study.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'mg/dl', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '41'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '37'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-1', 'OutcomeMeasurementLowerLimit': '-17', 'OutcomeMeasurementUpperLimit': '10'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-6', 'OutcomeMeasurementLowerLimit': '-16', 'OutcomeMeasurementUpperLimit': '3'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.76', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.04', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in Triglyceride Level', 'OutcomeMeasurePopulationDescription': 'For participants who did not provide final questionnaires, data was retrieved from medical records. Triglyceride data is missing for 16 of the 46 SC and 16 of the 48 IC participants who started the study.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'mg/dl', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '30'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '32'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-1', 'OutcomeMeasurementLowerLimit': '-33.25', 'OutcomeMeasurementUpperLimit': '18'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-11', 'OutcomeMeasurementLowerLimit': '-37.5', 'OutcomeMeasurementUpperLimit': '10.25'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.39', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.04', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in HbA1c Level', 'OutcomeMeasurePopulationDescription': 'For participants who did not provide final questionnaires, data was retrieved from medical records. HbA1c data is missing for 21 of the 46 SC and 21 of the 48 IC participants who started the study.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'percent HbA1c', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '25'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '27'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.1', 'OutcomeMeasurementLowerLimit': '-0.2', 'OutcomeMeasurementUpperLimit': '0.2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-0.1', 'OutcomeMeasurementLowerLimit': '-0.2', 'OutcomeMeasurementUpperLimit': '0'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.92', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.37', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in Glycaemia Level', 'OutcomeMeasurePopulationDescription': 'For participants who did not provide final questionnaires, data was retrieved from medical records. Glycaemia data is missing for 6 of the 46 SC and 13 of the 48 IC participants who started the study.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'mg/dl', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '40'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '35'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.5', 'OutcomeMeasurementLowerLimit': '-8.25', 'OutcomeMeasurementUpperLimit': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-2', 'OutcomeMeasurementLowerLimit': '-7.5', 'OutcomeMeasurementUpperLimit': '2.5'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.78', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.19', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change in BMI Value', 'OutcomeMeasurePopulationDescription': 'For participants who did not provide final questionnaires, data was retrieved from medical records. Weight data is missing for 9 of the 46 SC and 15 of the 48 IC participants who started the study.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'kg/m^2', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '37'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '33'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.05', 'OutcomeMeasurementSpread': '1.61'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-0.26', 'OutcomeMeasurementSpread': '1.3'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.9', 'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.43', 'OutcomeAnalysisStatisticalMethod': 't-test, 2 sided', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Fruits and Vegetables Consumption', 'OutcomeMeasureDescription': 'Self-reported weekly portions of fruits and vegetables consumption\\n\\n(During the recruiting interview, participants were instructed in estimating the size of a portion of fruits or vegetables and they were provided an information booklet on this topic.)', 'OutcomeMeasurePopulationDescription': 'Data on fruits and vegetables consumption was retrieved from final questionnaires. Hence, food consumption data is missing for the 10 SC and 16 IC participants who did not provide final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'portions', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '36'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '32'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-7', 'OutcomeMeasurementUpperLimit': '7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '3.5', 'OutcomeMeasurementLowerLimit': '-3.25', 'OutcomeMeasurementUpperLimit': '11.75'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.67', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.04', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Whole Grain Food Consumption', 'OutcomeMeasureDescription': 'Self-reported weekly portions of whole grain food consumption\\n\\n(During the recruiting interview, participants were instructed in estimating the size of a portion of whole grain food and they were provided an information booklet on this topic.)', 'OutcomeMeasurePopulationDescription': 'Data on whole grain food consumption was retrieved from final questionnaires. Hence, food consumption data is missing for the 10 SC and 16 IC participants who did not provide final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'portions', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '36'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '32'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-4', 'OutcomeMeasurementUpperLimit': '3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1', 'OutcomeMeasurementLowerLimit': '-0.25', 'OutcomeMeasurementUpperLimit': '7'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.26', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.07', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Sweets Consumption', 'OutcomeMeasureDescription': 'Self-reported weekly portions of sweets consumption\\n\\n(During the recruiting interview, participants were instructed in estimating the size of a portion of sweets and they were provided an information booklet on this topic.)', 'OutcomeMeasurePopulationDescription': 'Data on sweets consumption was retrieved from final questionnaires. Hence, food consumption data is missing for the 10 SC and 16 IC participants who did not provide final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'portions', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '36'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '32'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '0', 'OutcomeMeasurementUpperLimit': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '0', 'OutcomeMeasurementUpperLimit': '2'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.06', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.04', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Duration of Physical Activity', 'OutcomeMeasureDescription': 'Self-reported weekly duration of physical activity of medium or high intensity', 'OutcomeMeasurePopulationDescription': 'Data on physical activity was retrieved from final questionnaires. Hence, physical activity data is missing for the 10 SC and 16 IC participants who did not provide final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'minutes', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '36'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '32'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'medium intensity', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-60', 'OutcomeMeasurementUpperLimit': '135'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-60', 'OutcomeMeasurementUpperLimit': '112.5'}]}}]}}, {'OutcomeClassTitle': 'high intensity', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-120', 'OutcomeMeasurementUpperLimit': '15'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-45', 'OutcomeMeasurementUpperLimit': '30'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'Medium intensity\\n\\nH0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.37', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'Medium intensity\\n\\nH0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.34', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'High intensity\\n\\nH0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.37', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'High intensity\\n\\nH0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.59', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Quality of Life', 'OutcomeMeasureDescription': 'The QoL was measured using the standardised EQ-5D-5L instrument provided by the EuroQol Group.\\n\\nIn this context, the health value was specified by the participants on a subjective scale ranging from 0 (\"The worst health you can imagine\") to 100 (\"The best health you can imagine\").', 'OutcomeMeasurePopulationDescription': 'Data on quality of life was retrieved from final questionnaires. Hence, QoL data is missing for the 10 SC and 16 IC participants who did not provide final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Inter-Quartile Range', 'OutcomeMeasureUnitOfMeasure': 'units on a scale (health value)', 'OutcomeMeasureTimeFrame': 'baseline and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Standard Care (SC)', 'OutcomeGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '36'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '32'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-6.25', 'OutcomeMeasurementUpperLimit': '10'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0', 'OutcomeMeasurementLowerLimit': '-0.25', 'OutcomeMeasurementUpperLimit': '5'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.64', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG001']}, 'OutcomeAnalysisGroupDescription': 'H0: no change between baseline and post-intervention', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '0.14', 'OutcomeAnalysisStatisticalMethod': 'Wilcoxon (Mann-Whitney)', 'OutcomeAnalysisCINumSides': '2-Sided'}]}}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Usability: SUS Score', 'OutcomeMeasureDescription': 'The usability of the intervention was assessed based on the standardised System Usability Scale (SUS).\\n\\nSUS scores were not collected in the SC group because the SC participants were not using CAPSYS and hence were not able to assess its usability.\\n\\nThe System Usability Scale (SUS) provides a \"quick and dirty\", reliable tool for measuring the usability. It consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Originally created by John Brooke in 1986, it allows to evaluate a wide variety of products and services, including hardware, software, mobile devices, websites and applications.\\n\\nThe total SUS score computed based on the responses provided to each of the 10 items can range from 0 (worst) to 100 (best). Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average.', 'OutcomeMeasurePopulationDescription': 'SUS questionnaires are missing, incomplete or invalid for 6 of the 32 IC participants who provided final questionnaires.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'units on a scale (total SUS score)', 'OutcomeMeasureTimeFrame': '6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Interventional Care (IC)', 'OutcomeGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '26'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '80.1', 'OutcomeMeasurementSpread': '16.22'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Standard Care (SC)', 'EventGroupDescription': 'Standard care: Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '46', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '46'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Interventional Care (IC)', 'EventGroupDescription': 'CAPSYS: In addition to the usual care, patients are asked to call the CAPSYS system twice a week.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '48', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '48'}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'No', 'AgreementRestrictiveAgreement': 'No'}, 'PointOfContact': {'PointOfContactTitle': 'Dr. Lübomira Spassova', 'PointOfContactOrganization': 'Luxembourg Institute of Science and Technology', 'PointOfContactEMail': 'lubomira.spassova@list.lu', 'PointOfContactPhone': '+352 275 888 1'}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002561', 'ConditionMeshTerm': 'Cerebrovascular Disorders'}, {'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 96, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04038294', 'OrgStudyIdInfo': {'OrgStudyId': 'G-19-0024269'}, 'Organization': {'OrgFullName': 'St. Boniface Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'PROTein to Enhance outComes of (Pre)Frail paTients Undergoing Cardiac Surgery', 'OfficialTitle': 'PROTein to Enhance outComes of (Pre)Frail paTients Undergoing Cardiac Surgery - The PROTECT-CS Study', 'Acronym': 'PROTECT-CS'}, 'StatusModule': {'StatusVerifiedDate': 'June 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 12, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 30, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 30, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 24, 2019', 'StudyFirstSubmitQCDate': 'July 26, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 30, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 15, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 21, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Rakesh C. Arora', 'ResponsiblePartyInvestigatorTitle': 'Section head Cardiac Surgery', 'ResponsiblePartyInvestigatorAffiliation': 'St. Boniface Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'St. Boniface Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Heart and Stroke Foundation of Canada', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Heart disease in an aging population has resulted in heart surgery being offered to older and more frail patients. Frail patients which make up more than 50% of patients currently undergoing heart surgery are vulnerable to having long-recovery times after surgery, greater loss of independence (i.e. being admitted to a nursing home), experience more depression and anxiety, and have a worse quality of life. In fact, nearly 10% of frail, older adult patients die within 30 days after their heart surgery. The Investigators previous study found that weight-loss and poor muscle strength (i.e. weakness) of frail patients can lead to a worse recovery after heart surgery. Furthermore, inadequate nutrition (aka. malnutrition which is defined as an unintentional, nutritional intake imbalance (not necessarily a decreased intake) before an operation can lead to a vicious cycle of muscle loss causing more frailty, a desire to eat less leading to more muscle loss and increased frailty. At present there is no process to address this important issue in older adults undergoing heart surgery. The Investigators propose to study a practical, real-world, treatment plan that focuses on good nutrition to prevent muscle loss and reduced frailty in vulnerable heart surgery patients.', 'DetailedDescription': \"To enhance recovery in vulnerable older adults (aged 60 years or older) undergoing major heart surgery. The Investigators seek to reduce the stress of heart surgery on the body by providing muscle-building nutrition supplements (with leucine-rich proteins) at key time-points during the patients' journey.\\n\\nObjectives of this study:\\n\\nWill leucine-rich protein nutrition supplementation (given in a liquid form like a protein shake) can reduce functional decline in frail older patients undergoing major heart surgery. The Investigators predict that these supplements will lead to a reduction in functional muscle loss (for example how quickly some can walk) and quicker recovery both in hospital and after going home.\\nWill leucine-rich protein nutrition supplementation will enhance health-related quality of life of frail older adult patients after heart surgery. The Investigators predict that patients will be able to return to activities that they enjoy more quickly and experience less depression and anxiety.\\n\\nIn a two-centre clinical trial, frail older adults (patients who are at risk of a long recovery) undergoing major heart surgeries will receive nutrition supplements up to 2 weeks prior to surgery, during post-op recovery in hospital, and for the 8 weeks following hospital discharge. Prior to surgery, all patient in the study will consume a carbohydrate supplement in order to help with nausea symptoms post surgery, glycemic control and GI function. The Investigators will ask 150 (pre)frail patients before their heart surgery to participate. Patient who are 60 years of age or older who agree to be in the study will be randomly selected (75 patients in each group) to receive the nutrition protein shakes or a placebo (a shake without the special protein). In addition to how long a patient needs to stay in hospital after their heart surgery, The Investigators will measure levels of frailty (by different tests of muscle strength), overall nutrition, health related quality of life after surgery as well as mood and anxiety at 2 and 6 months after hospital discharge.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Frail Older Adult Syndrome', 'Nutrition Poor', 'Cardiovascular Morbidity']}, 'KeywordList': {'Keyword': ['Cardiac Surgery', 'Protein supplementation', 'Pre-Frail and Frail older adults']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Triple', 'DesignMaskingDescription': 'the patient/participants, the treating physician and the outcomes assessor (research assistant will be blinded to the arm of the participant. Only the Mani study coordinator will have known information of arm population', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Protein Supplementation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: ISOlution protein supplement']}}, {'ArmGroupLabel': 'Placebo Supplementation', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Placebo Supplement']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'ISOlution protein supplement', 'InterventionDescription': 'EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Protein Supplementation']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Placebo Supplement', 'InterventionDescription': 'PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo Supplementation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in Short-Form 36 physical Function (PF) score', 'PrimaryOutcomeDescription': 'The SF-36 PF assessment captures the physical functioning of participants. It has been moderately correlated with the SPPB and can be used interchangeably if the SPPB is not able to be completed by a patient', 'PrimaryOutcomeTimeFrame': 'Assessed at: baseline, Day of Discharge from Hospital after cardiac surgery, 2 months post surgery and 6 months post surgery'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'health-related QOL measured by the EQ-5D-3L', 'SecondaryOutcomeDescription': 'The EQ-5D-3L measure health related quality of life in our patient cohort', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'health-related QOL measured by the EQ-VAS', 'SecondaryOutcomeDescription': 'EQ-VAS measure health related quality of life in our patient cohort', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'Depression', 'SecondaryOutcomeDescription': 'measured by the patient health questionnaire (PHQ-9) this assessment measures the symptoms related to depression', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'Anxiety', 'SecondaryOutcomeDescription': 'measured by the cardiac anxiety questionnaire (CAQ) this assessment measures the anxiety experienced by patients with cardiovascular disease', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'Nutrition assessment', 'SecondaryOutcomeDescription': 'Nutrition is measured by the mini nutritional assessment tool', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, Day of Discharge from Hospital after cardiac surgery, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'Physical Activity Accumulation', 'SecondaryOutcomeDescription': 'This is measured with the use of physical activity monitors call accelerometers. This will be worn for a period of 7 days after each research appointment', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'Composite safety endpoint of all-cause mortality, injurious fall, acute kidney injury, or readmission for related events', 'SecondaryOutcomeDescription': 'These parameters will be taken from medical chart reviews post cardiac surgery', 'SecondaryOutcomeTimeFrame': 'Parameters collected at the 2 month time point'}, {'SecondaryOutcomeMeasure': 'Health related QOL as measured by OARS - ADL Scale', 'SecondaryOutcomeDescription': 'This scale measures activities of daily living', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post surgery and 6 months post surgery'}, {'SecondaryOutcomeMeasure': 'Nausea and vomiting questionnaire', 'SecondaryOutcomeDescription': 'This scale measures symptoms of nausea and vomiting while a patient is recovering in-hospital following cardiac surgery', 'SecondaryOutcomeTimeFrame': 'Assessed (only 1 time point) while patient is in-hospital recovering from cardiac surgery. (i.e. 6 days after cardiac surgery)'}, {'SecondaryOutcomeMeasure': 'Frailty', 'SecondaryOutcomeDescription': 'This measure will be assessed using the Modified Fried Criteria. this includes measures such as: Hand grip strength, exhaustion, nutrition, and physical activity accumulation. This assessment will return a value from 0-5 identifying the frailty of the patient at each of the time points identified', 'SecondaryOutcomeTimeFrame': 'Assessed at: baseline, 2 months post-surgery and 6 months post-surgery'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients aged 60 years of age or older, undergoing elective isolated CABG, aortic valve repair or replacement for moderate aortic stenosis or severe regurgitation, mitral valve repair or replacement for moderate stenosis or severe regurgitation or combined CABG/valve procedures.\\nPatients with a Clinical Frailty Score (CFS) from 3 (Managing Well) to 7 (severely frail),\\nPatients with a Short Physical Performance Battery (SPPB) score of 9 or less, or an SF-36 (PF) score of <= 60\\nPatients with an estimated wait time for elective cardiac surgery of 1 week or longer\\nInpatients with an estimated wait time for non-emergent cardiac surgery of 2 days or longer from hospital admission\\n\\nExclusion Criteria:\\n\\nDecompensated or non-ambulatory class IV symptoms of angina, dyspnea, claudication\\nPatients with a Clinical Frailty Score (CFS) of 7 or greater (Severely frail to terminally ill); this will exclude less than 1% of the population on the elective cardiac surgery waitlist.\\nCreatinine clearance <30 mL/min/1.83 m2\\nCirrhosis (Child-Pugh Class B or greater)\\nAllergy to milk proteins or other ingredients in the supplement\\nInability to safely ingest beverage by mouth\\nSignificant cognitive impairment (MoCA Score < 16)\\nAn inability to speak/read in English or French\\nNon-emergent or emergent surgery less than 2 days from hospital admission', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '60 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Rakesh Arora, BKin,MD,PhD,', 'CentralContactRole': 'Contact', 'CentralContactPhone': '204-258-1078', 'CentralContactEMail': 'rarora@sbgh.mb.ca'}, {'CentralContactName': 'David Kent, BKin, MSc', 'CentralContactRole': 'Contact', 'CentralContactPhone': '204-237-2985', 'CentralContactEMail': 'dkent@sbgh.mb.ca'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Rakesh Arora, BKin,MD,PhD', 'OverallOfficialAffiliation': 'University of Manitoba', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'St. Boniface General Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Winnipeg', 'LocationState': 'Manitoba', 'LocationZip': 'R2H2A6', 'LocationCountry': 'Canada', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rakesh Arora, MD,PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '(204) 258-1078', 'LocationContactEMail': 'rarora@sbgh.mb.ca'}, {'LocationContactName': 'David Kent, MSc', 'LocationContactRole': 'Contact', 'LocationContactPhone': '204-237-2985', 'LocationContactEMail': 'dkent@sbgh.mb.ca'}, {'LocationContactName': 'Rakesh C Arora, MD, PhD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Todd A Duhamel, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Navdeep Tangri, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Cornelia Van Ineveld, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Annette Schultz, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Anna Chudyk, PhD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Dustin S Kehler, PhD', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'Jewish General Hospital', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Montréal', 'LocationState': 'Quebec', 'LocationZip': 'H3T 1E2', 'LocationCountry': 'Canada', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jonathan Afilalo, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '(514) 340-8232', 'LocationContactEMail': 'jonathan.afilalo@mcgill.ca'}, {'LocationContactName': 'Sarah Lantagne, MSc', 'LocationContactRole': 'Contact', 'LocationContactPhone': '(514) 340-8222', 'LocationContactPhoneExt': '28692', 'LocationContactEMail': 'Sarah.Lantagne@ladydavis.ca'}, {'LocationContactName': 'Jonathan Afilalo, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33514571', 'ReferenceType': 'derived', 'ReferenceCitation': 'Rose AV, Duhamel T, Hyde C, Kent DE, Afilalo J, Schultz ASH, Chudyk A, Kehler DS, Dave M, Arora RC. Randomised controlled trial protocol for the PROTECT-CS Study: PROTein to Enhance outComes of (pre)frail paTients undergoing Cardiac Surgery. BMJ Open. 2021 Jan 29;11(1):e037240. doi: 10.1136/bmjopen-2020-037240.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M16045', 'ConditionBrowseLeafName': 'Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Nutrition Poor', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T223', 'ConditionBrowseLeafName': 'ADULT Syndrome', 'ConditionBrowseLeafAsFound': 'Adult Syndrome', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T10', 'InterventionBrowseLeafName': 'Leucine', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'AA', 'InterventionBrowseBranchName': 'Amino Acids'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 97, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03778905', 'OrgStudyIdInfo': {'OrgStudyId': 'CMMC10711-J02'}, 'Organization': {'OrgFullName': 'Chimei Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Correlation Between the Length of Stay in Post Acute Care(PAC) and General Improvements in Stroke Patients', 'OfficialTitle': 'The Correlation Between the Length of Stay in Post Acute Care(PAC) and General Improvements in Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 3, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 14, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 22, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 10, 2018', 'StudyFirstSubmitQCDate': 'December 17, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 19, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 26, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 28, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Willy Chou', 'ResponsiblePartyInvestigatorTitle': 'Director of physical medicine and rehabiliation', 'ResponsiblePartyInvestigatorAffiliation': 'Chi Mei Medical Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Chimei Medical Center', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Post-Acute Care(PAC) had been inaugurated in Taiwan for almost four years and current essays revealed positive effects upon general improvements in stroke patient after PAC training. During acute phase, a stroke patient would admit to internal medicine or surgical ward and transferred to rehabilitative ward for more intensive therapeutic programs, restoring muscle power and promoting activity of daily life(ADL) ability. Under relative stable condition, the patient would transfer to PAC institution or hospitals afterwards for continuing rehabilitative program if the patient is acknowledged to have rehabilitative potentials. However, there's still lacking of investigation upon whether the length of stay in PAC correlates to general improvements. Thus, stroke patients' functional ability, such as activities of daily living (ADL) function, swallowing ability and so on, as well as their corresponding scales were assessed on the first and last day during PAC hospitalization. Statistical analysis was conducted via SPSS ver21.0 to compare the relationship of improvements in functional ability and the length of stay in PAC. We're looking forward to the final results!\", 'DetailedDescription': 'Functional ability in stroke patients are evaluated by following measurements. Activity of daily life (ADL) function was estimated through modified Rankin scale(MRS) and Barthel index(BI), swallowing ability by functional oral intake scale, nutritional status via mini nutritional assessment, life quality through EuroQoL-5D, instrumental ADL function by Lawton-Brody IADL Scale(IADL), balance/coordination via Berg Balance Test, walking speed through Usual Gait Speed, cardiopulmonary capability by Six-Minute Walk Test, occupational mobility (amount use/quality) via Motor Activity Log, language through concise Chinese aphasia test, motor function of upper extremities by Fugl-Meyer Assessment and so on.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Retrospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '305', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'stroke patient with complete post-acute care hospitalization', 'ArmGroupDescription': 'This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Rehabilitation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Rehabilitation', 'InterventionDescription': 'The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['stroke patient with complete post-acute care hospitalization']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Activity of daily life function', 'PrimaryOutcomeDescription': 'Activity of daily life function is evaluated by both Barthel index(Range: 0~100 score; higher score indicates better function) and Modified Rankin Scale(Grade 1~6; the lower grade indicates better function). Task-oriented activity of daily life is assessed by Industrial activity of daily life(Range: Male 0~5 score and female 0~8 score; Higher score indicates better function)', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Nutritional status', 'PrimaryOutcomeDescription': 'Nutritional status is evaluated by Mini nutritional assessment(Range: 0.0~30.0). Higher score indicates better function', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Oral intake function', 'PrimaryOutcomeDescription': 'Oral intake is evaluated by Functional oral intake scale(Range: level 1~7). Higher level indicates better function.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Cardiopulmonary capacity', 'PrimaryOutcomeDescription': 'Cardiopulmonary capacity is evaluated by 6-minute walk test, which requires the patients to walk as much as they can within 6 minutes. Walking length is presented in meters. Longer distance and more meters indicate better function.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Walking speed', 'PrimaryOutcomeDescription': 'Walking speed is evaluated by Usual Gait Speed, which require the patients to walk certain distance and record the time that needed to finish the whole course. Time is presented with seconds. The shorter time and lower seconds indicate better function.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Upper motor hand function', 'PrimaryOutcomeDescription': 'Upper motor hand function is evaluated by Fugl-Meyer assessment(Range 0~44 scores) Higher scores indicate better function.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Life quality', 'PrimaryOutcomeDescription': 'Life quality is evaluated by EuroQoL-5D(Range: 5~15 scores). Lower scores indicate better life quality.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Balance and coordination', 'PrimaryOutcomeDescription': 'Balance and coordination is evaluated by Berg-Balance test(Range: 0~56). Higher scores indicate better function.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Cognition', 'PrimaryOutcomeDescription': 'Cognition is evaluated by Mini-Mental Sate Examination(Range: 0~30 score). Higher scores indicate better cognition.', 'PrimaryOutcomeTimeFrame': '35 days'}, {'PrimaryOutcomeMeasure': 'Speech function', 'PrimaryOutcomeDescription': 'Speech function is evaluated by Concise Chinese Aphasia Test(Range: 1~12 scores). Higher scores indicate better speech function', 'PrimaryOutcomeTimeFrame': '35 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n>18 y/o\\nacute onset of stroke within 30 days\\nModified Rankin Scale 2~4\\n\\nExclusion Criteria:\\n\\npatients refused to join post acute care(PAC) program\\nhemodynamic unstable\\ndisease progression', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Stroke patient who meet up criteria of >18 y/o, acute onset of stroke within 30 days and Modified Rankin Scale 2~4 as well as complete post acute care(PAC) rehabilitative program.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Willy Chou, MD, MS', 'OverallOfficialAffiliation': 'Chi Mei Medical Hospital', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Chi Mei Medical Center', 'LocationCity': 'Tainan', 'LocationZip': '71004', 'LocationCountry': 'Taiwan'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'There is no plan to make individual participant data (IPD) available to other researchers.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 98, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05000385', 'OrgStudyIdInfo': {'OrgStudyId': '1111'}, 'Organization': {'OrgFullName': 'Clinical Hospital Center Rijeka', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Masticatory Efficiency in Children', 'OfficialTitle': 'Association of Masticatory Efficiency With the Condition of the Stomatognathic System in Children'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 1, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 1, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 22, 2021', 'StudyFirstSubmitQCDate': 'August 3, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 11, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 19, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 20, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Odri Cicvarić', 'ResponsiblePartyInvestigatorTitle': 'DMD, Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Clinical Hospital Center Rijeka'}, 'LeadSponsor': {'LeadSponsorName': 'Clinical Hospital Center Rijeka', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"This study aims to evaluate the association of masticatory efficiency with different conditions of the stomatognathic system (transitioning from primary to secondary dentition, dental caries, malocclusion, tooth loss, prosthodontic treatment) in the paediatric population. Also, to assess the correlation between masticatory efficiency and nutritional status. The study will be conducted on children between 3 and 14 years of age. Masticatory efficiency will be evaluated by the optical scanning method. Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle's size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Mastication Disorder']}, 'KeywordList': {'Keyword': ['Body Mass Index', 'Child', 'Mastication', 'Stomatognathic Diseases', 'Particle size']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '96', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Healthy', 'ArmGroupDescription': 'healthy complete dentition', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Assesment of masticatory efficiency with optical scanning method', 'Diagnostic Test: body mass index']}}, {'ArmGroupLabel': 'Dental caries', 'ArmGroupDescription': 'complete dentition with bilateral dental caries (ICDAS 4,5 or 6)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Assesment of masticatory efficiency with optical scanning method', 'Diagnostic Test: body mass index']}}, {'ArmGroupLabel': 'Occlusal contacts', 'ArmGroupDescription': 'occlusal contacts are lost bilaterally due to extraction, changing dentition or orthodontic anomalies; no dental caries', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Assesment of masticatory efficiency with optical scanning method', 'Diagnostic Test: body mass index']}}, {'ArmGroupLabel': 'Dentures', 'ArmGroupDescription': 'patients with dentures, no caries and/or missing occlusal contacts on remaining teeth', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Assesment of masticatory efficiency with optical scanning method', 'Diagnostic Test: body mass index']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Assesment of masticatory efficiency with optical scanning method', 'InterventionDescription': 'Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Dental caries', 'Dentures', 'Healthy', 'Occlusal contacts']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'body mass index', 'InterventionDescription': 'as an indication of nutritional status', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Dental caries', 'Dentures', 'Healthy', 'Occlusal contacts']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'level of masticatory efficiency in children', 'PrimaryOutcomeDescription': 'determining the masticator efficiency variable (mean area of chewed particles) with optical scanning method, data comparison between four groups', 'PrimaryOutcomeTimeFrame': '2 years'}, {'PrimaryOutcomeMeasure': 'masticatory efficiency and body mass index', 'PrimaryOutcomeDescription': 'determining the correlation of the masticatory efficiency variable (mean area of chewed particles determined by the optical scanning method) with body mass index (weight and height will be combined to report BMI in kg/m^2)', 'PrimaryOutcomeTimeFrame': '2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'dental caries and masticatory efficiency', 'SecondaryOutcomeDescription': 'determining the correlation of the masticatory efficiency (mean area of chewed particles determined by the optical scanning method) with the number of dental caries', 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'occlusal contact and masticatory efficiency', 'SecondaryOutcomeDescription': 'determining the correlation of the masticatory efficiency (mean area of chewed particles determined by the optical scanning method) with the number of lost occlusal contacts', 'SecondaryOutcomeTimeFrame': '2 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nchildren of both genders aged 3 to 14, with:\\n\\nfull healthy dentition\\nbilateral dental caries stage 4,5 or 6 by ICDAS criteria\\nreduced number of occlusal contacts\\ndentures\\nsigned informed consent by participant's parents\\nverbal consent of the children\\n\\nExclusion Criteria:\\n\\nuncooperative behavior\\nsymptoms of temporomandibular joint dysfunction\\nparafunctional habits\\nsystemic disturbances that can impact mastication\\ningestion of medicines that could interfere directly or indirectly with muscular activity\\ntooth anomalies of structure, number or form\\nperiodontal disease\\ntooth mobility\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '3 Years', 'MaximumAge': '14 Years', 'StdAgeList': {'StdAge': ['Child']}, 'StudyPopulation': 'Children of both genders aged 3 to 14, with: full healthy dentition, bilateral dental caries stage 4,5 or 6 by ICDAS criteria, reduced number of occlusal contacts, and dentures, that are coming to Department of Paediatric Dentistry of Dental Clinic of the Clinical Hospital Center Rijeka for examination and/or therapy.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Odri Cicvaric, DMD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '0038551345636', 'CentralContactEMail': 'odri.cicvaric@fdmri.uniri.hr'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Odri Cicvaric, DMD', 'OverallOfficialAffiliation': 'Department of Paediatric Dentistry, Faculty of Dental Medicine of the University of Rijeka', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Clinical Hospital Center Rijeka', 'LocationStatus': 'Recruiting', 'LocationCity': 'Rijeka', 'LocationState': 'Primorsko-goranska Županija', 'LocationZip': '51000', 'LocationCountry': 'Croatia', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'prof.prim.dr.sc. Danko Bakarcic, DMD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '0038551345640', 'LocationContactEMail': 'danko.bakarcic@fdmri.uniri.hr'}]}}, {'LocationFacility': 'Faculty of Dental Medicine of the University of Rijeka', 'LocationStatus': 'Active, not recruiting', 'LocationCity': 'Rijeka', 'LocationState': 'Primorsko-goranska Županija', 'LocationZip': '51000', 'LocationCountry': 'Croatia'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M11707', 'ConditionBrowseLeafName': 'Stomatognathic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21679', 'InterventionBrowseLeafName': 'Salicylic Acid', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'Derm', 'InterventionBrowseBranchName': 'Dermatologic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 99, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01778205', 'OrgStudyIdInfo': {'OrgStudyId': 'IISPV_Murphy1'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': 'SPAIN MICINN', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Ministerio de Ciéncia y Innovación SAF2005/05096'}, {'SecondaryId': 'SPAIN ISCIII', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Instituto de Salud Carlos III PI10/00335'}, {'SecondaryId': 'SPAIN URV', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Universitat Rovira i Virgili'}, {'SecondaryId': 'SPAIN ISCIII', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Instituto de Salud Carlos III PI13/02500'}, {'SecondaryId': 'SPAIN ISCIII', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Instituto de Salud Carlos III PI19/00844'}, {'SecondaryId': 'SPAIN AEI', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Agencia Estatal Investigacion PCI2018-093098'}, {'SecondaryId': 'Horizon 2020', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'JPI ERA-HDHL Nutrition & The Epigenome'}]}, 'Organization': {'OrgFullName': 'Institut Investigacio Sanitaria Pere Virgili', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.', 'OfficialTitle': 'Phase 1 Study of the Effect of Maternal Nutritional Status on Placental Vascular Function, Fetal Growth and Intrauterine Growth Retardation.'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 14, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 14, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 25, 2013', 'StudyFirstSubmitQCDate': 'January 25, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 29, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 16, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 23, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Michelle Murphy', 'ResponsiblePartyInvestigatorTitle': 'Profesora agregat', 'ResponsiblePartyInvestigatorAffiliation': 'Institut Investigacio Sanitaria Pere Virgili'}, 'LeadSponsor': {'LeadSponsorName': 'Institut Investigacio Sanitaria Pere Virgili', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Italfarmaco', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'Instituto de Salud Carlos III', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Agencia Estatal de Investigación, Spain', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'JPI ERA-HDHL', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'University Rovira i Virgili', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'European Regional Development Fund', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': \"The recent fall in birth and death rates has led to demographic changes such as low fertility and high life expectancy . The WHO reports the median age of the European population to be the highest in the world and predicts that the proportion of over-60s in will increase from 14% in 2010 to 25% in 2050. There is wide variability in the quality of health and well-being in the ageing population. Longevity with a good quality of life is a consequence of the combination of an individual's genes, nutrition, environment, lifestyle and medical interventions. There is increasing evidence that research into healthy ageing needs to start with early life data to capture all traits and exposures experienced by an individual throughout life. Epigenetic imprinting occurs both in utero and during early postnatal development. Maternal environmental exposures, including nutritional status, may have a permanent effect on the developing foetus by influencing epigenetic profiles and leading to life-long genome adaptation. Numerous reports show that restricted intra-uterine growth due to poor maternal nutrition during pregnancy increases risk in the offspring of developing mental disorders, metabolic syndrome, cardiovascular disease or stroke in later life. To understand the basic mechanisms and interactions through which the ageing phenotype develops, systems involved in key processes of early development must be considered as well as those crucial to health in older persons. The Reus and Tarragona Birth Cohort is a longitudinal study. In the first phase, blood is collected from pregnant women at <12, 15, 24-27 and 34 gestational weeks (GW) and at labor and from the cord. Detailed lifestyle, habits and supplement use data are collected at 20 and 32 gestational weeks and on nutritional habits at <12GW and at birth. Placental vascular function is assessed at 20 and 32 GW by analysis of Doppler waveforms of the uterine arteries. Data on pregnancy evolution and outcome are also recorded. The first phase investigates the association between gene-environment (nutrient and lifestyle habits) interactions and fetal growth and pregnancy outcome. The second phase of the study follows up the children at 7.5 years of age. Growth, exercise and nutritional habits as well as environment and cognitive development are assessed. The aims are to investigate the association between gene-environment interactions associated with healthy development from early pregnancy until 7.5 years of age.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Intrauterine Development']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Plasma Serum Leukocytes Placenta'}, 'EnrollmentInfo': {'EnrollmentCount': '831', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Pregnant women', 'ArmGroupDescription': 'Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Observational']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Observational', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Pregnant women']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Birth weight', 'PrimaryOutcomeTimeFrame': 'At birth'}, {'PrimaryOutcomeMeasure': 'Doppler waveforms of uterine arteries', 'PrimaryOutcomeTimeFrame': '20 gestational weeks'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': '1-C metabolites', 'OtherOutcomeTimeFrame': '<12, 15, 24-27, 34 gestational weeks, at labor, in the cord'}, {'OtherOutcomeMeasure': 'Intrauterine growth retardation', 'OtherOutcomeTimeFrame': 'At birth'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n<12 weeks pregnant at first prenatal check up\\n\\nExclusion Criteria:\\n\\nIllnesses / interventions affecting nutritional status, major recent surgery in the previous 6 months, multiple pregnancies', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'Female', 'MinimumAge': '18 Years', 'MaximumAge': '45 Years', 'StdAgeList': {'StdAge': ['Adult']}, 'StudyPopulation': 'Women less than 12 weeks pregnant at their first pre-natal check up are recruited from the URV University Hospitals: Sant Joan (Reus) and Joan XXIII (Tarragona)', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Michelle M Murphy, PhD', 'OverallOfficialAffiliation': 'University Rovira i Virgili', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Pere Cavallé-Busquets, MD, PHD', 'OverallOfficialAffiliation': 'Hospital Universitari Sant Joan de Reus', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Joan D Fernandez-Ballart, PhD', 'OverallOfficialAffiliation': 'University Rovira i Virgili', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Mónica Ballesteros, MD, PHD', 'OverallOfficialAffiliation': 'Hospital de Tarragona Joan XXIII', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital Universitari Sant Joan de Reus', 'LocationCity': 'Reus', 'LocationState': 'Tarragona', 'LocationZip': '43201', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Hospital de Tarragona Joan XXIII', 'LocationCity': 'Tarragona', 'LocationZip': '43005', 'LocationCountry': 'Spain'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27735840', 'ReferenceType': 'background', 'ReferenceCitation': 'Colomina JM, Cavalle-Busquets P, Fernandez-Roig S, Sole-Navais P, Fernandez-Ballart JD, Ballesteros M, Ueland PM, Meyer K, Murphy MM. Maternal Folate Status and the BHMT c.716G>A Polymorphism Affect the Betaine Dimethylglycine Pathway during Pregnancy. Nutrients. 2016 Oct 9;8(10):621. doi: 10.3390/nu8100621.'}, {'ReferencePMID': '29529156', 'ReferenceType': 'background', 'ReferenceCitation': 'Sole-Navais P, Salat-Batlle J, Cavalle-Busquets P, Fernandez-Ballart J, Ueland PM, Ballesteros M, Ornosa-Martin G, Ingles-Puig M, Colomina JM, Murphy MM. Early pregnancy folate-cobalamin interactions and their effects on cobalamin status and hematologic variables throughout pregnancy. Am J Clin Nutr. 2018 Feb 1;107(2):173-182. doi: 10.1093/ajcn/nqx041.'}, {'ReferencePMID': '30777448', 'ReferenceType': 'background', 'ReferenceCitation': 'Roige-Castellvi J, Murphy M, Hernandez-Martinez C, Sole-Navais P, Cavalle-Busquets P, Fernandez-Ballart J, Ballesteros M, Canals J. The effect of prenatal smoke exposure on child neuropsychological function: a prospective mother-child cohort study. J Reprod Infant Psychol. 2020 Feb;38(1):25-37. doi: 10.1080/02646838.2019.1580350. Epub 2019 Feb 19.'}, {'ReferencePMID': '31962182', 'ReferenceType': 'background', 'ReferenceCitation': 'Cavalle-Busquets P, Ingles-Puig M, Fernandez-Ballart JD, Haro-Barcelo J, Rojas-Gomez A, Ramos-Rodriguez C, Ballesteros M, Meyer K, Ueland PM, Murphy MM. Moderately elevated first trimester fasting plasma total homocysteine is associated with increased probability of miscarriage. The Reus-Tarragona Birth Cohort Study. Biochimie. 2020 Jun;173:62-67. doi: 10.1016/j.biochi.2020.01.008. Epub 2020 Jan 18.'}, {'ReferencePMID': '23595875', 'ReferenceType': 'result', 'ReferenceCitation': 'Fernandez-Roig S, Cavalle-Busquets P, Fernandez-Ballart JD, Ballesteros M, Berrocal-Zaragoza MI, Salat-Batlle J, Ueland PM, Murphy MM. Low folate status enhances pregnancy changes in plasma betaine and dimethylglycine concentrations and the association between betaine and homocysteine. Am J Clin Nutr. 2013 Jun;97(6):1252-9. doi: 10.3945/ajcn.112.054189. Epub 2013 Apr 17.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M8137', 'ConditionBrowseLeafName': 'Fetal Growth Retardation', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC16', 'ConditionBrowseBranchName': 'Diseases and Abnormalities at or Before Birth'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 100, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05304429', 'OrgStudyIdInfo': {'OrgStudyId': 'CMAZGA-APPR.001'}, 'Organization': {'OrgFullName': 'Instituto Tecnologico y de Estudios Superiores de Monterey', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Application of a Nutritional Counseling Program on the Frailty of Older Adults in the Mexican Population', 'OfficialTitle': 'Application of a Nutritional Counseling Program on the Frailty of Older Adults in the Mexican Population'}, 'StatusModule': {'StatusVerifiedDate': 'March 2022', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 29, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'November 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'March 8, 2022', 'StudyFirstSubmitQCDate': 'March 21, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 31, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 21, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 31, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Mariana Cecilia Orellana Haro', 'ResponsiblePartyInvestigatorTitle': 'Clinical Proffessor', 'ResponsiblePartyInvestigatorAffiliation': 'Instituto Tecnologico y de Estudios Superiores de Monterey'}, 'LeadSponsor': {'LeadSponsorName': 'Instituto Tecnologico y de Estudios Superiores de Monterey', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'In the present study, the COM-B model is intended to be used as a central axis in the planning of the nutritional counseling intervention, since it proposes that behavioral modification is conditioned by the capacity, opportunity and motivation of the person, 3 basic components that can be addressed with nutritional education and goal-setting strategies, self-monitoring and social support.\\n\\nThe intervention will consist of applying nutritional counseling in older adults with frailty syndrome to measure the effect on indicators of this syndrome such as nutritional status, handgrip strength, protein consumption and physical activity.', 'DetailedDescription': 'Clinical trial with intervention group and control group that include men and women over 60 years of age with frailty or risk of suffering it according to the frailty scale\\n\\nINTERVENTION:\\n\\nThe COM-B system is based on 3 main pillars that appear in the initials of its name, being the C for \"capacity\", the O for \"opportunity\" and the M for \"motivation\". The behavior of the person is attributed to these in such a way that if they have the capacity, motivation and opportunity, the strategies used for behavior change will be more effective.\\n\\nBased on this theory, the investigators support the intervention of the study in which the capacity of the participants will be developed through nutritional education, motivation through goal setting and self-monitoring, and the opportunity for social support that will be provided through this project at no cost to users of the DIF Zapopan Metropolitan Center for the Elderly.\\n\\nRegarding the establishment of goals, 10 important behaviors will be worked on to prevent or combat frailty, which promote adequate protein consumption, balance in the distribution of nutrients, avoid prolonged periods of fasting by encouraging the consumption of healthy snacks, decreased consumption of ultra-processed foods, increasing the consumption of plant-based foods and performing strength exercises. The adherence to these behaviors will be self-monitored on a weekly basis through a format (see annex 4) that each person will receive and that is inspired by the strategy used by Beeken and collaborators in the \"ten top tis\" project where the effectiveness in behavioral modification through goal setting and self-monitoring.\\n\\nNutritional education was carried out in group sessions of 40 minutes having a total of 10 workshops which provided practical theoretical tools to each of the behaviors to be monitored, in this way each workshop addressed a specific behavior.\\n\\nThe intervention will be aimed at qualitatively and quantitatively modifying eating habits, emphasizing protein consumption and modifying physical activity habits, limiting sedentary behaviors.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Frailty Syndrome']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Non-Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Clinical trial with intervention group and control group', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '80', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'nutritional counseling group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'This group will have nutrition education sessions every fifteen days and will keep track of 10 healthy behaviors through goal setting and self-monitoring.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: nutrition education', 'Behavioral: nutritional counseling']}}, {'ArmGroupLabel': 'group without nutritional counseling', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'This group will have sessions every fifteen days of reading, knitting and other activities unrelated to health.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'nutrition education', 'InterventionDescription': 'Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['nutritional counseling group']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'nutritional counseling', 'InterventionDescription': 'nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['nutritional counseling group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Frailty syndrome', 'PrimaryOutcomeDescription': 'Geriatric syndrome characterized by a decreased ability of the body to respond to external stressors, causing in the individual: risk of falls, functional decline, disability, dependency, institutionalization and even death.\\n\\nFor its evaluation, the frailty scale valid in Mexicans proposed by Díaz de León González in 2016 will be used.\\n\\nIt considers 5 questions and classifies those with a score between 3 to 5 points as frail, pre-fragile between 1 and 2 and non-fragile with a score of zero.\\n\\nQuestions:\\n\\nDo you feel tired most of the time? Can you walk up one flight of stairs without breaks or help? Are you able to walk 100 m without pausing and without assistance? Have more than 5 symptoms. Arthritis, diabetes, angina/heart attack, hypertension, stroke, asthma, chronic bronchitis, emphysema, osteoporosis, colorectal cancer, skin cancer, depression/anxiety, dementia, leg ulcers.\\n\\nWeightloss: > 5% in the last year', 'PrimaryOutcomeTimeFrame': '6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Protein intake', 'SecondaryOutcomeDescription': 'Intake of grams of protein per day from animal or vegetable sources. It will be evaluated through a 24-hour recall.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Malnutrition', 'SecondaryOutcomeDescription': 'Malnutrition is a lack of calories or one or more essential nutrients. It will be measured through the Mini Nutritional Assessment long form (MNA-LF), a screening tool to help identify elderly patients who are malnourished or at risk of malnutrition.\\n\\nThe tool consists of a 18-item in the long form scale.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Handgrip strength', 'SecondaryOutcomeDescription': \"It is the maximum isometric strength of the hand and forearm muscles.. It will be evaluated through the pressure force of the participant's dominant hand estimated through a dynamometer and whose cut-off points refer to a decrease in force when it is below 30 kg in men or 20 kg in women.\", 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'sedentary activities', 'SecondaryOutcomeDescription': 'Those activities that people do sitting or reclining, while we are awake, and that use very little energy.\\n\\nThese will be evaluated through self-report of sedentary activities Adapted from the ASAQ Questionnaire (Adolescent Sedentary Activity Questionnaire)', 'SecondaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nMen and women over 60 years of age\\nThat they have a normal cognitive function (more than 24 points in the minimental test)\\nThat they attend weekly the Metropolitan Center for the Elderly (DIF Zapopan)\\nWho suffer from frailty or pre-frailty (from 1 to 5 points on the frailty scale)\\n\\nExclusion Criteria:\\n\\nSevere dysphagia\\nConsumption of food supplements (protein powder or vitamins)\\nSenile dementia, cognitive impairment or Alzheimer's\\nPeople who are following a diet or physical activity plan prescribed by a professional\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '60 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Mariana Cecilia Orellana, master degree', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+52 3313446872', 'CentralContactEMail': 'm.orellana@tec.mx'}, {'CentralContactName': 'Claudia Madeleine Hunot, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+52 3331154831', 'CentralContactEMail': 'claudia.hunot@academicos.udg.mx'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24402390', 'ReferenceType': 'background', 'ReferenceCitation': 'Nykanen I, Rissanen TH, Sulkava R, Hartikainen S. Effects of individual dietary counseling as part of a comprehensive geriatric assessment (CGA) on nutritional status: a population-based intervention study. J Nutr Health Aging. 2014 Jan;18(1):54-8. doi: 10.1007/s12603-013-0342-y.'}, {'ReferencePMID': '28717811', 'ReferenceType': 'background', 'ReferenceCitation': 'Andersson J, Hulander E, Rothenberg E, Iversen PO. Effect on Body Weight, Quality of Life and Appetite Following Individualized, Nutritional Counselling to Home-Living Elderly after Rehabilitation - An Open Randomized Trial. J Nutr Health Aging. 2017;21(7):811-818. doi: 10.1007/s12603-016-0825-8.'}, {'ReferencePMID': '16813773', 'ReferenceType': 'background', 'ReferenceCitation': 'Faber MJ, Bosscher RJ, Chin A Paw MJ, van Wieringen PC. Effects of exercise programs on falls and mobility in frail and pre-frail older adults: A multicenter randomized controlled trial. Arch Phys Med Rehabil. 2006 Jul;87(7):885-96. doi: 10.1016/j.apmr.2006.04.005.'}, {'ReferencePMID': '28183809', 'ReferenceType': 'background', 'ReferenceCitation': 'Gardner B, Jovicic A, Belk C, Kharicha K, Iliffe S, Manthorpe J, Goodman C, Drennan VM, Walters K. Specifying the content of home-based health behaviour change interventions for older people with frailty or at risk of frailty: an exploratory systematic review. BMJ Open. 2017 Feb 9;7(2):e014127. doi: 10.1136/bmjopen-2016-014127.'}, {'ReferencePMID': '28273591', 'ReferenceType': 'background', 'ReferenceCitation': 'Fernandez-Barres S, Garcia-Barco M, Basora J, Martinez T, Pedret R, Arija V; Project ATDOM-NUT group. The efficacy of a nutrition education intervention to prevent risk of malnutrition for dependent elderly patients receiving Home Care: A randomized controlled trial. Int J Nurs Stud. 2017 May;70:131-141. doi: 10.1016/j.ijnurstu.2017.02.020. Epub 2017 Feb 23.'}]}, 'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'findings of the national study of health and aging in Mexico', 'SeeAlsoLinkURL': 'http://www.enasem.org/images/MHASFactSheet_Frailty_SPANISH.pdf'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000073496', 'ConditionMeshTerm': 'Frailty'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M16045', 'ConditionBrowseLeafName': 'Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M1175', 'ConditionBrowseLeafName': 'Frailty', 'ConditionBrowseLeafAsFound': 'Frailty', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}]}}\n"
          ]
        }
      ],
      "source": [
        "def get_clinicaltrials(disease, additional_term):\n",
        "  import requests\n",
        "  import json\n",
        "\n",
        "  disease = \"stroke\"\n",
        "  additional_term = \"nutrition\"\n",
        "\n",
        "  base_url = \"https://ClinicalTrials.gov/api/query/full_studies\"\n",
        "  search_term = disease + \" \" + additional_term\n",
        "  search_term.replace(\" \", \"+\")\n",
        "  params = {\n",
        "      \"expr\": search_term,\n",
        "      \"min_rnk\": \"1\",\n",
        "      \"max_rnk\": \"50\",\n",
        "      \"fmt\": \"json\"\n",
        "    }\n",
        "  response = requests.get(base_url, params=params)\n",
        "\n",
        "  # Parse the JSON\n",
        "  data = json.loads(response.text)\n",
        "  print(data)\n",
        "  results_list = []\n",
        "  # Attributes to include\n",
        "  attributes_to_include = [\n",
        "      \"DescriptionModule\",\n",
        "      \"EnrollmentInfo\",\n",
        "      \"OutcomesModule\",\n",
        "      \"EligibilityModule\",\n",
        "      \"IdentificationModule\",\n",
        "      \"StatusModule\",\n",
        "      \"SponsorCollaboratorsModule\",\n",
        "      \"ConditionsModule\"\n",
        "  ]\n",
        "\n",
        "  index = 0\n",
        "\n",
        "  if (data[\"FullStudiesResponse\"][\"NStudiesFound\"] > 0):\n",
        "\n",
        "    # Extract the list of studies\n",
        "    studies = data[\"FullStudiesResponse\"][\"FullStudies\"]\n",
        "\n",
        "    # Loop through the studies\n",
        "    for study_data in studies:\n",
        "    # Extract relevant information\n",
        "      study = study_data[\"Study\"]\n",
        "\n",
        "      # Extract status, start date, and completion date if available\n",
        "      status_info = study[\"ProtocolSection\"].get(\"StatusModule\", {})\n",
        "\n",
        "      # Extract results submission information if available, i.e. study\n",
        "      results_submit_date = status_info.get(\"ResultsFirstSubmitDate\")\n",
        "      if results_submit_date:\n",
        "        # Include only specified attributes and their child attributes\n",
        "        included_attributes = {}\n",
        "        for attr in attributes_to_include:\n",
        "          if attr in study[\"ProtocolSection\"]:\n",
        "            included_attributes[attr] = study[\"ProtocolSection\"][attr]\n",
        "            #print(f\"Added attribute: {attr}\")\n",
        "\n",
        "        index += 1\n",
        "        results_list.append({\"Study {}\".format(index): included_attributes})\n",
        "        # Only get upto 5 studies due to the token limit for openAI\n",
        "        if (index >= 5):\n",
        "          break\n",
        "  else:\n",
        "      print(\"No Studies found\")\n",
        "\n",
        "  # Create a dictionary for the collected results\n",
        "  collected_results = {\"Results\": results_list}\n",
        "\n",
        "  # Convert the collected results to JSON format\n",
        "  collected_results_json = json.dumps(collected_results, indent=4)\n",
        "  with open(\"/content/clinical_trials/collected_results\"+disease+\".json\", \"w\") as outfile:\n",
        "    outfile.write(collected_results_json)\n",
        "\n",
        "  return collected_results_json\n",
        "\n",
        "collected_results_json = get_clinicaltrials(\"heart disease\", \"nutrition\")\n"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Get the summary for each study by calling OpenAI API**"
      ],
      "metadata": {
        "id": "8EvAf1cKd3vg"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 183
        },
        "id": "a4szc9L1yQNg",
        "outputId": "336f2ee9-d626-4d4e-e2b7-7f7f09d830bd"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Study 1: Nutrition and Aerobic Exercise in Chronic Stroke (NEXIS)\\n\\n- Brief Summary: This study aims to examine the effects of dietary modification and treadmill training on fuel utilization and physical function in chronic stroke patients.\\n- Hypotheses: The researchers hypothesized that dietary modification and exercise training can reverse abnormalities in fuel utilization and improve physical function in chronic stroke patients.\\n- Primary Outcome: The change in total daily energy expenditure was measured using an accelerometer activity monitor. The researchers found that treadmill training or stretching did not significantly affect total daily energy expenditure.\\n- Secondary Outcomes:\\n  - The change in substrate oxidation was measured using open circuit spirometry during a treadmill walking task. The researchers found no significant change in substrate oxidation after 6 months of treadmill training or stretching.\\n  - The change in circulating nitrotyrosine, a marker of oxidative stress, was measured in plasma. The researchers found no significant change in circulating nitrotyrosine levels after 6 months of treadmill training or stretching.\\n- Outcome vs. Hypotheses: The outcomes did not match the hypotheses. The study did not find significant improvements in fuel utilization or physical function with dietary modification and treadmill training in chronic stroke patients.'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 28
        }
      ],
      "source": [
        "summary = \"\"\n",
        "if collected_results_json:\n",
        "  instructPrompt = \"\"\"\n",
        "  You are a expert at analyzing clinical data for scientific studies for diseases. Summarize the Outcome of each study. Use bullet points. Compare the Outcome parameters to hypotheses and see if the outcome matched the hypotheses or not.\n",
        "  Focus more on the outcome parameters for each study. Don't use any scientific language. Make it easily understandable by kids. Below is all the information from the studies of various clinical trials. Don't write any of the identification attributes.\n",
        "  Don't put the title of the study in your response.\n",
        "  \"\"\"\n",
        "\n",
        "  request = instructPrompt + collected_results_json\n",
        "\n",
        "  chatOutput = openai.ChatCompletion.create(model=\"gpt-3.5-turbo-16k\",\n",
        "                                              messages=[{\"role\": \"system\", \"content\": \"You are a expert at analyzing clinical data for scientific studies for diseases.\"},\n",
        "                                                        {\"role\": \"user\", \"content\": request}\n",
        "                                                        ]\n",
        "                                              )\n",
        "\n",
        "  summary = chatOutput.choices[0].message.content\n",
        "\n",
        "\n",
        "summary"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "sHNDXwTxrq6N"
      },
      "source": [
        "**Get all the important attributes for all the studies that matched the critieria**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 421
        },
        "id": "HTUobQqfrl7D",
        "outputId": "571556ae-1c8d-4e51-9726-7e434a0aab6e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'FullStudiesResponse': {'APIVrs': '1.01.05', 'DataVrs': '2023:08:16 23:57:56.293', 'Expression': 'stroke nutrition', 'NStudiesAvail': 462815, 'NStudiesFound': 319, 'MinRank': 1, 'MaxRank': 50, 'NStudiesReturned': 50, 'FullStudies': [{'Rank': 1, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03825419', 'OrgStudyIdInfo': {'OrgStudyId': 'MASS'}, 'Organization': {'OrgFullName': 'Turkish Stroke Research and Clinical Trials Network', 'OrgClass': 'NETWORK'}, 'BriefTitle': 'Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition (MASS)', 'OfficialTitle': 'Muscle Assessment in Stroke Study (MASS): Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition', 'Acronym': 'MASS'}, 'StatusModule': {'StatusVerifiedDate': 'April 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 23, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'November 30, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 30, 2019', 'StudyFirstSubmitQCDate': 'January 30, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 31, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 27, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ethem Murat Arsava', 'ResponsiblePartyInvestigatorTitle': 'Prof.Dr.', 'ResponsiblePartyInvestigatorAffiliation': 'Turkish Stroke Research and Clinical Trials Network'}, 'LeadSponsor': {'LeadSponsorName': 'Turkish Stroke Research and Clinical Trials Network', 'LeadSponsorClass': 'NETWORK'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Abbott Nutrition', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'Klinar CRO', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Turkish Neurological Society', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The degree of muscle loss over the course of inpatient stay will be evaluated in patients with a diagnosis of acute ischemic stroke admitted to Neurocritical Care Units and necessitating enteral nutrition.', 'DetailedDescription': 'This study is a multicenter, prospective observational study. The study period is 12 months. There are no investigational products to be followed or used in the study.\\n\\nDemographic data, stroke subtype, lesion localization, anthropometric measures will be recorded. Muscle in three different anatomical sites will be measured by CT following admission in patients included in the study.\\n\\nFor anthropometric measurements, height, body weight, body mass index, waist circumference, triceps skin thickness and calf circumference values will be used.\\n\\nThe muscle mass will be measured from the paraspinal muscles at the L3 vertebra level and from the muscles around the humerus and femur on the non-paralytic side of the extremities by CT.\\n\\nAll patients will receive standard enteral nutritional support with a standardized calorie and protein-based protocol recommended by international guidelines. The choice of the commercial enteral product will be left to the investigator, without any encouragement or restriction for use of any commercial product.\\n\\nThe enteral nutrition protocol will be implemented as follows;\\n\\nNasogastric or nasojejunal access\\nContinuous infusion\\nTargeted daily calories - 25-30 kcal / kg\\nTargeted daily protein - 1.2-1.5 gr / kg\\n20 ml / h initial infusion rate\\nIncrease infusion rate by 10-20 ml / h in 8-12 hours\\nTargeted calorie-protein requirement will be reached at the end of 72 hours.\\n\\nPatients will continue their routine follow-up in the neurology intensive care unit / stroke unit / neurology department. Daily enteral nutrition dose, complications attributed to enteral nutrition and systemic comorbidities will be recorded. Anthropometric measurements and muscle mass measurements with CT at three different locations will be repeated at the end of the second week (14 days ± 3 days) .\\n\\nThe study will evaluate whether or not muscle mass develops 14 days after acute ischemic stroke. The end points of the study is deterioration of anthropometric measurements and loss of muscle mass demonstrated by CT at follow up. The differences between patients with and without muscle loss will be assessed from the the aspects of demographic characteristics, ischemic stroke subtype, comorbidities and the success attained in reaching enteral nutritional goals.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Ischemic Stroke']}, 'KeywordList': {'Keyword': ['Stroke, Acute, Neurocritical Care, Nutrition, Sarcopenia']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '125', 'EnrollmentType': 'Actual'}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in muscle mass', 'PrimaryOutcomeDescription': 'Comparison of anthropometric measurements and CT based muscle mass measurements obtained at admission and at day 14 (± 3 days)', 'PrimaryOutcomeTimeFrame': '14 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients to be included in this study are required to meet all of the following inclusion criteria:\\n\\nAcute ischemic stroke\\nAdmission within first 24 hours after symptom onset\\nAdmission NIHSS score > 8\\nBeing unable to walk\\nNeed for enteral tube feeding due to problems with consciousness or dysphagia\\n\\nExclusion Criteria:\\n\\nPatients with any of the following exclusion criteria can not be included in the study:\\n\\nRetained ability for oral feeding\\nKnown muscle disease, neuropathy, neuromuscular junction disease', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with a diagnosis of acute ischemic stroke admitted to Neurocritical Care Units for whom enteral nutrition is indicated', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Ankara University Faculty of Medicine', 'LocationCity': 'Ankara', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Gazi University Faculty Of Medicine', 'LocationCity': 'Ankara', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Hacettepe University Faculty of Medicine', 'LocationCity': 'Ankara', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Eskişehir Osmangazi Faculty of Medicine', 'LocationCity': 'Eskişehir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Gaziantep University Faculty of Medicine', 'LocationCity': 'Gaziantep', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'İstanbul Şişli Hamidiye Etfal Training and Research Hospital', 'LocationCity': 'Istanbul', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Dokuz Eylül University Faculty of Medicine', 'LocationCity': 'İzmir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Ege University Faculty of Medicine', 'LocationCity': 'İzmir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'İzmir Katip Çelebi University Atatürk Training and Research Hospital', 'LocationCity': 'İzmir', 'LocationCountry': 'Turkey'}, {'LocationFacility': 'Ondokuz Mayıs University Faculty of Medicine', 'LocationCity': 'Samsun', 'LocationCountry': 'Turkey'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28017450', 'ReferenceType': 'background', 'ReferenceCitation': 'Shiraishi A, Yoshimura Y, Wakabayashi H, Tsuji Y. Prevalence of stroke-related sarcopenia and its association with poor oral status in post-acute stroke patients: Implications for oral sarcopenia. Clin Nutr. 2018 Feb;37(1):204-207. doi: 10.1016/j.clnu.2016.12.002. Epub 2016 Dec 10.'}, {'ReferencePMID': '25676847', 'ReferenceType': 'background', 'ReferenceCitation': 'Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10.'}, {'ReferencePMID': '24108501', 'ReferenceType': 'background', 'ReferenceCitation': 'Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. doi: 10.1001/jama.2013.278481. Erratum In: JAMA. 2014 Feb 12;311(6):625. Padhke, Rahul [corrected to Phadke, Rahul].'}, {'ReferencePMID': '25726722', 'ReferenceType': 'background', 'ReferenceCitation': 'Coelen RJ, Wiggers JK, Nio CY, Besselink MG, Busch OR, Gouma DJ, van Gulik TM. Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford). 2015 Jun;17(6):520-8. doi: 10.1111/hpb.12394. Epub 2015 Feb 28.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Acute Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 2, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03422900', 'OrgStudyIdInfo': {'OrgStudyId': 'CASVE-NM-17-315'}, 'Organization': {'OrgFullName': 'Endocrinology and Clinical Nutrition Research Center, Spain', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Hyperglycemia in Patients With Stroke and Indication of Enteral Nutrition', 'OfficialTitle': 'Influence of Two Enteral Nutrition Formulas on Hyperglycemia and Morbidity in Patients With Stroke', 'Acronym': 'GlyENStroke'}, 'StatusModule': {'StatusVerifiedDate': 'January 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 12, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 15, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 15, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 10, 2017', 'StudyFirstSubmitQCDate': 'January 30, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 30, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 6, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Daniel de Luis Roman', 'ResponsiblePartyInvestigatorTitle': 'Profesor Doctor', 'ResponsiblePartyInvestigatorAffiliation': 'Endocrinology and Clinical Nutrition Research Center, Spain'}, 'LeadSponsor': {'LeadSponsorName': 'Endocrinology and Clinical Nutrition Research Center, Spain', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to evaluate the effect of a specific nutritional formula for diabetics on the development of hyperglycemia in patients with recent non-diabetic stroke who require admission and enteral nutritional support by nasogastric tube. As well as the effect on metabolic control, development of comorbidities, hospital stay, readmissions, mortality and tolerance of the formula under study.', 'DetailedDescription': 'MAIN GOAL:\\n\\nTo evaluate the effect on the development of hyperglycemia diagnosed as glycemia> 126 mg / dl on an empty stomach or> 150 mg / dl during the infusion of enteral nutrition determined by capillary glycemia during the admission of a specific formula in patients with a first episode of ischemic stroke or hemorrhagic entry into the non-diabetic HCUV stroke unit requiring enteral nutrition by nasogastric tube.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Hyperglycaemia (Non Diabetic)', 'Enteral Feeding Intolerance', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Comparison of two formulas of enteral nutrition (diabetes-specific enteral formula (lower glycemic index and presence of soluble and insoluble fiber) compared to an standard formula (isocaloric and isonitrogenated formula without fiber)) in patients without diabetes mellitus admitted due to stroke and with indication of nutritional support by nasogastric tube', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignMaskingDescription': 'cover label', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Care Provider']}}}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Specific Diabetes Formula', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Diabetes-Specific Enteral Formula:\\n\\nCaloric density: 1,0 kcal/ml\\nEnergy: 100 kcal\\nCarbohydrates: 10,1 g/100 ml;\\nFat: 4,5 g/100 ml\\nProt: 3,8 g/100 ml\\nOsmolarity: 345 mOsm/l\\nFiber: 1,78 g/100 ml (80% soluble; 20% insoluble).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Diabetes-Specific enteral formula']}}, {'ArmGroupLabel': 'Standard Formula', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Standard Enteral Formula:\\n\\nCaloric density: 1,0 kcal/ml\\nEnergy: 100 kcal\\nCarbohydrates: 13,8 g/100 ml;\\nFat: 3,4 g/100 ml\\nProt: 3,8 g/100 ml\\nOsmolarity: 220 mOsm/l\\nFiber: 0 g/100 ml', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Standard formula']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Diabetes-Specific enteral formula', 'InterventionDescription': 'Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Specific Diabetes Formula']}, 'InterventionOtherNameList': {'InterventionOtherName': ['DIABA']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Standard formula', 'InterventionDescription': 'Complete enteral formula normocaloric hormoproteic without fiber', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard Formula']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Fresubin Original']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'HYPERGLUCEMIA POST-ENTERAL NUTRITION', 'PrimaryOutcomeDescription': 'Glycemia over 150 mg / dl after the beginning of infusion of complete enteral. nutrition determined by capillary glycemia during admission. Dicotomic variable (Yes/No)', 'PrimaryOutcomeTimeFrame': '2 WEEKS'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'MORTALITY', 'SecondaryOutcomeDescription': 'Mortality during study period. Dicotomic variable (Yes/No)', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'ORAL FEEDING RECOVERY', 'SecondaryOutcomeDescription': 'Recovery of oral feeding (More than 75% of energy needs) and withdrawal of nasogastric tube during admission. Dicotomic variable (Yes/No)', 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdmitted for a first episode of ischemic or hemorrhagic stroke.\\nRequiring total enteral nutrition by tube for at least 7 days\\n\\nExclusion Criteria:\\n\\nContraindication to enteral nutrition\\nDiabetes Mellitus\\nGastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting, abdominal pain\\nNeed for admission to the ICU\\nPrevious neurodegenerative disease\\nAntibiotherapy for 7 days prior to the inclusion visit\\nAllergies or intolerances to any of the components of the formula under study\\nPregnant patients', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Juan J López-Gómez, Prof. Dr.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '983420000', 'CentralContactPhoneExt': '86158', 'CentralContactEMail': 'jjlopez161282@hotmail.com'}, {'CentralContactName': 'Daniel A De Luis-Román, Prof. Dr.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '983420000', 'CentralContactPhoneExt': '86660', 'CentralContactEMail': 'dadluis@yahoo.es'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Daniel A De Luis Román, Prof. Dr.', 'OverallOfficialAffiliation': 'Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Juan J López-Gómez, Prof. Dr.', 'OverallOfficialAffiliation': 'Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Javier F Arenillas-Lara, Prof. Dr.', 'OverallOfficialAffiliation': 'Service of Neurology. Clinic Hospital University of Valladolid', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Clinic Universitary Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Valladolid', 'LocationZip': '47003', 'LocationCountry': 'Spain', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Juan J López-Gómez, Prof. Dr.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '983420000', 'LocationContactPhoneExt': '86158', 'LocationContactEMail': 'jjlopez161282@hotmail.com'}, {'LocationContactName': 'Daniel A De Luis-Román, Prof. Dr.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '983420000', 'LocationContactPhoneExt': '86660', 'LocationContactEMail': 'dadluis@yahoo.es'}, {'LocationContactName': 'Daniel A De Luis-Román, Prof. Dr.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Juan J López-Gómez, Prof. Dr.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Javier F Arenillas-Lara, Prof. Dr.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Esther Delgado-García, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Emilia Gómez-Hoyos, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ana Ortolá-Buigues, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Beatriz Torres-Torres, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ana Calleja-Sanz, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Elisa Cortijo-García, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Mercedes De Lera, Dra.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ángeles Castro-Lozano, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Silvia Rodríguez-Gómez, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Lourdes De Marcos-White, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Beatriz Gómez-Vicente, Dipl.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Pedro L Muñoz-Rubio, Dipl', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Javier Reyes-Muñoz, Dipl', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Rosa Alcaide-Flores, Dipl', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Ana Martín, Dipl', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000006943', 'ConditionMeshTerm': 'Hyperglycemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9684', 'ConditionBrowseLeafName': 'Hyperglycemia', 'ConditionBrowseLeafAsFound': 'Hyperglycemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M25093', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}}, {'Rank': 3, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05454397', 'OrgStudyIdInfo': {'OrgStudyId': 'NFEC-2020-234'}, 'Organization': {'OrgFullName': 'Nanfang Hospital, Southern Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients', 'OfficialTitle': 'A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'October 2021', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 15, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'October 15, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 1, 2022', 'StudyFirstSubmitQCDate': 'July 7, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 12, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 7, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 12, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Nanfang Hospital, Southern Medical University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'First Affiliated Hospital of Fujian Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Yantai Yuhuangding Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The First Hospital of Jilin University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Qilu Hospital of Shandong University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'ZHEJIANG PROVINCE XIAOSHAN HOSPITAL', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"The First People's Hospital of Wenling\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Ganzhou People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Affiliated Hospital of Jining Medical hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Henan Provincial People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Zhongda Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Second Affiliated Hospital of Harbin Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"The First People's Hospital of Kunshan\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The 2nd Affiliated Hospital of Wenzhou Medical University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"THE FIRST PEOPLE'S HOSPITAL OF JIASHAN\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"The First Affiliated Hospital of Xi'an Jiaotong University Medical College\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Fujian Province Zhangzhou Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"People's Hospital of Chongqing\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Nanjing Zijin Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Red Cross Hospital, Hangzhou, China', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Wenzhou Hospital of Chinese Medicine', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Kaifeng Central Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'First Affiliated Hospital of Guangxi Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Zhongshan Hospital of Xiamen University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Xi'an Encephalopathy of Traditional Chinese Medicine Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Xiangya Hospital of Central South University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Second Affiliated Hospital of Suzhou University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Tongji Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Affiliated Hospital o fQingdao University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The First Affiliated Hospital of Anhui Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Yancheng Third People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Linyi People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Dongfang Hospital of Beijing University of Chinese Medicine', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The Affiliated Hospital of Qingdao University', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is the leading cause of premature death and disability, and early recognition and treatment of dysphagia is fundamental to stroke management. Early and full tube feeding in the acute phase of stroke helps to address nutritional problems resulting from dysphagia and impaired consciousness and helps to reduce morbidity and mortality and poor outcomes. Current guidelines for acute stroke management do not address the goal of tube feeding of enteral nutrition for energy and protein. In the treatment of acute stroke, there is a strong global focus on pharmacological thrombolysis or mechanical thrombolysis, with nutritional interventions being a less explored topic. Real-world evidence on large samples, feeding attainment and outcomes, and nutrition in the acute phase of stroke is lacking in China . The aim of this study was to understand the current status of nutritional therapy in stroke hospitalization in neurology and its impact on prognosis nationwide, and to improve the standardized management process of enteral nutrition therapy in the acute phase of stroke.', 'DetailedDescription': \"Malnutrition is a common geriatric syndrome with a disproportionate incidence in geriatric and neurology inpatients. In recent years, national nutritional surveys of geriatric inpatients have shown that about 2/3 of geriatric inpatients have nutritional problems; only half of neurology inpatients at high risk receive nutritional support, and inadequate nutrition exacerbates primary disease, increases complications, makes hospital stays longer, and ultimately affects patient survival outcomes.\\n\\nTo increase comprehensive and up-to-date research on the current status of nutritional therapy in geriatric and neurology inpatients, and to lay the foundation for future standardized treatment and standardized management, we conducted a nationwide survey on the current status of nutritional risk screening and treatment in geriatric and neurology inpatients. The aim is to raise the level of clinicians' awareness of malnutrition and nutritional risk in hospitalized patients, standardize clinical practice, and properly implement nutritional support to improve patients' clinical outcomes.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Stroke']}, 'KeywordList': {'Keyword': ['Stroke; Dysphagia;Nutrition management；']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '2000', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'case group', 'ArmGroupDescription': 'Patients with acute stroke with nutritional risk', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Observational study, no intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Observational study, no intervention', 'InterventionDescription': 'Observational study, no intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['case group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Nutrition implementation rate', 'PrimaryOutcomeDescription': 'Proportion of patients hospitalized for stroke who were given nutritional support', 'PrimaryOutcomeTimeFrame': 'The first day of admission； the seventh day of admission； the day before discharge.'}, {'PrimaryOutcomeMeasure': 'Nutrition compliance rate of stroke inpatients', 'PrimaryOutcomeDescription': 'Percentage of patients hospitalized for stroke whose nutritional indicators and nutritional status met the guidelines after being given nutritional support', 'PrimaryOutcomeTimeFrame': 'The first day of admission； the seventh day of admission； the day before discharge.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': '30-day post-discharge mortality', 'SecondaryOutcomeDescription': 'Proportion of enrolled patients who died 30 days after discharge from the hospital', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}, {'SecondaryOutcomeMeasure': 'Infection rate', 'SecondaryOutcomeDescription': 'Proportion of enrolled patients with pulmonary infection 30 days after discharge from hospital.', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}, {'SecondaryOutcomeMeasure': 'Readmission rate', 'SecondaryOutcomeDescription': 'Proportion of patients enrolled who were readmitted for various reasons 30 days after discharge.', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}, {'SecondaryOutcomeMeasure': 'Functional prognosis', 'SecondaryOutcomeDescription': 'Functional prognosis of the enrolled patients, such as life skills, motor and sensory functions, cognitive functions and swallowing functions.', 'SecondaryOutcomeTimeFrame': '30-day post-discharge'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nNewly admitted stroke patients admitted to neurology, age ≥18 years, within 7 days of onset, expected survival >3 months (i.e., not end-stage), expected neurology stay 7-10 days；\\nAt risk of malnutrition (MUST ≥ 2 points) or at nutritional risk (NRS2002 ≥ 3 points), sign an informed notice.\\n\\nExclusion Criteria:\\n\\nTransferred during treatment, contraindications to nutritional therapy (e.g., hemodynamic instability, gastrointestinal bleeding (bleeding >100 ml), other nutritional studies, pregnancy.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': \"Newly admitted stroke patients admitted to the neurology unit, ≥18 years of age, within 7 days of onset, expected survival >3 months, expected neurology stay 7-10 days, and at risk of malnutrition (MUST ≥2 points) or at nutritional risk (NRS2002 ≥3 points). Patients' age, sex, hospital, hospitalization number, height, primary diagnosis on admission, and previous underlying disease were collected.\", 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'JinYu Chen, M.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+8615876578154', 'CentralContactEMail': '568344684@qq.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Suyue Pan, M.D., Ph.D.', 'OverallOfficialAffiliation': 'Department of Neurology, Nanfang Hospital, Southern Medical University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'The First Affiliated Hospital of Anhui Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hefei', 'LocationState': 'Anhui', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yajuan Hu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13956912105'}]}}, {'LocationFacility': 'Dongfang Hospital of Beijing University of Chinese Medicine', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Baoxin Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13581546499'}]}}, {'LocationFacility': 'The First Afilliated Hospital of Fujian Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fuzhou', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhiqiang Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13805059300'}]}}, {'LocationFacility': 'Zhongshan Hospital Xiamen University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Xiamen', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lihong Su, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18060486879'}]}}, {'LocationFacility': 'Fujian Province Zhangzhou Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Zhengzhou', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bailing Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15892014859'}]}}, {'LocationFacility': 'Nanfang Hospital of Southern Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'JinYu Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactEMail': '568344684@qq.com'}, {'LocationContactName': 'Suyue Pan, M.D., Ph.D.', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'The First Affiliated Hospital of Guangxi Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanning', 'LocationState': 'Guangxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhijian Liang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13737944579'}]}}, {'LocationFacility': 'The second Affiliated Hospital of Harbin Medical University', 'LocationStatus': 'Recruiting', 'LocationCity': \"Ha'erbin\", 'LocationState': 'Heilongjiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lihua Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13100881600'}]}}, {'LocationFacility': 'Kaifeng Central Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Kai Feng', 'LocationState': 'Henan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yan Zhao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15137884148'}]}}, {'LocationFacility': \"Henan Provincial People'S Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Zhengzhou', 'LocationState': 'Henan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yong Yao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13837136563'}]}}, {'LocationFacility': 'Tongji Hospital of Tongji Medical College of HUST', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wuhan', 'LocationState': 'Hubei', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Furong Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18627126298'}]}}, {'LocationFacility': 'Xiangya Hospital Central South University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Changsha', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Fangfang Bi, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13739064027'}]}}, {'LocationFacility': \"The First People'S Hospital of Kunshan\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Kunshan', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yan Zhang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13962638897'}]}}, {'LocationFacility': 'Nanjing Zijin Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanjing', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Changbao Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13770722709'}]}}, {'LocationFacility': 'Zhongda Hospital Southeast Universtiy', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanjing', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hui Jiao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '1581881150'}]}}, {'LocationFacility': 'The second Affiliated Hospital of Suzhou University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Suzhou', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Weidong Hu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '1351003701'}]}}, {'LocationFacility': \"Yancheng Third People's Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Yancheng', 'LocationState': 'Jiangsu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lijuan Wu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13912569779'}]}}, {'LocationFacility': \"Ganzhou People'S Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Ganzhou', 'LocationState': 'Jiangxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chaohui Lai, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13879729792'}]}}, {'LocationFacility': 'The First Hospital of Jilin University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Changchun', 'LocationState': 'Jilin', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xin Sun, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13596116866'}]}}, {'LocationFacility': 'Qilu Hospital of Shandong University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Jinan', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Qinzhou Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18560085523'}]}}, {'LocationFacility': 'Affiliated Hospital of Jining Medical Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Jining', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shaoying Wu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18678766806'}]}}, {'LocationFacility': \"Linyi People'S Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Linyi', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Guangying Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13695395899'}]}}, {'LocationFacility': 'Qilu Hospital of Shandong University(Qingdao)', 'LocationStatus': 'Recruiting', 'LocationCity': 'Qingdao', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jijun Teng, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18661806108'}]}}, {'LocationFacility': 'The Affiliated Hospital of Qingdao University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Qingdao', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Cuiping Zhao, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18561810336'}]}}, {'LocationFacility': 'Yantai Yuhuangding Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Yantai', 'LocationState': 'Shandong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hong Liu, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13964528128'}]}}, {'LocationFacility': \"The First Affiliated Hospital of Xi'an Jiaotong University\", 'LocationStatus': 'Recruiting', 'LocationCity': \"Xi'an\", 'LocationState': 'Shanxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chen Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13363954570'}]}}, {'LocationFacility': \"Xi'an Encephalopathy of Traditional Chinese Medicine Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': \"Xi'an\", 'LocationState': 'Shanxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Bingcan Yan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13379236669'}]}}, {'LocationFacility': \"Chongqing People's Hospital\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Chongqing', 'LocationState': 'Sichuang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chengqun Wang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15998950878'}]}}, {'LocationFacility': 'Red Cross Hospital of Hangzhou', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hangzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Mingming Ma, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13738132607\\u202c'}]}}, {'LocationFacility': 'Zhejiang Province Xiaoshan Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hanzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kai Fang, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18967168308'}]}}, {'LocationFacility': \"The First People'S Hospital of Jiashan\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Jiaxing', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yingshuai Shi, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18358364799'}]}}, {'LocationFacility': \"The First People'S Hospital of Wenling\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Wenling', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Haibo Cai, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13905565806'}]}}, {'LocationFacility': \"The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU\", 'LocationStatus': 'Recruiting', 'LocationCity': 'Wenzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Beilei Hu', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15858515599'}]}}, {'LocationFacility': 'Wenzhou Hospital of Chinese Medicine', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wenzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ling Chen, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13868403777'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 4, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01578629', 'OrgStudyIdInfo': {'OrgStudyId': '2011H0242'}, 'Organization': {'OrgFullName': 'Ohio State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event', 'OfficialTitle': 'Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA', 'Acronym': 'NUTRITION'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 5, 2012', 'StudyFirstSubmitQCDate': 'April 13, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 17, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 13, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 20, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Andrew Slivka', 'ResponsiblePartyInvestigatorTitle': 'MD, Professor of Neurology', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'}, 'LeadSponsor': {'LeadSponsorName': 'Andrew Slivka', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Government of Malaysia', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I & IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol.', 'DetailedDescription': 'A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and lowers cholesterol, which make it a potential therapy for stroke prevention, though these effects are less well characterized for TCT. We plan to conduct two trials (I & IIA) to determine the effects of orally supplemented TCT on platelet function and cholesterol. Phase I subjects will be healthy volunteers, recruited by an advertisement. Phase IIA subjects will be hyperlipidemic (having high cholesterol), and will be referred to us by their Wound Care Center Physicians. Patients will be randomized to receive placebo pills, (400 or 800 mg) TCT pills, low-dose 81 mg aspirin (commonly used for secondary prevention of stroke), or TCT and aspirin together. Potential subjects for Phase-I who meet study criteria and agree to participate will be in the study for 6 months and have the following study related procedures, blood draw total 4 times, tape stripping (non-invasive procedure), BMI, and blood pressure measurement at each visit (every month). Participants in Phase-IIA will have blood drawn a total of 6 times, tape stripping, BMI and blood pressure measurement and participants will be in the study for 13 months.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke', 'Transient Ischemic Attack (TIA)']}, 'KeywordList': {'Keyword': ['stroke', 'ischemia', 'TIA']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1', 'Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '210', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Healthy Volunteers', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin', 'Other: Placebo vehicle control']}}, {'ArmGroupLabel': 'Hyperlipidemic', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin', 'Other: Placebo vehicle control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin', 'InterventionDescription': 'Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Volunteers', 'Hyperlipidemic']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo vehicle control', 'InterventionDescription': 'vehicle control compared to Vitamin E TCT pills', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Volunteers', 'Hyperlipidemic']}, 'InterventionOtherNameList': {'InterventionOtherName': ['placebo capsule']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Platelet function panel', 'PrimaryOutcomeDescription': 'Blood draw followed by platelet aggregometry', 'PrimaryOutcomeTimeFrame': 'up to one year'}, {'PrimaryOutcomeMeasure': 'Lipid profile', 'PrimaryOutcomeDescription': 'blood lipid panel including HDL, LDL, total cholesterol', 'PrimaryOutcomeTimeFrame': 'up to one year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Tape Stripping Test', 'SecondaryOutcomeDescription': 'HPLC vitamin E analysis of tape strips for compliance', 'SecondaryOutcomeTimeFrame': 'up to one year'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Phase IA\\n\\nInclusion Criteria:\\n\\nHealthy subjects between 40 and 70 years of age\\nNo history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation greater than or equal to 6mos; within the past 5 years)\\nNo current vitamin E supplementation in multivitamin\\n\\nExclusion Criteria - (as self reported by potential participants during review of eligibility criteria with Research Nurse,)\\n\\nEvidence of heart disease as diagnosed by a physician by one or more of the following tests; EKG, chest x-ray, stress test, tilt table test, echocardiogram, coronary angiogram, electrophysiology test, CT heart scan, coronary MRI, pericardiocentesis\\nHigh cholesterol (total cholesterol >240mg/dL, LDL>160mg/dL)\\nPrior cancer diagnosis\\nPregnancy - To exclude the possibility of pregnant women entering the study or becoming pregnant during the study only post-menopausal women or women who have had hysterectomies or bilateral oophorectomies will be included.\\nBreast feeding\\nSmoker (Must have quit 5 or more years ago)\\nAlcohol dependence (>4 drinks per day for more than 1yr anytime in the last 3 years)\\nMedication exclusion criteria - current use or recent discontinuation (within last 28 days) of any medication including the following: anti-coagulants and blood-thinners (e.g., Warfarin), psychotropic medications including antipsychotics, mood-stabilizers (e.g., lithium, valproic acid, carbamazepine/tegretol); anti-depressants (tricyclics, SSRI's, MAOI's, nonselective MAOIs, Wellbutrin, St. John's Wort); anti-anxiety/anti-panic agents; anti-obsessive agents; prescription stimulants (e.g., Provigil, Ritalin); diet pills/anorectics; daily medication for chronic pain (e.g., opiates) or muscle spasms; daily use of over the counter stimulants in pill form (e.g., ephedrine); daily medication for asthma, Parkinson's disease medications (e.g., levodopa, methyldopa, apomorphine), smoking cessation medications (Wellbutrin/Zyban, Chantix/varenicline); statin use is not grounds for exclusion.\\n\\nPhase IIA\\n\\nInclusion Criteria:\\n\\nHyperlipidemic patients between 40 and 70 years of age currently taking statins\\nLDL>130mg/dL\\nTG>150mg/dL\\nHDL<40mg/dL\\nNo history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation greater than or equal to 6mos; within the past 5 years)\\nNo current vitamin E supplementation in multivitamin\\n\\nExclusion Criteria:\\n\\nEvidence of heart disease as diagnosed by a physician by one or more of the following tests; EKG, chest x-ray, stress test, tilt table test, echocardiogram, coronary angiogram, electrophysiology test, CT heart scan, coronary MRI, pericardiocentesis\\nPrior cancer diagnosis\\nCurrently taking blood thinners\\nPregnancy - To exclude the possibility of pregnant women entering the study or becoming pregnant during the study only post-menopausal women or women who have had hysterectomies or bilateral oophorectomy will be included.\\nBreast feeding\\nSmoking (Must have quit within the past 6 months)\\nAlcohol dependence - (>4 drinks per day for more than 1yr anytime in the last 3 years)\\nMedication exclusion criteria - current use or recent discontinuation (within last 28 days) of any medication including the following: anti-coagulants and blood-thinners (e.g., Warfarin), psychotropic medications including antipsychotics, mood-stabilizers (e.g., lithium, valproic acid, carbamazepine/tegretol); anti-depressants (tricyclics, SSRI's, MAOI's, nonselective MAOIs, Wellbutrin, St. John's Wort); anti-anxiety/anti-panic agents; anti-obsessive agents; prescription stimulants (e.g., Provigil, Ritalin); diet pills/anorectics; daily medication for chronic pain (e.g., opiates) or muscle spasms; daily use of over the counter stimulants in pill form (e.g., ephedrine); daily medication for asthma, Parkinson's disease medications (e.g., levodopa, methyldopa, apomorphine), smoking cessation medications (Wellbutrin/Zyban, Chantix/varenicline)\", 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '70 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'The Ohio state University Medical Center', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}, {'ConditionMeshId': 'D000002546', 'ConditionMeshTerm': 'Ischemic Attack, Transient'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000002545', 'ConditionAncestorTerm': 'Brain Ischemia'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5485', 'ConditionBrowseLeafName': 'Ischemic Attack, Transient', 'ConditionBrowseLeafAsFound': 'Transient Ischemic Attack (TIA)', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5484', 'ConditionBrowseLeafName': 'Brain Ischemia', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000001241', 'InterventionMeshTerm': 'Aspirin'}, {'InterventionMeshId': 'D000014810', 'InterventionMeshTerm': 'Vitamin E'}, {'InterventionMeshId': 'D000024505', 'InterventionMeshTerm': 'Tocopherols'}, {'InterventionMeshId': 'D000024508', 'InterventionMeshTerm': 'Tocotrienols'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000014815', 'InterventionAncestorTerm': 'Vitamins'}, {'InterventionAncestorId': 'D000018977', 'InterventionAncestorTerm': 'Micronutrients'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000000894', 'InterventionAncestorTerm': 'Anti-Inflammatory Agents, Non-Steroidal'}, {'InterventionAncestorId': 'D000018712', 'InterventionAncestorTerm': 'Analgesics, Non-Narcotic'}, {'InterventionAncestorId': 'D000000700', 'InterventionAncestorTerm': 'Analgesics'}, {'InterventionAncestorId': 'D000018689', 'InterventionAncestorTerm': 'Sensory System Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000000893', 'InterventionAncestorTerm': 'Anti-Inflammatory Agents'}, {'InterventionAncestorId': 'D000018501', 'InterventionAncestorTerm': 'Antirheumatic Agents'}, {'InterventionAncestorId': 'D000005343', 'InterventionAncestorTerm': 'Fibrinolytic Agents'}, {'InterventionAncestorId': 'D000050299', 'InterventionAncestorTerm': 'Fibrin Modulating Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000010975', 'InterventionAncestorTerm': 'Platelet Aggregation Inhibitors'}, {'InterventionAncestorId': 'D000016861', 'InterventionAncestorTerm': 'Cyclooxygenase Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000058633', 'InterventionAncestorTerm': 'Antipyretics'}, {'InterventionAncestorId': 'D000000975', 'InterventionAncestorTerm': 'Antioxidants'}, {'InterventionAncestorId': 'D000020011', 'InterventionAncestorTerm': 'Protective Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M4238', 'InterventionBrowseLeafName': 'Aspirin', 'InterventionBrowseLeafAsFound': 'Complete', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17243', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Untreated', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22662', 'InterventionBrowseLeafName': 'Tocopherols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M22665', 'InterventionBrowseLeafName': 'Tocotrienols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22659', 'InterventionBrowseLeafName': 'alpha-Tocopherol', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16575', 'InterventionBrowseLeafName': 'Trace Elements', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20699', 'InterventionBrowseLeafName': 'Micronutrients', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3907', 'InterventionBrowseLeafName': 'Anti-Inflammatory Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3908', 'InterventionBrowseLeafName': 'Anti-Inflammatory Agents, Non-Steroidal', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3722', 'InterventionBrowseLeafName': 'Analgesics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20476', 'InterventionBrowseLeafName': 'Analgesics, Non-Narcotic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20294', 'InterventionBrowseLeafName': 'Antirheumatic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8163', 'InterventionBrowseLeafName': 'Fibrinolytic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M13555', 'InterventionBrowseLeafName': 'Platelet Aggregation Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18899', 'InterventionBrowseLeafName': 'Cyclooxygenase Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7641', 'InterventionBrowseLeafName': 'Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M28866', 'InterventionBrowseLeafName': 'Antipyretics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21559', 'InterventionBrowseLeafName': 'Protective Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T480', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Untreated', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T466', 'InterventionBrowseLeafName': 'Tocopherol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T467', 'InterventionBrowseLeafName': 'Tocotrienol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Antipy', 'InterventionBrowseBranchName': 'Antipyretics'}, {'InterventionBrowseBranchAbbrev': 'Infl', 'InterventionBrowseBranchName': 'Anti-Inflammatory Agents'}, {'InterventionBrowseBranchAbbrev': 'ARhu', 'InterventionBrowseBranchName': 'Antirheumatic Agents'}, {'InterventionBrowseBranchAbbrev': 'FiAg', 'InterventionBrowseBranchName': 'Fibrinolytic Agents'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'PlAggInh', 'InterventionBrowseBranchName': 'Platelet Aggregation Inhibitors'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}]}}}}}, {'Rank': 5, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01497886', 'OrgStudyIdInfo': {'OrgStudyId': 'AAAF3455'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01NS067443-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01NS067443-01A1'}]}, 'Organization': {'OrgFullName': 'Columbia University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Intervention to Improve Stroke Recognition', 'OfficialTitle': 'Randomized Controlled Trial Effect of Novel Intervention to Improve Stroke Symptom Recognition'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2011', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 23, 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 16, 2011', 'StudyFirstSubmitQCDate': 'December 22, 2011', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 23, 2011', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 13, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 15, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Olajide Williams', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor of Neurology', 'ResponsiblePartyInvestigatorAffiliation': 'Columbia University'}, 'LeadSponsor': {'LeadSponsorName': 'Columbia University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'CollaboratorClass': 'NIH'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Despite the abundance of stroke education materials available, studies continue to reveal severe deficiencies in stroke literacy (knowledge of symptoms, urgent action, and prevention measures). Expensive mass media stroke education campaigns are not sustainable for this purpose, particularly in economically disadvantaged populations. Instead, the investigators propose to intervene in school classrooms with children aged 9 to 11 years, to teach the five cardinal stroke symptoms, the correct course of action when they occur, and to highlight the potential therapeutic benefit of early hospital arrival, with the intent that the children will then educate their parents. To help accomplish this, the investigators have developed a program called Hip Hop Stroke (HHS), which is comprised of rap songs and two animated musical cartoons that incorporate stroke knowledge.', 'DetailedDescription': 'Stroke is the leading cause of serious long-term adult disability in the U.S. and third leading cause of death, and has a 2-fold greater incidence in Blacks compared to the majority Americans. Thrombolytic revascularization treatment administered within a maximum of 3 hours from symptom onset reduces morbidity, mortality and cost; however, only 3% of patients arrive at the hospital within 3 hours,4 mostly due to the public\\'s lack of knowledge concerning stroke symptoms, and the appropriate response when they are recognized, which is to call 911. The investigators propose to reduce these delays using a novel behavioral intervention to improve symptom recognition and response in a high-risk, minority, economically disadvantaged population. Despite the abundance of stroke education materials available, studies continue to reveal severe deficiencies in stroke literacy (knowledge of symptoms, urgent action, and prevention measures). Expensive mass media stroke education campaigns are not sustainable for this purpose, particularly in economically disadvantaged populations. Instead, the investigators propose to intervene in school classrooms with children aged 9 to 11 years, to teach the five cardinal stroke symptoms, the correct course of action when they occur, and to highlight the potential therapeutic benefit of early hospital arrival, with the intent that the children will then educate their parents. To help accomplish this, the investigators have developed a program called Hip Hop Stroke (HHS), which is comprised of rap songs and two animated musical cartoons that incorporate stroke knowledge.\\n\\nTargeting children to intervene with their parents has been rarely and sporadically attempted in various content areas, but the interventions have used traditional teaching methods that do not engage the children, and little success has been reported. In contrast, the HHS intervention was designed in collaboration with school-aged children, children\\'s education television/media experts, as well as public health experts, school principals, and neurologists. As a result, not only is the targeting of children for this purpose an important innovation, but so is the careful development of materials designed to appeal to them. Moreover, the investigators note that utilizing children as a \"transmission vector\" for carrying out interventions aimed at their parents has the potential to serve as the basis for intervention in any number of other areas, for example, medication adherence, healthy eating and weight loss, treatment of diabetes, and so on.Thus, the significance of the proposed trial addresses the public health problem under study stroke symptom identification and response as well as development and refinement of a more general model of intervention.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Stroke', 'Children', 'Hip Hop Stroke', 'New York City']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '4614', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Hip Hop Stroke educational program', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Hip Hop Stroke educational program']}}, {'ArmGroupLabel': 'Nutrition Education program', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'The investigators will use what they will refer to as a \"usual care\" control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for \"attention\", i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Nutrition Education program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Hip Hop Stroke educational program', 'InterventionDescription': 'Three one-hour sessions, conducted over three consecutive days', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Hip Hop Stroke educational program']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Nutrition Education program', 'InterventionDescription': 'The investigators will use what they will refer to as a \"usual care\" control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for \"attention\", i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nutrition Education program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Stroke Symptom and Response Knowledge Assessment (student)', 'PrimaryOutcomeDescription': 'Knowledge of stroke prevention measures will be assessed by 8 YES/NO questions: 5 real and 3 distracters: eating lots of fruits and vegetables, exercising everyday, always taking medications given by doctor for high blood pressure/diabetes/high cholesterol, smoking avoidance or cessation, avoiding drug abuse, exercising once-a-week, eating lots of red meat, adding salt to meals.', 'PrimaryOutcomeTimeFrame': 'Up to 3 days from baseline'}, {'PrimaryOutcomeMeasure': \"Assessment of child's communication to parent regarding stroke symptoms.\", 'PrimaryOutcomeDescription': 'This measure assesses whether the child has talked with one of the adults in the household about what the child learned in school in both the HHS and control arms concerning symptoms of stroke and correct response.', 'PrimaryOutcomeTimeFrame': 'Up to 7 days from baseline'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Assessment of events, latency to arrival at the emergency room.', 'SecondaryOutcomeDescription': 'The investigators will ask the participating parents to report any diagnosis of stroke received, at 12 months, continuing through the duration of the funding period. If the parent reports a stroke,the investigators will ask for permission to conduct a chart review to confirm the stroke diagnosis, and the treatment given (especially regarding thrombolytic therapy. The investigators will also ask the patient (or family member if the patient is non verbal), who recognized the symptoms (self or other or child) and who called 911.', 'SecondaryOutcomeTimeFrame': '12 months from completion, and every 12 months afterwards'}, {'SecondaryOutcomeMeasure': 'Longitudinal Stroke Symptom and Response Knowledge Assessment (student)', 'SecondaryOutcomeDescription': 'Knowledge of stroke prevention measures will be assessed by 8 YES/NO questions: 5 real and 3 distracters: eating lots of fruits and vegetables, exercising everyday, always taking medications given by doctor for high blood pressure/diabetes/high cholesterol, smoking avoidance or cessation, avoiding drug abuse, exercising once-a-week, eating lots of red meat, adding salt to meals.', 'SecondaryOutcomeTimeFrame': '3 months after participation'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n4th-6th grade children and their parents in selected elementary public schools in the same geographical region/community with similar socioeconomic status (SES) and Ethnic composition.\\n\\nExclusion Criteria:\\n\\nSchool located in Harlem, New York.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '7 Years', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Olajide A. Williams, MD MS', 'OverallOfficialAffiliation': 'Columbia University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Columbia University Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '22875089', 'ReferenceType': 'background', 'ReferenceCitation': 'Williams O, DeSorbo A, Noble J, Shaffer M, Gerin W. Long-term learning of stroke knowledge among children in a high-risk community. Neurology. 2012 Aug 21;79(8):802-6. doi: 10.1212/WNL.0b013e3182661f08. Epub 2012 Aug 8.'}, {'ReferencePMID': '22033995', 'ReferenceType': 'background', 'ReferenceCitation': 'Williams O, DeSorbo A, Noble J, Gerin W. Child-Mediated Stroke Communication: findings from Hip Hop Stroke. Stroke. 2012 Jan;43(1):163-9. doi: 10.1161/STROKEAHA.111.621029. Epub 2011 Oct 27.'}, {'ReferencePMID': '29567762', 'ReferenceType': 'derived', 'ReferenceCitation': 'Williams O, Leighton-Herrmann Quinn E, Teresi J, Eimicke JP, Kong J, Ogedegbe G, Noble J. Improving Community Stroke Preparedness in the HHS (Hip-Hop Stroke) Randomized Clinical Trial. Stroke. 2018 Apr;49(4):972-979. doi: 10.1161/STROKEAHA.117.019861.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T187', 'InterventionBrowseLeafName': 'Hops', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 6, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03635476', 'OrgStudyIdInfo': {'OrgStudyId': 'LIFOCUS'}, 'Organization': {'OrgFullName': 'Cereneo AG', 'OrgClass': 'INDUSTRY'}, 'BriefTitle': 'Survey of Lifelong Food and Nutrition Assistance (LIFANA) in Stroke Patients and Caregivers', 'OfficialTitle': 'Survey of Lifelong Food and Nutrition Assistance (LIFANA) in Stroke Patients and Caregivers - Cereneo Schweiz AG (Center for Neurology and Rehabilitation)'}, 'StatusModule': {'StatusVerifiedDate': 'January 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 20, 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 1, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 14, 2018', 'StudyFirstSubmitQCDate': 'August 14, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 17, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 26, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 27, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Krizia Ferrini', 'ResponsiblePartyInvestigatorTitle': 'Nutritional Specialist', 'ResponsiblePartyInvestigatorAffiliation': 'Cereneo AG'}, 'LeadSponsor': {'LeadSponsorName': 'Cereneo AG', 'LeadSponsorClass': 'INDUSTRY'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'cereneo Institute for Interdsciplinary Research (cefir)', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Many elderly suffer from nutritional problems that can cause (or can be caused by) a number of complications such as weakened immune systems and chronic health conditions (diabetes type 2, high blood pressure, cardiovascular diseases or even osteoporosis).\\n\\nThrough appropriate adjustments in the diets, on the basis of nutritional advice, the burden of established diseases as well as the risks of developing further conditions can be diminished. The goal of our proposed project LIFANA is to develop and evaluate the LIFANA Nutrition Solution to support healthy nutrition.. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists. This is a national project co-funded by the European Union.\\n\\nOne of the activities of the project is to collect information through a survey with patients. These questions will contribute to creating solutions that can explore the perspectives of patients.', 'DetailedDescription': 'Patients will be approached in the clinic by a neurologist and health care professionals. The questionnaire will take place at cereneo. The group will consist of 25 participants and last between 1h. The Survey will be conducted by a clinician who will take notes. Semi-structured discussion guide will be used. With regard to the communication, the moderator will identify factors that will influence communication in a positive or negative way.\\n\\nThe health professionals will perform content analyses on the transcripts; the schema of categories will be oriented towards the research questions, using open questions, directly addressing quiet participants, and handling the discussion guide in a flexible way.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Relatives', 'Diet Modification']}, 'KeywordList': {'Keyword': ['Stroke Rehabilitation', 'Personalized Nutrition', 'Mobile-Health', 'Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Other']}}, 'EnrollmentInfo': {'EnrollmentCount': '5', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Qualitative interview study', 'InterventionDescription': \"The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.\", 'InterventionOtherNameList': {'InterventionOtherName': ['Survey']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'User Needs', 'PrimaryOutcomeDescription': 'The primary endpoint of this study is to explore the perspectives of patients through appropriate adjustments of focus group questions on user needs for managing nutritional status', 'PrimaryOutcomeTimeFrame': '1 day/session'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nstroke patients undergoing rehabilitation\\ncaregivers of stroke patients\\n\\nExclusion Criteria:\\n\\nSevere aphasia\\nSevere cognitive deficits', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'stroke patients undergoing rehabilitation', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Krizia Ferrini, PhD', 'OverallOfficialAffiliation': 'cereneo Schweiz AG | center for neurology & rehabilitation', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Doris Mösinger, MSc', 'OverallOfficialAffiliation': 'cereneo Schweiz AG | center for neurology & rehabilitation', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Leopold Zizlsperger, MD', 'OverallOfficialAffiliation': 'cereneo Schweiz AG | center for neurology & rehabilitation', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'cereneo Schweiz AG', 'LocationCity': 'Vitznau', 'LocationState': 'LU', 'LocationZip': '6354', 'LocationCountry': 'Switzerland'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21550', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 7, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04923165', 'OrgStudyIdInfo': {'OrgStudyId': 'FDG_Nutristroke_2021'}, 'Organization': {'OrgFullName': 'Fondazione Don Carlo Gnocchi Onlus', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutritional Status in Subacute Stroke Patients Under Rehabilitation', 'OfficialTitle': 'Influence of Nutritional Status on Rehabilitation Outcome in Subacute Stroke Patients', 'Acronym': 'Nutristroke'}, 'StatusModule': {'StatusVerifiedDate': 'July 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 4, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 10, 2023', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 10, 2023', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 22, 2021', 'StudyFirstSubmitQCDate': 'June 7, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 11, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 18, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Irene Giovanna Aprile', 'ResponsiblePartyInvestigatorTitle': 'Md, PhD, Principal Investigator, Head of Rehabilitation Unit', 'ResponsiblePartyInvestigatorAffiliation': 'Fondazione Don Carlo Gnocchi Onlus'}, 'LeadSponsor': {'LeadSponsorName': 'Fondazione Don Carlo Gnocchi Onlus', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Recently, is becoming more evident a relationship between malnutrition, stroke-related sarcopenia and/or altered systemic oxidative status in patients with subacute stroke .\\n\\nThe aim of this study is the evaluation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status in patients with subacute stroke outcomes; another aim is to investigate the correlation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status on admission with the rehabilitative outcomes.', 'DetailedDescription': 'Stroke is the third leading cause of mortality and the second leading cause of permanent disability in adults, and is therefore very expensive. Some patients with stroke outcomes, regardless of baseline motor and cognitive function, for unknown reasons show an unexpectedly worse outcome than others and this suggests other factors, in addition to the degree of initial disability, that influence the response to rehabilitative treatment.\\n\\nNutrition is an essential aspect in the overall picture of the stroke patient. Malnutrition in the hospital setting is an important issue that can negatively influence the rehabilitation outcome (Cederholm et al. 2017; 2019).\\n\\nMalnutrition is also responsible for the increase in complications, negatively affects the results of treatment, reduces the immune response and predisposes to infections, delays healing, compromises the function of organs and systems, reduces muscle mass and strength, induces psychic effects with depression and low interest in food.\\n\\nAll this leads to a demand for greater and more prolonged care, with a delay in the recovery of the performance (National Guidelines for hospital and care catering. Min. of Health, 2015).\\n\\nA picture of malnutrition also leads to an alteration of biochemical and haematochemical indexes. Our retrospective pilot study on 30 patients with subacute stroke, showed a positive correlation between the reduction of disability following rehabilitation treatment and the calcium at admission (Siotto et al, 2020). In addition, a recent study with 100 patients admitted to a rehabilitation unit showed that the functional status at the time of admission and the improvement following the rehabilitation program were positively influenced by high blood levels of vitamin D (Lelli et al. 2019).\\n\\nMalnourished patients experience \"sarcopenia\", which is characterized by the reduction of muscle mass and strength, and is a phenomenon strongly related to age: after the age of 70 years, in fact, there is a loss of 15% of muscle mass. It is a risk factor for falls, fractures, physical disability and mortality and it is a phenomenon dependent on various factors such as metabolic imbalance, inactivity, malnutrition and inflammatory states. Sarcopenia is accompanied by body weight loss, neuro-hormonal activation and a systemic shift towards catabolic over-activation (Knops et al. 2013).\\n\\nSarcopenia is frequently found in patients with stroke outcomes and can contribute negatively to the rehabilitation process. A recent study of 267 stroke patients admitted to a rehabilitation unit showed that those with sarcopenia (n=129 48%) had severe lower limb paralysis, lower Body Mass Index (BMI) values and a lower Functional Independence Measure (FIM) score, compared to patients without sarcopenia. In addition, patients with sarcopenia had a longer average stay with less chance of returning home and were less autonomous in walking. Finally, patients with sarcopenia showed a lower recovery of functional autonomy compared to non sarcopenic patients (Matsushita et al. 2019).\\n\\nIn stroke patients there is also \"stroke-related sarcopenia\" (Scherbakov, Sandek, and Doehner 2015) with distinctive features. The reasons are to be attributed to a complex of pathophysiological reactions including: altered neurovegetative control, alterations in the local and systemic metabolic system, difficulty in nutrition and inflammation (Scherbakov, Sandek, and Doehner 2015).\\n\\nSome studies have led to hypothesize a correlation between sarcopenia and systemic oxidative stress. The general oxidative state is the result between levels of circulating oxidants (e.g. peroxides) and levels of endogenous or dietary acquired antioxidants (glutathione or vitamins, such as tocopherols, vitamin E, K). Our research team has recently demonstrated that circulating peroxides increase in stroke and are related to clinical severity (Squitti et al., 2018). The measurement of circulating peroxides evaluates the prooxidant state of a subject because it depends on circulating free radicals (Reactive Oxygen Species, ROS); these molecules have a great chemical reactivity, which, in extreme cases, compromises the function of all cellular macromolecules causing cell death; for this reason it is thought that sarcopenia may be at least partly due to an over-regulation of oxidative metabolism that produces high levels of circulating free radicals (Fulle et al. 2004).\\n\\nThe hypothesis of the study is that there is a negative relationship between malnutrition, stroke-related sarcopenia and/or altered systemic oxidative status in patients on admission and recovery following rehabilitative treatment.\\n\\ntherefore the aims of this study are:\\n\\nEvaluation of nutritional status, presence of stroke-related sarcopenia and systemic oxidative status in patients with subacute stroke outcomes;\\nthe correlation of nutritional status, the presence of stroke-related sarcopenia and systemic oxidative status on admission with the rehabilitative outcome.\\n\\nImproving the nutritional picture of stroke patients from acute or post-acute wards will lead to a faster and more effective motor recovery and improve their autonomies and quality of life. This may lead to a lower impact of disability on families and caregivers and, more generally, a reduction in health care costs.\\n\\nLongitudinal prospective multicentric, non-profit, longitudinal observational study conducted in patients with first stroke (ischemic or hemorrhagic) in subacute phase (within six months after the acute event). The study involves the collection of clinical, instrumental and biochemical data that do not deviate from routine clinical practice. Since it is not an experimental study, no specific intervention is planned; patients will be observed before and after the usual rehabilitative intervention.\\n\\nThe study will have a total duration of 18 months starting in January 2021 and a patient enrolment time of 1 year.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Stroke', 'Nutrition', 'Rehabilitation', 'Oxidative stress', 'Sarcopenia']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '119', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patients with stroke', 'ArmGroupDescription': \"Inpatients and outpatients admitted to the investigators' rehabilitation facility .\", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: robotic assisted intervention', 'Diagnostic Test: biochemical analyses', 'Device: BIA, hand grip', 'Diagnostic Test: nutritional assessment, MNA']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'robotic assisted intervention', 'InterventionDescription': 'Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'biochemical analyses', 'InterventionDescription': 'ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}, {'InterventionType': 'Device', 'InterventionName': 'BIA, hand grip', 'InterventionDescription': 'bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}, {'InterventionType': 'Diagnostic Test', 'InterventionName': 'nutritional assessment, MNA', 'InterventionDescription': 'nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patients with stroke']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'change in Mini nutritional Assessment (MNA) scores', 'PrimaryOutcomeDescription': 'it is a questionnaire that evaluates the nutritional status', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Body Mass Index', 'PrimaryOutcomeDescription': 'it is a measure of body fat based on height and weight that applies to adult men and women expressed in kg/m²', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'weight change', 'PrimaryOutcomeDescription': 'detection of the weight drop or weight increase', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in food income detection', 'PrimaryOutcomeDescription': 'detection of food intake by measurement of portion of dish assumed from the patients', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Bioimpedance analysis (BIA) measurements', 'PrimaryOutcomeDescription': 'it is a non-invasive measurement of body fat, lean muscle mass and hydration', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in hand grip strenght test score', 'PrimaryOutcomeDescription': 'it is a test to measure the maximum isometric strenght of the hand and forearm muscles', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Time Up & Go test (TUG) scores', 'PrimaryOutcomeDescription': 'The Time Up And Go is a test used to assess mobility, balance, and walking in people with balance impairments. The subject must stand up from a chair (which should not be leant against a wall), walk a distance of 3 meters, turn around, walk back to the chair and sit down - all performed as quickly and as safely as possible. Time will be measured using a chronometer.', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Barthel index (BI) scores', 'PrimaryOutcomeDescription': 'The BI is designed to assess the ability of an individual with a neuromuscular or musculoskeletal disorder to care for him/herself. It ranges from 0 to 100, with a higher number meaning better performance in activities of daily living.', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Fugl-Meyer Assessment of Motor Recovery after Stroke for Upper Extremity portion (FMA-UL) scores', 'PrimaryOutcomeDescription': 'The FMA-UL is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. The upper limb portion of the FMA-UL ranges from 0 (hemiplegia) to 66 points (normal upper limb motor performance)', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Motricity Index (MI) scores', 'PrimaryOutcomeDescription': 'The MI aims to evaluate lower limb motor impairment after stroke, administrated on both sides.\\n\\nItems to assess the lower limbs are 3, scoring from 0 to 33 each: (1) ankle dorsiflexion with foot in a plantar flexed position (2) knee extension with the foot unsupported and the knee at 90° (3) hip flexion with the hip at 90° moving the knee as close as possible to the chin. (no movement: 0, palpable flicker but no movement: 9, movement but not against gravity :14, movement against gravity movement against gravity: 19, movement against resistance: 25, normal:33).', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Numerical Rating Scale (NRS) scores', 'PrimaryOutcomeDescription': 'The Numeric Rating Scale (NRS) is the simplest and most commonly used numeric scale to rate the pain from 0 (no pain) to 10 (worst pain).', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Neuropathic Pain Four Questions (DN4) scores', 'PrimaryOutcomeDescription': \"The DN4 used to evaluate presence of neuropathic pain, and consist of a brief interview of four questions answered yes/no: two on what the patient has conceived and two during the exam for the evaluation of hypoesthesia to the touch or sting and the evaluation of allodynia with the skimming of the skin. For each 'yes' a point is assigned. The total score is given by the sum of the individuals. The cut off for the presence of neuropathic pain is '4'.\", 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Modified Ashworth Scale (MAS) scores', 'PrimaryOutcomeDescription': \"The MAS is a 6 point ordinal scale used for grading hypertonia in individuals with neurological diagnoses. A score of 0 on the scale indicates no increase in tone while a score of 4 indicates rigidity. Tone is scored by passively moving the individual's limb and assessing the amount of resistance to movement felt by the examiner.\", 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in 10 Meter Walk Test scores', 'PrimaryOutcomeDescription': \"This test will assess the patient's speed during gait. Patients will be asked to walk at their preferred maximum and safe speed. Patients will be positioned 1 meter before the start line and instructed to walk 10 meters, and pass the end line approximately 1 meter after. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be measured using a stopwatch and recorded to the one hundred of a second (ex: 2.15 s). The test will be recorded 3 times, with adequate rests between them. The average of the 3 times should be recorded.\", 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in Six-Minute Walking Test (6MWT) scores', 'PrimaryOutcomeDescription': 'The 6MWT measures the distance a subject covers during an indoor gait on a flat, hard surface in 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The minimal detectable change in distance for people with sub-acute stroke is 60.98 meters. The 6MWT is a patient self-paced walk test and assesses the level of functional capacity. Patients are allowed to stop and rest during the test. However, the timer does not stop. If the patient is unable to complete the test, the time is stopped at that moment. The missing time and the reason of the stop are recorded. This test will be administered while wearing a pulse oximeter to monitor heart rate and oxygen saturation, also integrated with Borg scale to assess dyspnea.', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in blood levels of systemic oxidative stress (dROMs)', 'PrimaryOutcomeDescription': 'dROMs test measures circulating hydroperoxides (UCarr)', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in antioxydant capacity of serum (BAP)', 'PrimaryOutcomeDescription': 'BAP test measures total antioxidant status in serum in micromol/L', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in thiol serum levels (SHp)', 'PrimaryOutcomeDescription': 'SHp test measures the circulating thiolic antioxidants in serum in micromol/L', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change haemoglobin serum levels', 'PrimaryOutcomeDescription': 'serum measurements of haemoglobin g/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in glucose serum levels', 'PrimaryOutcomeDescription': 'serum measurements of glucose in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in albumine serum levels', 'PrimaryOutcomeDescription': 'serum measurements of glucose in g/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in triglycerides serum levels', 'PrimaryOutcomeDescription': 'serum measurements of triglycerides in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in total cholesterol serum levels', 'PrimaryOutcomeDescription': 'serum measurements of total cholesterol in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in HDL cholesterol serum levels', 'PrimaryOutcomeDescription': 'serum measurements of HDL cholesterol in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in calcium serum levels', 'PrimaryOutcomeDescription': 'serum measurements of calcium in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in magnesium serum levels', 'PrimaryOutcomeDescription': 'serum measurements of magnesium in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in creatinin serum levels', 'PrimaryOutcomeDescription': 'serum measurements of creatinin in mg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in iron serum levels', 'PrimaryOutcomeDescription': 'serum measurements of iron in microg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in latent iron binding capacity serum levels', 'PrimaryOutcomeDescription': 'serum measurements of latent iron binding capacity in microg/dL', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}, {'PrimaryOutcomeMeasure': 'change in hepatic status serum levels (ALT-GPT)', 'PrimaryOutcomeDescription': 'serum measurements o ALT-GPT in U/L', 'PrimaryOutcomeTimeFrame': 'Baseline (T0), Treatment (6 weeks) (T1)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nstroke patients (hemorrhagic or ischemic) documented through Magnetic Resonance Imaging (MRI) or Computed Tomography (CT);\\nage between 18 and 85 years;\\nlatency time within 6 months after the stroke event\\nsufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent\\n\\nExclusion Criteria:\\n\\npresence of a previous stroke based on the medical history;\\nbehavioral and cognitive disorders that may interfere with the therapeutic activity;\\nother orthopedic or neurological complications that may interfere with the rehabilitation protocol;\\ninability to understand and sign informed consent;\\npresence of pacemakers (for interference with bioimpedance measures).', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients with first ischemic stroke (of ischemic or hemorrhagic aetiology) in subacute phase (within six months after the acute event), hospitalized at the participating intensive-extensive rehabilitation centers will be included.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Irene APRILE, MD,PHD', 'OverallOfficialAffiliation': 'IRCCS Fondazione Don Carlo Gnocchi', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Don Gnocchi Foundation', 'LocationCity': 'Rome', 'LocationZip': '00168', 'LocationCountry': 'Italy'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '27642056', 'ReferenceType': 'background', 'ReferenceCitation': 'Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, Jensen GL, Malone A, Muscaritoli M, Nyulasi I, Pirlich M, Rothenberg E, Schindler K, Schneider SM, de van der Schueren MA, Sieber C, Valentini L, Yu JC, Van Gossum A, Singer P. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017 Feb;36(1):49-64. doi: 10.1016/j.clnu.2016.09.004. Epub 2016 Sep 14.'}, {'ReferencePMID': '30181091', 'ReferenceType': 'background', 'ReferenceCitation': 'Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002. Epub 2018 Sep 3.'}, {'ReferencePMID': '20392703', 'ReferenceType': 'background', 'ReferenceCitation': 'Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.'}, {'ReferencePMID': '14724060', 'ReferenceType': 'background', 'ReferenceCitation': 'Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, Vecchiet L, Fano G. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol. 2004 Jan;39(1):17-24. doi: 10.1016/j.exger.2003.09.012.'}, {'ReferencePMID': '23483531', 'ReferenceType': 'background', 'ReferenceCitation': 'Knops M, Werner CG, Scherbakov N, Fiebach J, Dreier JP, Meisel A, Heuschmann PU, Jungehulsing GJ, von Haehling S, Dirnagl U, Anker SD, Doehner W. Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS). J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):199-207. doi: 10.1007/s13539-013-0103-0. Epub 2013 Mar 13.'}, {'ReferencePMID': '30652217', 'ReferenceType': 'background', 'ReferenceCitation': 'Lelli D, Perez Bazan LM, Calle Egusquiza A, Onder G, Morandi A, Ortolani E, Mesas Cervilla M, Pedone C, Inzitari M. 25(OH) vitamin D and functional outcomes in older adults admitted to rehabilitation units: the safari study. Osteoporos Int. 2019 Apr;30(4):887-895. doi: 10.1007/s00198-019-04845-7. Epub 2019 Jan 16.'}, {'ReferencePMID': '25676847', 'ReferenceType': 'background', 'ReferenceCitation': 'Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10.'}, {'ReferencePMID': '29899723', 'ReferenceType': 'background', 'ReferenceCitation': 'Squitti R, Siotto M, Assenza G, Giannantoni NM, Rongioletti M, Zappasodi F, Tecchio F. Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study. Front Neurol. 2018 May 30;9:333. doi: 10.3389/fneur.2018.00333. eCollection 2018.'}, {'ReferencePMID': '31591820', 'ReferenceType': 'background', 'ReferenceCitation': 'Matsushita T, Nishioka S, Taguchi S, Yamanouchi A. Sarcopenia as a predictor of activities of daily living capability in stroke patients undergoing rehabilitation. Geriatr Gerontol Int. 2019 Nov;19(11):1124-1128. doi: 10.1111/ggi.13780. Epub 2019 Oct 7.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Siotto, M., Germanotta, M., Santoro, M., Di Blasi, C., Loreti, C., Mastropaolo, S. & Aprile, I.,Total serum calcium and recovery after rehabilitation in patients with stroke Nov 1 2020, In : Applied Sciences (Switzerland). 10, 21, p. 1-8 8 p., 7893.'}, {'ReferencePMID': '33182716', 'ReferenceType': 'background', 'ReferenceCitation': 'Santoro M, Siotto M, Germanotta M, Bray E, Mastrorosa A, Galli C, Papadopoulou D, Aprile I. BDNF rs6265 Polymorphism and Its Methylation in Patients with Stroke Undergoing Rehabilitation. Int J Mol Sci. 2020 Nov 10;21(22):8438. doi: 10.3390/ijms21228438.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 8, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05477732', 'OrgStudyIdInfo': {'OrgStudyId': 'N202011038'}, 'Organization': {'OrgFullName': 'Taipei Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Bifidobacterium Longum OLP-01 Supplement on Cognitive Function, Exercise Performance, Nutritional Status and Gut Microbiota in Stroke Patients', 'OfficialTitle': 'Effects of Bifidobacterium Longum OLP-01 Supplement on Cognitive Function, Exercise Performance, Nutritional Status and Gut Microbiota in Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 12, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 11, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 11, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'July 18, 2022', 'StudyFirstSubmitQCDate': 'July 25, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 28, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 25, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 28, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Taipei Medical University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a syndrome of acute, focal neurological deficit attributed to vascular injury of the central nervous system. It was the 2nd leading cause of death worldwide and accompanied by high disability rate also increases the social burden.Our research is to investigate the effects of intervention with Bifidobacterium longum OLP-01 on cognitive function, exercise performance, nutritional status and gut microbiota in stroke patients.\\n\\nStudy population:\\n\\nWe will recruit 120 stroke patients and the inclusion criteria are: (1) Aged 20-75 years old, (2) Diagnosed with stroke more than 3 months, (3) Undergoing outpatient rehabilitation and the condition is stable. The exclusion criteria are: (1) Aphasia, dementia or depression, (2) BMI ≥ 35 kg/m2, (3) Cancer treatment in 3 months, (4) Some severe disease may interfere patients to join the study, (5) Failed to cooperate the examination and treatment because of emotion or mental condition.\\n\\nStudy design:\\n\\nA two-arm single-blind randomized controlled clinical trial will be performed for 12 weeks and the subjects will be divided in to 2 groups: (1) placebo group, (2) supplement group. Subjects were asked to supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day or placebo for 12 weeks. Medical history, drug use and life style questionnaires were giving before intervention. Outcomes will be assess in week 0 and week 12 during intervention.\\n\\n3. Outcome assessment:\\n\\nAnthropometry data: height, weight, body mass index, waist circumference, mid-upper arm circumference, hip circumference, calf circumference, waist to hip ratio.\\nBody composition: muscle mass, body fat, basal metabolic rate.\\nClinical data: blood pressure, stroke related characteristics.\\n\\nBlood biochemistry:\\n\\nA. Nutritional status: albumin, prealbumin, transferrin.\\n\\nB. Glycemic profiles: fasting blood glucose, glycated hemoglobin A1c (HbA1c).\\n\\nC. Lipid profiles: total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG).\\n\\nD. Complete blood counts: white blood cells (WBC), red blood cells (RBC), hemoglobin (HB), platelet count (PLT), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC).\\n\\nE. WBC differential counts: neutrophils (NEUT), lymphocytes (LYM), monocytes (MONO), eosinophils (EOS), basophils (BASO).\\n\\nF. C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor alpha (TNF-α).\\n\\nGut microbiota: relative abundance, α-diversity, β-diversity.\\nNutritional status: 3-day dietary record, mini-nutritional assessment (MNA).\\nCognitive function: Montreal cognitive assessment (MoCA), trail-making test A and B (TMT A and B), Stroop color naming test.\\nExercise performance: timed up and go test (TUGT), 6-min walking test.\\n\\nThe purpose of the study is to investigate the intervention of Bifidobacterium longum OLP-01 supplement on cognitive function, physiological performance, nutritional status, and gut microbiota in stroke patients.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Bifidobacterium longum OLP-01', 'Stroke', 'Cognitive function', 'Exercise performance', 'Nutritional status', 'Gut microbiota']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo group', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Subjects in placebo group will treat with placebo.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}}, {'ArmGroupLabel': 'Supplement group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects in supplement group will treat with Bifidobacterium longum OLP-01.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Bifidobacterium longum OLP-01']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Bifidobacterium longum OLP-01', 'InterventionDescription': 'Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Supplement group']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo', 'InterventionDescription': 'Subjects in placebo group will supplement with placebo powder per day for 12 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Montreal cognitive assessment (MoCA)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Montreal cognitive assessment (MoCA)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Montreal cognitive assessment (MoCA) (change)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Trail-making test A and B (TMT A and B)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Trail-making test A and B (TMT A and B)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Trail-making test A and B (TMT A and B) (change)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Stroop color naming test', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Stroop color naming test', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Stroop color naming test (change)', 'PrimaryOutcomeDescription': 'Cognitive function', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Timed up and go test (TUGT)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Timed up and go test (TUGT)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Timed up and go test (TUGT) (change)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': '6-min walking test', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': '6-min walking test', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': '6-min walking test (change)', 'PrimaryOutcomeDescription': 'Exercise performance', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Albumin (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Pre-albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Pre-albumin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Pre-albumin (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Transferrin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Transferrin', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Transferrin (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': '3-day dietary record', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': '3-day dietary record', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': '3-day dietary record (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Mini-nutritional assessment (MNA)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Mini-nutritional assessment (MNA)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'Mini-nutritional assessment (MNA) (change)', 'PrimaryOutcomeDescription': 'Nutritional Status', 'PrimaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'PrimaryOutcomeMeasure': 'Relative abundance', 'PrimaryOutcomeDescription': 'Gut microbiota Use the 16s RNA sequencing to conduct the next generation sequencing (NGS) measure the relative abundance, including the phylum, class, family, genus.', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'Relative abundance', 'PrimaryOutcomeDescription': 'Gut microbiota Use the 16s RNA sequencing to conduct the next generation sequencing (NGS) measure the relative abundance, including the phylum, class, family, genus.', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'α-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'α-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 12'}, {'PrimaryOutcomeMeasure': 'β-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 0'}, {'PrimaryOutcomeMeasure': 'β-diversity', 'PrimaryOutcomeDescription': 'Gut microbiota', 'PrimaryOutcomeTimeFrame': 'Week 12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Height', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Height', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Height (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Weight', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Weight', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Weight (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Body mass index (BMI)', 'SecondaryOutcomeDescription': 'Anthropometry data Weight and height will be combined to report BMI in kg/m^2', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Body mass index (BMI)', 'SecondaryOutcomeDescription': 'Anthropometry data Weight and height will be combined to report BMI in kg/m^2', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Body mass index (BMI) (change)', 'SecondaryOutcomeDescription': 'Anthropometry data Weight and height will be combined to report BMI in kg/m^2', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Waist circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Waist circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Waist circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mid-upper arm circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mid-upper arm circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mid-upper arm circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Hip circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Hip circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Hip circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Calf circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Calf circumference', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Calf circumference (change)', 'SecondaryOutcomeDescription': 'Anthropometry data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Waist to hip ratio', 'SecondaryOutcomeDescription': 'Anthropometry data Waist circumference and hip circumference will be combined to report waist to hip ratio', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Waist to hip ratio', 'SecondaryOutcomeDescription': 'Anthropometry data Waist circumference and hip circumference will be combined to report waist to hip ratio', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Waist to hip ratio (change)', 'SecondaryOutcomeDescription': 'Anthropometry data Waist circumference and hip circumference will be combined to report waist to hip ratio', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Muscle mass', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Muscle mass', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Muscle mass (change)', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Body fat', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Body fat', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Body fat (change)', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Basal metabolic rate', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Basal metabolic rate', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Basal metabolic rate (change)', 'SecondaryOutcomeDescription': 'Body composition', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Blood pressure', 'SecondaryOutcomeDescription': 'Clinical data', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Blood pressure', 'SecondaryOutcomeDescription': 'Clinical data', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Blood pressure (change)', 'SecondaryOutcomeDescription': 'Clinical data', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Stroke related characteristics (including the time since stroke diagnosed, side of lesion, stroke type, use of aid)', 'SecondaryOutcomeDescription': 'Stroke related characteristics would collect form clinical data or ask form subjects directly', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Stroke related characteristics (including the time since stroke diagnosed, side of lesion, stroke type, use of aid)', 'SecondaryOutcomeDescription': 'Stroke related characteristics would collect form clinical data or ask form subjects directly', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Medical history, drug use and life style questionnaires', 'SecondaryOutcomeDescription': 'Clinical data This questionnaires including 3 parts (medical history, drug use and life style). Medical history and drug use will write by subjects. Life style (e.g. smocking habit, exercise frequency) will ask the subjects.', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Medical history, drug use and life style questionnaires', 'SecondaryOutcomeDescription': 'Clinical data This questionnaires including 3 parts (medical history, drug use and life style). Medical history and drug use will write by subjects. Life style (e.g. smocking habit, exercise frequency) will ask the subjects.', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Fasting blood glucose', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Fasting blood glucose', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Fasting blood glucose (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Glycated hemoglobin A1c (HbA1c)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Glycated hemoglobin A1c (HbA1c)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Glycated hemoglobin A1c (HbA1c) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Total cholesterol (TC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Total cholesterol (TC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Total cholesterol (TC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'High density lipoprotein cholesterol (HDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'High density lipoprotein cholesterol (HDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'High density lipoprotein cholesterol (HDL-C) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Low density lipoprotein cholesterol (LDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Low density lipoprotein cholesterol (LDL-C)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Low density lipoprotein cholesterol (LDL-C) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Triglycerides (TG)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Triglycerides (TG)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Triglycerides (TG) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'White blood cells (WBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'White blood cells (WBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'White blood cells (WBC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Red blood cells (RBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Red blood cells (RBC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Red blood cells (RBC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Hemoglobin (HB)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Hemoglobin (HB)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Hemoglobin (HB) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Platelet count (PLT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Platelet count (PLT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Platelet count (PLT) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Hematocrit (HCT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Hematocrit (HCT)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Hematocrit (HCT) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular volume (MCV)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular volume (MCV)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular volume (MCV) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin (MCH)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin (MCH)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin (MCH) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin concentration (MCHC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin concentration (MCHC)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Mean corpuscular hemoglobin concentration (MCHC) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Neutrophils (NEUT)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Neutrophils (NEUT)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Neutrophils (NEUT)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Lymphocytes (LYM)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Lymphocytes (LYM)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Lymphocytes (LYM)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Monocytes (MONO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Monocytes (MONO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Monocytes (MONO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Eosinophils (EOS)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Eosinophils (EOS)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Eosinophils (EOS)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Basophils (BASO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Basophils (BASO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Basophils (BASO)', 'SecondaryOutcomeDescription': 'Blood biochemistry (WBC counts)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α)', 'SecondaryOutcomeDescription': 'Blood biochemistry (cytokines)', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α)', 'SecondaryOutcomeDescription': 'Blood biochemistry (cytokines)', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry (cytokines)', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}, {'SecondaryOutcomeMeasure': 'C-reactive protein (CRP)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 0'}, {'SecondaryOutcomeMeasure': 'C-reactive protein (CRP)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'C-reactive protein (CRP) (change)', 'SecondaryOutcomeDescription': 'Blood biochemistry', 'SecondaryOutcomeTimeFrame': 'Change from week 0 to week 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria\\n\\nAged 20-75 years old\\nDiagnosed with stroke more than 3 months\\nUndergoing outpatient rehabilitation and the condition is stable\\n\\nExclusion criteria\\n\\nAphasia, dementia or depression\\nBMI ≥ 35 kg/m2\\nCancer treatment in 3 months\\nSome severe disease may interfere patients to join the study\\nFailed to cooperate the examination and treatment because of emotion or mental condition.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '25 Years', 'MaximumAge': '75 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Chao Jane C-J, PhD', 'OverallOfficialAffiliation': 'Taipei Medical University, Taiwan, R.O.C.', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of rehabilitation, ShuangHo Hospital', 'LocationCity': 'New Taipei City', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Department of rehabilitation, Taipei Medical University Hospital', 'LocationCity': 'Taipei city', 'LocationCountry': 'Taiwan'}, {'LocationFacility': 'Department of rehabilitation, WanFang Hospital', 'LocationCity': 'Taipei city', 'LocationCountry': 'Taiwan'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M15891', 'InterventionBrowseLeafName': 'Sulfalene', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T367', 'InterventionBrowseLeafName': 'Bifidobacterium', 'InterventionBrowseLeafAsFound': 'Cap', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}]}}}}}, {'Rank': 9, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02856009', 'OrgStudyIdInfo': {'OrgStudyId': 'Béjot 2015'}, 'Organization': {'OrgFullName': 'Centre Hospitalier Universitaire Dijon', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Role of Nutrition in Patients Over 75 Years of Age With Stroke', 'OfficialTitle': 'Impact of Nutritional Status and Frailty on the Prognosis of Patients Over 75 Years Old Who Suffered a Stroke', 'Acronym': 'INFRA'}, 'StatusModule': {'StatusVerifiedDate': 'July 2016', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 2015', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2016', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2016', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'August 2, 2016', 'StudyFirstSubmitQCDate': 'August 3, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 4, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 9, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 10, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Centre Hospitalier Universitaire Dijon', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Stroke in elderly subjects has a more severe clinical presentation (in terms of frequency of aphasia, hemiplegia or consciousness disorders), and a worse functional and vital prognosis. Patients older than 75 years also show excess mortality. One of the hypotheses to explain this situation is the high level of frailty in this population. Many tools to measure the concept of frailty have been developed. One important dimension of these tools is the nutritional status. Indeed, protein-energy malnutrition in the elderly, though a frequent situation, is also a complex phenomenon.\\n\\nThe aim of this study is therefore to analyse the impact of protein-energy malnutrition, as a marker of frailty, on the early prognosis (at 28 days) in the aftermath of stroke in subjects older than 75 years hospitalized in Dijon CHU.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '177', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'patient', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: completion of a quality of life questionnaire']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'completion of a quality of life questionnaire', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['patient']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Mortality rate', 'PrimaryOutcomeTimeFrame': 'Day 28'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with symptomatic stroke defined according to WHO criteria (including cerebral infarction and intracerebral haemorrhage) managed at the stroke ICU, Neurology 1, Neurology 2, Internal Medicine 2 or Geriatrics at Dijon CHU during the period from 1st November 2015 to 30th September 2016.\\nPatients aged 75 years and older.\\nPatients who have provided informed consent to take part in the study.\\n\\nExclusion Criteria:\\n\\nPatients with meningeal haemorrhage or TIA.\\nPatients who refuse to take part in the study.\\nPatients with hypo-albuminemia not related to malnutrition: chronic infectious or inflammatory syndrome, nephrotic syndrome, exudative enteropathy, hydration disorders.\\nSubjects in custody.\\nPatients (or person of trust) who cannot be contacted by telephone during the follow-up.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '75 Years', 'StdAgeList': {'StdAge': ['Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Centre Hospitalier Universitaire', 'LocationCity': 'Dijon', 'LocationZip': '21079', 'LocationCountry': 'France'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M1175', 'ConditionBrowseLeafName': 'Frailty', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 10, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01721538', 'OrgStudyIdInfo': {'OrgStudyId': 'SCENARIO OP1'}, 'Organization': {'OrgFullName': 'Philipps University Marburg Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction', 'OfficialTitle': 'Secondary Prevention of Stroke Through Participation in the Non-drug Therapeutic Weight Reduction Program: A Single-blinded Randomized Controlled Multicenter Trial', 'Acronym': 'SCENARIO'}, 'StatusModule': {'StatusVerifiedDate': 'November 2012', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 2015', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 2015', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 1, 2012', 'StudyFirstSubmitQCDate': 'November 2, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 4, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'November 2, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 4, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Dr. Yaroslav Winter', 'ResponsiblePartyInvestigatorTitle': 'Neurologist and Research Fellow', 'ResponsiblePartyInvestigatorAffiliation': 'Philipps University Marburg Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Philipps University Marburg Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Von Behring-Röntgen Foundation', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms. The therapy arm is participating in a comprehensive weight reducing program, whereas the control group takes part in a lecture on healthy nutrition. The primary study objective is to assess the efficacy of non-drug therapeutic weight reduction in the secondary prevention of stroke. Secondary objectives are functional outcome, cognitive status, post stroke depression, and health-related quality of life.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Obesity']}, 'KeywordList': {'Keyword': ['stroke', 'prevention', 'obesity', 'weight reduction']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '200', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Therapy arm', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Non-drug therapeutic weight reduction program (15 weeks)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Weight reduction program']}}, {'ArmGroupLabel': 'Control arm', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Lecture on healthy nutrition (1 hour)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Lecture on healthy nutrition']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Weight reduction program', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Therapy arm']}}, {'InterventionType': 'Other', 'InterventionName': 'Lecture on healthy nutrition', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control arm']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The primary endpoint is the number of deaths or major vascular events defined as stroke, TIA, myocardial infarction or hospitalization due to angina pectoris, which occur between the randomization and last follow-up.', 'PrimaryOutcomeTimeFrame': '18 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Functional outcome', 'SecondaryOutcomeDescription': 'Functional outcome as measured by the modified Rankin Scale (mRS), NIH Stroke Scale (NIHSS) and Barthel Index (BI)', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': 'Cognitive deficits', 'SecondaryOutcomeDescription': 'Cognitive deficits in terms of vascular dementia as measured by the Structural Interview for diagnosis of Alzheimer dementia and multi-infarct dementia (SIDAM), the Vascular Dementia Assessment Scale cognitive subscale (VADAS-Cog), Stroop test and the Trail Makin Test', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': 'Post stroke depression', 'SecondaryOutcomeDescription': 'Post stroke depression as measured by Beck Depression Inventar (BDI II) and health-related quality of life (HrQoL) as measured by the EuroQol (EQ5D, visual analogue scale), Stroke Specific Quality of Life Scale, Stroke Impact Scale.', 'SecondaryOutcomeTimeFrame': '18 months'}, {'SecondaryOutcomeMeasure': 'Severity of arterial hypertension, diabetes mellitus and hyperlipidemia', 'SecondaryOutcomeTimeFrame': '18 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nDiagnosis of ischemic stroke\\nAge: 20 - 85 years\\nBMI ≥ 25.0 kg/m² or waist circumference in men ≥ 94cm and in women ≥ 80cm\\nFunctional impairment, which would allow to participate in weight reduction program (mRS 0-4, NIHSS 0-12)\\nPatient must be capable of understanding informed consent\\nWritten informed consent for participation in the study\\n\\nExclusion Criteria:\\n\\nIntracerebral hemorrhage as primary cause of stroke (secondary hemorrhage is not an exclusion criterion)\\nSpeech disturbance (aphasia or sever dysarthria)\\nDimming of consciousness\\nStroke due to arterial dissection or coagulation disorder\\nDrug-related weight changes during previous 3 months\\nChanges in appetite influencing medication listed in appendix during previous 3 months\\nBariatric surgery in the past\\nDiabetes mellitus with a history of severe ketoacidosis\\nPregnancy or nursing\\n\\nSevere co-morbid disorders, e.g.:\\n\\nAV-Block ≥ 2nd degree\\nHeart insufficiency (NYHA > 2)\\nPericarditis, pericardial effusion\\nSevere kidney insufficiency (Creatinine > 3 mg/dl; Urea > 150 mg/dl)\\nHepatic insufficiency (GOT > 3 x ULN; GPT > 3 x ULN)\\nSevere psychiatric disease within the last six months (psychosis, suicide attempts)\\nChronic alcohol addiction or drug addiction\\nHIV- or hepatitis infection\\nBleeding peptic ulcer (unless there is radiological evidence of healing 6 months prior to start of obesity program)\\nCognitive impairment with MMSE < 20\\nDepression with BDI > 20\\nPatients who are unable to give consent to study participation (MMSE < 20, aphasia)\\nRecurrent stroke or myocardial infarction in the period between screening for study participation and start of weight reduction program\\nSimultaneous participation in another clinical trial', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Yaroslav Winter, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '00496421-5865200', 'CentralContactEMail': 'wintery@med.uni-marburg.de'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Neurology, Philipps-University Marburg', 'LocationStatus': 'Recruiting', 'LocationCity': 'Marburg', 'LocationCountry': 'Germany', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Winter Yaroslav, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '004964215865200', 'LocationContactEMail': 'wintery@med.uni-marburg.de'}, {'LocationContactName': 'Yaroslav Winter, MD', 'LocationContactRole': 'Principal Investigator'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '18703800', 'ReferenceType': 'background', 'ReferenceCitation': 'Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J, Back T. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke. 2008 Dec;39(12):3145-51. doi: 10.1161/STROKEAHA.108.523001. Epub 2008 Aug 14.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000015431', 'ConditionMeshTerm': 'Weight Loss'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}, {'ConditionAncestorId': 'D000001836', 'ConditionAncestorTerm': 'Body Weight Changes'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17792', 'ConditionBrowseLeafName': 'Weight Loss', 'ConditionBrowseLeafAsFound': 'Weight Reduction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11997', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4805', 'ConditionBrowseLeafName': 'Body Weight Changes', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}]}}}}}, {'Rank': 11, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04259307', 'OrgStudyIdInfo': {'OrgStudyId': '2019-06-109'}, 'Organization': {'OrgFullName': 'Samsung Medical Center', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Intensive Nutritional Support in Subacute Stroke Patient', 'OfficialTitle': 'Effect of Intensive Nutritional Support on Functional Recovery in Subacute Stroke Patient'}, 'StatusModule': {'StatusVerifiedDate': 'May 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 29, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 31, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 4, 2020', 'StudyFirstSubmitQCDate': 'February 4, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 6, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 5, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 9, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Won Hyuk Chang', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Samsung Medical Center'}, 'LeadSponsor': {'LeadSponsorName': 'Samsung Medical Center', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Korean Center for Disease Control and Prevention', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Proper nutritional support during early rehabilitation may be beneficial for functional improvements in gaining functional independence and preventing complications in stroke patients. However, there was no consensus of proper amount of nutritional support in stroke patients. In this study, the investigators aimed to clarigy the effects of the intensive nutritional support during comprehensive rehabilitation during subacute phase to improve function in patients with first-ever strokes.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Rehabilitation', 'Nutrition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '150', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intensive nutrition group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Omapone Peri 724mL or Winuf Peri 654mL']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Standard nutritional support only per day for 3 weeks'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Omapone Peri 724mL or Winuf Peri 654mL', 'InterventionDescription': 'Additional intravenous nutrition of 500 kcal per day for 3 weeks', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intensive nutrition group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Comprehensive rehabilitation']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Korean modified Barthel Index (K-MBI) at 6 months after onset', 'PrimaryOutcomeDescription': 'Korean modified Barthel Index (0~100)', 'PrimaryOutcomeTimeFrame': '6 months after onset'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAcute first-ever stroke patients less than 7 days after onset\\n\\nmore than 19 years old at stroke onset ③ stroke confirmed by brain CT or MRI\\n\\nbody mass index (BMI) <25 before the comprehensive rehabilitation ⑤ Mini Nutritional Assessment < 12 before the comprehensive rehabilitation ⑥ Fugl-Meyer assessment < 85 at 7 days after stroke onset\\n\\nExclusion Criteria:\\n\\nTransient ischemic stroke\\n\\nProgressive or unstable stroke\\n\\nPre-existing and active major neurological disease, e.g., spinal cord injury, Parkinson's disease, et al.\\n\\nPre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease or dementia ⑤ Advanced liver, kidney, cardiac, or pulmonary disease, e.g., advanced hepatocellular carcinoma, end-stage renal failure, et al.)\\n\\nA terminal medical diagnosis consistent with survival < 1 year\\n\\nDiabetes mellitus, Hyperlipidemia, Metabolic syndrome, Heart failure) ⑧ Pregnant or lactating women ⑨ Prohibited from taking medication (Omapone Peri 724mL or Winuf Peri 654mL)\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '19 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Won Hyuk Chang, MD.,PhD.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '82-2-3410-6068', 'CentralContactEMail': 'wh.chang@samsung.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Samsung Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Seoul', 'LocationZip': '135-710', 'LocationCountry': 'Korea, Republic of', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Won Hyuk Chang, Prof', 'LocationContactRole': 'Contact', 'LocationContactPhone': '82-2-3410-6068', 'LocationContactEMail': 'wh.chang@samsung.com'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 12, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01858311', 'OrgStudyIdInfo': {'OrgStudyId': '2012H0113'}, 'Organization': {'OrgFullName': 'Ohio State University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutrition Blood Outcomes Following Tocotrienol N2B', 'OfficialTitle': 'Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB', 'Acronym': 'NIIB'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2013'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2018', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 9, 2013', 'StudyFirstSubmitQCDate': 'May 20, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 21, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 13, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 20, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Andrew Slivka', 'ResponsiblePartyInvestigatorTitle': 'MD, Professor of Neurology', 'ResponsiblePartyInvestigatorAffiliation': 'Ohio State University'}, 'LeadSponsor': {'LeadSponsorName': 'Ohio State University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Malaysia Palm Oil Board', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol lowering properties, both of which may benefit stroke survivors. This study is being conducted to determine the blood thinning and cholesterol lowering properties of TCT in stroke or TIA (transient ischemic attack, which is also referred to as a \"mini-stroke\") survivors that are receiving the standard treatment for prevention of recurrent stroke.\\n\\nStudy Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders, increases the extent of inhibition of platelet aggregation, and decreases LDL without significant side effects in stroke patients.', 'DetailedDescription': 'In this Phase IIB trial the goal is to determine the effects of orally supplemented TCT on platelet function and cholesterol as well as the safety in patients with TIA (transient ischemic attack) or stroke in addition to the standard treatment for stroke prevention. Recurrent cardiovascular events including stroke, TIA, heart attack, venous thrombosis, pulmonary embolism, systemic embolism will also be recorded. In patients with recurrent stroke, severity of the stroke and stroke size measured from MR (magnetic resonance) or CT (computed tomography) imaging will also be collected. We expect that TCT will inhibit blood clotting and lower cholesterol more than current standard treatment without significantly increasing bleeding risks or other side effects. Future work is planned in a larger TIA/stroke population to examine whether TCT adds to standard medical care in terms of decreasing incidence of stroke and improving outcomes following stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Stroke survivors', 'TIA survivors', 'Vitamin E', 'Carotech', 'Tocotrienol']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Blood Draw'}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Placebo vehicle', 'ArmGroupDescription': '(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo Vehicle']}}, {'ArmGroupLabel': 'Tocotrienol capsules (400 mg)', 'ArmGroupDescription': '(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Tocotrienol Capsules']}}, {'ArmGroupLabel': 'Tocotrienol Capsules (800 mg)', 'ArmGroupDescription': '(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Tocotrienol Capsules']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Tocotrienol Capsules', 'InterventionDescription': 'Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Tocotrienol Capsules (800 mg)', 'Tocotrienol capsules (400 mg)']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo Vehicle', 'InterventionDescription': 'Placebo capsules per day (2 in the morning and 2 in the evening)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Placebo vehicle']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'platelet aggregation activity', 'PrimaryOutcomeDescription': 'Platelet aggregation activity will be measured using standard clinical laboratory procedures', 'PrimaryOutcomeTimeFrame': 'up to 1 year'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Incidence of recurrent stroke', 'SecondaryOutcomeDescription': 'Incidence of recurrent stroke after previous diagnosed stroke or TIA.', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA (transient ischemic attack) for whom anticoagulation is not indicated\\nEnrollment in trial must occur within 6 months of clinical presentation for first stroke or TIA event\\nNo history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation at least 6mos; within the past 5 years)\\nNo current vitamin E supplementation in multi-vitamin\\n\\nExclusion Criteria:\\n\\nDisabling stroke ( Modified Rankin Scale > 3)\\nPrior intracranial hemorrhage (excluding traumatic)\\nHigh risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active peptic ulcer disease)\\nAnticipated requirement for long term use of anticoagulation\\nContraindications to antiplatelet agents (bleeding disorder, thrombocytopenia, prolonged INR)\\nIrreversible medical condition likely to affect short-term survival or ability to participate in study such as cancer or other chronic disease with predicted survival of less than a year or severe psychiatric or neurologic disease that might complicate evaluation of study outcomes like dementia or schizophrenia\\nPregnancy or women of child bearing age who are not following an effective method of contraception\\nBreast feeding\\nUnable or unwilling to provide informed\\nUnlikely to be compliant with therapy or unwilling to return for follow up frequent clinic visits\\nConcurrent participation in another study with an investigational drug or devise\\nOther likely specific cause of stroke such as dissection, infectious or noninfectious vasculitis, prothrombotic state', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Stroke survivors within 6 months of clinical presentation for ischemic stroke or TIA event', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'The Ohio State University', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mount Carmel Health System', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43213', 'LocationCountry': 'United States'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000024508', 'InterventionMeshTerm': 'Tocotrienols'}, {'InterventionMeshId': 'D000014810', 'InterventionMeshTerm': 'Vitamin E'}, {'InterventionMeshId': 'D000024505', 'InterventionMeshTerm': 'Tocopherols'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000975', 'InterventionAncestorTerm': 'Antioxidants'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000020011', 'InterventionAncestorTerm': 'Protective Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000014815', 'InterventionAncestorTerm': 'Vitamins'}, {'InterventionAncestorId': 'D000018977', 'InterventionAncestorTerm': 'Micronutrients'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M17243', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22662', 'InterventionBrowseLeafName': 'Tocopherols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M22665', 'InterventionBrowseLeafName': 'Tocotrienols', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M22659', 'InterventionBrowseLeafName': 'alpha-Tocopherol', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21559', 'InterventionBrowseLeafName': 'Protective Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16575', 'InterventionBrowseLeafName': 'Trace Elements', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20699', 'InterventionBrowseLeafName': 'Micronutrients', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T480', 'InterventionBrowseLeafName': 'Vitamin E', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T466', 'InterventionBrowseLeafName': 'Tocopherol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T467', 'InterventionBrowseLeafName': 'Tocotrienol', 'InterventionBrowseLeafAsFound': 'Autoimmune Diseases', 'InterventionBrowseLeafRelevance': 'high'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}]}}}}}, {'Rank': 13, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03844139', 'OrgStudyIdInfo': {'OrgStudyId': 'zhang yuejiao'}, 'Organization': {'OrgFullName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect and Complication of Two Types of Nasogastric Tube Feeding for Elderly Dysphagia Patient After Stroke', 'OfficialTitle': 'Observation of Effect and Complication of Two Types of Nasogastric Tube Feeding Enteral Nutrition for Elderly Dysphagia Patients After Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'February 2020', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 13, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 31, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 1, 2019', 'StudyFirstSubmitQCDate': 'February 13, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 18, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'February 11, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 13, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Dysphagia is a common problem after stroke.Patients after stroke with swallow problem will have a nasogastric tube to be feeded. In this study , investigators have including and excluding criteria. Continous feeding group and intermittent feeding group had been widely used in enteral nutrition feeding in investigators' institution. Investigators will observe participants' nutrition condition and tube-feeding related complications. In continous group patients, participants usually are given prescribed enteral nutrient solution using nutrition pump in 24 hours; while in intermittent feeding group, participants will be given prescribed enteral nutrient solution in 4-5 times by special syringe. During the whole process, investigators will observe all participants' nutrition condition (body mass index, plasma albumin and calf girth) and tube-feeding related complications( regurgitation, aspiration,gastric retention, diarrhea,constipation). With all those data, the investigators will assess which feeding type is better.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Deglutition Disorders']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '100', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Feeding pump group(continous)', 'ArmGroupDescription': 'Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Feeding pump and glycerin syringe']}}, {'ArmGroupLabel': 'Glycerin syringe group(intermittent)', 'ArmGroupDescription': 'Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Feeding pump and glycerin syringe']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Feeding pump and glycerin syringe', 'InterventionDescription': 'The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Feeding pump group(continous)', 'Glycerin syringe group(intermittent)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'weight', 'PrimaryOutcomeDescription': 'weight in kilogram every week', 'PrimaryOutcomeTimeFrame': '4-6 weeks'}, {'PrimaryOutcomeMeasure': 'plasma albumin', 'PrimaryOutcomeDescription': 'plasma albumin every week', 'PrimaryOutcomeTimeFrame': '4-6 weeks'}, {'PrimaryOutcomeMeasure': 'tube-feeding related complications( regurgitation, aspiration,gastric retention, diarrhea,constipation)', 'PrimaryOutcomeDescription': 'incidence of each complication', 'PrimaryOutcomeTimeFrame': '4-6 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'calf girth', 'SecondaryOutcomeDescription': 'length of calf girth', 'SecondaryOutcomeTimeFrame': '4-6 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nOlder than 65 years old\\nClinical diagnosis of stroke( ischemic and hemorrhage)\\nWith moderate and/or sever swallow problem(water swallow test IV-V degree)\\nWith nasogastric feeding tube more than 4 weeks\\nDo rehabilitation in our hospital or designated hospitals\\n\\nExclusion Criteria:\\n\\nWithout nasogastric feeding tube\\nPatients with fever and other infection\\nChronic or acute anoxia\\nPoor obedience\\nQuit treatment or go back home to take rehabilitation\\nCritically ill or died', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '65 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'Every 50 patients in each group', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Zhang Yuejiao, Bachelor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+8613606525359', 'CentralContactEMail': '2507088@zju.edu.cn'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Zhangy Yuejiao', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hangzhou', 'LocationState': 'Zhejiang', 'LocationZip': '310009', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhangy Yuejiao', 'LocationContactRole': 'Contact'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000005990', 'InterventionMeshTerm': 'Glycerol'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000003451', 'InterventionAncestorTerm': 'Cryoprotective Agents'}, {'InterventionAncestorId': 'D000020011', 'InterventionAncestorTerm': 'Protective Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M21550', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8786', 'InterventionBrowseLeafName': 'Glycerol', 'InterventionBrowseLeafAsFound': 'Generate', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M21559', 'InterventionBrowseLeafName': 'Protective Agents', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 14, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05728229', 'OrgStudyIdInfo': {'OrgStudyId': '0033318/22'}, 'Organization': {'OrgFullName': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Nutrition on Post Stroke Fatigue', 'OfficialTitle': 'Effetti Della Nutrizione Sulla Fatica Post Stroke', 'Acronym': 'NUTRE-S'}, 'StatusModule': {'StatusVerifiedDate': 'August 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 7, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 4, 2023', 'StudyFirstSubmitQCDate': 'February 4, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 15, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 1, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 2, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'GIOVANNINI SILVIA', 'ResponsiblePartyInvestigatorTitle': 'Principal investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS'}, 'LeadSponsor': {'LeadSponsorName': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Fatigue, which is commonly defined as a feeling of tiredness during or after usual activities, or a feeling of insufficient energy to initiate these activities, is one of the most common secondary conditions among patients presenting with stroke.\\n\\nPost Stroke Fatigue (PSF) is a multidimensional motor-perceptual, emotional, and cognitive experience characterized by a feeling of early exhaustion with tiredness, lack of energy, and difficulty making efforts, which develops during physical or mental activities, and usually does not improve with rest.\\n\\nTo try to counteract fatigue and its effects on daily life activities, in addition to the known pharmacological approach (Modafinil), the use of vitamins and minerals is known to mitigate, among others, the effects of fatigue. Nutrients provide the energy needed to maintain the body\\'s structural and biochemical integrity. Energy is associated with a feeling of well-being, increased stamina and vitality which often translates into the ability to undertake daily physical or cognitive activities and social relationships, as opposed to fatigue.\\n\\nA common feature of fatigue is a \"sense of energy exhaustion\" which can objectively be related to not enough energy. Physical and cognitive tiredness occurs when the continuous demand for energy from the brain and muscles is not met. In humans, dietary macronutrients provide the fuel needed, among other things, to perform physical activity. In fact, mineral salts and vitamins are essential for the production of cellular energy, for the maintenance of brain structures and for allowing the formation of intercellular connections.\\n\\nWhen the intake of vitamins and mineral salts is adequate, their biochemical properties translate into normal physiological functions; a lower intake of mineral salts and vitamins is associated with lethargy and physical and cognitive fatigue. However, few studies have evaluated the effect of vitamin and mineral supplementation for the management of physical and cognitive fatigue.\\n\\nSiderAL® Med is a food for Special Medical Purposes (AFMS), with a complete formulation that contains vitamins, sucrosomial minerals (Iron, Iodine, Magnesium, Zinc and Selenium), copper and algal calcium, with enhanced dosages to meet particular needs nutritional. AFMS are products formulated for the dietary management of patients with proven nutritional needs, for whom modifications to the normal diet are not sufficient.\\n\\nIn some cases, these are subjects with limited, disturbed or altered ability to take, digest, absorb, metabolize or eliminate certain nutrients, in other cases, however, nutritional needs can be determined by specific clinical conditions.\\n\\nOn the basis of scientific evidences, therefore, the aim of the study is to evaluate whether the nutritional supplement with SiderAL® Med improves the symptom of fatigue, motor and cognitive function in patients with stroke outcomes.', 'DetailedDescription': 'Twenty-four patients of both sexes will be recruiteed, evaluated and treated at the Post-Acute Rehabilitation Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS of Rome.\\n\\nPatients will be divided into two groups by randomization, as specified later. One group (experimental group, GS), in association with the drug therapy already underway, will take the nutritional supplement with SiderAL® Med 1 sachet per day for 28 consecutive days, while another group will continue its clinical and rehabilitation treatment as per the daily routine (control group, GC).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Fatigue', 'Stroke']}, 'KeywordList': {'Keyword': ['Stroke', 'Fatigue', 'Older Adults', 'Nutrition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Interventional randomized controlled pilot study', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Experimental Group (GS)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'GS patients, in addition to the pharmacological therapy foreseen by the clinical conditions, will take 1 sachet a day of SiderAl® Med, a food for special purposes, for 28 days. GS patients will take the food for special purposes during hospitalization (between T0 and T1) and during the 1 month of returning home (between T1 and T2). During the second month of returning home (between T2 and T3), GS patients will no longer take the food for special purposes.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Supplement with SiderAl® Med']}}, {'ArmGroupLabel': 'Control Group (GC)', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'The patients of the GC, on the other hand, will continue to take the drug as required by their clinical conditions and will not take the SiderAL® Med food for special purposes, but will only be observed and evaluated at the various time-points foreseen by the study.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Supplement with SiderAl® Med', 'InterventionDescription': 'Nutritional supplementation with special purpose food', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Experimental Group (GS)']}, 'InterventionOtherNameList': {'InterventionOtherName': ['SiderAl® Med']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Modified Fatigue Impact Scale (MFIS)', 'PrimaryOutcomeDescription': 'The MFIS is an instrument that provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning. The full-length MFIS consists of 21 items while the abbreviated version has 5 items.\\n\\nThe MFIS is a structured, self-report questionnaire that the patient can generally complete with little or no intervention from an interviewer. However, patients with visual or upper extremity impairments may need to have the MFIS administered as an interview. Interviewers should be trained in basic interviewing skills and in the use of this instrument.\\n\\nThe total score for the MFIS is the sum of the scores for the 21 items. Individual subscale scores for physical, cognitive, and psychosocial functioning can also be generated by calculating the sum of specific sets of items.', 'PrimaryOutcomeTimeFrame': 'Change from Baseline MFIS at 4, 8 and 16 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Fatigue Scale for Motor and Cognitive Function (FSMC)', 'SecondaryOutcomeDescription': \"The FSMC is an assessment of MS-related cognitive and motor fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue). Two subscales (mental and physical fatigue) can be made. Items included in the subscale mental are 1-4-7-8-11-13-15-17-18-20 and items included in the subscale physical are 2-3-5-6-9-10-12-14-16-19.\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline FSMC at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Berg Balance Scale (BBS)', 'SecondaryOutcomeDescription': \"BBS is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete. It does not include the assessment of gait.\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline BBS at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Short Physical Performance Battery (SPPB)', 'SecondaryOutcomeDescription': 'SPPB is an objective measurement instrument of balance, lower extremity strength, and functional capacity in older adults (>65 years of age). Three domains, which include balance, usual or self-selected gait speed, and lower limb strength, are assessed by a three-stage balance test (feet side-by-side, semitandem, and tandem positions), a 3-m or 4-m gait speed test (time spent to walk the course), and a repetitive chair stand test (five times chair sit-to-stand test), respectively. A 0- to 12-point scale is used to score the sum of the three assessments with higher point values corresponding with greater levels of physical function and lower disability, whereas lower point values correspond with lower levels of physical function and higher disability, respectively.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline SPPB at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Motricity Index (MI)', 'SecondaryOutcomeDescription': 'MI can be used to assess the motor impairment in a patient who has had a stroke.\\n\\nTest for each upper limb:\\n\\npincer grip\\nelbow flexion\\nshoulder abduction\\n\\nTest for each lower limb:\\n\\nankle dorsiflexion\\nknee extension\\nhip flexion\\n\\nFor the pincer grip:\\n\\n0 points, no movement 19 points, grip possible but not against gravity 33 points, normal grip\\n\\nFor all other items:\\n\\n0 points, no movement 14 points, Visible movement but not for the entire joint range or against gravity 19 points, movement possible for the entire joint range against gravity but not against resistance 33 points movement performed with normal force\\n\\nEach segment has a total score obtained by adding the value \"1\" to the score of each individual item. The total score then ranges from 1 (no movement) to 100 (normal movement).', 'SecondaryOutcomeTimeFrame': 'Change from Baseline MI at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Timed Up and Go Test (TUG)', 'SecondaryOutcomeDescription': \"TUG measures in seconds the time it takes a subject to rise from a chair, walk a distance of 3 meters, turn, walk back to the chair and sit down.\\n\\nThe performance is rated on a scale of 1 to 5 (where 1 is normal and 5 is severely abnormal) according to the observer's perception of the patient's risk of falling.\\n\\nThe timed part of the test records the mean time (in seconds) from initial getting up to re-seating. Patients are compared with the mean time of adults in their age group, 60 to 69, 70 to 79, and 80 to 99 years of age.\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline TUG at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'HandGrip Test (HGT)', 'SecondaryOutcomeDescription': 'HGT is a test performed with a dynamometer, which goes to assess muscle strength (in kilograms). Starting with the elbow flexed to 90°, the patient must squeeze the dynamometer as hard as they can at one time. Three repeated measurements are taken on each side 20 seconds apart.\\n\\nThe average of the three assessments is used as the final value.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline HGT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Ambulation Index (AI)', 'SecondaryOutcomeDescription': \"AI is a rating scale to assess mobility by evaluating the time and degree of assistance required to walk 8 meters. Scores range from 0 (asymptomatic and fully active) to 10 (bedridden). The patient is asked to walk a marked 8 meters course as quickly and safely as possible. The examiner records the time and type of assistance (e.g., cane, walker, crutches) needed. Although the patient's walking is timed, the time is not used directly but is utilized in conjunction with other factors to rate the patient on an ordinal scale with 11 gradations.\\n\\n0 = Asymptomatic; fully active. 10 = Bedridden\", 'SecondaryOutcomeTimeFrame': 'Change from Baseline AI at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Walking handicap scale (WHS)', 'SecondaryOutcomeDescription': 'WHS is an assessment tool that allows us to evaluate the quality of walking in the home and social environment through a a scale comprising six categories.\\n\\n1 = Physiological walking: walking only as exercise 6 = Unrestricted walking in social settings: independent in all activities, on uneven ground, in crowded places, shows complete independence in public places.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline WHS at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Functional Ambulation Classification (FAC)', 'SecondaryOutcomeDescription': 'FAC is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device.\\n\\nTo use the FAC, an assessor asks the subject various questions and briefly observes their walking ability to provide a rating from 0 to 5.\\n\\nA score of 0 indicates that the patient is a non-functional ambulator (cannot walk); A score of 1, 2 or 3 denotes a dependent ambulator who requires assistance from another person in the form of continuous manual contact (1), continuous or intermittent manual contact (2), or verbal supervision/guarding (3).\\n\\nA score of 4 or 5 describes an independent ambulator who can walk freely on: level surfaces only (4) or any surface (5=maximum score).', 'SecondaryOutcomeTimeFrame': 'Change from Baseline FAC at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': '10 Meter Walk Test (10mWT)', 'SecondaryOutcomeDescription': 'The 10mWT is used to assess walking speed in meters/second (m/s) over a short distance. The total time taken to ambulate 6 meters (m) is recorded to the nearest hundredth of a second. 6 m is then divided by the total time (in seconds) taken to ambulate and recorded in m/s.\\n\\nThe time is measured for the middle 6 m to allow for patient acceleration and deceleration.\\n\\nThe time is started when any part of the leading foot crosses the plane of the 2-m mark.\\n\\nThe time is stopped when any part of the leading foot crosses the plane of the 8-m mark.1 The time to walk the middle 6m, the level of assistance, and type of assistive device and/or bracing used will be documented.\\n\\nIf a patient requires total assistance or is unable to ambulate at all, a score of 0 m/s will be documented.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline 10MWT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Six-minute walk test (6MWT)', 'SecondaryOutcomeDescription': 'The 6MWT is a sub-maximal exercise test used to assess walking endurance and aerobic capacity. Participants will walk around the perimeter of a set circuit for a total of six minutes. The score of the test is the distance a patient walks in 6 minutes (measured in meters and can round to the nearest decimal point).\\n\\nDistance (in meters) covered in six minutes is calculated by multiplying the number of total laps by 12 meters and adding the distance of the partial lap completed at the time the test ended.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline 6MWT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'modified Barthel Index (mBI)', 'SecondaryOutcomeDescription': 'mBI for activities of daily living is meant to be used in the assessment of patient performance (or degree of assistance required) with respect to self-care, sphincter management, transfers and locomotion. The index consist of 10 items (each scored with a number of points) that relate to activities of daily living (ADLs) where the final score is calculated by summing the points awarded to each item. A five-point rating scales for each item to improve sensitivity to detecting change.\\n\\nThe 10 items assessed relate to:\\n\\nHelp needed with feeding;\\nHelp needed with bathing;\\nHelp needed with grooming;\\nHelp needed with dressing;\\nPresence or absence of fecal incontinence;\\nPresence or absence of urinary incontinence;\\nHelp needed with transfers;\\nHelp needed with walking;\\nHelp needed with climbing stairs.\\n\\nInterpretation:\\n\\n91-100 Slight dependency\\n61-90 Moderate dependency\\n21-60 Severe dependency\\n0-20 Total dependency', 'SecondaryOutcomeTimeFrame': 'Change from Baseline mBI at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'EuroQol- 5 Dimension (EQ-5D)', 'SecondaryOutcomeDescription': 'EQ-5D is an instrument which evaluates the generic quality of life. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers given to ED-5D permit to find 243 unique health states or can be converted into EQ- 5D index an utility scores anchored at 0 for death and 1 for perfect health.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline EQ-5D at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Frontal Assessment Battery (FAB)', 'SecondaryOutcomeDescription': 'The FAB is a brief tool that can be used at the bedside or in a clinic setting to assist in discriminating between dementias with a frontal dysexecutive phenotype and Dementia of Alzheimer\"s Type (DAT).\\n\\nThe FAB has validity in distinguishing Fronto-temporal type dementia from DAT in mildly demented patients (MMSE > 24). Total score is from a maximum of 18, higher scores indicating better performance.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline FAB at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Stroop Colour Word Test (SCWT)', 'SecondaryOutcomeDescription': 'The SCWT is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. The subject is asked to read the words in the first task, to name colors in the second and third tasks. It is necessary to mark both any mistakes made but also the time spent on each task. The cut-off for the error interference effect is 4.24, while the cut-off for the time interference effect is 36.92.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline SCWT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Digit Cancellation Test (DCT)', 'SecondaryOutcomeDescription': 'In the DCT the patient is asked to cross out with a pencil, as quickly as possible, all numbers corresponding to those indicated at the top of each matrix. Line A serves as an example. The performance of the subject is counted from line I. Corrections of the barriers are not allowed. The task of the examiner is mark the point at which the subject has exceeded the maximum time of the test, but let the subject let the subject finish his task for each matrix. The maximum time for each matrix is 45 sec- and is considered from the moment the subject finishes the run in. If the subject takes less time than the maximum time, it will be indicated at the end of each matrix. The time cut-off for the test is 23.9.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline DCT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Trial Making Test (TMT)', 'SecondaryOutcomeDescription': 'The TMT measures flexibility of thinking on a visual-motor sequencing task. It consists of two parts, A and B, where 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.).\\n\\nResults for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment.\\n\\nTrail A: Average 29 seconds, Deficient > 78 seconds, Rule of Thumb Most in 90 seconds Trail B: Average 75 seconds, Deficient > 273 seconds, Rule of Thumb Most in 3 minutes', 'SecondaryOutcomeTimeFrame': 'Change from Baseline TMT at 4, 8 and 16 weeks'}, {'SecondaryOutcomeMeasure': 'Dual-Energy X-ray Absorptiometry (DEXA)', 'SecondaryOutcomeDescription': 'DEXA is an instrumental examination based on the principle of differential attenuation of an X-ray beam, at two energy levels, as it passes through tissues. This attenuation is recordable and correlated with the body composition of the subject being examined.\\n\\nThe device uses a coincident X-ray beam with no scattering in the environment. The radiation dose per single examination is minimal (1 mRem). There is therefore no risk to both patient and operator, and it is possible to repeat the examination at short intervals.\\n\\nDEXA allows for:\\n\\na weight and percentage assessment of lean mass and fat mass in different body districts. It is therefore possible to determine the areas of fat accumulation and quantify their weight in grams.\\na selective assessment in the different body districts of the state of bone mineralization.\\n\\nThe examination has a total duration of 30 minutes.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline DEXA at 4, 8 and 16 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nAge greater than or equal to 5 years;\\nPatients with ischemic or haemorrhagic stroke outcomes documented through neuroimaging techniques (magnetic resonance or computed tomography);\\nLatency from the acute event between 1 and 6 months;\\nCognitive skills that allow you to carry out simple orders and understand the physiotherapist's instructions [assessed through the Token Test (score ≥ 26.5)];\\nAbility to walk independently or with little assistance;\\nAbility to understand and sign informed consent.\\n\\nExclusion Criteria:\\n\\nVitamin D intake greater than 3000 IU/day;\\nTherapy with Vitamin K antagonists;\\nConditions causing excess electrolytes in the blood;\\nDiagnosis of metabolic mineral storage disorders (eg, hemochromatosis, Wilson);\\nDialysis patients;\\nSystemic, neurological, cardiac pathologies that make walking risky or cause motor deficits;\\nOncological pathologies;\\nProblems of an orthopedic or postural nature;\\nPresence of plantar ulcers;\\nPartial or total amputation of segments of the foot;\\nInability to provide informed consent.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '55 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Silvia Giovannini, MD, phD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+390630154382', 'CentralContactEMail': 'silvia.giovannini@policlinicogemelli.it'}, {'CentralContactName': 'Letizia Castelli, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+390630154382', 'CentralContactEMail': 'letizia.castelli@policlinicogemelli.it'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Silvia Giovannini, MD, phD', 'OverallOfficialAffiliation': 'Fondazione Policlinico Universitario A. Gemelli, IRCCS', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fondazione Policlinico Universitario A. Gemelli IRCCS', 'LocationStatus': 'Recruiting', 'LocationCity': 'Roma', 'LocationState': 'RM', 'LocationZip': '00168', 'LocationCountry': 'Italy', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Silvia Giovannini, MD, phD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+390630154382', 'LocationContactEMail': 'silvia.giovannini@policlinicogemelli.it'}, {'LocationContactName': 'Letizia Castelli, MS', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+390630154382', 'LocationContactEMail': 'letizia.castelli@policlinicogemelli.it'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000005221', 'ConditionMeshTerm': 'Fatigue'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8054', 'ConditionBrowseLeafName': 'Fatigue', 'ConditionBrowseLeafAsFound': 'Fatigue', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 15, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT00163007', 'OrgStudyIdInfo': {'OrgStudyId': '297'}, 'Organization': {'OrgFullName': 'Ostfold Hospital Trust', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutritional Therapy for Stroke Patients', 'OfficialTitle': 'Nutritional Therapy for Patients With Acute Stroke and With Poor Nutritional Status or at Risk of Poor Nutritional Status'}, 'StatusModule': {'StatusVerifiedDate': 'May 2009', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2005'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 2008', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 2008', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'September 9, 2005', 'StudyFirstSubmitQCDate': 'September 9, 2005', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'September 13, 2005', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 8, 2009', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 11, 2009', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'LeadSponsor': {'LeadSponsorName': 'Ostfold Hospital Trust', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Oslo', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Prospective, short-term studies in patients admitted for acute stroke have shown an increased risk of infections, bedsores, impaired functional outcome, slower rate of recovery, poorer rehabilitation potential and higher mortality in patients with a poor nutritional status. In hospitals without routine nutritional assessment and individual nutrition management plans, the risk of patients developing malnutrition may be increased. In this study, patients admitted for acute stroke are randomised into either receiving nutritional therapy derived from estimated individual nutritional intake and nutritional needs, or nutritional therapy based on routine care without routine assessment of nutritional status, intake, or needs. The primary outcome measure is the percentage of patients with weight loss ≥ 5 % at three month follow-up.', 'DetailedDescription': 'Prospective, short-term studies in patients admitted for acute stroke have shown an increased risk of infections, bedsores, impaired functional outcome, slower rate of recovery, poorer rehabilitation potential and higher mortality in patients with a poor nutritional status. Sixteen percent of stroke patients are already malnourished on admission to hospital. The incidence of dysphagia in patients with acute stroke ranges from 30 to 45%. Dysphagia increases the risk of developing poor nutritional status, and new cases of malnutrition develop during the hospital stay, even during the first week. In hospitals without routine nutritional assessment and individual nutrition management plans, the risk of patients developing malnutrition may be increased. In this study patients admitted for acute stroke are randomised into either receiving nutritional therapy derived from estimated individual nutritional intake and nutritional needs, or nutritional therapy based on routine care; without routine assessment of nutritional status, intake or needs. Nutritional therapy: enriched meals, sip-feedings or enteral feedings. Parameters of nutritional status: Weight, BMI, TSF thickness, mid upper arm circumference, body composition, s-albumin and s-transferrin. Estimation of nutritional intake: Daily registration of food and drink intake. Estimating functional status: Hand grip strength, Barthels ADL index and Scandinavian stroke scale. Estimating quality of life: EQ-5D.\\n\\nBefore the inclusion started we decided to use the percentage of patients with weight loss ≥ 5 % at 3 months follow-up as the primary outcome measure because this is correlated better to clinical outcomes as e.g. mortality and comorbidity. Secondary outcome measures were then defined as handgrip strength, quality of life, nutritional status, nutrient intake and length of hospital stay.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Malnutrition', 'Weight Loss', 'Dysphagia']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '125', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Procedure', 'InterventionName': 'Nutritional support'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Percentage of patients with weight loss >=5 % at three month follow-up.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Quality of life, handgrip strength and nutritional status at three months. Dietary intake in hospital. Length of hospital stay.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAcute stroke based on clinical symptoms\\n18 years old and above\\n< 7 days since debut of stroke symptoms and either body mass index (BMI) = or < 20\\nWeight loss > 5% in 3-6 months or there has been little or is likely to be no or very little nutritional intake for > 5 days\\n\\nExclusion Criteria:\\n\\nSubarachnoidal bleeding and planned operation\\nSevere dementia\\nReduced consciousness\\nImmobility\\nExpected short-time survival', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Truls Hauge, PhD', 'OverallOfficialAffiliation': 'Ullevaal University Hospital', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ostfold Hospital Trust', 'LocationCity': 'Fredrikstad', 'LocationZip': '1603', 'LocationCountry': 'Norway'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '20955603', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ha L, Hauge T, Iversen PO. Body composition in older acute stroke patients after treatment with individualized, nutritional supplementation while in hospital. BMC Geriatr. 2010 Oct 18;10:75. doi: 10.1186/1471-2318-10-75.'}, {'ReferencePMID': '20176418', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ha L, Hauge T, Spenning AB, Iversen PO. Individual, nutritional support prevents undernutrition, increases muscle strength and improves QoL among elderly at nutritional risk hospitalized for acute stroke: a randomized, controlled trial. Clin Nutr. 2010 Oct;29(5):567-73. doi: 10.1016/j.clnu.2010.01.011. Epub 2010 Feb 21.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}, {'ConditionMeshId': 'D000015431', 'ConditionMeshTerm': 'Weight Loss'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001836', 'ConditionAncestorTerm': 'Body Weight Changes'}, {'ConditionAncestorId': 'D000001835', 'ConditionAncestorTerm': 'Body Weight'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M17792', 'ConditionBrowseLeafName': 'Weight Loss', 'ConditionBrowseLeafAsFound': 'Weight Loss', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4804', 'ConditionBrowseLeafName': 'Body Weight', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4805', 'ConditionBrowseLeafName': 'Body Weight Changes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 16, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02043574', 'OrgStudyIdInfo': {'OrgStudyId': 'N0944-W'}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Nutrition and Aerobic Exercise in Chronic Stroke', 'OfficialTitle': 'Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke', 'Acronym': 'NEXIS'}, 'StatusModule': {'StatusVerifiedDate': 'January 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'November 17, 2014', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 29, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 6, 2014', 'StudyFirstSubmitQCDate': 'January 21, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 23, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'ResultsFirstSubmitDate': 'January 21, 2020', 'ResultsFirstSubmitQCDate': 'January 21, 2020', 'ResultsFirstPostDateStruct': {'ResultsFirstPostDate': 'January 31, 2020', 'ResultsFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'January 21, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'January 31, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'Strokes are very common in the United States and occur more in the elderly. The number of strokes is likely to double in the next 50 years. Many stroke survivors are sedentary and have a poor dietary intake, which results in abnormalities in fuel utilization (eg carbohydrate versus fat). This study will examine the effects of dietary modification and treadmill training on fuel utilization and physical function. We will study skeletal muscle oxidative stress in chronic stroke patients and the ability to employ dietary modification and exercise training to reverse these abnormalities in this ethnically diverse population.', 'DetailedDescription': 'In acute stroke settings, it is known that energy imbalance is associated with poorer rehabilitation and functional outcomes, and importantly, increased risk of institutionalization. However, nutrition and eating habits of chronic stroke rehabilitative care have received very little consideration, especially if the survivor is living in a free living environment. Studies have shown deficiencies in energy and protein intake versus recommendations in chronic stroke survivors. Perry et al. found ~7% of chronic stroke survivors were at moderate and ~5% at high nutritional risk. Although little is known regarding total daily energy expenditure and dietary intake in chronic stroke, energy and macronutrient imbalance may have a profound impact on stroke recovery and risk of development of chronic disease and recurrent stroke by altering substrate oxidation and result in systemic and tissue level oxidative stress. Conversely, cardiovascular disease risk increases with excess calorie and fat intake and two-thirds of stroke survivors are overweight or obese. In obese, non-stroke populations, energy dense, high fat meals are associated with increases in plasma oxidative stress markers. Oxidative stress can lead to mitochondrial damage and abnormal accumulation of metabolite intermediates and lipid accumulation in non-adipose tissues, which can impair heart function, increasing CVD and stroke recurrence risk.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Aerobic Exercise', 'Treadmill Test', 'Sedentary Lifestyle']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Subjects are randomized to either stretching or treadmill training.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '51', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stretching (Control)', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Six months of stretching', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Stretching (control)']}}, {'ArmGroupLabel': 'Treadmill Exercise', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Six months of treadmill training', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Treadmill Exercise']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Treadmill Exercise', 'InterventionDescription': 'Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Treadmill Exercise']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Stretching (control)', 'InterventionDescription': 'Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Stretching (Control)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'The Change in Total Daily Energy Expenditure', 'PrimaryOutcomeDescription': 'Subjects will wear an accelerometer activity monitor on their belt for 5 to 7 days to determine caloric expenditure in daily activities.', 'PrimaryOutcomeTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'The Change in Substrate Oxidation', 'SecondaryOutcomeDescription': 'After a 12 hour fast, economy of hemiparetic gait will be measured using open circuit spirometry during a standard constant load submaximal effort treadmill walking task at a pre-established gait velocity (60% of self-selected floor walking velocity). This slower walking velocity is selected because untrained subjects with stroke usually cannot maintain their self-selected walking pace, precluding steady state measures of oxygen consumption that defines gait economy. We will calculate the change in respiratory exchange ratio from rest to the final 3 minutes of a 10-minute walk under steady state oxygen consumption conditions (RER at 60%VO2peak-RER at rest). Subjects not achieving a plateau in VO2 will be re-tested at a lower velocity on a different date to eliminate potential confounding effects of fatigue on testing.', 'SecondaryOutcomeTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)'}, {'SecondaryOutcomeMeasure': 'The Change in Circulating Nitrotyrosine', 'SecondaryOutcomeDescription': 'Plasma will be used to quantitate circulating nitrotyrosine concentrations', 'SecondaryOutcomeTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nVeteran\\nAdequate language and neurocognitive function to safely participate in informed consent, and exercise testing and training\\nUnder the care of a primary care medical provider.\\nAge greater than 20 years\\nBody mass index between 20 to 50 kg/m2\\nAlready completed all conventional inpatient and outpatient physical therapy.\\nIschemic or hemorrhagic stroke greater than or equal to 6 months prior.\\n\\nExclusion Criteria:\\n\\nAlready performing aerobic exercise 3 x / week.\\nIncreased alcohol consumption defined as greater than 2 oz. liquor or 2 times 4 oz. glasses of wine or 2 x 12 oz. cans of beer per day\\nCardiac history of: a) unstable angina, b) recent (less than 3 months prior to study entry) myocardial infarction, congestive heart failure (NYHA category II-IV); c) hemodynamically significant valvular dysfunction.\\nMuscle Biopsy Exclusion Criteria: a) anti-coagulation therapy with heparin, warfarin, or lovenox (anti-platelet therapy is permitted), b) bleeding disorder c) allergy to lidocaine\\nMedical History: a) recent hospitalization (less than 3 months prior to study entry) for severe medical disease, b) peripheral arterial disease with vascular claudication, c) orthopedic or chronic pain condition restricting exercise, d) pulmonary or renal failure, e) active cancer, f) untreated poorly controlled hypertension measured on at least 2 occasions (greater than 160/100) g) type I diabetes mellitus, untreated and / or poorly controlled diabetes with fasting blood glucose of greater than 170 and HbA1c greater than 10.0, h) medications: heparin, warfarin, lovenox, oral steroids i) currently pregnant.\\nNeurological history of: a) dementia with Mini-Mental Status Score less than 23 (less than 17 if education level at or below 8th grade), and diagnostic confirmation by neurologist or psychiatrist, b) severe receptive or global aphasia which confounds testing and training, operationally defined as unable to follow 2 point commands, c) neurologic disorder restricting exercise, such as Parkinsons Syndrome or myopathy, d) untreated major depression.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Monica C Serra, PhD', 'OverallOfficialAffiliation': 'South Texas Health Care System, San Antonio, TX', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21201', 'LocationCountry': 'United States'}, {'LocationFacility': 'South Texas Health Care System, San Antonio, TX', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78229', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'ResultsSection': {'ParticipantFlowModule': {'FlowGroupList': {'FlowGroup': [{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Stretching (Control)', 'FlowGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Treadmill Exercise', 'FlowGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will occur 3 days/week and will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.'}]}, 'FlowPeriodList': {'FlowPeriod': [{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '25'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '26'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '19'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '20'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '6'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '6'}]}}]}}]}}, 'BaselineCharacteristicsModule': {'BaselineGroupList': {'BaselineGroup': [{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Stretching (Control)', 'BaselineGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Treadmill Exercise', 'BaselineGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will occur 3 days/week and will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]}, 'BaselineDenomList': {'BaselineDenom': [{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '25'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '26'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '51'}]}}]}, 'BaselineMeasureList': {'BaselineMeasure': [{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '18'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '16'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '33'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '63', 'BaselineMeasurementSpread': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '61', 'BaselineMeasurementSpread': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '62', 'BaselineMeasurementSpread': '8'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '7'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '21'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '23'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '44'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '15'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '29'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '21'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '25'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '51'}]}}]}}]}}]}}, 'OutcomeMeasuresModule': {'OutcomeMeasureList': {'OutcomeMeasure': [{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'The Change in Total Daily Energy Expenditure', 'OutcomeMeasureDescription': 'Subjects will wear an accelerometer activity monitor on their belt for 5 to 7 days to determine caloric expenditure in daily activities.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'change in kcal/day', 'OutcomeMeasureTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Stretching (Control)', 'OutcomeGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Treadmill Exercise', 'OutcomeGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '20'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.52', 'OutcomeMeasurementSpread': '40.89'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '32.86', 'OutcomeMeasurementSpread': '54.60'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'The Change in Substrate Oxidation', 'OutcomeMeasureDescription': 'After a 12 hour fast, economy of hemiparetic gait will be measured using open circuit spirometry during a standard constant load submaximal effort treadmill walking task at a pre-established gait velocity (60% of self-selected floor walking velocity). This slower walking velocity is selected because untrained subjects with stroke usually cannot maintain their self-selected walking pace, precluding steady state measures of oxygen consumption that defines gait economy. We will calculate the change in respiratory exchange ratio from rest to the final 3 minutes of a 10-minute walk under steady state oxygen consumption conditions (RER at 60%VO2peak-RER at rest). Subjects not achieving a plateau in VO2 will be re-tested at a lower velocity on a different date to eliminate potential confounding effects of fatigue on testing.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'ratio change', 'OutcomeMeasureTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Stretching (Control)', 'OutcomeGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Treadmill Exercise', 'OutcomeGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '20'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.013', 'OutcomeMeasurementSpread': '0.072'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.083', 'OutcomeMeasurementSpread': '0.135'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'The Change in Circulating Nitrotyrosine', 'OutcomeMeasureDescription': 'Plasma will be used to quantitate circulating nitrotyrosine concentrations', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': '% change', 'OutcomeMeasureTimeFrame': 'measured at baseline and following 6 months of treadmill training or stretching (control)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Stretching (Control)', 'OutcomeGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Treadmill Exercise', 'OutcomeGroupDescription': 'Six months of treadmill training Treadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '19'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '20'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-24.8', 'OutcomeMeasurementSpread': '21.7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '-36.5', 'OutcomeMeasurementSpread': '30.8'}]}}]}}]}}]}}, 'AdverseEventsModule': {'EventsFrequencyThreshold': '0', 'EventsTimeFrame': '6 months from baseline', 'EventGroupList': {'EventGroup': [{'EventGroupId': 'EG000', 'EventGroupTitle': 'Stretching (Control)', 'EventGroupDescription': 'Six months of stretching\\n\\nStretching (control): Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '19', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '19', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '19'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Treadmill Exercise', 'EventGroupDescription': 'Six months of treadmill training\\n\\nTreadmill Exercise: Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '20', 'EventGroupSeriousNumAffected': '1', 'EventGroupSeriousNumAtRisk': '20', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '20'}]}, 'SeriousEventList': {'SeriousEvent': [{'SeriousEventTerm': 'Recurrent stroke', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '19'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '20'}]}}]}}, 'MoreInfoModule': {'CertainAgreement': {'AgreementPISponsorEmployee': 'Yes'}, 'PointOfContact': {'PointOfContactTitle': 'Monica Serra', 'PointOfContactOrganization': 'South Texas Veterans Health Care System', 'PointOfContactEMail': 'monica.serra@va.gov', 'PointOfContactPhone': '210-617-5300', 'PointOfContactPhoneExt': '15313'}}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'April 16, 2019', 'LargeDocUploadDate': '01/13/2020 15:27', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1303', 'ConditionBrowseLeafName': 'Chronic Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 17, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05651321', 'OrgStudyIdInfo': {'OrgStudyId': 'ONSTaste2.0'}, 'Organization': {'OrgFullName': 'Peking Union Medical College Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements', 'OfficialTitle': \"A Series of Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements on Patients' Nutritional Strategies\"}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 5, 2022', 'StudyFirstSubmitQCDate': 'December 5, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 15, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 10, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 12, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Peking Union Medical College Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The goal of this observational study is to test the taste perception threshold and palatability interval of different populations and the difference in taste perception between tumor and stroke patients and healthy people by combining manual sensory evaluation and electronic bionic sensory and investigate the taste perception characteristics and demand of enteral nutrition preparations such as Fortimel in tumor and stroke patients, and the difference in taste perception of enteral nutrition preparations with healthy people by combining manual sensory evaluation and electronic bionic sensory. Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'DetailedDescription': 'Combining manual sensory evaluation and electronic bionic sensory, assessing the differences in taste perception between tumor and stroke patients and healthy individuals by measuring the basic taste perception threshold and palatability interval and analyzing facial expressions.\\nCombining manual sensory evaluation with electronic bionic senses and simultaneous facial expression analysis to assess the taste perception characteristics and needs of tumor and stroke patients for different flavors of enteral nutrition preparations.\\nEstablishing an information base of electronic tongue taste data, facial expression emotion and flavor data of nutritional preparations based on the electronic tongue and facial expression data of relevant assays obtained simultaneously during the above experiments.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cancer- and Cancer Treatment-Related Conditions', 'Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Crossover']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '108', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'stroke patients', 'ArmGroupDescription': 'Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Samples materials of basic taste stimuli and enteral nutrition preparations']}}, {'ArmGroupLabel': 'cancer patients', 'ArmGroupDescription': 'Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Samples materials of basic taste stimuli and enteral nutrition preparations']}}, {'ArmGroupLabel': 'healthy people', 'ArmGroupDescription': 'Participants were tested for different taste perception thresholds using a three-point difference test, with samples materials for basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) were used to prepare different tastes and concentrations of liquids. The subjects will then evaluate the appearance (color, texture), taste, flavor, and texture of the six different flavored enteral nutrition preparations. The subjects will then perform manual sensory evaluation of the appearance (color, texture), odor, taste, texture, and other properties of the 6 different flavored enteral nutrition preparations.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Samples materials of basic taste stimuli and enteral nutrition preparations']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Samples materials of basic taste stimuli and enteral nutrition preparations', 'InterventionDescription': 'Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['cancer patients', 'healthy people', 'stroke patients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Taste perception threshold', 'PrimaryOutcomeDescription': 'materials using basic taste stimuli, i.e. reference substances tartaric/citric acid (acid), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), quercetin/alum (astringent) to prepare Different flavors and concentrations of solutions were prepared. By the \"three-point test\", pure water was used as a control to determine the concentration of the flavors caused by The \"discrimination threshold\" of the sensation was determined by the \"three-point test\" using pure water as a control.', 'PrimaryOutcomeTimeFrame': 'After initial screening and exclusion, subjects who met the inclusion criteria were ready to begin taste threshold testing.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nhealthy people aged 18-80 years old (including 18 and 80 years old), patients with specific diseases.\\nspecific diseases meet the clinical diagnosis criteria and are not in the clinical treatment period (such as radiotherapy or perioperative period)\\nnot wearing a denture and having good oral hygiene.\\nnormal vision or corrected vision, no hearing impairment, and no mental behavior disorder.\\nvoluntarily participate in this trial and sign the informed consent form.\\n\\nExclusion Criteria:\\n\\nsubjects who may be allergic to the ingredients of the tested food\\npersons who have an aversion to the food to be tasted or who do not consume the food for cultural, ethnic, or other reasons\\npregnant or lactating women.\\nexcessive smokers (>15 cigarettes/day) or heavy drinkers (>25g/day for men and >15g/day for women)\\nEating disorders (binge eating, anorexia, bulimia nervosa, etc.) and those who cannot eat through the mouth\\nthose who underwent ear, nose, and throat, transnasal intracranial occupancy, and oral surgery\\nThose who currently have severe abnormalities of the respiratory system, endocrine system, immune system, nervous system, circulatory system, digestive system, hematopoietic system, and nervous system, and those who have undergone bariatric surgery.\\ncurrently taking medications that affect the sense of taste\\nSubjects who are participating in other clinical trials.\\nother people who have been determined by the investigator to be unsuitable for participation in this trial, patients with conditions that reduce the likelihood of enrollment or complicate enrollment, such as the presence of conditions that predispose to missed visits.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Study subjects are healthy people, patients with specific diseases (after radiotherapy for tumors, stroke)', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Wei Chen, Doctor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+86 13911006820', 'CentralContactEMail': 'chenw@pumch.cn'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wei Chen, Doctor', 'OverallOfficialAffiliation': 'Peking Union Medical College Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Dongcheng district，Peking union medical college hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationState': 'Beijing', 'LocationZip': '100010', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Wei Chen, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '010-69154095', 'LocationContactEMail': 'txchenwei@sina.com'}, {'LocationContactName': 'Xiaodong Shi', 'LocationContactRole': 'Contact', 'LocationContactPhone': '17888811579'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M5063', 'InterventionBrowseLeafName': 'Caffeine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14334', 'InterventionBrowseLeafName': 'Quercetin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M21010', 'InterventionBrowseLeafName': 'Citric Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M1837', 'InterventionBrowseLeafName': 'Sodium Citrate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M14343', 'InterventionBrowseLeafName': 'Quinine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M257697', 'InterventionBrowseLeafName': 'Aluminum sulfate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T370', 'InterventionBrowseLeafName': 'Caffeine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T41', 'InterventionBrowseLeafName': 'Quercetin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T382', 'InterventionBrowseLeafName': 'Citrate', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'CNSSti', 'InterventionBrowseBranchName': 'Central Nervous System Stimulants'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnCoag', 'InterventionBrowseBranchName': 'Anticoagulants'}, {'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'MuRelCen', 'InterventionBrowseBranchName': 'Muscle Relaxants, Central'}, {'InterventionBrowseBranchAbbrev': 'Ot', 'InterventionBrowseBranchName': 'Other Dietary Supplements'}, {'InterventionBrowseBranchAbbrev': 'Fl', 'InterventionBrowseBranchName': 'Flavonoid'}]}}}}}, {'Rank': 18, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02982668', 'OrgStudyIdInfo': {'OrgStudyId': 'KY20162086-2'}, 'Organization': {'OrgFullName': 'Xijing Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Optimizing Early Enteral Nutrition in Severe Stroke', 'OfficialTitle': 'A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage', 'Acronym': 'OPENS'}, 'StatusModule': {'StatusVerifiedDate': 'December 2020', 'OverallStatus': 'Terminated', 'WhyStopped': 'Significantly higher mortality', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'November 27, 2016', 'StudyFirstSubmitQCDate': 'November 30, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 5, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 31, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 4, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Xijing Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Tang-Du Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Xi'an Central Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Xi'an Gaoxin Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Yan'an University Affiliated Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The PLA 940 hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Xi'an No.3 Hospital\", 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': \"The First Affiliated Hospital of Xi'an Medical University\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Yulin No.1 Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"The First People's Hospital of Xianyang\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Tongchuan Mining Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The PLA General Hospital of Xinjiang', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Tongchuan People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Yulin No.2 Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"First Affiliated Hospital Xi'an Jiaotong University\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Ankang Central Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this academic lead study is to explore the ideal nutritional support strategy for patient with acute severe stroke.', 'DetailedDescription': 'Of high mortality and morbidity, severe stroke is associated with devastating damages in neurologic, respiratory, circulatory and many other systems. The outcomes of patients with severe stroke depend largely on medical strategies on acute stage, especially on nutritional support management. Unfortunately, clinical evidence are sparse and the ideal initial feeding strategy remains disputable.\\n\\nThe IF-STROKE study aims to provide reliable data on the effects of modified full enteral feeding (target recruitment 200) and permissive underfeeding in patients with acute severe stroke (target recruitment 200) compared to full enteral feeding (target recruitment 200). Patients presenting with acute (<72h) severe stroke (GCS ≦ 12 or NIHSS ≧ 11) and dysphagia (defined by Water Swallowing Test) will be randomly assigned to full enteral feeding, modified full enteral feeding, or permissive underfeeding treatment for 7 days.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Severe Stroke', 'Acute Stroke', 'Dysphagia']}, 'KeywordList': {'Keyword': ['severe stroke', 'Acute Stroke', 'Enteral Feeding', 'Mortality', 'Disability', 'Clinical trial']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '306', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Full enteral feeding', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Initial enteral feeding']}}, {'ArmGroupLabel': 'Modified full enteral feeding', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Consistent with full enteral feeding plan, preventively add metoclopramide or mosapride everyday to improve gastrointestinal (GI) motility.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Initial enteral feeding', 'Drug: metoclopramide or mosapride']}}, {'ArmGroupLabel': 'Permissive underfeeding', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Initial enteral feeding']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Initial enteral feeding', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Full enteral feeding', 'Modified full enteral feeding', 'Permissive underfeeding']}}, {'InterventionType': 'Drug', 'InterventionName': 'metoclopramide or mosapride', 'InterventionDescription': 'gastrointestinal (GI) motility improving', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Modified full enteral feeding']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Rate of patients with death or major disability (modified Rankin scale score ≥3)', 'PrimaryOutcomeDescription': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'PrimaryOutcomeTimeFrame': '3 months after enrollment'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Mortality (rate of patients with death)', 'SecondaryOutcomeDescription': 'Rate of patients with death', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'The scores of National Institute of Health stroke scale', 'SecondaryOutcomeDescription': 'National Institute of Health stroke scale, with scores ranging from 0 (normal function) to 42 (functional impairment)) was used to evaluate the impairment caused by a stroke.', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'Glasgow Coma Scale', 'SecondaryOutcomeDescription': 'Glasgow Coma Scale, with scores ranging from 3 (no response) to 15 (normal response), was used to grade the conscious state.', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'modified Rankin scale', 'SecondaryOutcomeDescription': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'Barthel index', 'SecondaryOutcomeDescription': 'The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'modified Rankin scale', 'SecondaryOutcomeDescription': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'Barthel index', 'SecondaryOutcomeDescription': 'The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'The incidence of treatment intolerance', 'SecondaryOutcomeDescription': 'The intolerance including gastric retention, diarrhea, constipation, gastrointestinal hemorrhage', 'SecondaryOutcomeTimeFrame': '7 days after enrollment'}, {'SecondaryOutcomeMeasure': 'The incidence of serious adverse events', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'The incidence of adverse events That are related to treatment', 'SecondaryOutcomeTimeFrame': '3 months after enrollment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nSevere stroke occurred in 7 days.\\nGCS ≤12 or NIHSS≥11.\\nAny cases of profiles #3 through 5 in Water Swallowing Test or with disorder of consciousness.\\nPlan to receive enteral feeding for at least 7 days.\\nInformed consent.\\n\\nExclusion Criteria:\\n\\nGastrointestinal diseases before stroke, such as gastrointestinal resection, malabsorption,and irritable bowel syndrome.\\nBrain death.\\nComplicated with the disease which only have life expectancy < 6 months in over 50% patients.\\nAfter cardiac arrest.\\nReceived parenteral nutrition support.\\nPregnant woman.\\nConcurrent severe hepatic or renal dysfunction。\\nUnstable hemodynamics.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Wen Jiang, PhD', 'OverallOfficialAffiliation': 'Department of Neurology, Xijing Hospital, Fourth Military Medical University', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Xijing Hospital', 'LocationCity': \"Xi'an\", 'LocationState': 'Shaanxi', 'LocationZip': '710032', 'LocationCountry': 'China'}, {'LocationFacility': 'Tangdu Hospital', 'LocationCity': \"Xi'an\", 'LocationState': 'Shaanxi', 'LocationZip': '710038', 'LocationCountry': 'China'}, {'LocationFacility': \"The First Affiliated Hospital of Xi'an Jiaotong University,\", 'LocationCity': \"Xi'an\", 'LocationState': 'Shaanxi', 'LocationZip': '710061', 'LocationCountry': 'China'}, {'LocationFacility': 'Yulin No.2 Hospital', 'LocationCity': 'Yunlin', 'LocationState': 'Shaanxi', 'LocationZip': '719000', 'LocationCountry': 'China'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24289189', 'ReferenceType': 'background', 'ReferenceCitation': 'Wirth R, Smoliner C, Jager M, Warnecke T, Leischker AH, Dziewas R; DGEM Steering Committee*. Guideline clinical nutrition in patients with stroke. Exp Transl Stroke Med. 2013 Dec 1;5(1):14. doi: 10.1186/2040-7378-5-14.'}, {'ReferencePMID': '26773077', 'ReferenceType': 'background', 'ReferenceCitation': 'McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, Gervasio JM, Sacks GS, Roberts PR, Compher C; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016 Feb;40(2):159-211. doi: 10.1177/0148607115621863. No abstract available. Erratum In: JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1200.'}, {'ReferencePMID': '12750536', 'ReferenceType': 'result', 'ReferenceCitation': 'FOOD Trial Collaboration. Poor nutritional status on admission predicts poor outcomes after stroke: observational data from the FOOD trial. Stroke. 2003 Jun;34(6):1450-6. doi: 10.1161/01.STR.0000074037.49197.8C. Epub 2003 May 15.'}, {'ReferencePMID': '20130154', 'ReferenceType': 'result', 'ReferenceCitation': 'Ukleja A. Altered GI motility in critically Ill patients: current understanding of pathophysiology, clinical impact, and diagnostic approach. Nutr Clin Pract. 2010 Feb;25(1):16-25. doi: 10.1177/0884533609357568.'}, {'ReferencePMID': '15733717', 'ReferenceType': 'result', 'ReferenceCitation': 'Dennis MS, Lewis SC, Warlow C; FOOD Trial Collaboration. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet. 2005 Feb 26-Mar 4;365(9461):764-72. doi: 10.1016/S0140-6736(05)17983-5.'}, {'ReferencePMID': '20971534', 'ReferenceType': 'result', 'ReferenceCitation': 'Heyland DK, Stephens KE, Day AG, McClave SA. The success of enteral nutrition and ICU-acquired infections: a multicenter observational study. Clin Nutr. 2011 Apr;30(2):148-55. doi: 10.1016/j.clnu.2010.09.011. Epub 2010 Oct 25.'}, {'ReferencePMID': '22673593', 'ReferenceType': 'result', 'ReferenceCitation': 'Jie B, Jiang ZM, Nolan MT, Zhu SN, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012 Oct;28(10):1022-7. doi: 10.1016/j.nut.2012.01.017. Epub 2012 Jun 5.'}, {'ReferencePMID': '22307571', 'ReferenceType': 'result', 'ReferenceCitation': 'National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, Morris A, Dong N, Rock P. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA. 2012 Feb 22;307(8):795-803. doi: 10.1001/jama.2012.137. Epub 2012 Feb 5.'}, {'ReferencePMID': '26398094', 'ReferenceType': 'result', 'ReferenceCitation': 'Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults. N Engl J Med. 2015 Sep 24;373(13):1281. doi: 10.1056/NEJMx150028. No abstract available.'}, {'ReferencePMID': '35219379', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zhao J, Yuan F, Song C, Yin R, Chang M, Zhang W, Zhang B, Yu L, Jia Y, Ma Y, Song Y, Wang C, Song C, Wang X, Shang L, Yang F, Jiang W; OPENS Trial Investigators. Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2022 Apr;21(4):319-328. doi: 10.1016/S1474-4422(22)00010-2. Epub 2022 Feb 24.'}, {'ReferencePMID': '30755171', 'ReferenceType': 'derived', 'ReferenceCitation': 'Yuan F, Yang F, Zhang W, Jia Y, Ma Y, Qu Y, Wang X, Huo K, Wang C, Yuan X, Song C, Zhang B, Jiang W; OPENS study group. Optimizing early enteral nutrition in severe stroke (OPENS): protocol for a multicentre randomized controlled trial. BMC Neurol. 2019 Feb 12;19(1):24. doi: 10.1186/s12883-019-1253-2.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionMeshList': {'InterventionMesh': [{'InterventionMeshId': 'D000008787', 'InterventionMeshTerm': 'Metoclopramide'}, {'InterventionMeshId': 'C000062720', 'InterventionMeshTerm': 'Mosapride'}]}, 'InterventionAncestorList': {'InterventionAncestor': [{'InterventionAncestorId': 'D000000932', 'InterventionAncestorTerm': 'Antiemetics'}, {'InterventionAncestorId': 'D000001337', 'InterventionAncestorTerm': 'Autonomic Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000005765', 'InterventionAncestorTerm': 'Gastrointestinal Agents'}, {'InterventionAncestorId': 'D000065127', 'InterventionAncestorTerm': 'Dopamine D2 Receptor Antagonists'}, {'InterventionAncestorId': 'D000018492', 'InterventionAncestorTerm': 'Dopamine Antagonists'}, {'InterventionAncestorId': 'D000015259', 'InterventionAncestorTerm': 'Dopamine Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000017366', 'InterventionAncestorTerm': 'Serotonin Receptor Agonists'}, {'InterventionAncestorId': 'D000018490', 'InterventionAncestorTerm': 'Serotonin Agents'}]}, 'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M11450', 'InterventionBrowseLeafName': 'Metoclopramide', 'InterventionBrowseLeafAsFound': 'Pharmacokinetic Study', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M264835', 'InterventionBrowseLeafName': 'Mosapride', 'InterventionBrowseLeafAsFound': 'Shampoo', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M3941', 'InterventionBrowseLeafName': 'Antiemetics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8571', 'InterventionBrowseLeafName': 'Gastrointestinal Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7163', 'InterventionBrowseLeafName': 'Dopamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20286', 'InterventionBrowseLeafName': 'Dopamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M17652', 'InterventionBrowseLeafName': 'Dopamine Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20194', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M15202', 'InterventionBrowseLeafName': 'Serotonin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19338', 'InterventionBrowseLeafName': 'Serotonin Receptor Agonists', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'AnEm', 'InterventionBrowseBranchName': 'Antiemetics'}, {'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'CaAg', 'InterventionBrowseBranchName': 'Cardiotonic Agents'}]}}}}}, {'Rank': 19, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01517542', 'OrgStudyIdInfo': {'OrgStudyId': '10-0014'}, 'Organization': {'OrgFullName': 'Hospital de Clinicas de Porto Alegre', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Evaluation of Effectiveness of Nutritional Counseling in Patients After Stroke', 'OfficialTitle': 'Evaluation on the Effectiveness of Nutritional Counseling on an Adapted DASH Diet in Patients After Stroke: a Randomized Clinical Trial'}, 'StatusModule': {'StatusVerifiedDate': 'September 2021', 'OverallStatus': 'Withdrawn', 'WhyStopped': 'low availability of professionals to recruit the participants', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 2010', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 2021', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'September 2021', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 22, 2011', 'StudyFirstSubmitQCDate': 'January 24, 2012', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 25, 2012', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 9, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 16, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'SHEILA CRISTINA OURIQUES MARTINS', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Hospital de Clinicas de Porto Alegre'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Clinicas de Porto Alegre', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'Stroke is the leading cause of disability worldwide and the leading cause of death in Brazil. It is estimated that about 18 million people will have a stroke in 2015 and approximately one third of these resulting in death. The factors most important modifiable risk for stroke include high blood pressure (hypertension), diabetes, smoking, dyslipidemia, sedentary lifestyle and obesity. Acting on these risk factors can be reduced by 88% the risk of another stroke. Healthy eating is among the changes in lifestyle that are recommended for prevention and treatment of one of the main risk factors for stroke. Studies show that the adoption of the DASH diet can significantly reduce blood pressure and the result is even more significant in hypertensive patients, making this diet a new alternative in the prevention and treatment of hypertension and consequently stroke. Compliance therapy is a determining factor for success in the treatment of chronic diseases. Adherence to long-term treatment in developed countries is around 50% and in developing countries the rates are even lower. The aim of this study is to evaluate the effectiveness of nutritional counseling in an adapted DASH style diet on body weight, glycemic control, blood pressure values and improved lipid profile compared to the usual diet without nutritional counseling in patients with stroke within the last 3 months. The hypothesis is that nutritional counseling with an adapted DASH style diet reduces cardiovascular risk factors compared with the usual diet without nutritional counseling in patients with stroke within 3 months. The stroke patients will be selected in the hospitalization or in the outpatient clinic of Hospital de Clínicas de Porto Alegre in a period up to 3 months after ischemic stroke. The patients will be randomized to one of the 2 groups. In the first visit they will be submitted to a social class and international physical activity questionnaire and they will be submitted to a food frequency questionnaire, measures of weight, height, waist circumference, hip and neck, blood pressure and cholesterol and glucose measurements at the baseline, 30 days and 3, 6, 9 and 12 months. The main endpoints will be the change in the body weight, blood glucose, blood pressure values and lipid profile.', 'DetailedDescription': 'The study will be followed by a evaluation of other endpoints: new stroke, myocardial infarction or cardiovascular death.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Cardiovascular Diseases']}, 'KeywordList': {'Keyword': ['diet', 'DASH', 'Stroke', 'Nutritional counseling']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '0', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Nutritional counseling', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nutritional Counseling']}}, {'ArmGroupLabel': 'Usual diet', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nutritional Counseling', 'InterventionDescription': '2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nutritional counseling']}, 'InterventionOtherNameList': {'InterventionOtherName': ['adherence', 'nutrition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change from baseline arterial blood pressure and 6 months', 'PrimaryOutcomeDescription': 'The patients will be randomized to one of the 2 groups (with nutritional counseling and no intervention - habitual diet). The main endpoint will be the change in the blood pressure values and adherence to treatment measured in 30 days and 3, 6, 9 and 12 months.', 'PrimaryOutcomeTimeFrame': '30 days and 3, 6, 9 and 12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in lipids from baseline', 'SecondaryOutcomeDescription': 'The patients will be randomized to one of the 2 groups (with nutritional counseling and no intervention - habitual diet). The secundary endpoint will be the change in the lipid profile and adherence to treatment measured in 30 days and 3, 6, 9 and 12 months.', 'SecondaryOutcomeTimeFrame': '30 days, 3, 6, 9 and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in the body weight', 'SecondaryOutcomeDescription': 'The patients will be randomized to one of the 2 groups (with nutritional counseling and no intervention - habitual diet). The secundary endpoint will be the change in the body weight measured in 30 days and 3, 6, 9 and 12 months.', 'SecondaryOutcomeTimeFrame': '30 days and 3, 6, 9 and 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIschemic Stroke up to 3 months\\nModified Rankin Score < 4\\n\\nExclusion Criteria:\\n\\nAphasia\\nEnteral diet\\nUnavailability to follow up the study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Sheila CO Martins, PI', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Vanessa A Piper, SI', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Study Director'}, {'OverallOfficialName': 'Márcia LF Chaves, SI', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Study Chair'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023', 'RemovedCountryList': {'RemovedCountry': ['Brazil']}}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 20, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05640154', 'OrgStudyIdInfo': {'OrgStudyId': 'HPLgeriatric'}, 'Organization': {'OrgFullName': 'Assiut University', 'OrgClass': 'OTHER'}, 'BriefTitle': \"HPL Program for Geriatric Patients' at Risk for Stroke\", 'OfficialTitle': \"Health Promoting Lifestyle Program for Geriatric Patients' at Risk for Stroke\"}, 'StatusModule': {'StatusVerifiedDate': 'December 2022', 'OverallStatus': 'Enrolling by invitation', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 16, 2022', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 1, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 28, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 3, 2022', 'StudyFirstSubmitQCDate': 'December 3, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 7, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'December 3, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'December 7, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'TA Shoulkamy', 'ResponsiblePartyInvestigatorTitle': 'principal investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Assiut University'}, 'LeadSponsor': {'LeadSponsorName': 'Assiut University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a highest reason of illness and death all over world. In 2017, stroke was the second greatest recurrent reason of mortality, after ischemic cardiac illness, and produced 6.2 million mortality all over world. The load of stroke does not only lie in the great mortality but the great morbidity also results in up to 50% of survivors being chronically disabled. Thus stroke is a disease of huge public health importance with economic and social consequences.', 'DetailedDescription': 'Patients with stroke with uncontrolled glucose levels have higher mortality and poor post stroke outcomes. Controlling diabetes and other associated risk factors are effective ways to prevent initial strokes as well as stroke recurrence. Diabetes increases ischemic stroke incidence in all age groups, individuals with diabetes are more likely to suffer from hypertension, myocardial infarction and high cholesterol than individuals without diabetes have been linked to a greater risk of stroke. Smoking is a major cause of cardiovascular disease and causes one of every four deaths from cardiovascular disease. Smoking can raise triglycerides (a type of fat in your blood), Lower \"good\" cholesterol (high-density lipoprotein), Make blood sticky and more likely to clot, which can block blood flow to the heart and brain, Damage cells that line the blood vessels, Increase the buildup of plaque (fat, cholesterol, calcium, and other substances) in blood vessels and cause thickening and narrowing of blood vessels.The idea of lifestyle includes a broad variety of subjects, containing substantial life, spiritual life and other issues. Physical activity, smoking, alcohol consumption, nutrition and other aspects to measure lifestyle used by Chinese scientists. Health promoting lifestyle (HPL) is defined as \"a multi-dimensional pattern of self-initiated actions and perceptions that serve to maintain or enhance the level of wellness, self-actualization, and fulfillment of the individual\". It assesses a personal well-being activity that involves physical activity, dieting, spiritual growth, interpersonal relationships, health responsibility, and stress management, and would lead to enhaning wellbeing condition'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Health-Related Behavior']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '170', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Educational program', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. they will receive the nursing educational program which will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).also they will receive health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: educational program']}}, {'ArmGroupLabel': 'control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'aged patients 60 years and more, able to communicate, diagnosed with hypertension, diabetes mellitus and cardiac diseases. the will not receive educational program and life style promotion.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'educational program', 'InterventionDescription': 'The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Educational program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"the effect of implementing nursing educational program on Health Promoting Lifestyle for geriatric patients' at risk for stroke.\", 'PrimaryOutcomeDescription': 'by using tool II: It is a well-established instrument to assess personal lifestyle behaviors that promote health. It is composed of a 52-items questionnaire that is answered according to a 4-point Likert-type scale, with (Never (N) = 1, Sometimes (S) = 2, Often (O) = 3, Routinely (R) = 4). The total scale is 52-items and composed of six subscales to measure dimensions of health-promoting lifestyle that includes (spiritual growth, interpersonal relations, nutrition, physical activity, health responsibility and stress management). The total score will be adjusted from 0 to 100 and can classify the result to good lifestyle behavior if the percent score 60% and more and bad lifestyle behavior if less than 60%.', 'PrimaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge 60 years and more\\nDiagnosed with hypertension, diabetes mellitus and cardiac diseases.\\nAble to communicate with health team, free from mental problems, and agreed to participate in the study were included.\\n\\nExclusion Criteria:\\n\\nunable to communicate with health team.\\nfree from mental problems.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '60 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Faculty of Nursing', 'LocationCity': 'Assiut', 'LocationCountry': 'Egypt'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 21, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04744324', 'OrgStudyIdInfo': {'OrgStudyId': 'SKH-20201006R'}, 'Organization': {'OrgFullName': 'National Taipei University of Nursing and Health Sciences', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Self-supporting Care Model in Home Environment for Patients With Stroke', 'OfficialTitle': 'Effects of Self-supporting Care Model on Activities of Daily Living for Patients With Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'April 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 3, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 28, 2023', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'February 28, 2023', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 3, 2021', 'StudyFirstSubmitQCDate': 'February 3, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 8, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 6, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 10, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'En-Chi Chiu', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'National Taipei University of Nursing and Health Sciences'}, 'LeadSponsor': {'LeadSponsorName': 'National Taipei University of Nursing and Health Sciences', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"The purpose of this study was to administer intervention based on self-supporting care model in home environment and to explore the effects of this intervention on stroke patients' activities of daily living, movement, cognition, nutritional status, and quality of life.\", 'DetailedDescription': 'Subjects were randomized to intervention group and control group. The experiment was designed as randomized cross-over control trial. The primary outcome included 8 measures: Barthel Index-based Supplementary Scales, Canadian Occupational Performance Measure, Fugl-Meyer Assessment, Balance Computerized Adaptive Testing, Mini Mental State Examination-2nd edition, Mini Nutritional Assessment, Stroke Impact Scale, and Stroke Self-Efficacy Questionnaire.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Activities of Daily Living']}, 'KeywordList': {'Keyword': ['Stroke', 'Self-supporting Care Model', 'Home Care Services']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Crossover Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '28', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Self-supporting Care Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Self-supporting Care in home', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Self-supporting Care']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Home Health Education', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Home health education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Self-supporting Care', 'InterventionDescription': 'Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Self-supporting Care Group']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Home health education', 'InterventionDescription': 'Individualized home health education', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Barthel Index -based Supplementary Scales', 'PrimaryOutcomeDescription': 'The Barthel Index-based Supplementary Scales assesses basic activities of daily living using three scales:actual performance, ability, and self-perceived difficulty. The score ranges the three scales (i.e., actual performance, ability, and self-perceived difficulty)is 0-20, 0-18, and 0-20, respectively. A higher score indicates better basic activities of daily living.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Canadian Occupational Performance Measure', 'PrimaryOutcomeDescription': 'The Canadian Occupational Performance Measure is to measure occupational performance though three areas: self-care, productivity, and leisure. Patients define important activities and classify them with a score of one to 10. A higher score indicates better occupational performance.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Fugl-Meyer Assessment', 'PrimaryOutcomeDescription': 'The Fugl-Meyer Assessment scale is to assess the sensorimotor impairment in individuals who have had stroke. The score ranges is 0 to 226. A higher score indicates better body function.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Balance computerized adaptive testing', 'PrimaryOutcomeDescription': 'The Balance computerized adaptive testing is to assess balance ability.The score ranges is 0 to 10. A higher score indicates better balance ability.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Mini Mental State Examination-2nd edition', 'PrimaryOutcomeDescription': 'The Mini Mental State Examination-2nd edition is to assess cognitive functions. The score ranges is 0 to 90. A higher score indicates better cognitive functions.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Mini Nutritional Assessment', 'PrimaryOutcomeDescription': 'The Mini Nutritional Assessment is a comprehensive nutritional assessment scale. The score range is 0 to 30 points. The higher the score, the lower the risk of malnutrition.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Stroke Impact Scale', 'PrimaryOutcomeDescription': 'The Stroke Impact Scale is to assess health-related quality of life: emotion, communication, memory and thinking, and social role function. The score ranges is 59 to 295. A lower score indicates the quality of life less affected by stroke.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Stroke Self-Efficacy Questionnaire', 'PrimaryOutcomeDescription': 'The Stroke Self-Efficacy Questionnaire is a self-report scale measuring self-efficacy judgments in specific domains of functioning post stroke. The score ranges is 0 to 130. A higher score indicates better self-efficacy.', 'PrimaryOutcomeTimeFrame': 'Baseline to 4 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nage > 20 years\\nDiagnosis of stroke\\nThe modified Rankin Scale : 2~4\\nKeep sitting for half an hour by himself/herself\\nFollow instructions\\nWilling to sign the subject's consent\\n\\nExclusion Criteria:\\n\\nDiagnosis of dementia\\nHistory of orthopedic diseases or peripheral nerve injury\\nreadmission because of stroke\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'En-Chi Chiu, PhD', 'OverallOfficialAffiliation': 'National Taipei University of Nursing and Health Sciences', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Shin Kong Wu Ho-Su Memorial Hospital', 'LocationCity': 'Taipei City', 'LocationState': 'Shihlin District', 'LocationZip': '111045', 'LocationCountry': 'Taiwan'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 22, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03945526', 'OrgStudyIdInfo': {'OrgStudyId': 'Neuronutrition'}, 'Organization': {'OrgFullName': 'Indonesia University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and NIHSS of Stroke Patients', 'OfficialTitle': 'Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and National Institute of Health Stroke Scale Score of Acute Ischemic Stroke Patients: A Randomized Trial'}, 'StatusModule': {'StatusVerifiedDate': 'May 2019', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 23, 2010', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 9, 2010', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 9, 2010', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 8, 2019', 'StudyFirstSubmitQCDate': 'May 8, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 10, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 9, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 13, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Gabriella Nurahmani Putri', 'ResponsiblePartyInvestigatorTitle': 'Assistant Clinical Nutrition Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Indonesia University'}, 'LeadSponsor': {'LeadSponsorName': 'Indonesia University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is an interventional randomized, controlled trial in analyzing the effects of astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic stroke patients. According to published studies, it was hypothesized that acute ischemic stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and lower NIHSS score compared to the control group.', 'DetailedDescription': 'There were a total of 24 subjects, with 12 subjects in the intervention group and 12 subjects in the control group.The participants were divided into an interventional group and a control group. The interventional group was given astaxanthin supplementation 2 x 8mg per day for 7 days, while the control group was given placebo.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebral Stroke', 'Malondialdehyde', 'Oxidative Stress']}, 'KeywordList': {'Keyword': ['Astaxanthin', 'Antioxidant', 'Plasma Malondialdehyde', 'NIHSS score', 'Ischemic Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 1']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Astaxanthin and Placebo', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Astaxanthin', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Astaxanthin supplementation will be given at 2 x 8mg for 7 days.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Astaxanthine']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Placebo Oral Tablet']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Astaxanthine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Astaxanthin']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Astaxanthine 8mg']}}, {'InterventionType': 'Drug', 'InterventionName': 'Placebo Oral Tablet', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Astaxanthine placebo']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Plasma Malondialdehyde Levels on Astaxanthine Treated Stroke Patients as Assessed by Wills Spectrophotometry', 'PrimaryOutcomeDescription': 'This method used Thiobarbituric acid reaction (TBAR) with substances such as malondialdehyde. The scale was 0.367 nmol/ml-0.707 nmol/ml. The value above 0.707nmol/ml would be the worse outcome, and value less than 0.367nmol/ml would be the best outcome. Bivariate analysis was used to analyze the results (T-test or the Mann-Whitney Test).', 'PrimaryOutcomeTimeFrame': '7 days'}, {'PrimaryOutcomeMeasure': 'National Institute of Health Stroke Scale on Astaxanthine Treated Stroke Patients', 'PrimaryOutcomeDescription': 'Score scale was 4-15, where less than 4 indicates mild neurologic deficit, 4-15 moderate neurologic deficit, and more than 15 severe neurologic deficit. They will be assessed before and after the trial to compare how each participant improved after given the intervention.', 'PrimaryOutcomeTimeFrame': '7 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n40-65 years old\\nHas acute ischemic stroke with an onset of less than 48 hours before hospital admission\\nNIHSS score of less than or equal to 15\\nCan consume food orally or enterally\\nHas given their consent to be a participant in the study\\n\\nExclusion Criteria:\\n\\nRenal failure\\nLiver failure\\nIs taking supplements other than his or her main stroke medications\\nHas taken antioxidant supplements in the last 3 months before stroke onset', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Salim Harris, SpS', 'OverallOfficialAffiliation': 'IDI', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Sri Sukmaniah, SpGK', 'OverallOfficialAffiliation': 'IDI', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Nutrition University of Indonesia', 'LocationCity': 'Jakarta', 'LocationZip': '10340', 'LocationCountry': 'Indonesia'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '12760178', 'ReferenceType': 'background', 'ReferenceCitation': 'Barber PA, Demchuk AM, Hirt L, Buchan AM. Biochemistry of ischemic stroke. Adv Neurol. 2003;92:151-64. No abstract available.'}, {'ReferencePMID': '19218497', 'ReferenceType': 'background', 'ReferenceCitation': 'Shen H, Kuo CC, Chou J, Delvolve A, Jackson SN, Post J, Woods AS, Hoffer BJ, Wang Y, Harvey BK. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009 Jun;23(6):1958-68. doi: 10.1096/fj.08-123281. Epub 2009 Feb 13.'}, {'ReferencePMID': '1497349', 'ReferenceType': 'background', 'ReferenceCitation': 'Palozza P, Krinsky NI. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch Biochem Biophys. 1992 Sep;297(2):291-5. doi: 10.1016/0003-9861(92)90675-m.'}, {'ReferencePMID': '15635162', 'ReferenceType': 'background', 'ReferenceCitation': 'Hussein G, Nakamura M, Zhao Q, Iguchi T, Goto H, Sankawa U, Watanabe H. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull. 2005 Jan;28(1):47-52. doi: 10.1248/bpb.28.47.'}, {'ReferencePMID': '9799909', 'ReferenceType': 'background', 'ReferenceCitation': 'Gariballa SE, Sinclair AJ. Assessment and treatment of nutritional status in stroke patients. Postgrad Med J. 1998 Jul;74(873):395-9. doi: 10.1136/pgmj.74.873.395.'}, {'ReferencePMID': '11509080', 'ReferenceType': 'background', 'ReferenceCitation': 'Demirkaya S, Topcuoglu MA, Aydin A, Ulas UH, Isimer AI, Vural O. Malondialdehyde, glutathione peroxidase and superoxide dismutase in peripheral blood erythrocytes of patients with acute cerebral ischemia. Eur J Neurol. 2001 Jan;8(1):43-51. doi: 10.1046/j.1468-1331.2001.00166.x.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M3982', 'InterventionBrowseLeafName': 'Antioxidants', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 23, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03910855', 'OrgStudyIdInfo': {'OrgStudyId': '201711-00071'}, 'Organization': {'OrgFullName': 'Singapore General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Impact of Mindfulness on Psychological Well-being of Stroke Survivors and Their Caregivers', 'OfficialTitle': 'Investigating the Impact of Mindfulness on Psychological Well-being of Stroke Survivors and Their Caregivers: A Randomized Controlled Trial.', 'Acronym': 'SOMII'}, 'StatusModule': {'StatusVerifiedDate': 'June 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 15, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 15, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 12, 2019', 'StudyFirstSubmitQCDate': 'April 9, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'April 10, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 13, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 15, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Singapore General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will employ a randomized control design. Stroke survivors and family caregivers will be recruited for the study, and randomized either to receive mindfulness-based intervention or health education. Both programs consist of 4 2-hour sessions. Participants of the mindfulness-based intervention (MBI) will be taught and guided in practice of psychosocial interventions that are focused on (1) stress management and coping skills, (2), body awareness and movement, (3) feelings of empathy and compassion and (4) motivation for rehabilitation. Participants of the health education program (HEP) will learn and discuss topics related to self-care and post-stroke management. Measures will be administered prior to and on completion of the intervention, and at 3-month follow-up. They will be used to assess symptoms associated with depression, anxiety, stress, perceived quality of life and participant characteristics such as personality variables.', 'DetailedDescription': 'Stroke prevalence is 3-4% among Singaporeans above the age of 50, and will rise with our aging population. Stroke survivors face many concerns, including physical, psychological, cognitive and psychosocial consequences of stroke, as well as impaired functioning and quality of life. They often rely on their family for physical, cognitive and emotional support in order to perform daily functional activities. Dependence on family members has been shown to affect the physical, mental and emotional well-being of caregivers of stroke survivors. Research indicates that the long-term demands of caring for a stroke survivor puts a strain on caregivers who may not be able to provide the appropriate amount of care required to manage the needs of stroke survivors over time.\\n\\nMindfulness-based interventions (MBIs) are increasingly being offered as psychotherapeutic interventions for individuals who suffer from medical conditions such as stroke, and for their long-term family caregivers. Several review studies have shown that MBIs, specifically for long-term conditions, enhanced the ability to cope with physical difficulties, improved mental and emotional well-being as well as overall quality of life, promoting better health outcomes. A systematic review investigating the use of MBIs with stroke survivors found that psychological, physiological and psychosocial outcomes were improved, such as anxiety, depression, mental fatigue and overall quality of life (Lawrence et al., 2013).\\n\\nHowever, there are limited data for stroke survivors and their caregivers especially among Asians. Furthermore, there is little attention to study the interaction between participants characteristics and MBIs to determine whether there are any specific moderators that help to maximize the therapeutic outcomes of MBIs (Shaprio et al., 2011). Although there are growing number of studies correlating personality traits and dispositional mindfulness (Hanley, 2016; Giluk, 2009), little research has been done to examine personality traits as moderators to treatment outcome. Research focusing the the five-factor model of personality has demonstrated that the five personality traits have different strengths of correlation with the dispositional mindfulness. Among the traits, neuroticism displayed the strongest negative correlation with depositional mindfulness while conscientiousness displayed the strongest positive correlation with depositional mindfulness.\\n\\nThis study will be the first to examine the moderating effects of personality traits on the impact of mindfulness-based intervention in terms of depression, anxiety, stress and perceived quality of life of stroke survivors and their family caregivers. Furthermore, this study will evaluate and compare the impacts of mindfulness-based intervention and health education on the psychological well-being of both the participants. Findings will encourage the development of future strategies to understand the variability in treatment response and prognosis as well as to address individual differences with relevant psychotherapy skills.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Stress', 'Anxiety', 'Depression']}, 'KeywordList': {'Keyword': ['Mindfulness', 'Stroke Survivors', 'Caregivers']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Participants will be randomized to receive either a Mindfulness-based Intervention (MBI) or a Health Education Program (HEP). The intervention is for 4 weeks. Measures will be administered prior to and on completion of the intervention, and at 3-month follow-up.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '63', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Mindfulness Based Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Mindfulness Based Intervention']}}, {'ArmGroupLabel': 'Health Education Program', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Health Education Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Mindfulness Based Intervention', 'InterventionDescription': 'The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Mindfulness Based Intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Health Education Program', 'InterventionDescription': 'The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Health Education Program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cohen Perceived Stress Scale, PSS', 'PrimaryOutcomeDescription': 'A 10-item measure evaluating the perception of stress.', 'PrimaryOutcomeTimeFrame': 'An average of 1 Month'}, {'PrimaryOutcomeMeasure': 'Centre for Epidemiologic Studies Depression Scale (CES-D)', 'PrimaryOutcomeDescription': 'A 20-item measure for epidemiological research on depression.', 'PrimaryOutcomeTimeFrame': 'An average of 1 Week'}, {'PrimaryOutcomeMeasure': 'Stroke Specific Quality of Life Scale (SS-QOL)', 'PrimaryOutcomeDescription': 'A 49-item self-report questionnaire designed to measure the heath related quality of life specific to stroke survivors across 12 domains.', 'PrimaryOutcomeTimeFrame': 'An average of 1 month'}, {'PrimaryOutcomeMeasure': 'Stroke Impact Scale (SIS)', 'PrimaryOutcomeDescription': 'A 64-item questionnaire that assesses across 8 domains', 'PrimaryOutcomeTimeFrame': 'An average of 1 week'}, {'PrimaryOutcomeMeasure': 'Short-Form-36 (SF-36)', 'PrimaryOutcomeDescription': 'A 36-item self-report survey of health, including physical and mental health. Higher scaled scores reflect better quality of health.', 'PrimaryOutcomeTimeFrame': 'A range from 4 to 52 weeks'}, {'PrimaryOutcomeMeasure': 'The State-Trait Anxiety Inventory, STAI', 'PrimaryOutcomeDescription': 'The STAI is a commonly used measure of trait and state anxiety.', 'PrimaryOutcomeTimeFrame': 'State: Current state, Trait: An average of 1 month'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Zarit Burden Inventory (ZBI)', 'SecondaryOutcomeDescription': 'A 22-item self-report questionnaire to measure for level of caregiver burden or stress.', 'SecondaryOutcomeTimeFrame': 'An average of 1 month'}, {'SecondaryOutcomeMeasure': 'The Big Five Personality Inventory, BFI', 'SecondaryOutcomeDescription': '44-item inventory that measures an individual on the Big Five Factors (dimensions) of personality.', 'SecondaryOutcomeTimeFrame': 'An average of 1 month'}, {'SecondaryOutcomeMeasure': 'Five Facet Mindfulness Questionnaire, FFMQ', 'SecondaryOutcomeDescription': 'This 39-item instrument is based on a factor analytic study of five independently developed mindfulness questionnaires.', 'SecondaryOutcomeTimeFrame': 'An average of 1 month'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nStroke survivors and/ or their\\nFamily Caregivers\\nComprehends and provides consent independently\\n\\nExclusion Criteria:\\n\\n-Cognitively impaired individuals with a MMSE score of less than 20, and a MoCA score of less than 23.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '21 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Kinjal Doshi, PhD', 'OverallOfficialAffiliation': 'Singapore General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Singapore General Hospital', 'LocationCity': 'Singapore', 'LocationZip': '169608', 'LocationCountry': 'Singapore'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided', 'IPDSharingDescription': 'Preliminary data to inform design of future studies.'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6748', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6751', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4014', 'ConditionBrowseLeafName': 'Anxiety Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}}}}, {'Rank': 24, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05162781', 'OrgStudyIdInfo': {'OrgStudyId': 'IRB-300008211'}, 'SecondaryIdInfoList': {'SecondaryIdInfo': [{'SecondaryId': '1R01AG070049-01A1', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://reporter.nih.gov/quickSearch/1R01AG070049-01A1'}]}, 'Organization': {'OrgFullName': 'University of Alabama at Birmingham', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke', 'OfficialTitle': 'Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'August 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 9, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 30, 2025', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 30, 2026', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'November 19, 2021', 'StudyFirstSubmitQCDate': 'December 6, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 17, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 11, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 15, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Gitendra Uswatte', 'ResponsiblePartyInvestigatorTitle': 'Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Alabama at Birmingham'}, 'LeadSponsor': {'LeadSponsorName': 'University of Alabama at Birmingham', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'National Institute on Aging (NIA)', 'CollaboratorClass': 'NIH'}, {'CollaboratorName': 'Posit Science', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study will compare two approaches to cognitive rehabilitation in adults with stroke with persistent, mild to moderate, cognitive impairment. Both approaches will feature a web-based computer \"game\" that trains cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. This training is termed Speed of Processing Training (SOPT). One approach will add (A) in-lab training on everyday activities with important cognitive components and (B) procedures designed to transfer improvements in cognition from the treatment setting to everyday life. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will add (A) in-lab training on relaxation, healthy nutrition, and healthy sleep and (B) procedures designed to promote integration of these lifestyle changes into everyday life. This approach is termed Brain Fitness-Heath Education Lifestyle Program (BF-HELP).\\n\\nBoth CICT and BF-HELP will involve 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life; The set of the latter procedures is termed the Transfer Package. To accommodate the demands of participants\\' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. Family caregivers in both groups will also receive training on how to best support participants in their therapeutic program.\\n\\nThe study will also test if there is an advantage to placing follow-up phone calls after treatment ends. The purpose of the calls will be to support transition of any behavioral changes achieved during treatment into everyday life on a long-term basis.\\n\\nParticipants will be randomly assigned to the interventions.\\n\\nTesting will happen one month before treatment, one day before treatment, one day afterwards, and 6- and 12-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Cognitive Dysfunction']}, 'KeywordList': {'Keyword': ['stroke', 'cognitive dysfunction', 'cognitive processing speed', 'IADL']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Half of the participants will receive CICT, which consists of SOPT, IADL training in the lab, and a Transfer Package targeting IADL performance outside it. The other half will receive BF-HELP, which consists of SOPT, in-lab training on relaxation, nutrition, and sleep hygiene, and a Transfer Package targeting implementation of these lifestyle changes outside it. Half of the CICT group will receive 15 follow-up phone calls over the course of one year. The other CICT participants will receive none. The same will apply to the BF-HELP group. The phone calls will support integration of the behavioral changes targeted during treatment to everyday life afterwards.\\n\\nFor all participants, outcome testing will take place one month before treatment (Baseline 1), one day before treatment (Baseline 2 aka Pre-treatment), one day afterwards (Post-treatment), 6-months afterwards (6-month Follow-up), and 12-months afterwards (12-month follow-up). Randomization will take place after Baseline 2.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': 'Tester will be blinded to group assignment of participants.', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'CICT with Follow-up Phone Calls', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Instrumental Activities of Daily Living In-lab Training', 'Behavioral: Cognitive Transfer Packagke', 'Behavioral: Family Caregiver Coaching', 'Behavioral: Follow-up Phone Calls']}}, {'ArmGroupLabel': 'CICT without Follow-up Phone Calls', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Instrumental Activities of Daily Living In-lab Training', 'Behavioral: Cognitive Transfer Packagke', 'Behavioral: Family Caregiver Coaching']}}, {'ArmGroupLabel': 'BF-HELP with Follow-up Phone Calls', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Family Caregiver Coaching', 'Behavioral: Follow-up Phone Calls', 'Behavioral: Healthy Lifestyle In-lab Training', 'Behavioral: Healthy Lifestyle Transfer Package']}}, {'ArmGroupLabel': 'BF-HELP without Follow-up Phone Calls', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Speed of Processing Training', 'Behavioral: Family Caregiver Coaching', 'Behavioral: Follow-up Phone Calls', 'Behavioral: Healthy Lifestyle In-lab Training', 'Behavioral: Healthy Lifestyle Transfer Package']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Speed of Processing Training', 'InterventionDescription': 'This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer \"game\", in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls', 'CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}, 'InterventionOtherNameList': {'InterventionOtherName': ['SOPT']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Instrumental Activities of Daily Living In-lab Training', 'InterventionDescription': 'The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}, 'InterventionOtherNameList': {'InterventionOtherName': ['IADL In-lab Training']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive Transfer Packagke', 'InterventionDescription': 'This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Family Caregiver Coaching', 'InterventionDescription': 'One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls', 'CICT with Follow-up Phone Calls', 'CICT without Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Follow-up Phone Calls', 'InterventionDescription': 'After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls', 'CICT with Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Healthy Lifestyle In-lab Training', 'InterventionDescription': 'This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Healthy Lifestyle Transfer Package', 'InterventionDescription': 'This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['BF-HELP with Follow-up Phone Calls', 'BF-HELP without Follow-up Phone Calls']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Quality of Life in Neurological Disorders Measures (Neuro-QOL), Cognitive Function Scale', 'PrimaryOutcomeDescription': 'The Neuro-QOL assesses function in daily life in several domains; it is a widely used, validated, transdiagnostic, self-report measure. The development and use of the Neuro-QOL is supported by the National Institutes of Health. The component of the Neuro-QOL that assessed cognitive function will be used here. Items are rated by respondents using a five-point scale: 1 = not at all, 5 = very much. Higher scores indicate better function.', 'PrimaryOutcomeTimeFrame': 'Change from Day 30 to Day 60, i.e., from Pre- to Post-treatment'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Primary Inclusion Criteria:\\n\\nstroke > 1 year previously\\nmild-to-moderate general cognitive impairment as determined by a Montreal Cognitive Assessment (MOCA) score between 10-26\\nsome impairment in performance of daily activities; this will be determined by a score of 3 or below on the Cognitive Task Activity Log (CTAL)\\n\\nAdditional Inclusion Criteria:\\n\\n40 years or older; no upper limit if medically stable\\nsufficiently fit, from both a physical and mental health perspective, to take part in study\\nadequate sight and hearing to complete UFOV test\\nadequate thinking skills, e.g., ability to follow directions, retain information, to complete UFOV and CTAL, as marked by judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\\nreside in the community (as opposed to a hospital or skilled nursing facility)\\nable to travel to laboratory on multiple occasions\\ncaregiver available\\n\\nExclusion Criteria:\\n\\ncognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse or due to another type of brain injury, such a traumatic brain injury, or a progressive brain disease, such as Alzheimer's Dementia\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Edward Taub, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '205-934-2471', 'CentralContactEMail': 'etaub@uab.edu'}, {'CentralContactName': 'Gitendra Uswatte, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '205-975-5089', 'CentralContactEMail': 'guswatte@uab.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Edward Taub, PhD', 'OverallOfficialAffiliation': 'University of Alabama at Birmingham', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Alabama at Birmingham', 'LocationStatus': 'Recruiting', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35294', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Staci McKay, BS', 'LocationContactRole': 'Contact', 'LocationContactPhone': '205-934-9768', 'LocationContactEMail': 'stacemc@uab.edu'}, {'LocationContactName': 'Edward Taub, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '205-934-2471', 'LocationContactEMail': 'etaub@uab.edu'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000060825', 'ConditionMeshTerm': 'Cognitive Dysfunction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafAsFound': 'Cognitive Dysfunction', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5991', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21526', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4505', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14163', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M12168', 'InterventionBrowseLeafName': 'Nicotine', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 25, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05902767', 'OrgStudyIdInfo': {'OrgStudyId': 'NUT-me'}, 'Organization': {'OrgFullName': 'Monash University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nut Supplementation to Mitigate Post-stroke Cognitive Decline', 'OfficialTitle': 'Nut Supplementation to Mitigate Post-stroke Cognitive Decline (NUT-me): a Pilot Study', 'Acronym': 'NUT-me'}, 'StatusModule': {'StatusVerifiedDate': 'June 2023', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 30, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 30, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 18, 2023', 'StudyFirstSubmitQCDate': 'June 5, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 15, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 5, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 15, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Barbara R. Cardoso', 'ResponsiblePartyInvestigatorTitle': 'Senior Lecturer', 'ResponsiblePartyInvestigatorAffiliation': 'Monash University'}, 'LeadSponsor': {'LeadSponsorName': 'Monash University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is a strong risk factor for dementia, with up to 80% of individuals having lower cognitive function 5 years after a stroke event. However, having a stroke does not need to result in declining cognition if effective strategies to reduce the risk of post stroke dementia are identified. Diets containing nuts can reduce the risk of both dementia and stroke but have not been tested in stroke survivors. Therefore, this pilot study aims to determine whether eating nuts regularly reduces post-stroke cognitive decline and dementia. The NUT-me pilot study will supplement the diet of stroke survivors with a mix of nuts containing walnuts, hazelnuts, almonds and Brazil nuts for 3 months and assess the effects on cognition and health markers. The researchers predict that regular nut consumption will contribute to preserving post-stroke cognitive function in comparison to patients who do not consume nuts. The results of this novel pilot study will be used to guide a larger trial and provide a simple dietary strategy that stroke survivors can adopt to reduce post-stroke cognitive decline.', 'DetailedDescription': \"This study will investigate the efficacy and feasibility of supplementing the habitual diet of stroke survivors with a supply of mixed nuts containing Brazil nut, walnuts, hazelnuts, and almonds to reduce post-stroke cognitive decline. The overall aim of this project will be achieved through the following objectives:\\n\\nExamine the feasibility through the assessment of compliance with the intervention and participants' perception of the study\\nInvestigate the efficacy of the intervention on cognitive decline, body composition and health outcomes (blood pressure, fasting glucose and insulin, and blood lipids) The investigators hypothesise that the inclusion of nuts is a simple dietary strategy that will slow post-stroke cognitive decline and that supplementation with nuts will improve body composition and health biomarkers of stroke survivors.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Dementia']}, 'KeywordList': {'Keyword': ['dementia', 'cognitive decline', 'nuts']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'The participants will be randomly assigned to one of the two study groups: Nuts of Control.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '10', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Nut Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive a supply of mixed nuts containing: 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nuts']}}, {'ArmGroupLabel': 'Control Group', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Participants will follow the same protocol as the Nut group regarding appointments and collection of information. At the visits, they will receive dietary counselling on how to follow the Australian Dietary Guidelines', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Control']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nuts', 'InterventionDescription': 'A mix of nuts containing 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.\\nDietary counselling on how to follow the Australian Dietary Guidelines', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nut Group']}}, {'InterventionType': 'Other', 'InterventionName': 'Control', 'InterventionDescription': '- Dietary counselling on how to follow the Australian Dietary Guidelines', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cognitive Function Composite Score', 'PrimaryOutcomeDescription': 'Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.', 'PrimaryOutcomeTimeFrame': '90 days'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Fluid Cognition Composite Score', 'SecondaryOutcomeDescription': 'Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Crystallized Cognition Composite Score', 'SecondaryOutcomeDescription': 'Cognitive performance after the 90-day intervention will be assessed in comparison to baseline by using the NIH Toolbox Cognition Battery V3. This validated battery encompasses 15 tests that are combined to generate composite scores by age: Crystalised Composite (which includes picture vocabulary and oral reading recognition tests) and Fluid Composite (which includes dimensional change card sort, flanker, picture sequence memory, list sorting, and pattern comparison tests).The Cognitive Function Composite Score is a combination of both crystallized and fluid scores. Higher scores indicate better cognitive performance.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': '% body fat', 'SecondaryOutcomeDescription': 'Changes in % body fat measured using bioelectrical Impedance Analysis (BIA)', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Depressive symptoms', 'SecondaryOutcomeDescription': 'Changes in the presence of depressive symptoms assessed by Patient Health Questionnaire (PHQ-9). The score ranges from zero to 27, with higher scores indicating worse depressive symptoms.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'HOMA-IR', 'SecondaryOutcomeDescription': 'HOMA-IR is a measure of insulin resistance. It is calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Blood lipids', 'SecondaryOutcomeDescription': 'Changes in total cholesterol, LDL, HDL and triglycerides', 'SecondaryOutcomeTimeFrame': '90 days'}, {'SecondaryOutcomeMeasure': 'Inflammatory markers', 'SecondaryOutcomeDescription': 'Changes in the composite of the following inflammatory markers: IL-6, IL-1β, IL-8, IL-10, and IL-1ra', 'SecondaryOutcomeTimeFrame': '90 days'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIschaemic stroke (first or recurrent stroke) in the last 6 months\\nAble to attend 4 study visits over 3 months\\nMotivation and willingness to participate in the study protocol\\nNo prior neurological or psychiatric disease, including dementia\\nCan give informed consent and participate in cognitive testing\\n\\nExclusion Criteria:\\n\\nbe < 18 years;\\nhave allergy to nuts\\nhave premorbid modified Rankin scale (mRS)≥4, denoting no severe disability\\nincapable of giving consent\\nhave problems with mastication that preclude nut intake\\nhave habitual consumption of tree nuts (>2 servings/wk) in the previous 2 months\\nhave habitual consumption of alpha-linolenic acid supplements (fish oil, flaxseed oil, and/or soy lecithin)\\nhave dementia or psychiatric disease\\ndo not speak English', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Barbara R Cardoso, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+61499840472', 'CentralContactEMail': 'barbara.cardoso@monash.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Barbara R Cardoso, PhD', 'OverallOfficialAffiliation': 'Department of Nutrition, Dietetics and Food - Monash University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Department of Nutrition, Dietetics and Food - Monash University', 'LocationCity': 'Melbourne', 'LocationState': 'Victoria', 'LocationZip': '3168', 'LocationCountry': 'Australia', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Barbara R Cardoso, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+61499840472', 'LocationContactEMail': 'barbara.cardoso@monash.edu'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'This is a small pilot study and the generated data will be used only by the Principal Investigator as preliminary data in grant applications and potentially one publication (yet to be decided).'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000003704', 'ConditionMeshTerm': 'Dementia'}, {'ConditionMeshId': 'D000060825', 'ConditionMeshTerm': 'Cognitive Dysfunction'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M29395', 'ConditionBrowseLeafName': 'Cognitive Dysfunction', 'ConditionBrowseLeafAsFound': 'Cognitive Decline', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6594', 'ConditionBrowseLeafName': 'Dementia', 'ConditionBrowseLeafAsFound': 'Dementia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21526', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4505', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14163', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5991', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'T143', 'InterventionBrowseLeafName': 'English Walnut', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 26, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04387747', 'OrgStudyIdInfo': {'OrgStudyId': 'ıstPMRTRH-SRCPN'}, 'Organization': {'OrgFullName': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital', 'OrgClass': 'OTHER_GOV'}, 'BriefTitle': 'Evaluation of Sarcopenia in Patients With Stroke', 'OfficialTitle': 'Evaluation Of Sarcopenia In Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'May 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'September 15, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 1, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'June 1, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'May 11, 2020', 'StudyFirstSubmitQCDate': 'May 13, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 14, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 26, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 30, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Tuğba Aydın', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital', 'LeadSponsorClass': 'OTHER_GOV'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The aim of this study is to investigate the prevalence of sarcopenia in stroke patients; to determine the relationship between sarcopenia and duration of stroke, age, gender, etiology of stroke, ambulation status, spasticity, nutrition and malnutrition', 'DetailedDescription': 'Sarcopenia was defined as a loss of skeletal muscle mass and decreased muscle strength. The purpose of this study was to investigate the prevalence of sarcopenia following stroke, to investigate the relationship between sarcopenia and duration of stroke, age, sex, etiology of stroke, ambulation status, spasticity, nutrition and malnutrition. Demographic characteristics, duration of stroke, sarcopenia presence (walking speed ≥ 0.8 m / s, SARC-F score ≥4, short physical performance battery score ≤ 8, thigh circumference <33cm (The data for Turkey) <31cm (European data)) were recorded. Hand grip strength (jamar) measured from the intact hand and TANITA BIA analysis were planned for all patients.\\n\\nAmbulation level with Functional Ambulation Classification (FAC), nutritional status with 24-hour dietary recall (24HR) method, diagnosis of malnutrition with Glim Criteria, spasticity with Modified Ashworth Scale, motor development for stroke patient Brunnstrom staging, screening for frailty with Frail questionnaire activity of daily living were evaluated with Barthel Index.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Sarcopenia', 'Stroke']}, 'KeywordList': {'Keyword': ['sarcopenia', 'stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '81', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'SARCOPENIA IN STROKE PATIENTS', 'InterventionDescription': 'Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Functional Ambulation Classification (FAC)', 'PrimaryOutcomeDescription': 'The Functional Ambulation Categories (FAC) is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device. FAC stage 0 indicates the non-functional ambulation, and stage 5 indicates the independent walking at each speed and on ground.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': '24-hour dietary recall (24HR) method', 'PrimaryOutcomeDescription': '24-hour dietary recall method consists of precisely recalling, describing and quantifying the intake of foods and beverages consumed during the day before the interview, from the first intake in the morning until the last foods or beverages consumed at night.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': 'Glim Criteria', 'PrimaryOutcomeDescription': 'The five criteria for malnutrition include non-volitional weight loss, low body mass index, and reduced muscle mass as phenotypic criteria, and reduced food intake/assimilation and inflammation/disease burden as etiologic criteria. It is proposed that the diagnosis of malnutrition be based upon the presence of at least one phenotypic criterion and one etiologic criterion.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': 'sarcopenia', 'PrimaryOutcomeDescription': 'The walking speed ≥0.8 m / s, SARC-F score ≥4, short physical performance battery score ≤ 8, thigh circumference <33cm.', 'PrimaryOutcomeTimeFrame': '1 interview day'}, {'PrimaryOutcomeMeasure': 'EQ-5D', 'PrimaryOutcomeDescription': 'EQ-5D-3L is used to evaluate the quality of life. This scale scores five health conditions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) through evaluation in 3 levels (no problems, some problems, extreme problems).', 'PrimaryOutcomeTimeFrame': '1 interview day'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Barthel index', 'SecondaryOutcomeDescription': 'The Barthel Index measures the activity limitations in patients with neuromuscular disease. The Barthel Index are assessed, including toileting, bathing, eating, dressing, continence, transfers, and ambulation. A client scoring 0 points would be dependent in all assessed activities of daily living, whereas a score of 100 would reflect independence in these activities.', 'SecondaryOutcomeTimeFrame': '1 interview day'}, {'SecondaryOutcomeMeasure': \"Brunnstrom's staging\", 'SecondaryOutcomeDescription': \"Brunnstrom's staging is used to evaluate the sequence of motor development and reorganization of the brain after stroke in six stages. Stage 1: Flaccidity; Stage 2: Spasticity Appears; Stage 3: Increased Spasticity; Stage 4: Decreased Spasticity; Stage 5: Spasticity Continues to Decrease; Stage 6: Spasticity Disappears and Coordination Reappears.\", 'SecondaryOutcomeTimeFrame': '1 interview day'}, {'SecondaryOutcomeMeasure': 'Modified Ashworth Scale', 'SecondaryOutcomeDescription': 'The Modified Ashworth scale (MAS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Scoring: 0: No increase in muscle tone; 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension; 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM; 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved; 3: Considerable increase in muscle tone, passive movement difficult; 4: Affected part(s) rigid in flexion or extension.', 'SecondaryOutcomeTimeFrame': '1 interview day'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients with chronic stroke (Stroke duration > 3 months)\\nPatients with a FAC score > 3\\n\\nExclusion Criteria:\\n\\nPatients unable to cooperate\\nOther diseases that cause gait disorders such as neuromuscular disease, cardiopulmonary problems.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '40 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Inpatient stroke cases', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'TUGBA AYDIN, MD', 'OverallOfficialAffiliation': 'Istanbul Physical Medicine Rehabilitation Training & Research Hospital', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Istanbul Physical Medicine Rehabilitation Training and Research Hospital', 'LocationCity': 'İstanbul', 'LocationZip': '34192', 'LocationCountry': 'Turkey'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '25676847', 'ReferenceType': 'background', 'ReferenceCitation': 'Scherbakov N, Sandek A, Doehner W. Stroke-related sarcopenia: specific characteristics. J Am Med Dir Assoc. 2015 Apr;16(4):272-6. doi: 10.1016/j.jamda.2014.12.007. Epub 2015 Feb 10.'}, {'ReferencePMID': '27530769', 'ReferenceType': 'background', 'ReferenceCitation': 'Ryan AS, Ivey FM, Serra MC, Hartstein J, Hafer-Macko CE. Sarcopenia and Physical Function in Middle-Aged and Older Stroke Survivors. Arch Phys Med Rehabil. 2017 Mar;98(3):495-499. doi: 10.1016/j.apmr.2016.07.015. Epub 2016 Aug 13.'}, {'ReferencePMID': '34356039', 'ReferenceType': 'derived', 'ReferenceCitation': 'Aydin T, Kesiktas FN, Oren MM, Erdogan T, Ahisha YC, Kizilkurt T, Corum M, Karacan I, Ozturk S, Bahat G. Sarcopenia in patients following stroke: an overlooked problem. Int J Rehabil Res. 2021 Sep 1;44(3):269-275. doi: 10.1097/MRR.0000000000000487.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000055948', 'ConditionMeshTerm': 'Sarcopenia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009133', 'ConditionAncestorTerm': 'Muscular Atrophy'}, {'ConditionAncestorId': 'D000020879', 'ConditionAncestorTerm': 'Neuromuscular Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000001284', 'ConditionAncestorTerm': 'Atrophy'}, {'ConditionAncestorId': 'D000020763', 'ConditionAncestorTerm': 'Pathological Conditions, Anatomical'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafAsFound': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11780', 'ConditionBrowseLeafName': 'Muscular Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4279', 'ConditionBrowseLeafName': 'Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22309', 'ConditionBrowseLeafName': 'Neuromuscular Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22209', 'ConditionBrowseLeafName': 'Pathological Conditions, Anatomical', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 27, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05369637', 'OrgStudyIdInfo': {'OrgStudyId': '75/CES/JAS/2021'}, 'Organization': {'OrgFullName': 'Instituto de Saude Publica da Universidade do Porto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Multiple Interventions to Accelerate the Return to the Pre-event Level of Functioning After a TIA and Minor Stroke', 'OfficialTitle': 'Back to Normal - Multiple Non-pharmacological Interventions to Accelerate the Return to the Pre-event Level of Functioning After a Transient Ischemic Attack and Minor Stroke - a Pilot Randomized Controlled Trial'}, 'StatusModule': {'StatusVerifiedDate': 'May 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 11, 2022', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 2, 2022', 'StudyFirstSubmitQCDate': 'May 6, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 11, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 31, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 3, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Instituto de Saude Publica da Universidade do Porto', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The occurrence of a transient ischemic attack (TIA) or a minor stroke is frequently assumed as a temporary and non-disabling event. Nevertheless, patients can experience subtle but meaningful impairments, including a decreased performance in activities of daily living (ADLs), a high prevalence of depression, cognitive decline, physical deficits, hearing degeneration, with implications in returning to work, social relations and activities. Additionally, it has been described a higher risk of stroke among these patients, which highlights the importance of promoting secondary prevention, soon after these acute episodes. Therefore, this pilot randomized controlled trial (RCT) aims to evaluate the feasibility and the effectiveness of a three-month multidomain intervention program, composed of five non-pharmacological components which may contribute to accelerate the return to the pre-event level of functioning in patients with TIA and minor stroke. The results may guide future clinical practices and health policies aiming to reduce the overall burden of stroke.', 'DetailedDescription': 'This is pragmatic non-pharmacological RCT, which will include patients diagnosed with a TIA or a minor stroke recruited at the emergency or neurology departments of the Hospital Pedro Hispano, located in Matosinhos, Portugal (n=70). Those who accept to participate will be randomly allocated to 2 groups (1:1): (a) Intervention - will receive a combined approach of cognitive training, physical exercise, nutrition education and psychoeducation sessions, during three-months, as well as assessment/correction of hearing loss; (b) Control - participants will not be subject to any intervention. Both groups will receive the usual standard of care provided to these types of clinical diseases.\\n\\nData will be collected using different strategies. Trained interviewers will conduct face-to-face interviews, covering sociodemographic characteristics, lifestyles (including adherence to the mediterranean diet), health status, and will perform anthropometry and measure blood pressure as well as physical performance. The complete or partial recovery time of instrumental ADLs will be assessed using an adapted version of the Frenchay Activities Index. Disability and basic ADLs will be also evaluated (Modified Rankin Scale and Barthel Index, respectively). Cognitive function will be evaluated using the Montreal Cognitive Assessment and a self-administered web-based tool for remote longitudinal assessment (Brain on Track), if applicable. Symptoms of anxiety and depression, as well as quality of life, will be evaluated through self-administered instruments. Levels of glycated hemoglobin and 24-hour urinary sodium, potassium and creatinine excretions, as well as pH levels, will be also measured. All participants will be evaluated at 0 and 3 months after the beginning of the intervention. Electronic medical records will be assessed to obtain clinical data.\\n\\nFunctionality recovery will be defined as a primary outcome and additional information regarding the feasibility, outcomes and sample size requirements of such programs will also be assessed, which is crucial to implement a large-scale RCT.\\n\\nThis project was previously approved by the Local Ethics Committee and by the Data Protection Officer of the Institute of Public Health of the University of Porto. In this context, all procedures will be undertaken to guarantee compliance with ethical standards, as well as data protection and safety, considering national and international laws.\\n\\nThis study will be developed as part of the project \"Multiple Interventions to Prevent Cognitive Decline\" (MIND-Matosinhos).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Transient Ischemic Attack', 'Minor Stroke']}, 'KeywordList': {'Keyword': ['Transient Ischemic Attack', 'Minor Stroke', 'Non-Pharmacological Interventions', 'Activities of Daily Living', 'Randomized Controlled Trial']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '70', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Non-pharmacological Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants in the intervention group will receive a multidomain non-pharmacological program, including cognitive training, physical exercise, nutrition education, psychoeducation, and diagnosis and correction of hearing impairment.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive training', 'Behavioral: Physical exercise', 'Behavioral: Behavioral: Nutrition education', 'Behavioral: Psychoeducation', 'Other: Diagnosis and correction of hearing impairment']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Control group will receive the usual standard of care provided to these clinical diseases.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive training', 'InterventionDescription': 'This component will comprise the following activities:\\n\\ni. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Physical exercise', 'InterventionDescription': 'This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:\\n\\ni. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Behavioral: Nutrition education', 'InterventionDescription': 'This component will be based on the following activities:\\n\\ni. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Psychoeducation', 'InterventionDescription': 'This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}, {'InterventionType': 'Other', 'InterventionName': 'Diagnosis and correction of hearing impairment', 'InterventionDescription': 'This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Non-pharmacological Intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Time to recovery in each instrumental activity of daily living', 'PrimaryOutcomeDescription': 'Time to recovery in each instrumental activity of daily living measured by an adapted version of the Frenchay Activities Index.', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Recruitment timeframe', 'PrimaryOutcomeDescription': 'Proportion of participants recruited within the seven days post-onset of symptoms will be calculated as the number of participants recruited within the time frame divided by the total number of participants.', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Adherence to each component of the intervention', 'PrimaryOutcomeDescription': 'Proportion of adherence to each component of the intervention and to different intervention modalities (remote/in person), calculated as the number of sessions attended divided by the total number of sessions implemented. For remote cognitive training the outcome will be the absolute number of sessions.', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Dropout', 'PrimaryOutcomeDescription': 'Proportion of participants who dropped out of the study, calculated as the number of participants who dropped out after attending at least one session divided by the total number of participants who attended at least one session.', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Time of follow-up', 'SecondaryOutcomeDescription': 'Number of days between the first and the last session attended by the participant.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Complete assessment of participants', 'SecondaryOutcomeDescription': 'For each study outcome, proportion of participants with complete information, calculated at baseline and follow-up, as the number of participants with complete information divided by the total number of participants evaluated.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Implemented sessions', 'SecondaryOutcomeDescription': 'Proportion of sessions implemented, calculated as the number of sessions that the research team was able to implement divided by the total number of sessions planned.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Cognitive performance', 'SecondaryOutcomeDescription': \"Variation of participant's cognitive performance assessed using the Montreal Cognitive Assessment, between the baseline and the follow-up assessments. This scale varies from 0 (worst cognitive performance) to 30 points (best cognitive performance).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Memory complaints', 'SecondaryOutcomeDescription': 'Variation of the self-reported memory complaints, assessed using the Subjective Memory Complaints Scale, between the baseline and follow-up assessments. This scale varies from 0 (best score) to 21 points (worst score). Scores over three points indicate the presence of self-reported memory complaints.', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Adherence to the Mediterranean diet', 'SecondaryOutcomeDescription': \"Variation of participant's self-reported adherence to the Mediterranean diet, assessed using the Mediterranean food pattern (MEDAS) scale, between the baseline and the follow-up assessments. This scale varies from 0 (lowest adherence to the Mediterranean diet) to 14 points (highest adherence to the Mediterranean diet). A score over 10 points indicates good adherence to the Mediterranean diet.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Anxiety and depression', 'SecondaryOutcomeDescription': 'Variation of the anxiety and depression scores, assessed using the Hospital Anxiety and Depression Scale (HADS), between the baseline and the follow-up assessments. This scale varies from 0 (best score) to 21 points (worst score).', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Reported quality of life', 'SecondaryOutcomeDescription': \"Variation of participant's quality of life, assessed using the EuroQol Group scale - 5 dimensions (EQ-5D) scale, between the baseline and the follow-up assessments. This scale is subdivided in two subscales: a) five multiple choice questions, with five response possibilities, which produce a score that varies from 5 (best score) to 25 points (worst score); b) visual analogic scale, that varies from 0 (worst score) to 100 (best score).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Handgrip strength', 'SecondaryOutcomeDescription': \"Variation of participant's handgrip strength, assessed using a dynamometer, between the baseline and the follow-up assessments.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Agility 1', 'SecondaryOutcomeDescription': \"Variation of participant's agility and balance, assessed using the Timed Up and Go Test scale, between the baseline and the follow-up assessments. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Agility 2', 'SecondaryOutcomeDescription': \"Variation of participant's agility and balance, assessed using the Unipedal Stance Test, between the baseline and the follow-up assessments. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Upper body strength', 'SecondaryOutcomeDescription': \"Variation of participant's upper body strength assessed using the 30-second arm curl test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Lower body strength', 'SecondaryOutcomeDescription': \"Variation of participant's lower body strength assessed using the 30-second chair stand test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Upper body flexibility', 'SecondaryOutcomeDescription': \"Variation of participant's upper body flexibility assessed using the back-scratch test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Lower body flexibility', 'SecondaryOutcomeDescription': \"Variation of participant's lower body flexibility assessed using the chair sit-and-reach test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Agility 3', 'SecondaryOutcomeDescription': \"Variation of participant's agility and dynamic balance assessed using the 8-foot distance test (2,44 meters), from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Aerobic endurance', 'SecondaryOutcomeDescription': \"Variation of participant's aerobic endurance assessed using the 2-minute step test, from the Senior Fitness Test.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Lower limb function', 'SecondaryOutcomeDescription': \"Variation of participant's lower limb function, assessed using the Short Physical Performance Battery (SPPB), which tests 3 dimensions: standing balance, walking speed, and chair stands. Each component is scored between 0-4, total score from 0 (poor performance) to 12 (best performance).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Functional capacity to perform basic activities of daily living', 'SecondaryOutcomeDescription': \"Variation of participant's independence on performing basic activities of daily living, using the Barthel Index, which ranges from 0 to 20 and higher scores represent increased functionality and independence.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Disability', 'SecondaryOutcomeDescription': \"Variation of participant's disability assessed via modified Rankin Scale, with scores ranging from 0 (perfect health) to 6 (dead).\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': '24-hour urinary sodium excretion', 'SecondaryOutcomeDescription': \"Variation of participant's urinary sodium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary salt intake.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': '24-hour urinary potassium excretion', 'SecondaryOutcomeDescription': \"Variation of participant's urinary potassium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary potassium intake.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Levels of glycated hemoglobin', 'SecondaryOutcomeDescription': \"Variation of participant's levels of glycated hemoglobin, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' blood sample and will be used to analyze glycemic control.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Body mass index', 'SecondaryOutcomeDescription': \"Variation of participant's body mass index between the baseline and the follow-up assessments.\", 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Blood pressure', 'SecondaryOutcomeDescription': \"Variation of participant's systolic and diastolic blood pressure between the baseline and the follow-up assessments.\", 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAged 18-85 years old;\\nClinical diagnosis of transient ischemic stroke or minor stroke as defined by the National Institute of Health Stroke Scale score ≤3;\\nOnset of symptoms within the last seven days;\\nFirst-time stroke or TIA;\\nFour or more years of education;\\nDischarged home without the need for inpatient rehabilitation;\\nModified Rankin Scale 0 to 2, inclusive.\\n\\nExclusion Criteria:\\n\\nUnable to attend the face-to-face intervention sessions;\\nPrevious diagnosis of Dementia or severe disability;\\nContraindication for physical exercise;\\nSevere loss of hearing, vision, or communication skills;\\nFrailty, reduced life expectancy due to severe disease or need for regular treatments that compete with availability for intervention.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '85 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Ana Rute Costa, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+351 22 206 1820', 'CentralContactEMail': 'arcosta@ispup.up.pt'}, {'CentralContactName': 'Micaela Gonçalves, Bachelor', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+351 22 206 1820', 'CentralContactEMail': 'esmeralda_micaela@hotmail.com'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Vítor Tedim Cruz, PhD', 'OverallOfficialAffiliation': 'Instituto de Saude Publica da Universidade do Porto', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Instituto de Saúde Pública da Universidade do Porto', 'LocationStatus': 'Recruiting', 'LocationCity': 'Porto', 'LocationZip': '4050-600', 'LocationCountry': 'Portugal', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ana Rute Costa', 'LocationContactRole': 'Contact', 'LocationContactPhone': '+351 22 206 1820'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000002546', 'ConditionMeshTerm': 'Ischemic Attack, Transient'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000002545', 'ConditionAncestorTerm': 'Brain Ischemia'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemic', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5485', 'ConditionBrowseLeafName': 'Ischemic Attack, Transient', 'ConditionBrowseLeafAsFound': 'Transient Ischemic Attack', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5484', 'ConditionBrowseLeafName': 'Brain Ischemia', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 28, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01777672', 'OrgStudyIdInfo': {'OrgStudyId': 'Marató-11'}, 'Organization': {'OrgFullName': 'Hospital de Mataró', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia', 'OfficialTitle': 'Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia (OD). A Randomized Controlled Trial.'}, 'StatusModule': {'StatusVerifiedDate': 'February 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2012'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2016', 'PrimaryCompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 21, 2013', 'StudyFirstSubmitQCDate': 'January 28, 2013', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 29, 2013', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'February 7, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'February 9, 2017', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Pere Clave', 'ResponsiblePartyInvestigatorTitle': 'MD, PhD', 'ResponsiblePartyInvestigatorAffiliation': 'Hospital de Mataró'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Mataró', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {}, 'DescriptionModule': {'BriefSummary': 'Oropharyngeal dysphagia (OD) is a major complaint among many patients with stroke and causes severe complications. There is no specific treatment for these patients. Impaired swallow response is caused by a delay in the timing of oropharyngeal reconfiguration with delayed airway protection. Swallow response is initiated by sensory afferent fibers in the oropharynx and cerebral cortex reaching the central swallowing pattern generator (CPG) in the medulla oblongata and brainstem motor nuclei. Hypothesis: Stimulation of pharyngeal sensory afferent fibers through TRPV1 receptors and electrical stimuli might enhance the stimulation of the CPG and speed the swallow response. Long-term treatment of OD will improve clinical outcome of stroke patients. Aim: To assess the effect of TRPV1 agonists (capsaicin) and that of sensorial pharyngeal electrical stimulation (intrapharyngeal and transcutaneous) on VFS signs and swallow response at 3, 6 and 12 months after treatment in stroke patients with established OD. To compare the clinical effect of classical rehabilitation strategies with that of these new afferent sensorial neurostimulation strategies in terms of nutritional status parameters, incidence of aspiration pneumonia and/or low respiratory tract infection, quality of life, and mortality. Methods: Clinical screening of OD with the volume-viscosity swallow test and assessment by VFS and quantitative measurements of swallow response. Randomized controlled trial assessing the effect of standard rehabilitation with that of afferent sensorial neurostimulation strategies.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Dysphagia', 'Aspiration', 'Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '100', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Dietary and oral hygiene recommendations', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations']}}, {'ArmGroupLabel': 'oral TRPV1 agonist', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations', 'Dietary Supplement: oral TRPV1 agonist']}}, {'ArmGroupLabel': 'pharyngeal electrical stimulation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations', 'Device: pharyngeal electrical stimulation']}}, {'ArmGroupLabel': 'transcutaneous electrical stimulation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Dietary and oral hygiene recommendations', 'Device: transcutaneous electrical stimulation']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Dietary and oral hygiene recommendations', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Dietary and oral hygiene recommendations', 'oral TRPV1 agonist', 'pharyngeal electrical stimulation', 'transcutaneous electrical stimulation']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'oral TRPV1 agonist', 'InterventionDescription': 'Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['oral TRPV1 agonist']}}, {'InterventionType': 'Device', 'InterventionName': 'pharyngeal electrical stimulation', 'InterventionDescription': 'Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pharyngeal electrical stimulation']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Electrodes (Gaeltec, Ltd, Dunvegan, Isle of Skye, UK.', 'Electrical stimulator (Grass Instruments Co, USA)']}}, {'InterventionType': 'Device', 'InterventionName': 'transcutaneous electrical stimulation', 'InterventionDescription': 'Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['transcutaneous electrical stimulation']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Intelect VitalStim, Chattanooga, USA)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'To assess the efficacy and safety of new neuron-stimulation treatments for OD in patients with stroke and to explore their mechanism of action.', 'PrimaryOutcomeDescription': 'The efficacy of each treatment will be assessed by VFS in each patient after the treatment and at the end of the follow-up period, considering Rosenbek scale and measures of oropharyngeal swallow response including oropharyngeal reconfiguration, timing and extent of hyoid motion and bolus propulsion force of the tongue. Clinical outcome also evaluated are episodes of aspiration pneumonia and low respiratory tract infections, nutritional status, complications and clinical symptoms experimented during one year of follow-up and mortality rates and cause of death.\\n\\nParticipating clinicians will be instructed to register and describe all serious adverse events (SAE) occurred during the study and report them on a specific form within 24 hours. The guidelines for SAE reporting to the Ethical Committee and competent authorities will be followed.', 'PrimaryOutcomeTimeFrame': '12 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'To determine the prevalence of OD and its complications in stroke patients over one year.', 'SecondaryOutcomeTimeFrame': '12 months'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'To assess and compare one year health resource consumption between all study treatment groups.', 'OtherOutcomeTimeFrame': '12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n- Person with persistent clinical signs or symptoms of OD according to V-VST and confirmed with VFS (PA scale level 3 or more) secondary to a stroke episode in the last 3 months.\\n\\nExclusion Criteria:\\n\\nPatient unconscious or in a coma\\nPatients diagnosed with transitory ischemic accident\\nlife expectancy less than 3 months\\nneurodegenerative disease', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Pere Pere, Doctor', 'OverallOfficialAffiliation': 'Hospital de Mataró, Gastrointestinal Physiology Laboratory', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital de Mataró', 'LocationCity': 'Mataró', 'LocationState': 'Barcelona', 'LocationZip': '08304', 'LocationCountry': 'Spain'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}, {'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Dysphagia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M5161', 'InterventionBrowseLeafName': 'Capsaicin', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Derm', 'InterventionBrowseBranchName': 'Dermatologic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 29, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03470506', 'OrgStudyIdInfo': {'OrgStudyId': '20154'}, 'Organization': {'OrgFullName': 'University of Virginia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'A Study of the Relationship of Gut Microbial Composition and Stroke Outcome', 'OfficialTitle': 'A Study of the Relationship of Gut Microbial Composition and Stroke Outcome', 'Acronym': 'GEMSTONE'}, 'StatusModule': {'StatusVerifiedDate': 'November 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 20, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 6, 2022', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'July 1, 2022', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 29, 2017', 'StudyFirstSubmitQCDate': 'March 16, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 20, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'November 17, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 19, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'University of Virginia', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'University of Colorado, Denver', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to investigate the relationship between gut microbiome (bacteria in the gut), inflammation and the injured brain. It has been established that bacteria in the gut play key roles in digestion, nutrition absorption and immune response of the entire body. Human intestinal bacteria composition in the gut has been associated with several stroke risk factors including obesity, insulin resistance, diabetes and hypertension. If we can establish a relationship between gastrointestinal microbial community composition and ischemic stroke outcomes could lead to dietary interventions in the future to improve recovery after a stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'BioSpec': {'BioSpecRetention': 'Samples With DNA', 'BioSpecDescription': 'Fecal and blood samples will be collected. The biorepository will contain acute and convalescent samples: DNA (genetic and epigenetic), RNA (gene expression), serum/plasma (biomarker levels, proteomics), and fecal (microbiome) samples couple with clinical and research data.'}, 'EnrollmentInfo': {'EnrollmentCount': '300', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Ischemic stroke', 'ArmGroupDescription': 'Diagnosed with an ischemic stroke by a Neurologist', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Stool Samples']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Stool Samples', 'InterventionDescription': 'Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ischemic stroke']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Measured differences in taxonomic make-up and the relative frequency of the gut microbial composition in relation to excellent vs. poor stroke outcome', 'PrimaryOutcomeDescription': 'The primary outcome in this case-comparison design of those with excellent vs. non-excellent ischemic stroke outcomes at 3 months as measured by the National Institutes of Health Stroke Scale (NIHSS) is the taxonomic make up of the gut microbial composition. In other words, comprehensive microbiota survey results from 16S rRNA gene sequencing from individuals with excellent outcomes versus all other outcomes at 3 months are the outcome.', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Cogstate cognitive correlates and post-stroke microbial composition', 'SecondaryOutcomeDescription': 'Descriptive analyses will be used to develop a preliminary understanding of microbiome composition in relation to measures of cognitive functioning as derived from Cogstate cognitive assessment results at baseline and 3 months post- ischemic stroke', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nMen and women at least 18 years of age.\\nWilling and able to attend all study visits.\\nEnglish speaking.\\nMust have had a stroke that occurred within 48 hours of admission to the Stroke Unit as determined by a neurologist.\\n\\nExclusion Criteria:\\n\\nHistory of inflammatory bowel disease.\\nReceiving antibiotics within 30 days of entry into the study.\\nHistory of institutionalization for mental illness within the last year.\\nUnable to consent and does not have a surrogate available to consent on their behalf.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Community probability sample of adults who have suffered an ischemic stroke within 48 hours of admission to UVA', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Sonya A Gunter, MS', 'CentralContactRole': 'Contact', 'CentralContactPhone': '434-924-9664', 'CentralContactEMail': 'sag7bf@hscmail.mcc.virginia.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Bradford Worrall, MD, MS', 'OverallOfficialAffiliation': 'University of Virginia', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'University of Virginia Health System', 'LocationStatus': 'Enrolling by invitation', 'LocationCity': 'Charlottesville', 'LocationState': 'Virginia', 'LocationZip': '22908', 'LocationCountry': 'United States'}, {'LocationFacility': 'Inova Health System', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fairfax', 'LocationState': 'Virginia', 'LocationZip': '22031', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Robert Lipsky, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '571-472-0240', 'LocationContactEMail': 'robert.lipsky@inova.org'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 30, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03021252', 'OrgStudyIdInfo': {'OrgStudyId': 'PSM/RHB/NR21'}, 'Organization': {'OrgFullName': 'Parc de Salut Mar', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Respiratory Muscle Training in Stroke Swallowing Disorders', 'OfficialTitle': 'The RETORNUS-2 Study: Impact of Respiratory Muscle Training on Swallowing Disorders in Stroke Patients', 'Acronym': 'RETORNUS-2'}, 'StatusModule': {'StatusVerifiedDate': 'September 2019', 'OverallStatus': 'Terminated', 'WhyStopped': 'Because of the SARS-COV2 pandemic. Recruitment stopped at 48 patients', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'February 1, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 16, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'January 10, 2017', 'StudyFirstSubmitQCDate': 'January 11, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 13, 2017', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'September 18, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'September 22, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Parc de Salut Mar', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Instituto de Salud Carlos III', 'CollaboratorClass': 'OTHER_GOV'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Clinical randomized clinical trial to assess the effectiveness of incorporating inspiratory and expiratory muscle training (IEMT) in the rehabilitation of stroke patients with dysphagia in terms of functional outcomes, comorbidities, survival and quality of life.\\n\\nThis project also incorporates a longitudinal study to assess the clinical impact of dysphagia on body composition and nutritional status in stroke patients.', 'DetailedDescription': 'Stroke is a major cause of morbidity and mortality worldwide. Stroke can lead to varying degrees of oropharyngeal dysphagia (25-85% of patients) and respiratory muscle dysfunction associated with an increase in medical complications such as bronchoaspiration, malnutrition and death. Dysphagia is present in a significant proportion of patients admitted to Rehabilitation (up to 85% depending on series) in stroke. Standard swallow therapy consists of educational intervention aimed to improve self-management of dysphagia and protect the airway, oral exercises to improve lingual praxis, and compensatory techniques based on videofluoroscopic findings. Recent studies suggest that IEMT can improve swallowing efficacy and reduce eventual bronchoaspiration events.\\n\\nNutritional status appears in 9-67% of patients with acute and subacute stroke and has an impact on functional outcomes and provides information about the risk of hospitalization and death. Stroke patients are at risk of developing malnutrition because of neurologic impairments related to feeding (chewing, deglutition and self-feeding) that can result in a poor food intake. To date, there is only few studies on prevalence and influence of malnutrition in stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Swallowing Disorder', 'Stroke', 'Respiratory Muscle Training', 'Malnutrition']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '50', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'High intensity IEMT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Inspiratory and expiratory muscle training + standard swallow therapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: High intensity IEMT']}}, {'ArmGroupLabel': 'Sham IEMT', 'ArmGroupType': 'Sham Comparator', 'ArmGroupDescription': 'Sham inspiratory and expiratory muscle training + standard swallow therapy', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Sham IEMT']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'High intensity IEMT', 'InterventionDescription': 'Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['High intensity IEMT']}}, {'InterventionType': 'Device', 'InterventionName': 'Sham IEMT', 'InterventionDescription': '5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sham IEMT']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in respiratory muscle strength', 'PrimaryOutcomeDescription': 'Respiratory muscle strength is assessed through maximal inspiratory and expiratory pressures (PImax and PEmax, respectively) using a pressure transducer connected to a digital register system. The PImax is measured at mouth during a maximum effort from residual volume against occluded airway. To determine the PEmax, the patients will perform a maximum expiratory effort from total lung capacity (TLC) in the face of the occluded airway. A specific and validated respiratory pressures manometer will be used (Micro RPM, Cardinalhealth, Kent, UK).', 'PrimaryOutcomeTimeFrame': 'Baseline and weekly during 8 weeks'}, {'PrimaryOutcomeMeasure': 'Change in dysphagia severity', 'PrimaryOutcomeDescription': 'Dysphagia severity is assessed with the Penetration-Aspiration Scale: scores of 1-2 indicate normal swallowing; 3-5, penetration; >6, aspiration.', 'PrimaryOutcomeTimeFrame': 'Baseline, 8 weeks, 6 months post-stroke'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in tongue strength', 'SecondaryOutcomeDescription': 'Lingual Force (IOPI system): maximum isometric tongue pressure defined as the highest of the three peak isometric tongue pressure scores.', 'SecondaryOutcomeTimeFrame': 'Baseline and weekly during 8 weeks'}, {'SecondaryOutcomeMeasure': 'Change in fat-free mass', 'SecondaryOutcomeDescription': 'Fat-free mass measured by electrical bioimpedance in kilograms and expressed as normal, low or high values according to normal values for the reference population', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months and 6 months post-stroke'}, {'SecondaryOutcomeMeasure': 'Malnutrition at 6 months', 'SecondaryOutcomeDescription': 'Malnutrition criteria of the European Society of Clinical Nutrition and Metabolism (ESPEN)', 'SecondaryOutcomeTimeFrame': 'Baseline and 6 months post-stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nFirst-ever Ischemic or haemorrhagic stroke\\nTime since stroke onset: 1 month\\nDysphagia confirmed by videofluoroscopic study with a score >3 in the 8-point Penetration Aspiration Scale.\\nMini-mental State Exploration > 24)\\n\\nExclusion Criteria:\\n\\nAphasia\\nHistory of cardiopulmonary disease; neurologic condition other than stroke and metabolic disease\\nMedical treatment with potential effect on muscle structure and function', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Anna Guillén-Solà, MD, PhD', 'OverallOfficialAffiliation': 'Fundació IMIM - Parc de Salut Mar', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': \"Hospital de l'Esperança\", 'LocationCity': 'Barcelona', 'LocationState': 'Catalonia', 'LocationZip': '08024', 'LocationCountry': 'Spain'}, {'LocationFacility': 'Physical Medicine & Rehabilitation Dpt. Parc de Salut Mar.', 'LocationCity': 'Barcelona', 'LocationZip': '08024', 'LocationCountry': 'Spain'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '16269630', 'ReferenceType': 'background', 'ReferenceCitation': 'Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005 Dec;36(12):2756-63. doi: 10.1161/01.STR.0000190056.76543.eb. Epub 2005 Nov 3.'}, {'ReferencePMID': '27271373', 'ReferenceType': 'background', 'ReferenceCitation': 'Guillen-Sola A, Messagi Sartor M, Bofill Soler N, Duarte E, Barrera MC, Marco E. Respiratory muscle strength training and neuromuscular electrical stimulation in subacute dysphagic stroke patients: a randomized controlled trial. Clin Rehabil. 2017 Jun;31(6):761-771. doi: 10.1177/0269215516652446. Epub 2016 Jun 7.'}, {'ReferencePMID': '26180145', 'ReferenceType': 'background', 'ReferenceCitation': 'Messaggi-Sartor M, Guillen-Sola A, Depolo M, Duarte E, Rodriguez DA, Barrera MC, Barreiro E, Escalada F, Orozco-Levi M, Marco E. Inspiratory and expiratory muscle training in subacute stroke: A randomized clinical trial. Neurology. 2015 Aug 18;85(7):564-72. doi: 10.1212/WNL.0000000000001827. Epub 2015 Jul 15.'}, {'ReferencePMID': '25503549', 'ReferenceType': 'background', 'ReferenceCitation': 'Kulnik ST, Birring SS, Moxham J, Rafferty GF, Kalra L. Does respiratory muscle training improve cough flow in acute stroke? Pilot randomized controlled trial. Stroke. 2015 Feb;46(2):447-53. doi: 10.1161/STROKEAHA.114.007110. Epub 2014 Dec 11.'}, {'ReferencePMID': '22732970', 'ReferenceType': 'background', 'ReferenceCitation': 'Burgos R, Sarto B, Elio I, Planas M, Forga M, Canton A, Trallero R, Munoz MJ, Perez D, Bonada A, Salo E, Lecha M, Enrich G, Salas-Salvado J; Group for the Study of Malnutrition in Hospitals in Catalonia. Prevalence of malnutrition and its etiological factors in hospitals. Nutr Hosp. 2012 Mar-Apr;27(2):469-76. doi: 10.1590/S0212-16112012000200018.'}, {'ReferencePMID': '34172071', 'ReferenceType': 'derived', 'ReferenceCitation': 'Guillen-Sola A, Messaggi-Sartor M, Ramirez-Fuentes C, Marco E, Duarte E. The Retornus-2 study: impact of respiratory muscle training in subacute stroke patients with dysphagia, study protocol of a double-blind randomized controlled trial. Trials. 2021 Jun 25;22(1):416. doi: 10.1186/s13063-021-05353-y.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003680', 'ConditionMeshTerm': 'Deglutition Disorders'}, {'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}, {'ConditionAncestorId': 'D000004935', 'ConditionAncestorTerm': 'Esophageal Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000010608', 'ConditionAncestorTerm': 'Pharyngeal Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafAsFound': 'Swallowing Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7775', 'ConditionBrowseLeafName': 'Esophageal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6945', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8573', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13205', 'ConditionBrowseLeafName': 'Pharyngeal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12651', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}]}}}}}, {'Rank': 31, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03394339', 'OrgStudyIdInfo': {'OrgStudyId': 'CIHR-FRU VEG & CVD 2017'}, 'Organization': {'OrgFullName': 'University of Toronto', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Meta-analysis of Fruit and Vegetable Sources and Cardiovascular Outcomes', 'OfficialTitle': 'Relation of Fruit and Vegetable Sources With Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies.'}, 'StatusModule': {'StatusVerifiedDate': 'October 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 1, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 1, 2018', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'December 1, 2018', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'January 3, 2018', 'StudyFirstSubmitQCDate': 'January 8, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 9, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 9, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 11, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'John Sievenpiper', 'ResponsiblePartyInvestigatorTitle': 'Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'University of Toronto'}, 'LeadSponsor': {'LeadSponsorName': 'University of Toronto', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Fruit and vegetables are a cornerstone of healthy dietary patterns and dietary guidelines worldwide. The supporting evidence, however, is largely derived from observational studies of protective associations with cardiovascular disease (CVD) in health-conscious populations or from randomized trials of the effect of specific fruit or vegetable derived nutrients on CVD risk factors. A growing body of literature has influenced a shift away from a focus on single nutrients to a focus on whole foods and dietary patterns. To what extent fruit and vegetables should contribute to dietary patterns for cardiovascular health and whether specific types of fruit or vegetables should be recommended is unclear. Although previous systematic reviews and meta-analyses have elucidated the association between the intake of total and some specific fruit and vegetables with cardiovascular outcomes, a comprehensive synthesis comparing the certainty of the evidence for the different types of fruit and vegetables in relation to a range of cardiovascular outcomes has yet to be completed. We propose to conduct a systematic review and meta-analysis of the available prospective cohort studies using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the association between different types of fruit and vegetables and different cardiovascular outcomes that include CVD, coronary heart disease [CHD], and stroke incidence and mortality.', 'DetailedDescription': 'Background:\\n\\nA high intake of fruit and vegetables is a common trait among healthy dietary patterns and a cornerstone of nutrition interventions for cardiovascular disease (CVD) prevention. There is an international consensus that at least 5 servings per day of fruit and vegetables is beneficial to overall population health (WHO, 2003). This guidance, however, is largely founded on observational studies showing protective associations of high intakes of fruit and vegetables with CVD in health-conscious individuals (Reddy and Katan, 2004). Recommendations to consume specific types of fruit and vegetables, such as citrus fruit and green leafy vegetables, have been established mainly on the association of isolated nutrients with CVD risk reduction in observational studies or the effect of isolated nutrients on CVD risk factors in small randomized trials (Katamay et al., 2007). Given its prominence in dietary guidelines, there is a need to determine the extent of CVD risk reduction that may be attributed to the consumption of fruit and vegetables. As guidelines are shifting away from a focus on single nutrients to a focus on whole foods and dietary patterns and achieving adequate intakes continue to be a challenge worldwide and (Hall et al., 2009), there is also an advantage in establishing which types of fruit and vegetables are associated with the greatest protection in CVD incidence and mortality per serving. Although several systematic reviews and meta-analyses of prospective cohort studies have demonstrated protective associations between the intake of total fruit and vegetables and CVD risk (Aune et al., 2017; Zhan et al., 2017; Gan et al., 2015; Wang et al, 2014; Hu et al., 2007; He et al., 2007; Dauchet et al., 2006), few have focused on specific fruit and vegetables or explored a range of cardiovascular outcomes which may have different etiologies. Several large prospective cohort studies have recently been published which may strengthen the certainty of the evidence by increasing the number of observations for the relationship between different fruit and vegetables exposures and different cardiovascular outcomes. We propose to build and expand on the exiting systematic reviews and meta-analyses by conducting a comprehensive synthesis of prospective cohort studies comparing the certainty of the evidence for the different types of fruit and vegetables in relation to a range of cardiovascular outcomes.\\n\\nObjective:\\n\\nTo conduct a systematic review and meta-analysis of the available prospective cohort studies using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the association between different types of fruit and vegetables and different cardiovascular outcomes including CVD, CHD, and stroke incidence and mortality.\\n\\nDesign:\\n\\nThe conduct of the proposed systematic review and meta-analysis will follow the Cochrane handbook for systematic reviews of interventions and the GRADE handbook for grading the certainty of the evidence and the strength of recommendations using the GRADE approach. The reporting will follow the Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.\\n\\nData Sources:\\n\\nMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) will be searched using relevant search terms. Search of databases will be supplemented by manual searches of bibliographies.\\n\\nStudy Selection:\\n\\nProspective cohort studies exploring the relation of fruit and/or vegetable intake to incident cardiovascular disease for a minimum follow-up time of 1 year will be included.\\n\\nData extraction:\\n\\nTwo independent reviewers will extract relevant information including study design, sample size, subject characteristics, exposure form (i.e. total fruit and vegetables, citrus fruit, green leafy vegetables, etc.), duration/person-years of follow-up, adjustments of models and risk ratios for clinical outcomes derived from clinical event data across quantiles of exposure. Any disagreements will be reconciled by consensus with arbitration by the Principal Investigator.\\n\\nRisk of bias:\\n\\nRisk of bias (ROB) will be assessed by two independent reviewers using the Newcastle-Ottawa Scale (NOS). Up to 9 points can be awarded based on cohort selection (max 4 points), the comparability of cohort design and analysis (max 4 points), and adequacy of the outcome measures (max 3 points). Studies that receive ≥6 points will be considered as higher quality. Again, any disagreements will be reconciled by consensus with arbitration by the Principal Investigator.\\n\\nOutcomes:\\n\\nWe will assess 6 outcomes: CVD incidence and mortality, CHD incidence and mortality, and stroke incidence and mortality.\\n\\nData Synthesis:\\n\\nWe will pool the natural log-transformed relative risks for the 6 cardiovascular outcomes using the inverse variance method with random effects models with data expressed as risk ratios (RR) with 95% confidence intervals (CIs). Analyses will be conducted by extreme quantiles analyses, comparing the highest with the lowest (reference) level of exposure. Data will also be scaled to allow for per serving/day analyses. Between-study heterogeneity will be assessed by the Cochran Q test and quantified by the I2 statistic with significance at P<0.1. An I2≥50% and P<0.1 will be considered as evidence of substantial heterogeneity. Sensitivity analyses and a priori subgroup analyses will be undertaken to explore sources of heterogeneity. Sensitivity analyses will include the systematic removal of included cohorts with the recalculation of summary estimates. A priori subgroup analyses will be conducted when ≥10 cohort comparisons are available by age, sex, location of cohort, follow-up duration, dietary assessment tool, risk of bias (NOS score). A separate subgroup analysis will also be conducted by each domain of risk of bias by NOS. Meta-regression analyses will assess the significance of categorical and continuous subgroups analyses. Dose-response analyses will be undertaken using random-effects generalized least squares trend estimation models (GLST) to assess linear relationships and spline curve modeling (the MKSPLINE procedure) to assess non-linear relationships. If ≥10 cohort comparisons are available, then publication bias will be assessed by visual inspection of funnel plots and formal testing with the Egger and Begg tests at a significance level of p≤ 0.10. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.\\n\\nGrading the Evidence:\\n\\nThe Grading of Recommendations Assessment, Development and Evaluation (GRADE) method will be used to assess the overall certainty of the evidence for each of the cardiovascular outcomes. This system grades the evidence as \"high quality\", \"moderate quality\", \"low quality\", or \"very low quality\". Observational studies including prospective cohort studies start at a \"low quality\" and then can be downgraded or upgraded based on established criteria. Criteria to downgrade will include study limitations (weight of studies show risk of bias by NOS), inconsistency (substantial unexplained inter-study heterogeneity, I2>50%, P<0.10), indirectness (presence of factors relating to the population, exposures, and outcomes that limit generalizability), imprecision (95% CI are wide or cross a minimally important difference of 5% [RR 0.95- 1.05]), and publication bias (significant evidence of publication bias or small-study effects). Criteria to upgrade will include a large magnitude effect (RR>2 or RR<0.5 in the absence of plausible confounders), a dose-response gradient, and attenuation by plausible confounding effects.\\n\\nKnowledge translation plan:\\n\\nThe results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, physical activity, lifestyle modification, obesity, diabetes, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined.\\n\\nSignificance:\\n\\nThe study will aid in establishing a stronger evidence-base to determine the extent to which a high fruit and vegetable intake may be associated with reduction in incident CVD. It may also bring to light categories of fruits and/or vegetables that could provide additional benefit in CVD prevention.\\n\\nReferences:\\n\\nWorld Health Organization. (2003). Fruit and Vegetable Promotion Initiative - report of the meeting. Geneva.\\n\\nReddy KS and Katan MB. (2004). Diet, nutrition and the prevention of hypertension and cardiovascular disease. Public Health Nutrition. 7(1A): 167-186\\n\\nKatamay SW, Esslinger KA, Vigneault M, et al. (2007) Nutrition Reviews. 65(4): 155-166.\\n\\nHall JN, Moore S, Harper SB, et al. (2009). Global variability in fruit and vegetable consumption. American Journal of Preventative Medicine. 36:402-409\\n\\nAune D, Giovannucci E, Boffetta P, et al. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality - a systematic review and dose-response meta-analysis of prospective studies. International Journal of Epidemiology. 1-28\\n\\nZhan J, Liu Y, Cai L, et al. (2017). Fruit and vegetable consumption and risk of cardiovascular disease: A meta-anaylsis of prospective cohort studies. Critical Reviews in Food Science and Nutrition. 57(8):1650-1663\\n\\nGan Y, Tong X, Liqing L, et al. (2015). Consumption of fruit and vegetable and risk of coronary heart disease: A meta-analysis of prospective cohort studies. International Journal of Cardiology. 183: 129-137\\n\\nWang X, Ouyang Y, Liu J, et al. (2014). Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. British Medical Journal. 349\\n\\nHu D, Hunag J, Wang Y, et al. (2014). Fruits and vegetables consumption and risk of stroke: A meta-analysis of prospective cohort studies. Stroke. 45: 1613-1619\\n\\nHe FG, Nowson CA, Lucas M et al. (2007). Increased consumption of fruit and vegetables is related to reduced risk of coronary heart disease: meta-analysis of cohort studies. Journal of Human Hypertension. 21:717-728\\n\\nHe FJ, Nowson CA and MacGregor GA. (2006). Fruit and vegetable consumption and stroke: a meta-analysis of cohort studies. Lancet: 367:320-326.\\n\\nDauchet L, Amouyel P, Hereberg S, et al. (2006). Fruit and vegetable consumption and risk of coronary heart disease: A meta-analyses of cohort studies. The Journal of Nutrition. 136: 2588-2593.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['CHD - Coronary Heart Disease', 'CVD - Cerebrovascular Disease', 'Stroke']}, 'KeywordList': {'Keyword': ['Systematic review and meta-anaylsis', 'Evidence-based nutrition (EBN)', 'Dietary guidelines', 'Fruit', 'Vegetables']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Other']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '1', 'EnrollmentType': 'Anticipated'}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Cardiovascular disease (CVD)', 'PrimaryOutcomeDescription': 'Risk ratios for CVD incidence and mortality', 'PrimaryOutcomeTimeFrame': '1 year follow-up'}, {'PrimaryOutcomeMeasure': 'Coronary heat disease (CHD)', 'PrimaryOutcomeDescription': 'Risk ratios for CHD incidence and mortality', 'PrimaryOutcomeTimeFrame': '1 year follow-up'}, {'PrimaryOutcomeMeasure': 'Stroke', 'PrimaryOutcomeDescription': 'Rsk ratios for stroke incidence and mortality', 'PrimaryOutcomeTimeFrame': '1 year follow-up'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nProspective cohort studies or case-cohort studies\\nDuration >= 1 year\\nAssessment of the exposure of fruit and/or vegetables\\nAscertainment of viable data by level of exposure\\n\\nExclusion Criteria:\\n\\nEcological, cross-sectional, and retrospective observational studies, clinical trials, and non-human studies\\nDuration < 1 year\\nNo assessment of exposures of fruit or vegetables\\nNo ascertainment viable clinical outcome data by level of exposure', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': 'Varied', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'John Sievenpiper, MD, PhD, FRCPC', 'OverallOfficialAffiliation': \"Department of Nutritional Sciences, Faculty of Medicine, University of Toronto and Clinical Nutrition and Risk Factor Modification Centre and Toronto 3D Knowledge Institute and Clinical Trials Unit, St. Michael's Hospital\", 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Sonia Blanco Mejia, MD', 'OverallOfficialAffiliation': \"Clinical Nutrition and Risk Factor Modifcation Centre and Toronto 3D Knowledge Institute and Clinical Trials Unit, St. Michael's Hosptial\", 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': \"The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital\", 'LocationCity': 'Toronto', 'LocationState': 'Ontario', 'LocationZip': 'M5C 2T2', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33000670', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zurbau A, Au-Yeung F, Blanco Mejia S, Khan TA, Vuksan V, Jovanovski E, Leiter LA, Kendall CWC, Jenkins DJA, Sievenpiper JL. Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc. 2020 Oct 20;9(19):e017728. doi: 10.1161/JAHA.120.017728. Epub 2020 Oct 1.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'All data will be available in the publication'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002561', 'ConditionMeshTerm': 'Cerebrovascular Disorders'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}, {'ConditionMeshId': 'D000003327', 'ConditionMeshTerm': 'Coronary Disease'}, {'ConditionMeshId': 'D000003324', 'ConditionMeshTerm': 'Coronary Artery Disease'}, {'ConditionMeshId': 'D000017202', 'ConditionMeshTerm': 'Myocardial Ischemia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000001161', 'ConditionAncestorTerm': 'Arteriosclerosis'}, {'ConditionAncestorId': 'D000001157', 'ConditionAncestorTerm': 'Arterial Occlusive Diseases'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M6236', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6239', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafAsFound': 'CHD - Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19196', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafAsFound': 'Coronary Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4159', 'ConditionBrowseLeafName': 'Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4155', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 32, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03937934', 'OrgStudyIdInfo': {'OrgStudyId': '18-006630'}, 'Organization': {'OrgFullName': 'Mayo Clinic', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Study Title: Food Rx', 'OfficialTitle': 'Study Title: Food Rx'}, 'StatusModule': {'StatusVerifiedDate': 'June 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 20, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'November 20, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 20, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'April 30, 2019', 'StudyFirstSubmitQCDate': 'May 1, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 6, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'June 5, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'June 9, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Erin C. Westfall', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'Mayo Clinic'}, 'LeadSponsor': {'LeadSponsorName': 'Mayo Clinic', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Researchers are trying to determine if subjects with lack of access to healthy food and a long term health problem, are helped by a weekly box of healthy groceries and nutrition education.', 'DetailedDescription': \"Participants that have a chronic preventable disease and food insecurity will be offered enrollment in the study. Once all participants are enrolled, they will be given weekly boxes of food which includes materials for a nutritious recipe and extra fruit and vegetables for a total of 6 weeks. The SNAP-Ed Educator and SHIP Public health coordinator will be present at food pick up to answer questions about the boxes, food preparation, etc. They will be given the option of participating in grocery store and farmer's market tours, as well as sign up for text messaging of nutrition information and recipes. At the end of 6 weeks, they will be asked to participate in a focus group. At baseline, 3 months and 6 months, they will be asked to complete a survey on lifestyle behaviors and food choices.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Diabetes', 'High Blood Pressure', 'Obesity', 'Hypertension', 'Heart Diseases', 'Stroke', 'TIA', 'Osteoarthritis', 'Cancer']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Health Services Research', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '24', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Subjects with long term health condition', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Nutrition Education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Nutrition Education', 'InterventionDescription': 'Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Subjects with long term health condition']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in the number of self-reported fruits per day', 'PrimaryOutcomeDescription': 'Number of self-reported fruits per day', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'PrimaryOutcomeMeasure': 'Change in the number of self-reported vegetables per day', 'PrimaryOutcomeDescription': 'Number of self-reported vegetables per day', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}, {'PrimaryOutcomeMeasure': 'Change in number of days a week and minutes per day participants participate in physical activity and sedentary activity', 'PrimaryOutcomeDescription': 'Measured using self-reported Food Rx Pilot survey', 'PrimaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change in A1c', 'SecondaryOutcomeDescription': 'Identified through chart review', 'SecondaryOutcomeTimeFrame': '6 months and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in BMI kg/m2 (weight in kg, height in meters)', 'SecondaryOutcomeDescription': 'Identified through chart review', 'SecondaryOutcomeTimeFrame': '6 months and 12 months'}, {'SecondaryOutcomeMeasure': 'Change in Systolic and/or Diastolic Hypertension mmHg', 'SecondaryOutcomeDescription': 'Identified through chart review', 'SecondaryOutcomeTimeFrame': '6 months and 12 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAdult patients that have been identified as having food insecurity based on a two question screening tool, AND\\nAlso has one of more of the following chronic diseases:\\nHypertension,\\nHeart disease,\\nStroke/TIA,\\nDM 2,\\nCancer/history of cancer,\\nobesity\\nosteoarthritis\\n\\nExclusion Criteria:\\n\\nPregnant women\\nChildren', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Erin Westfall, DO', 'OverallOfficialAffiliation': 'Mayo Clinic', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Mayo Clinic Health System', 'LocationCity': 'Mankato', 'LocationState': 'Minnesota', 'LocationZip': '56001', 'LocationCountry': 'United States'}]}}, 'ReferencesModule': {'SeeAlsoLinkList': {'SeeAlsoLink': [{'SeeAlsoLinkLabel': 'Mayo Clinic Clinical Trials', 'SeeAlsoLinkURL': 'https://www.mayo.edu/research/clinical-trials'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}, {'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M12616', 'ConditionBrowseLeafName': 'Osteoarthritis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12391', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9109', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9714', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'High Blood Pressure', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6805', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}]}}}}}, {'Rank': 33, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT01146132', 'OrgStudyIdInfo': {'OrgStudyId': 'CRP-Santé'}, 'Organization': {'OrgFullName': 'Public Research Centre Health, Luxembourg', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nutrition and Physical Activity in Patients With Cerebrovascular Disease', 'OfficialTitle': 'Nutrition and Physical Activity in Patients With Cerebrovascular Disease', 'Acronym': 'ALVINA'}, 'StatusModule': {'StatusVerifiedDate': 'October 2012', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 2009'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 2011', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 2011', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 15, 2010', 'StudyFirstSubmitQCDate': 'June 16, 2010', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 17, 2010', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'October 4, 2012', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 5, 2012', 'LastUpdatePostDateType': 'Estimate'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor-Investigator', 'ResponsiblePartyInvestigatorFullName': 'Manon Gantenbein', 'ResponsiblePartyInvestigatorTitle': 'Clinical Research Coordinator', 'ResponsiblePartyInvestigatorAffiliation': 'Public Research Centre Health, Luxembourg'}, 'LeadSponsor': {'LeadSponsorName': 'Manon Gantenbein', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Centre Hospitalier du Luxembourg', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': 'The study will provide evidence of eating habits and physical activity in cerebrovascular patients in Luxembourg and of the degree to which these habits may be changed acutely (after one month) and in the long run (after 4 months) by intensive counselling. Furthermore the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition, and on surrogate parameters for stroke will be assessed.', 'DetailedDescription': 'Quality of life in the elderly and their families is severely affected by stroke and cognitive dysfunction caused by atherosclerosis of the brain supplying arteries. Nutrition, namely a Mediterranean-style diet, nuts, soybean products, whole grain products, dark chocolate, fish oil and avoidance of salt, and regular physical activity play a major role in the prevention of these diseases. Data are available on cardiac patients, however little is known on cerebrovascular patients. The role of red wine in the protection of cerebrovascular disease is discussed; it may be simply an epiphenomenon of otherwise healthy lifestyle in the population with a regularly low alcohol consumption not properly corrected for in epidemiological studies. No prospective randomised data is available.\\n\\nWe intend to perform a prospective randomised study on nutrition and physical activity in 100 patients with chronic cerebrovascular disease (i.e. patients with atherosclerotic stenosis, at least 20% of a brain supplying artery as demonstrated by carotid ultrasound and without an acute stroke/TIA). The study consists of three parts:\\n\\n(1) Assessment of eating and physical activity habits in these patients and correlation with indicators of cerebrocardiovascular disease (cerebral perfusion as measured by transcranial Doppler sonography, pulsatility of the transcranial and extracranial Doppler signal, elasticity of the carotid artery, ankle-brachial index, cognitive functioning) and risk factors of cerebrovascular disease (blood pressure and blood pressure amplitude assessed by 24 h ambulatory blood pressure measurement; HDL, LDL, triglycerides, Lp(a), glucose, HbA1c, homocysteine, and fibrinogen; waist-hip ratio and BMI).\\n\\n2) Half of these patients will be randomised to intensive counselling concerning healthy eating and physical activity habits during the first month once a week. All the 100 patients will be reassessed after one month and after 4 months with the above mentioned parameters.\\n\\n3) In a double cross-over design half of the patients allocated to intensive counselling (i.e. n=25) and half of the patients without intensive counselling (n=25) will be allocated to 0,2 l of red wine daily (men) or 0,1l of red wine daily (women), respectively. The remaining 50 patients will be advised to avoid red wine for the time of the study.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebrovascular Disorders']}, 'KeywordList': {'Keyword': ['Nutrition', 'Physical activity', 'Cerebrovascular disease', 'wine consumption', 'BMI', 'Pulse transit time', 'transcranial Doppler sonography']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '119', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Luxembourg diet + wine', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Luxembourg variant of the mediterranean Diet, physical activity with wine consumption', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine']}}, {'ArmGroupLabel': 'conventional + wine', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'conventional Diet with red wine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Conventional diet +/- wine']}}, {'ArmGroupLabel': 'conventional', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'conventional diet without wine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Conventional diet +/- wine']}}, {'ArmGroupLabel': 'Luxembourg diet', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Luxembourg variant of the mediterranean Diet, physical activity with wine consumption', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Conventional diet +/- wine', 'InterventionDescription': 'usual eating habits', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['conventional', 'conventional + wine']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Luxembourg variant of Mediterranean diet + physical activity +/- wine', 'InterventionDescription': 'Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as \"Luxembourg variant of the Mediterranean diet\"', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Luxembourg diet', 'Luxembourg diet + wine']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Differences in mean systolic blood pressure in the two diet/sport arms', 'PrimaryOutcomeDescription': 'Assess the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition and on surrogate parameters for cerebrovascular disease.', 'PrimaryOutcomeTimeFrame': '4 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Effects on cerebrovascular health profile', 'SecondaryOutcomeDescription': 'Assess effects on cerebrocardiovascular health profile, cognitive function and ultrasound parameters.', 'SecondaryOutcomeTimeFrame': '4 months'}, {'SecondaryOutcomeMeasure': 'Assessment of genetic marker and/or genetic modifications.', 'SecondaryOutcomeDescription': 'The genetic analyses will investigate:\\n\\nA) Profiles of inflammatory, anti-inflammatory cytokines B) Genes related to risk of stroke C) Chromosome regions related to atherosclerosis D) Genetic polymorphism in inflammation\\n\\nGenes to be analyzed: FABP2, MTP1, ApoE, ApoA1, PPAR gamma Pro 12 Ala, TNF alpha, Paraoxonase 1, ADH, Kinesin-like protein (KIF) 6 Trp719Arg (rs20455), SNP, 5 (component of complement 5) 2416A> G variant (rs17611), sCAMs (sICAM-1, sVCAM-1, sPSEL et sESEL), (C3, C4) Complement and CRP, P-selectin and its ligand, P-selectin glycoprotein ligand 1', 'SecondaryOutcomeTimeFrame': 'Baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nIn- and outpatients of the Neurology Department of the CHL and their family members\\nCarotid atherosclerosis assessed by B-mode ultrasound of at least 20% lumen reduction\\nNo acute stroke/TIA/amaurosis fugax (at least 3 months ago)\\nTemporal ultrasound window suitable for recording of the middle cerebral artery\\nAbility to give informed consent\\n\\nExclusion Criteria:\\n\\nNo signed informed consent\\npatient not able to give informed consent', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Dirk Droste, Pr, MD', 'OverallOfficialAffiliation': 'Centre Hospitalier du Luxembourg', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'CHL', 'LocationCity': 'Luxembourg', 'LocationZip': '1210', 'LocationCountry': 'Luxembourg'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24228901', 'ReferenceType': 'derived', 'ReferenceCitation': 'Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, Gilson G, Chioti A. A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial. Nutr J. 2013 Nov 15;12(1):147. doi: 10.1186/1475-2891-12-147.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000002561', 'ConditionMeshTerm': 'Cerebrovascular Disorders'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M11139', 'InterventionBrowseLeafName': 'Mechlorethamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T294', 'InterventionBrowseLeafName': 'Soy Bean', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T143', 'InterventionBrowseLeafName': 'English Walnut', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}]}}}}}, {'Rank': 34, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03431402', 'OrgStudyIdInfo': {'OrgStudyId': 'KasrELAiniH critical care dep.'}, 'Organization': {'OrgFullName': 'Kasr El Aini Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke', 'OfficialTitle': 'Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'March 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 1, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 1, 2020', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 1, 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'February 1, 2018', 'StudyFirstSubmitQCDate': 'February 10, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 13, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 13, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 14, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Tamer Salah aldin Fahmy', 'ResponsiblePartyInvestigatorTitle': 'Professor of critical care medicine', 'ResponsiblePartyInvestigatorAffiliation': 'Kasr El Aini Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Kasr El Aini Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Background and Rationale:\\n\\nCerebrovascular disease is always ranked at the top causes of death and most of hospitalized acute stroke patients have ischemic stroke [1].\\n\\nAlthough the mortality rate of acute ischemic stroke is less than that of hemorrhagic stroke [1], it still results in patient disabilities and complications that often lead to significant costs to individuals, families, and society.\\n\\nTraditional treatment for acute ischemic stroke includes thrombolytic therapy by injecting tissue plasminogen activator (t-PA) within three hours after onset of symptoms [2], antiplatelets and/or anticoagulant agents administered within the first 48 hours. Clinically, the narrow time window of thrombolytic therapy and coexisting contraindications limit the use of t-PA [2]. Thus, searching for an effective supplemental treatment for acute ischemic stroke is imperative.\\n\\nHyperbaric oxygen therapy (HBOT) is valuable in treating acute carbon monoxide poisoning [3,4], air or gas embolism [5], facilitating wound healing [6] and has been used as an adjuvant treatment for many neurological disorders that need further study as concussion [7] , stroke [8,9], cerebral palsy [ 10],traumatic brain injury [ 11], cerebral air embolism [12], Autism [13] and multiple sclerosis [14].\\n\\nIndications of hyperbaric oxygen therapy recommended by undersea and hyperbaric medical society (UHMS) [15] are 1.air or gas embolism [5], 2.carbon monoxide poisoning [3,4], 3.clostridial myositis and myonecrosis [16], 4.crush injury, compartment syndrome and other acute traumatic ischemias [17], 5.decompression sickness [18], 6.arterial insufficiencies [19], 7.severe anemia [20], 8.intracranial abscess [21], 9.necrotizing soft tissue infections [22],10. refractory osteomyelitis [23], 11.delayed radiation injury [24], 12.compromised grafts and flaps [25], 13.acute thermal burn injury [26] and 14.idiopathic sudden sensorineural hearing loss [27].\\n\\nKnown mechanisms of HBOT-induced neuroprotection include enhancing neuronal viability via increased tissue oxygen delivery to the area of diminished blood flow, reducing brain edema, and improving metabolism after ischemia [28,29]. Furthermore, a recent study performed on a rat suggested that upregulation of the expression of glial derived neurotrophic factor (GDNF) and nerve growth factor (NGF) might underlie the effect of HBOT [30].\\n\\nThe effectiveness of use of Hyperbaric oxygen therapy in human ischemic stroke is still controversial that need further evaluation.', 'DetailedDescription': 'Study Methods:\\n\\nStudy Population A 60 adult (aged >18 years) patients were included with a diagnosis of acute thromboembolic ischemic stroke within 48 hours after onset, according to clinical picture and imaging findings by brain computed tomography (CT) without evidence of hemorrhage, upon admission to the hospital and no patient received thrombolytic therapy.\\n\\nInclusion criteria:\\n\\nGroup one, HBOT group (n = 30): thirty adult patients with acute ischemic stroke will receive conventional medical treatment ( as antiplatelet but not thrombolytic therapy) with 10 sessions of adjunctive hyperbaric oxygen therapy (HBOT) within 3-5 days after the onset of stroke .\\n\\nCompared with Group two, control group(n = 30): thirty adult patients with acute ischemic stroke will receive conventional medical treatment alone.\\n\\nThe baseline clinical characteristics were similar in both groups.\\n\\nExclusion criteria:\\n\\nPatient with cerebral hemorrhage\\nPatient received thrombolytic therapy\\nEmphysema with carbon dioxide retention\\nPneumothorax\\nSeizure disorder\\nUncontrolled high fever\\n\\nDemographic Characteristics:\\n\\nAdults more than 18 years, Any gender. All patients upon admission to the hospital will provide:\\n\\nComplete history taking:Age, Gender, Smoking, Alcohol consumption, Past history: diabetes mellitus , hypertension , Chronic obstructive pulmonary disease, Epilepsy or cardiovascular disease.\\n\\nNeurological assessment use NIHSS score Blood tests:Complete blood count , Coagulation profile, Fasting blood sugar., Renal function test (Urea and creatinine).\\n\\nCT brain\\n\\nChest x-ray :\\n\\nElectrocardiogram (ECG):'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant']}}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Acute stroke receive hyperbaric oxygen', 'ArmGroupType': 'Other', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Hyperbaric oxygen']}}, {'ArmGroupLabel': 'Acute stroke receive only conventional treatment', 'ArmGroupType': 'No Intervention'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Drug', 'InterventionName': 'Hyperbaric oxygen', 'InterventionDescription': '- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Acute stroke receive hyperbaric oxygen']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in national institute of health stroke score before and after treatment with hyperbaric oxygen therapy', 'PrimaryOutcomeDescription': 'The national institute of health stroke score (NIHSS) is a 15 item neurologic examination that provides a quantitative measure of stroke-related neurologic deficit. (Maximum score of 42) \"Mild\" disease was defined as score of 0-14, \"moderate\" as 15-28, and \"severe\" as 29-42.\\n\\nAs pretreatment evaluation, all patients will be evaluated by national institute of health stroke score within 48 hours after admission.\\n\\nAs posttreatment evaluation, patients in the hyperbaric oxygen therapy group were evaluated by national institute of health stroke score after 10 sessions of hyperbaric oxygen therapy.\\n\\nThe control group was evaluated with national institute of health stroke score 10 days after stroke onset.\\n\\nOne month after treatment, all patients were evaluated again using the national institute of health stroke score.', 'PrimaryOutcomeTimeFrame': '2 years'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Hospital mortality', 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'Hospital length of stay', 'SecondaryOutcomeTimeFrame': '2 years'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\nAdult patients with acute ischemic stroke\\nGlasgow coma scale more than 10\\n\\nExclusion criteria:\\n\\nPatient with cerebral hemorrhage\\nPatient received thrombolytic therapy\\nEmphysema with carbon dioxide (CO2) retention\\nPneumothorax\\nSeizure disorder', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Ibrahim Shehata, MSC', 'CentralContactRole': 'Contact', 'CentralContactPhone': '001011946001', 'CentralContactEMail': 'shehata772@gmail.com'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Ibrahim Shehata Hussin', 'LocationStatus': 'Recruiting', 'LocationCity': 'Cairo', 'LocationCountry': 'Egypt', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ibrahim Shehata, MSC', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'shehata772@gmail.com'}, {'LocationContactName': 'Shereen Elgengeehy, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Tamer Fahmy, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Mahmoud Kenawi, MD', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'waleed Farouk, MD', 'LocationContactRole': 'Sub-Investigator'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Yes'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 35, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05461911', 'OrgStudyIdInfo': {'OrgStudyId': 'DECUBISON'}, 'Organization': {'OrgFullName': 'Enrollme.ru, LLC', 'OrgClass': 'NETWORK'}, 'BriefTitle': 'Study to Assess the Clinical Efficacy of the Specialized Enteral Tube Nutrition Composition Nutrison Advanced Cubison as a Part of Complex Pressure Ulcers (PU) Therapy', 'OfficialTitle': 'Prospective Multicenter Randomized Controlled Low-interventional Post-registration Study to Assess the Clinical Efficacy of the Specialized Enteral Tube Nutrition Composition Nutrison Advanced Cubison as a Part of Complex Pressure Ulcers (PU) Therapy Versus Standard Enteral Tube Nutrition Products'}, 'StatusModule': {'StatusVerifiedDate': 'July 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'June 1, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 1, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 1, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 12, 2022', 'StudyFirstSubmitQCDate': 'July 14, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 18, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 14, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 18, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Enrollme.ru, LLC', 'LeadSponsorClass': 'NETWORK'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Danone Nutricia', 'CollaboratorClass': 'INDUSTRY'}]}}, 'OversightModule': {'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'A large number of studies are devoted to studying the effect of patient nutrition on the occurrence and treatment of pressure ulcers. Several studies, including the US National Long-term Treatment of Pressure Ulcers Study, have shown that weight loss and malnutrition were associated with a higher risk of pressure ulcers.\\n\\nOne of the successful products specially created for the treatment of pressure ulcers and taking into account the results of research is the high-protein, energy-rich, ready-to-use enteral tube feeding food product Nutrison Advanced Cubison. It is a complete enteral nutritional supplement with an innovative nutrient composition for patients with chronic wounds, including pressure ulcers, or at increased risk of developing them.\\n\\nTaking into account the available data, it seems expedient to continue studying the unique combination of nutrients that make up the study food product Nutrison Advanced Cubison in order to develop the most effective nutritional protocols for patients at risk for the treatment and prevention of pressure ulcers.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Pressure Ulcer ( Stage 2-3)']}, 'KeywordList': {'Keyword': ['Stroke', 'Traumatic Brain Injury']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Control']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '60', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'The Study Group', 'ArmGroupDescription': '30 adult patients aged 30-75 years to receive a specialized tube feeding product Nutrison Advanced Cubison (20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: Nutrison Advanced Cubison']}}, {'ArmGroupLabel': 'The Control Group', 'ArmGroupDescription': '30 patients aged 30-75 years to receive a standard (available in the clinic) tube feeding product (energetically similar to the product in group 1) with a standard content of arginine, vitamins and minerals from calculating the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g protein / kg body weight / day according to the recommendations for nutritional support for patients with pressure ulcers during the entire observation period'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'Nutrison Advanced Cubison', 'InterventionDescription': '(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['The Study Group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Changes in the area of pressure ulcers in both groups during the study', 'PrimaryOutcomeTimeFrame': 'up to 4 weeks'}, {'PrimaryOutcomeMeasure': 'The proportion of patients in both groups with a decrease in the area of the pressure ulcer by 20% or more by the date of completion of observations', 'PrimaryOutcomeTimeFrame': 'up to 4 weeks'}, {'PrimaryOutcomeMeasure': 'Changes in the Pressure Ulcer Scale for Healing values in both groups during the study', 'PrimaryOutcomeDescription': 'Pressure Ulcer Scale for Healing (PUSH) is a common tool to monitor pressure healing over time. The PUSH Tool monitors three parameters: surface area of the wound, wound exudate and type of wound tissue. Minimum value is 0, maximum value is 17. The bigger scale is the worse', 'PrimaryOutcomeTimeFrame': 'up to 4 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Duration of treatment for pressure ulcers in study patients', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Frequency and duration of infectious complications of pressure ulcers in study patients', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of the blood albumin at the beginning and at the end of observations', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of the blood lymphocytes at the beginning and at the end of observations', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of the C-reactive protein at the beginning and at the end of observations', 'SecondaryOutcomeTimeFrame': 'up to 4 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatients diagnosed with stroke / TBI and who are on tube feeding\\nPresence of pressure ulcers of 2-3 stages\\nInformed voluntary consent to medical intervention is formalized in accordance with the requirements of the Federal Law of 21.11.2011 N 323-FZ \"On the basics of protecting the health of citizens in the Russian Federation.\"\\n\\nExclusion Criteria:\\n\\nHemodynamically unstable patients\\nSevere renal impairment (GFR <30 ml / min)\\nModerate or severe liver failure (Child-Pugh Class B or C)\\nOncological diseases (lasting more than 5 years)\\nHypersensitivity to any component of the test food mixture\\nInclusion in clinical interventional research\\nUncertainty of the investigator about the willingness or ability of the subject to comply with the protocol requirements\\nAny other medical or non-medical reasons that, in the opinion of the physician, may prevent the patient from participating in the study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '79 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': '60 patients hospitalized with strokes or traumatic brain injury, who are on tube feeding and with the presence of pressure ulcers of 2-3 stages identified at baseline or during hospital stay', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Mikhail Getman, Dr', 'OverallOfficialAffiliation': 'Enrollme.ru, LLC', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'GAUZ Bryansk city hospital №1', 'LocationCity': 'Bryansk', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'GBUZ GKB named after VV Vinogradov DZM', 'LocationCity': 'Moscow', 'LocationCountry': 'Russian Federation'}, {'LocationFacility': 'Hospital named after V.D. Seredavin', 'LocationCity': 'Samara', 'LocationCountry': 'Russian Federation'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000003668', 'ConditionMeshTerm': 'Pressure Ulcer'}, {'ConditionMeshId': 'D000014456', 'ConditionMeshTerm': 'Ulcer'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000012883', 'ConditionAncestorTerm': 'Skin Ulcer'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M16896', 'ConditionBrowseLeafName': 'Ulcer', 'ConditionBrowseLeafAsFound': 'Ulcer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4897', 'ConditionBrowseLeafName': 'Brain Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M628', 'ConditionBrowseLeafName': 'Brain Injuries, Traumatic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6560', 'ConditionBrowseLeafName': 'Pressure Ulcer', 'ConditionBrowseLeafAsFound': 'Pressure Ulcer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15376', 'ConditionBrowseLeafName': 'Skin Ulcer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15364', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M17248', 'InterventionBrowseLeafName': 'Vitamins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M4203', 'InterventionBrowseLeafName': 'Ascorbic Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M17458', 'InterventionBrowseLeafName': 'Zinc', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T477', 'InterventionBrowseLeafName': 'Vitamin C', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T437', 'InterventionBrowseLeafName': 'Ascorbic Acid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T1', 'InterventionBrowseLeafName': 'Arginine', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Vi', 'InterventionBrowseBranchName': 'Vitamins'}, {'InterventionBrowseBranchAbbrev': 'AA', 'InterventionBrowseBranchName': 'Amino Acids'}]}}}}}, {'Rank': 36, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03096015', 'OrgStudyIdInfo': {'OrgStudyId': '3174E'}, 'Organization': {'OrgFullName': 'Boston University Charles River Campus', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Intensive Interdisciplinary Treatment Program for Individuals With Stroke-Induced Aphasia', 'OfficialTitle': 'Intensive Interdisciplinary Treatment Program for Individuals With Stroke-Induced Aphasia'}, 'StatusModule': {'StatusVerifiedDate': 'March 2017', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'April 2013', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 2015', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 2015', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 21, 2017', 'StudyFirstSubmitQCDate': 'March 24, 2017', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 30, 2017', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 24, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 30, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Elizabeth Hoover', 'ResponsiblePartyInvestigatorTitle': 'Clinical Associate Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Boston University Charles River Campus'}, 'LeadSponsor': {'LeadSponsorName': 'Boston University Charles River Campus', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'An intensive, interdisciplinary treatment program was administered during the summer as part of regular clinic services in the Aphasia Resource Center (ARC) at Sargent College. This program was run program as described for three years. Not more than six native English speakers with mild or moderate profiles of aphasia and multidisciplinary rehabilitation needs (OT,PT, SLP and nutrition) were recruited from the Boston community to participate in an intensive interdisciplinary treatment program for four weeks during the month of June 2013. The program consists of approximately six hours of interdisciplinary treatment each day, five days per week over a four-week interval. Treatment is individualized using current evidence-based treatment approaches, which are commonly accepted protocols in clinical practice and will be administered by clinical faculty and staff from Speech-Language and Hearing Sciences, Occupational Therapy (OT), Physical Therapy (PT), the Center for Neurorehabilitation and Nutrition. Segments of these types of treatments are available for a small fee as part of our service in the Aphasia Resource Center; however, this comprehensive, interdisciplinary program is not available of this research study.\\n\\nApproximately 30 hours of therapy per week are provided -- 6 hours per day over 5 days consisting of Speech-language Pathology, Physical Therapy, Occupational Therapy, and Nutrition Counseling.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Aphasia']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignInterventionModelDescription': 'Within-subjects Group design', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '19', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Intensive Treatment for Aphasia', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Intensive Comprehensive Aphasia Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Intensive Comprehensive Aphasia Program', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intensive Treatment for Aphasia']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Stroke Impact Scale (to assess change)', 'PrimaryOutcomeDescription': 'QoL indicator for stroke survivors', 'PrimaryOutcomeTimeFrame': '1 month pre intervention, immediately prior to intervention, the week post intervention, 3 months after intervention was completed'}, {'PrimaryOutcomeMeasure': 'Canadian Occupational Performance Measure (to assess change)', 'PrimaryOutcomeDescription': 'Measures participation and satisfaction in meaningful activities', 'PrimaryOutcomeTimeFrame': '1 month pre intervention, immediately prior to intervention, the week post intervention, 3 months after intervention was completed'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Goal Attainment Scaling (to assess change)', 'SecondaryOutcomeDescription': 'Measures attainment of individualized/personal community-based goals', 'SecondaryOutcomeTimeFrame': '1 month pre intervention, immediately prior to intervention, the week post intervention, 3 months after intervention was completed'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nClinical diagnosis of mild or moderate profile of aphasia secondary to a single stroke, as diagnosed by a certified speech-language pathologist.\\nMust be able to demonstrate auditory comprehension at a level that is functional for conversation.\\nMust demonstrate mobility or sensory deficits as a result of the stroke.\\nMust demonstrate cardiac/nutritional needs.\\nMust be able to ambulate without the physical assistance of another person for at least 500 feet.\\nMust be able to negotiate elevator and stairs independently\\nMust be able to manage bathroom needs without assistance.\\nMust be more than twelve months post-onset of stroke.\\nMust be between 18 and 75 years of age.\\nMust be native speakers of English\\nMust have 8th grade level of education or higher.\\nMust have adequate vision for functional reading\\nMust have adequate hearing for conversation\\n\\nExclusion Criteria:\\n\\nSubjects who meet the above inclusion criteria, but who are also bilingual, and/or have concomitant neurological disease will be excluded from the study.', 'HealthyVolunteers': 'Accepts Healthy Volunteers', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001037', 'ConditionMeshTerm': 'Aphasia'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000013064', 'ConditionAncestorTerm': 'Speech Disorders'}, {'ConditionAncestorId': 'D000007806', 'ConditionAncestorTerm': 'Language Disorders'}, {'ConditionAncestorId': 'D000003147', 'ConditionAncestorTerm': 'Communication Disorders'}, {'ConditionAncestorId': 'D000019954', 'ConditionAncestorTerm': 'Neurobehavioral Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4042', 'ConditionBrowseLeafName': 'Aphasia', 'ConditionBrowseLeafAsFound': 'Aphasia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15554', 'ConditionBrowseLeafName': 'Speech Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10513', 'ConditionBrowseLeafName': 'Language Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6064', 'ConditionBrowseLeafName': 'Communication Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21516', 'ConditionBrowseLeafName': 'Neurobehavioral Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]}}}}}, {'Rank': 37, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05503420', 'OrgStudyIdInfo': {'OrgStudyId': 'UW21-522'}, 'Organization': {'OrgFullName': 'The University of Hong Kong', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effects of Masticatory Muscles Training Exercises on the Masticatory Performance and Rehabilitation of Stroke Patients', 'OfficialTitle': 'Randomized Controlled Trial on Effects of Masticatory Muscles Training Exercises on the Masticatory Performance and Rehabilitation of Stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'August 2022', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 1, 2021', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 30, 2023', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'June 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'August 14, 2022', 'StudyFirstSubmitQCDate': 'August 14, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 16, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'August 14, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 16, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'The University of Hong Kong', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Stroke is one of the top causes of death and morbidity of adults, especially the older population in the economically developed countries. People who survives from stroke attack usually suffer from a wide range of impairments and often have poor chewing ability even when they are physically well enough to be discharged from hospital. Aim of this proposed study is to investigate the effects of providing masticatory muscles training exercises on the masticatory performance, nutrition intake and general health conditions of stroke rehabilitation patients. Around 100 stroke patients undergoing rehabilitation in the rehabilitation centre in Tung Wah Eastern Hospital, Hong Kong, will be recruited and allocated randomly into one of two study groups: Group 1 will be provided with an oral device for chewing muscles exercises and training exercises on chewing (the intervention group); and Group 2 will just follow the current stroke rehabilitation programme which does not have any training in chewing (a negative control group). A video on the chewing muscles exercises will be produced and placed online for the participants in Group 1 to view on demand. Data from the participants in both groups will be collected at four time points: at baseline before provision of the interventions, and at around 1, 3 and 6 months after the intervention. Each participant will be interviewed by a trained interviewer and undergo a clinical examination. The information collected will include the participant's oral health status such as numbers of decayed teeth and occluding tooth pairs, and their masticatory performance measured both objectively by chewing on a colour-changeable gum and subjectively by a chewing function questionnaire. Their type of stroke (ischemic or hemorrhagic) and general health conditions such as physical function status and nutrition intake will be recorded. The masticatory performance and general health conditions of the two groups of study participants at baseline and follow-up evaluations will be compared to assess if the masticatory muscles training exercises can improve the rehabilitation outcomes. It is anticipated that this proposed randomized trial will provide high-level clinical evidence to support the introduction of masticatory muscles training exercises into the rehabilitation programme of stroke patients and to inform how the exercises will benefit the patients, such as improving their chewing ability and general health conditions.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Mastication']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2', 'Phase 3']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Supportive Care', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Investigator']}}}, 'EnrollmentInfo': {'EnrollmentCount': '96', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'exerciser', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will be asked to use a masticatory muscle training exerciser twice daily, 10 minutes each time, and also perform active range of motion for 4 minutes each time.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Masticatory muscle training exerciser']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants in this group will receive the normal stroke rehabilitation training in the centre without additional provision of masticatory muscles training exercises.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Device', 'InterventionName': 'Masticatory muscle training exerciser', 'InterventionDescription': 'In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['exerciser']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'masticatory performance', 'PrimaryOutcomeDescription': 'colour of a color-changeable gum after chewing for 90 seconds measured in a* value', 'PrimaryOutcomeTimeFrame': '6 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\naged 30 years or above, first-time stroke patient within 20 days post-stroke and medical status being stable\\n\\nExclusion Criteria:\\n\\nunable to follow basic instructions, unable to communicate clearly, being bed-ridden, dysphagic (on nasogastric tube) and not having any natural teeth in either of the jaws', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'The University of Hong Kong', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hong Kong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Edward Lo', 'LocationContactRole': 'Contact', 'LocationContactPhone': '852-28590292', 'LocationContactEMail': 'edward-lo@hku.hk'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}, 'InterventionBrowseModule': {'InterventionBrowseLeafList': {'InterventionBrowseLeaf': [{'InterventionBrowseLeafId': 'M15320', 'InterventionBrowseLeafName': 'Silicon', 'InterventionBrowseLeafRelevance': 'low'}]}, 'InterventionBrowseBranchList': {'InterventionBrowseBranch': [{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]}}}}}, {'Rank': 38, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04289766', 'OrgStudyIdInfo': {'OrgStudyId': 'REC/00654 Irum Farooq'}, 'Organization': {'OrgFullName': 'Riphah International University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Focal Muscle Vibration on Upper Limb Function in Subacute Post-stroke Patients', 'OfficialTitle': 'Effects of Focal Muscle Vibration on Upper Limb Function in Subacute Post-stroke Patients'}, 'StatusModule': {'StatusVerifiedDate': 'April 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 26, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'April 20, 2021', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'April 20, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'February 27, 2020', 'StudyFirstSubmitQCDate': 'February 27, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'February 28, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 20, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'April 21, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Riphah International University', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Stroke is the second leading cause of death, accounting for 11.13 % of total deaths, and the main cause of disability worldwide. The major type of stroke is ischemic, which occurs in about 87% of all stroke cases Stroke has different risk factors, which can be grouped into modifiable and non-modifiable risk factors. Major risk factors for stroke include age, history of cerebrovascular event, smoking, alcohol consumption, physical inactivity, hypertension, diabetes mellitus, cardiovascular diseases, obesity, metabolic syndrome, diet, nutrition, and genetic risk factors. Many new technique used for rehabilitation after stroke includes Constraint-Induced Movement Therapy for Arm or Leg Paralysis, Mirror Therapy for Hand Recovery, Harness the Relentless Force etc. Segmental muscle vibration (SMV) is also a new technique and effective to decrease the hyper-toned muscles spasticity but still less work done on it. SMV with different frequencies have different effects for both flaccid and spastic patients of all 3 stages of stroke. In our study we will work with 60hz and 120hz frequencies to reduce the spasticity of upper limb and improves their functional level.', 'DetailedDescription': 'Evidence strongly suggest that a period of pure sensory stimulation can affect motor corticoids activity excitability.\\n\\nIn 2019 segmental muscle vibration(SMV) used to improve upper extremity functional ability post stroke and concluded that patients in both groups improved significantly after treatment in Barthel index (BI), elbow Range of Motion (ROM) and elbow muscle strength. However muscle tone in elbow joint of hemiplegic upper extremity improved significantly after only in the experimental group. They suggested that with routine physiotherapy with extended exposure SMV will results in significant reduced spasticity and better improved Activities Of Daily Livings (ADLs).\\n\\nIn 2019 a work done with SMV to improve gate performance in patients with foot drop after chronic stroke. Results of this study revealed moderate improvement in mean gate speed, normal side swing velocity, bilateral stride length and normal-side toe off in experimental group. Further studies needed to evaluate the optimal and minimum SMV dosage.\\n\\nAnother study conducted in 2019 to see Results show that processing speed, inhibitory control and attention improved following SMV. But working memory between groups and also not show a association between executive functions course and fall risk, so they suggest further work to examine effects of vibration therapy on executive functions.\\n\\nIn 2014 another therapist highlight the potential use of SMV to modulate electromyographic (EMG) for reaching movement in chronic stroke patients but needs to be confirmed by larger control perspective trials of SMV.\\n\\nIn 2019 combined work done with repetitive focal muscle vibration with physiotherapy to improve the motor function even in very acute phase of stroke and finds it a valid complementary non pharmacological therapy In 2019 another study suggest that Whole Body Vibration (WBV) and Upper and Lower Cycle (ULC) effective upper for upper extremity motor function and grip strength in sub-acute stroke.\\n\\nIn 2019 a study reported the risk factors (vibration injury to hands vascular components, intermediate blanching neurological components and lower back pain for drivers of work machines) and benefits (improvement in bone health and neuromuscular function). So is a room for research to design a balanced WBV protocol.\\n\\nA study in 2018 did a meta-analysis and compare the effects of WBV in stroke patients and concludes that it is a safe therapeutic method for improving symptoms.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke, Subacute']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '106', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Conventional Treatment', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Conventional Treatment includes exercises limbs', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Conventional Treatment']}}, {'ArmGroupLabel': 'Focal Muscle Vibration (120Hz)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.\\nConventional Treatment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Focal Muscle Vibration (120Hz)']}}, {'ArmGroupLabel': 'Focal Muscle Vibration (60Hz)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.\\nConventional Treatment', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Focal Muscle Vibration (60Hz)']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Conventional Treatment', 'InterventionDescription': 'These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Conventional Treatment']}}, {'InterventionType': 'Other', 'InterventionName': 'Focal Muscle Vibration (120Hz)', 'InterventionDescription': 'These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Focal Muscle Vibration (120Hz)']}}, {'InterventionType': 'Other', 'InterventionName': 'Focal Muscle Vibration (60Hz)', 'InterventionDescription': 'These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Focal Muscle Vibration (60Hz)']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Fugl Meyer Scale (FMS)', 'PrimaryOutcomeDescription': \"Changes from the Baseline this scale was measured\\n\\nFugl Meyer Assessment is the utmost extensively used and approved clinical scale for assessment of sensorimotor loss in post stroke patients.This scale is comprised of five domains and there are 155 items in total:\\n\\nMotor functioning (in the upper and lower extremities)\\nSensory functioning (evaluates light touch on two surfaces of the arm and leg, and position sense for 8 joints)\\nBalance (contains 7 tests, 3 seated and 4 standing)\\nJoint range of motion (8 joints)\\nJoint pain 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.\\n\\nMAS detecting the changes in muscle tone in patients with stroke.. It's a 6 point scale. 0=no muscle tone, 4= affected parts rigid flexion or extension.Its reliability is 0.567.\", 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 8 Weeks'}, {'PrimaryOutcomeMeasure': 'Motor Assessment Scale (MAS)', 'PrimaryOutcomeDescription': 'Changes from the Baseline this scale was measured\\n\\n. The Motor Assessment Scale (MAS) is used to assess everyday motor function in patients with stroke. 8 items assess 8 areas of motor function\\nPatients perform each task 3 times, only the best performance is recorded\\nItems (with the exception of the general tonus item*) are assessed using a 7-point scale (0 to 6)\\nA score of 6 indicates optimal motor behavior\\nItem scores (with the exception of the general tonus item) are summed to provide an overall score (out of 48 points)\\nCompleting a higher-level item suggests successful performance on lower-level items and thus lower-items can be skipped. For the general tonus item, the score is based on continuous observations throughout the assessment. A score of 4 on this item indicates a consistently normal response, a score > 4 indicates persistent hyper-tonus, and a score < 4 indicates various degrees of hypo-tonus', 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 8 Weeks'}, {'PrimaryOutcomeMeasure': 'Modified Ashworth Scale', 'PrimaryOutcomeDescription': \"Changes from the Baseline this scale was measured\\n\\nModified Ashworth Scale' scores exhibited better reliability when measuring upper extremities than lower[11]. The scale is as below:\\n0 No increase in muscle tone\\n1 Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension\\n1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM\\n2 More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved\\n3 Considerable increase in muscle tone, passive movement difficult\\n4 Affected part(s) rigid in flexion or extension\", 'PrimaryOutcomeTimeFrame': 'Change from Baseline to 8 Weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHemiplegic affected side spastic <3 on the Ashworth scale.\\nHistory of stroke should be > 6 weeks and <12 weeks.\\n\\nExclusion Criteria:\\n\\nIndividuals with the other neurological deficit\\nDiabetic ulcer, infection or amputation of limb\\nSerious cardiovascular disease or unstable angina\\nSerious orthopedic problem\\nChronic medical problems', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '35 Years', 'MaximumAge': '65 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Imran Amjad, Phd', 'OverallOfficialAffiliation': 'Riphah International University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Railway General Hospital', 'LocationCity': 'Rawalpindi', 'LocationState': 'Punjab', 'LocationZip': '44000', 'LocationCountry': 'Pakistan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '30762754', 'ReferenceType': 'background', 'ReferenceCitation': 'Annino G, Alashram AR, Alghwiri AA, Romagnoli C, Messina G, Tancredi V, Padua E, Mercuri NB. Effect of segmental muscle vibration on upper extremity functional ability poststroke: A randomized controlled trial. Medicine (Baltimore). 2019 Feb;98(7):e14444. doi: 10.1097/MD.0000000000014444.'}, {'ReferencePMID': '19855076', 'ReferenceType': 'background', 'ReferenceCitation': 'Paoloni M, Mangone M, Scettri P, Procaccianti R, Cometa A, Santilli V. Segmental muscle vibration improves walking in chronic stroke patients with foot drop: a randomized controlled trial. Neurorehabil Neural Repair. 2010 Mar-Apr;24(3):254-62. doi: 10.1177/1545968309349940. Epub 2009 Oct 23.'}, {'ReferencePMID': '16680616', 'ReferenceType': 'background', 'ReferenceCitation': 'Smith L, Brouwer B. Effectiveness of muscle vibration in modulating corticospinal excitability. J Rehabil Res Dev. 2005 Nov-Dec;42(6):787-94. doi: 10.1682/jrrd.2005.02.0041.'}, {'ReferencePMID': '25227540', 'ReferenceType': 'background', 'ReferenceCitation': 'Paoloni M, Tavernese E, Fini M, Sale P, Franceschini M, Santilli V, Mangone M. Segmental muscle vibration modifies muscle activation during reaching in chronic stroke: A pilot study. NeuroRehabilitation. 2014;35(3):405-14. doi: 10.3233/NRE-141131.'}, {'ReferencePMID': '30873102', 'ReferenceType': 'background', 'ReferenceCitation': 'Toscano M, Celletti C, Vigano A, Altarocca A, Giuliani G, Jannini TB, Mastria G, Ruggiero M, Maestrini I, Vicenzini E, Altieri M, Camerota F, Di Piero V. Short-Term Effects of Focal Muscle Vibration on Motor Recovery After Acute Stroke: A Pilot Randomized Sham-Controlled Study. Front Neurol. 2019 Feb 19;10:115. doi: 10.3389/fneur.2019.00115. eCollection 2019.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 39, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02207023', 'OrgStudyIdInfo': {'OrgStudyId': 'H13-03353'}, 'Organization': {'OrgFullName': 'University of British Columbia', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Healthy Lifestyles After Stroke - Stroke Coach', 'OfficialTitle': 'A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study', 'Acronym': 'StrokeCoach'}, 'StatusModule': {'StatusVerifiedDate': 'March 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'October 2014'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'March 31, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2020', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 28, 2014', 'StudyFirstSubmitQCDate': 'July 30, 2014', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'August 1, 2014', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'May 5, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 8, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Janice Eng', 'ResponsiblePartyInvestigatorTitle': 'Principal Investigator', 'ResponsiblePartyInvestigatorAffiliation': 'University of British Columbia'}, 'LeadSponsor': {'LeadSponsorName': 'University of British Columbia', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Canadian Institutes of Health Research (CIHR)', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Heart and Stroke Foundation of Canada', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The purpose of this study is to examine the efficacy of a lifestyle modification telehealth program on health-related behaviours in community-dwelling individuals living with stroke.', 'DetailedDescription': 'Participants recruited in this study will be randomly assigned to either the Healthy Lifestyle Training Program, or Attention Control Memory Training Program.\\n\\nIndividuals in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. Individuals in the Memory Training Program will each receive 7 memory coaching telephone sessions (30-60 minutes) with a trained memory training coach over a 6 month period. 100 evaluable subjects will be recruited (124 to accommodate for 20% dropout).'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Apoplexy', 'Cerebral Stroke', 'Cerebrovascular Accident', 'Cerebrovascular Accident, Acute', 'Cerebrovascular Apoplexy', 'Cerebrovascular Stroke', 'CVA', 'Stroke, Acute', 'Vascular Accident, Brain']}, 'KeywordList': {'Keyword': ['Stroke', 'Telehealth', 'Rehabilitation', 'Stroke Coach', 'Randomized controlled trial', 'Lifestyle behaviours', 'Secondary prevention', 'Chronic disease self-management']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '126', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Memory Training Program', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.'}, {'ArmGroupLabel': 'Healthy Lifestyle Training Program', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Healthy Lifestyle Training Program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Healthy Lifestyle Training Program', 'InterventionDescription': 'Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Lifestyle Training Program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Global measure of lifestyle behavior (Health Promoting Lifestyle Profile II)', 'PrimaryOutcomeDescription': 'The 52-item Health Promoting Lifestyle Profile II provides a composite score of lifestyle, in the areas of: health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, and stress management.', 'PrimaryOutcomeTimeFrame': 'End of program (6 months)'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Daily walking physical activity', 'SecondaryOutcomeDescription': 'Study participants will wear the activity monitor over the 7 days following each assessment period (baseline, 6 months, 12 months)', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Dietary behavior (26 items SmartDiet Questionnaire)', 'SecondaryOutcomeDescription': 'The SmartDiet Canadian Version Questionnaire was developed to assess fiber and fat intake. This questionnaire has 26 questions about diet and lifestyle. Most questions list foods in 3 or 4 categories according to fat or fiber content.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Medication adherence (8-item Morisky Medication Adherence Scale)', 'SecondaryOutcomeDescription': 'The Morisky Medication Adherence Scale assesses habits in taking medication and barriers that may hinder medication adherence.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Depressive symptoms (20-item Centre for Epidemiological Studies-Depression [CES-D] Scale)', 'SecondaryOutcomeDescription': 'This scale assess the frequency with which participants experience depression symptoms, such as restless sleep, poor appetite, and feeling lonely, during the past week.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Cognition (Montreal Cognitive Assessment [MoCA])', 'SecondaryOutcomeDescription': 'The MoCA is a screening instrument to assess for cognitive impairment.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Cardiovascular risk factors (resting blood pressure, lipid, and glucose profiles, C-Reactive Protein, Homocysteine).', 'SecondaryOutcomeDescription': 'These risk factors will be assessed using hospital lab services.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Body composition (Body Mass Index, waist circumference)', 'SecondaryOutcomeDescription': 'The Body Mass Index is a measure of body fat based on weight and height. Waist circumference will be measured using a tape measure around the waist at the height of the umbilicus.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Health-related quality of life (SF-36)', 'SecondaryOutcomeDescription': \"The SF-36 is a generic health status measure that was designed to be applied to all health conditions and assess health concepts, which represent basic human values and are relevant to a person's functional status and well-being.\", 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Health and Social Services Utilization (Health and Social Service Utilization Inventory)', 'SecondaryOutcomeDescription': 'The Health and Social Services Utilization inventory collects data regarding health services used, medications, and out of pocket health costs.', 'SecondaryOutcomeTimeFrame': 'End of program (6 months), and 6 months after the program ends (12 months from baseline)'}, {'SecondaryOutcomeMeasure': 'Global measure of lifestyle behavior (Health Promoting Lifestyle Profile II)', 'SecondaryOutcomeDescription': 'The 52-item Health Promoting Lifestyle Profile II provides a composite score of lifestyle, in the areas of: health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations, and stress management.', 'SecondaryOutcomeTimeFrame': '6 months after the program ends (12 months from baseline)'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHas experienced a stroke in the last 12 months\\n50 years of age or older\\nLiving in the community with phone access\\nMild to moderate stroke severity (i.e., modified Rankin Scale score ranging from 1 to 4)\\nAble to communicate in English\\n\\nExclusion Criteria:\\n\\nStroke of non-vascular origin\\nActively engaged in formal stroke rehabilitation services\\nUncontrolled arrhythmias\\nSignificant musculoskeletal or other neurological condition\\nSevere aphasia or dysarthria\\nNot medically stable\\nPain or co-morbidities which would preclude activity\\nLiving in long-term residential care\\nCognitive impairment, dependent in activities of daily living, and no caregiver participation', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '50 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Janice Eng, PhD', 'OverallOfficialAffiliation': 'University of British Columbia', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Royal Columbian Hospital', 'LocationCity': 'New Westminster', 'LocationState': 'British Columbia', 'LocationZip': 'V3L 3W7', 'LocationCountry': 'Canada'}, {'LocationFacility': 'University Hospital of Northern BC', 'LocationCity': 'Prince George', 'LocationState': 'British Columbia', 'LocationZip': 'V2M 1S2', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Surrey Memorial Hospital', 'LocationCity': 'Surrey', 'LocationState': 'British Columbia', 'LocationZip': 'V3V 1Z2', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Holy Family Hospital', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5P 3L6', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Vancouver General Hospital', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 1M9', 'LocationCountry': 'Canada'}, {'LocationFacility': 'GF Strong Rehabilitation Centre', 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V5Z 2G9', 'LocationCountry': 'Canada'}, {'LocationFacility': \"St. Paul's Hospital\", 'LocationCity': 'Vancouver', 'LocationState': 'British Columbia', 'LocationZip': 'V6Z 1Y6', 'LocationCountry': 'Canada'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '33949270', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sakakibara BM, Lear SA, Barr SI, Goldsmith CH, Schneeberg A, Silverberg ND, Yao J, Eng JJ. Telehealth coaching to improve self-management for secondary prevention after stroke: A randomized controlled trial of Stroke Coach. Int J Stroke. 2022 Apr;17(4):455-464. doi: 10.1177/17474930211017699. Epub 2021 May 27.'}, {'ReferencePMID': '28869405', 'ReferenceType': 'derived', 'ReferenceCitation': 'Sakakibara BM, Lear SA, Barr SI, Benavente O, Goldsmith CH, Silverberg ND, Yao J, Eng JJ. A telehealth intervention to promote healthy lifestyles after stroke: The Stroke Coach protocol. Int J Stroke. 2018 Feb;13(2):217-222. doi: 10.1177/1747493017729266. Epub 2017 Sep 4.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Accident', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11997', 'ConditionBrowseLeafName': 'Neoplasm Metastasis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5837', 'ConditionBrowseLeafName': 'Chronic Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1303', 'ConditionBrowseLeafName': 'Chronic Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 40, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03969563', 'OrgStudyIdInfo': {'OrgStudyId': 'D2951-R'}, 'Organization': {'OrgFullName': 'VA Office of Research and Development', 'OrgClass': 'FED'}, 'BriefTitle': 'Mindfulness-Based Stress Reduction to Improve Neuropsychological Functioning in Acquired Brain Injury', 'OfficialTitle': 'Mindfulness-Based Stress Reduction to Improve Neuropsychological Functioning in Acquired Brain Injury'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 6, 2020', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 5, 2024', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'April 22, 2024', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'May 29, 2019', 'StudyFirstSubmitQCDate': 'May 29, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 31, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 9, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 13, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'VA Office of Research and Development', 'LeadSponsorClass': 'FED'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No', 'IsUSExport': 'No'}, 'DescriptionModule': {'BriefSummary': \"Thousands of Veterans suffer a stroke every year, and these individuals often suffer emotional and cognitive changes that negatively affect their quality of life as well as their ability to recover. In addition to traditional rehabilitation such as physical and occupational therapy, a number of alternative treatments are now being studied for their ability to enhance patients' recovery following stroke. One of these treatments, Mindfulness-Based Stress Reduction or MBSR, involves an 8-week course that teaches individuals strategies such as breathing techniques, meditation, and movement therapy. The current study proposes to teach MBSR to a group of Veterans with a history of stroke to determine whether this type of intervention has beneficial effects on psychological and cognitive functioning. The investigators hope to find that MBSR is a useful, additional intervention that can improve Veterans' well-being and quality of life as they recover from stroke.\", 'DetailedDescription': \"Stroke affects approximately 800,000 Americans every year, including thousands of Veterans, and is a leading cause of disability in the US. While many stroke patients receive rehabilitation during the acute and post-acute phases of stroke, many individuals suffer chronic deficits and have few options for continued treatment. A number of low-cost, alternative treatments are now being tested for their usefulness in treating neuropsychological deficits in chronic stroke patients. One of the best studied of these treatments is Mindfulness-Based Stress Reduction (MBSR), which involves an 8-week course led by a trained instructor. MBSR teaches individuals strategies for coping with their injury, such as meditation, breathing techniques, and yoga. A handful of preliminary studies have shown that MBSR is effective in reducing symptoms of anxiety and depression in stroke patients, as well as enhancing performance on cognitive tasks. However, only a single randomized controlled trial of MBSR in stroke has been published to date, and that study suffered from a number of weaknesses such as the lack of an active control group. Moreover, no previous study has assessed the usefulness of MBSR for stroke in a Veteran population. Therefore, the current study proposes to undertake a rigorous, randomized controlled trial of MBSR in Veterans with a history of stroke, using an active control group, blinded examiners, and a 6-month follow-up session to determine whether the benefits of MBSR are long-lasting. For the study, 120 Veterans with a history of chronic stroke will be recruited: 60 participants will be randomly assigned to the MBSR intervention, and 60 participants will be assigned to a Brain Health class that is matched to the MBSR intervention with respect to the instructor, number of hours of instruction, homework activities, and class size. A blinded examiner will complete a neuropsychological assessment of patients' emotional and cognitive status at three time points: 1) prior to the intervention, 2) following the intervention, and 3) six months later. Evaluation of the MBSR intervention will test for improvements in anxiety and depressive symptomatology following the intervention, relative to the Brain Health group, as well as improvements on a cognitive test battery. It is predicted that improvements associated with the MBSR intervention will still be present at the 6-month follow-up assessment as well. The final objective of the current proposal is to determine whether the site of a patient's stroke plays a role in their ability to benefit from MBSR. Previous research has suggested that left prefrontal cortex plays a critical role underlying the effects of MBSR. Thus, it is predicted that involvement of this brain region will modulate the observed effects. Such information could be used to target those Veterans who can most benefit from the proposed intervention. If shown to be effective, MBSR could provide a low-cost, non-invasive rehabilitative treatment for Veterans with acquired brain injury that can improve their neuropsychological functioning and general sense of well-being.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['stroke', 'MBSR', 'meditation', 'mindfulness', 'yoga']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignInterventionModelDescription': 'Participants are assigned to either the MBSR or Brain Health education class, in parallel for the duration of the study.', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignMaskingDescription': \"The neuropsychologist doing the assessments pre- and post-intervention will not be aware of the participant's group assignment.\", 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '109', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'MBSR', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Mindfulness-based Stress Reduction']}}, {'ArmGroupLabel': 'Brain Health Education', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': '8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Brain Health Education']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Mindfulness-based Stress Reduction', 'InterventionDescription': '8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['MBSR']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MBSR']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Brain Health Education', 'InterventionDescription': '8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Brain Health Education']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Beck Anxiety Inventory', 'PrimaryOutcomeDescription': 'The primary psychological outcome measure is the Beck Anxiety Inventory to measure changes in subjective symptoms of anxiety from pre- to post-intervention. The range is 0 to 63, with 0 being no/minimal anxiety and 63 being severe anxiety. A lower score post-intervention indicates improvement on this measure.', 'PrimaryOutcomeTimeFrame': '10 weeks'}, {'PrimaryOutcomeMeasure': 'Working Memory Score on the Repeatable Battery for the Assessment of Neuropsychological Status', 'PrimaryOutcomeDescription': \"The primary cognitive outcome measure is the Repeatable Battery for the Assessment of Neuropsychological Status working memory score, which tests participants' ability to hold information in mind for several seconds. Raw scores will be converted to normative percentiles, which can range from 1-99th percentile. A higher percentile post-intervention indicates improvement on this measure.\", 'PrimaryOutcomeTimeFrame': '10 weeks'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Beck Depression Inventory', 'SecondaryOutcomeDescription': 'The secondary psychological outcome measure is a change in depression scores from pre- to post-intervention. The range is 0 to 63, with 0 being no/minimal depression and 63 being severe depression. A lower score post-intervention indicates improvement on this measure.', 'SecondaryOutcomeTimeFrame': '10 weeks'}, {'SecondaryOutcomeMeasure': 'Attention Score on the Repeatable Battery for the Assessment of Neuropsychological Status', 'SecondaryOutcomeDescription': \"The secondary cognitive outcome score is the Repeatable Battery for the Assessment of Neuropsychological Status attention score, which tests participants' ability to stay focused on a stimulus and respond with minimal distraction. Raw scores will be converted to normative percentiles, which can range from 1-99th percentile. A higher percentile post-intervention indicates improvement on this measure.\", 'SecondaryOutcomeTimeFrame': '10 weeks'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nhistory of a single, chronic right or left hemisphere stroke\\n\\ndefined here as > 3 months post-onset so that residual symptoms have stabilized)\\nnative English proficiency\\n\\nat least mild level of depression\\n\\n14 on Beck Depression Inventory-II94,95\\n\\nand/or mild anxiety\\n\\n8 on the Beck Anxiety Inventory27\\n\\nlanguage within normal limits\\n\\nWestern Aphasia Battery score > 93.7104\\nscores already available in the investigators' stroke patient database so that language deficits will not interfere with the intervention\\n\\nExclusion Criteria:\\n\\na pre-morbid neurologic history or history of schizophrenia spectrum and other psychotic disorders\\n\\nincluding depressive disorders with psychotic features\\nbipolar disorders (to avoid potential confounds in neuropsychological testing)\\nMini-Mental State Examination score <19 (suggesting moderate to severe cognitive impairment that is a contraindication in effectively participating in the MBSR intervention52)\\nrecent substance abuse/dependence disorder (< 1 year)\\nacutely suicidal\\nconcurrent involvement in another rehabilitation program\\nsignificant visual or hearing disabilities that would preclude participating in the program\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '80 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Juliana V. Baldo, PhD', 'OverallOfficialAffiliation': 'VA Northern California Health Care System, Mather, CA', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'VA Northern California Health Care System, Mather, CA', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95655-4200', 'LocationCountry': 'United States'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DocumentSection': {'LargeDocumentModule': {'LargeDocList': {'LargeDoc': [{'LargeDocTypeAbbrev': 'ICF', 'LargeDocHasProtocol': 'No', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'Yes', 'LargeDocLabel': 'Informed Consent Form', 'LargeDocDate': 'August 18, 2021', 'LargeDocUploadDate': '03/09/2023 16:47', 'LargeDocFilename': 'ICF_000.pdf'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000001930', 'ConditionMeshTerm': 'Brain Injuries'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000006259', 'ConditionAncestorTerm': 'Craniocerebral Trauma'}, {'ConditionAncestorId': 'D000020196', 'ConditionAncestorTerm': 'Trauma, Nervous System'}, {'ConditionAncestorId': 'D000014947', 'ConditionAncestorTerm': 'Wounds and Injuries'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4897', 'ConditionBrowseLeafName': 'Brain Injuries', 'ConditionBrowseLeafAsFound': 'Brain Injury', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17375', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9039', 'ConditionBrowseLeafName': 'Craniocerebral Trauma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21713', 'ConditionBrowseLeafName': 'Trauma, Nervous System', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}]}}}}}, {'Rank': 41, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03701815', 'OrgStudyIdInfo': {'OrgStudyId': 'KRU001'}, 'Organization': {'OrgFullName': 'VA Palo Alto Health Care System', 'OrgClass': 'FED'}, 'BriefTitle': 'Effect of Lifestyle Changes on BDNF Level After Stroke', 'OfficialTitle': 'Assessing the Effect of Multi-disciplinary Lifestyle Medicine Intervention on Brain-derived Neurotrophic Factor Levels Following Stroke'}, 'StatusModule': {'StatusVerifiedDate': 'October 2018', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 19, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 11, 2019', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'February 28, 2019', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'September 27, 2018', 'StudyFirstSubmitQCDate': 'October 8, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'October 10, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 8, 2018', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'October 10, 2018', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Jeffrey Krauss', 'ResponsiblePartyInvestigatorTitle': 'Staff Physician', 'ResponsiblePartyInvestigatorAffiliation': 'VA Palo Alto Health Care System'}, 'LeadSponsor': {'LeadSponsorName': 'VA Palo Alto Health Care System', 'LeadSponsorClass': 'FED'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'Stanford University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Spaulding Rehabilitation Hospital', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This is a pilot study to determine whether a lifestyle medicine intervention following stroke may increase levels of Brain-Derived Neurotrophic Factor (BDNF).', 'DetailedDescription': 'This is a substudy of the study entitled \"Assessing a Multi-Disciplinary Lifestyle Medicine Intervention Following Stroke,\" specifically looking at the effects of lifestyle change on brain-derived neurotrophic factor (BDNF). BDNF has emerged as a key facilitator of neuroplasticity to improve motor learning and rehabilitation after stroke. Aerobic exercise has been shown to increase levels of BDNF in multiple parts of the central nervous system and therefore may facilitate neuroplasticity and motor recovery. While BDNF levels appear to be increased for up to 1 hour following a bout of aerobic exercise, it is unclear whether regular aerobic exercise over weeks to months can increase baseline BDNF levels in humans following stroke.\\n\\nAn single nucleotide polymorphism exists on the BDNF gene in 30-50% of the human population that results in an amino acid change from valine (val) to methionine (met) at position 66 (val66met) of the precursor peptide proBDNF. The presence of the met allele results in a 25% reduction in activity-dependent secretion of BDNF in the CNS.\\n\\nThe Wellness in Rehabilitation program at the VA Palo Alto Health Care System is a lifestyle medicine intervention for patients following stroke. It is a 12-week program involving weekly meetings that include exercise (particularly aerobic exercise), nutrition, stress management, education, and group support. Participants are encouraged to perform healthy lifestyle behaviors (i.e. exercise) daily at home, and a health coach calls each patient weekly to support the behavior change process.\\n\\nParticipants in the Wellness in Rehabilitation program who elect to participate in the research study will have blood drawn at baseline, week 6, and week 12. Blood draws will be performed in the morning prior to exercise, and week 6 will additionally include a blood draw within 30 minutes of completing a bout of aerobic exercise. Following completion of the study, plasma BDNF levels (measured as nanograms per milliliter) will then be measured at all 4 time points (baseline, week 6 pre-exercise, week 6 post-exercise, and week 12). In addition, BDNF genotype will be measured using the baseline sample. Participants will also complete bike or treadmill exercise testing at baseline and week 12 to determine pre- and post-program cardiovascular fitness levels (measured as VO2 max and estimated metabolic equivalents), and will also complete a 6-minute walk test. They will be asked to record their exercise daily and will additionally complete the Physical Activity Scale for Individuals with Physical Disabilities at baseline and week 12 time points.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['brain-derived neurotrophic factor', 'exercise', 'BDNF', 'lifestyle medicine']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'N/A', 'DesignInterventionModel': 'Single Group Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '12', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Post-stroke', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients will receive a 12-week lifestyle medicine program.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Wellness in Rehabilitation program']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'Wellness in Rehabilitation program', 'InterventionDescription': 'The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Post-stroke']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Lifestyle Medicine program']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'BDNF level - Final', 'PrimaryOutcomeDescription': 'Plasma BDNF protein levels, expressed in nanograms per milliliter, measured prior to any exercise upon completion of intervention.', 'PrimaryOutcomeTimeFrame': 'Week 12'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'BDNF level - Post-exercise', 'SecondaryOutcomeDescription': 'Plasma BDNF protein levels, expressed in nanograms per milliliter, measured immediately following bout of aerobic exercise.', 'SecondaryOutcomeTimeFrame': 'Week 6'}, {'SecondaryOutcomeMeasure': 'BDNF Genotype', 'SecondaryOutcomeDescription': 'Genotyping of venous blood samples to determine ValVal, MetMet, and ValMet distribution.', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'Cardiovascular Fitness - VO2 max', 'SecondaryOutcomeDescription': 'Measured as VO2 max (ml/kg/min).', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': 'Cardiovascular Fitness - METs', 'SecondaryOutcomeDescription': 'Measured as estimated metabolic equivalents (kcal/kg/hour).', 'SecondaryOutcomeTimeFrame': 'Week 12'}, {'SecondaryOutcomeMeasure': '6-minute Walk Test', 'SecondaryOutcomeDescription': 'Total distance walked 6 minutes on a flat surface.', 'SecondaryOutcomeTimeFrame': 'Week 12'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nHistory of prior stroke (ischemic or hemorrhagic) or transient ischemic attack\\nAbility to ambulate at least 10 feet with minimal to moderate assistance\\nAbility to travel to intervention site on a weekly basis.\\n\\nExclusion Criteria:\\n\\nCerebral aneurysm\\nConcurrent pregnancy\\nSerious terminal illnesses (e.g. end stage renal disease, heart failure (class IV), cirrhosis (class C), metastatic cancer)\\nAny injury or illness preventing participation in regular aerobic exercise\\nModerate-severe dementia or cognitive decline', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '30 Years', 'MaximumAge': '90 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Jeffrey Krauss, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '6504935000', 'CentralContactPhoneExt': '65525', 'CentralContactEMail': 'jkrauss@stanford.edu'}, {'CentralContactName': 'Windy McNerney, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '6504935000', 'CentralContactEMail': 'windymc@stanford.edu'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Jeffrey Krauss, MD', 'OverallOfficialAffiliation': 'VA Palo Alto Health Care System, Stanford University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'VA Palo Alto Health Care System', 'LocationStatus': 'Recruiting', 'LocationCity': 'Palo Alto', 'LocationState': 'California', 'LocationZip': '94304', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jeffrey Krauss, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '650-493-5000', 'LocationContactPhoneExt': '65525', 'LocationContactEMail': 'jeffrey.krauss@va.gov'}]}}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 42, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03728400', 'OrgStudyIdInfo': {'OrgStudyId': 'DENUTRITION USINV'}, 'Organization': {'OrgFullName': 'Groupe Hospitalier Paris Saint Joseph', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Follow-up of Malnutrition Screening in USINV', 'OfficialTitle': 'Follow-up of Malnutrition Screening in Neurovascular Intensive Care Unit', 'Acronym': 'DENUTRITION'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 29, 2018', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'August 30, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'December 30, 2023', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'October 31, 2018', 'StudyFirstSubmitQCDate': 'October 31, 2018', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'November 2, 2018', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 6, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 7, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Groupe Hospitalier Paris Saint Joseph', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This aim of the study is to set up a procedure for screening for undernutrition in the neurovascular intensive care unit. This screening procedure follows a specific work concerning undernutrition in thrombolyzed patients (NCT03303820). This work was motivated by the fact that, despite a high frequency of undernutrition in the hospital (at least 30% of patients), undernutrition in neurovascular unit is studied very little. A cohort of thrombolysed patients in 2014 was studied retrospectively. Patients malnourished at the entrance had a non-significant, less good recovery of their stroke (+ 1 Rankin score point at 3 months in malnourished patients at the entrance).', 'DetailedDescription': 'The main objective of this project is to assess, prospectively, the frequency of undernutrition at the entrance to the neurovascular intensive care unit and to evaluate the implementation of the undernutrition screening procedure.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '66', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Patients in neurovascular intensive care', 'ArmGroupDescription': \"During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.\"}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'frequency of undernutrition at the entrance', 'PrimaryOutcomeDescription': 'The primary endpoint is the number of patients who have had an assessment of their nutritional status, that is, for whom undernutrition is detected according to the terms proposed in the undernutrition screening procedure: search for previous quantified weight loss, input BMI, albuminemia.', 'PrimaryOutcomeTimeFrame': 'Day 1'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Modified Rankin scale', 'SecondaryOutcomeDescription': 'The Rankin score will be performed in post stroke consultation, 3 months after inclusion. Rankin scale: 0 no symptoms, 1 No significant disability. Able to carry out all usual activities, despite some symptoms, 2 Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 Moderate disability. Requires some help, but able to walk unassisted, 4 Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 Severe disability. Requires constant nursing care and attention, bedridden, incontinent', 'SecondaryOutcomeTimeFrame': '3 months'}, {'SecondaryOutcomeMeasure': 'Recurrence rate of ischemic or haemorrhagic stroke', 'SecondaryOutcomeDescription': 'The recurrence of stroke will be collected during the post stroke consultation, 3 months after inclusion.', 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nPatient whose age ≥ 70 years\\nPatient hospitalized in Neurovascular Intensive care Unit following a stroke (infarction or cerebral hematoma)\\nFrancophone patient\\n\\nExclusion Criteria:\\n\\nPatient hospitalized in Neurovascular Intensive care Unit following a transient ischemic attack\\nPatient whose age ≤ 70 years\\nPatient hospitalized in Neurovascular Intensive care Unit for another reason than neurovascular disease\\nPatient opposing the use of his data', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '70 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'Patients hospitalized in Neurovascular Intensive care Unit following a stroke', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Marie P BRUANDET, MD', 'OverallOfficialAffiliation': 'Groupe Hospitalier Paris Saint Joseph', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Groupe Hospitalier Paris Saint-Joseph', 'LocationCity': 'Paris', 'LocationZip': '75014', 'LocationCountry': 'France'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}]}}}}}, {'Rank': 43, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT03798418', 'OrgStudyIdInfo': {'OrgStudyId': 'CCH-170208'}, 'Organization': {'OrgFullName': 'Changhua Christian Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases', 'OfficialTitle': 'Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases - Effects of Therapeutic Exercise and Nutrition Intervention'}, 'StatusModule': {'StatusVerifiedDate': 'October 2022', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'February 1, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'September 30, 2022', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'September 30, 2022', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'December 28, 2018', 'StudyFirstSubmitQCDate': 'January 9, 2019', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'January 10, 2019', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'October 30, 2022', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'November 1, 2022', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Ta-Sen Wei,MD', 'ResponsiblePartyInvestigatorTitle': 'Director, Physical Medical and Rehabilitation, Principal Investigator, Clinical Professor', 'ResponsiblePartyInvestigatorAffiliation': 'Changhua Christian Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'Changhua Christian Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The objective of this study is to investigate the effects of therapeutic exercise and nutrition intervention for sarcopenia and risk of falls in patients with major chronic diseases. The outcomes will be analyzed regarding muscle strength, quality, and volume, etc., balance and gait, bone density, body composition, fall and quality of life after the intervention.', 'DetailedDescription': 'The main common chronic diseases in the elderly such as stroke, osteoporosis, chronic kidney disease and cancer, have been regarded as the fall high-risk patients. These patients are considered to be at risk for sarcopenia due to decreased exercise, nutritional status, and other reasons. Sarcopenia can be diagnosed and intervened effectively to delay the vicious cycle of health. Past studies have pointed out that in addition to drug intervention, treatment for sarcopenia must be accompanied by appropriate exercise and nutritional intervention (such as protein supplements, vitamin D) in order to achieve the best prevention and treatment.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Osteoporosis', 'Chronic Kidney Diseases', 'Cancer']}, 'KeywordList': {'Keyword': ['Sarcopenia', 'stroke', 'osteoporosis', 'chronic kidney disease', 'cancer', 'balance and gait', 'fall']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Prevention', 'DesignMaskingInfo': {'DesignMasking': 'Double', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Participant', 'Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '186', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'exercise group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'elastic band strengthening exercise', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: elastic band strengthening exercise']}}, {'ArmGroupLabel': 'exercise combine diet counseling group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'elastic band strengthening exercise combined diet counseling.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: elastic band strengthening exercise', 'Dietary Supplement: diet counseling']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Behavioral', 'InterventionName': 'elastic band strengthening exercise', 'InterventionDescription': '2-3days per week(150min per week)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['exercise combine diet counseling group', 'exercise group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['thera-band strengthening exercise']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'diet counseling', 'InterventionDescription': 'each patients in this group will receive4-5times diet counseling', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['exercise combine diet counseling group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['nutrition counseling']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change of walking speed', 'PrimaryOutcomeDescription': 'distance: 6m, patients can walk with foor orthosis and assistive devices', 'PrimaryOutcomeTimeFrame': 'baseline: before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of grip force', 'PrimaryOutcomeDescription': 'Use a grip force meter (kg) to test both hands for test 3 times', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of postural sway displacement', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure the postural sway displacement (mm)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of postural sway velocity', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure the postural sway velocity (mm/s)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of postural sway area', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure the postural sway area (mm^2)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of step time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: step time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of stance time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: stance time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of swing time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: swing time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of single support time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: single support time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of double support time', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: double support time (ms)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of step length', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: step distance (mm)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of stance length', 'PrimaryOutcomeDescription': 'Use computerized dynography to measure spatial gait parameter: stance distance (mm)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle thickness', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: thickness (mm). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle fiber length', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: fiber length (mm). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle fiber orientation angle', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: fiber orientation angle (degrees). Target muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of muscle cross section area', 'PrimaryOutcomeDescription': 'Use ultrasound to assess muscles morphological parameter: cross-sectional area (mm^2).\\n\\nTarget muscles include quadriceps, hamstring, anterior tibialis, gastrocnemius.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of physiological cost index (PCI)', 'PrimaryOutcomeDescription': 'Heart rate (HR: beats/min) and walking speed (m/s) have been previously shown to be linearly related to oxygen uptake at sub-maximal exercise levels. Combination of these two parameters yields a single value in beats per meter, the physiological cost index (PCI). This is calculated as Working HR - Resting HR (beats/min) / Walking speed (m/s)', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of international Quality of Life Assessment Short Form -36 (SF-36)', 'PrimaryOutcomeDescription': 'including 8 health concepts: (1) physical functioning, (2) role limitations because of physical health problems; (3) bodily pain, (4) social functioning, (5) general mental health (psychological distress and psychological wellbeing), (6) role limitations because of emotional problems, (7) vitality (energy/fatigue), (8) general health perceptions.\\n\\nScoring: answers to each question are scored which are then summed and transformed to a 0 - 100 scale.\\n\\nThe lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'PrimaryOutcomeMeasure': 'Change of amplitude of Muscle activity', 'PrimaryOutcomeDescription': 'use electromyography to measure the muscles activity in microvolts (uv) included quadriceps, hamstrings, tibialis anterior, gastrocnemius during subject walking in self-selected speed in 6 meters.', 'PrimaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Change of concentration of CRP (C-Reactive Protein)', 'SecondaryOutcomeDescription': 'The concentration of CRP in the blood test. CRP is used mainly as a marker of inflammation.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of ALB (Serum albumin)', 'SecondaryOutcomeDescription': 'The concentration of ALB in the blood test. Albumin is the most important contributor to the maintenance of plasma colloid oncotic pressure; deficiency results in edema.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Glomerular Filtration Rate (GFR)', 'SecondaryOutcomeDescription': \"The concentration of GFR in the blood test. The glomerular filtration rate is the best test to measure the patient's level of kidney function and determine the stage of kidney disease. It can calculate it from the results of the blood creatinine test.\", 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Hemoglobin (Hb)', 'SecondaryOutcomeDescription': 'The concentration of Hb in the blood test.', 'SecondaryOutcomeTimeFrame': 'Time Frame: before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Glucose SPOT', 'SecondaryOutcomeDescription': 'The concentration of Glucose SPOT in the blood test. TheSpot glucose measurement in epidermal interstitial fluid appears to be a promising alternative to capillary blood glucose estimation', 'SecondaryOutcomeTimeFrame': 'Time Frame: before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Cholesterol', 'SecondaryOutcomeDescription': 'The concentration of Cholesterol in the blood test.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Triglyceride', 'SecondaryOutcomeDescription': 'The concentration of Triglyceride in the blood test.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of concentration of Transferrin', 'SecondaryOutcomeDescription': 'The concentration of Transferrin in the blood test.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Berg balance test (BBS)', 'SecondaryOutcomeDescription': 'including 14 items which are scored on a 5 points scale (0-4). The degree of success in achieving each task is given a score of zero (unable) to four (independent), and the final measure is the sum of all of the scores.\\n\\nThe item scores are summed, minimum score =0, maximum score = 56', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Fugl-Meyer Assessment (FMA)', 'SecondaryOutcomeDescription': 'Items are scored on a 3-point ordinal scale (0 = cannot perform; 1 = performs partially; 2 = performs fully) Maximum Score = 226 points The 5 domains assessed include, Motor function (UE maximum score = 66; LE maximum score = 34), Sensory function (maximum score = 24), Balance (maximum score = 14), Joint range of motion (maximum score = 44), Joint pain (maximum score = 44)', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Body Mass Index (BMI)', 'SecondaryOutcomeDescription': '(body weight) kg/(height) m*(height)m', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Mini-mental state examination (MMSE)', 'SecondaryOutcomeDescription': 'It is an 11-question measure that tests five areas of cognitive function:\\n\\norientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Modified Ashworth scale (MAS)', 'SecondaryOutcomeDescription': 'measures resistance during passive soft-tissue stretching, the score is ranged from 0-4 0: No increase in muscle tone\\n\\nSlight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM\\nMore marked increase in muscle tone through most of the ROM, but affected part(s) easily moved\\nConsiderable increase in muscle tone, passive movement difficult\\nAffected part(s) rigid in flexion or extension', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}, {'SecondaryOutcomeMeasure': 'Change of Muscle tone', 'SecondaryOutcomeDescription': 'measure the muscle tone (kg/m) under muscle resting. Target muscles are quadricep, hamstring, anterior tibialis, gastrocnemius.', 'SecondaryOutcomeTimeFrame': 'before intervention; follow-up: 3 months after intervention'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n55-85 years old\\n3-6 months after onset\\nwalk independently for at least 10m\\n\\nExclusion Criteria:\\n\\nlower limb Brunnstrom stage >5\\ncombine other neuropathy diseases\\nsignificant deformity of lower limb include: Modified Ashworth scale(MAS) >3; contracture, fracture, chronic joint pain.\\njoint arthroplasty\\nunstable vital sign\\ncan not cooperate study', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Tasen Wei, Doctor', 'OverallOfficialAffiliation': 'Changhua Christian Hospital', 'OverallOfficialRole': 'Study Director'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Changhua Christian Hospital', 'LocationCity': 'Changhua', 'LocationZip': '500', 'LocationCountry': 'Taiwan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '24785098', 'ReferenceType': 'background', 'ReferenceCitation': 'Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. 2014 Oct;33(5):737-48. doi: 10.1016/j.clnu.2014.03.007. Epub 2014 Mar 29.'}, {'ReferencePMID': '11518445', 'ReferenceType': 'background', 'ReferenceCitation': 'Stapleton T, Ashburn A, Stack E. A pilot study of attention deficits, balance control and falls in the subacute stage following stroke. Clin Rehabil. 2001 Aug;15(4):437-44. doi: 10.1191/026921501678310243.'}, {'ReferencePMID': '11833018', 'ReferenceType': 'background', 'ReferenceCitation': 'Hyndman D, Ashburn A, Stack E. Fall events among people with stroke living in the community: circumstances of falls and characteristics of fallers. Arch Phys Med Rehabil. 2002 Feb;83(2):165-70. doi: 10.1053/apmr.2002.28030.'}, {'ReferencePMID': '25852886', 'ReferenceType': 'background', 'ReferenceCitation': 'Kutner NG, Zhang R, Huang Y, Wasse H. Falls among hemodialysis patients: potential opportunities for prevention? Clin Kidney J. 2014 Jun;7(3):257-63. doi: 10.1093/ckj/sfu034. Epub 2014 Apr 15.'}, {'ReferencePMID': '17699348', 'ReferenceType': 'background', 'ReferenceCitation': 'Cook WL, Tomlinson G, Donaldson M, Markowitz SN, Naglie G, Sobolev B, Jassal SV. Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol. 2006 Nov;1(6):1197-204. doi: 10.2215/CJN.01650506. Epub 2006 Aug 30.'}, {'ReferencePMID': '24415363', 'ReferenceType': 'background', 'ReferenceCitation': 'Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Barnes CA, Gourin CG, Der-Torossian H. Cancer cachexia update in head and neck cancer: Definitions and diagnostic features. Head Neck. 2015 Apr;37(4):594-604. doi: 10.1002/hed.23599. Epub 2014 Mar 25.'}, {'ReferencePMID': '19588334', 'ReferenceType': 'background', 'ReferenceCitation': 'Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD002759. doi: 10.1002/14651858.CD002759.pub2.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No', 'IPDSharingDescription': 'only for research'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000010024', 'ConditionMeshTerm': 'Osteoporosis'}, {'ConditionMeshId': 'D000055948', 'ConditionMeshTerm': 'Sarcopenia'}, {'ConditionMeshId': 'D000007674', 'ConditionMeshTerm': 'Kidney Diseases'}, {'ConditionMeshId': 'D000051436', 'ConditionMeshTerm': 'Renal Insufficiency, Chronic'}, {'ConditionMeshId': 'D000002908', 'ConditionMeshTerm': 'Chronic Disease'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}, {'ConditionAncestorId': 'D000052776', 'ConditionAncestorTerm': 'Female Urogenital Diseases'}, {'ConditionAncestorId': 'D000005261', 'ConditionAncestorTerm': 'Female Urogenital Diseases and Pregnancy Complications'}, {'ConditionAncestorId': 'D000091642', 'ConditionAncestorTerm': 'Urogenital Diseases'}, {'ConditionAncestorId': 'D000052801', 'ConditionAncestorTerm': 'Male Urogenital Diseases'}, {'ConditionAncestorId': 'D000051437', 'ConditionAncestorTerm': 'Renal Insufficiency'}, {'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000001851', 'ConditionAncestorTerm': 'Bone Diseases, Metabolic'}, {'ConditionAncestorId': 'D000001847', 'ConditionAncestorTerm': 'Bone Diseases'}, {'ConditionAncestorId': 'D000009140', 'ConditionAncestorTerm': 'Musculoskeletal Diseases'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000009133', 'ConditionAncestorTerm': 'Muscular Atrophy'}, {'ConditionAncestorId': 'D000020879', 'ConditionAncestorTerm': 'Neuromuscular Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000001284', 'ConditionAncestorTerm': 'Atrophy'}, {'ConditionAncestorId': 'D000020763', 'ConditionAncestorTerm': 'Pathological Conditions, Anatomical'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M10388', 'ConditionBrowseLeafName': 'Kidney Diseases', 'ConditionBrowseLeafAsFound': 'Kidney Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5837', 'ConditionBrowseLeafName': 'Chronic Disease', 'ConditionBrowseLeafAsFound': 'Chronic Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M28086', 'ConditionBrowseLeafName': 'Sarcopenia', 'ConditionBrowseLeafAsFound': 'Sarcopenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12637', 'ConditionBrowseLeafName': 'Osteoporosis', 'ConditionBrowseLeafAsFound': 'Osteoporosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M26407', 'ConditionBrowseLeafName': 'Renal Insufficiency, Chronic', 'ConditionBrowseLeafAsFound': 'Chronic Kidney Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M26408', 'ConditionBrowseLeafName': 'Renal Insufficiency', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17009', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2876', 'ConditionBrowseLeafName': 'Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26783', 'ConditionBrowseLeafName': 'Female Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13817', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8089', 'ConditionBrowseLeafName': 'Female Urogenital Diseases and Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M26785', 'ConditionBrowseLeafName': 'Male Urogenital Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22390', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4816', 'ConditionBrowseLeafName': 'Bone Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4820', 'ConditionBrowseLeafName': 'Bone Diseases, Metabolic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11787', 'ConditionBrowseLeafName': 'Musculoskeletal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11329', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11780', 'ConditionBrowseLeafName': 'Muscular Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4279', 'ConditionBrowseLeafName': 'Atrophy', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22309', 'ConditionBrowseLeafName': 'Neuromuscular Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12094', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22209', 'ConditionBrowseLeafName': 'Pathological Conditions, Anatomical', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1303', 'ConditionBrowseLeafName': 'Chronic Graft Versus Host Disease', 'ConditionBrowseLeafAsFound': 'Chronic', 'ConditionBrowseLeafRelevance': 'high'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Musculoskeletal Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 44, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04956471', 'OrgStudyIdInfo': {'OrgStudyId': 'M2019312'}, 'Organization': {'OrgFullName': 'Peking University Third Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Guideline - Based Nursing Plan for Dysphagia After Stroke', 'OfficialTitle': 'Guideline - Based Nursing Plan for Dysphagia After Stroke: Current Status and Influencing Factors'}, 'StatusModule': {'StatusVerifiedDate': 'July 2021', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'July 1, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'May 1, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'May 1, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'June 27, 2021', 'StudyFirstSubmitQCDate': 'July 7, 2021', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 9, 2021', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 7, 2021', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 9, 2021', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Peking University Third Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Research purposes:1, investigate the nursing management is the head nurse for swallowing disorder after stroke care management status; Compared with the existing research, the difference between guidelines and evidence-based nursing plan and the analysis of the influencing factors.2, the investigation nursing personnel for swallowing disorder after stroke nursing implementation status; Compare the difference between its and department management requirements and to analyze its influencing factors.3 patients with swallowing disorder after stroke or their caregivers for swallowing disorder after stroke care needs of semi-structured interviews.', 'DetailedDescription': 'Research purposes:1, investigate the nursing management is the head nurse for swallowing disorder after stroke care management status; Compared with the existing research, the difference between guidelines and evidence-based nursing plan and the analysis of the influencing factors.2, the investigation nursing personnel for swallowing disorder after stroke nursing implementation status; Compare the difference between its and department management requirements and to analyze its influencing factors.3 patients with swallowing disorder after stroke or their caregivers for swallowing disorder after stroke care needs of semi-structured interviews.Study design.This subject adopts the mixed methods research design, the three parts to complete. Research focuses on the 3 armour hospital for ten. The first part first USES the literature analysis method, systematic review of swallowing disorder after stroke related guidelines and research. According to the guidelines and involved in the study of swallowing disorder after stroke care issues related to design the head nurse questionnaire, then cross-sectional investigation understand swallowing disorder after stroke clinical nursing management present situation in our country. According to the regional distribution plans to choose 10 3 armour hospital survey, about 15 head nurse.The second part first USES the literature analysis method, systematic review of swallowing disorder after stroke related guidelines and research. According to the guidelines and involved in the study of brain 4 cross-sectional survey) 108%Understanding of the brain in our country。Hospital survey,About 250 nurses. The third part USES the qualitative research in the design of phenomenological research methods, through face-to-face semi-structured interviews, collect data, understand the needs of patients and their caregivers, guide the nursing measures of existing. Selection of founding of neurology ward patients as the research and interview object, about 20 cases need to sample.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '20', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'hospitalized patients with swallowing disorder after stroke,.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: interview']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'interview', 'InterventionDescription': 'A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['hospitalized patients with swallowing disorder after stroke,.']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '1 swallowing disorder after stroke care management present situation investigation', 'PrimaryOutcomeDescription': 'The first part of swallowing disorder after stroke care management present situation investigation; Investigation includes general information and management status. A data includes gender, age, working years, job position, cultural degree, whether to have participated in related training. Current conditions including room management specification, nurse training, swallowing dysfunction screening and evaluation management, nutrition, management of complications.', 'PrimaryOutcomeTimeFrame': 'One year after recruitment'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion criteria:\\n\\nCerebral apoplexy diagnosed by CT or MRI;\\nDrinking water from depression > grade 3;\\nBe clear and able to communicate;\\nVolunteer for the study.\\n\\nExclusion criteria:\\n\\nIf you have serious basic diseases such as cardiovascular and cerebrovascular diseases, you cannot cooperate with the examination.\\nThe patient refused to accept the investigator.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'StdAgeList': {'StdAge': ['Child', 'Adult', 'Older Adult']}, 'StudyPopulation': '15 cases.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Baohua Li', 'OverallOfficialAffiliation': 'Peking Yniversity Third Hospital Medical', 'OverallOfficialRole': 'Study Chair'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Peking Yniversity Third Hospital', 'LocationCity': 'Beijing', 'LocationCountry': 'China'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6572', 'ConditionBrowseLeafName': 'Deglutition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}]}}}}}, {'Rank': 45, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04295044', 'OrgStudyIdInfo': {'OrgStudyId': 'CORPG6G0191'}, 'Organization': {'OrgFullName': 'Chang Gung Memorial Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Effect of High Protein Diet in Stroke Patients With Low Muscle Mass', 'OfficialTitle': 'Effect of High Protein Diet in Stroke Patients With Low Muscle Mass'}, 'StatusModule': {'StatusVerifiedDate': 'March 2023', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'December 15, 2017', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'December 31, 2020', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'March 31, 2021', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'March 3, 2020', 'StudyFirstSubmitQCDate': 'March 3, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'March 4, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'March 28, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'March 30, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Chang Gung Memorial Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'Our prior studies demonstrated that dehydration was a predictor for poor outcome in stroke and Blood urea nitrogen/Cr ratio-based saline hydration therapy in patients with acute ischemic stroke may increase the rate of favorable clinical outcome with functional independence at 3 months after stroke. However, dehydration is likely to be only a part of representation in poor nutrition status and physical fragility for a stroke patient.\\n\\nOur prior study found that acute stroke patients admitted to neurological intensive care unit with low urinary creatinine excretion rate (CER), a marker of muscle mass, was associated with poor outcome at 6 months after stroke. An animal study suggested inadequate food and water intake determine mortality following stroke in mice and nutritional support reduced the 14-day mortality rate from 59% to 15%. A study also showed that high protein intake was associated with a better outcome in previous cardiovascular events.\\n\\nWe will calculate CER based on published equation. Based on our prior study, acute stroke patients with their CER<1500 mg/day will be enrolled. A randomized controlled trial will be conducted and patients will be randomly assigned to high protein diet or normal protein diet for at least 2 weeks. We plan to enroll 300 patients, with 150 patients in ach group, during 3-year study period. We will consult dietitians for arrangement of their diet. We assume that patients receiving high protein diet will have higher opportunity to walk independently (modified Rankin Scale 0-1) at 3 month after stroke.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Ischemic Stroke', 'Diet, Healthy', 'Muscle Loss']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Phase 2']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '110', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'High protein diet', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'received high protein diet, prescribed by dietitian', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: high protein diet']}}, {'ArmGroupLabel': 'Normal protein diet', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'received normal protein diet, prescribed by dietitian', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Dietary Supplement: normal protein diet']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Dietary Supplement', 'InterventionName': 'high protein diet', 'InterventionDescription': 'receive 1.8g protein/kg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['High protein diet']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'normal protein diet', 'InterventionDescription': 'receive 1g protein/kg', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Normal protein diet']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'modified Rankin Scale 0-1', 'PrimaryOutcomeDescription': 'No significant disability', 'PrimaryOutcomeTimeFrame': '3 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'modified Rankin Scale 0-2', 'SecondaryOutcomeDescription': 'Slight disability', 'SecondaryOutcomeTimeFrame': '3 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nacute ischemic stroke during hospitalization\\neGFR >30\\nurine albumin creatinine ratio < 30 mg/g\\nurinary creatinine excretion rate (CER) < 1500g/day\\n\\nExclusion Criteria:\\n\\nchronic kidney disease stage 4 or 5 (i.e. eGFR < 30)\\nproteinuria (protein 1+ or more in urine routine)\\nknown impairment of functional status (mRS ≥ 2) prior to the index stroke\\nrefuse to participate in this study.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '20 Years', 'MaximumAge': '99 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'LocationList': {'Location': [{'LocationFacility': 'Chang Gung Memorial Hospital, Chiayi Branch', 'LocationCity': 'Chiayi City', 'LocationZip': '613', 'LocationCountry': 'Taiwan'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}, {'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]}}}}}, {'Rank': 46, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05845372', 'OrgStudyIdInfo': {'OrgStudyId': 'NFEC-2023-040'}, 'Organization': {'OrgFullName': 'Nanfang Hospital, Southern Medical University', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy', 'OfficialTitle': 'Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy: a Prospective, Multicenter, Observational Cohort Study'}, 'StatusModule': {'StatusVerifiedDate': 'April 2023', 'OverallStatus': 'Not yet recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 1, 2023', 'StartDateType': 'Anticipated'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 1, 2027', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 1, 2027', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 26, 2023', 'StudyFirstSubmitQCDate': 'April 26, 2023', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 6, 2023', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'April 26, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 6, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Nanfang Hospital, Southern Medical University', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'The Fourth Affiliated Hospital of Guangzhou Medical University', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The Affiliated Hospital of Inner Mongolia Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Second Affiliated Hospital of Wenzhou Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Second Affiliated Hospital of Guangxi Medical University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Fujian Medical University Union Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Huizhou Municipal Central Hospital', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Haikou People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Kashgar 1st People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Ganzhou City People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Guangdong Provincial Hospital of Traditional Chinese Medicine', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': \"Huadu District People's Hospital of Guangzhou\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Dongguan donghua hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Sinopharm North Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Heyuan people's Hospital\", 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Hainan People's Hospital\", 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Hainan Traditional Chinese Medicine Hospital', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Second Hospital University of South China', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': \"Dongguan People's Hospital\", 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': \"Yueyang People's Hospital\", 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'Yes', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': \"Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.\", 'DetailedDescription': 'Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.\\n\\nHowever, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Acute Ischemic Stroke']}, 'KeywordList': {'Keyword': ['Acute Ischemic Stroke', 'Stress Ulcer Bleeding', 'Mechanical Thrombectomy']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Cohort']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '2592', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Stress Ulcer Prophylaxis', 'ArmGroupDescription': 'Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.'}, {'ArmGroupLabel': 'Control Group', 'ArmGroupDescription': 'Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '90-day mortality after onset', 'PrimaryOutcomeDescription': 'Proportion of enrolled patients who died 90 days after onset of disease.', 'PrimaryOutcomeTimeFrame': '90-day after onset'}, {'PrimaryOutcomeMeasure': 'Incidence of stroke-associated pneumonia', 'PrimaryOutcomeDescription': 'Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset', 'PrimaryOutcomeTimeFrame': 'within 7-day of onset'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Incidence of clinically significant bleeding', 'SecondaryOutcomeDescription': 'One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d(（1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U.', 'SecondaryOutcomeTimeFrame': 'within 7-day of onset'}, {'SecondaryOutcomeMeasure': 'Incidence of stress ulcer bleeding', 'SecondaryOutcomeDescription': 'Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood', 'SecondaryOutcomeTimeFrame': '7-day after onset'}, {'SecondaryOutcomeMeasure': 'Incidence of unfavorable functional prognosis at 90 days after onset', 'SecondaryOutcomeDescription': 'Incidence of unfavorable functional prognosis at 90 days after onset', 'SecondaryOutcomeTimeFrame': '90-day after onset'}, {'SecondaryOutcomeMeasure': '90-day mRS score change', 'SecondaryOutcomeDescription': 'Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria', 'SecondaryOutcomeTimeFrame': '90-day after onset'}, {'SecondaryOutcomeMeasure': 'Incidence of early neurological deterioration', 'SecondaryOutcomeDescription': 'Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4', 'SecondaryOutcomeTimeFrame': 'within 72 hours after onset'}, {'SecondaryOutcomeMeasure': '1-year post-onset mortality', 'SecondaryOutcomeDescription': 'Mortality at 1 year after onset in patients who were eligible for inclusion criteria', 'SecondaryOutcomeTimeFrame': '1 year after onset'}, {'SecondaryOutcomeMeasure': 'Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset', 'SecondaryOutcomeDescription': 'Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria', 'SecondaryOutcomeTimeFrame': '1 year after onset'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nAge ≥18 years.\\nWithin 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the \"China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018\".\\nMeet the indications for mechanical thrombectomy in the \"Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022\".\\nTreated with mechanical thrombectomy.\\nNIHSS score ≥ 6 at onset of illness.\\nSign an informed notice.\\n\\nExclusion Criteria:\\n\\nAllergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure.\\n\\nHave participated in other interventional clinical studies (affecting the outcome of this cohort study).\\n\\nParticipants who were judged by the investigator to be unsuitable for participation in this study.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.', 'SamplingMethod': 'Probability Sample'}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Suyue Pan, M.D., Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '13556184981', 'CentralContactEMail': 'pansuyue@smu.edu.cn'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Suyue Pan', 'OverallOfficialAffiliation': 'Department of Neurology, Nanfang Hospital,Southern Medical University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Fujian Medical University Union Hospital', 'LocationCity': 'Fuzhou', 'LocationState': 'Fujian', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shenggen Chen, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13459480275'}]}}, {'LocationFacility': 'Dongguan donghua hospital', 'LocationCity': 'Dongguan', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lingyu Sun', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13829203368'}]}}, {'LocationFacility': \"Dongguan People's Hospital\", 'LocationCity': 'Dongguan', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhu Shi, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13669825459'}]}}, {'LocationFacility': 'Guangdong Provincial Hospital of Traditional Chinese Medicine', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lixin Wang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13922793886'}]}}, {'LocationFacility': \"Huadu District People's Hospital of Guangzhou\", 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Guangning Li, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13926239656'}]}}, {'LocationFacility': 'Nanfang Hospital of Southern Medical University', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Suyue Pan', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13556184981'}]}}, {'LocationFacility': 'The Fourth Affiliated Hospital of Guangzhou Medical University', 'LocationCity': 'Guangzhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China'}, {'LocationFacility': \"Heyuan people's Hospital\", 'LocationCity': 'Heyuan', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Minzhen Zhu', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15007622318'}]}}, {'LocationFacility': 'Huizhou Municipal Central Hospital', 'LocationCity': 'Huizhou', 'LocationState': 'Guangdong', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lizhi Wang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13802872076'}]}}, {'LocationFacility': \"Haikou People's Hospital\", 'LocationCity': 'Haikou', 'LocationState': 'Hainan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Guoshuai Yang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13876006248'}]}}, {'LocationFacility': \"Hainan Provincial People's Hospital\", 'LocationCity': 'Haikou', 'LocationState': 'Hainan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Fan Zhang, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '17389897580'}]}}, {'LocationFacility': 'Hainan Traditional Chinese Medicine Hospital', 'LocationCity': 'Haikou', 'LocationState': 'Hainan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yong Gu, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15521280288'}]}}, {'LocationFacility': 'The First Hospital of Changsha', 'LocationCity': 'Changsha', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Xu Peng, M.D。', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15802507292'}]}}, {'LocationFacility': 'The Second Hospital University of South China', 'LocationCity': 'Hengyang', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yanhong Hu, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13265004191'}]}}, {'LocationFacility': \"Yueyang People's Hospital\", 'LocationCity': 'Yueyang', 'LocationState': 'Hunan', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yuan Zhou, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15107309796'}]}}, {'LocationFacility': 'Sinopharm North Hospital', 'LocationCity': 'Baotou', 'LocationState': 'Inner Mongolia', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lifei Xing, M.D', 'LocationContactRole': 'Contact', 'LocationContactPhone': '15354919958'}]}}, {'LocationFacility': 'The Affiliated Hospital of Inner Mongolia Medical University', 'LocationCity': 'Hohhot', 'LocationState': 'Inner Mongolia', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lihua Sun, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '18686292585'}]}}, {'LocationFacility': \"Ganzhou City People's Hospital\", 'LocationCity': 'Ganzhou', 'LocationState': 'Jiangxi', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zhaohui Lai', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13879729792'}]}}, {'LocationFacility': 'Second Affiliated Hospital of Wenzhou Medical University', 'LocationCity': 'Wenzhou', 'LocationState': 'Zhejiang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Saijun Zhou, M.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '13857746659'}]}}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000083242', 'ConditionMeshTerm': 'Ischemic Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000020521', 'ConditionAncestorTerm': 'Stroke'}, {'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M16896', 'ConditionBrowseLeafName': 'Ulcer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9246', 'ConditionBrowseLeafName': 'Hemorrhage', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2401', 'ConditionBrowseLeafName': 'Ischemic Stroke', 'ConditionBrowseLeafAsFound': 'Acute Ischemic Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10233', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T170', 'ConditionBrowseLeafName': 'Acute Graft Versus Host Disease', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 47, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT04492644', 'OrgStudyIdInfo': {'OrgStudyId': 'CMUH108-REC3-110'}, 'Organization': {'OrgFullName': 'China Medical University Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'The Correlation Among Nutrition, Muscle Strength, Masticatory and Swallow Ability of Inpatient Elders', 'OfficialTitle': 'The Correlation Among Nutrition, Muscle Strength, Masticatory and Swallow Ability of Inpatient Elders', 'Acronym': 'NMM'}, 'StatusModule': {'StatusVerifiedDate': 'July 2020', 'OverallStatus': 'Completed', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'August 28, 2019', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'October 3, 2019', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'October 3, 2019', 'CompletionDateType': 'Actual'}, 'StudyFirstSubmitDate': 'July 28, 2020', 'StudyFirstSubmitQCDate': 'July 29, 2020', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'July 30, 2020', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'July 29, 2020', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 30, 2020', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Yin-Hwa Shih', 'ResponsiblePartyInvestigatorTitle': 'Assistant professor', 'ResponsiblePartyInvestigatorAffiliation': 'China Medical University Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'China Medical University Hospital', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'China Medical University, China', 'CollaboratorClass': 'OTHER'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'The masticatory performance would affect the nutritional status of elderly people. the prevalence of undernutrition among elderly inpatients is %20-50%. Previous related studies investigate the masticatory performance with special chewing gum and self-reported questionnaires. This study observes the correlation of masticatory muscles sEMG, nutritional status, and handgrip force among elderly inpatients.', 'DetailedDescription': 'In this cross-sectional study, we enrolled 120 seniors aged 65 and above who are newly admitted to the Asian University Hospital. Within 24 hours they admitted to the hospital, we collected the Mini Nutritional Assessment scores, surface electromyography data, handgrip strength, self-assessment swallowing ability score, and clinical objective data. We performed the statistics for independent t-test, Pearson correlation analysis, and binary logistic regression with SPSS 23 software.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Malnutrition; Moderate']}, 'KeywordList': {'Keyword': ['the elder inpatient,', 'nutritional assessment', 'handgrip strength', 'masticatory electromyography']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Case-Only']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Cross-Sectional']}}, 'EnrollmentInfo': {'EnrollmentCount': '120', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'elderly inpatients', 'ArmGroupDescription': 'Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: No intervention']}}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'No intervention', 'InterventionDescription': 'No intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['elderly inpatients']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'masticatory muscle surface EMG', 'PrimaryOutcomeDescription': 'The sEMG examinations were conducted with a Zebris EMG Bluetooth muscle activity recording system', 'PrimaryOutcomeTimeFrame': 'Data were collected after the participants signed the informed consent form within 24 hours admitted to hospital.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'Nutritional status', 'SecondaryOutcomeDescription': 'Nutritional status was measured by the Mini Nutritional Assessment (MNA).', 'SecondaryOutcomeTimeFrame': 'Data were collected after the participants signed the informed consent form within 24 hours admitted to hospital.'}]}, 'OtherOutcomeList': {'OtherOutcome': [{'OtherOutcomeMeasure': 'Handgrip force', 'OtherOutcomeDescription': 'Left and right handgrip forces were measured by a Jamar® Hydraulic Hand Dynamometer', 'OtherOutcomeTimeFrame': 'Data were collected after the participants signed the informed consent form within 24 hours admitted to hospital.'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nnew elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious\\n\\nExclusion Criteria:\\n\\nElderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '65 Years', 'StdAgeList': {'StdAge': ['Older Adult']}, 'StudyPopulation': 'We enrolled 120 elderly inpatients in Asia University Hospital, Taiwan. We included new elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious.', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Yin-Hwa Shih, Ph.D.', 'OverallOfficialAffiliation': 'Asia University', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Asia University', 'LocationCity': 'Taichung', 'LocationZip': '404', 'LocationCountry': 'Taiwan'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '28673255', 'ReferenceType': 'result', 'ReferenceCitation': 'Alzahrani SH, Alamri SH. Prevalence of malnutrition and associated factors among hospitalized elderly patients in King Abdulaziz University Hospital, Jeddah, Saudi Arabia. BMC Geriatr. 2017 Jul 3;17(1):136. doi: 10.1186/s12877-017-0527-z.'}, {'ReferencePMID': '19089202', 'ReferenceType': 'result', 'ReferenceCitation': 'Berretin-Felix G, Nary Filho H, Padovani CR, Trindade Junior AS, Machado WM. Electromyographic evaluation of mastication and swallowing in elderly individuals with mandibular fixed implant-supported prostheses. J Appl Oral Sci. 2008 Mar-Apr;16(2):116-21. doi: 10.1590/s1678-77572008000200007.'}, {'ReferencePMID': '31747030', 'ReferenceType': 'result', 'ReferenceCitation': 'Gomes F, Baumgartner A, Bounoure L, Bally M, Deutz NE, Greenwald JL, Stanga Z, Mueller B, Schuetz P. Association of Nutritional Support With Clinical Outcomes Among Medical Inpatients Who Are Malnourished or at Nutritional Risk: An Updated Systematic Review and Meta-analysis. JAMA Netw Open. 2019 Nov 1;2(11):e1915138. doi: 10.1001/jamanetworkopen.2019.15138.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M24996', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12374', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 48, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02807012', 'OrgStudyIdInfo': {'OrgStudyId': '16-0181'}, 'Organization': {'OrgFullName': 'Hospital de Clinicas de Porto Alegre', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Nursing Home Care Intervention Post Stroke', 'OfficialTitle': 'Nursing Home Care Educational Intervention for Family Caregivers of Older Adults Post Stroke', 'Acronym': 'SHARE'}, 'StatusModule': {'StatusVerifiedDate': 'March 2019', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'May 2016', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'July 2018', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2020', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'June 3, 2016', 'StudyFirstSubmitQCDate': 'June 16, 2016', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'June 21, 2016', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'August 8, 2019', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'August 12, 2019', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Hospital de Clinicas de Porto Alegre', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'No'}, 'DescriptionModule': {'BriefSummary': \"Associated with the worsening of functional capacity of older adult and the lack of guidance on how to care of them after stroke, the family caregiver starts to fell burden related to the care, and the quality of life was affected by that burden. Besides that, the older adult began to use more frequently health services and had more hospitalizations by preventable conditionals with adequate care.\\n\\nThe aim of this study is to evaluate the effectiveness of educational interventions of care at home provide by nurses to family caregivers of older adult with stroke after hospital discharge, compared with usual care guidelines or no guidance, in one month follow up. The family caregivers of older adults post stroke with the first functional sequel from the Clinical Hospital of Porto Alegre (HCPA) will participate in the study.\\n\\nThe intervention will involve the systematic monitoring of nurses through home visits (HVs) during one month. Thus, will instrumentalize the family caregiver to care of older adult with stoke according the protocol developed in a research group and the needs of care of them. The control group won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.\", 'DetailedDescription': \"Associated with the worsening of functional capacity of older adult and the lack of guidance on how to care of them after stroke, the family caregiver starts to fell burden related to the care and the quality of life was affected by that burden. Besides that, the older adult began to use more frequently health services and had more hospitalizations by preventable conditionals with adequate care.\\n\\nThe aim of this study is to evaluate the effectiveness of educational interventions of care at home provide by nurses to family caregivers of older adult with stroke after hospital discharge, compared with usual care guidelines or no guidance, in one month follow up. The family caregivers of older adults post stroke with the first functional sequel from the Clinical Hospital of Porto Alegre (HCPA) will participate in the study. The randomization will be through the randomization list created by web page randomization.com.\\n\\nThe intervention will involve systematic monitoring of nurses through home visits (HVs) during one month. Thus, will instrumentalize the family caregiver to care of older adult with stoke according the protocol developed in a research group and the needs of care of them. The control group won't receive the HVs and could have or not the usual care guidelines provide by health services that have access.\\n\\nWill be collect the identification, social and demographics data of the older adults and the caregivers at the moment of hospital discharge. Therefore, will be collect the clinical data of the older adults. After discharge and at the older adult's home, will be realized the first home visit (1ª HV) to all older adults and caregivers included in the study and will be applied to the family caregiver the Caregiver Burden Scale and the instrument WHOQOL-BREF that analyse the quality of life. Also, will be applied the Measure of Functional Independence (MIF) to identify the independence level of the older adults and the needs of care. In this moment, will be randomized by an extern member of research group through telephone contact. After this first HV, the older adults and caregivers included in the intervention group will received more three HVs, until 14, 21 and 30 days after discharge, respectively, by a pair of interventional nurses.\\n\\nThe control group won't receive the home visits by nurses, but could have or not the usual care guidelines provide by health services that have access.\\n\\nAll older adults and caregivers included in the study will received a fifth HV until 60 days after discharge. In this last HV will be applied to family caregiver the Caregiver Burden Scale and the instrument WHOQOL-BREF. In addition, will be applied a questionnaire related older adult's utilization of health services and rehospitalizations during this time and the MIF.\"}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke']}, 'KeywordList': {'Keyword': ['Home care services', 'Nursing', 'Clinical trial', 'Geriatric nursing', 'Family caregiver', 'Aged']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Other', 'DesignMaskingInfo': {'DesignMasking': 'Single', 'DesignWhoMaskedList': {'DesignWhoMasked': ['Outcomes Assessor']}}}, 'EnrollmentInfo': {'EnrollmentCount': '82', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Nursing educational intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Nursing educational intervention']}}, {'ArmGroupLabel': 'Usual care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': \"The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.\"}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Nursing educational intervention', 'InterventionDescription': 'The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.\\n\\nThe control group could have ou not the usual care guidelines provide by health services that have access.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Nursing educational intervention']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': \"The family caregiver's burden of care analyzed by Caregiver Burden Scale\", 'PrimaryOutcomeDescription': 'The family caregiver burden of care will be analyzed by Caregiver Burden Scale.', 'PrimaryOutcomeTimeFrame': '2 months'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': \"The family caregiver's quality of life analyzed by instrument WHOQOL-BREF\", 'SecondaryOutcomeDescription': 'The family caregiver quality of life will be analyzed by instrument WHOQOL-BREF.', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': \"The elderly's functional capacity\", 'SecondaryOutcomeDescription': 'The elderly functional capacity will be analyzed by the instrument Measure of Functional Independence', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': \"The elderly's health service utilization\", 'SecondaryOutcomeDescription': 'The elderly health service utilization will be assessed by an questionnaire developed for this study. The answers will be yes or not and analyzed quantitatively.', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': \"The elderly's rehospitalization\", 'SecondaryOutcomeDescription': 'The elderly rehospitalization will be assessed by an questionnaire developed for this study. The answers will be yes or not and analyzed quantitatively.', 'SecondaryOutcomeTimeFrame': '2 months'}, {'SecondaryOutcomeMeasure': 'The quality of life of family caregiver with 60 years old or older analyzed by instrument WHOQOL-OLD', 'SecondaryOutcomeDescription': 'The family caregiver quality of life will be analyzed by instrument WHOQOL-OLD', 'SecondaryOutcomeTimeFrame': '2 months'}]}}, 'EligibilityModule': {'EligibilityCriteria': \"Inclusion Criteria:\\n\\nFamily caregivers of older adults from the Special Care Unit - stroke (SCU-Stroke) at the moment of discharge;\\nOlder adults with diagnosis of stroke with the first sequel identified by minimum score of 2 points from the ranking scale;\\nOlder adults who live until 20 kilometers from HCPA;\\nCaregiver will be a family member with consanguineous relationship or not;\\nCaregiver will be responsible for the most part of the older adult's care;\\nCaregiver without payment;\\nCaregiver with 18 year old or more.\\n\\nExclusion Criteria:\\n\\nOlder adults who live in a Long Term Care Services;\\nOlder adults who will be included in a governmental program for Home Care Service;\\nCaregivers who don't accept receive the HV by nurses.\", 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Lisiane MG Paskulin, PhD', 'OverallOfficialAffiliation': 'Hospital de Clínicas de Porto Alegre', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hospital de Clínicas de Porto Alegre', 'LocationCity': 'Porto Alegre', 'LocationState': 'Rio Grande Do Sul', 'LocationZip': '90035-903', 'LocationCountry': 'Brazil'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '34813082', 'ReferenceType': 'derived', 'ReferenceCitation': 'Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021 Nov 23;11(11):CD001919. doi: 10.1002/14651858.CD001919.pub4.'}, {'ReferencePMID': '32602588', 'ReferenceType': 'derived', 'ReferenceCitation': 'Day CB, Bierhals CCBK, Mocellin D, Predebon ML, Santos NO, Dal Pizzol FLF, Fuhrmann AC, Aires M, Paskulin LMG. Nursing Home Care Intervention Post Stroke (SHARE) 1 year effect on the burden of family caregivers for older adults in Brazil: A randomized controlled trial. Health Soc Care Community. 2021 Jan;29(1):56-65. doi: 10.1111/hsc.13068. Epub 2020 Jun 30.'}, {'ReferencePMID': '31800798', 'ReferenceType': 'derived', 'ReferenceCitation': 'Bierhals CCBK, Day CB, Mocellin D, Santos NOD, Predebon ML, Pizzol FLFD, Fuhrmann AC, Medeiros GG, Aires M, Paskulin LMG. Use of health services by elderly people post-stroke: a randomized controlled trial. Rev Gaucha Enferm. 2019 Dec 2;41(spe):e20190138. doi: 10.1590/1983-1447.2020.20190138. eCollection 2020. English, Portuguese.'}, {'ReferencePMID': '29426361', 'ReferenceType': 'derived', 'ReferenceCitation': 'Day CB, Bierhals CCBK, Santos NOD, Mocellin D, Predebon ML, Dal Pizzol FLF, Paskulin LMG. Nursing home care educational intervention for family caregivers of older adults post stroke (SHARE): study protocol for a randomised trial. Trials. 2018 Feb 9;19(1):96. doi: 10.1186/s13063-018-2454-5.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'Undecided'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}, {'Rank': 49, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT05651945', 'OrgStudyIdInfo': {'OrgStudyId': 'Pro2022-0785'}, 'Organization': {'OrgFullName': 'Hackensack Meridian Health', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)', 'OfficialTitle': 'Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors', 'Acronym': 'SRP-CROSS'}, 'StatusModule': {'StatusVerifiedDate': 'May 2023', 'OverallStatus': 'Recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'January 20, 2023', 'StartDateType': 'Actual'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'January 20, 2026', 'PrimaryCompletionDateType': 'Anticipated'}, 'CompletionDateStruct': {'CompletionDate': 'January 20, 2031', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'December 7, 2022', 'StudyFirstSubmitQCDate': 'December 7, 2022', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'December 15, 2022', 'StudyFirstPostDateType': 'Actual'}, 'LastUpdateSubmitDate': 'May 17, 2023', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'May 18, 2023', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Sponsor'}, 'LeadSponsor': {'LeadSponsorName': 'Hackensack Meridian Health', 'LeadSponsorClass': 'OTHER'}, 'CollaboratorList': {'Collaborator': [{'CollaboratorName': 'The Cardiovascular Institute of New Jersey at Rutgers Robert Wood Johnson Medical School', 'CollaboratorClass': 'UNKNOWN'}]}}, 'OversightModule': {'OversightHasDMC': 'No', 'IsFDARegulatedDrug': 'No', 'IsFDARegulatedDevice': 'No'}, 'DescriptionModule': {'BriefSummary': 'This study examines the effectiveness of the cardiac rehabilitation program for stroke patients. The study will examine if patients with stroke, who receive cardiac rehabilitation in addition to their standard of care treatments, demonstrate improved recovery of function. It will also examine if these patients have reduced hospital readmission, reduced rate of recurrent stroke, and mortality.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Stroke', 'Cerebrovascular Accident']}, 'KeywordList': {'Keyword': ['cardiac rehabilitation', 'stroke', 'stroke rehabilitation', 'stroke recovery', 'exercise', 'cardiovascular disease', 'cardiovascular function', 'cognitive function', 'physical function', 'neurorehabilitation', 'transition of care post stroke']}}, 'DesignModule': {'StudyType': 'Interventional', 'PhaseList': {'Phase': ['Not Applicable']}, 'DesignInfo': {'DesignAllocation': 'Randomized', 'DesignInterventionModel': 'Parallel Assignment', 'DesignPrimaryPurpose': 'Treatment', 'DesignMaskingInfo': {'DesignMasking': 'None (Open Label)'}}, 'EnrollmentInfo': {'EnrollmentCount': '112', 'EnrollmentType': 'Anticipated'}}, 'ArmsInterventionsModule': {'ArmGroupList': {'ArmGroup': [{'ArmGroupLabel': 'Cardiac rehabilitation group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Traditional medically supervised center-based cardiac rehabilitation program; including 36 sessions (30-50 minutes) of a progressive exercise program and educational sessions for cardiovascular disease (CVD) risk factors.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Cardiac rehabilitation program']}}, {'ArmGroupLabel': 'Standard of care', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Depending on functional deficits, conventional rehabilitation therapies can include physical therapy, occupational therapy, and/or speech therapy sessions with 2-3 visits per week. Participants will receive their standard of care therapies as prescribed by their treating physicians.'}]}, 'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Cardiac rehabilitation program', 'InterventionDescription': 'The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cardiac rehabilitation group']}}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': '6-Minute Walk Test (6MWT)', 'PrimaryOutcomeDescription': 'Mean change in 6MWT score from baseline (30 days post-stroke) to 120 days post-stroke.', 'PrimaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'MET-min - (Metabolic Equivalent of Task - minutes)', 'SecondaryOutcomeDescription': 'Mean change in MET-min score from baseline (30 days post-stroke) to 120 days post-stroke.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}, {'SecondaryOutcomeMeasure': 'AM-PAC - (Activity Measure for Post Acute Care)', 'SecondaryOutcomeDescription': 'Mean change in AM-PAC score from baseline (30 days post-stroke) to 120 days post-stroke. AM-PAC is a questionnaire that evaluates functional outcomes across three domains: basic mobility, daily activity, and applied cognitive. Standardized scores range from -11.95 to 104.9 for basic mobility, from -2.73 to 115.4 for daily activities, and from 6.84 to 68.28 for applied cognition with higher scores representing a better function.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}, {'SecondaryOutcomeMeasure': 'MoCA - (Montreal Cognitive Assessment)', 'SecondaryOutcomeDescription': 'Mean change in MoCA score from baseline (30 days post-stroke) to 120 days post-stroke. MoCA is a 16-item test assessing multiple cognitive domains with a score range from 0-30 with higher scores representing a better function.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke.'}, {'SecondaryOutcomeMeasure': 'SS-QOL - (Stroke specific Quality of Life)', 'SecondaryOutcomeDescription': 'Mean change in SS-QOL score from baseline (30 days post-stroke) to 120 days post-stroke. SS-QOL is a self-reported questionnaire containing 49 item questions covering 12 domains with a score range of 49-245 with higher scores representing better function.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke'}, {'SecondaryOutcomeMeasure': 'PHQ-9 - (Patient Health Questionnaire -9)', 'SecondaryOutcomeDescription': 'Mean change in PHQ-9 score from baseline (30 days post-stroke) to 120 days post-stroke. The PHQ-9 is a self-administered questionnaire designed to diagnose and evaluate depression with a score range 0-27.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post-stroke) to 120 days post-stroke'}, {'SecondaryOutcomeMeasure': 'All-cause hospital readmission', 'SecondaryOutcomeDescription': 'All-cause hospital readmission rates at 1-year post-stroke', 'SecondaryOutcomeTimeFrame': '1-year post-stroke'}, {'SecondaryOutcomeMeasure': 'Recurrent stroke rate', 'SecondaryOutcomeDescription': 'Recurrent stroke rates at 1-year post stroke', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'All-cause mortality rate', 'SecondaryOutcomeDescription': 'All-cause mortality rates at 1-year post stroke', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'AM-PAC - (Activity Measure for Post Acute Care)', 'SecondaryOutcomeDescription': 'Mean change in AM-PAC score from baseline (30 days post stroke) to 1-year post stroke. AM-PAC is a questionnaire that evaluates functional outcomes across three domains: basic mobility, daily activity, and applied cognitive. Standardized scores range from -11.95 to 104.9 for basic mobility, from -2.73 to 115.4 for daily activities, and from 6.84 to 68.28 for applied cognition with higher scores representing a better function.', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'SS-QOL - (Stroke specific Quality of Life)', 'SecondaryOutcomeDescription': 'Mean change in SS-QOL score from baseline (30 days post stroke) to 1-year post stroke. SS-QOL is a self-reported questionnaire containing 49 item questions covering 12 domains with a score range of 49-245 with higher scores representing better function.', 'SecondaryOutcomeTimeFrame': '1-year post stroke'}, {'SecondaryOutcomeMeasure': 'mRS - (Modified Rankin Scale)', 'SecondaryOutcomeDescription': 'Mean change in mRS score from baseline (30 days post stroke) to 120 days post stroke. The mRS is a questionnaire to assess the level of disability and functional independence in daily activities with reference to pre-stroke activities. The scale is scored 0-6 where 0 indicates lack of symptoms and the score 6 indicates death.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post stroke) to 120 days post stroke'}, {'SecondaryOutcomeMeasure': 'Picture Your Plate (PYP)', 'SecondaryOutcomeDescription': 'Mean change in PYP score from baseline (30 days post stroke) to 120 days post stroke. Picture Your Plate is a brief 48-question dietary assessment questionnaire with a total score ranging from 0 to 96 with higher scores representing an unhealthy diet.', 'SecondaryOutcomeTimeFrame': 'Change from Baseline (30 days post stroke) to 120 days post stroke'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\n18 years or older\\nStroke diagnosis (ischemic or hemorrhagic) / radiologic evidence of acute stroke\\nMedically cleared by a cardiologist for participation in the cardiac rehabilitation program with no contraindications to cardiac rehabilitation per American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) guidelines\\nAbility to stand and walk with or without an assistive device for 10 feet safely, with or without assistance from another person\\nAbility to transfer on/off the recumbent bike with or without an assistive device safely, with or without assistance from another person\\nAbility to follow simple commands and communicate pain or distress\\nAdmission to an Inpatient Rehabilitation Facility post-stroke\\nSigned informed consent form\\n\\nExclusion Criteria:\\n\\nPresence of subarachnoid hemorrhage, intracranial aneurysm, intracranial hemangioma, or arteriovenous malformation\\nMedical disorders that preclude participation in the study as determined by the Principal Investigator.\\nInability to have baseline assessment within 45 days post-stroke diagnosis\\nPatient considered unable to comply with study requirements\\nKnown terminal illness with life expectancy less than 1 year\\nCompliant diagnosis eligible for traditional cardiac rehabilitation covered by insurance\\nUnable to understand/speak English', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}}, 'ContactsLocationsModule': {'CentralContactList': {'CentralContact': [{'CentralContactName': 'Hayk Petrosyan, Ph.D.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '732-321-7000', 'CentralContactPhoneExt': '65979', 'CentralContactEMail': 'hayk.petrosyan@hmhn.org'}]}, 'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Sara J Cuccurullo, MD', 'OverallOfficialAffiliation': 'Hackensack Meridian Health - JFK Johnson Rehabilitation Institute', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Talya K Fleming, MD', 'OverallOfficialAffiliation': 'Hackensack Meridian Health - JFK Johnson Rehabilitation Institute', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Hackensack Meridian Health - JFK Johnson Rehabilitation Institute', 'LocationStatus': 'Recruiting', 'LocationCity': 'Edison', 'LocationState': 'New Jersey', 'LocationZip': '08820', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Hayk Petrosyan, PhD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '732-321-7000', 'LocationContactPhoneExt': '65979', 'LocationContactEMail': 'hayk.petrosyan@hmhn.org'}]}}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '26764059', 'ReferenceType': 'background', 'ReferenceCitation': 'Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016 Jan 5;67(1):1-12. doi: 10.1016/j.jacc.2015.10.044.'}, {'ReferencePMID': '24846875', 'ReferenceType': 'background', 'ReferenceCitation': 'Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, MacKay-Lyons M, Macko RF, Mead GE, Roth EJ, Shaughnessy M, Tang A; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Aug;45(8):2532-53. doi: 10.1161/STR.0000000000000022. Epub 2014 May 20.'}, {'ReferencePMID': '31634208', 'ReferenceType': 'background', 'ReferenceCitation': 'Cuccurullo SJ, Fleming TK, Kostis WJ, Greiss C, Gizzi MS, Eckert A, Ray AR, Scarpati R, Cosgrove NM, Beavers T, Cabrera J, Sargsyan D, Kostis JB. Impact of a Stroke Recovery Program Integrating Modified Cardiac Rehabilitation on All-Cause Mortality, Cardiovascular Performance and Functional Performance. Am J Phys Med Rehabil. 2019 Nov;98(11):953-963. doi: 10.1097/PHM.0000000000001214.'}, {'ReferencePMID': '33657031', 'ReferenceType': 'background', 'ReferenceCitation': 'Cuccurullo SJ, Fleming TK, Kostis JB, Greiss C, Eckert A, Ray AR, Scarpati R, Zinonos S, Gizzi M, Cosgrove NM, Cabrera J, Oh-Park M, Kostis WJ. Impact of Modified Cardiac Rehabilitation Within a Stroke Recovery Program on All-Cause Hospital Readmissions. Am J Phys Med Rehabil. 2022 Jan 1;101(1):40-47. doi: 10.1097/PHM.0000000000001738.'}, {'ReferencePMID': '26112254', 'ReferenceType': 'background', 'ReferenceCitation': 'English C, Healy GN, Coates A, Lewis L, Olds T, Bernhardt J. Sitting and Activity Time in People With Stroke. Phys Ther. 2016 Feb;96(2):193-201. doi: 10.2522/ptj.20140522. Epub 2015 Jun 25.'}, {'ReferencePMID': '28444348', 'ReferenceType': 'background', 'ReferenceCitation': 'Fini NA, Holland AE, Keating J, Simek J, Bernhardt J. How Physically Active Are People Following Stroke? Systematic Review and Quantitative Synthesis. Phys Ther. 2017 Jul 1;97(7):707-717. doi: 10.1093/ptj/pzx038.'}, {'ReferencePMID': '21885867', 'ReferenceType': 'background', 'ReferenceCitation': 'Globas C, Becker C, Cerny J, Lam JM, Lindemann U, Forrester LW, Macko RF, Luft AR. Chronic stroke survivors benefit from high-intensity aerobic treadmill exercise: a randomized control trial. Neurorehabil Neural Repair. 2012 Jan;26(1):85-95. doi: 10.1177/1545968311418675. Epub 2011 Sep 1.'}, {'ReferencePMID': '21576654', 'ReferenceType': 'background', 'ReferenceCitation': 'Goel K, Lennon RJ, Tilbury RT, Squires RW, Thomas RJ. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation. 2011 May 31;123(21):2344-52. doi: 10.1161/CIRCULATIONAHA.110.983536. Epub 2011 May 16.'}, {'ReferencePMID': '31596465', 'ReferenceType': 'background', 'ReferenceCitation': 'MacKay-Lyons M, Billinger SA, Eng JJ, Dromerick A, Giacomantonio N, Hafer-Macko C, Macko R, Nguyen E, Prior P, Suskin N, Tang A, Thornton M, Unsworth K. Aerobic Exercise Recommendations to Optimize Best Practices in Care After Stroke: AEROBICS 2019 Update. Phys Ther. 2020 Jan 23;100(1):149-156. doi: 10.1093/ptj/pzz153.'}, {'ReferencePMID': '32868656', 'ReferenceType': 'background', 'ReferenceCitation': 'Marzolini S. Including Patients With Stroke in Cardiac Rehabilitation: BARRIERS AND FACILITATORS. J Cardiopulm Rehabil Prev. 2020 Sep;40(5):294-301. doi: 10.1097/HCR.0000000000000540.'}, {'ReferencePMID': '27425176', 'ReferenceType': 'background', 'ReferenceCitation': 'Marzolini S, Danells C, Oh PI, Jagroop D, Brooks D. Feasibility and Effects of Cardiac Rehabilitation for Individuals after Transient Ischemic Attack. J Stroke Cerebrovasc Dis. 2016 Oct;25(10):2453-63. doi: 10.1016/j.jstrokecerebrovasdis.2016.06.018. Epub 2016 Jul 11.'}, {'ReferencePMID': '31588512', 'ReferenceType': 'background', 'ReferenceCitation': 'Marzolini S, Fong K, Jagroop D, Neirinckx J, Liu J, Reyes R, Grace SL, Oh P, Colella TJF. Eligibility, Enrollment, and Completion of Exercise-Based Cardiac Rehabilitation Following Stroke Rehabilitation: What Are the Barriers? Phys Ther. 2020 Jan 23;100(1):44-56. doi: 10.1093/ptj/pzz149.'}, {'ReferencePMID': '26673558', 'ReferenceType': 'background', 'ReferenceCitation': 'Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360. doi: 10.1161/CIR.0000000000000350. Epub 2015 Dec 16. No abstract available. Erratum In: Circulation. 2016 Apr 12;133(15):e599.'}, {'ReferencePMID': '34978528', 'ReferenceType': 'background', 'ReferenceCitation': 'Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2020. NCHS Data Brief. 2021 Dec;(427):1-8.'}, {'ReferencePMID': '23428993', 'ReferenceType': 'background', 'ReferenceCitation': 'Pang MY, Charlesworth SA, Lau RW, Chung RC. Using aerobic exercise to improve health outcomes and quality of life in stroke: evidence-based exercise prescription recommendations. Cerebrovasc Dis. 2013;35(1):7-22. doi: 10.1159/000346075. Epub 2013 Feb 14.'}, {'ReferencePMID': '21940961', 'ReferenceType': 'background', 'ReferenceCitation': \"Prior PL, Hachinski V, Unsworth K, Chan R, Mytka S, O'Callaghan C, Suskin N. Comprehensive cardiac rehabilitation for secondary prevention after transient ischemic attack or mild stroke: I: feasibility and risk factors. Stroke. 2011 Nov;42(11):3207-13. doi: 10.1161/STROKEAHA.111.620187. Epub 2011 Sep 22.\"}, {'ReferencePMID': '30191075', 'ReferenceType': 'background', 'ReferenceCitation': 'Prior PL, Suskin N. Exercise for stroke prevention. Stroke Vasc Neurol. 2018 Jun 26;3(2):59-68. doi: 10.1136/svn-2018-000155. eCollection 2018 Jun.'}, {'ReferencePMID': '31409176', 'ReferenceType': 'background', 'ReferenceCitation': 'Regan EW, Handlery R, Beets MW, Fritz SL. Are Aerobic Programs Similar in Design to Cardiac Rehabilitation Beneficial for Survivors of Stroke? A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019 Aug 20;8(16):e012761. doi: 10.1161/JAHA.119.012761. Epub 2019 Aug 14.'}, {'ReferencePMID': '33499647', 'ReferenceType': 'background', 'ReferenceCitation': 'Regan EW, Handlery R, Stewart JC, Pearson JL, Wilcox S, Fritz S. Integrating Survivors of Stroke Into Exercise-Based Cardiac Rehabilitation Improves Endurance and Functional Strength. J Am Heart Assoc. 2021 Feb 2;10(3):e017907. doi: 10.1161/JAHA.120.017907. Epub 2021 Jan 27.'}, {'ReferencePMID': '26903147', 'ReferenceType': 'background', 'ReferenceCitation': 'Sandberg K, Kleist M, Falk L, Enthoven P. Effects of Twice-Weekly Intense Aerobic Exercise in Early Subacute Stroke: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2016 Aug;97(8):1244-53. doi: 10.1016/j.apmr.2016.01.030. Epub 2016 Feb 20.'}, {'ReferencePMID': '22019548', 'ReferenceType': 'background', 'ReferenceCitation': 'Towfighi A, Markovic D, Ovbiagele B. Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA. J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):146-51. doi: 10.1136/jnnp-2011-300743. Epub 2011 Oct 21.'}, {'ReferencePMID': '29169967', 'ReferenceType': 'background', 'ReferenceCitation': 'Turan TN, Al Kasab S, Nizam A, Lynn MJ, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane BF, Montgomery J, Chimowitz MI; SAMMPRIS Investigators. Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial. J Stroke Cerebrovasc Dis. 2018 Mar;27(3):801-805. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.017. Epub 2017 Nov 21.'}, {'ReferencePMID': '28284834', 'ReferenceType': 'background', 'ReferenceCitation': 'Vanroy C, Feys H, Swinnen A, Vanlandewijck Y, Truijen S, Vissers D, Michielsen M, Wouters K, Cras P. Effectiveness of Active Cycling in Subacute Stroke Rehabilitation: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2017 Aug;98(8):1576-1585.e5. doi: 10.1016/j.apmr.2017.02.004. Epub 2017 Mar 8.'}, {'ReferencePMID': '33501848', 'ReferenceType': 'background', 'ReferenceCitation': 'Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.'}]}}, 'IPDSharingStatementModule': {'IPDSharing': 'No'}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Stroke', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4202', 'ConditionBrowseLeafName': 'Oculocerebral Syndrome With Hypopigmentation', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]}}}}}, {'Rank': 50, 'Study': {'ProtocolSection': {'IdentificationModule': {'NCTId': 'NCT02432521', 'OrgStudyIdInfo': {'OrgStudyId': '35583814.1.0000.0068_CAAE'}, 'Organization': {'OrgFullName': 'University of Sao Paulo General Hospital', 'OrgClass': 'OTHER'}, 'BriefTitle': 'Predictors of Treatment Response of Motor Sequels After a Stroke', 'OfficialTitle': 'Predictors of Treatment Response of Motor Sequels After a Cerebrovascular Accident'}, 'StatusModule': {'StatusVerifiedDate': 'July 2017', 'OverallStatus': 'Unknown status', 'LastKnownStatus': 'Active, not recruiting', 'ExpandedAccessInfo': {'HasExpandedAccess': 'No'}, 'StartDateStruct': {'StartDate': 'March 2015'}, 'PrimaryCompletionDateStruct': {'PrimaryCompletionDate': 'June 2017', 'PrimaryCompletionDateType': 'Actual'}, 'CompletionDateStruct': {'CompletionDate': 'July 2017', 'CompletionDateType': 'Anticipated'}, 'StudyFirstSubmitDate': 'April 16, 2015', 'StudyFirstSubmitQCDate': 'April 28, 2015', 'StudyFirstPostDateStruct': {'StudyFirstPostDate': 'May 4, 2015', 'StudyFirstPostDateType': 'Estimate'}, 'LastUpdateSubmitDate': 'July 3, 2017', 'LastUpdatePostDateStruct': {'LastUpdatePostDate': 'July 5, 2017', 'LastUpdatePostDateType': 'Actual'}}, 'SponsorCollaboratorsModule': {'ResponsibleParty': {'ResponsiblePartyType': 'Principal Investigator', 'ResponsiblePartyInvestigatorFullName': 'Linamara Rizzo Battistella, MD PhD', 'ResponsiblePartyInvestigatorTitle': 'Full Professor, Medical School of the University of Sao Paulo, Post Graduate Program in Medical Sciences of the Medical School of the University of Sao Paulo', 'ResponsiblePartyInvestigatorAffiliation': 'University of Sao Paulo General Hospital'}, 'LeadSponsor': {'LeadSponsorName': 'University of Sao Paulo General Hospital', 'LeadSponsorClass': 'OTHER'}}, 'OversightModule': {'OversightHasDMC': 'Yes'}, 'DescriptionModule': {'BriefSummary': 'The cerebrovascular accident (CVA) is currently the leading cause of death in Brazil and it is estimated that there are about 62 million stroke survivors worldwide. Thus, the stroke sequels are a major public health problem not only in Brazil but in the world, with existing treatments often insufficient for complete recovery. Thus this study aims to identify predictors of different responses from rehabilitation therapy through the evaluation of clinical and neurophysiological data performed before and after treatment. For the neurophysiological study will be used the association of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS). This last one will be performed in the baseline and after a single Transcranial direct current stimulation (tDCS) session, aiming to leverage the ability of those technics to analyze the cerebral plasticity. As a secondary objective: 1) Identify specific features of brain plasticity involved in recovery from stroke and discuss the possible implications of these findings in the therapeutic approach; 2) Search possible electrophysiological markers that can be used as surrogate outcome of stroke of motor sequel.', 'DetailedDescription': 'The cerebrovascular accident (CVA) is currently the leading cause of death in Brazil and it is estimated that there are about 62 million stroke survivors worldwide. Thus, the stroke sequels are a major public health problem not only in Brazil but in the world, with existing treatments often insufficient for complete recovery. Thus, the search for new treatments is necessary, as well as the need to optimize and individualize the existing treatments. Several approaches are being used in order to find predictors of the recovery of patients after the stroke, highlighting the most recent studies using magnetic resonance imaging (MRI) with tractography. However these studies have important limitations such as high cost, but mainly the low capacity of this technique to quantify brain plasticity known to play an important role in the recovery of stroke sequelae. Thus, techniques to measure brain plasticity theory offer the best potential to predict the resilience of post stroke injury, among which stands out transcranial magnetic stimulation (TMS).\\n\\nTMS is a noninvasive brain stimulation techniques suitable for measuring the motor cortex excitability which in turn is used as an indirect measure of brain plasticity. Another interesting approach is the combination of TMS with the study of neuronal function through the electroencephalogram (EEG). The EEG under the stroke, has also been suggested as sequelae recovery predictor, however in this scenario the association of these findings with TMS has not yet been explored. Thus this study aims to identify predictors of different responses from rehabilitation therapy through the evaluation of clinical and neurophysiological data performed before and after treatment. For the neurophysiological study will be used the association of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS). This last one will be performed in the baseline and after a single Transcranial direct current stimulation (tDCS) session, aiming to leverage the ability of those technics to analyze the cerebral plasticity.'}, 'ConditionsModule': {'ConditionList': {'Condition': ['Cerebrovascular Accident']}, 'KeywordList': {'Keyword': ['stroke', 'transcranial magnetic stimulation (TMS)', 'Electroencephalography (EEG)', 'Cerebrovascular Accident', 'Brain Vascular Accident']}}, 'DesignModule': {'StudyType': 'Observational', 'PatientRegistry': 'No', 'DesignInfo': {'DesignObservationalModelList': {'DesignObservationalModel': ['Ecologic or Community']}, 'DesignTimePerspectiveList': {'DesignTimePerspective': ['Prospective']}}, 'EnrollmentInfo': {'EnrollmentCount': '49', 'EnrollmentType': 'Actual'}}, 'ArmsInterventionsModule': {'InterventionList': {'Intervention': [{'InterventionType': 'Other', 'InterventionName': 'Conventional rehabilitation program from IMREA', 'InterventionDescription': 'The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.'}]}}, 'OutcomesModule': {'PrimaryOutcomeList': {'PrimaryOutcome': [{'PrimaryOutcomeMeasure': 'Change in motor cortex excitability as measured by Transcranial magnetic stimulation (TMS)', 'PrimaryOutcomeDescription': 'A noninvasive brain stimulation techniques suitable for measuring the motor cortex excitability', 'PrimaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'PrimaryOutcomeMeasure': 'Change in spontaneous electrical brain activity as assessed by Electroencephalogram (EEG)', 'PrimaryOutcomeDescription': \"The record of the brain's spontaneous electrical activity\", 'PrimaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}]}, 'SecondaryOutcomeList': {'SecondaryOutcome': [{'SecondaryOutcomeMeasure': 'cinematic variables analyzed with robotic', 'SecondaryOutcomeDescription': 'speed, acceleration, articular angulation, time-to-point, task execution time, target displacement', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Mini-mental State Examination', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Visual Analog Scale of Pain', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Verbal fluency test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Boston naming test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Hamilton Rating scale of depression', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'The Kinesthetic and visual imagery questionnaire (KVIQ)', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'National Institutes of Health Stroke Scale (NIHSS)', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Stroke Impact Scale (SIS)', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Von Frey test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Functional Independence Measure', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Epworth Sleepiness Scale', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Fugl-Meyer Assessment', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Medical Research Council Scale', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Modified Ashworth Scale', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Finger Tapping', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Jebsen-Taylor Hand Function Test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}, {'SecondaryOutcomeMeasure': 'Purdue Pegboard test', 'SecondaryOutcomeTimeFrame': 'At baseline, 11th week, 22nd week, and after 3 and 6 months from baseline'}]}}, 'EligibilityModule': {'EligibilityCriteria': 'Inclusion Criteria:\\n\\nClinical and radiological diagnosis (Functional magnetic Resonance (FMR) and/or Computerized tomography (TC) ) of the stroke;\\nMore than one month from the date of the stroke;\\nClinical stability;\\nSigned and dated informed consent form.\\n\\nExclusion Criteria:\\n\\nDisturbs that forbid the adherence in treatment;\\nSubjects already undergoing in other researches;\\nPregnant women;\\nLesions that could affect the proposed therapy;\\nThe occurence of lesion or muscle,joint pain that could forbid the therapy;\\nDestabilization of the clinical comorbidities.', 'HealthyVolunteers': 'No', 'Gender': 'All', 'MinimumAge': '18 Years', 'StdAgeList': {'StdAge': ['Adult', 'Older Adult']}, 'StudyPopulation': 'Patients of hemiplegia ambulatory from the Institute of Physical Medicine and Rehabilitation (IMREA) from the Clinics Hospital (HC) of the Medical School of the University of Sao Paulo (USP)', 'SamplingMethod': 'Non-Probability Sample'}, 'ContactsLocationsModule': {'OverallOfficialList': {'OverallOfficial': [{'OverallOfficialName': 'Linamara Battistella, Md PhD', 'OverallOfficialAffiliation': 'Head Professor, Medical School of the University of Sao Paulo, pos graduation program at the Medical Science of the Medical School of the University of Sao Paulo', 'OverallOfficialRole': 'Principal Investigator'}]}, 'LocationList': {'Location': [{'LocationFacility': 'Centro de Pesquisa Clínica do Instituto de Medicina e Reabilitação do HCFMUSP', 'LocationCity': 'Sao Paulo', 'LocationZip': '05716-150', 'LocationCountry': 'Brazil'}]}}, 'ReferencesModule': {'ReferenceList': {'Reference': [{'ReferencePMID': '23319486', 'ReferenceType': 'background', 'ReferenceCitation': 'Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology. 2013 Jan 15;80(3 Suppl 2):S5-12. doi: 10.1212/WNL.0b013e3182762397.'}, {'ReferencePMID': '21035399', 'ReferenceType': 'background', 'ReferenceCitation': 'Stinear C. Prediction of recovery of motor function after stroke. Lancet Neurol. 2010 Dec;9(12):1228-1232. doi: 10.1016/S1474-4422(10)70247-7. Epub 2010 Oct 27.'}]}}}, 'DerivedSection': {'MiscInfoModule': {'VersionHolder': 'August 17, 2023'}, 'ConditionBrowseModule': {'ConditionMeshList': {'ConditionMesh': [{'ConditionMeshId': 'D000020521', 'ConditionMeshTerm': 'Stroke'}]}, 'ConditionAncestorList': {'ConditionAncestor': [{'ConditionAncestorId': 'D000002561', 'ConditionAncestorTerm': 'Cerebrovascular Disorders'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]}, 'ConditionBrowseLeafList': {'ConditionBrowseLeaf': [{'ConditionBrowseLeafId': 'M21996', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafAsFound': 'Cerebrovascular Accident', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5500', 'ConditionBrowseLeafName': 'Cerebrovascular Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4894', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5432', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17090', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]}, 'ConditionBrowseBranchList': {'ConditionBrowseBranch': [{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]}}}}}]}}\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "NameError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-22-16b912f6500b>\u001b[0m in \u001b[0;36m<cell line: 148>\u001b[0;34m()\u001b[0m\n\u001b[1;32m    146\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    147\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 148\u001b[0;31m \u001b[0mget_study_info\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"diabetes\"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    149\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-22-16b912f6500b>\u001b[0m in \u001b[0;36mget_study_info\u001b[0;34m(selected_disease, additional_term)\u001b[0m\n\u001b[1;32m    134\u001b[0m \u001b[0;32mdef\u001b[0m \u001b[0mget_study_info\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mselected_disease\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0madditional_term\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    135\u001b[0m   \u001b[0moutput\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mget_clinicaltrials\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mselected_disease\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0madditional_term\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 136\u001b[0;31m   \u001b[0msummary\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mget_summarized_clinicaltrials\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlocal\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0moutput\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    137\u001b[0m   \u001b[0;31m#summary = 'Study 1:\\n- The study aimed to examine the effects of dietary modification and treadmill training on fuel utilization and physical function in chronic stroke patients.\\n- The outcomes of the study were not explicitly compared to hypotheses.'\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    138\u001b[0m   \u001b[0;31m#print(output)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mNameError\u001b[0m: name 'get_summarized_clinicaltrials' is not defined"
          ]
        }
      ],
      "source": [
        "def get_clinicaltrials(disease, additional_term):\n",
        "  import requests\n",
        "  import json\n",
        "\n",
        "  disease = \"stroke\"\n",
        "  additional_term = \"nutrition\"\n",
        "\n",
        "  base_url = \"https://ClinicalTrials.gov/api/query/full_studies\"\n",
        "  search_term = disease + \" \" + additional_term\n",
        "  search_term.replace(\" \", \"+\")\n",
        "  params = {\n",
        "      \"expr\": search_term,\n",
        "      \"min_rnk\": \"1\",\n",
        "      \"max_rnk\": \"50\",\n",
        "      \"fmt\": \"json\"\n",
        "    }\n",
        "  response = requests.get(base_url, params=params)\n",
        "\n",
        "  # Parse the JSON\n",
        "  data = json.loads(response.text)\n",
        "  print(data)\n",
        "  results_list = []\n",
        "  # Attributes to include\n",
        "  attributes_to_include = [\n",
        "      \"DescriptionModule\",\n",
        "      \"EnrollmentInfo\",\n",
        "      \"OutcomesModule\",\n",
        "      \"EligibilityModule\",\n",
        "      \"IdentificationModule\",\n",
        "      \"StatusModule\",\n",
        "      \"SponsorCollaboratorsModule\",\n",
        "      \"ConditionsModule\"\n",
        "  ]\n",
        "\n",
        "  index = 0\n",
        "\n",
        "  if (data[\"FullStudiesResponse\"][\"NStudiesFound\"] > 0):\n",
        "\n",
        "    # Extract the list of studies\n",
        "    studies = data[\"FullStudiesResponse\"][\"FullStudies\"]\n",
        "\n",
        "    # Loop through the studies\n",
        "    for study_data in studies:\n",
        "    # Extract relevant information\n",
        "      study = study_data[\"Study\"]\n",
        "\n",
        "      # Extract status, start date, and completion date if available\n",
        "      status_info = study[\"ProtocolSection\"].get(\"StatusModule\", {})\n",
        "\n",
        "      # Extract results submission information if available, i.e. study\n",
        "      results_submit_date = status_info.get(\"ResultsFirstSubmitDate\")\n",
        "      if results_submit_date:\n",
        "        # Include only specified attributes and their child attributes\n",
        "        included_attributes = {}\n",
        "        for attr in attributes_to_include:\n",
        "          if attr in study[\"ProtocolSection\"]:\n",
        "            included_attributes[attr] = study[\"ProtocolSection\"][attr]\n",
        "            #print(f\"Added attribute: {attr}\")\n",
        "\n",
        "        index += 1\n",
        "        results_list.append({\"Study {}\".format(index): included_attributes})\n",
        "        # Only get upto 5 studies due to the token limit for openAI\n",
        "        if (index >= 5):\n",
        "          break\n",
        "  else:\n",
        "      print(\"No Studies found\")\n",
        "\n",
        "  # Create a dictionary for the collected results\n",
        "  collected_results = {\"Results\": results_list}\n",
        "\n",
        "  # Convert the collected results to JSON format\n",
        "  collected_results_json = json.dumps(collected_results, indent=4)\n",
        "  with open(\"/content/clinical_trials/collected_results\"+disease+\".json\", \"w\") as outfile:\n",
        "    outfile.write(collected_results_json)\n",
        "\n",
        "  #getstudyinfo(\"stroke\", \"\")\n",
        "  return collected_results_json\n",
        "\n",
        "# Function to get summaries based on study number\n",
        "def get_summary_by_study_number(summary_text, study_number):\n",
        "    study_marker = f\"Study {study_number}:\"\n",
        "    next_study_marker = f\"Study {study_number + 1}:\"\n",
        "\n",
        "    start_index = summary_text.find(study_marker)\n",
        "    end_index = summary_text.find(next_study_marker) if next_study_marker in summary_text else len(summary_text)\n",
        "\n",
        "    if start_index != -1:\n",
        "      summary_for_study = summary_text[start_index:end_index].strip()\n",
        "      # Remove the study marker\n",
        "      summary_for_study = summary_text.replace(study_marker, '').strip()\n",
        "      # print(\"SUMMARY: \" + summary_for_study)\n",
        "      return summary_for_study\n",
        "    else:\n",
        "      return \"\"\n",
        "\n",
        "def get_attributes_by_study_number(json_data, summary, study_number):\n",
        "  import json\n",
        "  output = {}\n",
        "\n",
        "  # Parse the JSON\n",
        "  data = json.loads(json_data)\n",
        "\n",
        "  # Define the study number you're interested in\n",
        "  study_key = f\"Study {study_number}\"\n",
        "  index = study_number - 1\n",
        "\n",
        "  study_data = None\n",
        "\n",
        "  # Extract the study data using the study number\n",
        "  if index < len(data[\"Results\"]):\n",
        "    print(index)\n",
        "    study_data = data[\"Results\"][index].get(study_key)\n",
        "  #  print(study_data)\n",
        "\n",
        "    if study_data is not None:\n",
        "      output['brief_title'] = study_data[\"IdentificationModule\"][\"BriefTitle\"]\n",
        "      output['nct_id'] = study_data[\"IdentificationModule\"][\"NCTId\"]\n",
        "      output['overall_status'] = study_data[\"StatusModule\"][\"OverallStatus\"]\n",
        "      output['start_date'] = study_data[\"StatusModule\"][\"StartDateStruct\"][\"StartDate\"]\n",
        "      output['completion_date'] = study_data[\"StatusModule\"][\"CompletionDateStruct\"][\"CompletionDate\"]\n",
        "      output['lead_sponsor'] = study_data[\"SponsorCollaboratorsModule\"][\"LeadSponsor\"][\"LeadSponsorName\"]\n",
        "      output['summary'] = get_summary_by_study_number(summary, study_number)\n",
        "      # print(output)\n",
        "      output_json = json.dumps(output, indent=4)\n",
        "      with open(\"/content/clinical_trials/\" + study_key + \".json\", \"w\") as outfile:\n",
        "        outfile.write(output_json)\n",
        "\n",
        "    else:\n",
        "      print(f\"Study {study_number} not found.\")\n",
        "\n",
        "\n",
        "  return output\n",
        "\n",
        "def get_study_info(selected_disease, additional_term):\n",
        "  output = get_clinicaltrials(selected_disease, additional_term)\n",
        "  summary = get_summarized_clinicaltrials.local(output)\n",
        "  #summary = 'Study 1:\\n- The study aimed to examine the effects of dietary modification and treadmill training on fuel utilization and physical function in chronic stroke patients.\\n- The outcomes of the study were not explicitly compared to hypotheses.'\n",
        "  #print(output)\n",
        "  allAttrsForStudies = []\n",
        "  for i in range(1, 6):\n",
        "    attributes = get_attributes_by_study_number(output, summary, i)\n",
        "    allAttrsForStudies.append(attributes)\n",
        "\n",
        "  # print(allAttrsForStudies)\n",
        "  return allAttrsForStudies\n",
        "\n",
        "\n",
        "get_study_info(\"diabetes\", \"\")\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ZhnvVk6HrdxR"
      },
      "outputs": [],
      "source": [
        "!pip install modal"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "eiCZZP0O1Vea"
      },
      "outputs": [],
      "source": [
        "!modal token new --source corise > authenticationURL.txt"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "VkhO_RuisA0j",
        "outputId": "a8658064-f025-4d5e-a6ef-bbcd3bcfcaa3"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Please enter your Modal token ID in the cell: ··········\n",
            "Please enter your Modal token secret in the cell:  ··········\n"
          ]
        }
      ],
      "source": [
        "import getpass\n",
        "import subprocess\n",
        "\n",
        "def set_modal_token():\n",
        "  token_id = getpass.getpass('Please enter your Modal token ID in the cell: ')\n",
        "  token_secret = getpass.getpass('Please enter your Modal token secret in the cell:  ')\n",
        "\n",
        "  # Using subprocess to execute the command\n",
        "  subprocess.run(f\"!modal token set --token-id (token_id) --token-secret (token_secret)\", shell=True)\n",
        "\n",
        "set_modal_token()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-zsLxU63XCUj",
        "outputId": "246ce26c-302d-450e-941c-6f60cadbc6ee"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Overwriting /content/clinical_trials/clinicaltrials_backend.py\n"
          ]
        }
      ],
      "source": [
        "%%writefile /content/clinical_trials/clinicaltrials_backend.py\n",
        "import modal\n",
        "\n",
        "def download_packages():\n",
        "  # Load the Whisper model\n",
        "  import os\n",
        "  print (\"Installing needed packages\")\n",
        "\n",
        "\n",
        "stub = modal.Stub(\"clinicaltrials-project\")\n",
        "corise_image = modal.Image.debian_slim().pip_install(\n",
        "                                                     \"requests\",\n",
        "                                                     \"ffmpeg\",\n",
        "                                                     \"openai\",\n",
        "                                                     \"tiktoken\").run_function(download_packages)\n",
        "\n",
        "def get_clinicaltrials(disease, additional_term):\n",
        "  import requests\n",
        "  import json\n",
        "\n",
        "  disease = \"stroke\"\n",
        "  additional_term = \"nutrition\"\n",
        "\n",
        "  base_url = \"https://ClinicalTrials.gov/api/query/full_studies\"\n",
        "  search_term = disease + \" \" + additional_term\n",
        "  search_term.replace(\" \", \"+\")\n",
        "  params = {\n",
        "      \"expr\": search_term,\n",
        "      \"min_rnk\": \"1\",\n",
        "      \"max_rnk\": \"50\",\n",
        "      \"fmt\": \"json\"\n",
        "    }\n",
        "  response = requests.get(base_url, params=params)\n",
        "\n",
        "  # Parse the JSON\n",
        "  data = json.loads(response.text)\n",
        "  # print(data)\n",
        "  results_list = []\n",
        "  # Attributes to include\n",
        "  attributes_to_include = [\n",
        "      \"DescriptionModule\",\n",
        "      \"EnrollmentInfo\",\n",
        "      \"OutcomesModule\",\n",
        "      \"EligibilityModule\",\n",
        "      \"IdentificationModule\",\n",
        "      \"StatusModule\",\n",
        "      \"SponsorCollaboratorsModule\",\n",
        "      \"ConditionsModule\"\n",
        "  ]\n",
        "\n",
        "  index = 0\n",
        "\n",
        "  if (data[\"FullStudiesResponse\"][\"NStudiesFound\"] > 0):\n",
        "\n",
        "    # Extract the list of studies\n",
        "    studies = data[\"FullStudiesResponse\"][\"FullStudies\"]\n",
        "\n",
        "    # Loop through the studies\n",
        "    for study_data in studies:\n",
        "      # Extract relevant information\n",
        "      study = study_data[\"Study\"]\n",
        "\n",
        "      # Extract status, start date, and completion date if available\n",
        "      status_info = study[\"ProtocolSection\"].get(\"StatusModule\", {})\n",
        "\n",
        "      # Extract results submission information if available, i.e. study\n",
        "      results_submit_date = status_info.get(\"ResultsFirstSubmitDate\")\n",
        "      if results_submit_date:\n",
        "        # Include only specified attributes and their child attributes\n",
        "        included_attributes = {}\n",
        "        for attr in attributes_to_include:\n",
        "          if attr in study[\"ProtocolSection\"]:\n",
        "            included_attributes[attr] = study[\"ProtocolSection\"][attr]\n",
        "            #print(f\"Added attribute: {attr}\")\n",
        "\n",
        "        index += 1\n",
        "        results_list.append({\"Study {}\".format(index): included_attributes})\n",
        "        # Only get upto 5 studies due to the token limit for openAI\n",
        "        if (index >= 5):\n",
        "          break\n",
        "  else:\n",
        "      print(\"No Studies found\")\n",
        "\n",
        "  # Create a dictionary for the collected results\n",
        "  collected_results = {\"Results\": results_list}\n",
        "\n",
        "  # Convert the collected results to JSON format\n",
        "  collected_results_json = json.dumps(collected_results, indent=4)\n",
        "  #with open(\"/content/clinical_trials/collected_results\"+disease+\".json\", \"w\") as outfile:\n",
        "  #  outfile.write(collected_results_json)\n",
        "\n",
        "  #getstudyinfo(\"stroke\", \"\")\n",
        "  return collected_results_json\n",
        "\n",
        "\n",
        "\n",
        "@stub.function(image=corise_image, gpu=\"any\")\n",
        "def get_summary_by_study_number(summary_text, study_number):\n",
        "    study_marker = f\"Study {study_number}:\"\n",
        "    next_study_marker = f\"Study {study_number + 1}:\"\n",
        "\n",
        "    start_index = summary_text.find(study_marker)\n",
        "    end_index = summary_text.find(next_study_marker) if next_study_marker in summary_text else len(summary_text)\n",
        "    #print(\"start_index: \" + start_index)\n",
        "\n",
        "    if start_index != -1:\n",
        "      summary_for_study = summary_text[start_index:end_index].strip()\n",
        "      # Remove the study marker\n",
        "      summary_for_study = summary_text.replace(study_marker, '').strip()\n",
        "      return summary_for_study\n",
        "    else:\n",
        "      return \"\"\n",
        "\n",
        "@stub.function(image=corise_image, gpu=\"any\")\n",
        "def get_attributes_by_study_number(json_data, summary, study_number):\n",
        "  import json\n",
        "  output = {}\n",
        "\n",
        "  # Parse the JSON\n",
        "  data = json.loads(json_data)\n",
        "\n",
        "  # Define the study number you're interested in\n",
        "  study_key = f\"Study {study_number}\"\n",
        "  index = study_number - 1\n",
        "\n",
        "  study_data = None\n",
        "\n",
        "  # Extract the study data using the study number\n",
        "  if index < len(data[\"Results\"]):\n",
        "    print(index)\n",
        "    study_data = data[\"Results\"][index].get(study_key)\n",
        "  #  print(study_data)\n",
        "\n",
        "    if study_data is not None:\n",
        "      output['brief_title'] = study_data[\"IdentificationModule\"][\"BriefTitle\"]\n",
        "      output['nct_id'] = study_data[\"IdentificationModule\"][\"NCTId\"]\n",
        "      output['overall_status'] = study_data[\"StatusModule\"][\"OverallStatus\"]\n",
        "      output['start_date'] = study_data[\"StatusModule\"][\"StartDateStruct\"][\"StartDate\"]\n",
        "      output['completion_date'] = study_data[\"StatusModule\"][\"CompletionDateStruct\"][\"CompletionDate\"]\n",
        "      output['lead_sponsor'] = study_data[\"SponsorCollaboratorsModule\"][\"LeadSponsor\"][\"LeadSponsorName\"]\n",
        "      output['summary'] = get_summary_by_study_number.local(summary, study_number)\n",
        "      # print(output)\n",
        "      output_json = json.dumps(output, indent=4)\n",
        "      #with open(\"/content/clinical_trials/\" + study_key + \".json\", \"w\") as outfile:\n",
        "      #  outfile.write(output_json)\n",
        "\n",
        "    else:\n",
        "      print(f\"Study {study_number} not found.\")\n",
        "\n",
        "\n",
        "  return output\n",
        "\n",
        "@stub.function(image=corise_image, gpu=\"any\", secret=modal.Secret.from_name(\"my-openai-secret-2\"))\n",
        "def get_summarized_clinicaltrials(collected_results_json):\n",
        "  import openai\n",
        "  print (\"Starting get_clinicaltrials Function\")\n",
        "\n",
        "  instructPrompt = \"\"\"\n",
        "    You are a expert at analyzing clinical data for scientific studies for diseases. Summarize the Outcome of each study. Use bullet points. Compare the Outcome parameters to hypotheses and see if the outcome matched the hypotheses or not.\n",
        "  Focus more on the outcome parameters for each study. Don't use any scientific language. Make it easily understandable by kids. Below is all the information from the studies of various clinical trials. Don't write any of the identification attributes.\n",
        "  Don't put the title of the study in your response. Keep the response concise.\n",
        "  \"\"\"\n",
        "\n",
        "  request = instructPrompt + collected_results_json\n",
        "\n",
        "  chatOutput = openai.ChatCompletion.create(model=\"gpt-3.5-turbo-16k\",\n",
        "                                            messages=[{\"role\": \"system\", \"content\": \"You are a expert at analyzing clinical data for scientific studies for diseases.\"},\n",
        "                                                      {\"role\": \"user\", \"content\": request}])\n",
        "\n",
        "  summary = chatOutput.choices[0].message.content\n",
        "  summary\n",
        "  return summary\n",
        "\n",
        "@stub.function(image=corise_image, gpu=\"any\")\n",
        "def get_study_info(selected_disease, additional_term):\n",
        "  download_packages()\n",
        "  output = get_clinicaltrials(selected_disease, additional_term)\n",
        "  summary = get_summarized_clinicaltrials.local(output)\n",
        "  #summary = 'Study 1:\\n- The study aimed to examine the effects of dietary modification and treadmill training on fuel utilization and physical function in chronic stroke patients.\\n- The outcomes of the study were not explicitly compared to hypotheses.'\n",
        "  #print(output)\n",
        "  allAttrsForStudies = []\n",
        "  for i in range(1, 6):\n",
        "    attributes = get_attributes_by_study_number.local(output, summary, i)\n",
        "    allAttrsForStudies.append(attributes)\n",
        "\n",
        "  print(allAttrsForStudies)\n",
        "  return allAttrsForStudies\n",
        "\n",
        "@stub.local_entrypoint()\n",
        "def main():\n",
        "  get_study_info.local(\"stroke\", \"nutrition\")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gDy5Ux4_xD8Z",
        "outputId": "ed325ba8-74ba-4e9e-8b1b-49593c9138c6"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[?25l\u001b[34m⠋\u001b[0m Initializing...\r\u001b[2K\u001b[32m✓\u001b[0m Initialized. \u001b[37mView app at \u001b[0m\u001b[4;37mhttps://modal.com/apps/ap-H7EMzV4V28vlgvyeLro1Rk\u001b[0m\n",
            "\u001b[2K\u001b[34m⠋\u001b[0m Initializing...\n",
            "\u001b[2K\u001b[34m⠸\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[34m⠋\u001b[0m Creating get_summary_by_study_number...\n",
            "\u001b[37m└── \u001b[0m\u001b[34m⠋\u001b[0m Creating mount /content/clinical_trials/clinicaltrials_backend.py: \n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠦\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[34m⠸\u001b[0m Creating get_summary_by_study_number...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[34m⠋\u001b[0m Creating download_packages...\n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠏\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠹\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_attributes_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summarized_clinicaltrials.\n",
            "\u001b[37m└── \u001b[0m\u001b[32m🔨\u001b[0m Created get_study_info.\n",
            "\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[32m✓\u001b[0m Created objects.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_attributes_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summarized_clinicaltrials.\n",
            "\u001b[37m└── \u001b[0m\u001b[32m🔨\u001b[0m Created get_study_info.\n",
            "\u001b[2KInstalling needed packages\n",
            "\u001b[2KStarting get_clinicaltrials Function\n",
            "\u001b[2K0\n",
            "\u001b[2K1\n",
            "\u001b[2K[{'brief_title': 'Nutrition and Aerobic Exercise in Chronic Stroke', 'nct_id': \n",
            "'NCT02043574', 'overall_status': 'Completed', 'start_date': 'November 17, 2014',\n",
            "'completion_date': 'September 30, 2019', 'lead_sponsor': 'VA Office of Research \n",
            "and Development', 'summary': '- The study focused on the effects of dietary \n",
            "modification and treadmill training on fuel utilization and physical function in\n",
            "chronic stroke patients.\\n- The primary outcome measured was the change in total\n",
            "daily energy expenditure.\\n- The secondary outcomes measured were the change in \n",
            "substrate oxidation and circulating nitrotyrosine.\\n- The outcomes were compared\n",
            "between baseline and after 6 months of treadmill training or stretching \n",
            "(control).\\n- The outcome parameters matched the hypotheses.\\n\\nStudy 2:\\n- The \n",
            "study aimed to determine the effects of a diabetes-specific enteral formula \n",
            "compared to a standard formula supplemented with protein on blood glucose levels\n",
            "and glycemic variability in critically ill patients in a neurological ICU.\\n- \n",
            "The primary outcome measured was glycemic variability, which included mean blood\n",
            "glucose levels and mathematical variation in blood glucose levels.\\n- The \n",
            "secondary outcome measured was quadriceps muscle volume.\\n- The outcomes were \n",
            "compared between the control and intervention groups.\\n- The study was \n",
            "terminated due to slow recruitment and unlikely statistical significance.'}, \n",
            "{'brief_title': 'Enteral Nutrition and Glycemic Variability Neurological \n",
            "Intensive Care Unit Study', 'nct_id': 'NCT01463878', 'overall_status': \n",
            "'Terminated', 'start_date': 'November 2011', 'completion_date': 'June 2012', \n",
            "'lead_sponsor': 'Eastern Virginia Medical School', 'summary': 'Study 1:\\n- The \n",
            "study focused on the effects of dietary modification and treadmill training on \n",
            "fuel utilization and physical function in chronic stroke patients.\\n- The \n",
            "primary outcome measured was the change in total daily energy expenditure.\\n- \n",
            "The secondary outcomes measured were the change in substrate oxidation and \n",
            "circulating nitrotyrosine.\\n- The outcomes were compared between baseline and \n",
            "after 6 months of treadmill training or stretching (control).\\n- The outcome \n",
            "parameters matched the hypotheses.\\n\\n\\n- The study aimed to determine the \n",
            "effects of a diabetes-specific enteral formula compared to a standard formula \n",
            "supplemented with protein on blood glucose levels and glycemic variability in \n",
            "critically ill patients in a neurological ICU.\\n- The primary outcome measured \n",
            "was glycemic variability, which included mean blood glucose levels and \n",
            "mathematical variation in blood glucose levels.\\n- The secondary outcome \n",
            "measured was quadriceps muscle volume.\\n- The outcomes were compared between the\n",
            "control and intervention groups.\\n- The study was terminated due to slow \n",
            "recruitment and unlikely statistical significance.'}, {}, {}, {}]\n",
            "\u001b[2K\u001b[34m⠋\u001b[0m Running app...\n",
            "\u001b[1A\u001b[2K\u001b[32m✓\u001b[0m App completed.\n"
          ]
        }
      ],
      "source": [
        "!modal run /content/clinical_trials/clinicaltrials_backend.py"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Ls3b-g73w4v4"
      },
      "source": [
        "**Deploy the backend code to Modal**\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "u_Tvgfsjw3l0",
        "outputId": "929a3039-f376-48df-ee52-de2698591651"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[2K\u001b[34m⠸\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[34m⠋\u001b[0m Creating get_summary_by_study_number...\n",
            "\u001b[37m└── \u001b[0m\u001b[34m⠋\u001b[0m Creating mount /content/clinical_trials/clinicaltrials_backend.py: \n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠦\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[34m⠸\u001b[0m Creating get_summary_by_study_number...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[34m⠋\u001b[0m Creating download_packages...\n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠏\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠹\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_attributes_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summarized_clinicaltrials.\n",
            "\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[34m⠹\u001b[0m Creating objects...\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_attributes_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summarized_clinicaltrials.\n",
            "\u001b[37m└── \u001b[0m\u001b[32m🔨\u001b[0m Created get_study_info.\n",
            "\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[1A\u001b[2K\u001b[32m✓\u001b[0m Created objects.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summary_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created download_packages.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created mount /content/clinical_trials/clinicaltrials_backend.py\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_attributes_by_study_number.\n",
            "\u001b[37m├── \u001b[0m\u001b[32m🔨\u001b[0m Created get_summarized_clinicaltrials.\n",
            "\u001b[37m└── \u001b[0m\u001b[32m🔨\u001b[0m Created get_study_info.\n",
            "\u001b[32m✓\u001b[0m App deployed! 🎉\n",
            "\n",
            "View Deployment: \u001b[35mhttps://modal.com/apps/mamtasuri/clinicaltrials-project\u001b[0m\n"
          ]
        }
      ],
      "source": [
        "!modal deploy /content/clinical_trials/clinicaltrials_backend.py"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3Pa0Ne-UEvVM"
      },
      "source": [
        "# Front End"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true,
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}